id,sequence,label,date,quarter,year,speaker,title,text,mystery indicator,VADER sentiment
DGX-2018-Q2-2018-07-24,3,Remarks,2018-07-24,2,2018,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I'm here with Steve Rusckowski, our Chairman, President and Chief Executive Officer; and Mark Guinan, our Chief Financial Officer.",0.3847579,0.66
DGX-2018-Q2-2018-07-24,4,Remarks,2018-07-24,2,2018,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and will discuss non-GAAP measures. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.",0.2934639,-0.065
DGX-2018-Q2-2018-07-24,5,Remarks,2018-07-24,2,2018,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS, excluding amortization expense. As a reminder, adjusted diluted EPS excludes excess tax benefits associated with stock-based compensation. Additionally, net revenues and selling, general and administrative expenses have been restated for the basis of prior-year comparisons to reflect the impact of the new revenue recognition standard that became effective January 1, 2018, and were adopted on a retrospective basis.",0.4763165,0.743
DGX-2018-Q2-2018-07-24,6,Remarks,2018-07-24,2,2018,Shawn Bevec,Executive Director-Investor Relations,"Under the new rules, the company now reports uncollectible balances associated with patient responsibility as a reduction in net revenues when historically these amounts were classified as bad debt expense within selling, general and administrative expenses.",0.4710241,-0.791
DGX-2018-Q2-2018-07-24,8,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn and thanks everyone for joining us today. This morning I'll provide you with the highlights on the quarter and review progress on our 2-point strategy, which continues to drive results. And then Mark will provide more detail on second quarter performance.",0.1983526,0.823
DGX-2018-Q2-2018-07-24,9,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The highlight of the quarter was establishing, our long-term strategic partnership with UnitedHealthcare, I'll share more on this relationship in a few minutes. We delivered strong earnings growth in the quarter driven by revenue growth and the benefits of tax reform. Here are some key highlights from the quarters; revenues were up 3%, despite some headwinds in the marketplace, reported EPS was up more than 14% from 2017, the adjusted EPS grew more than 20%.",0.1904448,0.929
DGX-2018-Q2-2018-07-24,10,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before I describe the progress we've made, I like to provide an update on PAMA. We continue to support efforts by our trade association to implement a market-based laboratory reimbursement schedule. On the legal front, ACLA has sued CMS, and both sides have submitted their briefs to the court, we're awaiting the judge to rule on the briefs or set the date to hear or oral arguments. In the meantime, we continue our outreach efforts to find the legislative solution.",0.3551895,0.848
DGX-2018-Q2-2018-07-24,11,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Earlier this month we were pleased to learn that CMS is asking stakeholders to provide comments and also improve future data collection and reporting periods on their PAMA. This is a proper step since as we said all along, PAMA's current reporting requirements undermine any effort to establish a sustainable market-based PAMA model and deliver the care that patients need. But the key will be what CMS does with the requested comments. And moreover the need for change is now. Changing data collection for the future reported periods does not undo the harm caused by the flawed data collection process that was used in connection with establishing the current rates.",0.1650741,0.864
DGX-2018-Q2-2018-07-24,12,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to the second quarter, we delivered on all five elements of our strategy to accelerate growth. The first element of our growth strategy is to grow 1% to 2% through strategically aligned accretive acquisitions. We completed our previously announced acquisition of the outreach laboratory services business of Cape Cod Healthcare in Massachusetts the leading provider of healthcare services for residents and visitors of Cape Cod. Our integration efforts from acquisitions completed in 2017, continue to drive revenue growth and our M&A pipeline remain strong.",0.4260297,0.904
DGX-2018-Q2-2018-07-24,13,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As we continued our conversations with hospital system CEO's from around the country, it's clear from those discussion there is a growing awareness of PAMA and the impact it has on their outreach laboratory business. CEO's are increasingly interested in talking more about how we can help them execute their last strategy. As you recall, this can involve improving their hospital lab operations, working with us on reference testing and potentially selling their outreach laboratory business to us.",0.0477759,0.929
DGX-2018-Q2-2018-07-24,14,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In addition to PAMA, hospital CEO's are also seeing the trend in health plans like Aetna and UnitedHealthcare partnering with high value providers like Quest to reduce laboratory spend and bring down the cost of care. Under the second element of our growth strategy, we continue to expand relationships with health plans and hospital health systems. In May we announced our long-term strategic partnership with UnitedHealthcare beginning on January 1, 2019, plus we'll be participating as a national provider of laboratory services for all UnitedHealthcare plan participants.",0.1406919,0.926
DGX-2018-Q2-2018-07-24,15,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're excited about this partnership, as it includes a broad range of value-based programs rewarding high quality, easily accessible laboratory services at the best value and real-time data sharing to drive more personalized health.",0.3327842,0.949
DGX-2018-Q2-2018-07-24,16,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're positioning ourselves to be well prepared to provide UnitedHealthcare members with a first-class customer experience. Our commercial team has already begun proactively reaching out to physician and customers to let to know, we'll be in that work with UnitedHealthcare on January 1. Additionally, we'll be fielding inquiries from customers who are committed to selling us an increasingly share of their UnitedHealthcare patient specimens in 2019.",0.014827,0.796
DGX-2018-Q2-2018-07-24,17,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're delivering on the third element of our growth strategy, which is to offer the broadest access to diagnostic innovation. We continue to see strong growth in prescription drug monitoring, QuantiFERON, tuberculosis test, noninvasive prenatal screening. In the second quarter, we did experience three dynamics which impacted the marketplace. First, the growth we saw in prescription drug monitoring marketplace although strong, it was less than expected because of policy changes opposed by some payers to limit testing. We're engaging directly with these payers to show the medical necessity of this testing and so far have had success getting at least one payer to reverse its policy change.",0.0899506,0.973
DGX-2018-Q2-2018-07-24,18,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second, in the hepatitis C market, we saw a faster than expected decline in genotyping and resistance testing. This was largely due to the rapid acceptance, so that these new hepatitis C therapy which works across multiple genes and does not require the same level of testing as previous therapies. We still see a tremendous opportunity in hepatitis C screening. Our screening business continues to grow and we estimate two-thirds of more than 70 million baby boomers still have yet to be screened.",0.12257,0.7
DGX-2018-Q2-2018-07-24,19,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally on vitamin D testing, it did slow the quarter due to increased reimbursement denials. We're working with payers and providers to ensure the appropriate testing is being performed for patients who need it. We continue to make strong progress, executing the fourth element of our growth strategy, which is to be the provider of choice for consumers.",0.3759473,0.927
DGX-2018-Q2-2018-07-24,20,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our Walmart locations continue to see increased traffic and the well received by customers. We're now operating in 12 Walmart locations in Florida and Texas and we'll be providing more around our consumer strategies including MyQuest, our digital experience and our consumer offering at our Investor Day in November.",0.2438221,0.494
DGX-2018-Q2-2018-07-24,21,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The fifth element of our growth strategy is to support population health with data analytics and extended care services. I'm excited about last month's launch of Quest Clinical Trial Connect a new patient recruitment service to help pharma companies and sterile to speed the development of new therapies. We have already engaged several pharma, biotech and sterile companies with this solution.",0.1472817,0.951
DGX-2018-Q2-2018-07-24,22,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In the area of population health in June, we released a study on employer wellness and screening at the American Diabetes Association Scientific Session showing a strong association between wellness participation and healthcare outcomes. The study showed that a third of the at-risk employees identified by screen who then participated in a behavioural health program to reduce diabetes risk, reduce glucose and hemoglobin A1c to normal levels. Also more than one-quarter participants lost 5% or more of body weight reducing the risk of many of BCD related conditions.",0.1555189,0.557
DGX-2018-Q2-2018-07-24,23,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",This news is catching the attentions of both employers and health plans as they proactively look for opportunities to vendor healthcare cost curve. We're strengthening already strong position in the marketplace. The second element of our 2-point strategy is to drive operational excellence. We're continued to drive efficiency and effectiveness within Quest to cover the cost of wage inflation and reimbursement pressure. I referenced to digitize our processes are improving the customer experience.,0.0790774,0.946
DGX-2018-Q2-2018-07-24,24,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So here are two simple real examples of improving opportunities in front of us. First, as we shared previously, processing a paper requisition takes approximately 4 minutes, the enablement allows us to improve both efficiency and quality. We're making progress in our efforts to get clients systemic, electronic requisitions today more than 70% of the requisitions we received are sent electronically and this is up from approximately 60% in 2016.",0.3818781,0.933
DGX-2018-Q2-2018-07-24,25,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second, we have developed a client from lead application, which allows physicians and their staffs to order specimen pickups. Since the launch of early last year over 5,000 clients have converted to online tick up through what we call, Quanum HCP Portal and we're adding 200 clients each week. Each day more than 13% of routine on-demand, pick up requests are received electronically through our new application. And we expect this rapid adoption will continue. Well this translates into - if you recall to our call centre in a significant fewer occurrences of our couriers arriving to find an empty lot box.",0.0642504,0.273
DGX-2018-Q2-2018-07-24,26,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now let me turn it over to Mark, who'll take you through the financial performance. Mark?",0.124547,0.0
DGX-2018-Q2-2018-07-24,27,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. Consolidated revenues of $1.92 billion were up 3% versus the prior year. As a reminder, we now report uncollectable balances associated with patient responsibility as a reduction of net revenues instead of bad debt due to a change in revenue recognition accounting.",0.3112164,-0.625
DGX-2018-Q2-2018-07-24,28,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenues for Diagnostic Information Services, or DIS for short, grew 3.3% compared to the prior year, driven largely by acquisitions. Volume, measured by the number of requisitions, increased 2.5% versus the prior year with acquisitions contributing approximately 200 basis points. Volume was softer than expected due in large part to the specific market dynamics highlighted by Steve earlier. Revenue per requisition in the second quarter grew by 20 basis points versus the prior year. As a reminder, revenue per req is not a proxy for price, it includes a number of variables such as unit price variation, business mix, test mix and test per req.",0.2894945,0.586
DGX-2018-Q2-2018-07-24,29,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"During the second quarter, unit prices headwinds remain consistent with those observed in the first quarter with a headwind of approximately 50 basis points from PAMA and less than 100 basis points from all other factors. After netting changes to PAMA, Medicare reimbursement pressure will increase in 2019, as we have indicated previously. Beyond unit price, other mix elements remained strong in the quarter and more than offset reimbursement headwinds.",0.0248815,0.527
DGX-2018-Q2-2018-07-24,30,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income for the quarter was $305 million or 15.9% of revenues compared to $319 million or 17.1% of revenues a year ago. On an adjusted basis, operating income was $340 million or 17.7% of revenues compared to $343 million or 18.4% of revenues last year. The decline in operating margin was due to several factors including investments using tax reform savings that had a 60 basis point adverse impact on operating margin, some of our larger acquisitions which are in the early stages of integration and therefore not yet delivering full margin and contribution and PAMA.",0.0703002,-0.361
DGX-2018-Q2-2018-07-24,31,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $1.57 in the quarter compared to $1.37 a year ago. Adjusted EPS was $1.75 up more than 20% from $1.45 last year. During the quarter uncollectable balances associated with patient responsibility, which we now call patient price concessions were flat year-over-year. Cash provided by operations year-to-date was $503 million versus $490 million last year. Capital expenditures year-to-date were $151 million compared to $107 million a year ago, which is in line with a higher CapEx spend planned for 2018.",0.4320695,0.0
DGX-2018-Q2-2018-07-24,32,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Now turning to guidance. We are narrowing our outlook for 2018 as follows; revenues now expected to be between $7.7 billion and $7.74 billion an increase of 4% to 4.5% versus the prior year; reported diluted EPS to be between $5.50 and $5.64; and adjusted EPS to be between $6.53 and $6.67; cash provided by operation continues to be approximately $1.3 billion and capital expenditures continue to be between $350 million and $400 million.,0.1161137,0.318
DGX-2018-Q2-2018-07-24,33,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In addition, keep in mind that the investments in the business we are making related to tax reform savings will continue to ramp up as we progress throughout the remainder of 2018. Some of these investments are related to preparing to be a national in network provider for UnitedHealthcare.",0.2460506,0.422
DGX-2018-Q2-2018-07-24,34,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our narrowed revenue guidance reflects our performance through the first half. As you think about the second half of the year consider the following; first, the actions we are taking in the areas of PDM and vitamin D testing; second, as Steve mentioned health systems are talking to us more about how we can help them execute their lab strategy. We have a few professional lab services agreements we expect to close in the second half. Taken together we expect the benefit of these items will build as we progress through the remainder of the year.",0.2657978,0.896
DGX-2018-Q2-2018-07-24,35,Remarks,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Finally, last year severe hurricane impacts should make for an easier comparison this year. The majority of the impact was in the third quarter with some carryover in the fourth quarter as well. To sum it up, we expect growth to accelerate throughout the second half and remain confident in our ability to achieve our 2018 outlook.",0.128752,0.856
DGX-2018-Q2-2018-07-24,37,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Mark. And to summarize, we grew revenues and delivered strong earnings in the second quarter. We're excited to build on the strategic relationship that we now have with UnitedHealthcare Group. And we remain focused on executing our 2-point strategy and we are confident, we'll meet our commitments for the remainder of 2018.",0.0042834,0.931
DGX-2018-Q2-2018-07-24,38,Remarks,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Now we'd be happy to take any questions. Operator?,0.969687,0.572
DGX-2018-Q2-2018-07-24,45,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So Patrick, thanks for the question. We have a tremendous opportunity in front of us. When we had launched the new relationship, we talked about the opportunities that have access to over 40 million lives. And we've already started, and we've started working on this aggressively. So we have detailed out by thousands of accounts which sales reps and which geographies will engage with customers.",0.6174629,0.89
DGX-2018-Q2-2018-07-24,46,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First of all, making them aware of the contractual changes, talk about what we need to do to potentially serve them in a broader way. And finally is, to be prepared to ramp this up as quickly as possible. And so what I will share with you is we've already left the blocks, we're off and running. We're engaging with customers throughout the United States. The receptivity of this is quite good. They're waiting for someone for some time for us to be back on contract. And the biggest opportunity for us is, for those accounts that might have another laboratory because we were not contract with United, now have an opportunity to continue to bring us more of their laboratory services work. And then second is, we have an opportunity just broadly in many accounts to gain more share. So we're optimistic about it and working hard at it.",0.1604613,0.98
DGX-2018-Q2-2018-07-24,48,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Patrick, just to underscore my comments, the conversations have increased. We're engaged in many more conversations today with CEO's of integrated delivery systems around their lab strategy. And in that regard, they are considering given what's happening with PAMA and given the change they see happening with health plans, for what they - should they going forward with their outreach business if they have it. So we're optimistic by the prospect.",0.8092257,0.908
DGX-2018-Q2-2018-07-24,49,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Again, there's three parts of our strategy. First is what we call professional laboratory services business. As Mark said, we've got a few opportunities in front of us. We're hopeful in the back half to be announcing a couple of these at least. Second is, it affords us an opportunity to do more other sophisticated testing, which we call reference testing in the hospitals. And usually, when we have those conversations, we then have a conversation around outreach. So there's more conversation today than a year ago in that funnel and that whole opportunity list continues to build for us.",1.5291598,0.948
DGX-2018-Q2-2018-07-24,56,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So Ricky, the hep C impact, we don't expect to be reversed. So that is kind of a permanent change. So we'll continue to have some headwinds on that particular part of hep C. But as Steve mentioned, screening continues to grow. So it's still an attractive business, it's just that the genotypic testing, which is largely going to go away. So continued headwinds on hep C but certainly, mitigating because there will be some business that obviously will remain in other drugs that do require that testing.",0.5169826,0.619
DGX-2018-Q2-2018-07-24,57,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On the prescription drug monitoring, we mentioned that we've got one payer who changed their position. We are well down the road in discussing that with a couple of other payers who made those changes. We're optimistic because we think that our view is the medically appropriate approach to this very necessary important area of testing. So we have some plans in place, and we're counting on not just the one payer being reversed, but there are couple of others we're feeling like we're making progress in that space.",0.4451027,0.887
DGX-2018-Q2-2018-07-24,58,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then on vitamin D, it's really a market that has probably not always been coded appropriately. There's changes in vitamin D that make a lot of people eligible for vitamin D testing. And there's some practices where people are still using old coding, not understanding that it's going to have an impact on the providers. So I think there is an increasing education around the appropriate use of vitamin D testing, which, of course, we support but then ensuring that you coded accurately as well to ensure that the providers could pay. So we're optimistic that some of that will be mitigated as well. And over time, and that's why we talked about increasing momentum throughout the back half of the year.",0.307267,0.954
DGX-2018-Q2-2018-07-24,59,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So the guidance for the full year does contemplating, obviously, what happened in the first half but what we will address for these three issues that we talked about in our remarks in the second half as well. So yes, it's in.",0.429654,0.768
DGX-2018-Q2-2018-07-24,61,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So thank you for the questions. First off, the investments that we talked about ramping up are included in that $75 million. So it's not incremental from the $75 million we talked about. We, in the beginning of the year, we talked about a portion of that being invested in our people in that $500 onetime bonus. We talked about some investments in the areas of accelerated growth, around advanced diagnostics and PBM. Well we didn't talk about the third piece and we couldn't because that was really earmarked for United.",0.1698262,0.95
DGX-2018-Q2-2018-07-24,62,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So it's still all contained within the initial $75 million we talked about. And then importantly, it's not all SG&A. A large portion of it is actually cost of sales. And its investment before the volume comes, but then once the volume comes, it's just cost of sales. So as we add incremental to draw centers incremental phlebotomist, couriers and laboratory tax ahead of that volume to ensure we're fully prepared for what we expect to come its in investments. But then over time, obviously, it's just the normal support you need to deliver our business.",0.0134281,0.886
DGX-2018-Q2-2018-07-24,63,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then in terms of 2019, Ricky, I'm not yet going to give any guidance for 2019. But I can assure you that when we gave the multiyear outlook when I presented in 2016 and we reaffirmed when PAMA was announced last fall, that all of that is contemplated. So we'll give you more granularity on that - on all those pieces at the Investor Day later in the year.",0.0963665,0.34
DGX-2018-Q2-2018-07-24,70,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So the - we didn't say it was 100. To clarify, it's less than 100. So that's kind of in the normal course of the last couple of years of some of the nongovernmental pricing headwinds that we've had. And it has to do with any other part of our business, whether it's extending third-party commercial contracts, whether it's the direct business in which we compete through hospital reference testing, or it can even be in the stage where it's permitted where we are actually billing physicians directly as a client who then mark up that work and then bill it to the third-party.",0.2345972,0.318
DGX-2018-Q2-2018-07-24,71,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we have certainly competition amongst all these areas and while we've certainly turned the tide of where pricing was some years ago, as we said, there's still some degree of headwinds in the balance of our business. And that's generally going somewhere between 50 and 100 basis points over the last several years quarter-to-quarter and continues to be less than 100 basis points. And we mentioned that when you take price and all the mix elements together, with favorable revenue per req of 20 basis points. So obviously with 50 basis points of PAMA, somewhere south of 100 basis points on other pricing, we have significantly lift from the other mix elements.",0.4723539,0.814
DGX-2018-Q2-2018-07-24,72,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then finally, we've talked about professional laboratory services, which is an increasing part of our growth. It is a business that has lower revenue per req because of the unique nature of what it is. It's basic testing done for hospital in-patients, where typically, we have fewer tests per req and more basic testing. We're not doing advanced diagnostics in that business and so on. So revenue per req tends to be lower and so that creates the mixed headwinds, it's math in terms of our revenue per req. It doesn't in anyway speak to its profitability. It's still a very attractive, profitable business. It just has a low req volume and more basic routine testing.",0.5319905,0.736
DGX-2018-Q2-2018-07-24,73,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Just to reiterate something we always say, and Mark said in his prepared remarks, we do this calculation on revenue per requisition. But really, when you get into managing the business and understanding how that eventually yields margins, there's a lot of other considerations. Some of this lower revenue per req business actually BNP more profitable than higher req - higher dollar per requisition. So it's not necessarily a surrogate for margins at all, so something to keep in mind.",0.0395387,0.648
DGX-2018-Q2-2018-07-24,74,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So in the quarter, we improved our revenue per requisition by 20 basis points, but you saw our margin were quite good in consideration for what we had to do with a lot of the different moving pieces, as Mark outlined.",0.1459638,0.746
DGX-2018-Q2-2018-07-24,76,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As I said in my prepared remarks, we're encouraged that they're asking us for input related to how to improve the data reporting. Albeit, we still believe what they did with the current Clinical Lab Fee Schedule was wrong and that needs to be corrected and we're challenging CMS in that regard. Prospective, we do need to get it right. We are pursuing a legislative solution to that. And we're engaging, as we have all along, with CMS, on how we conclude more labs and how do we get the statistics to really reflective of the market-based approach to laboratory services. So we're encouraged by that.",0.7291598,0.875
DGX-2018-Q2-2018-07-24,77,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second, on the physician fee schedule there will be modest tweaks in that. We think it's for 2019 not necessarily that notable for our business. That was a small piece of our anatomic pathology business that had billed that way. But nothing that's material for us.",0.5364086,0.0
DGX-2018-Q2-2018-07-24,81,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So we have been at a pretty steady rate of organic improvements in organic growth over the last number of quarters. And then obviously, we've fallen back from that. Really, the things that we talked about are really the primary drivers of that difference, A.J. So I'm not going to give a specific number. What I would say is those are the reconciliation between kind of the run rate organic performance we've been delivering consistently and what we delivered in the second quarter.",0.0627962,0.836
DGX-2018-Q2-2018-07-24,82,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So we outlined the three areas A.J., in the remarks. And if you look at the issues that we saw reflect what we thought we could have done versus what we really did do. So those three, we will quantify exactly of the three buckets the total will be broken down from. But they do outline the difference between expectations to the market, our expectations and what we actually delivered.",0.1360791,-0.103
DGX-2018-Q2-2018-07-24,84,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now with that said, we are taking actions for a few of those to reverse it in Q3 and Q4. We mentioned the work we're doing with payers on the prescription drug monitoring, the work we're doing with payers around vitamin D. As Mark said, the hep C care business, which is the genotyping and resistance testing business will essentially slow down because it's no longer needed to give the new therapy for AbbVie. But the screening business continues to be a big opportunity and there's plenty of baby boomers left that need to be screened. So even though it did slow in the quarter, we're working on things to reverse that in the second half.",0.3350906,0.718
DGX-2018-Q2-2018-07-24,86,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So first of all, on Optum, when we talked about our relationship with UnitedHealthcare group, it's well. We currently are now back in network in 2019 with UHC as an in-network provider laboratory services. That's big. As you know, we have partnered with them on revenue cycle management. We're one of their biggest customers. Third is, we provide wellness services for Optum. So we are their somewhat exclusive provider of wellness services for OptumCare when they sell those to payers. Also, we're - they're becoming one of our biggest customers. To your specific question in OptumCare, as you said, their buying physicians and they're buying many of our existing customers. And the opportunity to beat up the physician business supports yet another opportunity.",0.0514003,0.951
DGX-2018-Q2-2018-07-24,87,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So if that closes, they'll be close to - they have close to 50,000 physicians, and we're actively working with them on how we can better serve all their physicians, the existing accounts but also growing - their growing list of physicians in OptumCare. So this relationship continues to build, and we see a good growth prospect of building a bigger and better relationship with OptumCare as they consolidate those practices into their business going forward.",0.2441516,0.962
DGX-2018-Q2-2018-07-24,90,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","HCA. The Denver opportunity which is called the continental division is going well. We're optimistic that we can leverage that relationship throughout the rest of HCA. We continue to work that. And as Mark said, there will be more professional laboratory services relationships announced in the second half. So stay posted.",0.0286656,0.735
DGX-2018-Q2-2018-07-24,91,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. I would just add, A.J., and certainly you can ask them, but I'm very confident they would tell you that we've delivered the quality and the cost savings that they were looking for target up front. So now, of course, the question is what does that mean? Could it mean we expand to other sites? I would think, at the point in time, if we have something to announce, we are happy to announce it. But I think the good news is that both parties are happy with what was delivered and it's worked out very well.",0.650079,0.986
DGX-2018-Q2-2018-07-24,98,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. First of all, as we've mentioned in our remarks, the prenatal testing business continues to grow nicely. So we're optimistic about that. Second is if you look at just ongoing activity, and we've showed this many, many times, if you look at our existing accounts and we do the same account or same-store analysis. And if you look at activity within those accounts that we know we have, we haven't lost any share. I would say, just in general the market's stable. And I would say, just in general, that's true for let's just call it the more routine portion of our Women's Health business.",0.3627677,0.902
DGX-2018-Q2-2018-07-24,99,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue Jack to see a continuation of the slow decline in our path business. The change in practice guidelines back in 2013 did affect the marketplace, where women in the past used to go annually for their check, that's happening less frequently and that continues to be phased in, even though it's been about five years. But just in general, the general volume from our Women's Health business continues to be stable.",0.2481054,0.296
DGX-2018-Q2-2018-07-24,101,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So the contribution from M&A was similar, so there wasn't a big difference. Obviously what we're buying, Jack, is a business that's very similar to our core business. So you wouldn't see a tremendous mix difference that are differential between the volume and revenue contribution.",0.6386256,0.402
DGX-2018-Q2-2018-07-24,103,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So share repurchases, we actually were quiet in the quarter. We stepped out of the market due to what we thought was the impending announcement of UnitedHealthcare. So going forward, as we said, we're going to do the minimal level to meet our 50% or at least half commitment of cash returned to our - or free cash flow returned to our shareholders. Certainly, you should expect that level of activity. But any other share repurchases would be dependent on the amount of M&A activity we have in the back half.",0.4616904,0.932
DGX-2018-Q2-2018-07-24,110,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, what they used, Brian, for the majority of the data points for what we got in a refresh of a clinical fee schedule, the vast majority of the data points were from the two large nationals. So that was what was used. And we think that was incredibly flawed in its approach. Imagine what CMS buys from all the laboratories they buy it from thousands of laboratories, roughly 20% of what they buy is from the nationals. So the date they collected was a distortion of what they really buy.",1.0135091,0.273
DGX-2018-Q2-2018-07-24,111,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so this is one of the biggest points we have. They got to collect more data from more laboratories. And as you know, there's wide variation in this marketplace and the best value is from a company like Quest Diagnostics. So that was the data they collected. We're hopeful. Given this current request for more data, now they can collect more data. The advocacy by asking the question, they got it wrong and they need to get it right the next time they collected data. And again, we're challenging what they did in the first time around lawsuit. It's still in the court. We're hopeful that, that will progress, and we'll have a favorable consideration there.",0.2817133,0.953
DGX-2018-Q2-2018-07-24,112,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But in parallel with that, we're also looking for a legislative solution. So we're currently continue to work this because we believe, at its core, the refreshed clinical - the lab fee schedule was done wrongly. But given all that, what we've outlined in our guidance for this year, what we've outlined in our outlook for 2019 and 2020 is assuming worst case. That is if this sticks and it continues to be the case then that in fact will be what we'll absorb, and we will be able to manage the business and hit our outlook despite it. So hopefully, we'll have better news in that regard, but we're assuming the worst case.",0.5983526,-0.809
DGX-2018-Q2-2018-07-24,113,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then into the future, yes, there will be data points gathered from payers. But again, hopefully there'll be more laboratories included in data collection process, so therefore, that will move the needle quite a bit. So hopefully, that answers your question.",0.0859967,0.796
DGX-2018-Q2-2018-07-24,114,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So let me just quickly comment, Brian, on its impact on PAMA. So as we shared, we're very vocal with all the payers, not just getting United, and I certainly can't speak for our competitor. But I can tell you that when we go in there and say, hey, now there's full transparency. We know where the weighted volume median is amongst the national provider, we know we provide the best prices. And the fact that you already get the best prices from us and that we're going to be paying for potentially twice, with PAMA, means like you're not getting any better prices. And if anything, it's an opportunity - it has been opportunity for us to talk about getting paid for more because these are getting paid more because they think we paid a little bit more than we have been recently or historically, it's still a less better value than the majority of the people they're paying.",0.5189573,0.96
DGX-2018-Q2-2018-07-24,115,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And in fact, in the United contract, when we talk about value-based contracting, as we move volume away from those high-cost providers, part of the contract is what you'd call a bonus rate. So basically, we share the savings with our partner and that will ensure that as we're saving the healthcare system patients and the payers all money that it doesn't damage us from a PAMA perspective, but actually, it should be neutral to positive depending on how we're performing and where that volume growth comes from.",1.0075039,0.917
DGX-2018-Q2-2018-07-24,117,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, that's the opportunity in front of us, this relationship with United, and we we're having conversations with all the payers. Despite the two nationals having strong presence, there's still an opportunity to pick up share for the rest of the marketplace. We talk about the opportunity, when we talk about United, you have roughly more than 40 million lives, you go quickly through the mathematics of that. We basically have shared that their spend - laboratory spend is north of $7 billion in that regard.",0.3924217,0.968
DGX-2018-Q2-2018-07-24,118,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","If you look at the two large nationals, it's still a minority. It's still the opportunity given the trend in general in healthcare is to move more of those higher cost, more expensive laboratory volumes to us. And so what we're detailing right now is precisely that. We're knocking on the doors of many - thousands of customers, Brian. And they have many laboratories and many of those laboratories aren't the two large nationals, but there are many others. And in some cases, they have those laboratories because we were not in network with United.",0.1311367,0.681
DGX-2018-Q2-2018-07-24,119,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","They no longer need those laboratories to serve them and therefore, those supporters are big opportunities. So we need to think about this not just between us and the other large national but more importantly, the opportunity to really continue to gain share, particularly for the regional portion of this market.",0.5792422,0.955
DGX-2018-Q2-2018-07-24,126,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So Lisa, it is a traditional relationship. We're paid for activity. Generally, obviously, there's some portions where they're fully insured where they have an HMO plan. But for the most part, this is a traditional fee-for-service contract. The difference is that the rate is variable dependent on our performance. So when we talk about value-based contracting, and as I referenced earlier, there is incentive payments that we can earn by saving the money. When I say saving them, I'm talking about not just the United but obviously, the healthcare system and especially the patient.",0.235782,0.234
DGX-2018-Q2-2018-07-24,127,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,So there's an awful lot of work going to high-cost providers. Some of it's because they have significantly higher prices. So we've talked about hospitals and physician-owned laboratories but even some regional players. The other thing is that the payers are becoming increasingly aware that we don't all conduct ourselves in the same way. So price is one thing but the level of activity for a patient with for a patient with a given condition is also a driver. So you can have some labs that might have lower pricing with same pricing as we do but they're actually charging more because there's more activity for a given condition.,0.0746445,-0.604
DGX-2018-Q2-2018-07-24,128,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So really, the focus around what is the total cost per interaction with a patient in saving money on that by doing things medically appropriate at a good price. And to the extent that, that saves money for the system and overall stakeholder, some of that will come back to us. So there's incentives for us. A lot more detail will come down the road. We believe that, around the middle of next year or maybe a little ahead of that, United will talk about their preferred network and what some of the conditions are to be a preferred provider. But also some of the structures, including things that we are hopeful about including planned benefit design, where there is actually incentives for patients and others in the decision process financially to drive things towards that preferred network because that preferred network will be at the highest quality and the best value of any of the options within the network.",0.3127962,0.971
DGX-2018-Q2-2018-07-24,129,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So that's about what we can share right now. And we're very excited about it because that is different from, historically, where we would get a network and to a large extent, it would be kind of good luck, I hope you do well because you have great value. In this case, United and certainly we're talking with other payers about some of the relationships actually is going to be partnering with us, working to drive that, not just sitting on the sidelines and opening we do all of that on our own.",0.6595577,0.976
DGX-2018-Q2-2018-07-24,131,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, first of all, Safeway continues to go very well. We've said that we're approaching 200 stores. The results in those stores have been great. So we're very encouraged there. Second is we continue to build out the presence in Walmart. And the number will be a significantly higher than 12 stores, I can assure you of that. And yes, it's putting a draw stations in, but it's also providing better healthcare, more healthcare services, with what we call extended healthcare services.",0.12257,0.908
DGX-2018-Q2-2018-07-24,132,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The conversation has become very broad and deep. Matter of fact, today, I'm meeting with a very Senior Executive from Walmart about that about that opportunity. Our JV and specifically Walmart is doing in the healthcare. So we continue to build that out. And then third is we are testing. We're doing some pilots with some other retailers. As we mentioned in the past, we've done work with CBS in the Mediclinic's with their pending potential merger with Aetna. We have great relationship with Aetna, we have a great relationship with CBS. The opportunity that they see also is what we've been talking about here. So we're optimistic of working more productivity potentially with CBS and Aetna as they expand the potential merger with those two companies as well. So a lot in front of us. We have the right strategy, we're executing it and we're making a lot of progress.",0.1116969,0.971
DGX-2018-Q2-2018-07-24,136,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, we think - if you take a step back and look at where we're going. Our access with United would be greater than 90%. So we ought to remove the obstacles of not being in network with many of the majority health plans throughout the United States. And in the big states, as we mentioned, when we announced united relationship, the big states of New York, Texas, Florida and California, our access is greater than 95%, so a very strong access. So when we have access, we have an opportunity to compete for laboratory services and accounts. So that's number one. So great access, it's improving every day.",0.83229,0.978
DGX-2018-Q2-2018-07-24,137,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is the consumer is becoming increasingly important, particularly as employers have pushed more of the cost in healthcare to consumers. Consumers, patients are asking questions of what they could do to lower their out-of-pocket cost and also serve themselves in a better way. And so our consumer strategy addresses that, that is making sure that we have a great experience for that patient and the consumer. So many aspects are factored into that. One is what we've done with our electronic, our e-tools, we call it MyQuest. We not only have over 5 million registered users, the application continues to get stronger every day.",0.2728171,0.889
DGX-2018-Q2-2018-07-24,138,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","You now can get to lab results, you can schedule an appointment. You could see late times in a Patient Service Center throughout any area you're in and there will be more to come. So that's exciting, looking more and more like a contemporary consumer application every day. Second, our access gets better and better. We're refreshing over Patient Service Centers. You will see that if you go into a number of your Patient Service Center throughout the United States and then we augment that with the access through retailers, so we'll have more retail-like settings, making it much more physically easy for consumers to go to Quest Diagnostics.",0.1713344,0.956
DGX-2018-Q2-2018-07-24,139,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Third is we'll have products. And we have taken our experience in Arizona and also in Colorado, in Missouri with the direct-to-consumer offering. We now believe that's close to 20 states that we can go direct to consumers. We're working on driving that solution there'll be more to come in that regard in the fall. And with all that, when you take a step back and you say when the physician eventually knows that we're on network and they ask their patient, who would you like to go to, Quest or someone else? They remember that great experience. We have experiences as far as their data.",0.0691928,0.836
DGX-2018-Q2-2018-07-24,140,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And they also know that it's not ordered by the physicians, they can order product directly from us like a check up on their cholesterol or their diabetes and hemoglobin A1c. So we think directionally, it's going to help us gaining share in the marketplace because healthcare is becoming increasingly more of a consumer marketplace.",0.0128501,0.848
DGX-2018-Q2-2018-07-24,144,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, really not anything substantive. I mean, those businesses are within the same that cover the overall revenue per req.",0.1990521,0.402
DGX-2018-Q2-2018-07-24,146,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, the one difference is obviously, when you get denials that's going to have a negative impact. So when you don't and the tests aren't ordered like in a hep C case, then it kind of has a neutral impact. But certainly, when we do work and then get denied, obviously, that's a headwind to revenue per req.",0.2045814,-0.128
DGX-2018-Q2-2018-07-24,151,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, the first catalyst is PAMA, okay? So PAMA is a substantial change for hospitals renting outreach businesses. So in many hospital system outreach businesses, their Medicare mix is 25%, 30%, so not insignificant. And when they're looking at essentially a 30% cut over three years, it's a notable difference. That's number one.",0.0293245,0.783
DGX-2018-Q2-2018-07-24,152,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is they are seeing what's happening with United and also with Aetna. And they there are hearing that what those two large nationals have done will carry over to the rest of the health insurance market place. So they're realizing there will be pressure on their commercial race going forward for ancillary services and in this case, laboratory services. So with all that, so long as - we've already - we've always had great access around this - talking to them around their last strategy, but it is accelerating the pace of them considering their options going forward.",0.1802306,0.431
DGX-2018-Q2-2018-07-24,156,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So first of all, we're actively detailing out account by account what we need to do. The way we broadly think about is in three categories. One, we have great accounts. And account - a client might be using an old laboratory that they have to, because we work with the United, and we're going directly for those accounts and we'll try to flip those as quickly as possible. So as I said earlier, we've left the blocks and we're running. And we're detailing our thousands of accounts throughout United States with our sales force and with our regional teams.",0.0270181,0.915
DGX-2018-Q2-2018-07-24,157,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Number two, there is accounts kind of a mixed model where they're using multiple labs. And now where we have much more of significant share of their laboratory volume because we're back in network, it's an opportunity where they potentially get to a tipping point, and we potentially could become the majority of their lab service providers. So we have a number of accounts that the categories that way.",0.1789127,0.802
DGX-2018-Q2-2018-07-24,158,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the third category as we've outlined is, in some cases, we are not the majority in our another national competitor has more share. And we're also detailing out those to make sure we defend what we deliver, our value that we deliver everyday is quite good, our quality gets better, our service performance is outstanding, our consumer strategy is resonating. And so we think we have a very, very strong requisition - value proposition to defend that piece of our marketplace as well.",0.1588138,0.974
DGX-2018-Q2-2018-07-24,166,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So Ann, the denials are not increasing our DSOs. The denials we don't recognize revenue. So what's really driving it is handful of things, one of them is we're doing a significant laboratory conversion in one of our major labs and billing just ends up being a little more delayed. It's a rhythm of things that we've done over time. It's nothing to be concerned about. In fact, if you look at the aging of the DSOs, the profile has not really changed. So if you look at the key metric and what proportion of our DSOs are over 90 days, it hasn't changed even though the DSOs have gone up. So this is just a temporary spike and something that we're not concerned at all about and very confident that we're going to hit our $1.3 billion operating cash flow guidance that we provided.",0.4628752,0.725
DGX-2018-Q2-2018-07-24,168,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So our organic growth will markedly improve. We walked through the drivers. Obviously, it's an easier compare so that's part of it. We just to remind everybody about that, the majority of that compares in Q3, but we had a little bit of impact in Q4.",0.2942338,0.583
DGX-2018-Q2-2018-07-24,169,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So each of the quarters are going to get some lift from that. We mentioned, both Steve and I, that we have some professional laboratory services deals that we feel are very close. That's organic. And we're expecting to get some volume for that in the back of the year, with that accelerating sequentially. And then the actions that we talked about that we've taken around prescription drug monitoring and vitamin D denials, where we've gotten some of those addressed, and we're optimistic that a couple others are in the cusp that they will help as well.",0.1702212,0.807
DGX-2018-Q2-2018-07-24,170,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then of course, as we near the entry to the United contract, we would expect that some of that volume will flip over a little bit early. So when you put all of those pieces together, that's why we're highly confident. So we're not depending on executed M&A but obviously, to the extent that we do some deals between now and the end of the year that would just be additional upside.",0.5481833,0.485
DGX-2018-Q2-2018-07-24,172,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"No. It's not a huge percent. It's a small percentage. But every several million dollars makes a difference in quarterly performance. I think a lot of that is behind us, because we're not experts, but we believe that AbbVie has more than half the market already. And therefore, a lot of that is already behind us.",0.5308057,-0.269
DGX-2018-Q2-2018-07-24,173,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the other part is - there's two parts to what we call a hep C care, which is the testing we do if you've been prescribed the drug that is going to decline. Second part is the screening piece of this. So we did see a small decline in the growth rate, and we're hopeful there's still a tremendous opportunity in front of us that we're going to work with the pharmaceutical companies to continue to build on the awareness necessary in the marketplace. Because as I said in my prepared remarks, there's still a majority of baby boomers, 70 million of us, that still need to be screened. So that's slow as well in Q2. And we're hopeful in the back half with some of the work we're doing to build awareness with pharma, that should pick up as well.",0.3710049,0.96
DGX-2018-Q2-2018-07-24,174,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"But just to be clear, it' still growing, it just didn't grow as fast.",0.2954186,0.511
DGX-2018-Q2-2018-07-24,179,Question,2018-07-24,2,2018,Ralph Giacobbe,Credit Suisse,"Thanks. Good morning. Hopped on a little bit late, so I'm not sure if you gave this, but do you have a baseline of how much drug monitoring, hep C and vitamin D all in makeup of total requisitions? Just a rough ballpark?",0.7017417,0.665
DGX-2018-Q2-2018-07-24,180,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Ralph, we haven't provided that. We have other franchises, other testing segments that are obviously a lot larger. Certainly, our chemistry panels and our lipid panels and so on. I think these are already - obviously areas, not Vitamin D as much, but the Hep C and prescription monitoring are major growth drivers for us. And prescription drug monitoring, as Steve mentioned and I did as well, continues to be a growth driver. It's just slowed somewhat because of these policy changes that we, again, feel are inappropriate.",0.3242496,0.866
DGX-2018-Q2-2018-07-24,181,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"It really has to do everything with - around covering definitive testing after screening. The traditional practice has been, if you do a screen and it's positive, you move automatically or revert to the definitive on the same day with the same sample. And some of the payers for reasons that we are pushing back on deciding they would change that and make the patient come back in for a second trial. We don't think that's medically appropriate.",0.1591627,0.557
DGX-2018-Q2-2018-07-24,182,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So that was a big headwind in PDM why we slowed our growth. And then on hep C, certainly, we expect that to continue to grow. It's a nice business, but certainly, it's nowhere near some of the routine testing or other requisition volume that we see within our business.",0.3672986,0.758
DGX-2018-Q2-2018-07-24,183,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So what we did is we outlined three areas that caused us to have less than what we had expected in Q2. We started working already on Q2 on some of the remedies for that slow down. And so the ones that we outlined particularly around prescription drug monitoring, the growth rate was strong but not nearly as strong in the past, and again, what we talked about with Vitamin D.",0.3034596,0.901
DGX-2018-Q2-2018-07-24,184,Answer,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we've already started to work on these in Q2 that will carry over and will have some rebound in the portion of this. But what we want to do is provide visibility where we thought we were going to do - have a stronger performance in Q2, we did not. And we outlined those in the three that we provided to you.",0.2596376,0.44
DGX-2018-Q2-2018-07-24,185,Question,2018-07-24,2,2018,Ralph Giacobbe,Credit Suisse,"Okay. And is there anything separately - is there anything with the timing of the UNH contract we need to be aware of? In other words, I know the contract starts Jan 1, 2019. So you remain out-of-network for this year with UNH and sort of still charge the out-of-network rate or have you agreed to sort of annual network rate sooner even without the open network?",0.046807,0.52
DGX-2018-Q2-2018-07-24,186,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So I'm not going to comment on any specifics around rates, but we remain out-of-network, we've been adjudicated out-of-network for the balance of the year. And then as we said, starting January 1, we'll be in for majority of their plans, there's still some HMO plans that we are working for the details. But for the vast majority of United, we're going to be in network as of January 1.",0.0173776,0.676
DGX-2018-Q2-2018-07-24,187,Question,2018-07-24,2,2018,Ralph Giacobbe,Credit Suisse,"Okay. Last one if I could squeeze it in. Just - and I know you're going to guide for 2019 at this point, but can you give us a directional sense of margin as we think about next year? There's a lot of moving parts, obviously, with PAMA headwinds, UNH coming on, Aetna opening up, the investments you're making. In your mind, does that mean that make there's sort of a revenue boost and we should think about margins as generally flat? Or do you think you can get margin expansion or vice versa? Do you think there could be some margin contraction as we think just directionally of the margin trend for 2019?",0.4212627,0.673
DGX-2018-Q2-2018-07-24,188,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So Ralph, as I am sure you would expect, I can't comment on 2019 in any way specifically. But what I did talk about was on a multi-year basis that we would grow earnings, not earnings per share, but earnings faster than the top line over multi-year. So certainly, from a given year-to-year, that formula might be a little bit different. So we - that obviously implies continued margin expansion.",0.2049763,0.778
DGX-2018-Q2-2018-07-24,189,Answer,2018-07-24,2,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now margin - net margin, so obviously with tax reform, we took advantage of that and made some investments, which actually reduced our - before tax margin slightly this year, had some impact on that. But we would expect to continue that over multi-year look, and we'll give an update on that in November on our Investor Day.",0.0015798,0.25
DGX-2018-Q2-2018-07-24,191,Question,2018-07-24,2,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. Well, thanks for joining us today. We appreciate your support, and have a great day.",0.1650741,0.937
DGX-2017-Q2-2017-07-25,3,Remarks,2017-07-25,2,2017,Shawn Bevec,Executive Director-Investor Relations,"Thank you and good morning. I am here with Steve Rusckowski, our Chairman, President and Chief Executive Officer, and Mark Guinan, our Chief Financial Officer.",1.5474993,0.66
DGX-2017-Q2-2017-07-25,4,Remarks,2017-07-25,2,2017,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and also discuss non-GAAP measures. For this call, references to reported EPS refers to reported diluted EPS and references to adjusted EPS refers to adjusted diluted EPS excluding amortization. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K, and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K. The text of our prepared remarks will be available later today in the Investor Relations page of our Web-site.",0.5141572,0.34
DGX-2017-Q2-2017-07-25,6,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. This morning I'll provide you with the highlights of the quarter and review progress on our strategy. Then Mark will provide more detail on the results and take you through updates to our 2017 guidance.",0.8507414,0.823
DGX-2017-Q2-2017-07-25,7,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We turned in another strong quarter and are delivering on all five elements of our strategy to accelerate growth. Here are some highlights. Revenues grew approximately 2% on a reported basis and 2.3% on an equivalent basis. Reported EPS of $1.37 was flat from 2016, and adjusted EPS grew approximately 16% to $1.55, which includes an increase of $0.08 over the prior year of excess tax benefit associated with stock-based compensation. Based upon our progress in the first half, we have raised our outlook for revenues, EPS, and cash from operations for the full year 2017.",1.1990115,0.919
DGX-2017-Q2-2017-07-25,8,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before I describe the progress we've made to accelerate growth and drive operational excellence, what I'd like to do is briefly discuss PAMA. This month, a number of ACLA Board members met with the executive branch as well as key members of the Senate Finance Committee, that means energy and commerce held subcommittees, reiterating our belief that the current regulation effectively excludes hospital outreach labs, which are a significant segment of the laboratory marketplace.",0.7360791,0.965
DGX-2017-Q2-2017-07-25,9,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Last month our trade associations sent a letter to CMS recommending postponing the calculation of publication of the new clinical and fee schedule redefining the definition of then applicable laboratory to ensure in a good hospital outreach laboratories and upon gathering data from hospital outreach laboratories publishing new clinical and fee schedule rates effective not earlier than July 1, 2018. While we support reform of the Medicare payment system, we believe any modification should be market based and appropriately include all applicable independent and hospital outreach laboratories.",1.121911,0.934
DGX-2017-Q2-2017-07-25,10,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","At this point, we have made a strong case to CMS and Congress. While we continue to believe that CMS has not carried out the congressional intent of PAMA, we recognize that a new clinical and fee schedule could be in place by January of 2018 and we will be prepared.",1.2912685,0.637
DGX-2017-Q2-2017-07-25,11,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now let's review progress we've made executing our two-point strategy to accelerate growth and drive operational excellence. In the second quarter, we delivered on all five elements of our strategy to accelerate growth. The first element of our growth strategy is to grow 1% to 2% through strategically aligned accretive acquisitions, which we expect to achieve for the fifth consecutive year. We built out our leadership position in advanced diagnostics with our recently completed acquisition of Med Fusion and Clear Point.",1.0866557,0.954
DGX-2017-Q2-2017-07-25,12,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Under the second element of our growth strategy, we continue to expand relationships with hospital health systems. On May 1, we completed our acquisition of the outreach operations at PeaceHealth Laboratories and began managing 11 PeaceHealth Laboratories serving medical centers in three states in the Pacific Northwest. We began to recognize revenues from this acquisition in the POS agreement in the second quarter. Our existing professional lab services relationships with hospital systems such as RWJBarnabas, HCA, Montefiore, also continue to perform well and drive revenue growth.",1.0853377,0.917
DGX-2017-Q2-2017-07-25,13,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The third element of our growth strategy is to offer the broadest access to diagnostic innovation. Our acquisition of Med Fusion and Clear Point will not only accelerate Quest growth in U.S. oncology diagnostics but also host the promise of improving cancer care. Quest will become the preferred provider of the U.S. oncology diagnostics for the U.S. oncology network consisting of more than 1,400 independent community-based physicians. In addition, Quest will be a preferred provider of a full range of in-patient and out-patient diagnostic services for 12 hospitals of Baylor Scott & White Health in North Texas.",1.1555189,0.842
DGX-2017-Q2-2017-07-25,14,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Advanced diagnostics, including genetic and molecular-based tests as well as general diagnostics, grew in the quarter. Drivers of advanced diagnostics growth include Q-Natal, which is our offering for non-invasive prenatal screening, core infectious disease testing and Quantiferon TB testing were part of the growth. Within general diagnostics, prescription drug monitoring and Hepatitis C screening continued strong double-digit growth.",1.2405272,0.935
DGX-2017-Q2-2017-07-25,15,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We recently expanded our tumor profile offer through IBM Watson Genomics for Quest Diagnostics to include a 50 gene panel. With this enhanced insight, doctors can take more informed actions for treatment and feel more certain about the best path forward. Finally, last week we launched QHerit, a new genetic screening service that provides women and men with insight into genetic risk of passing on heritable disorders on to their offsprings.",1.1581549,0.526
DGX-2017-Q2-2017-07-25,16,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also made significant progress executing the fourth element of our growth strategy, which is to be the provider of choice for consumers. Our relationship with Safeway continues to expand as we are now operating in over 100 stores. We still have clear line of sight to be operating in 200 stores and now expect to reach that number by mid-2018. Patient satisfaction and convenient scores are above 90% for our Safeway locations and feedback from these sites remains overwhelmingly positive.",0.9331137,0.948
DGX-2017-Q2-2017-07-25,17,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We can't say it any better than two recent feedbacks we have received from our customers on our Safeway locations. One from a network member from Alexandria, Virginia recently wrote, 'I really like the location of this Quest center at Safeway, it saves me time, grocery shopping, pharmacy, plus blood test, all in the same location.' And my personal favorite is one from Longmont, Colorado where a customer goes on to say, 'the best blood draw I've ever had, you rock.'",0.8586491,0.917
DGX-2017-Q2-2017-07-25,18,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now this is an exciting era of the empowered healthcare consumer. More and more people are taking control of their health and asking to receive their lab results in the palm of their hand. More than 4 million patients are receiving their lab results through our MyQuest mobile application, and we are on track to reach 5 million users by the end of 2017.",1.647117,0.758
DGX-2017-Q2-2017-07-25,19,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, in late June we announced our collaboration with Walmart to help improve access to care and over time help lower healthcare cost of providing basic health care services. The collaboration will initially launch at approximately 15 Walmart stores in Florida and Texas by the end of 2017. These cobranded sites will initially provide laboratory testing services and over time offers are expected to expand to include other basic healthcare services. In the future, these services will help us deliver on the fifth element of our growth strategy, which is to support population health with data analytics and extended care services.",0.8810544,0.975
DGX-2017-Q2-2017-07-25,20,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to the second part of our two-point strategy to drive operational excellence, we remain on track to deliver $1.3 billion in invigorate run-rate savings as we exit 2017. As we indicated at our Investor Day last fall, we also believe we will be able to generate additional savings beyond 2017.",1.1565074,0.791
DGX-2017-Q2-2017-07-25,21,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As we drive operational efficiency, we continue to improve the customer experience. We are e-enabling our processes behind the scenes as well as in our patient service centers. More than 600 patient services are now live with e-check-in. We plan to deliver this digital experience to over 1,000 patient service centers by the end of this year. At these locations, patients use a tablet to sign in for their appointment, and are provided with an estimated wait time. They know they are in the system and when they will be seen. So that's good for patients, it's good for us too. On the back end of this system, data provides us real-time insight into patients' flow, enabling us to direct phlebotomists to the locations where they are needed most. Since we introduced this service earlier this year, more than 7 million people have utilized this service to date.",1.5156507,0.916
DGX-2017-Q2-2017-07-25,22,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally, 2017 is our 50th anniversary of empowering better health with diagnostic insights. We've had numerous events around the Company to mark the occasion, and our employees have enjoyed engaging with former leaders and learning more about our history. We are proud of our 50 year legacy and look forward to promoting a healthy world, building value, and creating an inspiring workplace over the next fifty years.",0.4952224,0.969
DGX-2017-Q2-2017-07-25,23,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So now, I'd like to turn it over to Mark and he will take us through our financial performance in more detail. Mark?",0.0962109,0.414
DGX-2017-Q2-2017-07-25,24,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. Starting with revenues, consolidated revenues of $1.94 billion were up 1.9% versus the prior year on a reported basis, while equivalent revenues grew 2.3%. Revenues for Diagnostic Information Services grew by 2.5% compared to the prior year, with approximately 40 basis points attributed to the PeaceHealth outreach acquisition which was completed in May.",1.3811216,0.612
DGX-2017-Q2-2017-07-25,25,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Volume, measured by the number of requisitions, increased 1.8% versus the prior year, of which 1.4% was organic. Revenue per requisition in the second quarter grew by 70 basis points versus the prior year. As a reminder, revenue-per-req is not a proxy for price. It includes a number of variables such as unit price variation, test mix and test per req.",1.0600316,0.402
DGX-2017-Q2-2017-07-25,26,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Unit price headwinds in the second quarter were less than 100 basis points. While price fluctuations can vary from quarter-to-quarter, we continue to expect that unit price headwinds will remain moderate in 2017 and consistent with the last few years. Beyond unit price and the impact of growth in our POS partnerships, other mix elements including test mix contributed between 100 to 200 basis points, which is consistent with the trends we've observed for several quarters.",0.8546603,0.382
DGX-2017-Q2-2017-07-25,27,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income for the quarter was $319 million or 16.4% of revenues, compared to $422 million or 22.1% of revenues a year ago. Keep in mind, our reported operating income in 2016 included a one-time gain related to the divestiture of our Focus Products business. On an adjusted basis, operating income was $343 million or 17.6% of revenues, compared to $324 million or 17% of revenues last year. Our Focus Diagnostics Products business contributed approximately $4 million of adjusted operating income in the second quarter of 2016, which adversely impacted the growth in our operating income year-over-year by approximately 1% point. Excluding the impact to Focus Diagnostics, operating income grew approximately 7%.",0.8704581,0.637
DGX-2017-Q2-2017-07-25,28,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $1.37 in the quarter, flat with the prior year period. As noted previously, our second quarter 2016 results included a large one-time gain associated with the Focus divestiture. Adjusted EPS was $1.55, up 16% from $1.34 last year. The Company recorded after tax net charges totaling $11 million in the second quarter or $0.08 per diluted share, representing restructuring, integration and other one-time costs, partially offset by gain on the sale of an equity interest.",0.6469194,0.872
DGX-2017-Q2-2017-07-25,29,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our effective tax rate in the quarter was approximately 32%, compared to approximately 48% in the prior year. The prior year tax rate was unusually high as a result of the Focus divestiture. The decrease in the effective tax rate was also driven by $13 million or $0.10 per diluted share in the quarter of excess tax benefit associated with the stock-based compensation, compared to a $2 million or $0.02 per share benefit last year. The benefit was almost entirely related to the exercise of stocks options which is impossible to forecast.",1.4514218,0.956
DGX-2017-Q2-2017-07-25,30,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Bad debt expense as a percentage of revenues was 4.2%, flat year-over-year and 20 basis points lower versus the prior quarter. For the first half of 2017, cash provided by operations was $490 million versus $464 million last year. Capital expenditures year-to-date were $107 million, compared to $104 million a year ago.",0.8183254,-0.848
DGX-2017-Q2-2017-07-25,31,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Before turning to guidance, I'd like to remind you that we now have annualized all of our portfolio changes as part of our efforts to refocus the business on Diagnostic Information Services. Therefore, the quarterly year-over-year comparison will no longer refer to equivalent growth, but the year-to-date comparisons will refer to equivalent growth for the remainder of 2017.",0.6587678,0.654
DGX-2017-Q2-2017-07-25,32,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"With that said, we are providing the following updated outlook for 2017. Revenue is now expected to be between $7.69 billion and $7.74 billion, an increase of 2.3% to 3.1% versus the prior year on a reported basis and an increase of 2.6% to 3.4% on an equivalent basis. Reported diluted EPS to be between $4.90 and $5 and adjusted EPS to be between $5.62 and $5.72. Cash provided by operations is now expected to be approximately $1.2 billion. And finally, capital expenditures remain between $250 million and $300 million.",0.7417062,0.557
DGX-2017-Q2-2017-07-25,33,Remarks,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our increased revenue, EPS, and cash from operations outlook is based on first half performance and reflects the completion of two previously announced acquisitions, including the PeaceHealth outreach deal in May as well as the Med Fusion and Clear Point labs which closed last week. In addition to our first half performance, our raised EPS outlook reflects the higher than expected level of excess tax benefit associated with stock-based compensation.",0.9885466,0.872
DGX-2017-Q2-2017-07-25,35,Remarks,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Mark. We turned in another strong quarter and are delivering on all five elements of our strategy to accelerate growth. Based on our progress in the first half, we have raised our outlook and are well positioned to meet our expectations. So with that, we'd be happy to take your questions. Operator?",1.1281713,0.947
DGX-2017-Q2-2017-07-25,38,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First of all, as we said in the past, we look at a lot of different external measures. Then we do an internal measure where we look at our same account measurement where we do a measurement where we know we have a good account and we look at year-on-year comparison of volumes. And what we've said in the past remains this quarter, we think the underlying volume in the market is stable, is the best way to summarize it.",0.4988468,0.852
DGX-2017-Q2-2017-07-25,39,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then to your second point about volume in the quarter, as you know we don't guide on volumes, we do guide on revenues and it's important that we continue to drive revenue growth, it's what we are entirely focused on. So I'll turn it over to Mark to provide a little bit of color around what's in the mix. Mark?",1.3462932,0.743
DGX-2017-Q2-2017-07-25,40,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So Amanda, as Steve said, I think we test in our imperfect fashion through the tools we have but the market is pretty stable. We haven't seen significant utilization declines and we certainly have not seem anything significant in terms of [indiscernible]. So, we are pleased with our volume, our advanced diagnostics, as Steve mentioned in his prepared remarks. Certainly volumes, and importantly revenues, wer4e up strong, our general diagnostics was solid, and then certainly POS is giving us some lift.",1.2424961,0.99
DGX-2017-Q2-2017-07-25,42,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I appreciate that. As we've talked about and raised the case, when we engage with a healthcare system integrated delivery network, we talk about three things. First of all, what we can do to help them with their in-patient laboratory, and that's what we refer to as professional laboratory services engagement. The second part of this is the inside diagnostics that I referenced, testing, and we believe we could be very effective provider of more and also help them with what they do, so a significant part of the discussion. And then the third case is that we are in that discussion to decide what their strategy is from hospital outreach, and [indiscernible] is a good example of that where we bought their operating [indiscernible], we're helping them with 11 of their hospital in-patient laboratories. And to your specific question, in that relationship we are also helping them with the reference work as well. So, in all these engagements, we typically become a stronger presence in that account for reference work.",1.0948929,0.983
DGX-2017-Q2-2017-07-25,45,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks for asking. We are quite excited about it as well. There are a lot of different reasons. That goes down there last week, we had our date one [indiscernible] with a town hall meeting and spent some time with the management team. So this acquisition actually kicks four elements of our accelerated growth strategy. First of all, obviously it's part of our growth through acquisition, so that's good news. Second is in terms of innovation, it brings to us a nice [indiscernible] up our portfolio around what we could do around oncology and precision medicine, so we are encouraged about that. Third is to your point, it brought it to present in the second largest state in the country, Texas, where we already have a strong presence. And then with this, it's all about providing better health care at better cost levels, and we think with some of the work they've done in the engagement for instance with U.S. Oncology, we can help with the data and understanding what we would do to form better cancer care, so four elements of our strategy. So we are encouraged by that.",1.2326194,0.992
DGX-2017-Q2-2017-07-25,46,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the relationship in Texas is strong, and so we are deeply engaged how we continue on what they built with that engagement and continue to grow from that given our broader presence now with us at Quest Diagnostics. So we're excited about it and we think it's a great acquisition as well. So thanks for the question.",1.1607908,0.966
DGX-2017-Q2-2017-07-25,48,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Absolutely. So first of all , we study with two of the largest states, Texas and Florida. We also have a strong presence in Florida, so two nice states, second and third largest state now in the country for us to make progress in the large states. Yes, we will look at some of their sectors for our patient service centers, but as importantly, what I said in my introductory remarks is, we are actually going to use this strong metric to provide some of the basic healthcare services that help with what we could do with population [indiscernible] to cost curve. So what are some of those things?",0.9439868,0.951
DGX-2017-Q2-2017-07-25,49,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now can we help with people dealing with hypertension and do blood pressure checks, can we make sure that people are staying out their [indiscernible] beyond a diuretic suffering, congested heart failure, that we help you with that by periodically taking your weight, making sure you stay in your diuretic staying range.",1.1607908,0.103
DGX-2017-Q2-2017-07-25,50,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We can also help with diabetes management. We're also working with some of the healthcare insurance companies where we could close gaps in care to help them with their quality scores so they get reimbursed by the healthcare that we all know is the best healthcare.,1.1627677,0.915
DGX-2017-Q2-2017-07-25,51,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So those are the basic healthcare services, and fortunately at Quest, we have the world's largest laboratory, so we'll be, absent for the last five years, we are in the field of diagnostic information services. We have over 20,000 health care workers, 10,000 [indiscernible] with 10,000 other health care workers that provide services already for wellness services from Florida that help insurance companies. We are also providing health checks for life insurance pre-qualification physicals and checks. So, we are leveraging those resources and its relationship as well. So, we are excited about it. We think it's a great opportunity for us to just expand our already unsurpassed access to the marketplace, but also engage with the ecosystem healthcare with some of these basic customer services that can in our mind really help them to cost curve for healthcare in populations that are difficult to get access to.",1.2695222,0.942
DGX-2017-Q2-2017-07-25,54,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So the current schedule as you know, we submitted the data already. That was delayed by two months because their portal was not available and so we recognized they'd listen to us and postpone it. We have put it in our data. Those people that are submitting the data have done that by the end of May. The current schedule thereon is to publish tentative rates in September, so the schedule that they currently have published.",0.8355848,-0.422
DGX-2017-Q2-2017-07-25,55,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","However, we have shared with them that we believe that several things are going on with the data they had collected. One is they haven't included all the data from those laboratories that they are buying from, typically hospital outreach. We believe their approach still limits the size of the sample, and we shared that. And also this has been reinforced by the officer and Inspector General that [indiscernible] that only 5% of the laboratories are being asked to submit data will submit data, which is about 69% of what they actually buy from.",1.0866557,0.71
DGX-2017-Q2-2017-07-25,56,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second is what we have heard from some of the smaller laboratory association that affect some of the data input. So we have shared this with them because some of the smaller laboratories did not have good access to retrospective data. And while our concern is that they use that data for the basis of publishing at tentative [indiscernible] fee schedule in the fall, it won't be right. So our strong recommendation to them, and we have got word from Congress broadly, many different leaders of Congress as well as the center [indiscernible], we believe the best thing for us all is to take some time to get it right. So our recommendation is to postpone it.",0.6243822,0.85
DGX-2017-Q2-2017-07-25,57,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We have made a recommendation of how we believe they could collect the data. That will take some time. We think if they work in that aggressively, they possibly could publish the due clinical and fee schedule no earlier than July of 2018. So that's the path we are on, but the current schedule we have is that they are going to extend the schedule to get out some rates in the fall with the refresh clinical and fee schedule in the first of next year, and as we said in our introductory remarks, we are prepared for that but working hard because we believe it does not reflect the impression or intent to get a full sampling of the marketplace and get that data in a good form and get good quality data to establish a rate for itself. So we are pushing that in a big way across the trade association.",0.6896211,0.805
DGX-2017-Q2-2017-07-25,58,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I think the key is there still remains a lot of uncertainty around PAMA. I'm sure you drew that from Steve's comments. And fortunately, we don't have the data to determine what the projected outcome will be, whether it's the timing or the impact. I do think it's good to go back to the final rule periodically and just remind everybody that the methodology is that CPT code by CPT code calculation, and so weighted median based on the data that they have collected compared to the rates that they are currently paying, and that any CPT code can be cut as much as 10% per year for the first three years and then beyond that for 2021 to 2023 the final rule dictates that any CPT code could be changed by as much as 15%. So that is the final rule in terms of the application of the rule and the outcome. I'm sure as you drew, there's still a lot to be answered.",1.0264613,0.459
DGX-2017-Q2-2017-07-25,61,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to be excited about the prospect here. And again, to start at the highest level of possible systems, and I have shared in the past their lab strategies are on the shortlist of strategic things they are talking about. And so they welcome meetings with us to help them think through this. And in that context, a big part of this is how we can help them become more efficient with their hospital in-patient laboratory, and it is that spectrum. The broadest capability is we help them manage it, the leverage of our procurement. They also learn from our best practices of running the world's largest laboratory.",1.0853377,0.974
DGX-2017-Q2-2017-07-25,62,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And to answer your question about across that spectrum, where is that set, I would say it's equally distributed across the lowest level of involvement, the most no predominant necessarily of one end of that spectrum. But to your last question, once we get in the account and we begin to develop the relationship, we do see increased levels of engagement by the customer with us and we do broaden our services broadly and we do spend more time on what we'd do to help with them their reference work, and then also in that context, we do continue the conversation about their outreach strategy if they are in the outreach business.",0.814168,0.71
DGX-2017-Q2-2017-07-25,63,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the way we see it is we start with an engagement but that's just the beginning of engagement. And then we also use this as a discussion broadly of what we could do for them in terms of what their mission is and their strategy, which gets us into discussion about population health and what we could do in data analytics. We've got a lot of capabilities there, we have talked about that in the past, we've seen a nice value-added. These new extended care services are of great interest, particularly those integrated delivery system, that are taking on risk [indiscernible] they are quite interested and probably can leverage these access points for putting in place with our two [indiscernible] with Walmart is one example.",1.5364086,0.98
DGX-2017-Q2-2017-07-25,64,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, this strategy is really a strategy of how we serve possible systems in a bigger way, and one aspect of what we could do with them is around their professional answers is engagement in their in-patient laboratory, but it's much broader than that.",1.6688633,0.25
DGX-2017-Q2-2017-07-25,65,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And I would just add, Don, you asked about the revenues and as you implied, directionally, the deeper the relationship, the higher the revenues before actually on-site running their in-hospital laboratory and having those employees work less than we have to build that out for them. So that would be a higher revenue type arrangement. But I'm sure as you can imagine, there's not a lot of margin in that stop. So a greater part of the margin is really driven around rationalized and test menu, moving a subset of that off-site where we can drive not only better costs but shorter cycle time because we are running those tests every day. That's one of the [indiscernible] when we have a POS type arrangement, it's not just about cost, and that's where preponderance of the revenue and the margin comes. It's really just driven by I'd say hospital preference. As you have heard Steve say in the past, we have seen one hospital, lab strategy we have seen one. It's really nothing endemic to the particular hospital structure that dictates the POS arrangements. It's really just our comfort level.",1.4079779,0.598
DGX-2017-Q2-2017-07-25,68,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now what we talked about five years ago just for the world's largest laboratory, but the business that we want to focus on is Diagnostic Information Services. And so, the information and the services portion of our portfolio is the big portion of what we've really put our shoulder into over the last several years, and you are seeing some of the contributions in the way of business in the last few years. So let me just walk through what that means and where do we see this going.",1.0408567,0.115
DGX-2017-Q2-2017-07-25,69,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So in that strategy, we believe that hospital systems were becoming stronger. We knew that hospitals were acquiring physician practices. And therefore it was quite important for us rather than thinking about the hospitals as primarily a competitor, we thought [indiscernible] partner with them with their lab strategy, and that has worked well. They are all over trying to become more efficient. They are trying to understand how they can provide better patient care. And then finally, they are realizing that being in the outreach business is not necessarily something that they all want to focus on and therefore they can team up with us and we're a good provider of that. So it's a nice service [indiscernible].",0.9509061,0.97
DGX-2017-Q2-2017-07-25,70,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then as we get in, similar to what I said to Donald in the last question, it's all about their strategy and their strategy is to be a broader provider of integrated health services within a geography, and we could help them with that. So we have brought out a broad line of information products. We launched this a couple of years ago with the [indiscernible], we call it Quanum. And in that portfolio of products, we offer capabilities to take a look at your utilization for diagnostics, allows the data to be put on the table to ask questions about are we doing a proper work-up to make sure we have an informed decision that happens, that [indiscernible] what happens next in healthcare, which is an important part of delivering good health care at lower cost.",1.0467875,0.881
DGX-2017-Q2-2017-07-25,71,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is we also served up with a nice access to the workflow within the physicians workflow, the ability to look at all past data from our relationship with [indiscernible], and that data we think is valuable to get a full view of what happens to that patient. So those data analytic services I think are helpful. So that's the conversation we also get into.",0.6392092,0.875
DGX-2017-Q2-2017-07-25,72,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as we work on this discussion, they are all interested in how they retain their current patients and grow the patient population as well as their membership, and we all see that there is a sea change happening where the consumer is much more engaged and that's why we think it's very important for us and we put a lot of energy on broadening and expanding our brand and what we believe our brand stands for. As a matter of fact, we have talked about our brand and our tagline being action from inside. Our vision is to have better health with diagnostic insight, not just [indiscernible].",0.6705107,0.932
DGX-2017-Q2-2017-07-25,73,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So in that consumer strategy, which is part of our growth strategy, there's multiple aspects to that. One is the migrating access. So we believe our retail strategy helps us with that. We started with Safeway, we said we're going to do more, we recently announced our relationship with Walmart. So we think that's expanding our access.",1.3686985,0.637
DGX-2017-Q2-2017-07-25,74,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is to provide products that are consumer-oriented. We have talked in the past earnings call about what we're doing to be a provider of testing directly to consumers. We have launched a pilot, we're doing some of that in Arizona. We are now expanding that pilot of selling testing where states allow it to be done, to Missouri, to Colorado. We have a great business that's growing around wellness. We have a product coupled for wellness. We have expanded that to the field of sports where we have the sport diagnostic product. We have done the work with [indiscernible]. So there's a whole portfolio of more consumer-oriented products that we've rolled out as well.",0.8220758,0.934
DGX-2017-Q2-2017-07-25,75,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then we have also improved on the access and consumers remarkably want to have all their health information, and frankly we're quite surprised by the pickup of our MyQuest application, I mentioned in my introductory remarks over 4 million of people have registered with us. We believe we are tracking to be on track to get above 5 million users.",0.9268534,0.708
DGX-2017-Q2-2017-07-25,76,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, if you look at all those elements, we believe that this positions us nicely as that diagnostic information services company that's thought of when the consumer will have [indiscernible] the diagnostic testing, and over time we believe with better transparency, because we do offer we believe one of the strongest [indiscernible] proposition in the marketplace, the physician will ask the consumer which laboratory do you want to test and to go to and they will remember this great experience that they had at Quest Diagnostics. They will have information that's provided to them. They will have access to products and they will be able to easily access our capabilities, and so the choice will be given to us, and that's our strategy. We picked up the powerful element of our strategy and it's where healthcare is headed. Consumers will have more choice and consumers will direct more at healthcare.",1.0418451,0.959
DGX-2017-Q2-2017-07-25,77,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we are making a lot of progress, we're excited about it and we think that's going to help us with our core business today but over time it will become a larger piece of our portfolio over time that we really do direct healthcare in a better way where it is needed, which is not necessarily only in hospitals but throughout the health care system and communities that are touched not by traditional healthcare but other places like our retail strategy. So that's where we are going with it.",0.9439868,0.942
DGX-2017-Q2-2017-07-25,79,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So in terms of capital deployment, it's really dependent on whether we have strategically appropriate deals that create value for our shareholders. So really that will depend on our deal pipeline and what might come to closure. In terms of your expectations for share buybacks, we talked about keeping our way, so pretty flat to the extent that we wouldn't execute more M&A. You've seen more share buybacks but I think you shouldn't consider pretty much flat share count.",1.657188,0.938
DGX-2017-Q2-2017-07-25,80,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And certainly from a tax rate, as we mentioned it's impossible for me to predict option exercises. So outside of the stock base comp piece, you should expect the effective tax rate that's pretty much on the historical level that we've seen in the upper 30s as opposed to the rate we saw this quarter in the low 30s, really driven by the stock based comp.",1.7582938,0.765
DGX-2017-Q2-2017-07-25,81,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now if we were to have significant exercises in the quarter, that obviously could depress it, but that's why we've been very intentional in calling out what that impact is year-over-year so that you can understand that it's really not operational.",1.3898104,-0.178
DGX-2017-Q2-2017-07-25,84,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Part of our discussion with these hospital systems were on their lab strategy, they see pressure on rates broadly. They are feeling pressure from their commercial insurance relationships, but they also are looking forward and realizing that the clinical and fee schedule will be refreshed. And as we talked about in the past, they have more exposure than we do to that. Roughly 12% of our revenues is a much more meaningful percentage of their laboratory revenues. So, when we engage in these conversations, one aspect of their consideration of what they are going to run [indiscernible] is they are going to be under pressure both on the commercial side as well as on Medicare.",1.8873147,0.699
DGX-2017-Q2-2017-07-25,85,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But the other aspect as you know is related to what their strategy is, do we want to put more capital and increasing more complicated area, and in some cases they decide not to. Second is they realize that our scale is significant and as we move away from a fee-for-service model to a much more value based reimbursement model, it's still longer to be in activity, it's going to be making sure we have the best cost per service unit and our cost structure is far superior than any other cost structure.",0.9927512,0.93
DGX-2017-Q2-2017-07-25,86,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, in many of the cases we are engaged around this and in some cases where we have bought their [indiscernible] business, it's because they see reimbursement changing and they believe that they have to move to team up with someone like Quest that has a very efficient model delivering the necessary diagnostic services, so as part of that overall strategy for the integrated delivery system, a part of this is looking at pressure and range, but it's more comprehensive than that as well, Issac.",1.2827018,0.824
DGX-2017-Q2-2017-07-25,88,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so we shared this at our Investor Day. Look at the market we compete in, ourselves and the nearest competitor, less than 25% share. We have a very compelling value proposition where we offer some of the best pricing and we believe best service and quality on the planet, and we believe we should have more share. We're working hard at gaining that organically but we are also believing that we can consolidate more of this marketplace and that's why we have the strategy of 1% to 2% growth through those strategic [indiscernible] acquisitions. We have announced a number this year with [indiscernible], we're moving forward down with Med Fusion and also we also announced recently [indiscernible] in Massachusetts. So our march continues to drive that strategy. So we think the commercial rate pressure on the rest of the marketplace will help accelerate the strategy we are on and we should over time take up more share both organically and through acquisitions.",0.9584843,0.947
DGX-2017-Q2-2017-07-25,91,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I can't handicap it, but I will share that we are actively working the communication with CMS, and when I say we, it's the Board of Directors and all members of ACLA are actively talking to our Congress members both on House side as well as the Senate side. We have also met a couple of times with the leadership at CMS. The leadership at CMS understands this well, understands that the current approach has issues associated with it, and our simple messaging on this is take the time to get it right. We continue to support the idea of paying or having CMS pay market-based pricing. To get the right data, take the right approach to bringing on those rates is important for all of us.",1.1891269,0.953
DGX-2017-Q2-2017-07-25,92,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And what we remind them of is the reason why we have PAMA is reflective of the work that's to protect access to Medicare Act, and it's important for Congress and it's part of their congressional [intent] not to just pay at the lowest rates but to make sure that they pay for what they use, and the reason for this is there's many parts of this country that are not served by the large national laboratories. And the concern that they are now aware of is if in fact, if this is not done in the right way, rates could be cut, smaller labs that are very necessary in smaller rural areas, in some segment of the marketplace the majority of what the testing is has provided the Medicare marketplace could be substantially cut, and the example of that is what's happening in nursing homes where a majority of their single testing is basically the most routine tests that are done for many small laboratories all over this country.",1.4771005,-0.092
DGX-2017-Q2-2017-07-25,93,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we remind Congress and we remind CMS of where we started and why we believe paying market based price is quite important. So, what I'll share is we think they are very, very responsive to listening to our concerns. We realize there is an element of administration. They realize that what was put in place was put in place over the last couple of years. They realize there is an opportunity to work with us to get it right. So we remain hopeful but I can't handicap it.",0.9482702,0.758
DGX-2017-Q2-2017-07-25,95,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We have been at a point where we don't have the capacity to do deals that make sense and we spend a lot of time looking at deals, we say no to more deals than we say yes to. It's important. We continue to go back to our philosophy on doing acquisitions. They have to be strategically aligned and also we have to make money on those deals. And a key part of making money on those deals is making sure we have the right integration plan. And so, as we integrate this, we have a small structural team that helps us with the integration but also a large part of the integration happens in our regions as well.",1.2072488,0.696
DGX-2017-Q2-2017-07-25,96,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, if you look at the distribution of some of these deals, they have been distributed throughout the United States. We have done a number up in the north. [Indiscernible] being one example of that, Harvard Health Care being another example, but most recently we are doing this deal out in our western region with PeaceHealth and we are working on that with enough capacity to pull that off. So, our capacity has not been [indiscernible] at all. It's more the [indiscernible] factor to making sure we have deals that we believe are strategically aligned and we could make money on.",1.3574959,0.727
DGX-2017-Q2-2017-07-25,99,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I appreciate that. First of all, the relationship is getting nowhere near. We said we are going to focus on two largest states, Florida and Texas, and we're going to pick 15 sites that will be our initial pilot sites. And what we'll provide at those sites are some of our patient service center capabilities like we've done with Safeway, but we believe there's more we could do on those sites with basic healthcare services.",1.1891269,0.382
DGX-2017-Q2-2017-07-25,100,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And what will specifically get done is really dependent upon where we forge relationships with healthcare insurance companies, their integrated delivery systems for ACOs within those geographies where we think there could be some value of providing with basic healthcare services in those great access points that Walmart has.",0.8639209,0.758
DGX-2017-Q2-2017-07-25,101,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","This will be a joint venture. We are the majority holder of ownership in that joint venture. We have not provided visibility or guidance of how large this will be, but we are hopeful that this year we'll be off to a good start and we'll share more in due course as we get into it.",0.6392092,0.902
DGX-2017-Q2-2017-07-25,102,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second part of your question, as we said when we announced Safeway, Safeway was an excellent relationship. We are proud of what we have done. We are half way into what fully we can realize, about 100 stores, we've got another 100 to go to get to 200. What we are doing with Walmart we think is complementary and every one of the retail strategies that are - retail companies that are in our space have a different strategy.",0.4421746,0.778
DGX-2017-Q2-2017-07-25,103,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we continue to enjoy a nice good working relationship with [CBS] [indiscernible]. We believe Walgreens has a different strategy as well. And what we will do is - Walmart and what we will do with Safeway, we believe there are other ways we could work with other retailers that could be complementary to what we agree to do with these two that we have announced so far.",0.4747941,0.91
DGX-2017-Q2-2017-07-25,104,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Just to add, Ricky, the impact this year is immaterial. I mean as you can imagine, it's 15 stores where we're really just going to be ramping up over the balance of the year. The value creation is well in front of us and it goes beyond just having a blood draw center. It's really those additional services that Steve talked about. So Walmart certainly has the foot traffic, millions of people every day. We have not only got the ability to do the laboratory testing, but as Steve mentioned earlier, we've got the on-call specialist and actually do a lot of in-home assessments, biometrics and things well beyond laboratory testing that can supplement our ability to provide additional services.",0.6552133,0.872
DGX-2017-Q2-2017-07-25,105,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So more to come on Walmart, it's not exclusive. We mentioned that the links with Safeway was not exclusive. There are many, many retail centers available. Even though we have over 2,000 patient service centers, approximately a little over half would kind of be candidates for retail outlook. So it wouldn't be all of our patient service centers, and so if you look at 1,000-plus potential patient service center opportunities, certainly between Safeway and Walmart and potentially somebody else, we are going to barely cover a small portion of their footprint. So this is not looking at blocking up and excluding other people, it's really just partnering and finding a way to get more efficient on our capital deployment and where we will [indiscernible] and other services.",1.2954186,0.819
DGX-2017-Q2-2017-07-25,107,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So yes, Ricky, you are correct, the increase in guidance on the revenue side is almost exclusively from M&A. We're very pleased with our organic revenue performance for the first half. It's certainly not out of our original guidance range. So the increase in revenue guidance is really driven by the deals.",2.0560821,0.926
DGX-2017-Q2-2017-07-25,108,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As I mentioned on the earnings side, we actually strongly enough from the first half that there is some organic impetus in the increased guidance, and then the other piece is really around the stock-based comp reducing our effective tax rate in the first half. M&A, our new deals, is not expected to contribute anything meaningful on the EPS side in the back half of the year. So it's really driven by organic health and by this tax benefit.",1.2187994,0.891
DGX-2017-Q2-2017-07-25,109,Answer,2017-07-25,2,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then back to the question that was asked earlier about assumptions for the back half, right now that guidance assumes a tax rate that is more in the going-in rate in the high 30s. We shared that there was $0.06 of excess tax benefit last year. That was in our original assumptions and guidance for this year. Obviously we have exceeded that greatly in the first half but I am not counting on any extraordinary excess tax benefit from stock based comp in the back half. So should that happen and it's not really forecast, something we can forecast, then that could lower the tax rate.",2.0154028,0.676
DGX-2017-Q2-2017-07-25,112,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We are working our way through that. The Safeway relationship is different than what we're going to do at Walmart and we already have working relationships with some other retailers. I mentioned CBS and Walgreens, different strategies, all these have different strategies. And frankly, I think we'd like to have a handful of strong national brands that we work with. We'd like to make some progress with those before we expand too broadly. So we have two now and working relationships with others.",1.2009885,0.908
DGX-2017-Q2-2017-07-25,113,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we are totally focused on executing against what we've said we would do with Safeway. We feel good about that. We just launched this new relationship with Walmart. We want to make sure we make progress in 2017. And as far as others, in due course we will talk about that as we work with them on their own trend, [indiscernible] how we could be helpful, but a good way of thinking about this, we started with one, we've now moved to two and a handful will be a good number that we could then manage over time to provide what we do and help them with their health strategy.",1.3532125,0.961
DGX-2017-Q2-2017-07-25,115,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we are open to working with others. We want to make sure that what we do doesn't in any way contradict what we are doing with some other partners. But as you know, Walgreens continues to broaden their health presence. They have a working relationship as you know with Med Express. Med Express will provide healthcare services and that strategy will change over time. And as you know, most of these retailers work with all different brands, no matter what category and laboratory services are going to be different. So, they are selling all different bands in their stores, so therefore they are open to different brands and we believe that this strategy is good for us to think about how we could team up with different people in the ecosystem in healthcare and every one of these players has different strategy. So, we think there is an opportunity here as well.",1.0975288,0.718
DGX-2017-Q2-2017-07-25,116,Answer,2017-07-25,2,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay, so that concludes our day. We had a strong first half in 2017. We look forward to continue to meet our commitments by executing our two-point strategy, which is to accelerate growth and drive operational excellence. We appreciate your time on this call and we hope you have a great day. Take care.",0.56771,0.976
DGX-2020-Q3-2020-10-22,4,Remarks,2020-10-22,3,2020,Shawn Bevec,Executive Director-Investor Relations,"Thank you and good morning. I'm here with Steve Rusckowski, our Chairman, Chief Executive Officer and President, and Mark Guinan, our Chief Financial Officer.",0.2881715,0.66
DGX-2020-Q3-2020-10-22,5,Remarks,2020-10-22,3,2020,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties, including the impact of the COVID-19 pandemic that may affect Quest Diagnostics' future results include but are not limited to those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.",0.3807886,-0.065
DGX-2020-Q3-2020-10-22,6,Remarks,2020-10-22,3,2020,Shawn Bevec,Executive Director-Investor Relations,"The company continues to believe that the impact of the COVID-19 pandemic on future operating results, cash flows, and/or financial condition will be primarily driven by the pandemic's severity and duration, the pandemic's impact on the U.S. healthcare system and the U.S. economy, and the timing, scope and effectiveness of federal, state and local governmental responses to the pandemic which are drivers beyond the company's knowledge and control.",0.6173591,0.0
DGX-2020-Q3-2020-10-22,7,Remarks,2020-10-22,3,2020,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS from continuing operations and references to adjusted EPS refer to adjusted diluted EPS from continuing operations. References to base testing volumes or base business refer to testing volumes excluding COVID-19 molecular and serology testing volumes.",0.0087325,0.0
DGX-2020-Q3-2020-10-22,8,Remarks,2020-10-22,3,2020,Shawn Bevec,Executive Director-Investor Relations,"Finally, growth rate associated with our long term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth are compounded annual growth rates.",0.1643292,0.927
DGX-2020-Q3-2020-10-22,10,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Shawn, and thanks everyone for joining us today.",0.6065898,0.7
DGX-2020-Q3-2020-10-22,11,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest had a very strong third quarter, benefiting from continued demand from COVID-19 testing as well as the rapid recovery from healthcare utilization. We have performed over 22 million COVID-19 molecular and serology tests to date, more than any other provider. We've also developed and introduced several new innovations that are contributing to enabling the country's ability to return to work, the classroom, and on the athletic field.",0.646458,0.757
DGX-2020-Q3-2020-10-22,12,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I'm extremely proud of all that Quest Diagnostics has accomplished through the COVID-19 pandemic and I want to thank our 47,000 employees for their hard work and dedication.",0.2827018,0.827
DGX-2020-Q3-2020-10-22,13,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","This morning I'll discuss our performance for the quarter, our role in the COVID-19 pandemic, and update you on our non-COVID base business, and then Mark will provide more detail on the third quarter results and our updated financial outlook for the remainder of the year.",1.183196,0.0
DGX-2020-Q3-2020-10-22,14,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our financial performance in the third quarter was very strong. For the quarter, total revenue grew by more than 42% to $2.79 billion. Earnings per share increased by more than 164% on a reported basis to $4.14 and nearly 145% on an adjusted basis to $4.31. These results reflect continued demand for COVID-19 testing and continued recovery of our base testing volumes as healthcare systems resume non-urgent care and elective surgeries. Organic base testing volumes orders declined high single digits in July and improved in the quarter to mid to high single digit declines in September versus the prior year.",0.7654036,0.913
DGX-2020-Q3-2020-10-22,15,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Demand for COVID-19 testing came from several areas: clinical testing ordered by healthcare providers as the virus spread throughout much of the country, especially for non COVID-19 pre-surgical patients and people in high risk populations like nursing homes and prisons; in retail testing in our standard network access points, such as our drive-through sites offered across the country by CVS and Wal-Mart; workplace testing as employers sought to return employees to the job and their offices; university testing to facilitate the return of students to campus life, including sports; and our consumer testing direct testing offered by Quest Direct.",0.3439868,-0.026
DGX-2020-Q3-2020-10-22,16,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've also demonstrated innovation and agility in bringing COVID-19 testing to our nation. In the quarter, we were granted an emergency use authorization, or EUA to offer unobserved self-collection. We were the first provider to receive an EUA due to the pandemic or [indiscernible]. Finally, we teamed up with Wal-Mart and DroneUp to pilot a program for contactless delivery of specialty kits using drones.",0.6889621,0.25
DGX-2020-Q3-2020-10-22,17,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Also in the quarter, we announced an initiative along with our Quest Diagnostics Foundation to address and reduce healthcare disparities in underserved communities, including those impacted by COVID-19. This value-based commitment builds on our existing work with [indiscernible] health centers and will focus on serving people of color, elderly and underserved populations in locations throughout the United States. Quest plans to donate testing services and fund a range of initiatives estimated to total more than $100 million. Our goal is to improve access to testing and drive awareness of value of diagnostic innovations and managing health.",0.706425,0.866
DGX-2020-Q3-2020-10-22,18,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before updating you on our base business, what I'd like to do is comment on our recent CMS change to Medicare payment for COVID-19 testing and our decision to return the CARES Act funding to the government.",0.7805601,0.738
DGX-2020-Q3-2020-10-22,19,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In conjunction with our trade association, we've been currently reviewing the new reimbursement policy for high throughput COVID-19 molecular testing from CMS will impact laboratory and patients we serve. Last week's announcement removes uncertainty that was an overhang on COVID-19 testing reimbursement.",0.2497529,-0.34
DGX-2020-Q3-2020-10-22,20,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally, we're grateful for the CARES Act funding from last spring which provided us at an important time of great uncertainty for our country. Now several months into the pandemic, we no longer require this funding and as a result, we will be returning these funds to the government. That was the right thing to do.",1.0046129,0.842
DGX-2020-Q3-2020-10-22,21,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're making progress on our strategy to accelerate growth in the base business, so as a reminder, the five elements of our strategy to accelerate are to grow more than 2% per year through strategically aligned, accretive acquisitions; expand relationships with health plan and hospital health systems; offer the broadest access to diagnostic innovation; be recognized as the consumer friendly provider of diagnostic information services; and then finally, support population health with data analytics and extended care services.",0.3828666,0.941
DGX-2020-Q3-2020-10-22,22,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Now I'll share a few highlights from our strategy to accelerate growth.,0.2889621,0.586
DGX-2020-Q3-2020-10-22,23,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our M&A pipeline remains strong. Since the second quarter, we close our acquisition of Mid America Clinical Laboratories, referred to as MACL, which is Indiana, and we did a couple two small tuck-in acquisitions. Our recent acquisitions have been performing well during the pandemic; for example, our Memorial Hermann outreach acquisition announced earlier this year, as well as this recent MACL acquisition have driven growth in both COVID-19 testing and our base business. We've also seen growth in advanced diagnostics from our acquisition of Blueprint Genetics.",0.3044481,0.93
DGX-2020-Q3-2020-10-22,24,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second growth driver, expanding relationships with health plan and hospital health systems is also delivering. Our hospital reference testing volumes excluding COVID-19 have returned to growth year over year. Given the challenges that hospitals are facing, we expect many more to be open to discussions about how Quest can help them achieve their lab strategy, so in professional lab services this year we have logged a record amount of bookings, represent larger and longer term agreements than in the past.",0.5324547,0.852
DGX-2020-Q3-2020-10-22,25,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also continue to make progress on our health plan strategy. Within the UnitedHealthcare preferred laboratory network, we're helping United reduce out-of-PLN lab spending through the previously announced zero out-of-pocket benefit. In addition, United has added enhancements that reduce the administrative burden for physicians and patients related to those tests requiring preauthorization. Then in August, we entered into a new strategic relationship with Anthem in 12 states. We're working with Anthem to improve quality and efficiency in delivery of laboratory services. Then finally, additionally we're working with major national payors to enable their members to access COVID-19 testing through Quest's relationships with major retailers.",0.5298188,0.934
DGX-2020-Q3-2020-10-22,26,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We made progress on our third element of our strategy to accelerate growth by offering the broadest access to innovation. In the quarter, we launched three new combined COVID-19 and respiratory virus tests, reducing time for physician to diagnose and treat patients by identifying nearly 20 viral and bacterial infections from a single swab. We also launched our automated next generation sequencing solution that enables individuals to access genetic testing insights about hereditary diseases at consumer price points through Ancestry Health.",0.4494234,0.919
DGX-2020-Q3-2020-10-22,27,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally, we grew our direct-to-consumer services in the quarter. Quest Direct test offerings continue to resonate with consumers. In the quarter, we launched our COVID-19 active infection test, offering consumers a choice of using an at-home kit or getting the specimen collection done at a drive-through location. Also, we made remarkable progress in the surge of sign-ups to our My Quest patient portal. Today, roughly 13 million patients have a My Quest account to make appointments or receive their results through their smartphone or their computer. In the third quarter, on average more than 100,000 patients per week signed up for this service. This is more than double the rate we experienced before the pandemic.",0.2724876,0.863
DGX-2020-Q3-2020-10-22,28,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, the second part of our two-point strategy is to drive operational excellence by continuing to pursue our goals to reduce our cost base by 3% per year. We also see more opportunities ahead to drive further productivity gains while at the same time enhancing our customer experience and overall service levels.",0.6583196,0.855
DGX-2020-Q3-2020-10-22,29,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Here's a couple of examples. We have standardized on the Siemens immunoassay platform in 14 of our 18 regional laboratories. The solution drives workflow efficiencies and has enabled more than a 50% reduction in our equipment footprint. We are still in the early stages of these realized savings but so far, we're pleased with this progress. Then also, our new flagship laboratory in Clifton, New Jersey is being prepared to go live in early 2021. When complete, this state of the art facility will be the most highly automated in our laboratory network and will represent the final regional lab to be converted to our standard operational system, which we call [indiscernible]. This will mark the culmination of a multi-year initiative to simplify, streamline and standardize our regional laboratory operations.",0.5018122,0.924
DGX-2020-Q3-2020-10-22,30,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Now I'd like to turn it over to Mark to take you through the results and update you on our outlook. Mark?,0.5713344,0.361
DGX-2020-Q3-2020-10-22,32,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In the third quarter, consolidated revenues were $2.79 billion, up roughly 43% versus the prior year. Revenues for diagnostic information services grew approximately 44% compared to the prior year, which reflected significant demand for COVID-19 testing services offset by a modest decline in base testing volumes. Volume measured by the number of requisitions increased 19.7% versus the prior year with acquisitions contributing approximately 3%.",0.0809637,0.402
DGX-2020-Q3-2020-10-22,33,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We continued to experience improving performance in our base business in the third quarter. Orders for organic base testing compared to our pre-pandemic business declined high single digits in July and improved to a mid to high single digit decline in September versus the prior year. For the entire third quarter, base testing volumes declined roughly 5% versus the prior year and benefited from recent M&A and the new PLS [indiscernible] that Steve highlighted earlier.",0.3633491,0.787
DGX-2020-Q3-2020-10-22,34,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We also experienced a significant contribution from COVID-19 testing during the third quarter, performing approximately 9.9 million molecular tests and 1.5 million serology tests. We exited the third quarter averaging approximately 93,000 COVID-19 molecular and 11,000 serology tests per day.",0.6042654,0.202
DGX-2020-Q3-2020-10-22,35,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per requisition increased 20.9% versus the prior year, driven largely by COVID-19 testing. This was partially offset by unit price headwinds of approximately 1.7% in the third quarter, in line with our prior expectations. This included the ongoing impact of PAMA.",0.1702212,0.273
DGX-2020-Q3-2020-10-22,36,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income was $718 million or 25.8% of revenues compared to $313 million or 16% of revenues last year. On an adjusted basis, operating income was $831 million or 29.8% of revenues compared to $349 million or 17.9% of revenues last year. The year-over-year increase in operating margin was driven by strong revenue growth in the third quarter, reflecting the relatively high drop-through on incremental volume in our business.",0.4249605,0.802
DGX-2020-Q3-2020-10-22,37,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Reported EPS was $4.14 in the quarter compared to $1.56 a year ago. Adjusted EPS was $4.31 compared to $1.76 last year.,0.671406,0.0
DGX-2020-Q3-2020-10-22,38,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Cash provided by operations was approximately $1.46 billion year to date through September 30 versus $895 million in the same period last year. Cash from operations in the third quarter includes approximately $138 million of provider relief under the CARES Act. As a result of our strong financial position, we are planning to return the entire CARES Act funding we received, which Steve noted earlier.",0.8491311,0.931
DGX-2020-Q3-2020-10-22,39,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Additionally, we are accelerating the redemption of our senior notes maturing in April of 2021. We will use the proceeds of the bond offering that we completed in May 2020 to repay these notes. We expect to complete the early debt redemption in November.",0.6879937,-0.361
DGX-2020-Q3-2020-10-22,40,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Turning to guidance, we raised our full year 2020 outlook as follows: revenues now expected to be between $8.8 billion and $9.1 billion, an increase of approximately 13.9% to 17.8% versus the prior year; reported EPS expected to be in a range of $8.22 to $9.22 and adjusted EPS to be in a range of $9 to $10; cash provided by operations is expected to be at least $1.75 billion, and capital expenditures are expected to be approximately $400 million.",0.6800948,0.318
DGX-2020-Q3-2020-10-22,41,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We continue to operate under the uncertainty caused by the COVID-19 pandemic. Continued recovery in the base business as well as demand for and duration of COVID-19 molecular testing are significant swing factors that remain challenging to forecast. With that high degree of uncertainty in mind, please consider the following: the midpoint of our full year outlook generally assumes base testing volumes to remain modestly below last prior year levels as we exit 2020; COVID-19 testing volumes averaging nearly 90,000 tests per day for the molecular test and 10,000 tests per day for the serology test in Q4; COVID-19 molecular reimbursement generally stable with recent trends. Our performance through mid October is slightly above these assumptions, but again our guidance reflects the uncertainty of the current environment.",0.8187204,-0.307
DGX-2020-Q3-2020-10-22,42,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Finally, as Steve mentioned, we are currently in the early stages of launching our recently announced initiatives with the Quest Foundation to reduce heath disparities in underserved communities. As we move forward, we expect to exclude the costs associated with this multi-year initiative in determining our adjusted results.",0.5398894,-0.226
DGX-2020-Q3-2020-10-22,43,Remarks,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"While we aren't prepared to share a detailed outlook for 2021 today, I'd like to offer some considerations for next year. First, we are likely to have an easy compare in our base business for much of the year, especially in Q2. Second, demand for COVID-19 testing is likely to persist well into 2021. We believe that molecular PCR testing will continue to play a very important role in diagnosing, tracking and tracing active COVID-19 infections and that there will eventually be a growing need for serology testing as vaccines and additional therapies come to the market. Third, we are working to understand the details of the recent CMS announcement regarding COVID-19 molecular reimbursement for 2021, and finally as a reminder, there will be no Medicare reimbursement costs under PAMA in 2021 given the one-year delay included in the CARES Act.",0.4139021,0.945
DGX-2020-Q3-2020-10-22,45,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Mark. To summarize, we had a very strong third quarter and have performed over 22 million COVID-19 molecular and serology tests to date. We've also developed and introduced a number of new innovations allowing the country to get back to work, into the classroom, and onto the athletic fields. We've seen further signs of recovery in healthcare utilization as our base testing volume continued to recover rapidly throughout the third quarter. Finally, again I'm extremely proud of all that Quest Diagnostics has accomplished throughout this very difficult time, and I thank all the 42,000 people at Quest Diagnostics for all their hard work and dedication.",0.4233937,0.908
DGX-2020-Q3-2020-10-22,46,Remarks,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Now we'd be happy to take any of your questions. Operator?,0.7878089,0.572
DGX-2020-Q3-2020-10-22,51,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me start with the operational piece of that, Ann. First of all, we're running about a capacity of 200,000 tests per day, even though what you heard from our guidance is less than that in terms of actual results. We've done that for two reasons. One is to be prepared for the fall where we're anticipating further demand for COVID-19 testing, and then secondly is when we have more capacity and we result less, it helps us with turnaround time, so I'm happy to share that right now we're averaging less than two days for testing for COVID-19.",0.2260297,0.836
DGX-2020-Q3-2020-10-22,52,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","What I'll also say, as I said in my early introductory remarks, we're trying to understand the exact guidelines, and I'm sure there will be more detail from CMS In terms of recovery--excuse me, reimbursement changes. When we're looking at turnaround times, we're looking at it today from specimen collection to results, and that's also by calendar day, and there will be more specificity on this from CMS but--you know, there will be more clarity around that.",0.9996705,0.648
DGX-2020-Q3-2020-10-22,53,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we're performing well with, I think, capacity versus our demand, and we're not stopping there. We're actually increasing our capacity as we speak. We're working out some of the last capacity we can get out of some of the new systems we put in place, and secondly we're looking at applying pooling to some of our IBB platforms, so that should get us to eventually coming out of this year at 250,000 per day versus the 200,000 today, so we should be able to meet the demand and keep our turnaround times at the level I've already indicated.",0.4728171,0.204
DGX-2020-Q3-2020-10-22,55,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so just to add to that, Ann, the devil's in the details. We need to understand exactly when the clock starts on turnaround time. Based on where we think it should end up, we expect to be in very good shape around meeting the criteria. At this point, assume we have to get more than half of those tests turned around in two days or less, and obviously we need clarification and certainty around that, and that's for obviously Medicare, and we still also need to work through some of the issues with the commercial payors as well to understand how it's going to work with them. That's why we're cautious in terms of committing too much to what this pronouncement by CMS means. We have a lot of work to do, but certainly we're optimistic as we look at it that we should be able to meet that requirement.",0.0505529,0.875
DGX-2020-Q3-2020-10-22,56,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On cash flow, as you see, we're obviously feeling much better about our cash flow at this point. The fact that we're repaying the debt early from April that we issued as a pre-issuance in May shows our confidence, returning $138 million which of course is deducted from our projection when I said at least $4.75 billion, so we're expecting a very strong cash year.",0.3917852,0.831
DGX-2020-Q3-2020-10-22,57,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"You know, Steve mentioned we have a very strong M&A pipeline, and I've said many time to investors I would prefer to do M&A because when we do it, we're highly confident that that's a better return for our shareholders, but we do have very strict criteria. We have to find deals that meet those criteria, so I'm optimistic that we will deploy a chunk of that for M&A and then at some point you can expect us to return to our normal capital strategy as we move forward throughout the calendar year, or early next year.",0.5908373,0.834
DGX-2020-Q3-2020-10-22,61,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks for the question, Stephen. As we mentioned, volume improved from July, so really September versus August is fairly flat, so yes, there was a little stagnation in improvement in the baseline, not completely surprising given the recent uptick in COVID again. So it hasn't gotten worse for us, but it did not continue its improvement, and that's why when I talked about what we expect in Q4, we don't expect a full recovery any time this calendar year. Obviously we have a very broad range - $300 million, so within that range there's multi variables, but in terms of the base business, we're not counting on in the middle of that a complete recovery. We're not expecting it to move materially away from where it's been the last couple months, but that would kind of get you to that lower end and upper end of the range, depending on that along, of course, with COVID testing as well, where they go from that midpoint.",0.4577409,0.791
DGX-2020-Q3-2020-10-22,62,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So not counting on anything, but certainly improvement could lead us toward that upper end, and if it eroded a little bit, it could lead us towards the lower end of our guidance.",0.9676145,0.649
DGX-2020-Q3-2020-10-22,63,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, and we're watching that carefully. If you go back and hear what I said, we started off July at high single digits, and then also as I indicated in September, it was mid to high, so slight improvement there but we're watching it as we enter the fourth quarter and as we sit here in the fourth quarter in October.",0.7637562,0.501
DGX-2020-Q3-2020-10-22,66,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure, so Ricky, first I'll confirm that direct-to-consumer does come with a higher price point. Certainly there are other expenses that go with direct-to-consumer. We've actually invested incrementally in some marketing to drive awareness and so on, but from a gross margin perspective, the consumer testing is higher than our core business. Recall even though we feel good about that business, it's still a very small part of our overall enterprise.",0.6263823,0.262
DGX-2020-Q3-2020-10-22,67,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Then between COVID and base, obviously we don't get into gross margin on specific test offerings, but the one benefit I will point out on COVID is that there's no patient responsibility, so when you think about it - and I don't have the precise numbers, but just let's say because our overall enterprise, about 20% of our revenues come from patients, if we collect, as we've shared, $0.70 on the dollar, you can imagine that there is about a 6% higher margin on that particular business because it's 100 reimbursed by payors instead of having any patient responsibility, so there is some benefit to the gross margin. But in COVID, it really is unrelated to price and really has everything to do with the coverage policies and not having that inability to collect all the money that we're due.",0.2041864,0.717
DGX-2020-Q3-2020-10-22,69,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so Ricky we managed our workforce carefully over the last six to nine months. As you'll recall, the second quarter we had to trim down our workforce, so we furloughed over 6,000 people, we reduced work schedules, we cut salaries including myself and Mark and our board, and then we saw the steady recovery in our base business coupled with the COVID testing that we've done.",0.878089,0.273
DGX-2020-Q3-2020-10-22,70,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we've reinstated salaries, we have brought back full work weeks and we've brought back the vast majority of the furloughed employees, and actually we've hired people, so we've hired people where we need to hire people, particularly in areas like specimen processing. You can see with the volumes we're seeing, you have to have a lot of people to receive all these specimens to sort it out before they go into the lab.",1.4415157,0.414
DGX-2020-Q3-2020-10-22,71,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But I'll tell you, we're still being very, very careful before we add another person. We're being very careful in overhead, and Mark can go through exactly what's in our expenses, but we've been very limited in hiring in our expense categories and will continue to be very [indiscernible] with our hiring for our overhead with our laboratory operations and our operations in general. The reason for that is we want to make sure we don't' get ahead of ourselves. We feel we got good leverage in the third quarter, as you see, and we believe we have a workforce in place to manage the demand we're getting right now. We're constantly looking at what we think the future demand will be, but we want to make sure we don't get ahead of ourselves.",0.5311367,0.819
DGX-2020-Q3-2020-10-22,72,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We indicated what we think the fourth quarter's going to be. We are building capacity to get more COVID-19 testing done. We have plenty of capacity available for serology without adding a lot of staff, with the exception of some of the volume based jobs as I mentioned, and so as we get deeper into the fourth quarter and we get into the beginning of next year, we'll then assess if we need to add some people. But so far, we've done some modest hiring, we're back to full workforce, and we're watching it, frankly, daily and we want to make sure we don't add people before we need them.",0.6023064,0.382
DGX-2020-Q3-2020-10-22,73,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so we don't have any proactive plans to add resources, Ricky. We're going to continue to monitor demand in our business, and we have the flexibility generally to ramp in a fairly short window as volumes move in one direction or the other. I can confirm no plan to add to the expense base in Q4 in anticipation of anything next year at this point.",0.5754344,0.681
DGX-2020-Q3-2020-10-22,74,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And interestingly enough, this is a last point because we do have this natural hedge on this, is despite where we are with the economy, we still have attrition in some of our draws, so we're in some places still trying to keep up. There are other options for people particularly with some of our non-exempt employment jobs, and therefore if things turn down, we could carefully turn off our spigot as well.",0.6537068,0.801
DGX-2020-Q3-2020-10-22,77,Question,2020-10-22,3,2020,Ralph Giacobbe,Credit Suisse,"Great, thanks. Good morning. I want to go back to the reimbursement comments, and specifically in your prepared remarks on the CMS reimbursement tweak and it removing an overhang. I guess I just want to be clear on what the expectation is now, sort of post the PHE period, assuming you meet those turnaround times. Does it sustain the $100 level, am I interpreting that right or not?",0.8258345,0.933
DGX-2020-Q3-2020-10-22,78,Question,2020-10-22,3,2020,Ralph Giacobbe,Credit Suisse,"And then second piece is related just post that PHE period, my understanding is the commercial rate for COVID will be the default to your contracted rate, or there's a rate negotiation that takes place. Is that correct, and then how should we think of that commercial rate off the $100 baseline? Thanks.",0.469521,0.44
DGX-2020-Q3-2020-10-22,79,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so let me start with where we saw some uncertainty and therefore the word we used, overhang. First of all, for this year we had some uncertainty, as you know, in the third quarter about the emergency order that's in place, and that was extended to October. We are hopeful that the rate would continue at $100, and it's our expectation given that the new rate changes with the incentive that we outlined [indiscernible] on January, so therefore we're assuming the $100 for reimbursement for the remainder of this year. But up until we heard this, there was some uncertainty about 2020.",0.4378913,-0.077
DGX-2020-Q3-2020-10-22,80,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Then secondly, in 2021 remember the original rate was at $51 and it went up to $100, and so therefore the new reimbursement that's being spoken of, again if you get the turnaround time of two days, you're at $100, if you don't, it's $75, so that removes some of that uncertainty of it reverting back to where it was before we got the bump from $51 to $100.",0.6560132,-0.026
DGX-2020-Q3-2020-10-22,82,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, generally it's a renegotiation, Ralph. We had provisions in our contracts for new tests, and certainly the high throughput COVID-19 molecular test is one of those, so there is no provision for it to default automatically to any sort of relationship to CMS or what have you. We had to negotiate that, and I was successful in getting it to match CMS' rate, and certainly as we go forward we're going to have to continue to talk to our commercial payors and negotiate. There's no set answer at this point to where commercial reimbursement might go.",0.3578199,0.749
DGX-2020-Q3-2020-10-22,86,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The core volumes, I want to be clear, for the quarter were mid to high single digits with an improvement from July into August, and then fairly flat in September, and that was an apples to apples comparison, so M&A puts those core volumes in a better place and then also some of the new POS deals. But we didn't want to confound utilization by just reporting the base business. We wanted you to understand the apples to apples, almost same store analysis, and that's the one where we're down mid to slightly higher single digits for the full quarter.",0.0821485,0.844
DGX-2020-Q3-2020-10-22,87,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of next year, like everybody else, we're trying to figure out how quickly things might recover and to what extent. We're looking at all the same reports you are. Given the continued [indiscernible] utilization given the potential for the economy to have impact on utilization and other uncertainties, at this point we're not expecting any time soon to get the base volume back to the pre-pandemic levels, but with that said, it doesn't mean it couldn't happen. We're just not at this point assuming it, and while we haven't given guidance for 2021, we wanted to just give some of our initial thinking. But obviously when we come out with guidance, we're going to give you specifics around what those assumptions are, and at that point we'll have a lot more information.",0.6386256,0.013
DGX-2020-Q3-2020-10-22,88,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Some color around--you know, we've got variation around geography and around clinical franchises, so by way of example, New York City has still not recovered and we have a fair business in New York, so if you look at the percentage overall that's affected by New York not recovering. There's other parts of the country that are fully recovered, so we're watching that carefully and we're watching it by city. If things change by city or state, we can understand the consequence of that.",0.5242175,0.296
DGX-2020-Q3-2020-10-22,89,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Then secondly, we've got some clinical franchises that are back to pre-pandemic levels but we still have the laggers. We have our prescription drug monitoring business which is still below pre-pandemic levels, so if you look at it from a couple different dimensions, you can understand why we're below pre-pandemic, and then what it takes to get back to where we were going into 2020 and potentially get above it, it will require some of these areas to get back to normal levels that we saw in the winter months, before we hit the pandemic in March.",0.6747941,0.0
DGX-2020-Q3-2020-10-22,90,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"To Steve's point, there is a lot of complexity. We actually do have some geographies that are growing year over year, and then we have some like--and it's really [indiscernible]. If you look at Long Island, you look at Westchester County, you look at New Jersey right outside of Manhattan, they're in much better shape than Manhattan is, and we aren't sure whether that has anything to do with physician office and so on. We think it might be fewer commuters going into the city, they're getting their work done elsewhere instead of while they're at work during the day. But certainly we don't have any specific information on that at this point.",0.436019,0.807
DGX-2020-Q3-2020-10-22,93,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, thanks. I'll take the first part around point-of-care solutions. As you know, there's two point-of-care solutions. One of the point-of-care diagnostic solutions that were out there for some time provided by IBD manufacturers, and for all intents and purposes they were there for a number of months and they provided a role. Then most recently, I believe you are referring to what's happening with the antigen testing. We do believe there will be a role for antigen testing, particularly for monitoring and surveillance of a population. But we do understand for a lot of reasons why PCR and the return to the lab model is going to continue to be the gold standard.",0.5670511,0.84
DGX-2020-Q3-2020-10-22,94,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","One of the reasons for that, depending upon the quality of the antigen testing that might be applied, there are requirements around reflex testing to PCR for both positives and negatives, and also we believe that physicians do prefer PCR testing, and when we're offered, it means flu respiratory panel and COVID tests that will be a PCR, and we think with the flu season coming out that we are going to get some demand for it as well.",0.3499176,-0.052
DGX-2020-Q3-2020-10-22,95,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we believe that antigen testing will be a necessary part of our portfolio and we do expect to be bringing out a solution for antigen testing as part of our services we offer, but it will be complementary to the PCR testing that we're currently doing. Hopefully that provides some clarity of what we think the role will be.",0.8537068,0.829
DGX-2020-Q3-2020-10-22,96,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Then finally on the consumer piece, we do believe that there is increased interest in our direct-to-consumer offerings for the basic testing. As you all know, a number of patients have not gone to their doctors as they should. We do believe there is an opportunity for them to have their lipid panel checked for their cholesterol, make sure the statins are working properly - you know, [indiscernible] glucose A1c, sexually transmitted diseases. As we've mentioned, we've brought up serology testing direct to consumer and most recently COVID-19 testing. We believe there is interest in a very convenient approach to getting testing, and we couple this with a telehealth physician consult as part of our service and we do believe going forward, there is going to be increased demand for both telehealth in terms of its role in our business overall, and then secondly is testing and getting that either indirectly through Quest Direct or getting that through a telehealth provider as well.",0.8032949,0.935
DGX-2020-Q3-2020-10-22,97,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're very well positioned in that regard with our relationships with telehealth companies but also with Quest Direct. Before the pandemic, we kicked this program off, and so we have a nice platform that's been building up volume and we feel that there's going to be more opportunities in front of us as the demand, given the circumstances, continues to have a lot of interest from consumers.",1.3341021,0.917
DGX-2020-Q3-2020-10-22,101,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, well we're encouraged. As I mentioned in my prepared remarks, the hospital business is actually growing again versus last year, and that's encouraging, and that's without COVID-19, so that's an encouraging trend. We see hospitals back in business and we're seeing the testing that you would expect from those hospitals, and we're doing well in that marketplace. This is where what we traditionally called our reference testing business.",0.2537068,0.95
DGX-2020-Q3-2020-10-22,102,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Then in addition to this, over the years we have built up a professional lab services business. This isn't just a new program - we've been working on this for over five or six years, and we've built up a nice portfolio of referenceable accounts and that's serving us well. We are penning a number of long term, multi-year contracts this year that will provide growth for us in '21 for certain, and we see continued growing interest from integrated delivery systems on how we can help them with their lab strategy.",0.6787479,0.936
DGX-2020-Q3-2020-10-22,103,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As you know, many of these hospital systems are having a difficult time through the pandemic, and now speaking with many of the CEOs, and I actually had a conversation Tuesday with one, they're looking at a variety of options to get more efficient, get more effective. One of the areas that we've talked about for years, and I think it's going to keep building momentum, is walking in and having a conversation around their lab strategy, which includes the reference testing, the sophisticate testing they send out, how it can help save their money through the acute care laboratory. Then it does beg the question of what they do with their outreach business, and in some cases they sell that to us, and that's what we did with Memorial Hermann this year, with MACL, and we're seeing more and more prospects.",0.860626,0.951
DGX-2020-Q3-2020-10-22,104,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So it continues to receive strong interest, and this year was really a banner year for bookings, and we'll see that in the growth in '21.",1.0184514,0.836
DGX-2020-Q3-2020-10-22,106,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes Don, as you know, we don't generally prospectively announce the size of a contract, but what we will see as we report our quarterly results and we talk about our growth and where it's coming from, the POS contribution, so certainly moving forward you're going to see the evidence of what Steve just talked about in some of these very large bookings and deals that we're just starting to implement and that will accelerate our growth into 2021.",0.2389415,0.916
DGX-2020-Q3-2020-10-22,110,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so I did not intend to imply that PCR volumes will be reduced in Q4. Actually the midpoint of the guidance assumes it stays where it is, where we are right now, and as I shared, through the first couple of weeks of October we're actually slightly ahead of the midpoint of guidance. I wanted to clarify that.",0.0296209,0.625
DGX-2020-Q3-2020-10-22,111,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of margin, really nothing of significance. We did have in Q3 a significant catch-up expense on our bonus. As I'm sure you could imagine, early in the year we were projecting to significantly miss our targets, and then Q3 really reversed that and got us to a point where we're expected to exceed our targets, so in Q4 we would just have, assuming we deliver, the Q4 proportion of that.",0.1820695,0.602
DGX-2020-Q3-2020-10-22,112,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So actually, there was in Q3 a significant incremental expense to catch up our bonuses that will not be repeated in Q4, so there's nothing of huge significance other than there are some of the cost actions that Steve referenced that we have reinstated to normalcy, so we did have some reductions in July on salaries and in Q4, those will be fully to where they were pre-pandemic, and then we did reinstate the 401K match late in Q3 and that will be fully reinstated in Q4. So there are a couple of what I'd call headwinds, but those are really just returning us to pre-pandemic levels, and then normally in Q4 we just have some other margin pressures, given the holidays and some other things that we manage through, but nothing of note.",0.5841232,0.31
DGX-2020-Q3-2020-10-22,113,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Finally, there is a small amount of incremental investment. I referenced on the things that we're doing around supporting our consumer business. We want to continue to build that business. We think it's going to be increasingly important, and so we do have the opportunity given our business performance to invest, and so there's a little bit of commercial investment into our consumer business that's a step up from where it's been in Q3.",0.6532385,0.778
DGX-2020-Q3-2020-10-22,117,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to work on our relationship with UnitedHealthcare. As we said, in '19 we made some really good progress picking up share related to the PLN. We had a lot of things to do in the fall of 2019 related to employers, zero out of pocket and preauthorization work, and we really felt good about January and February. We actually did see a nice progression of our volumes and then we hit the pandemic in March.",0.4510708,0.926
DGX-2020-Q3-2020-10-22,118,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to work those programs and matter of fact, this week I was spending time with United on this and we continue to work on everything we can do to move more of their lab purchases to the PLN, and obviously specifically to us, and there will be other programs that we're working with them by geography, by state to be able to make sure that employers and patients and integrated delivery systems understand the value of what we deliver.",0.769028,0.765
DGX-2020-Q3-2020-10-22,119,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Remember if you go back to where we started, we believe that by the improvement in access with United and Verizon and Anthem in Georgia as of the time of our last investor day, it afforded us about a $4 billion opportunity in market, and we believe that we should be able to get about 25% of that. We received some of that in 2019 and we believe there's more opportunity in front of us.",0.4418451,0.886
DGX-2020-Q3-2020-10-22,120,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So what I can share with you is we continue that work in 2020 and we do expect it will continue to help us pick up some share in '21 to accelerate our growth.,0.2546952,0.849
DGX-2020-Q3-2020-10-22,121,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I just want to remind everyone, Pito, that the zero out of pocket still has a ways to go, so they started with their fully insured small plans and then expanded it, and then it's going to go out to the sponsored plans. Obviously that's marketed to the employers who are paying those bills, and the good news is we're collaborating with them on that and trying to demonstrate how that will save the employers a whole lot of money. To this point, most of the movement has been through other activity, things that United has done to encourage physicians to stop using out-of-network providers, having us go in and show them the benefits of moving that lab ordering to us and the PLN member, but still a lot of runway in front of us in terms of how that might benefit.",0.3108215,0.887
DGX-2020-Q3-2020-10-22,122,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The lower burden is really just a new thing. We're putting in some pretty significant requirements around some of the higher cost testing, and they realize that two things - one is that the PLN members can really have more responsible panels or an approach to clinical testing. The second thing is obviously we have good prices as compared to some of the other providers, and we've mentioned in the past that some of the managed Medicaid payors, so outside of United, have used this approach in specifically toxicology to drive better value. You know, with toxicology exploding over the last couple years, they put in some very tight restrictions on utilization, and seeing that the national labs tend to do this responsibly and have better prices, they exempted us from a pre-auth. So not only does it make it easier on physicians and patients, but it tends to steer more work to us because the administrative burden is lower. United sees that in the same areas where they're trying to control some of the growth in high cost testing, but that benefit to us is to come yet.",0.4838073,0.935
DGX-2020-Q3-2020-10-22,125,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Matt, we're watching it carefully. We believe that when somebody presents themselves with symptoms, they want to rule out COVID, and we believe that PCR testing will be the option. As we mentioned, we brought out a new solution which we feel really good about - with a single swab, you can test for influenza, you can also test for other viral and bacterial issues, and that is going to be very convenient for physicians just to quickly diagnose and then treat the patients effectively.",0.5327842,0.898
DGX-2020-Q3-2020-10-22,126,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now what you bring up, we're watching it carefully because with all of us being socially distant and all of us doing a better job of hygiene and schools not being entirely back in session, it might actually lower the infection rate this year, but we're not certain of that, and so we're watching that.",0.2121911,-0.158
DGX-2020-Q3-2020-10-22,127,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Mark, do you want to talk about reimbursement for some of the--",0.3818781,0.077
DGX-2020-Q3-2020-10-22,128,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, you know, it's still to be determined. Basically for reference, CPT code 87631, which is the respiratory multiplex panel with three to five targets is $142 today; 87632, with six to 11 targets, is $218, and then 87631 reflux with 12 to 25 targets is $416, so still to be determined exactly where we come out on this. Still have negotiations with the commercial payors, but at least we could reference in the past for some of these multiplex panels, you know, the reimbursement is reasonable.",0.1777251,0.502
DGX-2020-Q3-2020-10-22,133,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, we're doing our share of serology, running around 10,000 per day. We've got plenty of capacity in front of us. We believe it's going to play an increasingly important role as we get into 2021, as the vaccine becomes available. We're actively engaged with those pharmaceutical companies that are doing the trials for the vaccine and trying to understand where we might play a role [indiscernible] either with the vaccine or post vaccine, and serology has a role there.",0.4981878,0.926
DGX-2020-Q3-2020-10-22,134,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're also doing some serology population health testing. We've done some work for states and we're doing work for the CDC, and we believe that that work will continue to give us a good handle on what is happening with the progression of disease and have an early warning signal if we're moving in the wrong direction, so more to come. We're working through that. We do believe it's going to be a growing and bigger opportunity in 2021 and more visibility of that as we understand where the vaccine is, understand the progression of where we are with the pandemic.",0.5515651,0.226
DGX-2020-Q3-2020-10-22,135,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Then also, we will be bringing new solutions out to the marketplace that will provide more and more utility around serology, and more to come on that. But we're working on the science and we believe there's more we can do to contribute towards the pandemic as we go, particularly as we see how the pandemic progresses.",0.9331137,0.178
DGX-2020-Q3-2020-10-22,136,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of discussions with the payors, it's still early, Brian. There is not clarity around the exact role that serology is going to play, and while we believe there is going to be an important role, it's not at a point where we're in detailed discussions with the payors yet.",0.3534755,0.236
DGX-2020-Q3-2020-10-22,139,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, sure. Remember we talked about 200,000 tests per day for capacity, and [indiscernible] resulted in the third quarter about 100,000 per day. Roughly 20% to 25% of that volume is done on what we call our LDTs, and that's where we've been leveraging the pooling capability. It's particularly useful. It has good improvements in productivity and efficiency where you have low prevalence populations because when you do the pooling, when one well lights up, you have to test for that well, and you get a few 14, 15% positivity rates in locations, the mask doesn't mark it out any more, so we're applying it in the right way. It's primarily around our LDT portion of our capacity.",0.1186161,0.96
DGX-2020-Q3-2020-10-22,140,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","What I mentioned in earlier comments was we're looking at applying that to our IBD platform as well, and that will be helpful in moving our capacity from 200 up to 250.",1.8527183,0.599
DGX-2020-Q3-2020-10-22,141,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, and just to remind everyone, as Steve said, the efficiency is really highly dependent on the positivity rate, and while we do save on reagents, it's not an order of magnitude less expensive. The real economic benefit of pooling comes from capacity increase, so our ability to do more testing and the margins we get on that testing, not a huge difference. There is a benefit but not a huge difference in the cost per individual test that we pool.",0.1895735,0.811
DGX-2020-Q3-2020-10-22,145,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Mark, you want to start with '21 comments and the economy?",0.3594728,0.077
DGX-2020-Q3-2020-10-22,146,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so Lisa, it's hard to know specifically what's driving the dampened utilization. Certainly things have opened up a lot more than they were in the spring, so whereas physician offices were closed, I think there was a huge fear in a large part of the population around engaging with the healthcare system at all because of the risk potentially of catching COVID when you went into a physician office. While I wouldn't suggest that's eliminated, certainly that has improved dramatically, so there is some overhang left there certainly but the unemployment rate is probably a contributor right now - we don't know for certain, and we wouldn't expect that to change dramatically certainly in the next six months, or who knows how long before it might turn around. So we're being cautious around our thinking for next year, and we wanted to share that. Obviously people will form their own opinions, but we would expect unemployment to have some dampening on utilization going into next year.",0.4873618,0.498
DGX-2020-Q3-2020-10-22,147,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of the COVID volumes, we haven't modeled and we haven't given guidance for '21, but maybe three, six months ago some of us had hoped that COVID might be behind us this calendar year. Clearly, that does not look like it's going to happen, but all this depends on how quickly the vaccines get rolled out, how effective they are, and even once they get rolled out, we see a role, so whether it's a level of testing we're seeing today or something a little less, we expect there to be a meaningful amount of COVID testing, including the PCR testing throughout a reasonable part of next year.",0.1220379,0.908
DGX-2020-Q3-2020-10-22,148,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, and just to add to that, remember with the economy, and we saw this back in the Great Recession, whatever happens to the economy will affect access, and so access is important to us [indiscernible]. Second is consumer confidence, and we know a large portion of the population is paying for healthcare out of their own pocket, and therefore they're going to think twice about utilizing it, so we are thinking about that as we think about models in '21.",0.5772652,0.854
DGX-2020-Q3-2020-10-22,149,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now with that said, if you look at where we are with our base business versus where it was and you think about the math for the full year, it should be an easy comparison, as Mark said in his comments about '21. Even if it's down versus '19, just to look at the comparison of what the full year will be for '20 versus '21, given where we are right now, that makes for an easy comparison.",0.2556837,0.7
DGX-2020-Q3-2020-10-22,150,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As far as PCR, remember we brought out our first PCR test on March 9 and we've been ramping rapidly, so we have not had a full year from PCR. We're hitting our stride, we're building capacity because we do anticipate more demand, winter is coming and we're all anticipating more demand as we enter the winter, clearly in the first quarter, and then we'll start to see hopefully some of the vaccines. As we all know, those won't be broadly deployed immediately and the pandemic and the virus will be with us for a large portion of '21, so if you think about the full year of '21 for COVID-19 versus what we did in 2020, there's still going to be a lot of volume for testing and you have the full 12 months versus essentially a half year for PCR in 2020. It's something to think about as you do your models.",0.6339374,0.424
DGX-2020-Q3-2020-10-22,151,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, and to Steve's point, for this year based on our guidance expectations, we see our base volume down organically in the high teens, so even if it's down a couple hundred basis points in 2021, it will still be an easy compare for the full year.",0.7685624,0.681
DGX-2020-Q3-2020-10-22,154,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well you know, it's by states, really the big four states. California shut down first, we saw a steady rebound, they're still not back to pre-pandemic levels, particularly in some of the large cities like LA. If you go into Texas, we actually saw a good rebound in Texas. We have a great presence in Texas, both in Houston and Dallas, and despite some of the flare-ups we saw in the summer, they still continue to be in the range of where we were pre-pandemic. Look at Florida - it went down in the spring into the summer, there's still issues in Florida. We're still not where they were pre-pandemic. Then if you go to the northeast, New York and Boston and Connecticut, actually we've seen some nice steady recovery with the exception of, as we've indicated earlier, New York City, but specific to the Borough of Manhattan. We still have a ways to go to recover there, so we're watching those, particularly related to infection rates.",0.0771005,0.772
DGX-2020-Q3-2020-10-22,155,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But where we have had some of these flare-ups, interesting enough, like in the States of Texas and Florida in the summer months, it did not have a negative of a consequence to our base business as we saw back in the spring, so we're watching it carefully. But so far, we're getting there.",0.0688633,0.827
DGX-2020-Q3-2020-10-22,156,Answer,2020-10-22,3,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Then again, you can't ignore that clinical franchise element of this because some of the portion of the buy-in effects are related to these specific businesses, like prescription drug monitoring, and there's other issues related to what it takes to get those back to pre-pandemic levels that are not related to the geography at all.",0.3285008,0.0
DGX-2020-Q3-2020-10-22,157,Answer,2020-10-22,3,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I can't say they're precisely negatively correlated, but actually that would be my representation. Areas with the lowest positivity rates, like New York, actually are down the most, so we haven't seen a huge parallel movement between spikes in COVID over the last several months and a downturn in utilization. It actually has kind of gone in the opposite direction.",0.6966825,0.805
DGX-2020-Q3-2020-10-22,158,Answer,2020-10-22,3,2020,Shawn Bevec,Executive Director-Investor Relations,"Okay, so thank you all for your questions. We appreciate your support on this call today and in general, and we wish you all a great day.",0.5940725,0.942
DGX-2020-Q1-2020-04-22,4,Remarks,2020-04-22,1,2020,Shawn Bevec,Executive Director-Investor Relations,"During this call we may make forward-looking statements and we'll discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties including the impact of the COVID-19 pandemic that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent Annual Report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.",1.494046,-0.065
DGX-2020-Q1-2020-04-22,5,Remarks,2020-04-22,1,2020,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS excluding amortization expense. References to adjusted operating income for all periods excludes amortization expense. Finally, growth rates associated with our long-term outlook projections including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth are compound annual growth rates.",1.8970627,0.941
DGX-2020-Q1-2020-04-22,7,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. We are definitely living in extraordinary times. The COVID-19 pandemic has changed the way we all live, work and engage with one another. While the crisis will likely continue to impact our lives in the weeks and months ahead, one thing we can be highly certain of -- we will get through this.",2.0751236,0.802
DGX-2020-Q1-2020-04-22,8,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So this morning, I will discuss our performance before the crisis hit, the impact the crisis has had in our role in it, and the actions we are taking to mitigate the impact going forward. And then Mark will provide more detail on the first quarter results and our financial position.",2.1265239,-0.848
DGX-2020-Q1-2020-04-22,9,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our financial performance in the first quarter was off to a strong start in January and February. Through February year-to-date, total revenues grew more than 4%. Total revenues grew more than 6%. Even after adjusting for the calendar benefit and favorable weather in the first two months of the year, organic volume grew more than 4%.",1.3996705,0.856
DGX-2020-Q1-2020-04-22,10,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","However, in March, social distancing and shelter-in-place measures were instituted to combat the spread of COVID-19 and we began to see substantial declines in our business. In the last two weeks of the quarter, we experienced a reduction of volumes in excess of 40%.",1.6850082,-0.153
DGX-2020-Q1-2020-04-22,11,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We saw the impact across all metropolitan markets, not just in hot spots like New York City. In April, volume declines continue to intensify as we are seeing signs that volume declines are bottoming out at around 50% to 60%. As you know, Quest Diagnostics has played a pivotal role in bringing COVID-19 testing capacity to the nation.",1.5772652,0.599
DGX-2020-Q1-2020-04-22,12,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Since we launched COVID-19 testing with a molecular laboratory developed tests, performed at our Advanced Diagnostic Laboratory at San Juan Capistrano, California. We have performed and reported results of nearly 1 million test to providers and patients across the United States. This is approximately a quarter of all testing done in the United States.",2.290939,0.796
DGX-2020-Q1-2020-04-22,13,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to provide testing for -- from 12 laboratories. Through these laboratories who are now able to perform more than 50,000 COVID-19 tests per day. We've also limited our backlog with a current turnaround time of one to two days and less than one day for priority hospital patients.",1.76771,-0.226
DGX-2020-Q1-2020-04-22,14,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've maximized our output by effectively managing the global supply chain. This has enabled us to have sufficient supplies to collect specimens for patients, runner test and also protect our employees. This has been a team effort that requires a great deal of collaboration.",1.6319605,0.863
DGX-2020-Q1-2020-04-22,15,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Since early March, we've been in regular contact with the federal government and state and local governments. And this has happened at all levels. We're working closely together with our payers, IVD manufacturers, retailers and our trade associations to bring as much testing capacity as possible to the American people.",1.1189456,0.0
DGX-2020-Q1-2020-04-22,16,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've also joined forces with Walmart to make our drive through testing sites available to anyone who may be exhibiting symptoms of the virus, as well as all health care workers and first responders, whether or not they're exhibiting symptoms. We're currently operating in approximately 10 sites in 5 states and have line of sight to approximately 20 locations by the end of the month. There are no out-of-pocket costs for testing at these sites.",1.9466227,0.477
DGX-2020-Q1-2020-04-22,17,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're also supporting state and local government COVID-19 testing efforts across the country. Finally, we are pleased to see CMS decide to increase the reimbursement for high throughput molecular COVID-19 testing to $100 last week. This is a strong recognition of the vital role laboratories are playing to support the nation's response to the COVID-19 pandemic and we hope to see other payors follow CMS's lead.",1.2589786,0.958
DGX-2020-Q1-2020-04-22,18,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As we look to the next phase of managing the virus, we've begun to perform antibody testing, which could be useful in improving our understanding of infection rates in a certain area, as well as providing a likely indication of immunity for an individual.",0.3196046,0.836
DGX-2020-Q1-2020-04-22,19,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Antibody testing, also known as serology testing is a blood based test. We're moving from a testing pilot in which we initially supported a handful of hospitals and health systems to making the test available to all of our customers nationwide using a variety of test platforms.",0.2158155,0.318
DGX-2020-Q1-2020-04-22,20,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","By mid-May, we anticipate having the capacity to perform over 200,000 antibody tests per day. I'm very proud of how our Quest colleagues have stepped up in so many ways. There are so many heroes at Quest from our scientific and medical staffs who have quickly brought up and validated new tests, through our operations teams, to our procurement teams, to our front line phlebotomists, couriers, pilots and specimen processors. And we've taken extra precautions to protect our employees with mandatory temperature checks at our labs and require use of protective equipment such as gloves, lab coats, masks, face shields, all this very depended on circumstances.",2.1686985,0.895
DGX-2020-Q1-2020-04-22,21,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our employees take pride in their work because so many Americans depend on the insights of our testing delivers to make decisions to improve care. These efforts for all of us are inspiring. COVID-19 testing is critical to managing the pandemic. And while the volume of testing is substantial, it is that nearly enough to offset the reductions we're seeing in the rest of our business.",1.5439868,0.869
DGX-2020-Q1-2020-04-22,22,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","During this difficult time, we're managing the business for the realities of today and to assure its long-term health. While we cannot say with precision. What the overall impact the COVID-19 pandemic will have in our business, we do know it will have significant impact in our [technical difficulty]. We are taking actions to mitigate that impact.",1.7288303,0.178
DGX-2020-Q1-2020-04-22,23,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","At the end of March, we withdrew our full-year 2020 outlook because we no longer had confidence in the outlook we provided in January. And we have taken a series of temporary actions to manage our workforce costs and conserve cash, to support the business and to navigate our way through the pandemic.",1.7420099,0.586
DGX-2020-Q1-2020-04-22,24,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",This started with a 25% pay cut for me and reductions for salaried employees ranging from 20% for the most senior executives to 5% depending on level. Each of the members of our company's Board of Directors will forego 25% of their cash compensation. These pay reductions will be in place for 12 weeks.,1.6342669,-0.44
DGX-2020-Q1-2020-04-22,25,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've also suspended contributions to our 401(k) and deferred compensation plans through the remainder of the year. We've approved furloughs for more than 5,500 employees, or approximately 12% of our workforce whose work has diminished and also have indicated an interest to us. We've reduced hours for non-exempt employees where possible and as necessary. And then finally we've reduced overtime, frozen virtually all hiring and promotions; and dismissed temporary and contract workers.",0.4579901,0.402
DGX-2020-Q1-2020-04-22,26,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're taking a balanced approach to implement these difficult measures. We also want to maintain flexibility because we know when the crisis ends, our volumes will begin to recover and we'll need our colleagues more than ever. This is a challenging time for all of us and in response to that we've established an employee relief fund for those colleagues who need assistance. Importantly, none of these changes will impact our ability to deliver critical COVID-19 testing.",1.8586491,0.273
DGX-2020-Q1-2020-04-22,27,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, I'd like to cover a few other topics. The passage of the CARES Act, the M&A environment and some early thoughts on how the lab industry may evolve in the wake of the COVID-19 pandemic. The CARES Act became law in late March, delivering much needed stimulus the country as we battle this crisis. The stimulus package included a number of benefits request and other health care providers.",0.5808896,0.822
DGX-2020-Q1-2020-04-22,28,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First, the Act provided coverage for critical COVID-19 testing at no out-of-pocket costs for nearly all patients. Second, regarding PAMA, the CARES Act suspended the PAMA price cuts that had been scheduled for 2021. In addition, the new round of data collection has been delayed another year into the first quarter of 2022 and will continue to use data from the first quarter of 2019. This is important as it allows ample time to implement the recommendations of the MedPAC study to identify a better way to collect the data that reflects private market rates as Congress initially intended.",1.3024712,-0.311
DGX-2020-Q1-2020-04-22,29,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Third, the Act appropriates $100 billion to health care providers for expenses or lost revenues that are attributed to COVID-19. Quest received approximately $65 million from the initial tranche of the $30 billion distributed to providers earlier this month. Finally, Medicare sequestration will be suspended from May to December this year. This 8-month sequestration holiday will afford us a small benefit.",0.6046129,0.542
DGX-2020-Q1-2020-04-22,30,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, turning to the M&A environment, we continue to make progress. We're pleased that we completed the Memorial Hermann transaction as well as its integration phase, and this is an important complex relationship with a very prominent healthcare system.",1.0481054,0.881
DGX-2020-Q1-2020-04-22,31,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","There are other transactions in the pipeline that we were very close to announcing before the crisis. While they are on hold, our strong conviction is that these discussions will resume, which will be in the third quarter and will be a very good position at that point to complete those transactions.",0.2144975,0.338
DGX-2020-Q1-2020-04-22,32,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, I'd like to share some thoughts on industry dynamics, post crisis. Given the many challenges that hospitals will face, we expect many to be open to discussions about Quest and how we can help them achieve their lab strategy. At the same time, we know that many smaller regional labs have had their own challenges. This could produce opportunities for tuck-in acquisitions. If any, the crisis could be an additional catalyst to drive the consolidation we've been forecasting for several years.",0.2813839,0.361
DGX-2020-Q1-2020-04-22,33,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before I close, I just want to say once again how proud I'm to be part of the Quest team at this historic time. Our employees have stepped up in every way to serve the nation during this time of need. The challenges have brought all of us at Quest closer together, changing the way we work and collaborate, making us stronger as a team. We have become more agile, customer-focused and unified. We will emerge from this crisis stronger with substantial opportunities in front of us.",0.2787479,0.841
DGX-2020-Q1-2020-04-22,34,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, I would like to turn it over to Mark, who will take you through the results as well as our thoughts on our financial position. Mark?",0.969687,0.557
DGX-2020-Q1-2020-04-22,35,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the first quarter, consolidated revenues were $1.82 billion, down 3.7% versus the prior year. Revenues for diagnostic information services declined 3.8% compared to the prior year. As Steve noted earlier, our business performance was strong in January and February, but we experienced a substantial decline in volumes in March. Volume measured by the number of requisitions decreased 2.4% versus the prior year. Excluding acquisitions, volumes declined 2.7%.",0.5110585,0.696
DGX-2020-Q1-2020-04-22,36,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Before describing some of the volume trends we saw in March and early April, I do want to spend a moment on the strong performance of our business prior to the COVID-19 pandemic. Through February, year-to-date total revenue growth was just over 4%, with organic revenue growth of just over 3.5%.",0.0920221,0.832
DGX-2020-Q1-2020-04-22,37,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Total volume growth was strong at 6.3%. Volume through February included a calendar benefit due in part to leap year, as well as mild winter weather. Adjusting for these benefits and the impact of acquisitions, organic volume growth in the first two months of 2020 was nearly 4.5%, indicating that the strong progress you made in 2019 continued into 2020.",0.3621643,0.965
DGX-2020-Q1-2020-04-22,38,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As we moved into March, we started to see single-digit volume declines through the first two weeks of the month. Stay-at-home measures were implemented in several states by the third week of March, volume declines accelerated to nearly 40%. And by the last week of the month, volume declines across the business started to approach 50%.",1.1935229,0.0
DGX-2020-Q1-2020-04-22,39,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So far in April, we have indications that volume declines have stabilized in the 50% to 60% range. These declines include the benefit of COVID-19 molecular testing, which has been running at approximately 30,000 tests per day on average or approximately 6% volume growth through April.",1.7867299,0.681
DGX-2020-Q1-2020-04-22,40,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per requisition declined 1.2% versus the prior year, primarily driven by higher reimbursement pressure. Unit price headwinds were slightly more than 2% in the first quarter in line with our prior expectations. This includes the impact of PAMA, which amounted to a headwind of approximately 100 basis points.",0.2342022,-0.296
DGX-2020-Q1-2020-04-22,41,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income was $175 million or 9.6% of revenues compared to $248 million or 13.2% of revenues last year. On an adjusted basis, operating income was $225 million or 12.3% of revenues compared to $286 million or 15.1% of revenues last year. The year-over-year decline in operating margin was entirely due to declining revenue in March as a result of COVID-19.",0.7409163,0.0
DGX-2020-Q1-2020-04-22,42,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Note that operating margin was up meaningfully year-over-year through February, primarily driven by the strong volume and revenue growth highlighted previously. Reported EPS was $0.73 in the quarter compared to a $1.20 a year-ago. Adjusted EPS was $0.94 compared to $1.40 last year.",2.07109,0.71
DGX-2020-Q1-2020-04-22,43,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Cash provided by operations was $247 million in the first quarter versus $275 million last year. I'd like to take a moment to discuss our financial position and our ability to access additional capital. As of March 31, we had $342 million of cash on hand and $1.3 billion of borrowing capacity was available under existing credit facilities. These facilities consist of $529 million available under our secured receivables credit facility and $750 million available under our senior unsecured revolving credit facility. There were no outstanding borrowings under these facilities as of March 31.",1.6370458,0.949
DGX-2020-Q1-2020-04-22,44,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In April, we borrowed $100 million under our secured receivables credit facility and $100 million under our senior unsecured revolving credit facility. Our secured receivables facility is subject to certain financial covenants with respect to the receivables that comprise the borrowing base and secure the borrowings under the facility.",0.5722749,0.927
DGX-2020-Q1-2020-04-22,45,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our unsecured revolving credit facility is also subject to certain financial covenants to limitations on indebtedness. In particular, the unsecured revolving credit facility requires us to maintain a leverage ratio of no more than 3.5x EBITDA as of the last day of each fiscal quarter. As of March 31, we were in compliance with all applicable financial covenants.",1.0872828,-0.026
DGX-2020-Q1-2020-04-22,46,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The COVID-19 pandemic is likely to impact our ability to comply with these covenants, beginning as early as the end of the second quarter. In this scenario, we would not be able to borrow against these credit facilities and then lenders would have the right to demand payment of any amount outstanding.",1.5398894,0.813
DGX-2020-Q1-2020-04-22,47,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,We have been in advanced discussions with our lead lender regarding an amendment to certain financial covenants of our unsecured revolving credit facility. We believe this would provide us with the necessary flexibility to remain in compliance for the remainder of 2020.,1.1508689,0.671
DGX-2020-Q1-2020-04-22,48,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Based on these discussions and the strong support from our lead lender, we are confident we will be able to enter into this amendment later in the quarter. If, for some reason we are unable to enter into this amendment, we believe that our investment grade credit rating would provide us with access to alternate sources of financing. Finally, as noted in our earnings release this morning, we are also suspending share repurchases through the end of the year under our existing repurchase authorization.",1.6793049,0.919
DGX-2020-Q1-2020-04-22,49,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"To summarize, we believe our financial position and ability to access additional capital is strong and our Board of Directors remain committed to the company's quarterly dividend at this time. As many of you know, we withdrew our 2020 guidance on March 31, given the unprecedented uncertainty caused by COVID-19 pandemic. We expect to provide updated 2020 guidance at a more appropriate time when visibility improves around the impact of COVID-19 and the duration of current stay-at-home measures in place across the United States.",0.0469984,0.872
DGX-2020-Q1-2020-04-22,50,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"While we aren't providing guidance today, I'd like to share some details for you to consider as you build your models. As many of you know, our business is one of high fixed costs. We have modeled a number of different volume scenarios over the near to medium term and at this point our best estimate is that volumes for the business excluding COVID-19 testing will be down 50% to 60% in the second quarter.",1.0975513,0.848
DGX-2020-Q1-2020-04-22,51,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Once the COVID-19 crisis mitigates or passes and stay-at-home measures begin to lift, we believe our volume will slowly improve but to a lower level in 2020 than where we started the year. While we have taken several cost reduction steps, which we first shared in an 8-K on April 13, these steps are not sufficient to enable us to generate a profit at this volume assumption. If the conditions affecting lower lab utilization continue throughout the second quarter, it is highly likely we will incur a net loss.",0.9127172,-0.296
DGX-2020-Q1-2020-04-22,52,Remarks,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Molecular COVID-19 testing does serve as a partial offset to the volume declines we're experiencing across the rest of the business. We expect that demand for molecular COVID-19 testing will remain high throughout the second quarter and likely the foreseeable future. In addition to the uncertainty around health care utilization in lab volume trends, another unknown is the impact of serology testing. We believe there's significant potential in serology testing, but reimbursement and customer demand are still in front of us.",1.1883886,-0.052
DGX-2020-Q1-2020-04-22,54,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","To summarize, we were very pleased with January and February performance, but saw a material decline in last two weeks of March. We are managing the company for the long-term and are taking a series of actions to protect our financial flexibility.",0.2405272,0.822
DGX-2020-Q1-2020-04-22,55,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest has been at the tip of the spear in responding to the crisis, and we will continue to play a critical role in the next phase of containing COVID-19. While there's uncertainty in the near-term, we look forward to the gradual improving conditions we see in front of us. Eventually, the healthcare system will start to return to normal and when that happens, Quest will emerge from the crisis stronger with significant opportunities in front of us.",0.7736409,-0.402
DGX-2020-Q1-2020-04-22,56,Remarks,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, we'd be happy to take any questions you have. Operator?",1.693575,0.572
DGX-2020-Q1-2020-04-22,64,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. All right, Ann. All right. So all around antibody testing and serology testing. So as you read our press release yesterday, we launched our broad implementation of serology testing. We actually brought up a week or so ago, our first limited LDT laboratory developed tests on the EUROIMMUN platform. And we did that in two of our facilities and we did that for limited customers, hospitals and at risk individuals. So we had some experience with it.",1.0744646,-0.178
DGX-2020-Q1-2020-04-22,65,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then second, as we brought up our first platform, which is an app platform, and we announced last night, that will -- platform is in many of our sites and we will bring that up quickly. And then we will have a few other platforms we bring up in the course of April into May. And that will allow us to get to that 200,000 tests per day number by mid-May. We've run seven days a week, 24 hours a day. That's about 1.5 million per week. And so you can think about 6 million per month.",0.8197694,0.296
DGX-2020-Q1-2020-04-22,66,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, to answer your questions, we're not stopping there. We've got more capacity in front of us. We are always dependent though on the capacity coming out of the IVD manufacturers with the reagents that we need. So somewhat of the limiting factor has less to do with us where we have lab capacity, but more related to the reagents and the supply chain from our suppliers. So we're working with them as well. So that's what we're willing to say we'll have in the month of May.",0.9670511,0.435
DGX-2020-Q1-2020-04-22,67,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, how broad would this be? What we announced in a press release and you see the guidance from the FDA, while we do believe are several things, one is after a certain number of days and the best indication is after 14 days of being infected, the person can have an IGG response. That's the last antibody. And therefore, it is obviously a good measurement that you have been infected in the past. It's important to those individuals that have not been tested and made it -- might have been asymptomatic. So it's another good indication of infection rate within the geography or within a population. That's number one.",0.3469522,0.796
DGX-2020-Q1-2020-04-22,68,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Point number two is based upon other viruses. We believe that there may be immunity for some period of time. This is what we need to study. And that's why we have the conditions on our press release that we need to have more evidence and this is why we need to do more of it. The vast majority of viruses in the past have had immunity for a period of time, but we need to confirm this with evidence. So with that said, I would share with you we have tremendous interest in both continuation of the molecular testing that has to be done going forward. And then second is combining it with serology testing. This is happening at the state level for broad infrastructure needs.",0.4,0.788
DGX-2020-Q1-2020-04-22,69,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","You might have seen a new announcement by the state of California. They're going to start to test asymptomatic members -- excuse me, citizens within California. Second is employers. We have actually leveraged our capability with our employer population health business, which we used to call our wellness business, where we have this product called Blueprint for Wellness and we work with employers. And we leverage that now in building on those relationships with employers in their return to work programs. And so that's giving us a nice leverage point. And the return to work programs vary by industry. It matters a great deal if you're a manufacturer and you have plants, or if you're an office environment or if you're a food processor, so we have a number of engagements going on with employers. And those employers are working with their states and are working with their cities and towns and local communities, as they think about what needs to happen and within those geographies, because there is wide variation, that's what's happening with the constraints around return to work and shelter-in-place in schools.",0.416804,0.951
DGX-2020-Q1-2020-04-22,70,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, we are working with the states. Many of the states have mounted now task forces to look at what needs to happen next with test -- testing. As I said, California has made now a broader announcement of what they want to do to expand testing. We see this coming from out from a number of states. We're right in the middle of all those conversations. In fact yesterday, I did a press conference with the governor of Connecticut, Governor of Lamont in Connecticut, where we work proactively with one of our partners, Hartford HealthCare and expanding testing in the state of Connecticut.",0.2079077,0.44
DGX-2020-Q1-2020-04-22,71,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So as Mark said, there's substantial opportunities in front of us both for the molecular testing, which has to be done to rule in, rule out COVID-19. And then you, coupled with the opportunities we see for serology or antibody testing as well for overall surveillance within a population and returning to work. So a good opportunity in front of us.",1.1123558,0.924
DGX-2020-Q1-2020-04-22,76,Question,2020-04-22,1,2020,Ralph Giacobbe,Credit Suisse,"Thanks. Hey, good morning. Thanks for all the detail. So you mentioned the minus 50% to minus 60% volume ex COVID, I guess first just want to clarify that the profit loss commentary is inclusive of COVID-19, so sort of it's an all-in number or is it enough to offset that profitability loss? And then how do you think about decremental margin with that type of revenue decline? If you can give us any sense there that would be helpful as well. Thanks.",0.3940493,0.959
DGX-2020-Q1-2020-04-22,78,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure, Steve. So, Ralph, the statement around net loss would be a volume inclusive of COVID testing continue to be down around 50% to 60%. Now, what that does not include is serology. So as I said in my prepared remarks, the -- well, we're encouraged by the potential demand and a lot of the things that Steve just explained are either in mid-term or a late stage conversations around stepping up some testing for government entities, for employers, etcetera. We haven't been performing that test. Obviously, we just launched serology, so we wanted to be cautious about forecasting in any way how meaningful serology would be.",1.8625592,0.751
DGX-2020-Q1-2020-04-22,79,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"But based on all the things we've talked about, it could be significant. We also don't know the reimbursement rate yet, but hopefully fairly soon. And I think the trigger for commercial rates will largely be based on where CMS comes out. So we're all waiting on that. So that net loss comment and the 50% to 60% would include the current level of PCR where we said we're averaging about 30,000 tests a day. It's offsetting about 6% of our loss, but it does not contemplate significant upside if it happens from serology testing at some point in this quarter. And then on a margin perspective, obviously, if we losing money, the answer to that, but from a drop through perspective, because we are high fixed costs and we've already counted on as much adjustment to our cost structure as we can optimize through our furloughs, through reduced hours to some of those salary reductions for the next twelve weeks. We're largely fixed cost after that.",0.8732227,-0.316
DGX-2020-Q1-2020-04-22,80,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So therefore any sort of volume changes would likely be at a very high ratio, if things were to get worse. As we said, we believe we've bottomed out because we've seen some stability over the last couple of weeks. There's some encouraging signs in some of the areas that were most impacted because not all geographies are created equal. So, some of those are bouncing back a little bit. But at this point, we wanted to be cautious, we wanted to be conservative, we wanted to tell you what we know today. And therefore the outlook for the quarter is not based on speculation. That is based on what we're seeing and what we know today.",1.1895735,0.226
DGX-2020-Q1-2020-04-22,87,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure, sure. So let me start, then Mark will I'm sure, add to it. First of all, Invigorate continues. That's a regular cadence and one of our two strategies that we have is to drive operational excellence and a portion of that is our efficiency program and we continue to look for that 3% of our cost basis for years. So that hasn't changed. So we continue to work on those programs. And in that regard, one of our flagship programs that we talk about is the new Clifton Laboratory that will allow us to consolidate the footprint to allow us to put in some new platforms, the immunoassay platform we talked about in the past, that project continues. But what I'll say, we're in the process of refreshing our plans because some of those plans might change. So, for instance, construction in the state of New Jersey might slip some. So some of those might change.",1.5116969,0.956
DGX-2020-Q1-2020-04-22,88,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then secondly, some of the expectations around costs within a given year in terms of magnitude might be lower because some of it is volume dependent. However, in terms of percentage, if we're at lower volume levels, they'll be even higher percentages given some of this is fixed. So we're refreshing our perspective, but the goal of getting at least 3% of our cost basis for a year still stands. But we haven't provided an absolute number beyond the 3% in the past. So, Mark, would you like to add to it?",1.6461285,0.361
DGX-2020-Q1-2020-04-22,89,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, I think Steve summarized it well. A lot of our Invigorate is around volume related activities, whether it's labor, whether it's our lab throughput, whether it's the draws we're doing in a patient service centers. So any sort of savings, certainly will continue as we implement some of the cost improvement efficiency opportunities, but they will be proportional. So obviously the dollars will be less. We always talked about 3% on a $6 billion plus cost base. Obviously if the cost base goes down, given lower volumes, you can expect lower dollar savings. The other thing I would add is that a lot of our efficiency programs are, design along the normal level of testing. So it is difficult to operate as efficiently when you lose half your volume on a given line, some places even more than that and given assays.",0.2831754,0.352
DGX-2020-Q1-2020-04-22,90,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So the efficiency around reagents and other things operational, things like labor flexibility and so on. So there is some offset to our Invigorate program and lost efficiencies, while we continue at this low level of volume because we're not going to rescale our business obviously to that extent. We're considering this to be temporary at some point, even though I caution we don't expect to be fully back to the level we were prior to COVID. We at some point we'll be back to much more significant testing. I mean, some of our cancer screening is down, very, very significantly. We all know at some point we have to come back and do that work because cancer doesn't go away. So, Invigorate will continue. It will be proportional. There will be some offsets because of the inherent lower efficiencies at these volume levels.",0.0706951,0.476
DGX-2020-Q1-2020-04-22,93,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So volume has not turned around. We said it stabilize. So when you asked about whether things in March and now we're seeing them pick up, what I would say is that, we worked across what we call our clinical franchises, and there's absolutely differences depending on the acuteness of the condition and the necessity of the testing. But there's some very acute important areas of adjustments and like cancer screening led testing in children, etcetera, that are down significantly just because physician offices are closed and people are uncomfortable going out, or people being told not to go out except for extreme necessary situations. So while we absolutely see some levels of difference across the testing venue and how much it's down, some more than 50% to 60%, some less than that. I can't tell you that we've seen more discretionary type testing come back dramatically yet.",1.7594728,-0.183
DGX-2020-Q1-2020-04-22,102,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So let me start. So on reimbursements, we were really encouraged by CMS upping the rate to $100. We're current -- currently working -- approaching all the commercial insurance companies on what their rate will be. And we don't have an answer on that, but we're encouraged that CMS went up and that's usually an indication that gives us leverage working with the commercial insurance companies. So more to come on that. Second, as Mark said, we still do not have the CMS rate for a serology testing. That's an important fact for us to establish reimbursement for serology, which would be, as we said, a significant opportunity. As far as scale, I mentioned in my comments, we are driving capacity gains going forward. We're bringing up some new platforms, trying to get some additional units. We're looking for different approaches of how we can get more productivity and more capacity from our existing platforms. And that is on the molecular side, will equally be on the serology side. And we have actually been asked by the White House task force to think creatively of what we can do to expand our capacity beyond what we have done so far. So we're thinking our way through that.",0.0975288,0.971
DGX-2020-Q1-2020-04-22,103,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As I said, we're right now at 50,000 tests per day, and that's for molecular. We're trying to get plans in place to bring us north of that number. But nothing that we can say at this point, but we're aggressively pursuing it. We are encouraged by what we saw last night come out of the Senate and hopefully the House will deliberate and we'll get the next round of funding. And some portion of that will come to us, because we do need to continue to do the testing in this country. And it so depended on both tests happening, molecular testing, as well as the serology tests going forward. So encouraged with the progress we're making, more in front of us. And yes, we will push hard to get more out.",0.0392092,0.948
DGX-2020-Q1-2020-04-22,104,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as I said earlier, when I am asked the question about capacity on serology we have to look at the whole supply chain, the front end and the back end. So, yes, we have the lab capacity. But one of the issues we had on molecular side is not having the supplies, the swabs in the right places. We actually have shipped out in excess of a million swabs and we haven't resulted in excess of a million. So we have some inventory sitting out there. And also on the back end, it's very dependent upon IVD manufacturers providing us with the reagents and the kits o be able to increase our capacity as well. So we're working with them. And I can tell you, we're getting a lot of help from the task force, the White House, help from the states, everyone is rolled up their sleeves and trying to get more capacity out there. So there will be more coming, but what we've said so far is what we feel comfortable so far, I would say. Mark, you like to add to that?",1.8494234,0.927
DGX-2020-Q1-2020-04-22,105,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. Let me add a couple of things. So, Jack, almost without exception and certainly all of the national payers and large regional payers, the commercial reimbursement for the PCR test was based on the rate for Medicare and was not a subset or proportion, which obviously it's in the industry practice, but was with at or above the CMS rate. So therefore, I'm confident that we're going to do well. As you know, CMS has updated this price. We are in advanced discussions and I think it's very probable that most, if not all the company, the commercial payers will recognize the higher rate from CMS and our commercial rates will change. So I'm optimistic there.",1.114534,0.927
DGX-2020-Q1-2020-04-22,106,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of the second half of the year, as we said, we're very careful. We -- none of us know how this is going to play out, but you can do the math. So if you know, the capacity for serology is in any way meet the demand and Steve talked about 200,000 a day, you have the PCR currently today at 50,000 tests a day combined, those represent almost half of our normal daily testing volume. And given that we don't know serology yet, but we're hopeful the price will be fairly close to an average requisition price for us.",2.0493681,0.705
DGX-2020-Q1-2020-04-22,107,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And we know that the PCR testing is above that with the CMS rate revision. One would assume that the value of a requisition will be somewhat similar to what our average is today. So, again, I don't know how much the core volume will recover, how quickly it will happen, etcetera. But if there is some recovery and if there is some high level of demand for the COVID-19 testing, as we're all hearing publicly, then you can do the numbers and you can see that the back half of the year could be very different than the second quarter.",0.3349131,0.226
DGX-2020-Q1-2020-04-22,108,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And just to remind everyone there is a difference. And hopefully it's clear between the molecular testing, which requires a health care professional in most cases to do the specimen collection. And in many cases, they're protected with full garb of personal protection equipment. So that created a bottleneck of people getting tested. And we've worked on some different approaches to that. As a matter of fact, in the Walmart, the Walmart sites, we have observed self collection where actually we have an approved kit from the FDA where it is a nasal swab, but the person can use that swab themselves, but it has to be observed by health care professional.",1.1904448,0.912
DGX-2020-Q1-2020-04-22,109,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But in the case of Walmart, what actually happens is the person drives up, they provide the order to a health care worker in those parking lots that aren't nearly as protective as what we need to do before, they confirm all the information. The health care worker provides information that close up their window and they do the self collection themselves and it's observed through the window. So that's proven to be highly efficient. And we're looking at other ways of collecting that trend on the molecular side. So that has been a little bit of a bottleneck too on that and we're improving how we get the specimens.",1.1607908,0.906
DGX-2020-Q1-2020-04-22,110,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Remember, serology is blood based. And so it leverages all our infrastructure. And so as you know we have 12,000 phlebotomists, we have 2,200 patient service centers, we have 4,000 phlebotomists and physicians' offices. And so when this starts to light up, that provides us a nice opportunity to collect those specimens quickly and potentially tag those orders onto other orders that might be coming in from the health care delivery system as health care starts to turn on. So when you think about serology and you think about the front end being much simpler and much more pervasive and leveraging everything already have, not exceptional like the molecular test has been so far.",1.1861614,0.872
DGX-2020-Q1-2020-04-22,115,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, Ricky, our Medicaid revenues, as you know, are low single digits. Currently Medicaid is typically lower priced than Medicare, typically priced lower than commercial rates. Now when you talk about unemployment, absolutely, we've thought about that. And one of the reasons amongst many that we're cautious about whether volumes bounce back to where they were earlier in the year was the potential for continued unemployment higher than obviously we've had in the number of years. And so, therefore we are recognizing that potential as we think about the balance of the year. And quite frankly, going forward, the other dynamic is if you look historically and obviously we try to do that, I'm sure others have to try to predict what might happen this time, there are some notable differences. One of them is the Affordable Care Act does provide more of a safety net for those who lose their jobs. So that's a positive.",1.5154028,0.566
DGX-2020-Q1-2020-04-22,116,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"But the other thing is, given the magnitude and the speed at which people have become unemployed, it's really difficult to model and predict what that might do to utilization. We are being very cognizant of collectability, not just from patients, but from hospital systems, from physicians. So we're monitoring very, very closely our receivables and collection rates. And we are anticipating likely headwinds on collectability of our revenue going forward, given everything that's going on. So that's certainly on our radar. But the other dynamic is, given that utilization has -- in the last couple of months dropped significantly, one might assume that a greater portion of our revenues would be coming from patients because people will be more slowly or not getting through their deductible and calendar basis relative to where they may have in the past.",1.2815956,0.851
DGX-2020-Q1-2020-04-22,117,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we've looked at all of these things and that obviously it will be a headwind. But there's no model we can point to historically to say this is exactly what it means. I mean, in the last significant recession, our collectability rate actually did not materially decline. Utilization was impacted, but we did not have a higher rate of what used to be bad debt. Now it's mostly patient concessions. But given all the dynamics this time, we think that that's a likely possibility. However, you do have the safety net through the Affordable Care Act of expansion of Medicaid in many states. So how all those pieces put together? I can't fully predict, but trust me we're thinking about all that. And as we see trends and as we understand those impacts, as always, we'll be extremely transparent around what we're seeing.",1.306872,0.599
DGX-2020-Q1-2020-04-22,120,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So you start to see some of the individual states starting to loosen up their shelter-in-place and started to loosen up employers coming back to work. And so we're watching that carefully, so we can kind of indicate where we need to bring back our capacity. We talked about our costs programs. We've talked about furloughs. I want to make sure it's clear. Our furlough program was a program where we offered it to employees, but they had requested from us and we had to grant it. And so we grant out furlough. It allows them to continue to benefits request, but also allows them to collect unemployment and apply to the CARES Act for a weekly stipend. But it also allows us to bring them back. And so they have an obligation to come back when we need them. So as these states start to turn back on, we will bring back the capacity we need to turn it back on. But we're watching that Ricky carefully to understand what's gone down and when did we start to see some recovery by state and by clinical franchise going forward.",0.5607908,0.941
DGX-2020-Q1-2020-04-22,121,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, the one other thing I'd add is that while shelter-in-place certainly has a significant impact on utilization and some of the greatest volume decreases were in those geographies, as we mentioned, every major metropolitan area in the country was seeing significant declines. Maybe not to the same extent in late March and then into early April, regardless of whether we had shelter-in-place. We are not as true outside the urban areas, but in the metropolitan areas people were being cautious, including physician offices, etcetera in -- how they were accepting patients and whether they were staying open or not and patients were being cautious about whether going out or not, given all the media attention and so on and so forth. So while there is absolutely a correlation with shelter-in-place rules, it's more than that, that has been depressing utilization.",2.0896524,0.124
DGX-2020-Q1-2020-04-22,123,Answer,2020-04-22,1,2020,Shawn Bevec,Executive Director-Investor Relations,"Folks, there's a number of people still in the queue. And we're getting towards the bottom of the hour and we'd like to get to most of you, so please limit to one question.",1.6073035,0.7
DGX-2020-Q1-2020-04-22,129,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, well, to start with, if you look at the numbers that come out of the White House in their press briefings, we said that we've done over a million tests. We're close to 25% of the total country's testing. Obviously, we have better percentages, a higher percentage in certain states grew up broader presence. And some states are really just ramping up their testing in a bigger way. If they look at Florida, where we have a big presence that's just really started to light up in a big way. As far as the opportunity in front of us, we are encouraged by the opportunity we see. We're waiting to see how quickly it does ramp up and just what kind of pickup there will be from physicians on serological testing and how fast that ramp will be. But we're building enough capacity to respond to it. And again, a lot of our capacity will be highly depended upon the equipment we have and the reagents we get. So if there's more, we're hopeful we can build on what we have, but we are very limited by that. So we're going to keep our eye on it, push it as one of the two testing categories that should be done to respond to the virus and see how quickly it ran. So we will keep you updated as we learn more.",1.338715,0.788
DGX-2020-Q1-2020-04-22,131,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I would say both. And I think there's as I mentioned earlier, we're working with employers because many employers are trying to understand how they bring back to employees. And there's wide variation in employers, but these employee programs will both test your employees for the virus with the molecular tests, and they'll also test them for the antibody tests. And we might do those, particularly the antibody test in different types of venues like corporate sponsored events where we can -- now where we can draw the specimen quickly as we do, corporate events they were for flu shots or Blueprint for Wellness program. So we already have that capability of ramping up these corporate programs. And those will be quite different than the traditional way of doing testing that we have with physicians or hospitals today.",0.8912685,0.572
DGX-2020-Q1-2020-04-22,136,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Mark, you start the first one, I had a hard time hearing the first question. Mark, did you pick it up?",0.3617792,-0.103
DGX-2020-Q1-2020-04-22,137,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Go ahead. If you wouldn't mind repeating, you talked about future wellness.",0.4561611,0.44
DGX-2020-Q1-2020-04-22,139,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So on that one, it's very hard to predict. And just like you're asking, it could go either direction. We don't have any sort of crystal ball better than anybody else. Obviously, in my prepared remarks and then one of my answers, I expressed a concern that we're deferring critical diagnostic testing that's important for our health and well-being. And one would hope that at some point we say, that's really important, we've got to find a way to get it done regardless of what risks might be around COVID and whether that bounces back to where it was before or whether to your point could it potentially be more because COVID is obviously much riskier for those with pre-existing conditions that we're all familiar with and that means we want even more tightly manage that. I certainly can't predict it. I'm not sure, if Steve wants to comment anything differently. So that's unclear. But as we said, as we progressed through this and we all learned together, we will be highly transparent around what we're seeing so that you all can understand as much as possible how that is playing out. Then, Steve, the other one was on PAMA lab consolidation.",1.0845182,0.763
DGX-2020-Q1-2020-04-22,140,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. We see an opportunity. So if you think about what's happening within the healthcare provider market, we're an indication that volumes are down. You have all the data on possible missions. You have data on physician visits. You see it reflected in our volumes being down. And so hospitals and as we all know, 50% of physicians now are employed by hospital systems are going to be struggling as they enter this quarter. And we'll be looking at opportunities to become more efficient, reduce their cost, generate some cash. And so we believe there could be an opportunity for us to continue our consolidation strategy in the back half the year, it is more of these systems and some of those dialogues we've had for years maybe become more active now because there's now more likely to think about creative ways that they can work with a company like Quest on their lab strategy.",0.691598,0.956
DGX-2020-Q1-2020-04-22,141,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we think that could be another catalysts for consolidation. And as you know, this is also a fragmented industry. There's other regional, especially laboratories. And it also might have worsened other opportunities for us to consolidate. So we believe this is a good opportunity in the long-term for us to continue our strategy of accelerating our growth and consolidating the marketplace. And in the short-term, it's difficult, but in the mid to long-term, we think it could be yet another opportunity to do what we've said we wanted to do.",1.8428336,0.754
DGX-2020-Q1-2020-04-22,146,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So as I said, we are not going to speculate, because it shows too hard to predict. So, yes, there's absolutely some potential for volume bouncing back from where it is now. We're not assuming any material improvement for the quarter, not because we know that won't happen, but because we think that's the appropriate point of view to take in order to make sure people are aware of some of the potential downside. We also haven't built in any significant serology volumes into those assumptions. And we've heard a lot of discussion today around that potential demand and ramping up fairly quickly. We don't know to what extent. So I don't want anyone to assume we have too much precision around this 50% to 60% down for the quarter and a, net operating loss. But that's potential if it does stay where it is and we don't get significant serology testing or significant upwards in our PCR testing. I don't know if you want to add anything, Steve, to that.",0.6532385,0.829
DGX-2020-Q1-2020-04-22,148,Answer,2020-04-22,1,2020,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",1.0688013,0.0
DGX-2020-Q1-2020-04-22,152,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, absolutely. Our strategy to accelerate growth continues. One of those strategies is to continue to build our advanced diagnostics platform. Again, that's all genetics and molecular. The acquisition that we did complete early this year was a nice platform capability acquisition. We feel good about that company coming into Quest Diagnostics. The integration is going well. There's a lot of opportunities in front of us with a genetic base testing. And our plans for that do not change given the crisis step that we have.",0.4682043,0.891
DGX-2020-Q1-2020-04-22,159,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, we've been working with all the Telehealth providers and platforms in this many different models as we know. So we do see that as another channel, if you will, or another type of capability as health care provision. And this crisis has burned some of those models there and established some credibility and some comfort with patients. And so we do believe that will become a larger percentage of our volume. And when you have those engagements, many of you on the call probably have had those engagements, they do order testing. And then it follows the workflow that we have for testing within Quest Diagnostics. And then depending upon the model we've used in the platforms, the use is telemedicine going to be your primary care physician or would they be an adjunct to it and therefore, we have the connectivity to connect back to the EMR in the primary care physician. So good opportunity. We have strong relationships with many of the Telehealth platforms, big and small. We actually are always prospecting what new startups and ventures are coming up with new capabilities. There's been a lot of new front end capabilities, triage capabilities that you see to run COVID-19, which has been interesting, some of which we're very well of -- we're aware of and have good relations with. So it is changing and this crisis has brought more visibility to it. So we believe that's a good opportunity for us and we're very well positioned with those companies going forward.",0.7861614,0.983
DGX-2020-Q1-2020-04-22,165,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. What I'll say, Erin, is it can't hurt. This crisis has brought to the forefront the importance of testing. And I never believed when I joined this company over eight years ago, that would be on the front page of every news story in America and all over the media, but we are. So it's much easier now for us to make our case with members of Congress, to the administration in HSS with the value of testing and the need for us to get fairly reimbursed. And also to reinforce the intent of Congress in making sure we get a new process put in place that properly reflects the market rates. So it is actually a very good fact for us. We're going to leverage that. Just to remind everyone the CARES Act did change the timing. I had those in my prepared remarks. And then second is we still have the lawsuit going on, which is still happening. And we're hopeful we'll get a decision sometime this year on that.",1.3871499,0.975
DGX-2020-Q1-2020-04-22,170,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So that was a unique situation. They created a pot of money of $30 billion emergency relief. There were no stipulations for how you would get that money. In fact, we are surprised, it showed up in our bank account. It was based on proportional billings to Medicare and that probably divided up at $30 billion. So anyone who had billed Medicare in the prior year got a portion of that. The other parts of this bill are, for various aspects of getting testing up and running. I will turn to Steve to cover some of that, but there's nothing else that quite mirrors that emergency relief fund where we got the $65 billion. So while there's opportunities for us to utilize some of the other funds, it's not as straightforward and it's not as simple as what happened with that emergency relief fund. So, Steve.",0.5209321,0.829
DGX-2020-Q1-2020-04-22,171,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. And I'll just say the package that was just approved by the Senate last night, we don't have a lot of clarity of any specificity underneath the hood, if you will. And then also, as you know, it's going to be debated in the House. So we'll be watching and giving them input as they refine it. But it is critical to get America turn back on, that we have the resources and we're properly reimbursed and paid for the work we do. And as I said, we are the leader for a portion -- a large portion of the country is testing. And therefore, I would expect that some portion of that money we could tap into as a resource for us, but it's uncertain at this time what it will be and if any.",1.4873147,0.214
DGX-2020-Q1-2020-04-22,177,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So just to give you a scale again of what our different businesses. Of our business, roughly a billion of it before crisis was coming from hospitals. To give you an idea of the scale and -- and then a billion of our business is -- are related services like our population health business with employers, our employer drug testing business, our insurance business. And so the remainder is really physician driven, okay? So, roughly $6 billion of our $8 billion before crisis was -- is physician driven. So those referrals are obviously very important because that's where we get the vast majority of our volume.",1.1749588,-0.442
DGX-2020-Q1-2020-04-22,178,Answer,2020-04-22,1,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then on serology testing, Brian, well, we've never shared a dollar amount. You can look at some of the CMS rates. We've made it clear through our trade association that we don't think the crosswalk that they probably would default to is sufficient. Obviously you saw -- in the first case for the PCR, we weren't successful initially. They established a rate and then they reconsidered, looked at it and almost doubled it. So we're hopeful that in the case of serology, there's some pretty compelling evidence and detail that we're going to get a serology rate for the COVID testing that's more commensurate with the cost that its -- we're going to incur in order to perform it.",0.3882306,0.934
DGX-2020-Q1-2020-04-22,179,Answer,2020-04-22,1,2020,Shawn Bevec,Executive Director-Investor Relations,"Steve, closing remarks.",1.908706,0.0
DGX-2020-Q1-2020-04-22,180,Answer,2020-04-22,1,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. Well, thanks everyone, for joining us today. Glad we got everyone's questions and we appreciate your continued support and you have a great day.",0.8085667,0.957
DGX-2019-Q4-2020-01-30,4,Remarks,2020-01-30,4,2019,Shawn Bevec,Executive Director-Investor Relations,"During this call we may make forward-looking statements and we'll discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent Annual Report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.",1.4241863,-0.065
DGX-2019-Q4-2020-01-30,5,Remarks,2020-01-30,4,2019,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS from continuing operations and references to adjusted EPS refer to adjusted diluted EPS from continuing operations, excluding amortization expense. References to adjusted operating income for all periods excludes amortization expense. Finally, growth rates associated with our long-term outlook projections including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth are compound annual growth rates.",0.023022,0.941
DGX-2019-Q4-2020-01-30,7,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. Well, this morning I'll discuss the fourth quarter and review progress on our two-point strategy. And then Mark will provide more detail on the results, then take you through our 2020 guidance. But we had a solid fourth quarter and ended the year by delivering record revenues, earnings and cash from operations. Strong volume growth from expanded health than planned network access, combined with outstanding execution of our operational excellence strategy helped us offset significant reimbursement pressure.",1.7621087,0.975
DGX-2019-Q4-2020-01-30,8,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","For the fourth quarter, we grew revenues 4.8%, reported EPS was $1.86 and adjusted EPS was $1.67, up nearly 24% from the same period in 2018. Volume growth remained strong at 4.1%. For the full year of 2019, revenues grew 2.6%, reported EPS grew 16% to $6.13 and adjusted EPS grew 4% to $6.56 and volume grew 4.3%. In addition, we are increasing our quarterly dividend by nearly 6%. And this is the ninth increase since 2011.",2.262603,0.802
DGX-2019-Q4-2020-01-30,9,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before getting into the more details of the fourth quarter, I'd like to discuss how Quest is squarely within healthcare's AAA, as well as covered on PAMA and the recent passage of the LAB Act. So many providers within healthcare are focusing on healthcare's AAA, which is all about improving medical quality and the patient experience, while reducing the cost of care.",2.369028,0.863
DGX-2019-Q4-2020-01-30,10,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Quest is dedicated to provide a great medical and service quality. One example is that we drive six input quality in our logistics performance by tracking specimen pickups. We're proud that our quality enables us to become a member of UnitedHealthcare's preferred lab network.,1.5327842,0.881
DGX-2019-Q4-2020-01-30,12,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally, Quest offers the best value in the lab industry. Test prices for many of our smaller boutiques and hospital competitors can be two to five times higher than our prices and sometimes even more. So taken together, our medical quality, patient experience and competitive pricing delivers a value proposition that is second to none in our industry.",1.9532125,0.866
DGX-2019-Q4-2020-01-30,13,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I'd like to update you on three fundamental changes to the marketplace, which I believe favor Quest. First, PAMA. This is the largest hub in Medicare reimbursement this industry has ever seen.",2.1360791,0.637
DGX-2019-Q4-2020-01-30,14,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second, receive health plans focusing on the wide variation in price for health care delivery. And they are looking at opportunities to work with fewer higher value providers. Our expanded network access with UnitedHealthcare and the implementation of the preferred lab network are perfect examples of this.",0.7037891,0.898
DGX-2019-Q4-2020-01-30,15,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",And then third is the increasing consumerization of health care. Consumers are shouldering more and more of the cost of health care and they're looking for the best value. We believe Quest Diagnostics is the best deal in town.,0.4846787,0.953
DGX-2019-Q4-2020-01-30,16,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",I'd like to quickly comment on PAMA and the latest development regarding the passage of the LAB Act. We were pleased to see the LAB Act become law in late December. And it is the first step in fixing CMS's deeply through data collection process. The Lab Act will delay the data reporting period for one-year to the first quarter of 2021. It will also require MedPAC to identify a better way to collect the data that reflects private market rates as Congress initially intended.,1.5742998,0.718
DGX-2019-Q4-2020-01-30,17,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As many of you know the one-year delay now means that CMS will delay on the existing fee schedule for the basis of cuts in 2021. Despite the increase in reimbursement reduction caps from 10% in 2020 to 15% in 2021, we expect the PAMA headwinds in 2021 to be relatively consistent with 2019 and 2020.",1.5917628,-0.542
DGX-2019-Q4-2020-01-30,18,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Additionally ACLA, our trade associations continues its legal challenge against HHS. Both sides have submitted their briefs to the courts and the matters in the hands of the judge. We expect a decision sometime this year.",1.6487644,0.226
DGX-2019-Q4-2020-01-30,19,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, turning to our recent performance and progress. The first part of our two-point strategy is to accelerate growth, which has five elements; grow more than 2% per year through accretive strategically aligned acquisitions; expand relationships with health plans and hospital health systems; offer the broadest access to diagnostic innovation. We're recognizes as the consumer-friendly provider of diagnostic information services. And then finally, support population health with data analytics and extended care services.",2.0224053,0.935
DGX-2019-Q4-2020-01-30,20,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now let me take you through a few highlights from our strategy to accelerate growth. Our acquisition pipeline remains strong. During the fourth quarter, we announced the acquisition of Boston Clinical Laboratories, a small regional laboratory in Massachusetts.",1.752883,0.71
DGX-2019-Q4-2020-01-30,21,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also recently announced two new acquisitions. The first, Blueprint Genetics. It strengthens our leadership position in advanced diagnostics, through proprietary bioinformatics, which is often a bottleneck in next-generation sequencing. Blueprint's proven platform and specialty genetics, especially, variant interpretation and reporting is expected to significantly speed the average rate at time of interpretation.",2.4649094,0.612
DGX-2019-Q4-2020-01-30,22,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also announced a multifaceted long-term collaboration with the Memorial Hermann Health System, one of the largest not-for-profit health systems in Southeast Texas. As part of the agreement, Quest will acquire Memorial Hermann's outreach lab services business and manage all 17 of its inpatient hospital labs in Greater Houston under our professional lab services agreement. The transaction is expected to close in the second quarter.",1.0369028,0.875
DGX-2019-Q4-2020-01-30,23,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, we recently signed a professional laboratory services agreement with an eight hospital health system in Tennessee. We continue to see accelerating revenue and volume growth as a result of our branded health plan network access.",1.6306425,0.7
DGX-2019-Q4-2020-01-30,24,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The sequential acceleration in volumes demonstrates our ability to drive continued market share growth. We look forward to the further rollout of United's Preferred Lab Network, featuring $0 out-of-pocket cost for members. The test growth drivers in the quarter and full year include drug monitoring, tuberculosis testing of both QuantiFERON and T-SPOT, hemepath, our blood cancer test and Cardio IQ. Each of these test categories posted solid contributions to revenue growth.",0.5555189,0.758
DGX-2019-Q4-2020-01-30,25,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Overall, our G-based and esoteric testing grew approximately 5% for the year, an acceleration from low single-digit growth a year ago. And then, our second part of our two-point strategy is to drive operational excellence. We delivered on our 2019 goal to reduce our cost base by 3% by continuing to drive increases in productivity. We see more opportunities ahead to drive further productivity gains, while enhancing the customer experience.",2.9097199,0.872
DGX-2019-Q4-2020-01-30,26,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So here's three examples. First, our immunoassay platform consolidation is expected to provide brief throughput, autonomy and more efficient footprint, while saving us approximately $35 million annually when fully implemented. Second, we are optimizing our lab network through investments in our new flagship laboratory in Clifton, New Jersey. When operationally active in 2021, our new lab is expected to consolidate three regional hub labs, double our average throughput and provide 30% more capacity.",2.1950577,0.848
DGX-2019-Q4-2020-01-30,27,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then third, we're using digital technology to enhance the customer experience. Nearly nine million patients have downloaded the MyQuest digital platform, which enables them to make appointments and receive their results.",1.8596376,0.0
DGX-2019-Q4-2020-01-30,29,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks Steve. In the fourth quarter, consolidated revenues were $1.93 billion, up 4.8% versus the prior year. Revenues for Diagnostic Information Services grew 5.1%, compared to the prior year, driven by strong volume growth an easy compare and acquisitions, partially offset by higher reimbursement pressure.",1.8376777,0.859
DGX-2019-Q4-2020-01-30,30,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Volume measured by the number of requisitions increased 4.1% versus the prior year. Excluding acquisitions, volumes grew 3.4%. Importantly, we continue to see a sequential acceleration in organic volume growth in the fourth quarter after considering the benefit of the extra revenue day in the third quarter.",0.8226698,0.852
DGX-2019-Q4-2020-01-30,31,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per requisition increased 1.2% versus the prior year, primarily driven by an easy compare, partially offset by higher reimbursement pressure. Unit price headwinds were approximately 2.5% in the fourth quarter. This includes the impact of PAMA, which amounted to a headwind of nearly 120 basis points.",0.4778831,0.422
DGX-2019-Q4-2020-01-30,32,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As a reminder, the PAMA impact includes both direct cuts to the clinical lab fee schedule, as well as modest indirect price changes primarily from Medicaid. Reported operating income was $363 million or 18.8% of revenues, compared to $220 million or 12% of revenues last year.",1.1240126,-0.026
DGX-2019-Q4-2020-01-30,33,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On an adjusted basis, operating income was $329 million or 17% of revenues, compared to $295 million or 16% of revenues last year. The year-over-year increase in adjusted operating margin was primarily driven by strong volume growth and ongoing productivity improvements related to our invigorate initiatives, partially offset by higher reimbursement pressure.",1.7010269,0.881
DGX-2019-Q4-2020-01-30,34,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Additionally, patient concessions were down approximately 40 basis points year-over-year. Reported EPS was $1.86 in the quarter, compared to $0.92 a year ago. Adjusted EPS was $1.67, up approximately 24% from $1.36 last year. Cash provided by operations was $1.24 billion in 2019 versus $1.2 billion last year and capital expenditures were $400 million in 2019, compared to $383 million a year ago.",0.7496051,0.0
DGX-2019-Q4-2020-01-30,35,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now turning to guidance. Our outlook for 2020 is as follows; revenue is expected to be between $7.8 billion and $7.96 billion, an increase of approximately 1% to 3% versus the prior year. Reported EPS expected to be greater than $5.51 and adjusted EPS to be greater than $6.6; cash provided by operations is expected to be between $1.25 billion and $1.3 billion and capital expenditures are expected to be between $375 million and $400 million.",0.1520537,0.743
DGX-2019-Q4-2020-01-30,36,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"There are several considerations that I will review as you think about 2020 and beyond. First, we will continue to face significant reimbursement pressure this year in large part due to the ongoing headwinds from PAMA. Total reimbursement pressure in 2020 is expected to be slightly more than 200 basis points, of which PAMA and associated impacts are expected to be approximately $80 million to $85 million. We estimate a similar impact from PAMA in 2021.",0.2116904,-0.382
DGX-2019-Q4-2020-01-30,37,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Second, it's no secret that the tightening labor market has resulted in rising wage pressure. To remain competitive, we are investing in employee pay and benefits. The incremental cost is included in our guidance. Third, despite the continued reimbursement headwinds, we are making disciplined strategic investments in our advanced diagnostics capabilities that we expect will be slightly dilutive to our earnings in 2020 by roughly $0.15. A portion is related to our acquisition of Blueprint Genetics. The remainder is related to investments in liquid biopsy and next-generation sequencing automation.",0.4249605,0.128
DGX-2019-Q4-2020-01-30,38,Remarks,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Fourth, our revenue guidance contemplates some M&A carryover, plus the two deals we recently announced. And finally, our revenue guidance includes contributions from the PLS relationships that Steve mentioned earlier. Keep in mind that revenue and volume contributions from PLS typically take a couple of quarters for rent.",0.2586888,0.471
DGX-2019-Q4-2020-01-30,40,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, thanks, Mark. Well, to summarize, we had a solid fourth quarter and ended the year by delivering record revenues, earnings and cash. Quest is well positioned in 2020 to grow revenues and earnings despite another year of meaningful reimbursement pressure. And then, finally, our guidance for 2020 is realistic and achievable.",0.2665568,0.881
DGX-2019-Q4-2020-01-30,41,Remarks,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, we'd be happy to take your questions. Operator?",0.785832,0.572
DGX-2019-Q4-2020-01-30,42,Remarks,2020-01-30,4,2019,Shawn Bevec,Executive Director-Investor Relations,Operator?,1.45647,0.0
DGX-2019-Q4-2020-01-30,47,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So thanks, Ricky, for the question. So to remind everyone, we have a long-term goal of having 1% to 2% of growth through acquisitions as part of our five strategies to accelerate growth. What we have shared is that we made good progress against that over the last several years. And because of the three elements that we see at play in our marketplace, we do believe that it affords us an opportunity to consolidate the market.",0.8441516,0.968
DGX-2019-Q4-2020-01-30,48,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So last fall, we did increase our expectation and our goal to get to about 2% through acquisitions. And if you look at 2018, we beat that number. If you look at what we just reported for 2019, we're a little light. But if you look at 2018, 2019, we're about that 2% level. And that 2% is a CAGR, because as you know all acquisitions are somewhat lumpy. We're going to have some stronger quarters. We're going to have some weaker quarters in terms of acquisition growth, but we're shooting for that 2%. So what we just announced in the last several weeks we think are good indications that we continue to work on our pipeline. We play -- Blueprint Genetics is a good opportunity to invest in advanced diagnostics that will provide some growth and some capabilities to organizations that we think are helpful to accelerate growth.",0.6431631,0.983
DGX-2019-Q4-2020-01-30,49,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then second is what we also announced around Memorial Hermann is a great example of what we have done in the past and we'll continue to do more of. And we're actively engaged with many other integrated delivery systems around that concept. And to remind you it's comprehensive where we're helping them with their hospital laboratory, making them more efficient. In that regard we're helping them with their reference testing for the hospital. And then finally in the Memorial Hermann case we bought their outreach business.",0.5024712,0.957
DGX-2019-Q4-2020-01-30,50,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",And so what we have shared in the past our funnel is strong. But these deals become more complicated. They're big systems. They have many hospitals as many stakeholders. So this is just taking more time. So funnel is good. And we just announced two deals. And so we think we're starting 2020 with a good pop of acquisitions and we're also hopeful there will be more to come throughout the year. So Mark?,0.3897858,0.939
DGX-2019-Q4-2020-01-30,51,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And on your integrate question, Ricky. Thank you. When you think about the pieces that are headwinds and tailwinds, you mentioned the headwinds certainly we've got the pricing pressure we talked about 200 basis points, we've got our typical way to inflation on about $3 billion wage bill and then we said there's incremental pressure on that. And then you've got the investments.",0.8732227,0.128
DGX-2019-Q4-2020-01-30,52,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So the 3% productivity, we drive in order of magnitude through our invigorate program alone would not be enough to offset all of that and drive bottom line growth. But importantly the other tailwind is organic volume growth and the contribution of other acquisitions between -- besides Blueprint. And so that's really -- it's all fungible. But that's how we're able to grow our bottom line.",0.3479463,0.813
DGX-2019-Q4-2020-01-30,53,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So invigorate alone about 3% productivity, it take 2% price, it take a couple hundred basis points against our wage bill of $3 billion, it take the advanced diagnostic investments. They're larger than just invigorate. So it's really the organic growth of our business and the contribution of the profitable outreach acquisitions that really help us to grow the bottom line.",0.2318325,0.943
DGX-2019-Q4-2020-01-30,59,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, let me provide a little bit of color then Mark will add to it. So what we shared throughout 2019. Given our volume growth and what we just reported the volume growth we're picking up share. And, yes, we're picking up share from United as we had expected. And then second we'll we pick up share for United, we believe we're actually picking up share from other payers and other portions of the business.",0.5980231,0.973
DGX-2019-Q4-2020-01-30,60,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also have managed our Aetna relationship quite well. It continues to be a strong partner of ours with them letting back into the network of one of our competitors -- as well. So we feel good about the progress made in 2019. And what I say it was implied in our guidance for 2020 is a continuation of that market share gain program and our acceleration of growth strategy. As we said back in Investor Day 2018, we believe that the new access changes that we now have afford us about $1 billion worth of opportunity.",0.106425,0.975
DGX-2019-Q4-2020-01-30,61,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We have a good start on that in 2019. And clearly we have more opportunity in 2020 and beyond. Incumbent at all that assumes that we're going to pick up share. And as I said, there's a lot of aspects of that and we're just getting started with - for a lab network for United. And so therefore finding our guidance is picking up share again and some of that will come from the United. Mark?",0.6599671,0.949
DGX-2019-Q4-2020-01-30,62,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So when you look at our performance last year, we would say that the typical non-network access piece was probably similar to our historic and historically over the last couple of years or get roughly 50 to 100 basis points of growth. And so the growth beyond that you can pretty much attribute to network access.",1.1796998,0.878
DGX-2019-Q4-2020-01-30,63,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And I want to remind is that it's not just United we also got into Horizon Blue Cross in New Jersey. We got into a portion of Anthem in Georgia. And as Steve mentioned, while the United and the other two plans access increased helped those, specifically it also helped us grow and other payers as well.",0.0509479,-0.042
DGX-2019-Q4-2020-01-30,64,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we are definitely growing share and that share is coming from multiple competitors not just our chief competitor. The other thing I'd say, you asked about January, well we're not going to comment on January, specifically obviously. we're almost 112 of the way through 2020. And if we were in any way concerned about that progress we certainly would have built that into our guidance. So we're considering January performance thus far as we communicate guidance today.",0.6808847,0.924
DGX-2019-Q4-2020-01-30,66,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, sure. We actually did a very thorough job of evaluating all the different alternatives. We have selected a vendor for that. And we've started the deployment of the systems that we have to deploy to allow us to achieve that eventual $35 million in savings. And so we've started to deploy those as some of our larger facilities.",1.0388797,0.71
DGX-2019-Q4-2020-01-30,75,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So Lisa, I don't recall $0.15. I don't think that's something that would represent the reimbursement pressure. So when you're looking at non-PAMA related headwinds. As we've shared over the last 18 months or so, a lot of that is not coming from third-party, the traditional payer reimbursement but it's increasingly coming from the portion of our business that is direct to client bill. And the largest piece of that is hospitals, it's the high end testing we do what we typically refer to as reference work. And we've described how when you think of the set of criteria that a hospital like basis decision in terms of relationship, test, menu, quality, history and price there's been more of a shift to price over the last several years. And we're speculating a lot of that is driven by some of the pressure they're under.",2.4281201,0.34
DGX-2019-Q4-2020-01-30,76,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, whereas, in the past you might extend the contract with the understanding that you had a good reasonable price and they had good quality and all those kind of things. More and more of these are going to RFP where there's an opportunity for price competitors to come in and compete on price very highly. So that's one of the dynamics that have definitely increased is the hospital-based client build.",1.0706951,0.935
DGX-2019-Q4-2020-01-30,77,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,The other one we've talked about is in several states where there are no any markup laws. Physicians can actually send work to us. And build a third-party themselves. And you basically mark up the work that we do. And that is a direct build this an office that we compete. And you can imagine that if there's profit mode for those customers. Any nickel they can say from any lab is something that's attractive to them.,0.4146919,0.557
DGX-2019-Q4-2020-01-30,78,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,So that is definitely a source of a lot of our pricing headwinds. And then there is a small piece in third-party payer as well as some older contracts are getting renegotiated and getting more in line with the current pricing environment.,0.1844392,0.62
DGX-2019-Q4-2020-01-30,80,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, on the retail strategy, it goes back to as I outlined our five strategies to accelerate growth. And it's all part of our consumer strategy and the consumer strategy is those multiple strategies. And one piece of it is, we want to have better physical presence. And so we've been working on getting better physical presence for a number of years.",0.6803954,0.881
DGX-2019-Q4-2020-01-30,81,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","To remind everyone we have about 2,100 patient service centers. We have over 4,000 lobotomists and physicians' offices, so in excess of 6,000 access clients. And with those patient service centers what we started on this strategy, we had about 20% and we're retail like settings, more strip walls convenient locations, not in medical office parts. And our goal is to get to 50%. So we want to have 50% of our centers in more retail like settings. And so to help us with that, we actually have formed some partnerships with Safeway, relationship has gone well. We're in about 150 stores. We then added to that our joint venture with Walmart. We continue to make progress there with their patient service centers. You also might see that Walmart is making some other loans in health care. We're engaged with them on that.",0.4263591,0.954
DGX-2019-Q4-2020-01-30,82,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",And then finally as we continue to talk to you and have relationships with other retail like partners in health care as they continue to advance their strategies as well. So you're building at 20%. We're about 30% now with retail like settings. We've got more work to do to get the 50% but that's our goal.,0.461285,0.631
DGX-2019-Q4-2020-01-30,83,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We believe it's important that we have more retail like settings, because as I said in my introductory remarks, this market is getting more and more consumer oriented every day. We believe that the consumer will look at the value proposition we'll look at the triple aim. So I remind you it's great health care, it's great experience at great pricing, and we think our strategy delivering really points us to the right direction.",0.8932455,0.97
DGX-2019-Q4-2020-01-30,84,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The physical presence and the convenience of walking into a Quest diagnostic facility, we think, is part of that. So progress made, but more work to do and we're really fortunate to have some of the partners we have and we think we're on the path of getting to that 50%.",0.9133443,0.746
DGX-2019-Q4-2020-01-30,93,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our non-exempt workforce is where we feel the pressure. Non-exempt workforce, there's various areas of our value chain. We have about 12,000 lobotomist. We have over 3,500 couriers running our logistics operations in automobiles. We have thousands of what we call specimen processors. And so, if you look at the front end of our value chain, that's where we see some pressure.",0.4899506,0.103
DGX-2019-Q4-2020-01-30,94,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So what we're finding and it's all very local, is that we have pressure in some of those geographies to up our wages more than we have historically, because we have to be competitive with other competitors, if you will, for those resources. So that's putting pressure on our wage bill. So, Mark, do you want to give a perspective on what that means in terms of scale?",0.8639209,-0.34
DGX-2019-Q4-2020-01-30,95,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So we're not going to size it specifically. But as Steve mentioned, this competition for those areas doesn't just come from the lab industry or specifically for healthcare. Obviously, with lobotomist, it's healthcare. But when you think about couriers, people drive vehicles are desired by multiple industries.",0.8913902,0.586
DGX-2019-Q4-2020-01-30,96,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then, the same thing for the specimen processing, which generally is, I don't like the term, but unskilled labor. And so, there's many, many other industries as well that might be a target for that labor. And so, we are not really responding. I'll answer a question that you didn't ask, but might be in people's mind to increases in minimum wage.",0.0138231,0.527
DGX-2019-Q4-2020-01-30,97,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We don't generally have people at minimum wage. It's really more responding to market forces in the specific markets where we were finding higher levels of attrition and finding it harder to attract the talent that they need. So, really, as we look at this in the near term, it's an increase to our annual wage inflation. But in the longer run we see the value coming back in lower turnover and higher quality employees.",0.5462085,0.778
DGX-2019-Q4-2020-01-30,99,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","If I heard the question correctly, you're asking for some color around Blueprint Genetics of the $0.15. And just provide a little bit of strategic logic and operation and how this will work? So, again, we're investing in advanced diagnostics. We have shared that we want to continue to accelerate it.",0.8586491,0.572
DGX-2019-Q4-2020-01-30,100,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We just reported that if you look at our genetic and esoteric testing was up by about 5% last year. We continue to invest in that in a number of areas. And, specifically, we believe the acquisition of Blueprint Genetics bring some nice capabilities and a proven commercial organization into Quest. It brings us some nice capabilities atypically related to the variant interpretation that I talked about in my remarks. And then also specifically applying that to some of the specialty categories. They have over 200 panel tests today.",0.0042834,0.71
DGX-2019-Q4-2020-01-30,101,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, if you look at their coverage, okay and their depth of interrogation of the data. It provides us a nice capability to leverage what they've already done but also bring to that where we want to do more, typically around rare diseases where we like and interrogate the data to find the insight. So we're really encouraged about the capability we're just onboard. And Mark? We talked about the impact on our earnings in 2020. Want to provide some color to it?",0.1057661,0.899
DGX-2019-Q4-2020-01-30,102,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, sure. So I would differentiate these investments from the wage inflation and arguably the wage inflation has increased in our long-term cost structure all other things equal. And the reason we call these out is because we don't expect these to be long-term dilutive, certainly Blueprint not only will turn from being dilutive to accretive over a period of time but as Steve mentioned, the capabilities that it brings to us to actually create value in other areas including being more competitive winning more business but also reducing the cost structure and other work that we do in this space.",0.2815956,0.948
DGX-2019-Q4-2020-01-30,103,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The work we're doing on liquid biopsy is something that will come to a point within the next couple of years. And so either we will stop investing or hopefully self investing and be successful. So it will no longer be a drag on our earnings. And then certainly the work we're doing around low-cost sequencing is also a short-term investment and we're highly confident that that will be successful and certainly will no longer be a drag on our earnings. So these are really temporal investments, that doesn't mean that there won't be other things that we invest in in a couple of years. But these specific investments will be fairly short term.",0.7207741,0.865
DGX-2019-Q4-2020-01-30,108,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So Preferred Lab Network, we've said in the past it really got started in the fall where UnitedHealthcare where their fully insured books starting to pull some of the principles of deferred network. And then beyond that it's really just getting started in 2020. And we're optimistic that that will provide us again to gain share. So Mark specifically to...",0.4115321,0.863
DGX-2019-Q4-2020-01-30,109,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes I'd say thus far what's publicly shared by United and we've talked about is they're starting last August. They're really focusing on how to network usage. And they've done a number of things to try to reduce that including sharing that information with members of the PLN, where we can go out and target some of those accounts and explain to the physician why there's a benefit in steering that to a preferred lab member including importantly the quality and other things that really limited the number of people that were included in the preferred lab network.",0.6575829,0.925
DGX-2019-Q4-2020-01-30,110,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"But they're also doing some other things with the physician directly that you probably should ask United about as they've shared with us that they're giving incentives for them to above and beyond what we might do when we go and call on them and explain why it's in the patient's best interest, we're also doing some things to make in the physician's best interest to move away from using out-of-network providers. And there's a fair amount of out-of-network amongst all of the major payers that is a source of higher cost and quite often not the quality that you'll find in the members of the PLN.",0.0853081,0.977
DGX-2019-Q4-2020-01-30,111,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of the PLN itself as we shared there were a couple of states that were rolled out in their fully insured book. Beginning in January they're small accounts, they expanded more broadly. And in the middle of the year there's going to be pretty much a full rollout including their larger members and they're fully insured book throughout that time they still have to sell the members where ultimately even though it's fully insured over time have to agree because it could have implications for premiums and so on all of that takes time.",0.0319905,0.796
DGX-2019-Q4-2020-01-30,112,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then there's the sponsored plans, which is the next step. So this is a long-term initiative that certainly is reaping some benefit. But it's not in terms of the step change where this is going to overnight move on dramatically. And that's why we talked about multiyear tailwind for a lot of the efforts because some of this is going to take some time. So all in the right direction, but something that is going to take a while to get to where its ultimate level would be.",0.2914692,0.402
DGX-2019-Q4-2020-01-30,113,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So Erin you asked about the lab stewardship program. And let me bring it back to, again we're actively working our strategy to build relationships with health systems, hospital health systems. We've been actively working on this for a number of years. And when we go into a health system and it is at the C-suite. We talked about our ability to help them meet their hospital more efficient and effective in diagnostics.",0.7347611,0.937
DGX-2019-Q4-2020-01-30,114,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then secondly, as part of that the sophisticated testing that is sending out, we could do more for them and we can do a better job of how we manage that.",0.6477759,0.758
DGX-2019-Q4-2020-01-30,115,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then thirdly, when we always get into those conversations, we then now with PAMA. And with the pressure for commercial sales, we have conversations around their outreach business. Does that continue to make sense for them to have it? In the case of more there was an example where again a hospital services business. So as we get in there it's all about building a relationship. We help them manage their diagnostics.",0.7654036,0.382
DGX-2019-Q4-2020-01-30,116,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And our last stewardship program is being deployed through many of our good accounts, it's going quite well. And this is all about getting smarter about diagnostics. And it goes back to the notion of a triple lane, it's about better health care, it's about better experience that's at lower cost. And what we're finding is as you get more analytics like everything, what you find out is there's over utilization and we need to get rid of that to make them more efficient. But what we're also finding is there's under utilization. And so we become more of a consultative adviser in terms of diagnostics. And one thing that we like to talk about is there's nothing more expensive than a bio-diagnosis for a hospital setting.",0.6477759,0.971
DGX-2019-Q4-2020-01-30,117,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so with their last stewardship program and where the relationships, we're working proactively with our partners to be able to deliver a better answer for the specialist. And again Memorial Hermann is a great recent example of the listening to our story, understanding what we're going to do for them and now we have a new partner in one of the largest cities in the United States. So we're really encouraged about the progress we've made over the number of years in the prospects in front of us.",0.5281713,0.953
DGX-2019-Q4-2020-01-30,121,Question,2020-01-30,4,2019,Bill Quirk,Piper Jaffray,"Hi. Thanks. Good morning, everyone. I guess",0.7840945,0.7
DGX-2019-Q4-2020-01-30,123,Question,2020-01-30,4,2019,Bill Quirk,Piper Jaffray,"I guess, a multipart question here, Steve. So first, we appreciate that there's considerable pullback by some providers, concerning the executive order around hospital pricing transparency. However, since this does include diagnostics, should we be thinking about this as a potential added risk from a long-term reimbursement standpoint? And then also, and separately, given the interest in the preferred lab networks by a number of payers, not just United, should we expect additional announcements in 2-20 concerning some of the new formation of these? Thanks, guys.",0.7575854,0.726
DGX-2019-Q4-2020-01-30,124,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, thanks, Bill. The first part of your question has to do with transparency and surprise bills and pushback from providers, about that, and its complex, as you know. But going back to my prepared remarks, we believe, if you just look at the value proposition we bring into marketplace, we'd like to get more and more exposure to the prices that are out there for us.",1.0971993,0.915
DGX-2019-Q4-2020-01-30,125,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Because as I said, with the full confidence, we believe, we're the best deal in town. And so, making sure consumers see that, making sure physicians see that, making sure that plans are working with us to move more of their laboratory services to a great value provider like Quest Diagnostics is what the strategy is all about.",0.321911,0.973
DGX-2019-Q4-2020-01-30,126,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, the more visibility of that is a good thing for us. And we're doing this with the plans and the preferred lab network is part of that. We're also doing this with employers with the plans, because as those employers look at their employee cost of healthcare, they're looking at what they can do to help their employees out and we believe our category is a good example of where they can do that. But if they do it for us, they could do it also with other healthcare services like radiology and physical therapy. So, we think it's a good opportunity for us.",0.8560132,0.94
DGX-2019-Q4-2020-01-30,127,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then, finally, you asked the question about preferred lab network. We continue to work with other partners. We have the nationals, but we also have a number of regionals. And as you know, we enjoy a large presence in Florida. If you look at Florida Blue Cross Blue Shield, even though they haven't announced a preferred lab network, we are very strong in Florida and we have a great relationship with them.",0.7887974,0.954
DGX-2019-Q4-2020-01-30,128,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So in essence, you could say they are our preferred labs, even though we haven't announced it. So as we work through where we go with this long-term, you'll see what others are willing to provide publicly. But this will continue to be a trend that we'll keep on working. Mark?",1.1176277,0.0
DGX-2019-Q4-2020-01-30,129,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And when you think about the preferred lab network, whether or not another major payer is very overt in announcing a preferred lab network or not, you will see. But some of the elements within the preferred lab network, we already had for some payers before our relationship with United. And some of them have actually expanded some of those.",0.1042654,0.422
DGX-2019-Q4-2020-01-30,130,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So when you touch on what are some of the advantages of the preferred lab network, one of them is, when I described the out-of-network usage and having the payer actually partner with us to educate physicians around the cost of prescribing high -- the high price out-of-network labs and how that impacts our patients with deductibles and how it could impact denials and so on and so forth. So we're doing that with a number of payers.",0.6824645,0.422
DGX-2019-Q4-2020-01-30,131,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"There's also a plan, a very large managed Medicaid plan that had put in some pre-authorization requirements for certain test categories, where they were concerned about the size of the panels and the appropriate clinical appropriateness of some of the offerings. And because we -- and then, some others, it's not us alone, do it appropriately, they've actually created, in essence, what they call a gold card, which means that we're exempt from that pre-authorization.",0.1903633,0.642
DGX-2019-Q4-2020-01-30,132,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So not only does that avoid a headwind for us, so that's the second thing, is it makes it easier for physicians to order from us. They don't have to go through perhaps. So actually in essence it should steer more work to us. And then finally another one I'd comment is in the past as we described it what we do outreach acquisitions. It was a huge windfall for everybody. Other than us, certainly we would still get great economic benefit as I've laid out in the past at Investor Day is about how they're very, very accretive despite the pricing dissynergies.",0.4530016,0.926
DGX-2019-Q4-2020-01-30,133,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,And so what we've partnered with a number of payers on is that actually we share in some of that price savings initially. So it's not all a windfall for the payers and others. But actually some of that value comes to us. So a less severe pricing dissynergy headwind for the first couple of years.,0.9304897,0.321
DGX-2019-Q4-2020-01-30,134,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So that's just a couple of examples that you may not hear a very, very over an announcement about a preferred lab network and where the payers are partnering with us in the areas that they know we bring critical value to really drive more volume towards us.",0.949842,0.026
DGX-2019-Q4-2020-01-30,142,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, yes. So, thank you for the question. And our professional lab services business is something we've built over time. We've got a nice referenceable book of business and clients that we continue to build on. We actually did say in our prepared remarks that we announced another relationship in Tennessee.",0.4685338,0.898
DGX-2019-Q4-2020-01-30,143,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Memorial Hermann is yet another example. And what I'll share with you - you'll hear more about more professional and lab services business going forward. In our 2019 results we did have some growth from it. I'll Mark comment on the specifics around that.,0.8691928,0.586
DGX-2019-Q4-2020-01-30,144,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But we believe it's an important element of again walking in and having an engaged conversation with good delivery systems around their lab strategy. And helping them make their hospital laboratory better, more efficient and more effective as an important part of that. And so now we have a proven trucker being able to do it. We have augmented that with their lab stewardship program and then we also have logged with that with our clear ability to be able to acquire outreach businesses. It will provide more of the sophisticated testing, particularly around advanced diagnostics. So it's moving along nicely and it's becoming a real stand for us and delivering the growth that we expected. Mark?",0.5350906,0.988
DGX-2019-Q4-2020-01-30,145,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And I think the 50 basis points is plus or minus a reasonable number. Certainly as we look at the last couple of years the contribution that could accelerate because we do do some PLS deals, as we mentioned this morning state of Tennessee that are just PLS deals stand-alone. But then as part of what we really still believe will be increased indices broad deals with hospital partners around selling the outreach around getting that reference work and doing the PLS deal, especially if some of these are larger systems.",0.6488942,0.875
DGX-2019-Q4-2020-01-30,146,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And we have a very deep pipeline. PLS contribution could grow to be larger than that. Certainly we'll talk about that as we see that happening. So yes, the 50 basis points is reasonable, very happy with it and that's something that we're hoping and certainly could see accelerating down the road.",0.6220379,0.942
DGX-2019-Q4-2020-01-30,147,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes the interesting thing too that we mentioned in the press release for Memorial Hermann, but many of these systems also have their own plans -- their own health plan. So what we're finding is kind of a secondary benefit has become their preferred or their exclusive provider laboratory service within their plans, and Memorial Hermann is a good example of that. So it's an added benefit of having these relationships.",0.5011532,0.946
DGX-2019-Q4-2020-01-30,153,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah absolutely. So first of all if you think about our value chain. We actually do the draws for about 40% of our volume, okay? That's not through our true bottoms that are even each in service centers or in physician offices. That trend is actually moving more to our site. So we're doing more and more to us. It's a small gradual shift to us, which says 60% is still provided by physicians or our clients and hospitals. So think about the our front end if you will of the value chain that way.",0.9841845,0.567
DGX-2019-Q4-2020-01-30,154,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","What we believe is if we have a better experience and in better locations, we're going to be able to get share. And so we believe that we're we are growing the front end that we deliver ourselves faster than our overall growth because of this shift in the marketplace and also the experience being good as well.",1.0543657,0.936
DGX-2019-Q4-2020-01-30,155,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as far as other relationships all -- this is a health care service providers are looking at their strategy. We mentioned Walmart earlier, they're a big player in health care. They're getting bigger with the opening of some clinics. We have great partnership with Aetna, and onwards with CVS, CVS Health is building up pumps, which is an extension of what they've done with their MinuteClinic. We were a partner of theirs with MinuteClinic.",0.9413509,0.889
DGX-2019-Q4-2020-01-30,156,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as that strategy evolves we'll have a presence with them and others as we go forward. So -- and also we will continue to organically to do some of the retailization if you will of our fleet of patient service centers, because we do see opportunities within local druggists to do some of it ourselves. So it is a multiyear strategy that we keep on making progress against and partnerships continue to be an important part of it.",0.5630972,0.735
DGX-2019-Q4-2020-01-30,161,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So first of all as we said, I think we have a lot more interest today than we did two or three years ago with integrated delivery systems. But what we just announced with Memorial Hermann is complex and so these deals just take a longer period of time.",0.2233937,0.67
DGX-2019-Q4-2020-01-30,162,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We do already have over the years a number of significant systems. If you remember when we bought the outreach business from Dignity, which is a major player on the West Coast. PeaceHealth is another example. I'll remind you we have a long-standing relationship with UPMC in Pittsburgh. We have a long-standing relationship with INTEGRIS in Oklahoma City.",0.4474465,0.71
DGX-2019-Q4-2020-01-30,163,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So we have a long history of working actively with these great delivery systems long before the deal before -- with UMass. And I would argue this is a good example of a large system in a large city coming in our direction. And a good proof point that there will be more like this to come.,0.1976936,0.912
DGX-2019-Q4-2020-01-30,164,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the reason why Memorial Hermann chose us is because we have this proven history of being able to pull it off. We can help them with their hospital. We can help them with the reference work, we can buy their outreach business. We can integrate it. We could tie in to their physicians, we can help them with their health plan. So we have a long-standing history and credibility with a referenceable book of clients that serves us well.",0.6889621,0.883
DGX-2019-Q4-2020-01-30,165,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Because laboratory testing is an essential part of running an integrated delivery system, it's 2% of costs, 70% healthcare decision-making. It's critical that we're working with a partner, they get it right. So, Brian, I think, we do continue to see this as a good indication that there will be more to come. And this is a major system that we're happy to be able to announce.",1.4454695,0.649
DGX-2019-Q4-2020-01-30,172,Question,2020-01-30,4,2019,Ralph Giacobbe,Credit Suisse,"Just, I was hoping you can give a little bit more on sort of the underlying volume and pricing mix assumptions just embedded in guidance? And then, secondly, just quickly, I wanted to clarify the wage pressure comment. I though, Mark, I heard you say a couple of hundred basis points higher, just want to make sure I heard that right? Thanks.",0.1298984,0.755
DGX-2019-Q4-2020-01-30,173,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. So let me address the wage piece and then I'll turn it back to Steve on the volume of the guidance. So no, a couple of hundred basis points of the total wage pressure. So what we're saying is that, historically, it was at a given level. And we were pretty consistent with how we did our annual merit increases. And then, this year we're funding more increases. So, in total, it's several hundred basis points.",0.1342812,0.543
DGX-2019-Q4-2020-01-30,174,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. And so, if you look at our initial guidance of 1 to 3, contemplated in 1 to 3 growth are the acquisitions that we've talked about, which we historically have done, which says that there's organic growth in there. We've also said that we have less reimbursement pressure in 2020 than we had in 2019. We've sized that to be about 200 basis points of an idea of the scale. That helps us some. Okay?",0.5011532,0.795
DGX-2019-Q4-2020-01-30,175,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We then have these new deals that we just talked about, they're going to provide PLS. As we said, they're going to start to ramp particularly in the second quarter. So that will help us with some of the growth. And so, therefore, when you go through all the math, we have to have volume growth. And we have to pick up share and that's implied in our guidance.",0.4932455,0.886
DGX-2019-Q4-2020-01-30,176,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So entirely consistent. Okay? What we've told to you before, is that 2019 was a good start. But it doesn't start with 2019. We're going to continue to build on that momentum. And we will continue to see access improvement of gains and share with the preferred lab network, with the other payers that we brought into it, our full last year and that implied in our guidance as grow through acquisition. And growth through market share gains related to work with the payers and other parts of our strategy.",0.8747941,0.94
DGX-2019-Q4-2020-01-30,180,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. I mean, it gets a little bit complicated. So there's an extra calendar day in Q1. But it's actually not really a full day because of the data we could it is. So it gets a little bit complicated. So there's - in the year there's definitely an extra day. There's a chunk of that in the first quarter. If you recall in 2019 we called out an extra day in Q3. So you should think about that when you size Q3 because that will not repeat the way the calendar is falling.",0.371248,0.586
DGX-2019-Q4-2020-01-30,181,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then there's the typical seasonality around some of the floating holidays. And then the last thing I'd point out is that some of the fixed holidays in terms of the day of the week matters. So when you look at where things like the 4th of July and Christmas and New Year's fall, there can be a difference, the worst being if those are a Tuesday, Wednesday and the best thing if those are weekends. So I'd point to those being some of the things. But you - I'm sure you can imagine that within a 200 basis point range of revenue guidance we've contemplated all the scenarios that might play out there.",0.6030806,0.891
DGX-2019-Q4-2020-01-30,185,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,So let me address the latter. Interest expense and tax rate will be pretty consistent. The other area where we've had a number of people ask questions recently as equity earnings. And that growth has been certainly largely driven by our JV with IQVIA our Q Square JV that we set up several years ago that have been continuing to drive earnings growth.,0.7424961,0.92
DGX-2019-Q4-2020-01-30,186,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,One of the investments that we called out our liquid biopsy investment actually comes to us through an investments that we have with a third party. And the accounting rules dictate that we have to take our share of those losses and even months an investment in this company. That will be in the equity earnings line so that will dampen somewhat the equity earnings growth but it's all again in that $0.15 that I called out earlier. So I'll turn it back to Steve for the other part of your question margins.,0.564376,0.34
DGX-2019-Q4-2020-01-30,187,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, margins, we've been consistent where we haven't guided around margins because we have a mix of businesses. We're driving growth and we're driving a return on invested capital. And we had provided outlook around growth and earnings per share. We think that's the best way for us to drive shareholder value. So we're not going to really comment on what the margins will be year-on-year. But we go through the math, you can get it from private markets could be based upon the top line growth and what we have guided as far as our EPS growth.",0.447117,0.967
DGX-2019-Q4-2020-01-30,188,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And the other thing is that margins are not given. So if we're at the low end of that revenue guidance versus the high end, it will have the impact on margins because as we've shared previously that organic revenue growth comes through a higher drop-through than our fully loaded margin. And we're depending on that as I shared with Ricky with her initial question. Our invigorate program alone can offset in a large proportion of the headwinds. But really the bottom line growth and the margin -- any margin expansion will come through that organic revenue growth.",0.8293839,0.886
DGX-2019-Q4-2020-01-30,189,Answer,2020-01-30,4,2019,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",1.8827732,0.0
DGX-2019-Q4-2020-01-30,195,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, the Blue was a small competitor. As we've shared in the past in this point of care, we certainly get some flu testing when the flu season spike. So yeah it was a little bit of tailwind, but not anything notable.",0.8913902,0.502
DGX-2019-Q4-2020-01-30,196,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of our strategy, I want to ask Steve",0.6690363,0.077
DGX-2019-Q4-2020-01-30,197,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So Jack we're always looking at aligning our adjustments around our strategy and having a balanced approach. And related to acquisitions we shared, typically what you're seeing for us is acquisitions falling in one of three categories. One is regional laboratories. We've talked about Boston Clinical Labs that's a small regional laboratory we just acquired. We did one in Missouri last year. So we'll continue to pursue those.",0.2405272,0.202
DGX-2019-Q4-2020-01-30,198,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Second hospital outreach business is Memorial Hermann is a good example of that. We like those deals are accretive to our earnings. They provide real growth. We really like the stickiness if you will of the customer relationships we take on board and it keep capability building. And so Blueprint Genetics is an example of capability building.,0.2586491,0.891
DGX-2019-Q4-2020-01-30,199,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We thought it would be prudent for us to make an investment there. We think it's very consistent with our strategy. It's modest in size, but it's going to give us a nice capability around bioinformatics, around the variant, interpretation that I spoke to. It'll allow us to achieve that strategy of accelerating growth in advanced diagnostics, which is a category we shared in the past, our definition in genetics and molecular we do over $1 billion. And we believe that that is prospectively a great opportunity for us to continue to invest and that's why we made it.",0.0975288,0.976
DGX-2019-Q4-2020-01-30,200,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we will continue down that path of a balanced approach consistent with our strategy with deals that we can make money for shareholders and trust that will make any deal including the ones we just announced, we have a path to value creation for our shareholders.",0.3212521,0.778
DGX-2019-Q4-2020-01-30,201,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And just one final comment. I mean typically Jack with our acquisitions the value creation has to come directly from the book of business we're buying. And while certainly the book of business we're buying from Blueprint will become better from a profitability standpoint. Really the value creation goes well beyond that book. And as we've mentioned earlier capabilities it brings will benefit everything we do in that space. And so the capability, a description that Steve gives really means that it's going to create better margins and better competitiveness in space outside the specific test menu and book of business that we're acquiring.",0.3846761,0.976
DGX-2019-Q4-2020-01-30,207,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Typically, I don't give any kind of guidance beyond the current year, Ann. But what I will say is that, this is the largest year for Clifton, 2020, we're expecting to be operational in 2021. The Clifton facility has been the driver certainly this year, last year and even back into 2018 and the increase in our relative level of capital spending. We haven't announced any similar plans like that. So you might infer from that that capital spending might come down a little beyond 2020.",0.8556837,0.735
DGX-2019-Q4-2020-01-30,209,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We haven't by year, what we have disclosed that it was about $0.25 billion investment over three years.",1.3716639,0.0
DGX-2019-Q4-2020-01-30,211,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,You might have seen as well that we recorded a gain on the property sale with self focus,1.0860979,0.671
DGX-2019-Q4-2020-01-30,212,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So we sold our Teterboro property and we're going to lease back right now until we exited and moved to Clifton and that was a big contributor to the year-over-year GAAP earnings gain. We adjusted that out of our adjusted income, but it was a nice cash inflow.",0.5209226,0.775
DGX-2019-Q4-2020-01-30,213,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as you know, Ann, that goes into financing, not into operating cash flow. And actually the tax on the gain actually goes against operating cash flow in 2020. So from an accounting perspective, it's a little bit disconnected. But we actually got quite a bit of cash from the sale of Teterboro at the end of fourth quarter of 2019.",0.2892916,0.527
DGX-2019-Q4-2020-01-30,214,Answer,2020-01-30,4,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So when we built the business case on Clifton investment, we assumed a certain sell price for the Teterboro facility. We really exceeded that expectation. So we feel good about the business case and what we're putting our capital budget against.",0.3633491,0.788
DGX-2019-Q4-2020-01-30,217,Answer,2020-01-30,4,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Sure. So thank you very much. Appreciate your engagement. We appreciate your support and look forward to seeing you in our travels. Have a great day.,0.2339374,0.962
DGX-2019-Q2-2019-07-23,4,Remarks,2019-07-23,2,2019,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I'm here with Steve Rusckowski, our Chairman, Chief Executive Officer and President; and Mark Guinan, our Chief Financial Officer.",1.6504366,0.66
DGX-2019-Q2-2019-07-23,5,Remarks,2019-07-23,2,2019,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.",1.1743848,-0.065
DGX-2019-Q2-2019-07-23,6,Remarks,2019-07-23,2,2019,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS from continuing operations, and references to adjusted EPS refer to adjusted diluted EPS from continuing operations, excluding amortization expense. References to adjusted operating income for all periods exclude amortization expense. Finally, growth rates associated with our long-term outlook projection including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth, are compound annual growth rates.",1.3000794,0.931
DGX-2019-Q2-2019-07-23,8,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. This morning, I'll discuss the second quarter and review progress on our two-point strategy. And then, Mark will provide more detail on the results.",2.2250412,0.823
DGX-2019-Q2-2019-07-23,9,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Our volume growth accelerated in the second quarter and we continued to build momentum through the first half of 2019. Our expanded network access continued to accelerate volume growth and our strategy to drive operational excellence improved efficiency. Both have helped to offset the significant reimbursement pressures we are experiencing this year.,2.2095552,0.925
DGX-2019-Q2-2019-07-23,10,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","For the second quarter, we grew revenues despite significant reimbursement pressure; reported EPS was $1.51, down about 4% from the same period of 2018; adjusted EPS was $1.73, down about 1%; volume growth remained very strong at 4.4% as the expected volume continued to accelerate in the second quarter. Year-to-date, volume growth is now at 4%.",2.4204283,0.802
DGX-2019-Q2-2019-07-23,11,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, let me briefly update you on three fundamental changes in the laboratory marketplace. They are PAMA, our expanded network access, increased consumerization of health care. First, PAMA-driven reimbursement pressure remains a catalyst for structural change in the marketplace. Our Medicare rates in the first half of 2019 were down by 10% from the prior year, which is in line with our expectation. The next data reporting period remains scheduled for the first quarter of next year. However, we are encouraged by the introduction of the Laboratory Access for Beneficiaries Act or LAB Act introduced in the House last month.",1.9799012,0.813
DGX-2019-Q2-2019-07-23,12,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The LAB Act would be the first step towards ensuring clinical laboratory service rates under PAMA are sustainable and Medicare beneficiaries have adequate access to crucial laboratory services. By delaying the next round of PAMA data reporting by one year, the Lab Act will provide all applicable laboratories with additional time to report private payor data. A second provision in the Lab Act would require a neutral third party to produce recommendations to Congress and how to improve the PAMA data collection and rate setting process.",2.0247117,0.886
DGX-2019-Q2-2019-07-23,13,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second structural change affecting our industry is our expanded network access, and PAMA is becoming more focused than ever on driving better value in their lab spend.",2.3258649,0.802
DGX-2019-Q2-2019-07-23,14,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're partnering with UnitedHealthcare to reduce access cost created by other network labs, the further value to our customers and members. On July 1st, we became the UnitedHealthcare preferred lab network provider and have begun an aggressive outreach campaign to physicians and UHC members.",1.7476112,0.599
DGX-2019-Q2-2019-07-23,15,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Beginning August 1st, providers referring members to out-of-network labs will be able to complete an online approval process. In addition, Anthem has begun to implement its own strategy that lowers laboratory rates to hospital-based providers, aligning them better with the rates currently paid to the independent laboratories. Also, we continue to have conversations with other health plans on value-based care initiatives and PLN like elements. Some of our recent contract extensions contain these features.",2.183196,0.881
DGX-2019-Q2-2019-07-23,16,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally, we continue to see increased attention on the variation in health care costs. Last month, the White House released the health care executive order designed to bring more transparency to the health care system. As consumers of health care get more information on the disparities in the cost of care, we believe this trend favors high value providers like Quest.",2.2280066,0.972
DGX-2019-Q2-2019-07-23,17,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, turning to our recent progress and our strategy to accelerate growth, which has five elements: Grow more than 2% per year through accretive, strategically aligned acquisitions; expand relationships with health plans and hospital health systems; offer the broadest access to diagnostic innovation; be recognized as the consumer-friendly provider of diagnostic information services; and then, finally, support population health in data analytics and extended care services.",2.0866557,0.912
DGX-2019-Q2-2019-07-23,19,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The trial seeks to provide better outcomes for rare cancer types for which there is no standard treatment. Key test growth drivers in the quarter included tuberculosis testing, with straight to both QuantiFERON and T-SPOT, Cardio IQ, and mutual testing. Each of these categories drove strong revenue growth.",2.2507414,0.691
DGX-2019-Q2-2019-07-23,20,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our QuestDirect consumer testing business continues to gain popularity. Earlier this month, we launched a new consumer initiative Lyme disease tests. We also drove sequential volume growth in consumer testing in each month in the second quarter.",2.5067545,0.863
DGX-2019-Q2-2019-07-23,21,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second part of our two-point strategy is to drive operational excellence. We remain on track to deliver 3% cost efficiencies for 2019 by continuing to drive increases in productivity. Some examples are using digital technology to enhance the customer experience, drive growth and reduce our carbon footprint. We have begun to eliminate paper documentation for Medicare beneficiaries who have financial responsibility for non-covered services. This has reduced denials and contributed to our invigorated savings.",2.3051071,0.917
DGX-2019-Q2-2019-07-23,22,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're also working to help patients follow through when their physician orders a lab test. We started sending reminder emails to patients whose physicians have ordered tests for them electronically. We're now sending text messages that remind them to nearly one third of our patients who scheduled appointment online, which reduces the no-show rate. Both of these initiatives are expected to help reduce the number of lab orders that go unfulfilled.",2.24514,0.44
DGX-2019-Q2-2019-07-23,23,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, let me turn it over to Mark, who will take you through the financial performance. Mark?",2.0151565,0.0
DGX-2019-Q2-2019-07-23,25,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In the second quarter, consolidated revenues were $1.95 billion, up 1.8% versus the prior year. Revenues for diagnostic information services grew 2% compared to the prior year, driven by strong volume growth and acquisitions, partially offset by higher reimbursement pressure and patient concessions. Volume measured by the number of requisitions, increased 4.4% versus the prior year. Excluding acquisitions, volumes grew 2.9%.",2.4913112,0.727
DGX-2019-Q2-2019-07-23,26,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As we said before, not all volume is created equal and we regularly emphasize our strategy to be price disciplined. Recently, we had a few of our capitated contracts open for renewal. These contracts, while profitable in the past, represented large volumes at very low margins. In the competitive contract renewal process, apparently one of our competitors was willing to offer lower rates that were prospectively very unprofitable for us. Therefore, rather than accept the rate cut, we walked away from the business. Walking away had very little top and bottom line impact, but did create a 70 basis-point headwind volume to our organic volume growth and will do so throughout the balance of the year. We believe this is important for you to understand as you assess our relative volume performance. Despite that headwind, organic volume growth accelerated in the second quarter, consistent with our expectations.",2.1994471,0.9
DGX-2019-Q2-2019-07-23,27,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per requisition declined by 2.3% versus the prior year, driven primarily by higher reimbursement pressure and patient concessions. Unit price headwinds were approximately 2.3% in the second quarter. This includes the impact of PAMA, which amounted to a headwind of approximately 120 basis points. As a reminder, the PAMA impact includes both direct cuts to the clinical fee schedule as well as modest indirect price changes from Medicaid and a small number of floating rate contracts.",2.0398894,-0.25
DGX-2019-Q2-2019-07-23,28,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income was $307 million or 15.7% of revenues compared to $305 million or 15.9% of revenues last year. On an adjusted basis, operating income was $352 million or 18% of revenues compared to $362 million or 18.9% of revenues last year. The year-over-year decline in operating margin was primarily attributable to higher reimbursement pressure and higher patient concessions, largely offset by strong volume growth and ongoing productivity improvements related to our Invigorate initiatives.",1.6445498,0.836
DGX-2019-Q2-2019-07-23,29,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was a $1.51 in the quarter compared to $1.57 a year ago. Adjusted EPS was $1.73, down approximately 1% from $1.75 last year. Cash provided by operations was $596 million year-to-date versus $503 million last year. And capital expenditures were $132 million year-to-date compared to $151 million a year ago.",1.8692733,0.0
DGX-2019-Q2-2019-07-23,30,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, turning to guidance. Our outlook for 2019 is as follows: Revenue is expected to be between $7.6 billion and $7.75 billion, an increase of approximately 1% to 3% versus the prior year; reported EPS is expected to be greater than $5.29 and adjusted EPS to be greater than $6.40; cash provided by operations is expected to be approximately $1.3 billion; and capital expenditures are expected to be between $350 million and $400 million.",2.2030016,0.743
DGX-2019-Q2-2019-07-23,31,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Before closing, I would like to review a few reminders as you think about the remainder of 2019.",2.5130332,0.361
DGX-2019-Q2-2019-07-23,32,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"First, we continue to expect more than $200 million of reimbursement pressure this year due to PAMA, our new in-network health plan contracts in 2019, and the modest reimbursement pressure we typically experience each year from other sources. Second, we continue to expect that volumes will gradually increase as we progress through 2019, just as they have through the first half of the year. Third, we have approximately one extra revenue day in the third quarter. Finally, we expect the strongest revenue and earnings growth in the fourth quarter of 2019, due to an easier comparison.",2.3274092,0.84
DGX-2019-Q2-2019-07-23,33,Remarks,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,I will now turn it back to Steve.,2.3203002,0.0
DGX-2019-Q2-2019-07-23,35,Remarks,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","To summarize, our growth accelerated in the second quarter due to our expanded network access, and we continued to build momentum through the first half of 2019. Our strong volume growth combined with our strategy to drive operational excellence enabled us to help offset the significant reimbursement pressures we're experiencing this year. We're excited to be back for being a new Preferred Lab Network status, with UnitedHealthcare, and the opportunities to extend this approach through other players in the marketplace are with us. And then, finally, we believe we're well-positioned to meet our commitments in 2019.",2.107084,0.964
DGX-2019-Q2-2019-07-23,38,Question,2019-07-23,2,2019,Ralph Giacobbe,Credit Suisse,"Thanks. Good morning. Can you maybe help on how volume progressed through the quarter, if you're still seeing a build sort of month to month there, if it has stabilized? And then, I just wanted to kind of clarify what you said around sort of the capitated contract that you lost? Is that a regional or a national contract? And then, just help us on kind of the timing on when it happened? And just broader thoughts, obviously, there's a lot of discussion around the open network approach and sort of structural changes there. So, this goes sort of against that tide. So, maybe flush that out a bit for us. Thanks.",1.6567489,0.933
DGX-2019-Q2-2019-07-23,42,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Let me start and then I'll pass it to Mark. First of all, we continue to talk about we're always looking at the marketplace and trying to understand what's going in the marketplace. And with all our measurements and metrics that we have, and we've talked about for many years now the same store analysis, we still believe the market is stable. We see stable volumes in our physician accounts and also our hospital business seems to be stable versus the prior year. So, Mark, can you add some color beyond that?",2.3054366,0.807
DGX-2019-Q2-2019-07-23,43,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, it's hard to tease out specifically. I think, to Steve's point, we don't think the market has been accelerating in terms of its growth. So, we say market access, if you're asking specifically around United versus more generally, as we shared in the prepared remarks other than Aetna, we're obviously -- we had a major competitor who entered that contract. We were the sole national. And we're growing at every single major health plan. So, in terms of market access, it's not just United. Obliviously, it just makes us more competitive; it enables us to win the office. And so, therefore, we're seeing growth across the board, not just limited to United or Horizon.",2.050158,0.959
DGX-2019-Q2-2019-07-23,45,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, you saw in our results that we inched up a little bit Q2 versus Q1 in terms of the amount of our revenue from some acquisitions. So, we're feathering in some of the acquisitions and they are delivering well. Second is, as we said before and we'll continue to say and our funnel remains strong. We have a number that support our ambition to be close to 2% this year and into future. So, we keep on working on that. And just what I said in my remarks, the pressures that we see are now becoming real and becoming more visible. And those pressures are with PAMA cuts, some of that does extend itself, particularly for hospital outreach businesses and for Medicare rates, and then the commercial changes that I talked about in my prepared remarks are clearly going to impact the hospital marketplace and the independent lab marketplace. And so because of that we continue to have a lot of conversations around integrated delivery systems, lab strategies. And you again saw that we announced this new deal with Catholic Health systems out of Long Island, which is another supporting proof point that we continue to advance our strategy in that front. And the pipeline will be there to support our strategy, as we indicated.",2.0128501,0.949
DGX-2019-Q2-2019-07-23,46,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As Steve highlighted and as you noted, we did the transaction in the second quarter. As Steve commented, we did get more growth from the M&A, we closed a deal, regional acquisition, Boyce and Bynum in the first quarter. So, obviously, we've got the first full quarter of growth from that in Q2. And I would say, there is no attitudinal change in terms of people's view around potentially getting out of outreach, hospital customers. And certainly, some of the regional labs are feeling the PAMA pain. I think, the interesting dynamic that we've seen has been actually more of the conversations with hospital systems are getting broader. So, it's not just about outreach but actually about doing a PLS deal, doing a reference deal and potentially selling the outreach, like we did with PeaceHealth last year, and that's a positive. But on the other side, those take longer. And an outreach deal can be done much more quickly. So, that dynamic has emerged a little bit over last year, so, which adds a little bit to the timeframe to get these transactions completed.",2.0604265,0.976
DGX-2019-Q2-2019-07-23,49,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, I'll start again and Mark will follow. We continue to execute our plan for 2019. We indicated in our first quarter that we have planned for a number of restructuring efforts to start to kick in, start to kick in, in the second quarter. That will continue in the back half of the year. So, we feel good about that. So, we think we have our handles on the levers of cost in the right way. And then, second, Ross, is we continue to drive our operational excellence program. I did say in my remark, it's 3% of our cost saves, and I'll remind everyone, that's about $200 million. And we continue to yield good results from that. We continue to see good productivity across the board. And yes, that's expense areas but also in cost of sales. And we will continue that into 2020 or 2021. So, Mark?",1.9034596,0.864
DGX-2019-Q2-2019-07-23,50,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. Ross, I thank you for reminding everyone. There were really the two drivers, if you look into Q2 versus Q1. One was the investments that we did at the beginning of our new access in terms of some marketing, adding some commercial resources, et cetera. Certainly, we haven't stepped back on the commercial resource. We have stepped back on some of the marketing campaign information. There were also some things that were expensive because we were betting on the commanding patient service centers, adding some logistics, assuming the volume would come, making sure we were in position. Now, that volume is coming, it just became kind of the classic typical cost of sale. So, it's not incremental expense. And then, the other key driver was the restructuring that we completed at the end of the first quarter, which had taken out, on a run rate basis, a substantial amount of expense. That will continue throughout the balance of the year and going forward.",1.9466825,0.866
DGX-2019-Q2-2019-07-23,54,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, typically, in terms of commercial pricing, typically those contracts run on the calendar year. There's been a couple of exceptions where we've done things in the midyear. So, there really wasn't anything in terms of commercial price changes between Q1 and Q2, nor, as you know, is there anything different than PAMA? So, this was really driven by mix. Some of it was some test mix as have some seasonality that can drive things up or down in the rev per req. But as we've noted, that doesn't always necessarily directionally align with profitability, even though it does drive changes in rev per req. And then, of course, losing some of the capitated revenue certainly is a lift from a mixed perspective. And then, finally, PLS is a driver as well. Because as we shared in the past, those tend to be more basic requisitions, got a lot of complex testing, and, certainly as the PLS grows, business grows disproportionately; to the rest of the business it can add or put a drag on our revenue per req.",2.2851501,0.893
DGX-2019-Q2-2019-07-23,55,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then finally, patient concessions. When you look at the patient concession rate in the second quarter versus the first quarter, it was improved. And, a lot of that is really the result of the efforts that we've had to really improve the collectability of a lot of the tools that we put in place at our patient service centers with our real time adjudication to give people that cost upfront, the ability to collect the credit card as well as really working hard with our partner Optum to get better information on pensions, do a better job of presenting the bill and overall collecting at a higher rate.",2.2456556,0.947
DGX-2019-Q2-2019-07-23,58,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, sure. Well, first of all, let's go back to the opportunity this year. The biggest opportunity is best to access -- health insurance access we have for over a decade. And the PLN is going to be nice to have and it will provide some more momentum, and we believe it's a nice lever for us. And yes, we talk a lot about the effect that will have with United. But as we talked about, we're having a number of conversations with other payers. And then, finally is some of the new contract extensions that we already have signed include some of the elements that we will talk about.",1.6629325,0.978
DGX-2019-Q2-2019-07-23,59,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","United will be releasing more and more as we go and they will provide details. As I did mention in my remarks, if you are out of network, it's going to require more authorization to allow that to happen. So, that's one point. Second is what we've said in the past is there clearly will be a benefit design change, so less out of pocket cost for consumers. And then, third, there will be physician incentives. So, when you think about what's going to be the big element, it's all around benefit design, less out of pocket cost for consumes, physicians being managed to drive towards that preferred lab network and then finally is really making sure there is no leakage to other network. And it will be stronger than ever with United and we see a lot of momentum with other payers as well.",1.9785832,0.968
DGX-2019-Q2-2019-07-23,60,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, more to come on that, Ann. But, we're off and running and working this hard, and we do believe it's going to be an additional lever. We don't let it overshadow that the biggest opportunities were back in network. And what I also said in my remarks, yes we had good growth obviously from United but all our major health plans grew with the exception of that network, we actually did expect the modest decline which we saw.",1.3970346,0.723
DGX-2019-Q2-2019-07-23,61,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, just to add, Ann, to Steve's point that a lot of the benefits of the PLN type elements is still in front of us. So, it hasn't driven the volume growth to this point, it's an enabler to continue to drive. So, what are some of those things and it's going to be different by payer type. But these are concepts that we've talked about and various payers have embraced some of these or are all of these to a certain extent. A lot of them are rooted in us getting additional payment or a bonus payment what have you as we've shown the ability to scale work to better value away from higher cost providers.",0.7969984,0.947
DGX-2019-Q2-2019-07-23,62,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, we've gotten that in a couple of contracts recently where we have a metric in a way of showing that as they save money, as their members save money that we get a piece of that. And so, we're aligning those incentives. Number one is around treatment of preauthorization, which is a huge driver for denial. So, and a couple of payers we've gotten -- as our chief competitors and some others, the lab that have shown themselves to be high quality, actually differentiate themselves positively from a service perspective and other things around panels and how conduct themselves. We've actually gotten the status where they wave the preauthorization. So, it's an advantage for us from a physician ordering perspective that payers, as we know, if you send the work to these, following labs that who are going to be okay with it. So, therefore, you don't require a preauth. So, that's another element that we've gotten in some of our contracts.",2.2251185,0.951
DGX-2019-Q2-2019-07-23,63,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Steve mentioned some of the zero out of pocket, and some of the payers are coming up with products that they are offering, but obviously got market. We'll see the adoption rate and then some other payers have voiced an interest in going heavily in that kind of plan benefit design. So, again, it's not as if there's a one size fits all. That's why we talk about these being in elements in some of the other payers. And then, finally, there is a lot of interest in kind of sharing we'll call it the win fail game from our outreach acquisition. So, when we buy hospital outreach, obviously those commercial rates immediately go to our negotiated rates, which is a huge savings for patients, huge savings for the payer and the notion that, hey, this is good for all stakeholders, and we should share some of that value.",2.1461295,0.989
DGX-2019-Q2-2019-07-23,64,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, those are a couple of details that certainly have gotten a lot of traction with the payers. And as Steve pointed out, that is in front of us. So, when I say in front of us, we've gotten those in some of the contracts but obviously, we have to perform and we have to earn those. And then, those are upside going ahead.",2.1015008,0.178
DGX-2019-Q2-2019-07-23,67,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. It's one of our strategies for growth. And several parts of being what's consumer diagnostic information service provider, we have talked about in the past, just to remind everyone, we have really digitized and brought our patient experiences to today's world. And so, when you look into a Quest patient service center, it will remind everyone of the other experiences they have in their other experiences as a consumer and as a health care experience. So, a lot of progress there.",1.8036244,0.89
DGX-2019-Q2-2019-07-23,68,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is we continue to make progress on the tools and the access and information. So, MyQuest app, which is our smartphone app, has continued to expand its registration, and continued to expand the capability so you can schedule appointment online, you can see wait times at patient service centers, you obviously get your results. And we now have over 7 million registered users, which is remarkable.",1.8257002,0.875
DGX-2019-Q2-2019-07-23,69,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And there is a last piece of this, which is your specific question, is the physical presence we think is quite important. So, we have continued to manage our retail strategy and move our patients service centers to a more retail setting over time. Right now, we have roughly 200ish patient service centers between our Safeway relationship and Walmart. Walmart is about 70 of that. And we continue to evaluate the best path forward to eventually have about 50% of our 2,200 patient service centers in more retail like settings.",1.8632619,0.843
DGX-2019-Q2-2019-07-23,70,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, what I'll also share is we have said that roughly 25%, let's call it, 500 of our current patient service centers are more retail like, not all with retailers, but as we evolve over time, with our current retail relationships and with possible others, that number will grow to be about half of our fleet of patient service centers. And our experience in those is quite good. We believe that the patient obviously experience better with much more consumer experience, our employees, there is -- a lot of us like it better. We can consolidate our operations at the fewer sites. And the patient have access. They walk in, they can walk around with the pager, as they can do some shopping, they can eat after they've been fasting. So, overall, m our perspective it's quite good. And then, our relationship with retailers is good as well because they benefit from that store traffic. So, we feel positive about the response and results so far and we will continue to drive it.",2.060626,0.991
DGX-2019-Q2-2019-07-23,71,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The only thing I would Lisa is that there is some always some outliers. But if you look at on average, our retail draw sites continue to increase the amount of activity. We had the highest average amount of draws in our Walmart sites in June that we've had since we started this. So, we're very happy with the amount of traffic we're getting, we're feeling really good about the presence. And of course, our volume is growing. So, there is things that are probably driving it. So, part of it is awareness. People are starting to figure out, we've got these draw sites in Walmart and getting comfortable going there, and we'd expect that to continue over time.",2.1117694,0.935
DGX-2019-Q2-2019-07-23,74,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, I would just say, as an overarching comment and it's embedded in our introductory remarks that we have PAMA, and PAMA to some extent is independent of what's happening on the commercial side. But, we now continue to see pressure from commercial payers on hospital outreach. So, yes, we mentioned Anthem but I will also share that there is pressure from other payers, typically with those that we work with, to push down the rates for all the ancillary services and obviously that includes labs, that includes radiology and includes other ancillary services that are provided by the hospital. And, Kevin, two parts to this. One is just in general to move more of the volume to most -- the highest value reach provider like ourselves in lab, but second is because we add a cost to consumers. And the consumers, given the high percentage of corresponsive health plans that have high deductibles and high out of pocket costs for these expensive hospital based services, the payers are looking at more aggressive strategies to normalize the rates more.",1.7331137,0.728
DGX-2019-Q2-2019-07-23,75,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, yes, we call that Anthem is proactively having a strategy but we see this in many other places with many other commercial payers that are pushing back on what they've done in the past with ancillary services in general but specific to lab.",1.9947282,0.249
DGX-2019-Q2-2019-07-23,76,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, Kevin, I would encourage you to ask Anthem directly. There is a -- I don't know, they've led a couple of places with pathology. There is a publically available document, which we're referencing. And as you might imagine, before we said anything, we checked with them to make sure they were comfortable with the statement that we are attributed to. For more detail, I would encourage you to ask Anthem about the schedule and how broadly they're doing it and so on. But, there is something they've published and put out in the public domain.",1.6184834,0.914
DGX-2019-Q2-2019-07-23,77,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. And part B of this, Kevin, I mentioned in my remarks, the movement across the country towards more price transparency. As you know there is wide variation in our marketplace with ourselves having what we believe the best value proposition on the planet, great quality, great service at some of the lowest prices. And in that regard, actually there was a story today in the journal, which speaks to a number of the payers, providing apps and services, if you will, to provide visibility to consumers to do a better job of shopping. And they called out Anthem, as we did, but others including Humana and UnitedHealthcare that are working proactively as by way of another example, to help consumers manage their costs.",1.9196046,0.92
DGX-2019-Q2-2019-07-23,84,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, we absolutely expect the revenue, despite any sort of comps -- I'm sorry, the volume, to increase on an organic basis. So, it may not happen every week, may not happen every day, every month. But when we look at Q3 and Q4, we expect to continue to see improvements versus the second quarter in our year-over-year organic volume.",1.2124803,0.718
DGX-2019-Q2-2019-07-23,87,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, as we shared with you our five strategies, one of which is the proactively conversations with integrated delivery systems on their lab strategy, and also the access to health care as well within geographies where we had issues with not having good access with some of their patients. So, this continues to be a nice growth driver for us. We announced the Catholic Health Systems deal in Long Island. We did announce some other relationships last year and they studied in and built throughout 2019. And I'll just close with say the funnel continues to build. In the past, we shared where we're going and we have conversation where the lab strategy. It starts with how we can make them more efficient and this is what we call professional lab services or PLS, and this is their in-patient hospital lab and it's a cost matter. So, we could save them anywhere from 10% to 20% of their costs. So, that's an opportunity.",2.2889621,0.978
DGX-2019-Q2-2019-07-23,88,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second, as we get into that, we look at them to rationalize and to become more efficient in their sophisticated reference testing that we said out. That's another opportunity. And then, the third piece, it's very unusual not to have this conversation. We didn't have a conversation about their outreach where they are in the commercial marketplace with us and does it make a sense for us to them to continue to be in it or should we buy their business. So, those discussions continue to progress. We have a bigger funnel than ever. We've backed out the United States. We know all the integrated delivery systems with big outreach businesses, we know those that have substantial number of beds in their cost centers and that continues to be a nice growth driver for us.",1.8955519,0.975
DGX-2019-Q2-2019-07-23,91,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Great question, yes, they are competitors. So, it's not something we can speak to. Obviously, we control our own towards pricing. We've been pretty vocal and consistent that we feel our price is already really good. There is an awful lot of competitors in this marketplace that have prices that are multiple of our price, and we are an excellent value. There was no need for Quest to offer lower price. So in terms of other people's motivation to drop price further in some instances, that's a question you will need to put to them.",2.1105845,0.922
DGX-2019-Q2-2019-07-23,97,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me just start and then Mark will give details. What we showed in the first half is we've delivered on what we set for expectations that we wanted to show the moment to build throughout the first half of 2019 that we did. So, we're pleased with the results in the first half. Second is, we're midway through the year. And we thought it was prudent at this point to maintain our outlook. I'm not going to ahead of ourselves, but what Mark said earlier is and what we've said about this year but also in general about the growth opportunities in front of us, it will continue to build throughout 2019, but this is not just a build for 2019. It will conclude the build in 2020, 2021. So, Mark little more color around the rest of the year?",1.6797364,0.836
DGX-2019-Q2-2019-07-23,100,Question,2019-07-23,2,2019,Bill Quirk,Piper Jaffray,"So, kind of a multi-part question here, guys. First, I think the answer is no. But, is there any negative effects from Anthem? Second piece is with respect to the capitated contract loss, was that contemplated in the original guidance? And then, lastly, just any comment with respect to genomics business, given that the principal supplier into that industry had obviously cited some challenges in that space couple weeks ago? Thank you.",2.085915,0.563
DGX-2019-Q2-2019-07-23,103,Question,2019-07-23,2,2019,Bill Quirk,Piper Jaffray,"Yes. The first part of the Anthem question was just, I think the impact here was predominantly for hospitals. I just want to confirm, guys, that you're not seeing any negative effects from some of the Anthem reimbursement changes that they're implementing.",1.8910891,0.718
DGX-2019-Q2-2019-07-23,104,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"No. We have a contract -- multiple contracts with Anthem. We contract with them regionally that we have a negotiated price and so on. And certainly, we are not in the ZIP code of the hospitals that they are now starting to say need to be rationalized. So, this is really a movement to get everyone -- it's not targeting anyone specifically, except for the outliers to be more in a more consistent rate. So, we feel we're already in that in that ZIP code. And certainly there's going to be no changes in the current timeframe because we have contracts with Anthem. On the capitated, we really don't give guidance on volume. So, was this a possibility that we contemplate it? Yes, certainly. But as I pointed out in my prepared remarks, it's had minimal impact to our revenue, and certainly no impact to our bottom line. So, really, it's more of a volume effect. And we try to encourage our stakeholders to not -- to pay quite as much attention to volume because of very reason. So, we thought given the magnitude of this change we're going to make sure that you understood, there was a big volume shift from us to others or to another direct headwind but really no financial or economic negativity to us, just volume.",1.7657978,-0.122
DGX-2019-Q2-2019-07-23,106,Question,2019-07-23,2,2019,Bill Quirk,Piper Jaffray,"Just a comment, Steve, on your outlook for the consumer genomics business, given one of the principal suppliers a couple of weeks ago.",1.8910891,0.0
DGX-2019-Q2-2019-07-23,107,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Got you. Thank you. As you know, we have relationship with the Ancestry and that's a good relationship and continues to build. No material effect on our -- at our growth plus or minus. So, I would just say in general fairly stable. Second is I did remark about our consumer testing business, which for us is a nice platform that is growing nicely and we're very pleased with the pick-up around our general diagnostic testing. And I mentioned that we just introduced a new line with these tests. But we're going to use that as well as a platform for consumer genetics in the future. So, more to come. But overall, stable environment as we see it. As you know we're not the only provider of the Ancestry at this time. And it's not a big piece of our revenue. So, stable business for us at this point and still good opportunity in front of us.",2.3248764,0.979
DGX-2019-Q2-2019-07-23,110,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First of all, the term esoteric is an industry term. We have defined our genetic and molecular as being what we call advanced diagnostics, and we don't break out specially that business and provide color. But in general, what we've said in the past, it's a business and an opportunity that's been growing mid single digits, and we want to continue to accelerate it and it's active part of our strategy. And within the quarter we felt good about the progress we made in that business in a number of fronts. We had some good growth and some portions of women's health. And in addition to that we define it esoteric. Esoteric, it typically includes a toxicology presence. Prescription drug monitoring continues to be a nice, big growing business for us. We're pleased with the progress and the quarter as well. And just in general, I think, our esoteric or more sophisticated testing, we had good year-on-year compressions, better than last year in the hospital presence, that's not all esoteric but in general a lot of it is. And then, as we pull more growth in a general diagnostics business, it typically will also pull some of advanced diagnostics or esoteric business as well. So, overall, as we raise the tide, it's going to help all the boats in the harbor, including advanced or esoteric as well as general diagnostics.",1.9545305,0.988
DGX-2019-Q2-2019-07-23,113,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First of all, recall, we've been talking about three changes in the marketplace, the PAMA effect, and could argue, it really just got started within 2018. And because of some of the nuances of how payment works, it was somewhat muted related to some of the offsets to the fee reduction, which grew about 10%. So, the first year, '19 is the second year, is a full year, no muting any of the effects, acts and then another effect in 2020. So, that is starting to become more visible in hospital outreach businesses, and administrations of hospitals are becoming more aware of that.",2.0095552,-0.361
DGX-2019-Q2-2019-07-23,114,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the second part of that is it will spill over and has already spilled over to Medicaid. Typically Medicaid in all states is lower than Medicare. And then, finally, as I talked earlier, a lot of the commercial payers are pushing back on, wide discrepancy of health care costs, specifically in our space, in laboratory, wide variations where hospital rates could be 2 to 10 times higher than our rates. And the last piece is the reason why they're pushing on this is because consumers are paying for more and more health care every day, employers are asking questions about it and it's getting visibility in Washington.",2.3700165,0.637
DGX-2019-Q2-2019-07-23,115,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, those three changes in the marketplace, they're getting a lot of visibility for -- from the administration of any and it's great delivery system. And then second is small regional operators clearly see a different environment going forward.",2.1518946,0.778
DGX-2019-Q2-2019-07-23,116,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But sometimes we're asked question what inning we're in, okay, in anything we do. I would say, in this front, for those three structural changes, we're still in the early innings, but it's building momentum as we get into the middle of the game. So, I think we're now beyond the start, and we're starting to get a lot more visibility to it. And there's going to be a lot more change in 2020 and that can be affecting decisions of whether hospitals stay the business or whether regionals continue to operate as the operator consider their options and considering selling the business. And it is part of our strategy to be a consolidator in a smart way since we are the leader.",2.121911,0.612
DGX-2019-Q2-2019-07-23,119,Answer,2019-07-23,2,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, they were definitely low margin, as I referenced. We've actually maintained some of the work at a higher rate. So, there's an offset to the lost OM, because in the particular states that this took place, they're obligated to pay us for a subset of test, even if we're not in contract, and they're obligated to pay us at a rate that's of much higher. So, therefore, you can get that detail in the prepared remarks. But that's why it is really very little, if any OM impact. That's a partial offset to the revenue, not a 100% because it's lower volume, less revenue, even though at a much higher rev per req but not enough to compensate in total. So, it's within certainly rounding overall annual revenue, it's not a huge number with that offset and on an OM basis, it's really had no impact because we continue to get paid for some of the work that we've maintained.",1.7105055,-0.505
DGX-2019-Q2-2019-07-23,122,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, first of all, on direct-to-consumer, we've been at this for a while. We've actually started to test the water. We built a business with the relationship with the New York Football Giants and we call it Sports Diagnostics, and really put our toe in the water of understanding very specific segments, how we can market a product directly to consumers, how we can fulfill that order because it's a different order fulfillment change resulted. So, we had to build some capability years ago to do that.",2.0701812,0.44
DGX-2019-Q2-2019-07-23,123,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then, second is we actually tested the waters on our general diagnostics business is the state of Arizona several years ago. We have a joint venture partner with Banner Health. And as you recall, one of our competitors, given in that state they passed legislation where consumers no longer needed a physician order to order laboratory test. And so, we actually priced out about 100 tests and found out in fact in Arizona there was a market. And so, we took that success and we moved it to Missouri and to Colorado. And then this past fall, we actually expanded it to 48 continental states. About so, 22 of those states who no longer need a physician order, and that's what we've also done in the other 26 states, is we lit up a self help network with PWN to provide in order for consumers that they need it. So, we're deeply engaged in this. We worked out some of the things operationally from years ago with all those experiences and we're off and running. And as I said in my prepared remarks, we are very pleased with the sequential improvement and sequentially actually month upon month we're seeing some nice volume growth.",1.8883031,0.957
DGX-2019-Q2-2019-07-23,124,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And there is a segment. Now, this is all private pay. And we price it accordingly for private pay. And there is a segment where people rather cold get some of these tests done without engaging their health care insurance company. So, off and running, and we're pleased with it and show results. The second part of the question had to do with -- Mark, could you remind of the second question?",2.1476112,0.505
DGX-2019-Q2-2019-07-23,126,Answer,2019-07-23,2,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We will take it from there. Well, thank you everyone for joining us today. We appreciate your support, and have a great day. Thank you.",1.8276771,0.939
DGX-2021-Q1-2021-04-22,3,Remarks,2021-04-22,1,2021,Shawn Bevec,Executive Director-Investor Relations,"Thank you and good morning. I'm here with Steve Rusckowski, our Chairman, Chief Executive Officer and President; and Mark Guinan, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to earnings press release. Actual results may differ materially from those projected.",0.2071977,0.66
DGX-2021-Q1-2021-04-22,4,Remarks,2021-04-22,1,2021,Shawn Bevec,Executive Director-Investor Relations,"Risks and uncertainties including the impact of the COVID-19 pandemic that may affect Quest Diagnostics future results include, but are not limited to those described in our most recent Annual Report on Form 10-K and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K.",0.1529505,-0.065
DGX-2021-Q1-2021-04-22,5,Remarks,2021-04-22,1,2021,Shawn Bevec,Executive Director-Investor Relations,"The company continues to believe that the impact of the COVID-19 pandemic on future operating results, cash flows, and/or its financial condition will be primarily driven by: the pandemic's severity and duration; healthcare-insured, government, and client-payer reimbursement rates for COVID-19 molecular tests; the pandemic's impact on the US healthcare system and the US economy; and the timing, scope, and effectiveness of federal, state and local governmental responses to the pandemic, which are drivers beyond the company's knowledge and control.",0.1410426,0.0
DGX-2021-Q1-2021-04-22,6,Remarks,2021-04-22,1,2021,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS. References to base testing volumes or base business refer to testing volumes, excluding COVID-19 testing.",0.1262239,0.0
DGX-2021-Q1-2021-04-22,7,Remarks,2021-04-22,1,2021,Shawn Bevec,Executive Director-Investor Relations,"Growth rates associated with our long-term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth are compound annual growth rates. Finally, revenue growth rates from acquisitions will be measured against our base business.",0.2228103,0.945
DGX-2021-Q1-2021-04-22,9,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. Quest had a strong first quarter with our base businesses to continuing to recover the near pre-pandemic levels. Contributions from acquisitions and PLS relationships accelerated growth in the base business and helped offset the reduction in demand for COVID-19 testing, which was in line with industry trends.",0.3044481,0.905
DGX-2021-Q1-2021-04-22,10,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In March, for the first time since the pandemic began, monthly organic revenue in the base business grew versus our 2019 baseline. As we noted at our recent Investor Day, Quest is well positioned to grow as the US exits the pandemic and people return to normal activities and address the routine care issues that have been neglected over the past year.",0.0813839,0.226
DGX-2021-Q1-2021-04-22,11,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Also, as you saw in our press release this morning, our Board of Directors increased the company's share repurchase authorization by $1 billion for the second time this year. And we expect to launch an accelerated share repurchase, or ASR, in the amount of $1.5 billion in the coming days.",0.507084,0.671
DGX-2021-Q1-2021-04-22,12,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","This morning I'll discuss our performance for the first quarter of 2021, provide perspective on industry dynamics and update you on our base business, and then Mark will provide more detail on our financial results.",0.3818781,0.273
DGX-2021-Q1-2021-04-22,13,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But before we get into the details of the quarter, we wanted to share our perspective on the ongoing role of COVID-19 testing, more than a year into the pandemic, as well as provide our thoughts on recent news regarding PAMA. COVID-19 testing remains critical as supplies of vaccine continue to be available to all Americans. Testing will help control the spread of the virus in addition to reducing hospitalization and saving lives, continue testing will be key to helping segments of the economy reopen as more Americans become vaccinated. Vaccination is front and center in the minds of most people now, and testing remains a critical element of safely returning to life.",0.1775947,0.778
DGX-2021-Q1-2021-04-22,14,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I'd also like to share our perspective on some of the most recent developments regarding PAMA. So we're encouraged that MedPAC recently reported that it is exploring alternative data collection methods under PAMA that are less burdensome for laboratories, one of the alternatives mentioned is surveying a representative sample of independent hospitals and physician office laboratories, instead of recording all laboratories to submit data.",0.2042834,0.609
DGX-2021-Q1-2021-04-22,15,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've been saying for years that CMS got the data collection process wrong, and didn't follow the attempts of Congress. MedPAC found that hospital outreach and physician office labs reported higher payer rates and independent labs, and that independent labs were over represented in the first round of PAMA data reporting.",0.1087315,-0.25
DGX-2021-Q1-2021-04-22,16,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We agree on both counts. The independent analysis by MedPAC also provides evidence that the Medicare clinical fee schedule would have been 10% to 15% higher if CMS had used a more representative sample that included more data from hospitals and physician office labs. The findings refute the claim that CMS collected more hospital outpatient and physician office lab data would not have impacted the rates calculated by CMS.,0.7140033,0.361
DGX-2021-Q1-2021-04-22,17,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We believe that access to accurate and reliable testing remains critical, not just as part of our nation's ongoing response to the pandemic, but also for the millions of seniors who have delayed routine screening and care over the past year. We need to fix PAMA to avoid the next round of cuts on the horizon in 2022, and to help ensure seniors have continued access to critical lab services they need and rely on.",0.2135091,0.178
DGX-2021-Q1-2021-04-22,18,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Additionally, we were disappointed by the recent dismissal by a U.S. District Court of ACLA's challenge to PAMA. We are working with ACLA to determine next steps with respect to this litigation. We continue to work with policymakers to establish a clinical laboratory fee schedule that is truly representative of the full market and supports continued innovation, and access by the laboratory service -- services as Congress originally intended.",0.15486,0.758
DGX-2021-Q1-2021-04-22,19,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Now I'll turn into our results from the first quarter. Total revenues grew by more than 49% to $2.7 billion. Earnings per share increased by more than 375% on a reported basis to $3.46 and nearly 300% on an adjusted basis to $3.76. Cash provided by operations nearly tripled to $731 million.,0.2853377,0.511
DGX-2021-Q1-2021-04-22,20,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As I mentioned earlier, in the first quarter, our base business performed at its highest level since the start of the pandemic and continue to recover throughout the quarter. Demand for COVID-19 testing slowed in the quarter, reflecting an industry-wide trend.",0.16771,-0.128
DGX-2021-Q1-2021-04-22,21,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We performed an average of 101,000 COVID-19 molecular tests a day in the first quarter, which is well below our current capacity of approximately 300,000 tests per day. We are engaged on several fronts to bring needed testing to schools, businesses and industries by travel and entertainment, which rely on bringing people back together safely and in large numbers.",0.0029654,0.869
DGX-2021-Q1-2021-04-22,22,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","With the current focus on schools Quest is well positioned to help with our extensive logistics network, as well as our ability to offer high quality, cost-effective classroom PCR testing using pooling. We want to help to get the kid back in school, and we're working with a range of partners to get it done quickly and efficiently.",0.3818781,0.917
DGX-2021-Q1-2021-04-22,23,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to make progress on our two-point strategy to accelerate growth and drive operational excellence. We discussed our strategy in detail a few weeks ago at our Investor Day, so we talk today to take you through a few highlights of the quarter.",0.1397035,0.859
DGX-2021-Q1-2021-04-22,24,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We are excited about our agreement to acquire the outreach laboratory services business of Mercy, one of the nation's most highly integrated multi-state healthcare systems, and as we indicated at Investor Day, we're having board discussion with leaders of larger health systems like Mercy.",0.0629325,0.922
DGX-2021-Q1-2021-04-22,25,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The Mercy outreach laboratory services business currently operates from 31 hospitals and clinical laboratory serving providers and patients in Arkansas, Kansas, Missouri and Oklahoma. And we're on track to complete this acquisition by mid-year.",0.293575,0.557
DGX-2021-Q1-2021-04-22,26,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our professional laboratory services relationship with Hackensack Meridian Health began in January and is off to a good start, contributing revenue for the quarter. We originally announced the sale of our 40% minority share in Q Solutions to IQVIA for $750 million.",0.2995058,0.7
DGX-2021-Q1-2021-04-22,27,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",IQVIA has a strategic vision and ability to lead Q Solutions on the next phase of the journey as a global leader in central lab services. And Quest will support it as a strategic lab partner.,0.0642504,0.772
DGX-2021-Q1-2021-04-22,28,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We made good progress, taking advantage of health plan access in the first quarter. UnitedHealthcare implemented an initiative removing out-of-network benefits for insured groups in selected states. We also brought a linkage in redirection efforts with Anthem in eight more states during the quarter. And we're seeing benefits from these initiatives.",0.07743,0.898
DGX-2021-Q1-2021-04-22,29,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, we've renewed our long-standing strategic relationship with EmblemHealth to provide comprehensive clinical laboratory services for more than 3 million members of EmblemHealth and its affiliate ConnectiCare.",0.4662273,0.25
DGX-2021-Q1-2021-04-22,30,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Turning to our strategy to drive operational excellence. We are on track to once again deliver 3% savings across the business.,0.0573311,0.625
DGX-2021-Q1-2021-04-22,31,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In the process, we're also improving the customer experience and quality and in the quarter, we achieved year-over-year improvement in 14 of 19 top tier quality metrics, which we track to gauge our operational performance.",0.5242175,0.765
DGX-2021-Q1-2021-04-22,32,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, I'll turn it over to Mark to provide more details on our financial performance. Mark?",0.4830313,0.0
DGX-2021-Q1-2021-04-22,33,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the first quarter, consolidated revenues were $2.72 billion, up 49% versus the prior year. Revenues for diagnostic information services grew approximately 52%, compared to the prior year, which reflected ongoing demand for COVID-19 testing services into a lesser extent continued recovery in our base testing revenue, which increased versus the prior year.",0.6244076,0.542
DGX-2021-Q1-2021-04-22,34,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Volume, measured by the number of requisitions increased 25.6% versus the prior year, with acquisitions contributing 4%. The impact of severe winter weather during the quarter negatively impacted volumes by approximately 2.5%. Compared to our first quarter 2019 baseline, total base testing volumes increased 1.5% and benefited from M&A and new POS partnerships that began in 2020. Excluding the net impact of weather in the first quarter as well as M&A and new PLS wins over the last year; base testing volumes declined approximately 7% in the first quarter versus the 2019 baseline and down 5% in March. This represents more of a same-store view of the recovery in our base business since the pandemic began.",0.6172986,0.829
DGX-2021-Q1-2021-04-22,35,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"While COVID-19 testing volumes declined faster than expected throughout Q1, the decline coincided with reduced demand across the industry. Importantly, these volumes have stabilized over the last several weeks. We resulted approximately 9.1 million molecular tests and nearly 900,000 serology tests, contributing nearly 21% to volume growth in Q1 versus the prior year. We exited the first quarter averaging approximately 73,000 COVID-19 molecular tests and 8,000 serology tests per day.",1.0015798,0.527
DGX-2021-Q1-2021-04-22,36,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per acquisition increased 20.5% versus the prior year, driven largely by COVID-19 testing. Modest unit price headwinds were in line with our expectations. Reported operating income in the first quarter was $660 million, or 24.3% of revenues, compared to $175 million or 9.6% of revenues last year.",0.5627962,0.273
DGX-2021-Q1-2021-04-22,37,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On an adjusted basis, operating income in Q1 was $708 million, or 26% of revenues compared to $225 million or 12.3% of revenues last year. The year-over-year increase in operating margin was driven by the strong revenue growth in the first quarter due to continued demand for COVID-19 testing and the ongoing recovery in our base business.",0.5280411,0.772
DGX-2021-Q1-2021-04-22,38,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $3.46 in the quarter, compared to $0.73 a year ago. Adjusted EPS was $3.76, compared to $0.94 last year. Cash provided by operations was $731 million in the first quarter versus $247 million in 2020.",0.9395735,0.0
DGX-2021-Q1-2021-04-22,39,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We completed $410 million in share repurchases in Q1, and we ended the quarter with approximately $1.2 billion in cash on the balance sheet. Included in net proceeds from the Q 2 divestiture in April, we currently have more than $1.8 billion in cash available for deployment. Following the $1 billion increase in our share repurchase authority that we announced today, we now have the ability to execute approximately $2.5 billion in additional buybacks this year. We expect to launch an accelerated share repurchase transaction of approximately $1.5 billion in the coming days.",0.7045814,0.859
DGX-2021-Q1-2021-04-22,40,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Turning to guidance. We've updated our outlook for the first half of 2021 as follows: revenues expected to be between $5 billion and $5.2 billion, an increase of approximately 37% to 43% versus the prior year.",0.1508689,0.318
DGX-2021-Q1-2021-04-22,41,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Reported EPS expected to be in a range of $7.51 and $8.01 and adjusted EPS to be in the range of $6.30 and $6.80. Cash provided by operations is expected to be at least $1 billion and capital expenditures are expected to be approximately $200 million.,0.728278,0.0
DGX-2021-Q1-2021-04-22,42,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Before concluding, I'll briefly review some assumptions embedded in our updated first half outlook and considerations to think about for the remainder of 2021. We expect continued steady improvement in our base business throughout 2021.",0.9020537,0.459
DGX-2021-Q1-2021-04-22,43,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On a same-store view, excluding M&A and new PLS wins, we see the base business remaining slightly below our 2019 baseline in the second quarter. We continue to anticipate a full recovery in our base business compared to our 2019 baseline in the second half of 2021.",0.8953397,0.694
DGX-2021-Q1-2021-04-22,44,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We are assuming COVID-19 molecular testing volumes will average roughly 50,000 tests per day in Q2 and no meaningful change in COVID-19 serology testing volumes compared to Q1.",1.7018167,0.026
DGX-2021-Q1-2021-04-22,45,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Given the significant progress of vaccination in the U.S., we continue to expect the decline in clinical demand for COVID-19 molecular testing in the second half of 2021 versus our expectations for the first half.",0.4261453,0.477
DGX-2021-Q1-2021-04-22,46,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Return to life testing such as the K-12 school testing program should partially offset declining clinical demand later in the year. And while we continue to believe strongly in the value of COVID-19 serology testing, we are not assuming a material increase in demand for serology testing going forward.",0.9237757,0.138
DGX-2021-Q1-2021-04-22,47,Remarks,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Finally, COVID-19 molecular reimbursement held relatively steady in the first quarter, and we currently expect this trend to continue through Q2, with the public health emergency being extended through mid-July. This is likely to trend lower in the second half of the year, as our mix of COVID-19 molecular volumes shift from clinical diagnostic testing to return to life surveillance testing.",1.0967615,-0.586
DGX-2021-Q1-2021-04-22,49,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. And to summarize, we're off to a very strong start in 2021. Our base business continues to recover back to near pre-pandemic levels as people address the routine care issues that they have neglected over the past year.",0.3640857,0.743
DGX-2021-Q1-2021-04-22,50,Remarks,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, I'd just like to thank all Quest employees who continue to serve the needs of people who rely on Quest every day. And so with that, we'd be happy to take your questions. Operator?",1.0971993,0.827
DGX-2021-Q1-2021-04-22,53,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, Kevin.",0.9360791,0.766
DGX-2021-Q1-2021-04-22,55,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Mark?,0.6994471,0.909
DGX-2021-Q1-2021-04-22,56,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. So Kevin, when we talk about the base business, and sorry for any confusion, it being up in March. That included our new PLS wins, which were significant and also M&A. So it's the total base business that was not an organic number. What we tried to do was delineate where the -- what we call same-store, so kind of the apples and apples versus 2019 to give you a sense of where we think utilization is. So separate from new significant PLS wins and M&A where that base business performance is. So when we talk about expecting to be slightly down in Q2, that's that organic non-PLS utilization, same store number, not our total base business performance.",0.0629325,0.625
DGX-2021-Q1-2021-04-22,57,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So Mark, it'd be good to share our implied view on what's going to happen COVID testing in Q2.",1.1954976,0.799
DGX-2021-Q1-2021-04-22,58,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So we talked about 100,000 a day in Q1. We talked about an expectation about 50,000, we also shared that we exited Q1 over 70,000, so that would imply a significant ramp down throughout the second quarter. And that's based on our expectation that vaccines will continue to roll out, we'll get more and more people who'll be protected and less and less clinical demand. And of course, we'll see how that plays out, but that is certainly within the guidance that we're providing today, how we see the next several months.",0.1637562,0.936
DGX-2021-Q1-2021-04-22,59,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So if you assume Kevin, our base business, it would include acquisitions in PLS and organic growth. But let's just focus on organic growth. The steady improvement that we've seen in Q1 continues in Q2. And then it's somewhat offset by what we are anticipating with COVID, and that gives us the expectation around ranges of guidance in the second quarter. So hopefully, that's helpful.",0.7796209,0.856
DGX-2021-Q1-2021-04-22,60,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. And just to close it out, Kevin, I would point to the numbers that we quoted for Q1 of minus 7%. That's the same-store performance number. And we -- obviously, March was stronger than that. February was impacted by weather, as we said. But that -- we expect that minus 7% to improve, as Steve said, throughout Q2, but not yet to get positive.",1.3625592,0.382
DGX-2021-Q1-2021-04-22,63,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, Erin.",1.5812191,0.429
DGX-2021-Q1-2021-04-22,65,Question,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And just somewhat tied to that as well, I mean, how should we be thinking about the broader excess capacity across the competitive landscape post-COVID? And how does that impact your positioning?",0.5023697,0.511
DGX-2021-Q1-2021-04-22,66,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hey, Steve, let me take the guidance question first, and then I'll turn it over to you. So Erin, our current guidance, obviously, is only through the second quarter, and we're not counting on any M&A that hasn't already been transacted. And even the deal that we announced Mercy is not going to close and generate any significant volume or revenue in the second quarter. So the current guidance does not anticipate future M&A. Steve?",0.5324547,0.915
DGX-2021-Q1-2021-04-22,67,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So we feel good about the discussions and the funnel of prospects we have for what we have characterized as our hospital strategy. There continues to be a lot of pressure on these pre-delivery systems. They are considering their last strategy is one of the options to help them. And we have a number of examples over the past six months on delivering on the strategies that we've talked about for years. And so the answer to your question, we do see a continuation of interest in the building funnel with more prospects to come.",1.1479407,0.863
DGX-2021-Q1-2021-04-22,68,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","What we shared at Investor Day is we reaffirmed our outlook that we would grow through acquisition around 2% per year. What we shared is that, we historically have delivered on that at the three years prior to 2021. And we believe that's still a good guidance number for us for this year, and going forward, it's implied in our outlook for growth.",0.7492586,0.982
DGX-2021-Q1-2021-04-22,69,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So finally, as we do see the trends in general, just like all health care on consolidation. We do see systems interested in thinking about what's most important to them. And what's your strategy and Quest help them with their lab strategy. And likewise, we see, if you will, fewer and fewer in network providers with the health clients. And if you want to think about that, that is a consolidation play as well. And when those two forces happening, there will be more share in the hands of fewer, and our plan is to gain share. So all the megatrends and changes that are happening in the industry, we believe have actually improved to support what we've said for some time, and that our view is both for what's happening with hospitals and also what's happening with health plans.",1.6444811,0.0
DGX-2021-Q1-2021-04-22,71,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Good morning, guys. Thanks for taking my questions. Within the routine market, can you give us some more color on strength and weaknesses in different parts of the country? Looking at your customers, can you give us some color on dock offices versus hospitals versus the baseline and their routine tests? Any details you can give us on what types of test are normalizing and sort of what are the laggard areas?",0.5242175,0.906
DGX-2021-Q1-2021-04-22,72,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. Sure. So let me take a run around all the different customers the way we look at the market. So geographically, we have seen good recovery in Texas and the South West. We're actually seeing, really in the last several weeks, starting a much better recovery in California in the West Coast, which is good news. We see the South East starting to recover and bring us back to the 2019 levels that we spoke to earlier. So I would say those are moving in the right direction.",0.3410214,0.0
DGX-2021-Q1-2021-04-22,73,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now the offset to that is long as you've seen the spikes and the hotspots in the Midwest and when that happens in the lockdowns and people are concerned about going into health through delivery, that's going to affect our business. So we've seen some of that, let's say, in the Midwest.",0.721911,0.0
DGX-2021-Q1-2021-04-22,74,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally the Northeast and the Northeast including New York and Pennsylvania and going into New England. It's still behind, and it's recovering slowly, but we're the most off, if you will, in the Northeast. So that's the geographic swing.",0.7087315,0.66
DGX-2021-Q1-2021-04-22,75,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As far as physician business versus hospital business, the hospital business is actually very close to where we were. We're encouraged by that. We see remissions getting back to 2019 levels. We see outpatient procedures getting back to 2019 levels. So that business is tracking nicely compared to where we were.",0.5436573,0.34
DGX-2021-Q1-2021-04-22,76,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then the physician side, it all depends on what type of physician. Primary care is starting to turn on oncology, particularly those that have postponed diagnosis and treatment for oncology starting to turn on.",0.5364086,0.166
DGX-2021-Q1-2021-04-22,77,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And at the same time, we still see our prescription drug monitoring business or mental health and behavioral health and drugs and abuse still down versus where we were at 2019. And that's an issue that varies by state to work in that. So that gives you a feel for what's going geographically. What's going on by physician, but also by what we described as clinical franchises. Mark, anything you'd like to add to that?",0.200659,0.557
DGX-2021-Q1-2021-04-22,79,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Yeah.,1.1172982,0.0
DGX-2021-Q1-2021-04-22,81,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Good morning.,0.6523888,0.87
DGX-2021-Q1-2021-04-22,84,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So let me take a shot at that, Ralph, thanks. The higher revenue is absolutely driven by stronger-than-expected recovery in the base business. So as you point out, we've acknowledged and we record every couple of weeks, COVID testing has ramped down faster than we had anticipated throughout the first quarter. We continue to expect to have that ramp down, but the base business has recovered stronger, is most certainly more than an offset on the revenue side.",1.6781201,0.557
DGX-2021-Q1-2021-04-22,85,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of the ASR, it is in the guidance. I just want to remind everyone that we have had committed to $900 million in share repurchases that was already in the guidance for the first half. We did $410 million in Q1.",0.9897314,-0.318
DGX-2021-Q1-2021-04-22,86,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then part of the ASR is related to the proceeds from the sale of our 40% ownership in our JV with IQVIA, and that is slightly accretive when you consider the loss of the equity earnings. So you need to look at over $600 million of the ASR as really offsetting the -- foregoing those equity earnings.",0.5130332,0.831
DGX-2021-Q1-2021-04-22,87,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We had already committed to $900 million in the previous guide in the first half, so almost $500 million there. So when you combine that, the share repurchases are really just up by several hundred million. So I want to make sure everyone is clear on the math there. So it is reflected in the guidance.",0.5398894,0.0
DGX-2021-Q1-2021-04-22,89,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hey, good morning guys, congrats on the quarter. I guess, my question for you guys, Steve as you think about what you saw in Q1, specifically in March with the assumption of volumes in the core. What are you seeing in terms of acuity levels, like rep number of tests per req, or even revenue per req that you saw in March, is that carrying over already into April, just any color you can share with us on that? Thank you.",0.4530478,0.941
DGX-2021-Q1-2021-04-22,90,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So thanks, appreciate the question. Mark was encouraging, and we're watching April, carefully. And we do look at the number of test per requisition to see if we're getting more density, if you will, of testing for requisition, and we talked about new made explanation for increase in the calculation of revenue per req have to do with the COVID test, the straight calculation. But we have historically seen a, let's say, modest expansion of the newer test for variety of reasons, we offer more.",0.2441516,0.318
DGX-2021-Q1-2021-04-22,91,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second, there is a higher level of acuity and chronic disease and aging of the population. So we have generally seen a general increase in that. But nothing that was really notable that's standing out within March.",0.5242175,0.0
DGX-2021-Q1-2021-04-22,93,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, Jack.",1.4421746,0.811
DGX-2021-Q1-2021-04-22,94,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Good morning. I was wondering, if you could give us an update around your thinking around COVID testing for the second half of the year? What do you expect in terms of, the base in terms of testing levels, and then also if you can give us an update as to how you think the school testing opportunity could shake out your reference that at the beginning. How do you feel your positioning is for the upcoming awards there?",0.3341021,0.296
DGX-2021-Q1-2021-04-22,95,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So you go back to where we started off the year. What we said is we do expect COVID, PCR testing to decline throughout the year and we mentioned in our remarks, you could see that in Q1, and we see it happening in the country. So as Mark said earlier, we do expect that continuing trend in Q2 and that will continue into the second half.",0.6602965,0.649
DGX-2021-Q1-2021-04-22,96,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now with a little bit offset, we do see this transition from what we described as more clinical uses of the PCR testing, roll in and roll out COVID for hospitals, roll in, roll out patients seeing their physicians and moving it to return to life activities, and there's a lot of activity around that, Jack. A lot of activity, I mentioned in the remarks, what's going on around schools. There's two funding mechanisms for that from the U.S. government. We've actively engaged with a number of, let's call it, systems integrators that will be coordinating the efforts beyond the laboratory testing. We're well-positioned there.",1.3973641,-0.258
DGX-2021-Q1-2021-04-22,97,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Secondly, is corporations are now thinking about how they get people back physically into their places of work, maybe albeit not as full-time as they want for. But despite the vaccination progress, they're still going to be testing requirements with the return to work activities.",0.721911,0.7
DGX-2021-Q1-2021-04-22,98,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then let me just say the entertainment piece of this is big, too. We see the sports teams, want to put paints back in the stands. We see New York City, interested in getting people back. The tourism as they get into the fall and turning back on the city, we mentioned in our prior remarks and other calls and meetings that we participated in this pilot study with New York to provide a check, if you will provide access for an individual over the course of the day. So that type of activity will be a larger portion of what we do for COVID testing in the back half.",0.6530478,0.0
DGX-2021-Q1-2021-04-22,99,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now with all that said, we're not providing guidance for the back half, but we do see continued PCR testing in the back half, but it's going to change in this nature. And also, we do believe COVID-19 testing and PCR testing will continue in 2022. This is not going away fast.",0.0299835,0.0
DGX-2021-Q1-2021-04-22,101,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hey, good morning, Matt.",0.431631,0.938
DGX-2021-Q1-2021-04-22,102,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks for - yeah, good morning. Thanks for taking my question. I guess, maybe a two part. The first would just be a follow-up to Jack's question, Steve, in terms of how much of that return to life testing opportunity really is going to be in a sort of a reference lab setting with the day or to turnaround time versus a point-of-care setting. But my question though was about the consumer market. I just wanted to get your take on sort of the PWN Everlywell combination and if that changes any of your approach or the competitive dynamics in that space?",1.0912685,0.884
DGX-2021-Q1-2021-04-22,103,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Yeah. So first of all, as you know, not all tests are created equal. And PCR still is the gold standard. And we do provide a solution with antigen testing, okay, as part of appropriate utilization of that testing, particularly for surveillance. But as we know, the antigen testing, sensitivity and specificity has been for let's say day two through day five of a potentially infected person. But the PCR test is really the gold standard to rollout, if someone has been exposed in the early days, there were rule out the pick are exposed in the late days. And so the sensitivity and specificity we have with our PCR testing is quite good. And so physician sell that, and therefore, that's why we're so confident that it will continue to be an important part of how we fight this pandemic.",0.5983526,0.7
DGX-2021-Q1-2021-04-22,104,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As far as the consumer, the consumers trying to figure out to get easy access to testing, and they will get that access in a variety of forms. And by the way, our turnaround time is now for PCR testing are much better on average than the two-ish days that we often thought about several months ago. We're now delivering results in less than the day for many - for many tests that come in. And the reason for that is, remember the remarks we're testing about 101,000 tests per day, and we have approximately 300,000 per day for capacity.",0.2247117,0.952
DGX-2021-Q1-2021-04-22,105,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So that allows us to have much better turnaround times, which we believe, as that becomes more and more visible and people want to get good access to the gold standard, they're going to rely on those places they can get access. So we continue our relationships with retailers. We're expanding our relationship with CVS has gone quite well. CVS is active on promoting good access to PCR testing around the drive ends and Walmart as well.",1.1255354,0.872
DGX-2021-Q1-2021-04-22,106,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then also with our direct to the Quest capability that we talked about at our Investor Day, we have put on that platform, both PCR testing as well as serology testing. And we are seeing high levels of interest from a consumer perspective of what they could do simply by getting collection kit in the mail and a FedEx envelope to ship that back and good turnaround tied to start up of MyQuest. So that will continue to build, as the consumers -- as we start to return to life in a safe way.",0.1420099,0.823
DGX-2021-Q1-2021-04-22,107,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I want to be assured that even if they are vaccinated or they have natural immunity, we are not locking into a situation that they might have been exposed in some ways that they fell through the cracks with all the caveats we have with the effectiveness of the vaccines, the questions about natural immunity, and then also, with the new variance as well.",0.5426689,0.941
DGX-2021-Q1-2021-04-22,108,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So because of that, we keep on working on better and more efficient and easier ways for Americans to get access to PCR testing. And we've got now, I think, a lot of good chance to do that, and that will continue to be an opportunity for us in the back half.",0.563981,0.813
DGX-2021-Q1-2021-04-22,109,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. And Steve, I'd like to add. I want to make sure that Matt and others understand how the surveillance works. And in this case, when you pool you get the economics to where it's affordable to do more broadly and more regularly, because we're going to be putting up to 10 individual samples in a single well. And so hence, the cost will be 10% or less per individual.",1.428515,0.691
DGX-2021-Q1-2021-04-22,110,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And what you sacrifice is, it's not a diagnostic, because we're not going to have the individuals identified in that well. The school or the entity that provides us the sample will have tool that they will know in test through that who the 10 people are. And if we come back to them with a positive result, they will apply a real diagnostic to those 10 individuals.",1.5446288,0.71
DGX-2021-Q1-2021-04-22,111,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So with that, we also don't have the obligation or the ability to retest. Whereas today, when we do pooling for clinical purposes, if we get a positive, we have to go back and retest the individual samples, so it actually is an inefficiency in our process.",0.6137441,0.557
DGX-2021-Q1-2021-04-22,112,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In order to get this to work, we don't do retesting of a sample. We don't have the capability of doing that. We notify the submitting entity that we had a positive in one of the pooled collection specimen tubes, and then they go forward and test those individuals.",0.4146919,0.0
DGX-2021-Q1-2021-04-22,114,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Good morning. Hey, Tycho.",1.5055292,0.0
DGX-2021-Q1-2021-04-22,116,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",You're on mute,0.5947282,-0.168
DGX-2021-Q1-2021-04-22,118,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then just on serology, can you talk a little bit about you're not modeling a decrease in 2Q from 1Q, but PCR is going down. Can we assume the same level of serology testing throughout the back half of the year and explain maybe what the resilience is there? Thanks.",0.8537068,0.077
DGX-2021-Q1-2021-04-22,119,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Mark, do you want to talk the ASR?",0.7638231,0.878
DGX-2021-Q1-2021-04-22,120,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Well, the ASR is in our updated guidance. So there's not upside per se relative to before we announced the ASR, as I tried to walk through the math, about a little less than $400 million of the repurchases are truly incremental in terms of an EPS lift, because we had already committed to the full $900 million, and we had about $500 million remaining in Q2 that was already in the guidance. So that $1.5 billion goes down to $1 billion incremental. A little over $600 million of that is the proceeds from our divestiture of our stake in Q 2 , that's slightly accretive. But not materially relative to the -- for mature of the equity earnings there. So it's really less than $400 million of share repurchases that were incremental to what we guided to previously. And that is built into the updated guidance.",1.3195103,-0.296
DGX-2021-Q1-2021-04-22,121,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of implied operating margin, obviously, we have a range. So we can't answer that with precision. But if you take the midpoint, you can all do the math. As we get a lower mix of COVID testing at our assumption of the $100 reimbursement, obviously, realization in AWR that's less than that, $100 price point. And that mix is toward the base business that will erode the margin slightly.",0.6607425,0.178
DGX-2021-Q1-2021-04-22,122,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But the offset to that is the base business recovers, we're very leveraged. So the variable drop-through on that base business recovery, certainly much higher than our enterprise and historical fully loaded operating margin, but it's not quite as high as the COVID PCR.",0.4494234,0.863
DGX-2021-Q1-2021-04-22,123,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Serology, we imply that it will continue at the same level. We are pushing on the value of serology going forward. We believe that the semi-quant capability that we offer has nice insight into what response is happening in patients in general with the virus and therefore, that has value. We also believe that between historic PCR and serology, knowing that you've had the viruses important for Americans to know so.",0.5901153,0.947
DGX-2021-Q1-2021-04-22,124,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We keep on pushing down the value, and we will continue to look at new tests beyond that. We will be immune response long-term includes T cells. We don't have that, but we continue to look at that has been the prospect. So you should assume for now it's stable with what we've seen so far, but we continue to believe that's more and more valuable in the quarter. We continue to work on developing the test to support that.",1.6444811,0.0
DGX-2021-Q1-2021-04-22,127,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then second, more is like long-term strategically. We're hearing the payers talk a lot about digital-first strategies and being like the front door to health care you guys talked about expanding relationship with payers like Anthem. So are you having any conversations with payers on how you can be part of that digital-first strategy in those digital networks? And if so, do you see that as an opportunity to accelerate more narrow networks that will drive volume toward you, and actually, would that require any additional investments or you think you have the infrastructure for that already?",0.3924217,0.0
DGX-2021-Q1-2021-04-22,128,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Mark, you take the first one, I'll take the second one.",0.7456556,0.932
DGX-2021-Q1-2021-04-22,129,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure, Steve. Thanks for the Ricky. Again, just to reiterate, the first half, we delivered over 100,000 PCR COVID tests per day. We're assuming half that in Q2. So that's certainly contributing to the margin decline, as you talked about, implied in the guidance for the first half, implicitly in Q2. When you think about the base business, we're still uncertain how all those moving parts will play out in the second half, which is why we've not provided second half guidance that we want to wait until we can confidently give guidance that we're highly confident will be delivered.",1.293049,0.832
DGX-2021-Q1-2021-04-22,130,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So what I would point to is that's the transition period, really look at an Investor Day and how we talked about 2022. And talking about getting our base business fully recovered by the end of this year, back to growth through the growth pillars and back to a margin level, pre-pandemic and then obviously improving beyond that, as we talked about a CAGR where our bottom line grows significantly faster than our top line by 700 basis points.",1.7444708,0.944
DGX-2021-Q1-2021-04-22,131,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we feel very confidence in the earnings power of the base business. Certainly, we're going to have a step down from the pandemic bubble, where we did several billion dollars of COVID testing last year, and significant COVID testing this year. But the base business should be very healthy coming out of the pandemic once COVID testing drops to a minimal level. We'll be right back to the operating rhythm. Our expectation is that you saw early in 2019 when we were growing a business January, February, more than 5% on a volume basis, and you saw strong improvements in our operating margin. Steve?",1.0135091,0.502
DGX-2021-Q1-2021-04-22,132,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Yeah. Just to transition. So as you recall in our Investor Day, we went to a walk, if you will, to bridge you from the pandemic years of 2020 and 2021 into 2022. Mark went through chart with some math, which gave you kind of our indication for 2022. And also, as I said earlier, is we do believe there would be some COVID testing, but the base business will be recovering, and we'll get growing - going forward in 2022 based upon our outlook.",0.8784185,0.991
DGX-2021-Q1-2021-04-22,133,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So the last question you add, Rick, you have to deal with the digital front end and digital-first and we're excited about this because we're very well positioned. This isn't something that we have just started working on. We've been working on it for a while. First of all, if you go back to a large provider like Quest, we're very much embedded in the ecosystem of connectivity already. We have over 500 interfaces of all the different electronic medical records, obviously, that's the big players like the Cerner, but there's hundreds of others. And so therefore, we have a real strong interoperability capability. And that's helpful because when you're in the workflow because from a disposition perspective, that allows you to more streamline the different service offerings like laboratory to fewer players. And then secondly is this past year, we've seen the acceptance, if you will of telehealth, it has been growing nicely but out explosively, and we did see explosive growth in 2020 and we believe that overall, that acceptance, if you will, of that front end, be an accepted way to first engage with the healthcare that this system will continue. And the payers are working on that and providers are working on that, and they're working with other partners, and we're very well positioned with those other partners.",1.2711697,0.542
DGX-2021-Q1-2021-04-22,134,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So who are those partners? Those partners are some of the telehealth companies that you know. And those telehealth companies, as they become much more indebted in healthcare delivery, let's call the digital equipment , will rely on a fewer number of laboratory service providers, and therefore, we're very well positioned as more of a small handful of what just described as the deferred lab network that we are ready with United, but for this new world that we see.",0.7028007,0.945
DGX-2021-Q1-2021-04-22,135,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And with all that, we do believe that our direct-to-consumer initiative will have an opportunity as well, because consumers equally are wanting to engage with upgrade delivery. They not always need to engage with this physician. And therefore, with the prospects we see of growing that business and the opportunity for consumers to serve themselves, if you will, which is a big opportunity for us.",0.7495881,0.649
DGX-2021-Q1-2021-04-22,136,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As far as investment, we are investing. We were fortunate enough to have the capabilities in 2020 and 2021. If you again go back to what we shared at Investor Day, we said we're investing about $75 million over a period over the last two years, 2020 and 2021.",0.1149918,0.961
DGX-2021-Q1-2021-04-22,138,Answer,2021-04-22,1,2021,Shawn Bevec,Executive Director-Investor Relations,Operator?,0.1410426,0.0
DGX-2021-Q1-2021-04-22,141,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, Derik.",0.9924217,0.813
DGX-2021-Q1-2021-04-22,144,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then I think the second question is, when you look at your -- you're at 100,000-ish test, you've got 300,000 capacity. How are you using -- how do you utilizing that capacity? Is it more -- are you ramping down your IVD platforms versus your LDT platforms? Just to assume that it's more of the IVD, because the LDTs are more profitable. But just would love some idea on sort of like how you're utilizing your installed base. Thank you.",0.3509061,0.856
DGX-2021-Q1-2021-04-22,145,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So the first part, yes, we did see an increase in the availability and use of the antigen testing and point-of-care testing throughout the last 12 months that clearly has picked up in the back half of 2020. We see that continue in 2021.",0.4563427,0.957
DGX-2021-Q1-2021-04-22,146,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So if you look at the industry trackers of how much testing we are doing in this country, clearly, it has dropped off, and therefore, volumes have dropped off as well. We believe in those tracking mechanisms, it's predominantly PCR. However, we think there could be some point-of-care antigen testing in there, but we believe it does not include all the testing that's happening. So if you look at it, look, happy for PCR testing throughout the United States and if you look at the excellence that are coming from least point-of-care and antigen providers, you see that the actual level of testing is almost at the same level that we were in the summer, but in different forms.",1.1268534,0.797
DGX-2021-Q1-2021-04-22,147,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So the answer to your question is, yes, there is a transition from PCR is exclusively what we have to more of the capabilities around point-of-care and antigen testing. However, going back to what I said, all tests are not created equal. And so we're also working with clients to make sure they realize where antigen testing can be helpful for a period of time. And also what you need to reflex into PCR and where you can use point-of-care and costs are not all created equal. So it has come down because of what we described, but there continues to be a strong role for PCR through the remainder of 2021 and also into 2022.",1.6444811,0.0
DGX-2021-Q1-2021-04-22,149,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hey, guys, thanks for follow-up question here. Could you give us a little more details on the changes of what the UnitedHealthcare did for out-of-network providers in the quarter, what markets did they make this change in, what impacts did you see in your volumes from these changes? Thanks so much.",0.5110379,0.938
DGX-2021-Q1-2021-04-22,150,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Yeah. So what we have been working on as a journey to pick up share, if you will, it can be mated what we shared in March at our Investor Day is we really kicked off the network program in 2019. We saw a good progress there. We're actually very encouraged by what we saw in 2020, it's very early days, and then we have the pandemic.",0.7031301,0.989
DGX-2021-Q1-2021-04-22,151,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But it didn't stop our activity. So what we shared is we actually picked up some share over that period of time, but we have more share to gain. And there's a list of activities we're working with United to support picking up share and getting it to at least that 25% level, one of which is what we're providing is limiting the other network policy and benefit design for their fully insured book. And where that has happened because we have other examples of the topic, it does move share to us. We don't provide specifics on states and specifics on how much did this contribute to share. But it did have a nice impact for us to allow us to pick up share. And so we continue that market.",0.4112026,0.93
DGX-2021-Q1-2021-04-22,152,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But I'll also share that we didn't share everything we're doing. There are many other programs, and some of this is working with their plan sponsors. Their employers, some of this is working with their regions, specific opportunities with providers. When we do an outreach purchase and relationship within the geography, whose work on expensive venue to a less expensive venue, which is Quest, and all of those are active relationships that we have to continue to build share with United and other payers is equally will continue to work programs with the Anthem and others.",0.2497529,0.0
DGX-2021-Q1-2021-04-22,154,Answer,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Hello.,1.0843493,0.7
DGX-2021-Q1-2021-04-22,155,Question,2021-04-22,1,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, good morning. So quickly on 2022, at the Investor Day, the company provided a baseline EPS range of $7.40 and $8, and I believe fund to the higher end of that range. And that was what assumption that base business recovery return to pre-pandemic levels toward the end of the year. With the potential -- I mean, the recovery come faster than expectation, how should we think about that range that provided at the Investor Day? Thanks.",0.6889621,0.0
DGX-2021-Q1-2021-04-22,156,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Mark? Hey, Mark you there?",1.2590837,-0.034
DGX-2021-Q1-2021-04-22,157,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. So the -- what I would say is, I'm not in a position to update that what we provided at Investor Day, because we could get in a rhythm of constantly getting asked to update that. So next time we'll comment will be when we provide guidance for 2022. But of course, as we have that broader range, there's a lot of different considerations, what the remaining level of COVID testing, what's the reimbursement level. Where is the base business at? When we gave the $7.48, as we said, we're expecting the base business to be fully recovered this year to be back to 2019 baseline and starting to grow. But depending on the pace of some of these initiatives that are being rolled out by several payers, not just United by Anthem and some of the other major players depending on the economy, depending on, obviously, potential expansion of covered lives. There's a lot of variables that we'll know a lot more about by the end of the year before we give guidance for 2022.",1.428515,0.84
DGX-2021-Q1-2021-04-22,158,Answer,2021-04-22,1,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So stronger recovery of the base business, good fact, I wouldn't say at this point that, the faster decline in COVID testing yet necessarily implies anything for 2022 around our comments. Because we assumed it would still be around, and you heard from others as well. Nobody thinks is going away. And we were not expecting it to be anywhere near the significance that it was in 2020 and in 2021.",0.8360979,0.521
DGX-2021-Q1-2021-04-22,159,Answer,2021-04-22,1,2021,Shawn Bevec,Executive Director-Investor Relations,"So - and then you've got the ASR we just announced. So there's a lot of different moving pieces. So we'll give you an update on 2022, when we provide our guidance for 2022. We just wanted to ground people at Investor Day, because the pandemic really confounded everyone's ability to understand our long-term earnings power, and that's why we thought it was important to make a specific comment on 2022.",0.5946017,0.954
DGX-2021-Q1-2021-04-22,160,Answer,2021-04-22,1,2021,Shawn Bevec,Executive Director-Investor Relations,"Good. So I think we've covered all the questions. We appreciate you joining the call. We appreciate your continued support, and have a great day, everybody. Take care.",0.6372056,0.527
DGX-2021-Q4-2022-02-03,3,Remarks,2022-02-03,4,2021,Shawn Bevec,Executive Director-Investor Relations,"Thank you and good morning. I'm joined by Steve Rusckowski, our Chairman and Chief Executive Officer and President; Mark Guinan, our Chief Financial Officer and Jim Davis, our Executive Vice President, General Diagnostics and Chief Executive Officer-Elect.",1.023022,0.66
DGX-2021-Q4-2022-02-03,4,Remarks,2022-02-03,4,2021,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and we'll discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties, including the impact of the COVID-19 pandemic that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K.",0.8687483,-0.065
DGX-2021-Q4-2022-02-03,5,Remarks,2022-02-03,4,2021,Shawn Bevec,Executive Director-Investor Relations,"The company continues to believe that the impact of the COVID-19 pandemic on future operating results, cash flows and/or its financial condition will be primarily driven by the pandemic severity and duration, health care insurer, governments and clients payer reimbursement rates for COVID-19 molecular tests, the pandemic's impact on the U.S. health care system and the U.S. economy, and the timing, scope and effectiveness of federal, state and local governmental responses to the pandemic, including the impact of vaccination efforts, which are drivers beyond the company's knowledge and control.",0.6784864,0.751
DGX-2021-Q4-2022-02-03,6,Remarks,2022-02-03,4,2021,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS. Any references to base business, testing, revenues or volumes refer to the performance of our business, excluding COVID-19 testing. Growth rates associated with our long-term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth, are compound annual growth rates. Finally, revenue growth rates from acquisitions will be measured against our base business.",0.8854194,0.945
DGX-2021-Q4-2022-02-03,8,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn and thanks everyone for joining us today. Over the past two years, our 50,000 quest employees have risen to the challenge of COVID-19, innovating, persevering, and remaining committed to the patients and customers we serve. While doing so, they also grew our base business by more than 19% in 2021, achieving record levels. I'm extremely proud of what we have accomplished as a team. So we have a lot of news to cover this morning. And I want to get into that so we can have your questions. So let's get started.",0.0273476,0.93
DGX-2021-Q4-2022-02-03,9,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So first, I'll start by sharing some color on the leadership transition we've announced this morning. Then we'll review our performance for the fourth quarter and the full year of 2021. And then finally Mark will provide more detail on our financial results and talk about our financial outlook for 2022.",0.2695222,0.422
DGX-2021-Q4-2022-02-03,10,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So as you have seen, in our announcement this morning, we've begun implementing a gradual leadership succession plan, under which Jim Davis, Executive Vice President of General Diagnostics will succeed me to become Chief Executive Officer on November 1, 2022. At that time, I will continue to serve on the Quest Board of Directors as Executive Chairman.",0.0995058,0.612
DGX-2021-Q4-2022-02-03,11,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest Diagnostics is a great company that is well-positioned to continue to deliver shareholder value. As I approached a decade in the role, the Board and I determined that now is the right time to begin to turn over the helm to a new leader. Jim Davis is extremely well qualified to be CEO, having managed a large part of this company in his role as Executive Vice President. He has deep knowledge of Quest, the healthcare industry and the corporate world, gained through more than 35 years of business experience. Jim is widely respected and will be a strong CEO.",0.0500824,0.96
DGX-2021-Q4-2022-02-03,12,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","When I took this role nearly 10 years ago, Quest was not growing, nor realizing its potential. We launched a new strategy, our new Quest to drive transformational change. To drive that change, we built a new leadership team, and Jim has been a key member of that team. We built a business strategy to accelerate growth and drive operational excellence. To drive growth, we focused on improving relationships with health plans, hospital health systems, and expanding fast growing businesses, and advanced diagnostics, and consumer testing.",1.2431631,0.935
DGX-2021-Q4-2022-02-03,13,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In addition, we've added about 2% revenue growth on average through accretive, strategically aligned acquisitions over the last several years. We have driven operational excellence, and our Invigorate program has consistently improved quality and customer experience, while generating 3% productivity each year. And we've made more inclusive by increasing the diversity on our Board, and amongst our management ranks.",0.4932455,0.914
DGX-2021-Q4-2022-02-03,14,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally, we established Quest for Health Equity in 2020, over $100 million committed to reduce healthcare disparities among underserved in the United States, particularly communities of color. I am very proud of what we've accomplished together. And if you consider the opportunities in front of us, in many ways, we're just getting started.",0.4642504,0.915
DGX-2021-Q4-2022-02-03,15,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We have a strong team and Jim as a key leader in our transformation. He runs our General Diagnostics business, which accounts for more than 80% of revenues and three quarters of our employees. He manages operations, including sales and marketing, patient services, logistics, laboratories, billing and customer services. He also oversees the Drive Operational Excellence strategy, which includes our Invigorate program. He has provided enterprise oversight for pandemic response. And if that wasn't enough, he's also lead the development of Quest ESG strategy.",0.6289951,0.883
DGX-2021-Q4-2022-02-03,16,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So Jim, congratulations. I look forward to working very closely with you through this transition.",0.0065898,0.634
DGX-2021-Q4-2022-02-03,17,Remarks,2022-02-03,4,2021,James E. Davis,CEO and President,"Hey, thanks Steve, and I really look forward to working closely with you over the next eight months, and ensuring a very successful transition. It's a tremendous honor to have the opportunity to succeed you in Quest and lead Quest into the next stage of our growth. We have a very powerful vision in Quest of empowering better health and diagnostic insights.",1.3651298,0.98
DGX-2021-Q4-2022-02-03,18,Remarks,2022-02-03,4,2021,James E. Davis,CEO and President,"Our business strategy is straightforward and well understood. And our company has never been more central to patients and to the health care system, as we've seen during this pandemic. I really look forward to working with the management team and all 50,000 employees to build on the strong foundation that Quest has put in place. Quest's future is really bright. And we're extremely well positioned to continue to create value for shareholders, and all that we serve.",0.9591945,0.947
DGX-2021-Q4-2022-02-03,19,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Jim. Now at the same time Mark is planning to retire this year. Mark has been in his role for more than eight years, and helped navigate us to the strong position where it is today. We have begun a process in which I will be working closely with Jim to identify Quest's new CFO, and Mark will participate in the selection process. He will remain in the role through the transition.",0.476112,0.735
DGX-2021-Q4-2022-02-03,20,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Mark, I want to thank you for your many contributions, your partnership and your friendship. You've been a key member of our leadership team and we have transformed Quest and accelerated its growth.",0.1947282,0.807
DGX-2021-Q4-2022-02-03,21,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Dave. I appreciate the kind words. I just want to take a minute to say that I'm proud to be part of an important company that makes a positive contribution to the country, and I've enjoyed being part of it. Now it's time for me to step back and retire. I'm looking forward to participating in the process to identify my successor who can support Steve and Jim in Quest's next phase of growth.",0.7180095,0.978
DGX-2021-Q4-2022-02-03,22,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now turning to our results, we closed out 2021 with another record year of revenue, earnings and cash from operations. Our base business recovered throughout the year, and we experienced strong demand for COVID-19 testing services. So for the full year 2021, total revenues grew by more than 14% to $10.8 billion.",0.092257,0.422
DGX-2021-Q4-2022-02-03,23,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Earnings per share increased by nearly 49% on a reported basis to $15.55, and more than 27% on an adjusted basis to $14.24. Cash provided by operations increased by more than 11% to $2.2 billion. And for the fourth quarter, total revenues were $2.7 billion, a decrease of roughly 9% versus 2020 when COVID-19 volumes were surging. Earnings per share were $3.12 on a reported basis, and $3.33 on an adjusted basis, both down approximately 26% versus the prior year.",0.2609555,0.765
DGX-2021-Q4-2022-02-03,24,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So I'd like to share some perspective on the role of COVID-19 testing going forward. A lot of progress has been made in the battle against COVID-19. But we believe it isn't going away anytime soon. Our molecular product began this year strong, with volumes peaking in January. Testing will continue to play an important part of managing COVID-19, and we believe that molecular testing remains the gold standard. We continued to perform well throughout the surge, maintaining average turnaround times of two days or less for COVID molecular testing.",0.2115321,0.915
DGX-2021-Q4-2022-02-03,25,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We will continue to maintain appropriate testing capacities and staffing levels to be prepared for any additional surges throughout this year if they emerge. We also continue to believe there will be a bigger role for serology testing, and how we measure COVID-19 protection going forward. Ultimately we expect COVID-19 testing to eventually more flu-like and become a permanent part of our portfolio going forward.",0.1509061,0.226
DGX-2021-Q4-2022-02-03,26,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now turning to our base business, we continue to make progress executing our two point strategy to accelerate growth and drive operational excellence, while we delivered 2% revenue growth on our base business from acquisitions again last year. In the fourth quarter, we acquired the assets of Labtech Diagnostics, a regional independent laboratory, serving physicians and patients primarily in South and North Carolina, Georgia and Florida. This is the first full service laboratory owned by Quest in South Carolina.",0.3515651,0.915
DGX-2021-Q4-2022-02-03,27,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also recently announced our acquisition of Pack Health, a patient engagement company that helps individuals adopt healthier behaviors to improve outcomes. This acquisition will bolster our extended care capabilities. Since 2012, we have completed more than 40 acquisitions, including outreach laboratories, regional independent laboratories and capability enhancing deals. And over the last four years, we've achieved our target of greater than the average of 2% revenue growth on our base business each year from acquisitions.",0.0850082,0.956
DGX-2021-Q4-2022-02-03,28,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, our M&A appetite remains strong. In 2021, we took full advantage of our strong health plan access, which is approximately 90% of all commercial insurer advice in this country. We also made good progress working together with our plans to help companies and their employees save money by reducing denials and out of network leakage. Our clients also recognize the value of working with us and we have grown our health plan revenues faster than our overall revenues to the best level we've ever seen.",0.1347611,0.977
DGX-2021-Q4-2022-02-03,29,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hospital health system revenues have grown more than 20% compared to 2019 levels, excluding COVID-19 testing, driven largely by the strength of our professional laboratory services contract. Our performance in 2021 benefited from our two largest PLS contracts to-date, Hackensack Meridian Health and Memorial Hermann. Altogether our PLS business without COVID-19 exceeded a record $500 million in annual revenue last year. Hospitals continuously faced pressure throughout the pandemic. Post-pandemic we believe the same will be true.",0.0919275,0.782
DGX-2021-Q4-2022-02-03,30,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We believe there will be a continued consolidation and ongoing challenges that afford Quest an opportunity to implement our flexible solutions that help hospitals become more effective and productive. Advanced diagnostics is critical to the future of healthcare. We're building strong momentum in our key growth drivers, which include consumer and hereditary genetics, oncology and pharma services. In 2021 these test categories accounted for several 100 million dollars of advanced diagnostics portfolio, and they are growing more than 25% versus 2020, and nearly 33% versus 2019.",0.2095552,0.959
DGX-2021-Q4-2022-02-03,31,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We are investing aggressively in areas with potential for future differentiation to grow our advanced diagnostics value proposition, including automatic tests, next gen sequencing, bioinformatics, the sales force and customer service. We're leveraging our scale and expertise to give patients and fighters greater access to important innovations such as liquid biopsy, and digital pathology. Advanced diagnostics is one of the fastest growing areas of our portfolio. Our strategy and investments in this area will enable us to achieve high single digit revenue growth going forward.",0.2171334,0.859
DGX-2021-Q4-2022-02-03,32,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now we're equally excited about the opportunities we see in our direct-to-consumer test vertical. Revenues for QuestDirect services nearly doubled to more than $70 million in 2021, driven by both the base business growing and COVID-19 testing. We expect that non-COVID consumer diagnostic market will experience double digit growth over the next several years. And we're on track to build a $250 million direct-to-consumer business by 2025. We're ramping up our investments in to business, launching a new improved digital experience later this year. And we're also investing in enhancements to the in-person customer experience at our patient service centers.",0.0685338,0.886
DGX-2021-Q4-2022-02-03,33,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So lots of good stuff in 2022. We're building on our long term relationships with Walmart by recently launching a consumer initiated laboratory testing on walmart.com, through our solution powered by QuestDirect. And the MyQuest platform now has nearly 23 million users, up more than 3 million in the past quarter. We are very excited about our longer term growth opportunities in advanced diagnostics and direct-to-consumer testing and our increasing investments we made in 2021 to strengthen our business and accelerate growth beyond the pandemic.",0.3920923,0.954
DGX-2021-Q4-2022-02-03,34,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","These investments were made possible with the record cash and earnings we generated over the past two years. We shared part of our two point strategy is to drive operational excellence. We remain laser focused on improving both operation quality and efficiency which go hand in hand. Through 2021 the Invigorate program exceeded our goal of 3% productivity improvement. We made good progress last year in procurement supply savings as well as reducing unplanned denials, and improving patient collections at the time of service.",0.2102142,0.988
DGX-2021-Q4-2022-02-03,35,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","While we faced modest inflationary wage pressure in 2021, on the supply cost side, we have more than offset any increases with cost savings from our suppliers. Historically, our Invigorate productivity savings have been net of any inflationary increases. Beyond that we continue to drive additional productivity improvements with platform consolidation and greater use of automation and artificial intelligence.",0.3874794,0.823
DGX-2021-Q4-2022-02-03,36,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now turning to our sales force -- excuse me, now turning to our workforce. Quest employees are highly engaged, based on results of our quality surveys. In a challenging labor market, we are focused and are still seeing improvement and engagement in retention. Our team has done a lot to create an inspiring workplace. And we continue to do everything we can to attract, recruit and retain talent. We're entering 2022 in a strong position within the lab industry and more broadly throughout healthcare. Our base business is poised to build off the record revenues we've achieved last year and we're investing to accelerate growth.",0.2392092,0.981
DGX-2021-Q4-2022-02-03,37,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We expect to see continued demand for COVID-19 testing services, albeit at lower levels than the last two years. The delay of the 2022 PAMA cuts announced last year was a good outcome for industry and Medicare beneficiaries. However, we will continue to be hard at work in 2022, with our trade association and Members of Congress with the goal of arriving at a permanent fix to PAMA.",0.1186161,-0.226
DGX-2021-Q4-2022-02-03,38,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We remain committed to our capital employment strategy of returning the majority of our free cash flow to our shareholders. This morning, we raised our dividend for the 11th time since 2011. We expect to have more than $1 billion in cash available this year for M&A and share repurchases. So putting it all together, our 2022 guidance reflects strong momentum and investment in our base business, balanced with the inevitable but expected decline in COVID-19 testing revenues.",0.1874794,0.665
DGX-2021-Q4-2022-02-03,39,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before turning over to Mark, I'd like to recognize and thank once again, all of our employees who really have been at the frontlines of the pandemic and continue to serve the healthcare needs of patients who depend on Quest every day. Now Mark will provide more detail on our performance and our 2022 guidance. Mark?",0.2336079,0.612
DGX-2021-Q4-2022-02-03,40,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks Steve. In the fourth quarter consolidated revenues were $2.74 billion, down 8.6% versus the prior year. Revenues for Diagnostic Information Services declined 8.5% compared to the prior year. The decline reflected low revenue from COVID-19 testing services versus the fourth quarter of 2020, partially offset by continued growth in our base testing revenue. Compared to 2019, our base DIS revenue grew approximately 6% in the fourth quarter, and was up more than 1% excluding acquisitions.",0.4008689,0.527
DGX-2021-Q4-2022-02-03,41,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Volume measured by the number of requisitions increased 1.3% versus the prior year, with acquisitions contributing 1.1%. Compared to our fourth quarter 2019 baseline total base testing volumes increased by more than 10%. Excluding acquisitions, total base testing volumes grew approximately 5% versus 2019 and benefited from new PLS contracts that have ramped over the last year. The progress we've made in our base business throughout 2021 continued in the fourth quarter, and base testing volumes remained consistent with our prior outlook.",0.3341232,0.809
DGX-2021-Q4-2022-02-03,42,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As many of you know COVID-19 testing volumes moderated early in the fourth quarter, following the peak of the Delta wave in September, but then surged again in early December as the Omicron variant spread across the U.S. Together with our JV partners Sonora Quest, we resulted approximately 7.9 million molecular tests. Quest alone resulted roughly 7.3 million molecular tests and nearly 730,000 Serology tests in the fourth quarter. In January, our COVID-19 molecular volumes averaged approximately 120,000 tests per day, and over 139,000 per day, including Sonora Quest, with volumes peaking in the middle of the month.",1.7969984,-0.361
DGX-2021-Q4-2022-02-03,43,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per acquisition declined 9.8% versus the prior year, driven primarily by lower COVID-19 molecular volume. In the fourth quarter increases in our base revenue per acquisition were more than offset by the impact of recent PLS revenues. Modest unit price headwinds remained consistent with our expectations.",0.1512638,-0.043
DGX-2021-Q4-2022-02-03,44,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income in the fourth quarter was $536 million, or 19.5% of revenues, compared to $795 million, or 26.5% of revenues last year. On an adjusted basis operating income in Q4 was $579 million, or 21.1% of revenues, compared to $860 million or 28.6% of revenues last year. As you may recall, updated 2021 guidance we shared in October contemplated a lower adjusted operating margin both year-over-year and versus 3Q. The year-over-year decline was primarily driven by lower COVID-19 testing revenue and higher COVID-19 testing costs, headcount and wage increases and ramping strategic growth investments.",0.2689573,0.153
DGX-2021-Q4-2022-02-03,45,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"It's important to note that over time, a growing portion of our COVID-19 molecular testing volumes have come from non-traditional channels, which carry additional expenses and logistics cost. Also spiking COVID-19 positivity rates across the country in December eliminated our tooling capability, which further increased COVID-19 testing costs later in the quarter. In addition, we also experienced higher than anticipated employee healthcare costs in the fourth quarter, primarily related to COVID-19.",0.1413902,0.785
DGX-2021-Q4-2022-02-03,46,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $3.12 in the quarter, compared to $4.21 a year ago. Adjusted EPS was $3.33, compared to $4.48 last year. Cash provided by operations was $2.23 billion in 2021, versus $2.01 billion in the prior year. We completed our $1.5 billion ASR in November, and repurchased that additional 310 million in stock in the fourth quarter. This brings total share repurchases to more than $2.2 billion in 2021. And we ended the year with $872 million on the balance sheet.",0.2772512,0.296
DGX-2021-Q4-2022-02-03,47,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Before turning to guidance, I'd like to comment on recent trends we've seen in our labor costs. As Steve noted, we've been managing through a challenging labor environment, while wage inflation including our annual merit increase is expected to be between 3% to 4% this year. The increase in our total salaries, wages and benefits is expected to be below 3% in 2022, given the reset of our annual performance compensation, and lower expected overtime. As a reminder, all of our employees are eligible for annual performance.",0.4624803,0.872
DGX-2021-Q4-2022-02-03,48,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now turning to guidance. We are giving full year 2022 results as follows. Revenue is expected to be between $9 billion and $9.5 billion, a decline of approximately 12% to 17% versus the prior year. Base business revenues are expected to be between 8.3 and 8.5 billion, an increase of approximately 3.5% to 6%. COVID-19 testing revenues are expected to be between $700 million and $1 billion, a decline of approximately 64% to 75% reported EPS expected to be in a range of $7.63 and $8.33, and adjusted EPS to be in a range of $8.65 to $9.35.",0.6251975,0.572
DGX-2021-Q4-2022-02-03,49,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Cash provided by operations is expected to be at least $1.6 billion and capital expenditures are expected to be approximately $400 million. Before concluding, I'll touch on some assumptions embedded in our 2022 guidance. As Steve said, we're entering 2022 in a strong position. Our guidance assumes COVID-19 molecular volumes to average between 65,000 to 80,000 tests per day in Q1, representing a decline from January wells, and approximately 20,000 to 35,000 tests per day for the full year.",0.8542654,0.649
DGX-2021-Q4-2022-02-03,50,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"For COVID-19 serology volumes the guidance assumes approximately 3,000 tests per day for the full year. Our guidance does not currently anticipate another COVID wave. We will remain ready from an operational standpoint to handle any future surges. Last month, the public health emergency was again extended another 90 days through April. We assume average reimbursement for COVID-19 molecular testing to hold relatively steady through this period. While the public health emergency could continue to get renewed beyond April, additional extensions are not captured in our guidance.",0.8187204,-0.402
DGX-2021-Q4-2022-02-03,51,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The revenues generated from COVID-19 testing have afforded us an opportunity to continue to increase investment in our business. As Steve noted earlier, we continued to ramp investment in our growth pillars, particularly the advanced diagnostics and direct-to-consumer testing opportunities. We are planning to invest approximately $160 million in our growth initiatives this year, which represents an additional $90 million in investments in 2022 versus 2021.",1.03594,0.921
DGX-2021-Q4-2022-02-03,52,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We also continue to incur hard costs to manage your business through the pandemic, including expenses to comply with CDC guidelines, address ongoing supply chain challenges and maintain adequate staffing levels. We currently forecast these expenses to be approximately $50 million in 2022.",0.3882306,0.202
DGX-2021-Q4-2022-02-03,53,Remarks,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As a reminder, we originally expected PAMA cuts of approximately $80 million in 2022. These cuts were delayed one year until 2023. Finally, we ended 2021 with approximately 124 million diluted shares outstanding. Our guidance assumes no change in our share count in 2022, and only enough share repurchases to offset our employee equity programs and to meet our commitment of the majority of our free cash flow to our shareholders.",2.9044234,0.84
DGX-2021-Q4-2022-02-03,55,Remarks,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Mark. Well, the Sunrise had another record year providing critical COVID-19 testing for our country and delivered record revenues, earnings and cash from operations. We also grew our base businesses to a record level of 19% versus the prior year. Quest is well positioned in 2022 to deliver on its commitments. I'm proud of the incredible accomplishments of our 50,000 Quest employees throughout the pandemic. And finally, our team is strong, the business has never been better, and Quest's future is bright as we begin a gradual transition to new leadership.",0.2771005,0.904
DGX-2021-Q4-2022-02-03,60,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"Thank you, Jack.",0.9215686,0.361
DGX-2021-Q4-2022-02-03,64,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, thanks, Jack, for the question. There is a lot of pressure in our industry, and particularly at hospitals. And so we are seeing continued interest and are working with hospital systems and helping them become more efficient and productive with their professional lab services business. That continues to be a big opportunity. You saw in our prepared remarks it grew nicely over the last couple of years. We have a half a billion dollar business, and therefore that moves, it moves our enterprise a significant level. So that's number one.",1.4425041,0.959
DGX-2021-Q4-2022-02-03,65,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Number two, is we are very strong, and we continue to drive operational excellence. As you all know, this is not new, it's institutionalized in Quest. We believe we have the cadence and the capabilities to continue to offset any inflationary pressure we have. And we've done that. We did it last year, we'll continue to do that going forward. And as I said, in my introductory remarks, our array included Invigorate. We talked about inflationary pressures on our cost of sales. By the Invigorate savings is a net number. So any increases, offset by the saving always been positive for us and getting more savings than cost increases.",0.4352554,0.935
DGX-2021-Q4-2022-02-03,66,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so despite, some pressures that we see, because of the current times, we're offsetting that, and going forward, we do see that smaller laboratories will have a tougher time keeping up with some of these structures. And therefore, we do have an advantage. We saw the acquisition, we just did a flap jack in South Carolina; we are achieving that 2% growth from acquisitions. So therefore, we believe our strategy has positioned us nicely going forward to take advantage of the changes in front of us given this different times than we've ever seen. So Mark anything you'd like to add to that.",0.001318,0.917
DGX-2021-Q4-2022-02-03,67,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, I think the other thing that's evolving jack that you didn't mention, I'm sure it's on your radar is moves towards transparency in pricing, whether it's surprise billing. Now, certainly is complicated. So even for us, it's not simple, would depend which commercial insurance, depends on who your carrier is and so on. So it's not simple to tell people exactly what their cost is. However, it's absolutely an advantage for the national labs , specifically for Quest. So we're encouraged by some of this. It's kind of one of those secrets that a lot of people aren't aware how much better our value is compared to others.",0.7575039,0.947
DGX-2021-Q4-2022-02-03,68,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we really see that together with some of the things you mentioned as another reason that we're going to continue to pick up share and really return to those historic rates we were having before the pandemic started, with greater access and the knowledge, tools and value that we bring well beyond our price, including our real time estimation tools, including our MyQuest app, and all the other things that really enhance the patient experience.",0.4316746,0.802
DGX-2021-Q4-2022-02-03,70,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, so to be clear, except for referral network, we have a JV with Sonora Quest. So we wanted to make sure that people were aware that we're doing some math around referral on the testing volumes that we don't actually to record that revenue, because we have a minority ownership stake. So we get a proportionate share of the earnings from Sonora Quest, as we do with our other minority holdings, as we do with our majority holdings to equity earnings. So we just wanted to drive that transparency.",0.1143328,0.821
DGX-2021-Q4-2022-02-03,71,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But in terms of pricing, and so on, so forth, I won't comment specifically on Sonora Quest. But it's not dissimilar, it's not a totally different profit structure than the things that we do ourselves. In Jack, during this less than 5% of our total volume is sent out to a referral lab. At this point in time, its effect on zero. So it's only during a surge, that we have to rely on external partner labs to help us.",0.8810544,0.023
DGX-2021-Q4-2022-02-03,72,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, what I did refer to Jack, and maybe that's what you were asking about was non-traditional channels. And so that's not where we're sending the work. It's actually how we're getting the specimens. So a lot of the work especially early was through traditional channels, or hospital partners, where we were going anyways, to collect specimens, and we would leverage all the Quest Logistics, in cases where we had people going to our ACE trauma centers, we're leveraging that.",0.3278418,-0.026
DGX-2021-Q4-2022-02-03,73,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In this case, we're actually getting it from other providers, CVS is the most notable one. As we do that, we have to have an incremental logistics structure with that incremental logistic runs. Then we do pay a fee. You kind of think about it kind of like phlebotomy, but all the work they do to collect the specimen, to engage the administrative costs of the patient to give them the results, and so there is a cost that maybe people weren't aware of when we're not getting that specimen to our traditional infrastructure.",1.0263591,0.543
DGX-2021-Q4-2022-02-03,82,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, so thanks for the question, Ann. It's important one. So first off, we're not deviating from our long term outlook. So we've shared a long term outlook in March of 2021. And while the CAGRs are going to change, because we're going to have a stronger year in 2022, and the carriers I quoted that that time, were putting 2022 forward, the absolute numbers we're not deviating from because they're largely the base fitness. So we still assume that COVID will materially decline, you know, time will tell. At that point, it's really all-round our base business.",0.1215815,0.911
DGX-2021-Q4-2022-02-03,83,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So when people are looking at the current profitability of the base business, and I can understand how this happens. One of the flaws of that is that there really -- you can't really do the two in isolation. So let me give some examples. Because we've had such a surprisingly strong year, this year relative to what we expected, driven by COVID, we're paying a significantly higher incentive performance bonus. And that's across the whole employee base. And, right now, that would not be expected to be repeated next year.",1.0085667,0.872
DGX-2021-Q4-2022-02-03,84,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So that, quote, inflated our costs. And so to assign all of that cost against the base business, which is what implicitly it's done, when you do COVID revenue times a certain margin drop through, and then you assume back against the base business, that is not accurate. The other thing is, we have significant incremental costs related to the pandemic, which I mentioned in the prepared remarks, around $50 million of cost. If COVID really goes away, we would expect those costs will largely go away. And those costs are really be assigned to COVID, not to the base business.",0.1028007,0.402
DGX-2021-Q4-2022-02-03,85,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We had quite a bit of overtime later in the year. And that was related to employee absences driven by the COVID surge, and we spent about $25 million more in 2021, then we historically spend in over time. And we would expect that would go away, as well, as COVID starts to step back. And so again, that that s implicitly put against the big business, when you do the high level math that I've seen a lot of people do. And so the way to think about the base business is obviously from our guidance, we are hundreds of millions of dollars above where we were in 2019.",0.2616145,0.273
DGX-2021-Q4-2022-02-03,86,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We expect to be back to the growth that we were experiencing pre-pandemic. I know, it seems like a long time. But if you look at the first two months, and we mentioned this several times of 2020, before the pandemic started, even after a full year of the network access teams we have in 2019, we're still growing mid-single digits. We're going to get back to that growth, okay, in the base business. And the profitability of the base business is going to be similar to what it was before 2019.",0.1759473,0.886
DGX-2021-Q4-2022-02-03,87,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So hopefully, that puts all the pieces together for you. Obviously, there's anything I can clarify, I'd be happy to take a follow up.",0.6474465,0.771
DGX-2021-Q4-2022-02-03,89,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Right, so some of those will ramp down, because there are discrete investments to get us where we need to get to. So for instance, a big piece of that is building what we need for our consumer is fantastic. And to move from where we were to a more Amazon like, not that we'll get completely there, but experience for patients who want to find tests and order it, pay their bill, et cetera is expensive. It takes a lot of work with marketing analytics to do the appropriate marketing and understanding of customer preferences, and respond to customers in appropriate way. A lot of IT investment in the near term to get us to that future state.",0.1278418,0.548
DGX-2021-Q4-2022-02-03,90,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now as we're growing that business to a $0.25 billion, which is what we said we would get to by 2025, there are going to be some ongoing costs, because we're adding people to support that business. It isn't a grown up business. And there are going to be some variable costs with that. However, as we grow those businesses, we're going to grow fast. And so some of those ongoing costs are going to get paid for that faster growth. And then I would say similarly, advanced diagnostics, as we accelerate that growth, some of the resources we're adding today that we're calling out pre that growth are going to be in the run rate and profitability going forward.",0.0665568,0.923
DGX-2021-Q4-2022-02-03,91,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So the costs don't go away completely, but they will ramp down because some of this is kind of startup expenses. And then that revenue, obviously in the end, the margin is going to pay for those incremental costs over the next several years.",0.7716639,-0.153
DGX-2021-Q4-2022-02-03,92,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Only it's after that . Remember, when we talked about this year, these investments really started in the back half of 2020. And we talked about an exceptional year in 2020. We talked about an exceptional year in 2021. And therefore we took advantage of the opportunity invested in accelerated growth entirely consistent with what we share with you as our growth portfolio portfolio. And what you're seeing in our results, our ranges, the benefits of those investments, you're seeing great growth in our focus areas of advanced diagnostics. I highlighted those areas of our portfolio that we focus on.",0.046458,0.966
DGX-2021-Q4-2022-02-03,93,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And these are not insignificant portions of our portfolio. I share my [indiscernible] several 100 millions of dollars of focus for us that are growing strong double digits versus last year versus 2019. And then secondly, is our consumer initiative testing business has grown considerably. We talked about $70 billion, almost half to 250 . And so therefore, we're already starting to see the benefits. So as with any of that we certainly expect a business return. We're getting some evidences of return already. '21 looks like more of it than '22. And so when we get into '23, you got to track that.",0.1433278,0.929
DGX-2021-Q4-2022-02-03,94,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","They were not served in the beginning. What we're putting on right time is exactly what we laid out on Investor Day. That is, we have a baseline coming out of '22 that we believe in, and what we just shared in our '22 guidance is entirely consistent with that. And we will continue to grow our earnings. The high growth, we highlighted 7% to 9%, and that will continue through '23 and '24. So we feel what we've done so far, and what we delivered is entirely consistent with what we believe the prospects of -- we do believe the opportunity in front of us are even more attractive than before, because we found the proceeds, was relative to accelerate the program was real.",0.2046129,0.904
DGX-2021-Q4-2022-02-03,95,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, just one point of clarification. So the 7% to 9% was when we thought we could do $7.40 $8 in 2022. And we said we'd be at the upper end of that. So you can pick your number between $7.40 and $8, carry forward $7 to $8, through '23 and '24. And that dollar level of EPS is what we're saying we can still do. Obviously, since 2022, is turning out based on our guidance, a lot higher than we said in March, the CAGR is going to be lower. But the absolute numbers we're still committed to at this point.",0.8372828,0.34
DGX-2021-Q4-2022-02-03,96,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Operator, we're going to go to the next question. I just want to let everyone know, we won't go past the bottom of the hour. We have a lot of folks in queue. We want to get to all your questions. Operator?",1.2385502,0.153
DGX-2021-Q4-2022-02-03,99,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Good morning, A.J.",2.5209321,0.44
DGX-2021-Q4-2022-02-03,101,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","A.J., thanks. We continue to believe that we can continue to deliver that 2% growth off our base business going forward. We've delivered that in the past, and we have every reason to believe that we will continue going forward. As I mentioned earlier, we continue to see hospitals looking at what we've done with other hospitals, and opportunity for them to rely on us as the testing and that product continues to build. And we continue to look at some outreach purchases with hospitals.",0.2276771,0.856
DGX-2021-Q4-2022-02-03,102,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then, as I mentioned, Labtech was a good example of a regional laboratory and a good piece of the United States that we picked up as well. And we continue to look at acquisitions that build on our portfolio. Remember, we have this lens of focusing on general diagnostics. Jim Davis, runs that business, in addition to that advanced diagnostics. But the third pieces are those services that take the information that we generate, and we provide services, and we do this employer population health. And we built on that business to work with health plans, on helping them manage the risk with the data and providing services that help them do that.",0.0039539,0.926
DGX-2021-Q4-2022-02-03,103,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So Pack Health fits into that direction for the company. And we've done some other acquisitions that help us with that direction as well. And you're going to hear more about -- we will continue to invest in that space going forward. And also in your question, does the management change slow us down in any way and here what we might do an acquisition, I would say to the contrary, you know, Jim's been part of the management team for over eight years. He's highly engaged in all acquisitions. He's been instrumental in executing all of our acquisitions. And all the businesses that he participated in are always part of the funnel building that we have.",0.1897858,0.784
DGX-2021-Q4-2022-02-03,104,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So Jim any remarks about the 40 acquisitions we've done, and your team to find more opportunities.",0.5192751,0.439
DGX-2021-Q4-2022-02-03,105,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"No, A.J., as Steve said, I've been part of all 40 of those acquisitions. And it's not going to slow down. We're not going to do -- we're going to do smart deals. We're going to be selective, but we're going to continue to build our base business. We're going to continue to find niche applications to build out our events diagnostics portfolio, and we're going to continue to focus on hospital outreach deals, those that are willing to get out of business. We're right there ready to help out.",1.0042395,0.866
DGX-2021-Q4-2022-02-03,111,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Thanks Patrick. Well, so there's a lot of attention these days on inflationary pressures. And we think we've handled those questions. We think it's all very manageable for us, in terms of our operational excellence programs, and finding the productivity, we need to offset it. So that's one piece of the equation. The other piece is what you're bringing up, is around pricing. And we feel good about what we delivered in that regard.",0.8082372,0.898
DGX-2021-Q4-2022-02-03,112,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Matter of fact, if you look at the results for '21, what you find is that their unit price changes, and this is freezing everything from volume in meds, and just looking at unit price changes is below that 100 basis points that we typically are guiding you to dial into expectations going forward. And that's not just for our commercial insurance contract. It's all our businesses, our hospital business, it's our client business, independent of what whose clients might be, physicians or some other organization we work with.",0.4962109,-0.077
DGX-2021-Q4-2022-02-03,113,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we continue to make progress on that. And we're particularly encouraged by the discussions we're having with our plans. We've shared in the past that actually, in the past, several negotiations, we've actually introduced price increases. And it is actually helping us that in fact, there is inflationary pressure across all of healthcare. So therefore, we're not alone, since we're a labor based business to pass along some of those costs to them.",0.1601318,0.829
DGX-2021-Q4-2022-02-03,114,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we're making good progress. And I say that the other piece of this, Patrick is, we continue to deliver great value. Our quality gets better, our service gets better. And we do that in a very competitive price already. And many of these plans believe that's in the best interest of them and their membership of growing share, is to make sure they rely on a handful of top flight laboratories, in the case of United Healthcare, they call that for labs network. And we had applied to that. And we had to demonstrate with evidence that, in fact, we have great quality. We have great service, and we're doing at very competitive prices.",0.0319605,0.993
DGX-2021-Q4-2022-02-03,115,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So that trend will continue. When you talk about that, we're going to eventually keep on pushing us to deliver more and more value, which helps you in terms of managing your network. We, in many cases are going to start looking at some price increases going forward. So good progress there. Thanks for asking the question. Mark, anything you want to add?",0.0968699,0.936
DGX-2021-Q4-2022-02-03,116,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, I just want to remind people of what we talked about, over our tenure. We have this Invigorate program, drives about 3% productivity. We call it productivity, because some of it is top line enhancing. It's not all around costs. And we've mentioned the fact that we have these pay fors . And one of them has been priced stretched. One of them has been annual labor inflation. And then we talked about the fact that as we got priced in a better place that actually was helping with margin expansion.",1.8420221,0.885
DGX-2021-Q4-2022-02-03,117,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we have enough productivity to do more than the pay fors. So now we look at where we are today, and as Steve mentioned, a much better position. I can't specifically say it's related to inflation. But I can assure you that that is part of the conversation in addition to PAMA, and the value that we bring in, so and so. We've really moved the conversation dramatically from when we started here, to more about value. And fortunately for us, I can share that in the last three national payer contracts, all three of them, we got an increase. That was modest. But you compare that to where we've been historically, great news.",0.6188784,0.944
DGX-2021-Q4-2022-02-03,118,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And that also means that even if we have a little more inflation, and I think we talked about this quite a bit, we've got plenty of Invigorate. And that Invigorate now, doesn't need to cover as much of the price erosion that we have historically. And that price erosion that Steve shared is really heavily in the clientele. And as we've talked over the last number of earnings calls that comes from the hospital clients who are under tremendous pressure, and we shared the reasons for that. And also in some states where physicians can do clientele markup, we have that pressure as well.",4.5912322,0.823
DGX-2021-Q4-2022-02-03,119,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And really with the commercial payers, we're in a really good place on prices lately.",0.7373618,0.493
DGX-2021-Q4-2022-02-03,121,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So what we're assuming in our values is getting some ranges of what we think COVID testing will be. Obviously, it's going to start higher in the first quarter, it's going to go down, as we're hopeful that this current surge will decline throughout the spring and into the summer. And as you mentioned, we did get the 90 day extension. And then we're not planning in the guidance that that will be extended, but we just don't know. So therefore, we're always assuming the worst case. And that if that were to come down, yes, we do believe there will be some price changes, if you will, with some of our partners.",0.0079077,0.128
DGX-2021-Q4-2022-02-03,122,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But again, what we've implied in the guidance is kind of volumes and some decline in pricing. And also the assumption that we're not going to get a renewal of the emergency order. But again, we don't know that. So Mark anything you'd like to add?",0.0642504,-0.026
DGX-2021-Q4-2022-02-03,123,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, just to remind you -- not that I need to remind you all that, the rates that CMS determined at $51. And so while we don't assume post PHE that everything falls immediately there, there's a pretty steep ramp down. And then so for the volume that is in our guidance beyond the PHE in late April, we're assuming a significantly lower reimbursement than we've experienced to-date and that we're expecting to get till late April.",0.1382306,0.681
DGX-2021-Q4-2022-02-03,131,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, so. I'm sure you understand Ricky, even if I was willing, I can't really give you an EPS number on the face. So I think the best thing I could do is, point you to pre-pandemic, revenue and earnings and tell you that if you look at the growth in the base business based on what we're giving in guidance, the profitability is not dissimilar. So you can kind of directionally place where that business might be. And the reason I can't really give is back to what I talked about earlier.",1.0849131,0.94
DGX-2021-Q4-2022-02-03,132,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So where do I assign the $50 million of pandemic expense? Arguably, if we didn't have COVID testing, we would still have that cost. And you'd say, okay, let's go about your base business. But the truth is that we also have the COVID testing in revenue. So again COVID revenue is going to go into the base business. And then importantly, when you talk about headwinds and tailwinds, we would expect that cost to go away and should be temporary, because it is specifically tied to CDC guidelines and other things.",0.5833333,0.542
DGX-2021-Q4-2022-02-03,133,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We talked about some of the others, you know, some things including there, like supply disruptions. I don't know how long that's going to last. And we all know, it's not just in our business. It's across all aspects of life today, and it's modeled to go away in 12 months, not sure. That's certainly something we want to absolutely make sure that we have what we need. And so we are paying premium costs right now, relative to what we did pre pandemics in insurance, get to our patient service centers, our laboratories have everything they need. And that's really kind of our insurance, which fortunately, we can afford to do right now. Because we also do have that COVID revenue and COVID margin.",0.5462085,-0.551
DGX-2021-Q4-2022-02-03,134,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So really, I think that's the best color I could give you which is the base business is in good shape. We activate Q4 organically back to where we were in 2019. We've done significant M&A over the last couple of years, we've built the PLS business. So beyond the organic clinical business, we're hundreds of millions of dollars higher. And while the profitability and all that may not be precisely the same directionally people could feel confident that the profitability has moved at least to that growth .",0.028436,0.958
DGX-2021-Q4-2022-02-03,135,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So to remind you, our base business in '21 was larger than what we had in 2019. So it has grown. So it has recovered. And we're going to grow on top of that. And that's implied in our guidance for base business. And we intentionally broke out basis from COVID assumptions for '22. So you can kind of dissect who or what's going on with that business. And I keep on reminding you of investments that we're making are part of our base business. And we started those investments in '21. They continue in '22, and therefore, that's going to help us accelerate growth.",0.2230643,0.511
DGX-2021-Q4-2022-02-03,136,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as Mark said, we feel very confident about the profitability of our base systems. And by the way, when I said in my introductory remarks, is we do not believe COVID is going to entirely go away. It's going to be part -- a permanent part of our portfolio. So you should assume there's some COVID testing in '23 as well. We will continue to still play a role with our PCR testing. And we believe there's a growing role for serology particularly related to our ability to be able to provide some insight around the protection that individuals have in their bodies. And we're going to have more on that to come.",0.2642504,0.902
DGX-2021-Q4-2022-02-03,137,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",But you put it together is -- and we believe the prospects for '23 and beyond are quite bright. So thank you.,0.3700165,0.815
DGX-2021-Q4-2022-02-03,138,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"Ricky, I would add one other thing. And that's as probably Mark stated at the pace business has recovered in 2019 levels are still not going to interject in terms of a headwind. There's still pent up demand for routine clinical care. If you look at the studies around HIV infection rates, hepatitis C infection rates, the data still indicates that there was a lack of routine clinical care during the pandemic. And we do think that should provide some headwinds going into the later part of this year and next year.",1.0630631,0.557
DGX-2021-Q4-2022-02-03,142,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Well, let me start, and then my colleagues will round it out, I'm sure. So this isn't going away anytime soon. I think obviously, that we're going to have COVID in '23. And we're going to provide testing around that. And as you know, because you're living with it everyday, like the rest of us, when somebody has some symptoms, you're ruling out COVID. In many cases, that is a PCR test, and that will continue. So therefore, you don't think about just being flu, but it's any type of respiratory illness, and it could be a common cold or another respiratory illness. So there'll be continuation of that, going forward.",0.0276771,-0.654
DGX-2021-Q4-2022-02-03,143,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And also, we keep on highlighting the value of serology. There is going to be increased role for us to provide insight on how much protection people have from vaccines or from natural immunity. And as we know, that's changing over time. And people want to have that insight to, manage the risk and work with their physician on that. So we think there, there's going to be increased value in that. So we do believe, in '23, this is going to be a permanent part of our portfolio.",0.0250412,0.827
DGX-2021-Q4-2022-02-03,144,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","It's hard right now to scale that and we'll learn more as we get into '22. But when we think about it, we actually think of this as an additional portion of a product line that we didn't have before the pandemic. So we actually decided that it was helpful to, achieve the value we think we have. And then as Jim said, base business continues to be in really strong shape. We crossed the growth of '19 sooner in '21, we're entering '22 in [indiscernible]. Our growth prospects, there continue to be ones that we continue to work. So that should continue to be a good opportunity for ourselves.",0.2481054,0.961
DGX-2021-Q4-2022-02-03,145,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we're filling our chips together well, and COVID is going to products provide more fuel for us to make these investments in our base business that help us and 23. So we Yes, we're focused on what the costs are, but we only make these investments if in fact, we expect to get the returns and you'll see those returns, both in '22. But also in '23 and beyond. So Mark anything you'd like to that?",0.0233937,0.815
DGX-2021-Q4-2022-02-03,146,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, thanks. Brian, it's a great question. And we can't predict with any certainty what's going to happen. I think the two unknowns are, how comfortable will physicians be with taking the specimen sample themselves in the office going forward? And maybe they'll be very comfortable like that with the flu where maybe they'll be like, no, I'd rather I'd rather not handle that. I'd rather not do that point of care test and all the risks that come with that. I'll just send it to a lab. But then the other one, really importantly, the economics. So the payers are going to have a lot of influence on whether this is done.",0.4395735,0.969
DGX-2021-Q4-2022-02-03,147,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now yes, point of care testing, arguably, some people do it for faster turnaround times. But a lot of it is done because they make money off of it. So depending on what the payers decide around point of care reimbursement that will have a large influence on how much of this work comes to us and how much that of it stays in the office. Then let me just stop and ask Jim to comment on this.",1.1386256,0.71
DGX-2021-Q4-2022-02-03,148,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","If you look at our volumes are impressive. We've had a challenge this year, because of the infection rate, and therefore our ability not to be able to fail to deliver on cooling , which is more capacity and lower costs. But that will come back with infection rate, which dropped. But as we go forward with this, we start to see this becoming more of an epidemic and less of a pandemic, then there's a lot of players in this marketplace, and Jim and his team are entirely focused on what we have for sure today, and what we could do going forward to gain some share going forward.",0.1004942,0.867
DGX-2021-Q4-2022-02-03,149,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So when you think about the opportunity around COVID, if you look at that market, you think about Quest Diagnostics, you think about the dynamics of the short run, where there's been some opportunistic players. We're not optimistic. This is going to be part of a permanent part of our portfolio. And therefore we also are pushing hard, and making sure that we get what we believe what you have to share in the short term. But also in the long term, we think there might be an opportunity as well to pick up some share. Jim, you'd like to add to that.",0.3947282,0.927
DGX-2021-Q4-2022-02-03,150,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"Yeah, what we did find during this last surge is we had a series of 10 default partners that we've referred work out to, when we couldn't handle the volume, especially during peak days during the work. And at least 50% of those partners had gotten out of business and decided they just didn't want to rebrand for capacity. So while there may be the physical capacity out there, some of that physical capacity, especially on the PCR side has returned to the clinical kinds of work that those firms were doing, other molecular work.",1.5373609,0.361
DGX-2021-Q4-2022-02-03,151,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"So that is, I think advantages us in the future, if there is another surge here.",1.4250132,0.361
DGX-2021-Q4-2022-02-03,155,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, so we intentionally don't really target or comment on margins, because we believe value creation can come at different levels of margin. Then we talked about specifically on PLS, where it's great growth, great return on invested capital. And those are the two biggest correlators to shareholder value creation. But they come at a lower margin. So we don't worry about margin Pito per se, but I understand others do. And so to answer your question, there's a pretty broad range, you know, obviously, one year less than over multiple years when you put a CAGR with a couple 100 basis points differential on the top line and bottom line.",0.4474724,0.927
DGX-2021-Q4-2022-02-03,156,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So there's a lot of different combinations. So what I would say is, your EPS number that you mentioned, is not unreasonable. And you can figure out the revenue based on what we said, at Investor Day, and then what we're guiding to this year in terms of the base business, and yeah, at this point, we're not counting on COVID to be significantly larger than maybe a flu business or something like that. But certainly, we don't know. And there's a chance that it could be larger than that. And that will be determined over the next 12 months or so.",0.2551343,0.802
DGX-2021-Q4-2022-02-03,157,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So that's about strongest color I can give you right now, is back to what we said. If you're really good about our base business going forward, we're going to adapt to that growth level. And I want to remind everybody that when we grow organically, the drop down is much higher than that 17% or, the 19.5% that we delivered in Q4, and so on. It drops down at a level, you know, 50% or more depending if it's an existing customer, where we're expanding the menu, or it's a new customer, where we do have to invest a little maybe in logistics and in IT for the interfaces.",0.1050553,0.8
DGX-2021-Q4-2022-02-03,158,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"But growth brings with it margin expansion, in addition to Invigorate. That's why we're confident we can grow earnings faster than top line, from that period forward.",0.1251975,0.859
DGX-2021-Q4-2022-02-03,160,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, I mean, you can -- yeah, I mean, you can do the math. Yes. I mean",1.0408567,0.727
DGX-2021-Q4-2022-02-03,161,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,[Multiple speakers] about earnings per share.,1.7310427,0.296
DGX-2021-Q4-2022-02-03,162,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay, good. So what we -- Mark just said what we said is, we've always provided our outlook and guidance for our mix per share, because we do have a mix of business, we do have some lower margin business, that might be a good value creating opportunity for us, we're going to go after it like a PLS business. So our guidance for EPS would be expansion of EPS over time, rebasing it, if you will, for these changes that we've seen for the last two years. And Mark has reiterated our belief that our base business will fuel good opportunities for us to continue to deliver against that.",0.1594728,0.969
DGX-2021-Q4-2022-02-03,163,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","By the way, as we continue to gain share, variable gross margin is quite good. And as I said, we also believe there's going to be some COVID in '23. And it's hard to size it right now, but it's not going to go away soon.",0.0299835,0.391
DGX-2021-Q4-2022-02-03,164,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. And then the other thing is that, I'm not in any position to provide guidance in 2023. So that's why we're focusing every one of the things there. However, when you think about what can happen, COVID can be larger. We don't know, we're not counting at this point. And then we did mention we've got a -- we expect a billion dollars of cash this year. So between opportunity to quite a bit of M&A, and we'll see, or do share repurchases, those also aren't specifically contemplated.",0.0908373,0.756
DGX-2021-Q4-2022-02-03,165,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So that's why like locking down to a specific number is really difficult and probably not productive. So I would point you to what we said at investor day, and kind of assuming that that's reasonable if these things don't play out significantly differently from our current view of what 2043 might bring.",0.3487362,0.396
DGX-2021-Q4-2022-02-03,167,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Operator, next question.",1.8645799,0.0
DGX-2021-Q4-2022-02-03,171,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Great, thanks for the question. I'll weigh in and turn to Jim to add to the answer. We've been working on operational excellence for over a decade, and it has become institutionalized in our company culture, and embedded in how we do things. And it is, is a platform for how we're going to continue to grow. So your comment was around costs. We don't talk about cost, we talked about productivity, because there's a lot of aspects of what we do around Invigorate and some actually helps the top line, some actually helps getting more output with less labor. And yes, some helps us to become more efficient by less input from some of the materials that we use.",0.2738056,0.98
DGX-2021-Q4-2022-02-03,172,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we looked at an aggregate, and we continue to be bullish on our prospects. We believe that it is the ingredients for us to continue to deliver great value. That is when we do this we improve our quality, or service gets better. And oh, by the way, we become more and more productive to be able to make investments to fuel the growth. So it all fits together. And when we talk about this, and we talked about at Investor Day. We see an enormous opportunity for us to continue to digitize and innovate in operational excellence.",0.1581549,0.978
DGX-2021-Q4-2022-02-03,173,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so some of you have had the opportunity to tour through our latest lab of the future and that's our new facilities -- facility in Clifton, New Jersey. Sometimes if you come in, you'll see what we've done and take some of the learnings out of our Marlborough facility up in the Boston area. We brought that down to Clifton and we built on it. And that also gives us advantages of some consolidation with some of our new platforms. But Jim and the team are now taking that, and thinking about okay, what's next?",0.1841845,0.735
DGX-2021-Q4-2022-02-03,174,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay, so we think about innovation in our space, yes, there's innovation in terms of testing, and as far as diagnostic information services. But we equally think there's a lot of innovation and opportunity for us to move forward. So we continue to invest. And we talk about investments, we talk about the use of cash. As you notice, we've been putting about $40 million a year into our capital budget, which is investments and frankly, a lot of our innovation that allow us to fuel this productivity game. So Jim?",0.0326194,0.949
DGX-2021-Q4-2022-02-03,175,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"Yeah, I think Steve has touched on three key themes, automation, use of artificial intelligence, and the continued digitization of so many products. So Marlborough and Clifton are terrific examples of that. But as you know, they're all brand new laboratories. We've got 20 plus other laboratories in our network. And there's opportunities in every one of those laboratories without building new Greenfield sites to continue that automation journey. In particular, in our processing area, and what we call our fluid handling system, handling of blood and urine.",1.2617912,0.875
DGX-2021-Q4-2022-02-03,176,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"On the artificial intelligence side, you're going to see us move in pathology, psychology, microbiology, we've got some great examples of each of those departments today. We're deploying artificial intelligence systems that help with the readout of those images. And then Steve mentioned just the continued digitization. Now beyond the immunoassay platform where we consolidated around the [indiscernible], there are still other opportunities like that in our laboratories.",1.3190249,0.952
DGX-2021-Q4-2022-02-03,177,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"We recently ran a competition in your analysis, so likely to new vendors is next for that platform. And are rolling out those two platforms across all 23 Plus laboratories, it's going to generate a lot of productivity year over year. So as long as we have healthy third party vendors that continue to innovate, those innovations will come to our labs. And we'll continue along that 3% productivity journey.",0.6195019,0.823
DGX-2021-Q4-2022-02-03,178,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we're bullish on the prospects of continuing to drive productivity. I always react to this as a cost cutting goal. And this is not all about cost cutting goal. This is about working smarter. And this has been a key part of our strategy. And it fuels growth. And Jim mentioned some of the areas. I picture my internship [indiscernible] also digital pathology, which revolutionized our ability to diagnose and treat and to do that more productively. And this week, Jim is going up another laboratory to take a look at where we're going to make our next investment this year.",0.0879736,0.869
DGX-2021-Q4-2022-02-03,179,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So we're going to invest in the space. And we have a lot more opportunity in front of us. So it's exciting.,0.9255354,0.763
DGX-2021-Q4-2022-02-03,180,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"Yeah, I just want to add that, remember, this is not just in the lab. So there's a lot of productivity that's driven outside. And specifically, I'll give two examples, logistics. So we really have an incredible ability to be efficient with logistics, and continue to improve. So we have some cases where we have empty pickups, where we have some customers that don't give us specimens all the time. It's periodic. Now we have the ability and technology to not do that empty pickup. So that's an efficiency. We also get requests for what we call staff pickups, where somebody needs something quick turnaround, et cetera. And so the ability to most efficiently get one of our vehicles there has been enhanced through our technology.",1.8235294,0.946
DGX-2021-Q4-2022-02-03,181,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"The other one is in our patient draw centers. We really can increasingly move the administrative burdens off the phlebotomist, allow them to do phlebotomy by getting people to go to our website, put in their insurance information, everything. And so the phlebotomist spends a couple less minutes with each patient doing administrative doing phlebotomy. We drive up the productivity in our draw centers.",0.3147854,-0.153
DGX-2021-Q4-2022-02-03,182,Answer,2022-02-03,4,2021,James E. Davis,CEO and President,"So those are just a couple examples of productivity gains that aren't really cost reductions, but enhance our ability to do more with the same resources and drive up our quality and everything else outside the laboratory.",3.6597774,0.565
DGX-2021-Q4-2022-02-03,186,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, so what I can share is, go back to what we said in the prepared remarks, our consumer business was about $70 million last year, between the base and COVID, we did $2.7 million of COVID revenue. So the consumer initiated COVID testing was very small, at this point, and, it's strengthening. And again, as I said, we continue to enhance our website, when people go for that ordering, and testing and so on. But there's still more to come in terms of enhancing that experience for consumers and driving awareness for people. As you know, we're competing with a lot of people who see these stand up operations in parking lots, and so on and so forth, which draw their attention.",0.416145,0.83
DGX-2021-Q4-2022-02-03,187,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So we're working on making sure that they know we can do this and initiate themselves as opposed to going to a doctor or hospital for this. And we expect to get stronger and stronger moving forward as we enhance our overall consumer business through these investments we just mentioned.,0.2444811,0.758
DGX-2021-Q4-2022-02-03,188,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In terms of the margin profile, it's really not -- it's not all that different between the consumer and consumer can add in different ways. They can come to our patient draw center and have it done there. We do have home collection kits where they can be sent to their home. So a little different structure, but not materially different in profitability.",0.0431631,0.392
DGX-2021-Q4-2022-02-03,192,Answer,2022-02-03,4,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. Before Steve addresses that I just want to remind everybody that that $80 million was built into our long term outlook. We just assumed it would happen this year. So again, although it would be a year on year get to us, you know, incrementally in comparison, in the long term outlets, it was assumed that we would get that in 2022. So it's already built that.",0.4897314,0.361
DGX-2021-Q4-2022-02-03,193,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So thanks for the question. And as we said, we were thankful that it was delayed, again, the one year offset, as Mark indicated to 23. We think that's good for us, because it will gave us some time this year, to keep on working on a permanent fix with Congress. And we have been very active working with Congress last year. And as you know, Congress was very busy with the Infrastructure Bill, and other business and therefore we're fortunate enough to get in the postponed it, but it allows us time this year to keep on working on this to get a permanent fix.",0.5222405,0.757
DGX-2021-Q4-2022-02-03,194,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're encouraged by the level of support, brought up the importance of testing and the importance of having a strong industry. We're getting strong, bipartisan support, both from the House and from the Senate. We made a proposal of what we think should be changed to improve the data collection process, the sampling of market based data. We continue to support the notion and the philosophy of PAMA that is we should be paid a commercial rate. But we believe that CMS has it wrong .",0.1818781,0.964
DGX-2021-Q4-2022-02-03,195,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And in parallel with the Congress, we continue to have our lawsuit against CMS and the trade association. The judge has heard the arguments we'll see if we get some indication on a decision on that. Hard to call that, but that's still in the works as well. So our work right now this year is to push for permanent fix to PAMA. And we're better positioned now because the pandemic than before the pandemic because of the strength of this industry here in global awareness and appreciation of what we've done and the need for strong laboratory industry going forward.",0.4352554,0.96
DGX-2021-Q4-2022-02-03,200,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure, so let me start with that one. Because I think there was some questions around maybe with their turnaround time suffered, and we didn't get the $25 fee that comes with some of the government payers couple the current pairs. And actually, not really, AWR in Q4 was absolutely similar to what has been in the previous quarters. And our turnaround time performance was outstanding. We did in January when the surge came, we did a little bit, we did have a little bit of a hit to our turnaround time. But obviously, that's all contemplated in the guidance that we just provided and it wasn't a huge amount.",0.2428336,0.66
DGX-2021-Q4-2022-02-03,201,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","When you -- back to the early question, bonuses, and the bonuses, when we look at the bonuses, you know, most of it is really our 50,000 employees. So people think about bonuses, must be senior management. Most of the cost is really, we pay 3% bonus to even our wage workers. And then obviously, we have other staff members that you know, at higher targets. And every year we budget for what we call, one x whatever that target is. So for most of the people do 3%. And based on performance, and we feel we've had reasonable stretch performances, when we had historically, we have not paid significantly above 1x. And we've had a number of years where it's below 1x.",0.1397035,0.955
DGX-2021-Q4-2022-02-03,202,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But the COVID, unpredictability and the surge in revenues, enabled us to pay our employees significant bonuses, in 2020. And again, in 2021. And so if you look at, without getting too specific, and we've shared a number in the past, a $3 billion wage bill, that's gone up in the last couple of years as we've grown the company. So you can kind of as a floor, say 3%, obviously a little higher, because if people want a higher bonus, that's about 1x. And then, we're paying a bonus that's substantially higher than that, in 2021, like we did in 2020.",0.5146623,0.948
DGX-2021-Q4-2022-02-03,203,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The other thing is, we did pay out a $500 payment to the majority of our employees to compensate them for COVID expenses. In 2020, we adjusted it out of our adjusted earnings, because we were seeing COVID as temporal and extraordinary. But once you get to your second time doing it, even though I still think it's extraordinary, we just decided not to adjust it out. So we did have over a $20 million payment, late in the year, $500 to our wage employee and some of our lower compensated professionals as well.",0.4853377,-0.128
DGX-2021-Q4-2022-02-03,204,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So those are a couple of things that would go away and not be repeated like somehow, we had another surprising COVID year in 2022 like we had in 2021",0.3924217,-0.278
DGX-2021-Q4-2022-02-03,206,Answer,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, let's say it's less than $100 million, but substantially more than $50 million.",0.4691928,0.153
DGX-2021-Q4-2022-02-03,208,Question,2022-02-03,4,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thank you. Very good. Well, thanks, it's been a great session with you all. Thanks for all the great questions. And again, thanks for joining the call today and we appreciate your support. You guys have a great day.",1.0408567,0.987
DGX-2021-Q3-2021-10-21,3,Remarks,2021-10-21,3,2021,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I'm joined by Steve Rusckowski, our Chairman, CEO and President; and Mark Guinan, our Chief Financial Officer.",0.3540619,0.66
DGX-2021-Q3-2021-10-21,4,Remarks,2021-10-21,3,2021,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and we'll discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties, including the impact of the COVID-19 pandemic that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K.",0.8261445,-0.065
DGX-2021-Q3-2021-10-21,5,Remarks,2021-10-21,3,2021,Shawn Bevec,Executive Director-Investor Relations,"The company continues to believe that the impact of the COVID-19 pandemic on future operating results, cash flows and/or its financial condition will be primarily driven by the pandemic severity and duration, health care insurer, governments and clients payer reimbursement rates for COVID-19 molecular tests, the pandemic's impact on the U.S. health care system and the U.S. economy, and the timing, scope and effectiveness of federal, state and local governmental responses from the pandemic, including the impact of vaccination efforts, which are drivers beyond the company's knowledge and control.",0.6054512,0.751
DGX-2021-Q3-2021-10-21,6,Remarks,2021-10-21,3,2021,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS. Any references to base business, testing, revenues or volumes refer to the performance of our business, excluding COVID-19 testing. Growth rates associated with our long-term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth, are compound annual growth rates. Finally, revenue growth rates from acquisitions will be measured against our base business.",0.6562583,0.945
DGX-2021-Q3-2021-10-21,8,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. Well, we had a strong third quarter as COVID-19 molecular volumes increased throughout the summer, while our base business continue to deliver solid volume growth versus the prior year, and 2019. In late summer, we experienced some softness in the base business across the country, but saw a rebound, in September. Importantly, our base business continues to improve sequentially in the third quarter, which speaks to the ongoing recovery. We have raised our outlook for the remainder of the year based on higher-then-anticipated COVID-19 volumes, as well as continued progress we expect to see in our base business, despite rising labor costs and inflationary pressures.",0.0108731,0.955
DGX-2021-Q3-2021-10-21,9,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The momentum of our base business positions us to deliver the 2022 outlook we shared at our March Investor Day. So, this morning, I'll discuss our performance for the third quarter of 2021, and update you on our base business. And then Mark will provide more detail on our financial results, and talk about our updated outlook and underlying assumptions. But before turning to our results in the third quarter, I'd like to update you on the progress we've made in our quest for health equity initiative, a more than $100 million initiative aimed at reducing healthcare disparities in underserved neighborhoods.",0.8369028,0.772
DGX-2021-Q3-2021-10-21,10,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Since we've established it, just over a year ago, we have launched 18 programs across the United States and Puerto Rico, ranging from supporting COVID-19 testing and vaccination events to educating young students on healthy nutritional choices, to providing funding support for a long-haul COVID-19 clinic in Puerto Rico. Recently, we announced the collaboration with the American Heart Association that will expand research and mentorship opportunities for black and Hispanic scholars to drive hypertension management and COVID-19 relief. We're off to a good start, and I look forward to updating you on our continued progress as Quest for Health Equity enters its second year.",1.7555189,0.973
DGX-2021-Q3-2021-10-21,11,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, turning to our results for the third quarter, total revenue of $2.77 billion, down 40 basis points versus the prior year; earnings per share were $4.02 on a reported basis, down approximately 3% versus the prior year; and $3.96 on an adjusted basis, down 8% versus the prior year. The revenue and earnings declines in the third quarter reflect lower COVID-19 testing in 2021 versus the prior year, partially offset by continued recovery in our base business. Cash provided by operations increased by nearly 20% year-to-date through September, to approximately $1.75 billion.",3.2016474,0.273
DGX-2021-Q3-2021-10-21,12,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, starting with COVID-19 testing, our COVID-19 molecular volumes increased in the third quarter versus the second quarter, due to the spread of the Delta variant over the course of the summer. Testing began to increase meaningfully in mid-July, and peaked in early mid-September. Our observed positivity rate peaked in mid-August, and has steadily been declining across much of the country in recent weeks. We performed an average of 83,000 COVID-19 molecular tests a day in the third quarter, and maintained strong average turnaround times of approximately one day for most specimens throughout the surge.",2.1660626,0.875
DGX-2021-Q3-2021-10-21,13,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As clinical COVID-19 volumes declined, we are expanding our non-clinical COVID-19 testing to support the return to school, office, travel, and entertainment. We're making testing easy, fast, and affordable for school systems and other group settings across the country. We are currently performing K-12 school testing in approximately 20 states, with five additional states ready to come online. We're testing passengers on [Carnival] [Ph] cruise lines, and Quest exclusively provided testing at the Boston Marathon earlier this month. In the base business, we continue to make progress on our two-point strategy to accelerate growth, and drive operational excellence. Now, here are some highlights from the third quarter.",1.2678748,0.961
DGX-2021-Q3-2021-10-21,14,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our M&A pipeline remained strong. In the third quarter, we completed a small tuck-in acquisition of an independent lab in Florida. We continue to build on our exceptional health plan access of approximately 90% of all commercially insured lives in the United States. At our Investor Day, we discussed how we have fundamentally changed our relationship with health plans, and we continue to see the promise of value-based relationships come to life. So, here's a couple examples. We are working with national health plans to help their self-insured employers -- employer customers improve quality, outcomes, and lower the cost of care for both the employers and their employees.",1.8214168,0.933
DGX-2021-Q3-2021-10-21,15,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Also, effective October 1, we gained access to one million managed Medicaid members, in Florida, as their coverage transitions to [indiscernible] Sunshine Health Plan. We're getting good feedback from the provider community and our growing testing volumes through this expanded access opportunity. Our hospital health system revenue continues to track well above 2019 levels, driven largely by the strength of our professional laboratory services contracts. As we highlighted previously, 2021 performance is benefiting from two of our largest POS contracts to date, Hackensack Meridian Health, and Memorial Hermann. Altogether, our POS business is expected to exceed $500 million in annual revenue this year.",0.3680395,0.962
DGX-2021-Q3-2021-10-21,16,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Trends in our hospital reference business also remained steady, with third quarter base testing volumes above 2019 levels. We also generated consumer-initiated testing revenue through QuestDirect in the third quarter. While COVID testing has been strong contributor to growth, we expect our base direct-to-consumer testing to more than double this year. Recently, we soft-launched a comprehensive health profile on QuestDirect, similar to our Blueprint for Wellness offering for employers. This expanded health plan -- panel offers a deep dive into consumers' health profile with a battery of tests and biometric measurements to provide a personalized health quotient score that can be used to track health progress over time.",1.169028,0.912
DGX-2021-Q3-2021-10-21,17,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, our MyQuest app and patient portal now has almost 20 million users. In advanced diagnostics, we continue to ramp investments and see strong momentum in key growth drivers. We're seeing growth in non-evasive prenatal testing significantly above 2019 levels, and saw solid contribution in our specialty genetics portfolio from Blueprint Genetics. We continue to work closely with the CDC to sequence positive COVID specimens in an ongoing effort to track emergent variants, expanding all of the work that we performed in the quarter.",0.9357496,0.929
DGX-2021-Q3-2021-10-21,18,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, we plan to introduce a test service based on a new FDA-approved companion diagnostic [fumagillin] [Ph] for a therapy from Eli Lilly for a certain type of high-risk early breast cancer. Quest will be the first laboratory to offer it to physicians, nationally, at the end of the month.",1.799341,-0.511
DGX-2021-Q3-2021-10-21,19,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to our second strategy, driving operational excellence, we made progress and remain on track to deliver on our targeted 3% annual efficiencies across the business. Last week, we announced that we completed the integration and consolidation of our northeast regional operations into our new 250,000 square-foot next-generation lab, in Clifton, New Jersey. This state-of-the-art highly automated facility services, more than 40 million people across seven states.",0.0345964,0.859
DGX-2021-Q3-2021-10-21,20,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In patient services, we are seeing all time high numbers of patients making appointments to visit our Patient Service Centers. Now more than 50% of patient service center visits are now by the appointment versus walk-ins. And this enables patients to be very satisfied and also improves our ability to drive productivity for our Phlebotomist. Similar to our immunoassay platform consolidation, we recently procured a highly automated neuro analysis platform that is expected to generate millions in annual savings, once these new systems are standardized across our laboratory network.",2.0105437,0.802
DGX-2021-Q3-2021-10-21,21,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, I'd like to recognize and thank all of our nearly 50,000 employees who have worked tirelessly to provide critical COVID-19 testing to our country throughout the pandemic, and continue to serve the healthcare needs of patients who depend on Quest every day. As a demonstration of our gratitude, we're assisting our employees with a one-time payment of up to $500 designed to reimburse costs, they incurred during the pandemic. Additionally, another year of pandemic pressures and travel restrictions have made it very difficult for many employees to take their hard earned time off. Therefore, we're providing a payout of most unused paid time off for our hourly employees to ensure they don't forfeit their earned unused time at year end.",0.6392092,0.543
DGX-2021-Q3-2021-10-21,22,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now I'd like to turn it over to Mark, to provide more details on the third quarter financial performance and updated outlook for the remainder of 2021. Mark?",0.3782537,0.361
DGX-2021-Q3-2021-10-21,23,Remarks,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the third quarter, consolidated revenues were $2.77 billion, down 0.4% versus the prior year. Revenues for Diagnostic Information Services were essentially flat when compared to the prior year, which is reflected by lower revenue from COVID-19 testing services versus the third quarter of last year, largely offset by the strong ongoing recovery in our base testing revenue. Compared to 2019, our base DIS revenue grew approximately 6% in the third quarter, and it was up nearly 2%, excluding acquisitions.",2.2602686,0.612
DGX-2021-Q3-2021-10-21,24,Remarks,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Volume measured by the number of requisitions increased 5.3% versus the prior year with acquisitions contributing approximately 2%. Compared to our third quarter 2019 baseline, total base testing volumes increased 9%. Excluding acquisitions, total base testing volumes grew approximately 4% and benefited from new PLS contracts that have ramped over the last year. We saw a rebound in our base business volumes in September, following a modest softening in August that we believe was at least partially caused by the rise of the delta variance and the timing of summer vacations.",0.0059242,0.674
DGX-2021-Q3-2021-10-21,25,Remarks,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Importantly, our base business revenue and volume grew sequentially in the third quarter. This helps illustrate the ongoing recovery as historically total revenue and volume typically stepped down in Q3 versus Q2 due to summer seasonality. As most of you know, COVID-19 testing volumes grew in the third quarter versus Q2, which was in line with broader COVID-19 testing trends across the country. We resulted approximately 7.6 million molecular tests and nearly 700,000 serology tests in the third quarter. So, far in October, average COVID-19 molecular volumes have declined approximately 10% from where we exited Q3, but are still above the levels we expected prior to the surge of the delta variance, while the base business continues to improve since September.",0.1548183,0.743
DGX-2021-Q3-2021-10-21,26,Remarks,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Revenue per requisition declined 5.4% versus the prior year driven primarily by lower COVID-19 molecular volume and to a lesser extent recent PLS wins. Unit price headwinds remained modest and in line with our expectations. Reported operating income in the third quarter was $652 million or 23.5% of revenues compared to $718 million or 25.8% of revenues last year.,0.5225118,0.547
DGX-2021-Q3-2021-10-21,27,Remarks,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On an adjusted basis, operating income in Q3 was $694 million or 25% of revenues, compared to $831 million or 29.8% of revenues last year. The year-over-year decline in operating margin was driven by lower COVID-19 testing revenue, partially offset by the recovery in our base business. Reported EPS was $4.02 in the quarter, compared to $4.14 a year ago. Adjusted EPS was $3.96, compared to $4.31 last year. Cash provided by operations was $1.75 billion through September, year-to-date, versus $1.46 billion in the same period last year.",1.2744866,-0.296
DGX-2021-Q3-2021-10-21,28,Remarks,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Turning to guidance, we have raised our full-year 2021 outlook as follows. Revenue is expected to between $10.45 and $10.6 billion, an increase of approximately 11% to 12% versus the prior year. Reported EPS expected to be in the range of $4.69 and $15.09, and adjusted EPS to be in the range of $13.50 and $13.90. Cash provided by operations is expected to be approximately $2.2 billion, and capital expenditures are expected to be approximately $400 million. Before concluding, I'll touch on some assumptions embedded in our updated outlook. We expect COVID-19 molecular volumes to continue to decline from Q3 levels throughout the remainder of the year. At the low end of our outlook, we assume approximately 50,000 molecular tests per day in Q4, and serology volumes to hold relatively steady at approximately 5,000 tests per day.",0.721564,0.052
DGX-2021-Q3-2021-10-21,29,Remarks,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As you may know, late last week, the public health emergency was again extended another 90 days, through late January. We expect reimbursements of clinical COVID-19 molecular testing to hold relatively steady through the remainder of the year. However, we continue to assume average reimbursements to trend lower in Q4 as our mix of COVID-19 molecular volumes potentially shift from clinical diagnostic testing to more return-to-life surveillance testing. Finally, we continue to assume low single-digit revenue growth in our base business in Q4, versus 2019. Getting to the midpoint or higher end of our outlook ranges assumes stronger COVID-19 molecular testing volumes and/or stronger growth in our base business.",0.3522907,0.542
DGX-2021-Q3-2021-10-21,31,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. Well, to summarize, we had a strong third quarter. We have raised our outlook for the remainder of the year based on higher-than-anticipated COVID-19 volumes, as well as our continued progress we expect to see in our base business. And finally, the momentum of our base business positions us to deliver the 2022 outlook we shared at our March Investor Day.",1.5742998,0.927
DGX-2021-Q3-2021-10-21,32,Remarks,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, now, we'd be happy to take any of your questions. Operator?",2.891598,0.572
DGX-2021-Q3-2021-10-21,35,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thank you. Thanks. Good morning, everybody. Thanks for all the details and the guidance for '21. I really want to talk about into 2022, and sort of you reiterated your guidance from March, which I believe it was at the higher end of the $7.40 to $8.00 range. And I'm just wondering at this point, what are the assumptions baked in for COVID testing into next year? Do you anticipate that it's going to continue? Do you anticipate there's going to be a meaningful decline? Any color around how you think COVID testing will proceed into next year?",1.0721582,0.0
DGX-2021-Q3-2021-10-21,37,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. And, Kevin, just to be clear upfront, we haven't provided guidance yet for 2022; we provided an outlook. And we did confirm that today. And things have largely played out where we saw them for 2022, back in March, and base volumes have recovered. And we thought we were ahead in June, when it was close to being flat to 2019, and potentially saw some upside, obviously, with Delta, it's -- it took a little bit of a step back. But we still expect to enter 2022 with a base volume utilization level similar to pre-pandemic, so that's good. The second thing is we did assume that COVID will continue at a much lower level than we saw in '20 and '21, but still to be significant, and certainly much larger than our current flu testing. And we've referenced, in the past, that at some point COVID testing will still be here, but maybe more on the level of flu testing.",0.8870458,0.951
DGX-2021-Q3-2021-10-21,38,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"At this point, we feel comfortable with what we had assumed, back in March, around continued need for COVID testing for PCR. And we envision a stronger role for serology going into 2022, and think that's a potential. So, we feel good about that. And then, we did reference inflationary pressures. We certainly have longer-term contracts on a lot of our purchases, but things, like fuel, certainly were subject to inflation in the near-term and going into 2022. And then most notably, as many have talked, there's certainly inflation in wages and in benefits, and especially in wages.",1.3191153,0.835
DGX-2021-Q3-2021-10-21,39,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And that, as we look at that, we gave a range, and we still feel very comfortable that when you put all those pieces together, that the $8.5 billion baseline for revenue and the $7.40 to $8.00 is certainly still deliverable, maybe in slightly different way, and -- but still very comfortable, that that's likely where we're going to land when we do finally provide guidance for 2022.",1.4052133,-0.394
DGX-2021-Q3-2021-10-21,40,Question,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Just as a quick follow-up, can you in any way quantify the higher inflationary pressures, supply chain, any of that? Is there any way to put numbers around that?",0.5560821,0.946
DGX-2021-Q3-2021-10-21,41,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, I'm sure you're most interested in 2022, so, we'll see what we can provide when we come out with guidance, in early next year, to provide clarity. Certainly at this point, well, we're experiencing some of that given the performance of the business; it hasn't prevented us from significantly over-delivering our previous guidance. So, we'll take a note of consideration, Kevin. We appreciate the question. We'll see what we can do when we talk more about next year.",0.8755924,0.361
DGX-2021-Q3-2021-10-21,42,Question,2021-10-21,3,2021,Shawn Bevec,Executive Director-Investor Relations,Thank you.,1.3919026,0.0
DGX-2021-Q3-2021-10-21,45,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hey, good morning, guys. Congrats on the quarter. So, just a follow-up just as I think about costs and all the moving pieces. Obviously, the Clifton lab just opened. So, how are you thinking about the flow-through of the benefits from that and how it would potentially offset some of the inflationary pressures that you're seeing on the cost side?",0.4112026,0.969
DGX-2021-Q3-2021-10-21,46,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so, thanks, Brian, for the question. So, as you know, and what I reiterated in our prepared remarks, we've been marching with our two-point strategy for some time. And the second strategy is to drive operational excellence, and we have maintained, and just reiterated, that we do believe we can continue to deliver 3% efficiency or productivity gains going forward. And that 3% comes from a variety of programs across Quest Diagnostics, and one of which is what we did in Clifton. And I actually also reiterated a couple other programs on the prepared remarks, are working with our suppliers with new integrated platforms, what we're done around immunoassay, what we're doing around our [immuno urine] [Ph] analysis is -- are two good examples of more work we can get the benefits from, and there's others.",1.430972,0.982
DGX-2021-Q3-2021-10-21,47,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, there's a lot more efficiencies in productivity we can continue to get. And as I said before, this isn't cost-cutting, this is improvement. And so, every time we make an improvement in our operation we expect our quality improves, and our service performance improves, and it has. So, we continue to make progress. You see it in our numbers this year, and you'll continue to see it in our '22 numbers as well. And that's always been used to offset headwinds, and we do have headwinds, we've had headwinds from wage bill increases in the past, albeit maybe it could be a little bit higher going forward, given what we see in the labor market. And then second is, we have seen headwinds from price consequences as well, which we've been able to offset, and we'll have some of those in '22 as we've outlined before. And then, also any additional inflationary pressures, we will be able to offset most of that, if not all of that, to be able to hit the outlook, and we just reiterated our confidence, our ability to do that. So, hopefully that's helpful.",1.343207,0.873
DGX-2021-Q3-2021-10-21,48,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, I just wanted to add a reference that the Clifton lab and its increased productivity efficiency is really part of our invigorate work that we talk about 3% productivity every year. It's not over and above or separate whatever [technical difficulty] common is that what we've done there like we did up in Massachusetts. We have added more automation. Obviously, as you add automation, you insulate yourself a little bit from labor inflation. So, certainly, we have that going as we operate that lab, but it is built-in, and part of what my assumptions I had putting together that outlook for 2022 that we would achieve that ongoing 3% efficiency is not something specially",0.0888626,0.765
DGX-2021-Q3-2021-10-21,52,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, good morning. So, one follow-up question on the cost, I mean, clearly we're all interested in a magnitude of the potential impact of paper and inflation. So, maybe you can help us by reminding us what percent of your cost structure today is labor and how should we think about it breakdown between cost of goods and SG&A?",0.8942339,0.0
DGX-2021-Q3-2021-10-21,54,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, Ricky, we've shared in the past pre-pandemic, that about $3 billion of our cost was related to salary and benefits. Obviously with COVID moving around it's hard to cite the precise number with including the COVID testing. So, I think that should give you a pretty good idea of what proportion of our costs a $6 plus billion. Cost base we had prior to the pandemic has made up the labor at somewhere in the 50% range. And then as we said, as we continue to automate that certainly offset some of that, but also we are seeing an increased amount of demand for phlebotomy. So, that is going the other direction. We obviously considered a net benefit because giving access helps us grow our business and certainly makes us more attractive, especially in a world of consumerism. And it's a good thing, but it certainly will drive costs, the labor costs as a percentage of all of all costs in the other direction.",0.2077409,0.494
DGX-2021-Q3-2021-10-21,55,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then just a follow-up on the direct-to-consumer point, Steve, you mentioned a soft launch of comprehensive health plan, all that's directed in consumer. Can you just share with us what has been the response to date and maybe some data points about pricing?",0.0385502,0.984
DGX-2021-Q3-2021-10-21,56,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So, as I said in my introductory remarks, we have a product that we sold for years to employers called blueprint for wellness. And we offer it to request employees as well. So, it's a fabulous dipstick reading on an annual basis for people to get an indication what's going on with their health. And if we do it year upon year, you've got a good nice trending capability that I found beneficial since I've been here in question, I know many of our employees have as well and many of our customers. So, we're now using that is the product to introduce that through our direct-to-consumer channel request direct. We're very optimistic about the possibility that this has we believe that it has a unique capability that few others provide. And we also believe it's hitting the market at the right time, where many people have not gone to their primary health care providers. And we believe that there's a lot of opportunities now for people to directly engage with us as a consumer to buy this directly from us. As far as pricing marketing share what we're thinking about in terms of pricing, even though this is a soft launch.",1.6883886,0.932
DGX-2021-Q3-2021-10-21,57,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, it's going to be a couple of hundred dollars. And when you look at the individual elements that are contained in here, it's a reasonable price for everything that you get. And I can also tell you that we've gotten a lot of feedback that this score that we give people with really simplifies how to interpret the results is a huge consumer positive. So, a lot of reason to believe that this could get some additional momentum for our consumer business, and we think the pricing is reasonable and we feel that the product we're delivering is something that consumers really find interesting valuable.",0.5383855,0.732
DGX-2021-Q3-2021-10-21,58,Answer,2021-10-21,3,2021,Shawn Bevec,Executive Director-Investor Relations,"And just to follow-up on the price, we actually did some market research to understand that the value that this provides to consumers justifies the price that we're pricing it for initially. So, we feel good about value delivered and price charged.",0.9034136,0.0
DGX-2021-Q3-2021-10-21,59,Answer,2021-10-21,3,2021,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question?",0.8491664,0.0
DGX-2021-Q3-2021-10-21,62,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Good morning, Steve. Good morning, Mark and Shawn. I wanted to continue on the inflation topic, but looked at a different way. If operating costs were to remain elevated, do you think there's an appreciation by payers that the cost of doing business is moving higher? How do you feel about your ability to get price increases? Maybe just talk about recent negotiations.",1.5538715,0.982
DGX-2021-Q3-2021-10-21,63,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, but let me start it, Mark, please add. Yes, we've been on this march, as I said in my remarks to continue to demonstrate to our health plan partners, that we continue to deliver value and I believe we make -- we're making tremendous progress. One is that we're picking up access in the number of lives. I mentioned 90% of insured lives are -- we're a network within the United States. And we're happy about the progress of picking some more up this coming year. So, that's moving along.",0.9285008,0.964
DGX-2021-Q3-2021-10-21,64,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Second, as far as pricing is concerned, we continue to march through our contracts as they are up and renewal. And we have said in earlier calls that we're now very fairly arise and matter of fact, we believe we offer a very affordable price offering to the health plans and their memberships with great quality, great service and very competitive pricing so much so that we're part of these preferred lab networks. So, we're justified, we are getting some modest price increases and we do believe going forward that we can continue to pound that drum. And we are using what other people are using across the United States that in fact, now that we're renting a new inflationary period. Our costs are going up just like yours. And therefore, we need to start talking about modest price increases going forward. So, Mark, you'd like to add anything to that?",0.6974724,0.957
DGX-2021-Q3-2021-10-21,65,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, Jack, I think you appreciate, I'm sure a lot of people do as well that our health plan contracts typically are three to five years. So, it's not as if every health plan contract is up for renegotiation in any window of time. But so we've been socializing PAMA and how that is changing the dynamic and how they can look at the NLA rates and be competent that, that they have competitive rate because they know what the -- that's the market for the independent labs, which we've said is lower than the market, but the market for the independent labs. So, this whole notion of a price below Medicare, which was the historical practice is going away with PAMA. Now, you add inflation as you suggest and it's absolutely part of the conversation we've been having over the last number of months. And I can tell you that although it's not final. There is one national payer that we've been negotiating and it's not final, but it looks like the first price increase we will have gotten from them. And certainly my tenure and I'm sure more than a decade.",0.7800158,0.886
DGX-2021-Q3-2021-10-21,66,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we've been stabilizing as we shared our commercial negotiations to go from a world of price declines every contract extension to getting it more flat. And we actually have shared there's a handful of regional plans where we've got increases over the last couple years and now we have a national contract that I'm very optimistic we're going to get an increase. And so, how much of its inflation, how much of its PAMA, how much of it is our value proposition and seeing that working with us is a benefit for everyone versus training us as a commoditized provider of laboratory results. Can't tell you, but we're in a much better place.",1.6629325,0.184
DGX-2021-Q3-2021-10-21,67,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Just to remind everyone, our health plan channel business is a significant portion of our revenue every year. But what we've also highlighted, the reason why we do have unit price decreases and our typical assumptions annually is because we have other pressures in our business. We do have break business to physicians, which we call clients and our client business as under price pressure over the past several years. And that has contributed to the price pressure we see. Secondly, as we sell the hospitals and we're doing quite well in the hospital segment, but is price competitive. And then we have other product lines, where we sell our services directly to employers or to insurance companies is price pressure there as well. So, when we talk about our unit price changes, it's not all in the commercial health plan area. There's other area that we have price pressures as well.",1.2540362,0.382
DGX-2021-Q3-2021-10-21,69,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, everybody. I'm just trying to maybe ask you a high level question about how the pandemic is maybe impacting your business for the long term. It seems like in the pandemic we've seen people move away from just traditional physician office visits at some level virtual care, other alternative sites to get their primary care. Are you seeing and does that help you or hurt you if people go to these other avenues, which may generate testing volume, do you think you capture a disproportionate share of that? And then the other thing, I was going to ask you about the pandemic was related to the -- you've said that if you have outperformance because of COVID testing, you accelerated some of your programs for cost savings and other efficiencies. Should we think of that as just enhancing the visibility on the 3% cost reduction annual goal? Or are there things you're doing that might even present some upside to 2022 and beyond?",0.3252059,0.967
DGX-2021-Q3-2021-10-21,70,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, thanks A.J. for your question. Let me take the first one, I'll ask Mark to comment on the second part of your question. First of all, telehealth as we all know has really increased considerably during the pandemic and it has really hit an inflection pouring in in-patients and consumers are now very comfortable with getting a portion of their healthcare delivered through telehealth networks, whatever that might be. And as we have watched it initially, a lot of the telehealth visits started with mental health and behavioral health and have now transitioned to more general health and primary care and even specialized care. So, with all those visits happening in telehealth, you have to engage with the patient and have to be able to enter orders. And unfortunately for us, despite the pandemic and before the pandemic, we have strong relationships with all the telehealth companies. And as you would expect, they're only going to work for us with a small group of laboratories. And question would be one of those laboratories.",0.7360791,0.924
DGX-2021-Q3-2021-10-21,71,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we're very well positioned with the telehealth providers, but you also know that even though there are telehealth companies, telehealth is provided through integrated delivery systems, hospital systems in different ways, and they might use one of the telehealth provider platforms, but they're still providing that through their physicians and using their EMR. And so, when they enter the order, it's going to be into the order of the same way as in the past. So, we're watching it carefully. We do believe it's as a positive trend for us given what I just described, but it's complicated because it all depends how telehealth platforms are deployed in particularly with so many on physicians, by integrated delivery systems. And they're still conducting the business as they do. It all depends how they actually implement their telehealth services throughout their network and how that will affect our business. But again, for us, we believe it is a positive.",0.3512356,0.077
DGX-2021-Q3-2021-10-21,73,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, actually, A.J. could you repeat that the second part?",1.0500824,0.38
DGX-2021-Q3-2021-10-21,74,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",It had to do it accelerating our drive program because of our enhanced performance. And I think he's speaking to some of the acceleration and capital purchases that we've made and spending some additional money to get more improvements than what we would have realized if we didn't have the pandemic. A.J. is that a correct,1.5169687,0.0
DGX-2021-Q3-2021-10-21,76,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, we have had an opportunity to invest more than we probably would have otherwise given the stronger growth than we would have anticipated in 2021. We've talked about that. A lot of that investment has actually been more towards top line acceleration. So, we've talked about, what we're doing in advanced diagnostics, we talked about what we're doing, what requires to build a consumer business. So, I'd say a disproportionate amount of the opportunity, as we try to balance near term results with longer-term, value accretion has really been in top line. But yes, as we looked at some of the things we did during the pandemic, we have an opportunity to update our molecular equipment and into more efficient - into more state-of-the-art, probably faster than we normally would have cycled. So, that'll give us some efficiency that maybe wouldn't have otherwise. So, I wouldn't -- at this point suggest that we're ready to commit to more than the 3% productivity, because obviously that's the large number of unit of itself and small basis points changes are really significant. But directionally, I would say, yes, A.J., this pandemic goal was of value accretion in additional cash has enabled us to accelerate some investments. Most of it on the top line growth, but certainly some on the productivity side as well.",0.7030016,0.296
DGX-2021-Q3-2021-10-21,78,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, good morning. So, I just want to talk about the base volume trends. I know revenue was up versus 2019, but can you give us some color on how much your based volume trends are still down versus pre-pandemic, maybe ex some of the PLS deals that you've signed during the pandemic, and if it's still down maybe just to give a geographic breakdown and I guess my second question would be obviously testing was a very strong for molecular PCR test for COVID-19. Can you give us a breakdown, how much of that was contributed to like this back to life initiative, whether it's schools, cities, states more like maintenance testing, and I know you said in your prepared remarks that you assume revenue per test goes down in Q4. Can you give us what it was in Q3 and maybe just directionally what we should model for Q4? That would be very helpful. Thanks.",0.2566722,0.735
DGX-2021-Q3-2021-10-21,79,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Okay. Thanks, Ann. Mark, why don't you just start with giving the numbers on base business performance system there.",0.3151659,0.974
DGX-2021-Q3-2021-10-21,80,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, hopefully, I can clarify, base volume in total is obviously anything on COVID-related as we've been through the pandemic, we've been recording strong growth in base volume, which includes our M&A and our PLS, as you would expect. But we've also been trying to provide some color on utilization, in the absence of independence way to measure that. We look at our base volume ex, the acquired volume and facts the new PLS deals. And we've talked about that continuing to improve in addition to the growth we're getting from M&A and from PLS. So, in June, the organic base volumes and the new PLS deal was getting close to back to the 2019 levels. And then it kind of stabilized in August - in July, and it took a little bit of a step in August. And then as we see where we are through September and into October, it's getting back again, very close to being fully recovered in 2019. And that's why I said earlier that we would expect certainly by the end of this year and going into '22, that we'd be fully recovered.",0.2278831,0.426
DGX-2021-Q3-2021-10-21,81,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, it is regionally, very variable as we've talked in the past, and that really has not changed. There are certain regions that are actually above where they were in 2019, most notably our Southwest region, as we're looking at Florida in the south, the volume trends are above, and then a couple other areas that are kind of in that middle point. And then the one area of note that's really been lagging is the east, and it continues to lag while it certainly has improved from where it was several months ago. It's still down and kind of an outlier especially in the five boroughs of New York City.",0.5098736,0.599
DGX-2021-Q3-2021-10-21,82,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then quickly, I'll answer the question on the revenue expectations for molecular testing, and I'll let Steve talk about the back to life. So, we're still around $90 in the quarter. We're not expecting a meaningful decline in the fourth quarter. Certainly, if back to life really, really took off, which is not, what we're expecting in the middle of our guidance here, it could have a little bit of a row, but again, it's still net positive. It's just math. So, you can expect for your modeling purposes, that just a very, very slight decline in Q4, nothing of significance.",0.6395387,0.321
DGX-2021-Q3-2021-10-21,83,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the last question Ann, you had asked for the breakdown of what we describe is, first of all, the clinical portion of our PCR volumes versus return to life portion of our clinical volumes. And as you can expect, it's tough for us to know exactly particularly, which bucket we can put those in. But I can tell you that the trend line is trending towards more of the return to life. We see the infection rates coming down and we see programs that we've worked on going up, examples are the return to school programs, we mentioned 20 states and five more coming. We also doing some testing for employers if they have mandates in place where they're requiring vaccination or testing. So, we'll see some increase in testing related to again, employers bringing people back to the workplace and requiring testing or vaccination for that. So, I would say trending wise, it is a larger percentage than before, but it's very difficult for us to give you exact numbers on that because we just don't get it through the orders that we received. But we think what we've provided for guidance is clearly what's going to happen in '22.",0.8504119,0.0
DGX-2021-Q3-2021-10-21,85,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hey, good morning. Thanks. First, just a quick follow-up on a comment you made, can you give us a sense of how much flu testing you do a year, if that's what you're anchoring for baseline COVID testing going forward. And then separately, I was just hoping you could talk about COVID reimbursement and the outlook of that for next year? Obviously, you mentioned PHG got extended at least for the early part of next year, if that continues to expand, if you expect reimbursement to be better than what you assumed in that $8 EPS for next year? And then also, what about commercial pricing specifically for COVID is that that tied to PHG? Or help us understand sort of how that's negotiated and if there's a step down there for next year? Thanks.",0.2810544,0.077
DGX-2021-Q3-2021-10-21,87,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, it was quite a bit there, Ralph, we'll see if we can touch on all of them. So, we don't generally share the precise revenue for any given test offering, but it's significantly lower than our current levels of COVID and what we would anticipate. So, the flu is not the baseline for 2022. We still expect COVID testing to be multiples of our fleet revenues in 2022. And the reason flu testing is smaller than what the otherwise is. There's not a ton of molecular testing done. Physicians have become very comfortable with doing point of care. And even though the molecular is more precise, they feel that it gets good enough in the office and they have an opportunity to make money on it.",0.978278,-0.502
DGX-2021-Q3-2021-10-21,88,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, I would probably be several years, although I don't have the ability to call it precisely before we would expect COVID to be at our flu level. And then in terms of the pricing we have either specific agreements or general agreements that as long as in the commercial rates, that as long as the federal health emergency continues, that the pricing will reflect what we're being paid by the federal government. So, it's not mechanistically tied to every contract, but we know that the expectation would be when that goes away. And again, there's still always a possibility they can decouple that $100 reimbursement rates from the health emergency. So, there's some other risks as well, but as long as that continues, we would expect most of our commercial pricing to be at the same rate.",1.3748025,0.819
DGX-2021-Q3-2021-10-21,89,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then, obviously, when that goes away, that we would expect a negotiations to take it down to more the NLA level. So, when I talked about 2022 at the Investor Day, I talked about a reimbursement rate around $50, which is what the NLA is. And so, again, when you put all these pieces together, I want to be clear, we still fully expect to be in the upper end of that $7.40 and $8. I just wanted to caution against upside to that given everything that's going on with inflation and so on, because we do have some positive things that have developed over the last six months or so. And some of that is probably going to be partially offset if not largely offset by labor inflation. So, we're still pretty much where we were back in March. So, in the higher end of the $748, and then certainly at least $8.5 billion of revenue, which importantly ties back to the 2018 CAGR that we've shared with you at Investor Day, and so, just getting there in a little different way, but still getting to where we said we would be.",0.9522117,0.0
DGX-2021-Q3-2021-10-21,92,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Hi, good morning. So, a number of questions around labor issues, I actually want to ask about supply chain. I'm just curious if you're starting to see any challenges in sourcing anything, either for your PSCs or the labs, either longer lead times, and then if you're having any issues with the sample transport logistics?",2.3663921,0.959
DGX-2021-Q3-2021-10-21,93,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, so far Matt we're keeping up, we always have battles here and there, even despite the pandemic with supplies got a complicated business and a lot of pieces have to come together to do what we do, but not a meaningful disruption so far, but we're watching it carefully because we're not through this yet. So, the last part of this is around logistics and again, logistics have become a little more complicated given we do use commercial carriers for some portion of our logistics, but we've been managing our way through that. Fortunately, we have our own network of carriers. We have about 3,500 carriers and automobiles that are request employees. We have a fleet of small airplanes through some of the connections between our collection locations and our laboratories and they're employed by us. And so we're happy we had those in these uncertain times and we continue to have strong relationships with the national carriers as well, so far so good.",2.5192751,0.0
DGX-2021-Q3-2021-10-21,96,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, good morning guys. I follow-up on Ann's question around the base testing business, once you exclude M&A and POS, can you give us color on where the tests are coming in from specifically looking at primary care visits versus specialty visit versus hospital visits? Just curious if hospitals slowdown in fourth quarter with the COVID surge, does it impact anything on your fourth quarter growth?",1.0988468,0.76
DGX-2021-Q3-2021-10-21,97,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, first off, Pito to be clear, the utilization trend that I talked about being nearly fully recovery doesn't exclude all POS, it just since we're comparing to 2019, it's excluding some of the really large deals that we've done recently. So, that we don't cloud what we think utilization is. So, we had a PLS business of size back in 2019. I'm not taking that out, because obviously, that's part of the trend as well.",0.5950577,0.945
DGX-2021-Q3-2021-10-21,98,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, when you look at the sources, we've shared that -- the recovery has been pretty broad based. There's not a lot of differences especially now, early in the pandemic there were some we talked about for certain drug monitoring, certainly being one that was lagging. A lot of that was policy driven, a lot -- some of that, not all of it, but a lot of it's been addressed and certainly we've seen the toxicology or prescription drug monitoring business coming back in the same ballpark as some of our other clinical areas. We did see hospitals recovering faster early in the pandemic as a return to trading patients for elective surgeries and so on, physician office was a little more lagging, but at this point, as we talked about in the prepared remarks, the physician business is quite strong and we're seeing the volumes especially in some of the regions above where they were in 2019. So, we don't feel other than the east that there's been any sort of a fundamental change in either patient engagement with physician offices and or the prescribing practices for our diagnostics business specifically.",0.5265239,0.0
DGX-2021-Q3-2021-10-21,101,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, this is Casey on for Tycho. Two quick ones for you guys, the first one, do you think that the increased cash spent per requisition or test density trends that you've called out in 2021 will continue into 2022. And is that baked into that $7.40 to $8 EPS outlook. And then my second one is just on capital deployment. You guys have completed the ASR, right? So should we expect any more buybacks in 4Q and what share account should we use for our model for 4Q? Thank you.",0.015486,0.557
DGX-2021-Q3-2021-10-21,102,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, I'll take the first one. Mark, you take the second and versus on rec density that is the number of tests per requisition. We assume there's a lot of different moving parts as you know for our business. One of which is the mix of tests. The second is number of tests for requisition being able to we have channel mix changes. So, all of that is complicated in our outlook that we've provided. So, we assume that that's in there. And Mark, you want to talk about capital deployment question?",1.3661137,0.741
DGX-2021-Q3-2021-10-21,103,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So, the ASR should be wrapped up sometime in the next 30 days. So, therefore for at this point, even we did additional purchases once the window opens and not committing to anything at this point, because we always say there's a balance between potential M&A and share repurchases. It wouldn't have a significant impact on our way so this year. So, any sort of additional purchases of our shares repurchases would be more of an impact for 2022. And obviously, we'll talk about that in detail when we come up to the guidance for 2022 early next year.",1.9075829,0.0
DGX-2021-Q3-2021-10-21,106,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, this is [John] [Ph] on for Derek. I wanted to dig into the base business growth specifically within your advanced diagnostic business. Was there any notable trend for cancer and genetic testing, if you could comment on the growth trajectory that'd be great?",1.8003295,0.99
DGX-2021-Q3-2021-10-21,107,Answer,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","John, in our remarks, we're pleased with the recovery we've seen in advanced diagnostics and remind everyone that our definition of advanced diagnostics are entirely molecular and genetics. And when I say recovery and I did say molecular, it does not include our COVID testing. So, it's our base, if you will, molecular and genetic testing. And we saw very good growth in beyond recovery for our prenatal testing feel good about that. And we are seeing nice growth for our genetics business. And as you recall, we did an acquisition with blueprint genetics last year, and that's progressing nicely and give us some nice growth and strength in that business. So, we feel good about the recovery and growth we're seeing in those areas that we're really focused on and genetics in general is one of those areas.",0.907743,0.0
DGX-2021-Q3-2021-10-21,110,Question,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hey, thanks. So, do -- there's a labor and inflation costs issues you have talked about that you can absorb in your 2022 outlook. Does that have any change in the long-term sort of growth targets that you laid out for post 2022 in terms of earnings growth?",1.2181219,0.0
DGX-2021-Q3-2021-10-21,112,Answer,2021-10-21,3,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, I -- at this point, obviously we have a broad range, but I would say that just like we've done in other periods of time. We'll look for and identify offsets to that. So, I -- it's not significant enough that we should deviate on a multi-year outlook in terms of our earnings growth being in the high-single digits, and we -- although we have identified everything over the next several years. I'm sure as we move through time we'll look for other productivity opportunities to offset some of that.",0.2116904,-0.296
DGX-2021-Q3-2021-10-21,114,Closing,2021-10-21,3,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay, very good. So, thanks to everyone for joining our call today. We appreciate your continued support and everyone have a great day.",1.1947282,0.527
DGX-2018-Q4-2019-02-14,3,Remarks,2019-02-14,4,2018,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I am here with Steve Rusckowski, our Chairman, President and Chief Executive Officer; and Mark Guinan, our Chief Financial Officer.",1.1947605,0.66
DGX-2018-Q4-2019-02-14,4,Remarks,2019-02-14,4,2018,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables through our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent Annual Report on Form 10-K, and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K.",0.8703361,-0.065
DGX-2018-Q4-2019-02-14,5,Remarks,2019-02-14,4,2018,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS excluding amortization expense. Also, growth rate associated with our long-term outlook projections including total revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth are compound annual growth rates. As a reminder, the company now reports uncollectable balances associated with patient responsibility, which we will refer to as patient concession as a reduction in net revenues when historically these amounts were classified as bad debt expense within SG&A expenses.",0.1815295,0.802
DGX-2018-Q4-2019-02-14,7,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. This morning, we'll discuss the fourth quarter and full-year 2018, and review progress on our two-point strategy. Then Mark will provide more detail on the results and take you through our 2019 guidance. For the fourth quarter, revenues decreased 1.4%, reported EPS was $0.92, down about 50% from the same period of 2017, and adjusted EPS was $1.36, down 2.9%. Performance in the quarter reflects increased reimbursement headwinds as well as softer organic volume than we expected at investor day, and the change in estimate of reserves for revenue and accounts receivable, which Mark will cover later in the call.",0.1047776,0.896
DGX-2018-Q4-2019-02-14,8,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","For the full-year 2018, revenues grew 1.7%, reported EPS declined roughly 4% to $5.29. Adjusted EPS grew approximately 17%, to $6.31. In 2018, we grew revenues, adjusted earnings attached from operations despite some challenges in the marketplace. Mark will update you on the quarter, and share our perspective on 2019. Quest is well positioned in 2019 to grow share, and deliver revenue growth as our in-network status now extends to approximately 90% of commercially insured lives in the United States. Volumes are off to a good start this year. Our guidance for 2019 reflects our expectation that strong volume growth will continue throughout the year. It also reflects significant reimbursement pressure partially offset by our continued execution of our Invigorate program.",0.014168,0.966
DGX-2018-Q4-2019-02-14,9,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As we discussed at our investor day, in November, we are poised for growth based on three fundamental changes in the marketplace. First, panel-driven reimbursement pressure is a catalyst for structural change. In 2019, we expect about a 10% reduction in Medicare reimbursement rates, and a similar reduction in 2020. The impact of these cuts will be more significant on smaller independent hospital outreach laboratories which we believe could eliminate the majority of their profit, and will provide a catalyst for market consolidation. Second, payers are more focused than ever of driving better value in their [indiscernible], which supports our plan to gain share. And finally, nobody cares more about the variation in healthcare cost than employers and their employees, the country's largest payer. Increasingly, patients are motivated to find the high-value low-price providers, like Quest.",0.9215815,0.982
DGX-2018-Q4-2019-02-14,10,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we are very well-positioned to benefit from these trends. Our strategy to accelerate growth has five elements. Now, I'll share the progress we've made. First, we aim to grow more than 2% this year from M&A. In 2018, acquisitions contributed more than 3% to revenue growth. The nine deals we announced and closed, since the beginning of 2018, position us well to meet our 2019 target. Earlier this week, we completed the acquisition of a clinical laboratory services business of Boyce and Bynum, a leading provider of diagnostic and clinical laboratory services in the Midwest. The second element is to expand relationships with health plans and hospital health systems.",0.6092257,0.942
DGX-2018-Q4-2019-02-14,11,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First on health plans, we're entering 2019 with the best assets this company has had in over a decade. We've added 43 million lives, which represents about a billion dollar opportunity for Quest as a result of our in-network status with UnitedHealthcare, Horizon Blue Cross Blue Shield of New Jersey, and Blue Cross Blue Shield of Georgia. As I said earlier, we have already seen encouraging volume growth early in 2019 resulting from this expanded network access. Hospital health systems are facing unprecedented financial pressures, and are therefore motivated to discuss ways we can help them with their lab strategy. We recently signed two new professional laboratory services agreements in the Southeast region. In both relationships we will provide full lab management employing technical lab staff, providing operational lab oversight, and maintaining responsibility for the laboratory supply chain.",0.1453048,0.96
DGX-2018-Q4-2019-02-14,12,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As we outlined at our investor day, most hospital CEOs and CFOs are still not fully aware of PAMA which impacts hospital outreach labs. We believe that this impact of PAMA becomes increasingly more visible, hospital will be more motivated to work with us on their laboratory strategy. The third element of our growth strategy is to offer the broadest access to diagnostic innovation. We made key acquisitions to expand our capability and enhance our service offerings in 2018. We saw strong double-digit growth in 2018 from a number of key test categories, including prescriptive drug monitoring, tuberculosis testing, and Cardio IQ. In 2018, we made significant progress executing the fourth element of our growth strategy, which is to be the laboratory provider of choice for consumers.",0.6029654,0.973
DGX-2018-Q4-2019-02-14,13,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before arriving at a patient service center, patients can check in electronically through MyQuest and view estimated wait times before making an appointment. At the patient service center or in the physician's office, our enhanced real-time estimate let's patients know their financial responsibility before we collect their specimen. And then, once the results are available, patients can view them through MyQuest digital platform, which is now available for more than 6.5 million users, or they could review them on the Apple Health app. Next, we continue to build out our industry-leading retail strategy. At year-end, we'll be in more than 200 Safeway and Walmart locations. In 2018, we launched QuestDirect, a service which enables consumers to have a test without a doctor's script in the continental United States. And we're pleased with the volumes we've seen so far.",0.2388797,0.735
DGX-2018-Q4-2019-02-14,14,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The fifth element of our growth strategy is to support population health and data analytics and extended care services. Payers understand the value of the lab data and how it can help them improve their members' health outcomes. This has strengthened our value proposition as well. We're also growing revenues from pharmaceutical customers. Quest Clinical Trials Connect, which we launched in 2018, is helping pharma and CROs recruit patients for trials faster, better, and more efficiently. The second part of our two-point strategy is to drive operational excellence. Our Invigorate cost-cutting initiatives has been successful, and we see more opportunities ahead. We are confident there's an opportunity to continue to improve and save roughly 3% on a cost structure or about $200 million per year to offset increases in our wage bill as well as reimbursement pressures.",0.2714992,0.995
DGX-2018-Q4-2019-02-14,15,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","At a recent investor day, we identified a number of areas for improvement, such as reducing denials of patient concessions, further digitizing our business, continuing to standardize and automate and optimize their lab and patient service center networks. Given the increased reimbursement pressure in 2019, we're also closely managing our cost structure. We are rebalancing our resources by reducing expenses in some areas while ensuring we have the operational resources needed to deliver on the volume increases we expect this year.",0.0876442,0.818
DGX-2018-Q4-2019-02-14,16,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, let me turn over to Mark who will take you through our financial performance and our 2019 guidance in detail. Mark.",0.2724876,0.0
DGX-2018-Q4-2019-02-14,17,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the fourth quarter consolidated revenues were $1.84 billion, down 1.4% versus the prior year. Revenues for diagnostic information services declined 1.5% compared to the prior year, primarily due to a change in estimated adjustment to increase reserves for net revenue on accounts receivable that we previously highlighted in November. I will share more on this in a moment.",0.0007899,0.751
DGX-2018-Q4-2019-02-14,18,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Volume measured by the number of our acquisitions increased 3.4% versus the prior year. Excluding acquisitions, volumes grew 1.1%. Revenue per acquisition in the fourth quarter declined by 5.5%, versus the prior year, driven primarily by the reserve adjustments and increased denials in patient concessions. For the full-year, price headwinds were consistent with our expectations of slightly less than 1.5%.",0.2488152,0.542
DGX-2018-Q4-2019-02-14,19,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, I'd like to provide color on the reserve adjustment we made in the fourth quarter. You'll recall we discussed this at Investor Day. We recorded a change in estimate to increase our accounts receivable reserves by approximately $35 million. We did this based on the following: Unexpected increases in coverage denials and patient responsibility and a billing system conversion in one of our regional labs that resulted in timely filing denials and impacted our ability to precisely estimate reimbursement rates. Because these items were not typical with our historical experience we monitored them in accordance with our process increased our reserve levels. I am confident in our process and we have timed the level of precision around this complex estimation going forward.",0.1477093,0.886
DGX-2018-Q4-2019-02-14,20,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Before moving on, I'd also like to provide an update on the headwinds to our prescription drug monitoring hep C and vitamin D test categories that we've been testing over the prior couple of quarters. In prescription drug monitoring, we saw an increase in restricted payer policies that impacted both volume and reimbursement, but we lapsed denials for two of the more significant payers in the fourth quarter. In 2019, we continue to expect PDM reimbursement challenges as payers seek more clinical evidence to support coverage.",0.0323855,0.833
DGX-2018-Q4-2019-02-14,21,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Turning to hep C, as we noted previously, as these hepatitis C therapy reduces the need for genotype testing, while market share of this therapy continues to grow modestly, we expect to lapse the most significant headwinds by the second quarter. And finally, in vitamin D testing higher payer denials impacted both volume and revenue in 2018. One national payer implemented a more restrictive policy last March which we expect to lap in Q1, but we expect continued pressure on vitamin D testing in 2019. Moving on to the remainder of our fourth quarter results, reported operating income was $220 million or 12% of revenues compared to $269 million or 14.4% of revenues last year.",0.4154818,0.411
DGX-2018-Q4-2019-02-14,22,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On an adjusted basis, operating income was $271 million or 14.7% of revenues compared to $317 million or 17% of revenues in the prior year. Reported EPS was $0.92 in the quarter compared to $1.82 a year ago. Note the prior-year quarter included a tax benefit recorded as a result of the Tax Cuts and Jobs Act. Adjusted EPS was $1.36 down approximately 3% from $1.38 last year. Cash provided by operations was $1.2 billion in 2018 versus $1.18 billion in 2017. Capital expenditures in 2018 were $383 million compared to $252 million a year ago.",0.0059242,0.202
DGX-2018-Q4-2019-02-14,23,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now turning to guidance, we are providing the following outlook for 2019. Revenue is expected to be between $7.6 billion and $7.75 billion, an increase of approximately 1% to 3% versus the prior year. Reported EPS expected to be greater than 516 and adjusted EPS to be greater than 640. Cash provided by operations is expected to be approximately $1.3 billion, and capital expenditures are expected to be between $350 million and $400 million.",0.078594,0.743
DGX-2018-Q4-2019-02-14,24,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, there are several considerations that I will now review for you to think about in 2019. First, as we've shared previously, we are facing more than $200 million of reimbursement pressure this year. This headwind is expected to be relatively and evenly spread throughout the year. Second, based on the factors I discussed earlier, the fourth quarter of 2018 should create an easy compare in the fourth quarter of 2019. Third, our revenue guidance includes more than 1% revenue growth from M&A that has already been announced and executed. Fourth, as Steve mentioned, our volumes are off to a good start this year, and we expect them to continue to build throughout the year.",0.1943128,0.866
DGX-2018-Q4-2019-02-14,25,Remarks,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Finally, we are incurring incremental costs in the first quarter to support the volume growth from our expanded network access. We're also tightly managing our cost structure, and have undertaken a restructuring in the first quarter of 2019, and will begin to yield savings starting in the second quarter. As you think about the first quarter, we have approximately one less revenue day. And to remind you, denials in patient concession increased throughout 2018, and we are assuming these headwinds carry into 2019. Taking these into consideration with some of the items I just highlighted, we expect revenue to be flat to down in the first quarter, while adjusted EPS is expected to be similar to the adjusted EPS we reported in the fourth quarter.",0.063981,0.751
DGX-2018-Q4-2019-02-14,27,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. Well, to summarize, Quest is well positioned in 2019 to grow revenue and earnings. Our in-network status now extends to approximately 90% of the commercially insured lives in the United States, and volumes are off to a good start. Our guidance for 2019 reflects reimbursement pressures offset by strong volume increases, and continued execution of our Invigorate program.",0.4705107,0.945
DGX-2018-Q4-2019-02-14,28,Remarks,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, we'd be happy to take any of your questions. Operator?",0.7311367,0.572
DGX-2018-Q4-2019-02-14,34,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, let me start, and then I'll turn it to Mark. And thanks for asking the question. So start, we'd go back to what we shared with you in investor day. We still believe as the market leader we have a tremendous opportunity to gain share. And I think we just announced the kickoff of our journey to pick up share, and it starts in 2019. We also couple 2019 with the most significant reimbursement that this industry has ever seen, so in reimbursement costs, and so it's muting some of the share gains that we're going to pick up this year. But what we told you at investor day, there's two parts of our market share gains, is one is we do believe we can accelerate M&A, and we're actually targeting for 2% growth through M&A. What we said in our guidance, we only will put in our guidance what we have seen so far closed, so it's roughly 1% in the guidance for 2019.",0.7841845,0.981
DGX-2018-Q4-2019-02-14,35,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is, we will see organic growth, and we have to pick up the volumes to be able to offset that reimbursement pressure. But when you go through the math, we believe there's an opportunity for us to pick up share in '19, and that will continue in 2020. The second part of this is what's going on in the industry, and I'll come back to those three points again. One is, PAMA is hurting all of us, but it's going to hurt the non market leading laboratories much more significantly. We believe this will be a catalyst for further consolidation. Second is, with our better than ever access changes payers are working proactively with us in how they do a better job of managing our category of spend.",0.2817133,0.606
DGX-2018-Q4-2019-02-14,36,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, as consumers are pushing back on their physicians, pushing back on their employers and asking questions about the best value in the marketplace, and we are the best value in the marketplace; the best quality, the best service at the lowest price. So, Ross, we have really kicked off '19 with the beginning of a journey here to pick up share. And we believe with confidence that we can deliver that outlook that we outlined at investor day.",0.12257,0.976
DGX-2018-Q4-2019-02-14,38,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, sure, Steve. Ross, as I mentioned, and we've talked about several times, including the investor day, this year saw more dramatic changes throughout the year than certainly any one I've experienced since I've been at Quest. Denials were a big part of that. I'll start with the vitamin D change back in the second quarter, we saw more and more state Medicaid programs making decisions on cystic fibrosis, we've talked about prescription for monitoring and payers both tightening policies around same day of service for presumptive and definitive testing, which we think is clinically appropriate but they've put in policies to deny payment for one of those tests. We've seen them squeezing panels saying that they're going to pay for fewer and fewer analytes , and again we don't think that's necessarily clinically appropriate but that is the way many of them are paying now.",0.892575,0.026
DGX-2018-Q4-2019-02-14,39,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And even in the area allergy, there was an NCCI edit that was put in last year that resulted in significant denials in our allergy space. So, it was a tough year from a denials perspective. We have built all that into our 2019 guidance. And so when I talked about carrying the fourth quarter business into Q1, we fully accounted for all that in our thinking in the guidance we're providing. The other area of surprise was patient concessions. And we, based on what we knew going into the year, we're expecting a similar level of patient concessions. I'm sure you've seen and we referenced the Keiser Report that came out about the middle of the year that informed us and others that actually the average deductable went up significantly, so there was more being borne by patients.",0.1619273,0.533
DGX-2018-Q4-2019-02-14,40,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Obviously that meant more of our revenue was coming from patients, and we were just starting to see that in our collections because there's obviously a delay in the adjudication process to the payers, and then we -- as we send the bills out to the patients so we start to get an experience of the collection rate that may or may not match our historical rate, and was actually finding that it was being negatively impacted. The other thing I mentioned was we did have some issues with one of our lab conversions. We have done a number of these that we've shared. We're getting close to the endpoint in the standardization process. This particular lab was not a legacy Quest system, it was a system we had acquired a couple of years ago as part of an acquisition. We therefore did not do as well with this conversion as we did historically, and therefore we struggled, as I mentioned, with some filing deadlines and other things.",0.2369668,-0.424
DGX-2018-Q4-2019-02-14,41,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The other issue is this is in a geography where historically there's higher rate of payment concessions versus other geographies. So, as we got delays in our ability to send out bills and as we looked more and more to patients and less directly to the payers, that definitely created a headwind. The good news on that one is we fully expect that to be behind us. And so that's more of a temporal issue versus the denials, which as I said. And the overall level of patient responsibility will carry into 2019, and is fully baked within our guidance.",0.1536335,0.836
DGX-2018-Q4-2019-02-14,46,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, sure. So, what I said in my prepared remarks, it's off to a good start. And we expected that it would be off to a good start, so it's on our expectation that we expected to be able to pick up some of the volume early in the year. But what we also said is that it will continue to build throughout '19, and also this provides us a growth opportunity beyond '19, into '20, into '21, okay. So, when I talk about a billion dollars worth of opportunity, we'll see a portion of that in '19, and that's contemplated in our guidance. But there is a large portion of that billion dollars beyond '19. So it's tracking well. We're happy with the early volumes we see. And it will continue to build throughout the year.",1.7983526,0.979
DGX-2018-Q4-2019-02-14,50,Question,2019-02-14,4,2018,Ralph Giacobbe,Credit Suisse,"Just lab equipment size, an incremental $30 million headwind from Medicaid related to PAMA. Are you seeing similar -- I think you said over $200 million of reimbursement headwind, seemed a little bit worse than what you previously estimated, so wanted to understand that. And then if you could, real quick, you talked about incremental cost in the -- I think you said in the first quarter, hoping you can just size that, and whether that does go away for the rest of the year.",0.1164731,-0.006
DGX-2018-Q4-2019-02-14,52,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. Ralph, the $200 million is actually consistent with what I shared at investor day. The amount of PAMA headwinds outside the clinical lab fee schedule, where we're directly reimbursed from Medicare on fee for service, is not large. There's some Medicaid programs that have reduced their rates, they may have justified it or cited PAMA changes. It's hard to know whether these Medicaid rates are directly tied to PAMA. You can look across all the states, there seems to be potentially some direct relationship. Not all of them have changed the rates. So yes, there's a little bit of headwind in Medicaid as there typically is, that's not unusual, certainly not to the magnitude of the amount that you asked us about.",0.2590837,0.788
DGX-2018-Q4-2019-02-14,53,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then, we're not going to size the investment specifically, but what we wanted people to understand is when you look at the rhythm of the quarters coming to the year, on the cost side, not only do we not benefit from the restructuring of our cost base that we announced at the end of this quarter until Q2, but we also are actually spending more in Q1 as we're making people aware of our new access in all of the geographies where we need to inform patients and providers. We're adding [indiscernible] by adding patient service centers, extra couriers, doing all the things to ensure that as this volume comes the customer and stakeholder experience is outstanding. And obviously, we'll continue to monitor that as we see the volume, and either add more or less, but initially when you add that a little bit ahead of the volume it's cost versus cost of sales.",0.1421801,0.77
DGX-2018-Q4-2019-02-14,54,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, that's really what we wanted to make sure people understood. And then the other significant item in terms of the quarterly cycling, as I mentioned, is one fewer revenue day that it is significant. We pick it up in Q3, but losing a day billing Q1 versus last year is going to be a significant impact in the year-over-year comparison.",0.2460506,0.064
DGX-2018-Q4-2019-02-14,57,Question,2019-02-14,4,2018,Bill Quirk,Piper Jaffray,"Thank you. Good morning, everyone. So, a couple of questions here, so first off, on vitamin D, real quick, just want to confirm that this is lower volumes versus, say, pressure on reimbursement levels. Also on the Medicaid denials, was hoping you could expand on that a little bit because it's pretty much universally covered, at least based on our due diligence. And then lastly, just big picture question for Steve, based on your conversations, how much volumes from the hospitals do you think could be play for M&A over the three-year PAMA period -- initial PAMA period? Thank you.",0.834877,0.94
DGX-2018-Q4-2019-02-14,59,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so the Medicaid denials, and I'm not sure what you're referencing, Bill, but a combination of managed Medicaid where they put in more restrictive requirements, including preauthorization that often can result in denials. Also, some of it arguably clinically appropriate where they put in new intelligence to ensure that we only have this once in a lifetime. They may have had this done by a different lab. Historically we obviously weren't aware of it. We get an order, we think it's legitimate, we do the work, we provide it to the payer and they deny it based on it -- once in a lifetime policy. So those things are absolutely tightening in the cystic fibrosis. And we have had a couple of states, I don't have it at my fingertips, we'll circle back and do that actually, the state programs with traditional Medicaid that have stopped reimbursing cystic fibrosis as well. And vitamin D, as I mentioned, it was a combination. So certainly, we still continue to get and got orders with screening codes. Quite often vitamin D is ordered as a part of a bunch of other common laboratory testing. So we don't choose to not perform that test. Even if a diagnostic code initially is not one that suggest to get reimburse, so and absolutely the headwind to our revenue, revenue for rack. And has resulted in significant denials with the change in this national payer, but also as physicians have gotten educate them with the appropriate use and certainly, we're driving that. The industry is driving that, you have seen a fall-off because some of the vitamin D that was being ordered was prescreening and clinically that has been determined not to be appropriate. But there still is a number of vitamin D tests are coming to in the screen codes that really are not screening. The doctors just are not coding them appropriately, and unfortunately, those are resulting in denials and headwinds for us.",0.1477093,0.974
DGX-2018-Q4-2019-02-14,60,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So Bill, on your question about the opportunities around hospitals, let me start by reminding you and everyone that, what we said in the Investor Day is in 2018, we have a strong year for M&A. It's about 300 basis points roughly. And if you recall, you go back to one of those Investor Day slides up for use and charts we use, if you look at the distribution of the M&A, we've done past few years, it's really been a balance of acquiring hospital outreach, acquiring some outreach deals. Excuse me, some laboratory regional deals and they are finally buying some capabilities and services and advanced diagnostics. And if you look at the hospital deals, it's been, a good part, but not a majority of what we have acquired. And then, second is we still pick up let's say one regional app for year. And that, in fact, we just said in our prepared remarks that we closed on voice and vitamin Missouri.",0.2942339,0.913
DGX-2018-Q4-2019-02-14,61,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So it's a good example of doing that once again. And what we also indicated is prospectively, we do believe it's obviously for all three categories, is that M&A should be north of 2% going forward. And we also said we've only contemplated in our guidance, something around 1%, which are those deals for 2019. So some portion of that is the acceleration in the discussions we're having with hospitals around their lab strategy. And we have those discussions Bill, we also have discussions around professional laboratory services and that's an organic growth opportunity. And we announced again in our prepared remarks that we picked up two engagements in the back half '18 that we feel good about and we have more engagements in the pipeline as well. So you need to think about our hospital strategy really from a contributor to M&A because of that 2% but also equally the opportunity organically to pick up organic revenue growth through these professional laboratory services engagements that we continue to announce.",0.0293245,0.948
DGX-2018-Q4-2019-02-14,66,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So I'll start with the quarterly cadence Lisa. Yes, you're correct. So as we look at 2019, as I mentioned Q4, should be in we expected an easy compare to 2018 given the significant change enhancements that I referenced also and Steve will comment more color when we submitted, but we expect volumes to build. So while we certainly moved a bunch of offices and got incremental access volumes you know at the beginning of the year, we are continuing to compete that we expect to build more and more over time. And we also have referenced and are anticipating and hopeful that United will announce this preferred lab network. And we're hoping to be included that and we're expecting to be we're all waiting that announcement. We think that will benefit us as well, certainly with United patients. And yes, we have probably not gotten as much into the calendar impact on quarterly cycling in the past, but it is so significant, we're going to provide more transparency, so losing a day in the first quarter, getting a day in the third quarter, certainly well, change the year-over-year impact that is not insignificant. And then finally as you mentioned some of the timing of what we incurred some of the headwinds last year and when we left those and that will not happen in Q1. So therefore, we have some a topic compared to year-over-year in Q1 combined with the cost items that I mentioned earlier, so for all those reasons that compares much tougher in Q1.",0.0011848,0.992
DGX-2018-Q4-2019-02-14,67,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Last thing I would add is patient concessions. As we mentioned the beginning of the year, we did not anticipate a significant shift to patients away from the payers directly on where revenue would come from. Now that we saw what happened last year, we are building in a higher rate of patient concessions from day one. Obviously, over time as we look at our collections, we will adjust that, but that's certainly going to be a headwind in the first quarter as well. All of those things are built into the guidance that we provided for the year.",0.0849131,0.666
DGX-2018-Q4-2019-02-14,68,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so just to fill out the question around volume growth throughout the year and the first tranche of the first quarter, so what we shared in 2018 is when we announced that we're going to be back in network with United and Horizon and with anthem in Georgia. We started to communicate that to our customers. And so, what we will see in the first quarter is the first tranche, if you will, of those really good customers's request that they wanted us to get back into network and we're ready to flip those accounts as quickly as possible. So you'll see that and second part of this is, why it's going to continue to build, it's not everyone is flipping on day one. I mean, they provide us an opportunity for the rest of '19 and then into '20 and '21 and some of this is that some of the market is still hearing firsthand from us that we're back in network. So the answer to your question what do we need to do is we continue to work on communication. We do this with our sales force, it takes multiple calls to the customer and to be able to flip those accounts typically, sometimes we need to work out some of the IT integration issues to make sure we can get those orders and as a result of those some customers that might be relatively new and that just takes some time.",0.3176277,0.962
DGX-2018-Q4-2019-02-14,69,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So if you take the state of New Jersey we are essentially we're back in network with the Blue Cross Blue Shield system in New Jersey and with United. We picked up a lot of access, so we've got a number of accounts that were detailing to pick up the gun and a chair for those taking more time than maybe where we only had -- did have 10% of the volume of those loyal customers in that first tranche. So that's what we're going to need to do and we'll do in backup and that will continue in 2020 and 2021 where we still see more opportunities to pick up shares.",0.3011532,0.846
DGX-2018-Q4-2019-02-14,75,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And you're asking weather in calendar in Q4 Jack, or just?",0.1565074,0.0
DGX-2018-Q4-2019-02-14,77,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. So the other drivers of revenue per rack include things like mix, so for instance, our PLS business which, as we explained in the past had higher as lower revenue per rack at a higher growth rate than our overall core business. So that created some headwinds on a rev per rack. And then, what I referenced in terms of the fact that the business experienced an increasing level of denials throughout the year and also patient concessions relative to the prior year. So those things all maybe the tough compared year-over-year Q4 2017 versus Q4 2018, so it wasn't just the change in estimates but it is actually a recognition that that business have revenue per req as we are exiting the year.",0.0164745,0.512
DGX-2018-Q4-2019-02-14,78,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So those are some of the contributors. We certainly had a little bit of weather impact, it wasn't significant but it was a headwind in that as well. In terms of days, that was a small impact, small negative impact as well. And the other thing was that we had some price changes in the back half of the year that will annualize in 2019 before the end of the year. So you combine all those things and those certainly were the drivers in the year-over-year decrease in rev req.",0.383196,0.535
DGX-2018-Q4-2019-02-14,83,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure, sure, first of all, one would think when we announced in May that we're back in the United and we're the Nation's largest commercial laboratory that if in fact United were to go forward with a preferred migratory network that we would be included.",0.4088962,0.848
DGX-2018-Q4-2019-02-14,84,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now it's up to them to announce that. But we're clearly hopeful and planning on being one of the shortlist of laboratories that are included and in that, what we share with that in the past is that all payers and particularly United I think in my mind is taking the lead on this, is realizing that they could do more to do a better job in laboratory spending and by doing, by having a preferred laboratory network, they're going to tighten up the network and they will work with us on things that we can do to make sure that we drive market share gains. And that would include things like working with your customers that are so customers on benefit designs, it could include working with us on our hospital strategy where it could be in the best interest of all parties to think about a different network strategy within the geography. It also could include things that we're proactively going after certain geographies where we know there's an opportunity for us to gain share. So can announce it before it's announced but we're hopefully, we'll be included as you would expect, we should be given we're the largest national and given that we just announced that network and there'll be a lot of strategies within this to help us with our market deep plans that we've outlined through the course of the last six to nine months. So Mark, you would like to add to that?",0.1785832,0.986
DGX-2018-Q4-2019-02-14,85,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I think that covers and obviously we're respectful of United's desire and right to announce, we've applied for that lab network, there is a certain set of criteria as we looked at it, we're very confident. But ultimately we need to wait for United and then in terms of what the particular aspects are I think Steve has captured it well, largely it's leverage preferred, you preferred for a reason obviously it's better value but it's also quality metrics and other things that United is looking for their members and therefore United, the patients and everybody is in the ecosystem who is in that preferred lab network will all benefit if there's more work sent to those better value providers.",0.0600316,0.982
DGX-2018-Q4-2019-02-14,89,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Ricky, thanks for the question. Actually a majority of the payers are already there and in the managed Medicare space they've been following MLCP for a while and that's really where this emanated from, Cigna adopted it in 2018, the labs remaining significant payer who have to do early on, we obviously have a very close relationship with Aetna, we expect Aetna to move in that direction and certainly that is built within our assumption, we don't know exact timing, we don't know for sure but certainly in our assumptions and our guidance we are expecting Aetna to go there as well and therefore all the national payers to be there.",0.2705371,0.857
DGX-2018-Q4-2019-02-14,93,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure, Ann. So the guidance on operating cash flow of $1.3 billion is obviously commensurate with our pacing around earnings, it is not a significant change in working capital assumes within those number, there is other puts and calls around some tax items and so on and so forth that impact our operating cash flow, that we take into account. But largely the change year-over-year is based on our net earnings. In terms of cash deployment, I talked about the 350 to 400 for internal capital which obviously we view somewhere between 900 and 950 of free cash flow, our dividend now gets us to long way towards our majority commitment to our shareholders but certainly we need to do some share repurchases to get ourselves to that at least 50% commitment and that is built in our expectations to basically this point preventing dilution given our equity program.",0.2065561,0.912
DGX-2018-Q4-2019-02-14,94,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,We're now anticipating in that guidance that I provided a pick up from any reduction in ways down. So with the remaining free cash flow is going to be situationally dependent. So as Steve talked and I mentioned we have an main strategy we're expected to deploy chunk of that cash we're coming into the year with some good carryover based on deals that we've already executed but we just announced the closing of item beyond that we believe there's opportunity deploy more M&A but we're going to use the same financial discipline we always have and if we have a deal that with our money will create more value for shareholders we're going move forward on that deal and in a given point in time we don't have any excusable deal that meets our expectations then we will buy back shares as we have historically. So this point I don't have a specific plan or the balance of the year beyond our majority commitment and others and that's beyond the cash but we are deploying for the -- acquisition.,0.4743286,0.96
DGX-2018-Q4-2019-02-14,97,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, Brian, honestly we down pass some record due to specific comment on the specific payer. But what we have said is that were very nice shape. With 19 with our relationships, what we what we will say is that you know going into 19 we should have most of the nationals are in good shape, obviously they are with United where they would got out and the others will it will be a nice shape as well and then also these big states matter of fact, we talked about in their Investor Day, we pick up new strong bigger states United States. If you look at California with New York, Florida and Texas, about 110 million lives are shared very strong and our relationship with the other payer most states are quite strong. So we feel good about that and we're in nice shape in those states. And that is true to go back to your specific question about Florida. We feel good about our cousins in Florida, we have a strong working relationship with Florida Blue Cross Blue Shield and we feel we're in a nice position to deliver on good income share that we talked over all about doing at Quest Diagnostics in the state of Florida because of that relationship, and our great access that we have in Florida.",0.3354201,0.996
DGX-2018-Q4-2019-02-14,98,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"If I could just jump in real quick, I didn't hear the second part of Ann's question, my apologies, we jumped to Brian, so Ann and others, the reason we've chosen [indiscernible] this year is given some of the uncertainty this year, obviously, to make the call on how quickly we grow the volume, we move access, it's not a negative uncertainty, it's just more variability than we've experienced historically in terms of how the volume might come, where it will come from, et cetera. And so the guidance we're providing with the floor obviously is towards the lower end of our revenue guidance and to the extent that we hit the upper end of our revenue guidance, or even potentially surprise ourselves and beat that. Those would be the upside.",0.0695103,-0.227
DGX-2018-Q4-2019-02-14,99,Answer,2019-02-14,4,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So I think we've got our costs down pretty good. Really, the question is around the overall volume growth, the pace at which it comes and the source of which lies because obviously there's variability in the pricing and margin depending on which payer they come through. So that would be the opportunity to do better and hopefully that answers your question on why we chose to [indiscernible].",0.9845972,0.923
DGX-2018-Q4-2019-02-14,105,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, that's a good question. So we've been on raising awareness for consumers around the wide variation, and medical costs broadly, and related to that is a multi-pronged approach. First of all, in some states, we actually provided this at Investor Day. The states are actually providing visibility of a wide variation for consumers. So the state of Massachusetts, they're actually providing on their Web site and if you go on that Web site you'll see the wide variation of what the average commercial rates for Quest Diagnostics are versus hospital outreach laboratories. And the hope is in that state since consumers are picking up a fair share of the costs in health care that consumers will start to become aware of this and bring that information to their physician.",0.3360791,0.946
DGX-2018-Q4-2019-02-14,106,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the second part of this is physicians are the advocate, typically, for the patient, even though they have this relationship with the hospital systems and in some cases they sold their practice, but still they realize that this is coming out of their patients' pocket, they realized it could be a wide variation which for a number of a patients it's a considerable sum of money. And for those of us that are reasonably healthy might be once a year, but for many it's not once a year. So it's a considerable portion of our out-of-pocket cost.",0.137397,0.612
DGX-2018-Q4-2019-02-14,107,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we're making sure that the physicians are aware of this as well and then also you know that when you look at what we're doing with the payers the payers increasingly make it visible. And so the payers all reach out to their membership and have campaigns with simple messages like why pay more, and related to that it's not just the lab, you know -- I know many of you realized there's other ancillary services that you have the same issue. So for instance, radiology is getting a lot of visibility. So the help we're getting here as well is this topic in general is getting -- visibility from payers but equally from physicians and then with consumers asking questions. And then once they realize they can ask a question they demand that they [indiscernible] we are in network and therefore it's unacceptable that you tell them they can only go to the hospital lab. And they simply point to -- it's going to cost you extra money if they don't go to Quest, so Doc, why does this make sense? So that's what we're doing about it.",0.4566722,-0.072
DGX-2018-Q4-2019-02-14,112,Answer,2019-02-14,4,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. First of all, yes, we're here and we're only -- I guess, February 14th, happy Valentine's Day, but what we see in the first five or six weeks of the year as we said we're off to a good start. We haven't been asked about it, but I'll share, you know, we think utilization volumes are stable. We're not seeing big pickups or drops in our good customers. So therefore, we think utilization environment out there is relatively stable. So therefore, the volume is coming from share gains. And that's what we expected. So, good start. We're picking up share, and that's going to build throughout the year.",0.7706755,0.986
DGX-2018-Q4-2019-02-14,115,Closing,2019-02-14,4,2018,Shawn Bevec,Executive Director-Investor Relations,"Okay. So thanks everyone for joining us today. We appreciate your support and questions, and have a great day. Take care.",1.764488,0.95
DGX-2019-Q3-2019-10-22,3,Remarks,2019-10-22,3,2019,Shawn Bevec,Executive Director-Investor Relations,"Thank you and good morning. I am here with Steve Rusckowski, our Chairman, Chief Executive Officer and President, and Mark Guinan, our Chief Financial Officer.",0.4493252,0.66
DGX-2019-Q3-2019-10-22,4,Remarks,2019-10-22,3,2019,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.",0.0822969,-0.065
DGX-2019-Q3-2019-10-22,5,Remarks,2019-10-22,3,2019,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS from continuing operations and references to adjusted EPS refer to adjusted diluted EPS from continuing operations excluding amortization expense. References to adjusted operating income for all periods excludes amortization expense. Finally, growth rates associated with our long-term outlook projections - including total revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth are Compound Annual Growth Rates.",0.4096322,0.941
DGX-2019-Q3-2019-10-22,7,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Shawn. And thanks everyone for joining us today. This morning, I'll discuss the third quarter and review progress on our two-point strategy. Then Mark will provide more detail on the results and take you through updates to our 2019 guidance.",0.5456343,0.823
DGX-2019-Q3-2019-10-22,8,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We had a solid quarter of top and bottom line growth. While PAMA reimbursement pressures persist throughout the industry, our expanded network access and laser focus on driving operational excellence are enabling growth.",0.1080725,0.856
DGX-2019-Q3-2019-10-22,9,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Based on our progress to date we have updated our outlook and are well-positioned to meet our commitments for the year. For the third quarter, we grew revenues 3.5% despite continued reimbursement pressure. Reported EPS was $1.56, up nearly 3% from the same period in 2018. Adjusted EPS was $1.76, up nearly 5%. Volume growth remained very strong at 5.1% and year-to-date volume growth is up 4.3%.",0.1327842,0.918
DGX-2019-Q3-2019-10-22,10,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, I'd like to briefly update you on the three fundamental changes in the laboratory marketplace that we discussed at last year's Investor Day. And as you know they are our PAMA, our expanded network access and increased consumerization of healthcare.",0.2807249,0.557
DGX-2019-Q3-2019-10-22,11,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First, PAMA, the reimbursement pressure remains a catalyst for structural change in the marketplace. And there is mounting evidence that PAMA is hurting this industry. We see and hear the negative impact that PAMA is having whenever we evaluate potential lab acquisition targets. And CAP Today, a respected industry journal, recently highlighted how PAMA and other reimbursement pressures are already starting to drive consolidation in the industry.",0.0962109,-0.778
DGX-2019-Q3-2019-10-22,12,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As you know, here at Quest, we took a series of actions earlier this year to further reduce our costs to align with PAMA cuts. Some decisions that we made were difficult, and our employees have felt the changes. More PAMA reimbursement cuts are coming in 2020. Our industry continues to fight PAMA's flawed implementation in the courts and in Congress.",0.2945634,-0.818
DGX-2019-Q3-2019-10-22,13,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We recently received a favorable U.S. Court of Appeals decision to allow the lower court to review the merits of ACLA's case. ACLA submitted its initial brief last week, and a decision is expected in 2020. This is encouraging news, and so is the introduction of the Laboratory Access for Beneficiaries Act, or LAB Act, introduced in June by six members of Congress from both sides of the aisle and now with nearly 40 cosponsors. ACLA is also working to build support for a Senate companion bill to include the LAB Act in a larger end-of-year health care extender bill.",0.2286656,0.949
DGX-2019-Q3-2019-10-22,14,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",The second fundamental change affecting our industry is our expanded network access and payers becoming more focused than ever on driving better value in their lab spend. We are partnering with UnitedHealthcare to move testing volume to high-value labs like Quest from high-cost hospital and out-of-network labs. UnitedHealthcare began offering a product with zero dollar member out-of-pocket charges for laboratory testing for the majority of fully insured lives in select states on October 1. UnitedHealthcare will also make the lab savings program available for their self-insured employer groups beginning in 2020.,0.0378913,0.822
DGX-2019-Q3-2019-10-22,15,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, we continue to see the ongoing consumerization of health care with more and more health care costs borne by consumers. In September, the Kaiser Family Foundation reported that the annual premiums for employer sponsored health care coverage grew 5% for families, surpassing $20,000 for the first time. The number of employees in high deductible health plans has increased over the past decade.",0.5235585,0.9
DGX-2019-Q3-2019-10-22,16,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to our recent progress, the first part of our two-point strategy is to accelerate growth, which has five elements. To grow 2% per year through accretive, strategically aligned acquisitions; expand relationships with health plans and hospital health systems; offer the broadest access to diagnostic innovation; be recognized as the consumer-friendly provider of diagnostic information services; and then finally support population health with data analytics and extended care services.",0.1209226,0.912
DGX-2019-Q3-2019-10-22,17,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now let me take you through a few highlights from our strategy to accelerate growth in the quarter. Our acquisition pipeline remains strong. As we've said before, most deals in our pipeline are taking more time to develop than they have in the past.",0.1779242,0.71
DGX-2019-Q3-2019-10-22,18,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Conversations with hospital systems are getting broader. Hospital CEOs are also interested in how we can help them with their professional lab services and taking on more of their reference work. As a result of this complexity, proposed relationships take longer to develop.",0.892257,0.66
DGX-2019-Q3-2019-10-22,19,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hospital systems are also interested in learning more about our recently unveiled Quest Lab Stewardship, an innovative new service that employs machine learning to help optimize laboratory test utilization. We have partnered with hc1, a health care IT company, to provide a solution that gives Quest a differentiated offering in a competitive hospital marketplace.",0.4243822,0.949
DGX-2019-Q3-2019-10-22,20,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to see revenue and volume growth as a result of our expanding network access. In aggregate, growth continues across our top 50 major health plan customers. Key test growth drivers in the quarter included drug monitoring, continued strength in tuberculosis testing in both QuantiFERON and T-Spot; STD testing; and CardioIQ. Each of these test categories posted solid contributions to revenue growth in the quarter.",0.5199341,0.933
DGX-2019-Q3-2019-10-22,21,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",The second part of our two-point strategy is to drive operational excellence. We remain on track to deliver 3% cost efficiencies for 2019 by continuing to drive increases in productivity. We have some examples which include using digital technology to enhance the customer experience. We now have more than 8.2 million patients now making appointments and receiving their results through our MyQuest digital platform.,0.2174629,0.772
DGX-2019-Q3-2019-10-22,22,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've continued to drive productivity improvements across logistics, patient services and lab services, enabling us to reduce our overall cost per laboratory requisition. We are also putting new innovations to work while reducing costs. We are in the process of consolidating and simplifying our immunoassay platforms, moving to a single supplier. This approach enables greater throughput, a more efficient footprint, and is expected to save tens of millions of dollars per year.",0.5630972,0.878
DGX-2019-Q3-2019-10-22,24,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the third quarter, consolidated revenues were $1.96 billion, up 3.5% versus the prior year. Revenues for Diagnostic Information Services grew 3.7% compared to the prior year driven by strong volume growth and acquisitions, partially offset by higher reimbursement pressure. Volume, measured by the number of requisitions, increased 5.1% versus the prior year. Excluding acquisitions, volumes grew 3.7%.",0.3274092,0.84
DGX-2019-Q3-2019-10-22,25,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We benefitted from an extra revenue day in the third quarter, while the impact of Hurricane Dorian was a modest volume headwind. The net impact of these two items added roughly 1% to organic growth in the quarter.",0.4759084,0.649
DGX-2019-Q3-2019-10-22,26,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Recall, we also highlighted last quarter that we recently exited some capitated contracts. In the third quarter, this change represented a headwind of nearly 1% to our organic volume growth.",0.2101106,0.382
DGX-2019-Q3-2019-10-22,27,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Importantly, we continued to see a modest acceleration in our volume growth associated with our UnitedHealthcare contract. Revenue per requisition declined by 1.2% versus the prior year primarily driven by higher reimbursement pressure.",0.5631912,0.402
DGX-2019-Q3-2019-10-22,28,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Unit price headwinds were approximately 2.5% in the third quarter. This includes the impact of PAMA which amounted to a headwind of approximately 120 basis points. As a reminder, the PAMA impact includes both direct cuts to the Clinical Lab Fee Schedule as well as modest indirect price changes from Medicaid and a small number of floating rate contracts.",0.25,0.052
DGX-2019-Q3-2019-10-22,29,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income was $313 million, or 16% of revenues, compared to $304 million, or 16.1% of revenues last year. On an adjusted basis, operating income was $349 million, or 17.9% of revenues, compared to $333 million, or 17.7% of revenues last year. The year-over-year increase in adjusted operating margin was primarily driven by strong volume growth and ongoing productivity improvements related to our Invigorate initiatives, partially offset by higher reimbursement pressure. Additionally, patient concessions are down year-over-year.",0.3076619,0.881
DGX-2019-Q3-2019-10-22,30,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $1.56 in the quarter compared to $1.53 a year ago. Adjusted EPS was $1.76, up approximately 5% from $1.68 last year. Cash provided by operations was $895 million year-to-date versus $905 million last year. Capital expenditures were $228 million year-to-date, compared to $232 million a year ago.",0.5742496,0.0
DGX-2019-Q3-2019-10-22,31,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, turning to guidance, our updated outlook for 2019 is as follows: Revenues expected to be approximately $7.72 billion, an increase of approximately 2.5% versus the prior year. Reported EPS expected to be between $5.48 and $5.53 and adjusted EPS, to be between $6.45 and $6.50.",0.3163507,0.318
DGX-2019-Q3-2019-10-22,32,Remarks,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Cash provided by operations is still expected to be approximately $1.3 billion and capital expenditures are expected to be between $350 million and $400 million.,0.3613744,0.0
DGX-2019-Q3-2019-10-22,34,Remarks,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","To summarize, we had a solid quarter of top and bottom line growth. While PAMA reimbursement pressures persist throughout the industry, our expanded network access and laser focus on driving operational excellence are enabling growth. Based on our progress to date we have updated our outlook and are well-positioned to meet our commitments for the rest of the year.",0.2817133,0.914
DGX-2019-Q3-2019-10-22,39,Question,2019-10-22,3,2019,Ralph Giacobbe,Credit Suisse,"Good morning. Good morning. Thanks. I guess I wanted to ask on the pricing side, and just your comments on sort of the higher reimbursement pressure. I guess what's - just help us on sort of what's driving that outside of PAMA? And then if you could maybe just level set the expectation on sort of where expectations are for that pricing mix that kind of going forward, exclusive of PAMA? Thanks.",0.1193759,0.918
DGX-2019-Q3-2019-10-22,41,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So as we've shared before in the Investor Day last year, then also coming into this year, this year's pricing pressure is primarily driven by two factors, one is PAMA. The second one is getting back in with United. We moved from out-of-network rates to a market-based in network rate. So obviously, we have grown our volume dramatically. As we've said this year, we expected and we - still we are delivering enough incremental value to offset the price set, but it is a significant price headwind relative to the rates we were being reimbursed as out-of-network lab.",0.1939179,0.689
DGX-2019-Q3-2019-10-22,42,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"You don't have the typical pricing pressure that this industry has faced in the past. We've talked about it being for around 100 basis points or less. Number of those pricing pressures are coming from the client bill, it's not all third-party reimbursement where we're contractually agreed with the health plan and what those rates are in the hospital business and also where we sell directly to physicians and they're allowed to build a third party. There is a lot of competition. A lot of pricing pressure in that area and so while we've talked about, we're going to be price disciplined when we certainly walked away from some contracts that haven't made sense. The reality is that it's a very competitive environment. And that has not really changed.",0.2669826,0.361
DGX-2019-Q3-2019-10-22,43,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So the big change over the last two years, obviously PAMA last year, but it wasn't fully implemented, because you had some offsets to it in the first year that we've talked about previously. This was the first year of the full 10% of PAMA. And then additionally, we have the United price as well. And going forward, as we shared, we would expect this to get back to more of its historical rate. I'm not going to give any specific guidance for a given year. But there is no reason to believe once we get through the transition period in the United that we should be really facing in kind of the traditional pricing pressure in PAMA.",0.6919431,0.82
DGX-2019-Q3-2019-10-22,44,Question,2019-10-22,3,2019,Ralph Giacobbe,Credit Suisse,Okay. And could you just quantify that UNH pricing pressure this year?,0.1476778,-0.077
DGX-2019-Q3-2019-10-22,45,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Ralph, it's going to be $40 million to $50 million.",0.1973641,0.0
DGX-2019-Q3-2019-10-22,51,Question,2019-10-22,3,2019,Bill Quirk,Piper Jaffray,"So Steve, I want to follow up on a comment that you made concerning the decision to consolidate the immunoassay vendors. Can you speak a little bit about whether or not there's an opportunity here to consolidate some of your other testing methods things like clinical chemistry and hematology and such. And if so, can you just help us think a little bit about the timing? This is something we should think about over the next couple of years to help offset some of the PAMA pressure. Thanks.",0.6068349,0.781
DGX-2019-Q3-2019-10-22,52,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, sure, absolutely. So Bill, we were working on this for about seven years, getting smarter and more strategic with all our suppliers, and so we've done a lot of consolidation in the past and we'll continue to do more in the future. So as far as immunoassays, we're close to deciding on the supplier. I believe that will be announced shortly who that is. Of course it's a nice opportunity. And this is all part of our 3% productivity gains that we are dialing in to be able to offset PAMA. We need it to be able to offset PAMA deliver on the earnings uplift that we've provided at Investor Day.",0.0105437,0.933
DGX-2019-Q3-2019-10-22,53,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so part of that 3% is working with our suppliers and part of that working with the suppliers and the example of that is immunoassay while there is others. Another example would be the automation we're putting in place in some of our newer facilities, particularly we're investing this year in our branding facility here in New Jersey - in Clifton, New Jersey. It's a big project for us. That will have us new platform, but equally it will have us our latest approach to automation, which will increase our productivity, but also allow us to consolidate some facilities into one, so we get some productivity gains from that. But that's all part of that 3% when we need that 3% to offset the price pressure particularly with PAMA next year and maybe the year after.",0.123229,0.681
DGX-2019-Q3-2019-10-22,54,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And I just want to add some color there, Bill, make sure they understand this is not just consolidating our purchases. This is actually a new innovation in the platform where we can do multiple tests that previously were performed on separate pieces of equipment on a single piece of equipment. So this will drive, not just procurement efficiencies, but actually will drive operational efficiencies in our labs.",0.3254344,-0.195
DGX-2019-Q3-2019-10-22,58,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. Sure. What we're doing for our hospital client as part of our five-point strategy, we talk to them about three things in regards to the lab strategies. One is, can we make them more efficient in running their inpatient laboratory? So this is where we talk about Professional Laboratory Services or sometimes we use the acronym PLS, and we continue to have that dialogs about making them more efficient.",0.0863262,0.896
DGX-2019-Q3-2019-10-22,59,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We can - with good evidence now, save them about 10% to 20%. Part of that typically also is looking at the sophisticated send out of testing referred to as reference testing. And in that regard, consolidated was buying from - like potentially give them a better price. But the third part that we're looking at and this new offering allows as a tool to do a better job of getting smarter about what they're testing in the hospital is interrogate their order patterns and look for variation of their order patterns and look at ways of optimizing what the order within the hospital.",0.3001647,0.972
DGX-2019-Q3-2019-10-22,60,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And there's two part to that. One is to get more efficient at what you're ordering. So maybe third quarter as much in some cases, you should also order more because it's smarter diagnostic workup for the inpatient today, but the second part of this, which is more - even more intriguing what many hospital administrators are interested in is making sure that we have the right diagnosis.",0.3186161,0.865
DGX-2019-Q3-2019-10-22,61,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And if you look at the total quality and outcomes for our hospital stay, there's nothing more expensive than buying diagnosis. So what this tool allows us to do is to work with our clients on getting smarter on their inpatient diagnostics and as part of that, we clearly become more strategic than this vendor providing reference testing within that account.",0.5034596,0.691
DGX-2019-Q3-2019-10-22,62,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, the third piece of what we work with hospital systems when we have those discussions is you want to stay in the outreach business and we have bought some outreach businesses from hospitals. We have some within our numbers for this year and will continue to aggressively pursue buying outreach businesses as this industry consolidates. And I would tell you that many hospital systems are now well aware of PAMA and well aware of other reimbursement pressures they are having in their laboratory outreach business. So, as we mentioned in our commentary that funnel of discussions continues to grow.",0.1598023,0.751
DGX-2019-Q3-2019-10-22,66,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. So what will share with you - we always shared this every quarter. It feels like the market is stable. We don't see any notable changes in terms of volume increases within the marketplace both outside the hospital, and also inside the hospital so stable. So if you look at volume growth, we're clearly gaining share. And a large portion of that share of gains is coming from managed care relationships.",0.2032949,0.981
DGX-2019-Q3-2019-10-22,67,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","What we have also said is that our access changes, which is the best in over a decade, we'll continue to grow. It will continue to grow this year in 2019, but it will also have growth in 2020 and probably in 2021 as we take advantage of that opportunity that we see in front of those. That will be helped in 2020 for certain with - for lab network, particularly with UnitedHealthcare. So you should look for in 2020 continued growth again because of our expanded network access. So Mark, anything you'd like to add to that?",0.3285008,0.958
DGX-2019-Q3-2019-10-22,68,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, you asked about the PLN, it's still very, very early. To this date, I'd say very little, if any growth has come from the PLN is still in front of us, which is the good news. We talked at Investor Day about kind of three tranches of volume growth, Erin. We sized the new managed care access at about $1 billion at our price, our fair share. We fully expect to get to our fair share. But it's going to take several years there was a easier to convert accounts obviously came quickly, we call them Quest loyalist where we had the rest of the book of the office and they were sending some of the managed care work that we were out-of-network to those, to other labs that were in-network and they immediately moved that to us once we were in network.",0.3665087,0.98
DGX-2019-Q3-2019-10-22,69,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We never had some of the accounts where they have multiple labs. We showed you the picture when they were three, four sometimes five boxes outside. We've done a better job of consolidating some of that getting a more larger share of wallet per se in those positions that will take a period of time, but certainly, we've gotten some growth from that, but that will continue into the future.",0.8380727,0.848
DGX-2019-Q3-2019-10-22,70,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then there was the ones where we have had no, none of the work and a lot of that is in the hospital stay, hospital outreach and in some of the physician-owned laboratories that's where we really think the preferred lab network is going to be a big driver. We would be able to have a very simple message to patients. Hey, if you use one of the preferred labs and obviously we're one of the five zero out-of-pocket. That's a very simple message instead of trying to compare how expensive, what option might be the there, it's free to view if you use this lab. So we're very confident, very excited. This will be a multi-year tailwind and we're going to get to that fair share eventually of about $1 billion in our price.",0.7176145,0.925
DGX-2019-Q3-2019-10-22,74,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"They have not shared specific information, obviously. They are questions you could ask them because we're not the only preferred lab. So we obviously get the same information that preferred lab network providers do. They talk to us about, as we've shared the states where their role in the south making this available, and then they talk to us about the fact that their marketing into those whole insurance sponsored plans for 2020, rolling that out, still very early in that process, and they didn't give us any specific proportionality or percentage of their overall insured lives that are adapting this, but they - I'm sure you've heard them talk about it, we've heard them talk publicly and in the conversation we have, they are very, very confident that this is going to be something that people will embrace and that is going to make a difference.",0.5434439,0.876
DGX-2019-Q3-2019-10-22,80,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Sure. So on the first one, as I mentioned in our opening remarks, these deals are getting bigger and more complicated. And if it's more complex, it takes more time and there is good news in that and there is bad news in that. One is, it takes more time. That's bad news. The good news is, the bigger the more complicated. It's therefore we're clearly having discussion around how they could be - their partner for laboratory services around the three topics that I mentioned earlier.",0.1028007,0.361
DGX-2019-Q3-2019-10-22,81,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And what I did also share is that the interest level around what we can do when partnering continues to grow because of more people are well aware of the pressure on this portion of their business. I would say that was not nearly where we were last year at this time. So if you look at our growth rate from acquisition year-to-date, they're - it's just a little shy of that 2% we indicated last year. We're well north of that 2%.",0.3317957,0.823
DGX-2019-Q3-2019-10-22,82,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We still feel confident that over an extended period of time, we'll continue to be 2% or greater. And so, we feel confident between the three buckets that we acquire. One is hospital outreach, [indiscernible] (0:29:03) lot of engagement around that. Second is, regional laboratories. As I mentioned in my remarks, there continues to be interest in evaluating options for smaller operators because of the pressures that they see. And then finally, we continue to build capabilities and we have a number of acquisitions in the past around that. A good example of this immune attack, which is bringing us new capabilities around tuberculosis testing and also fit for an illness testing.",0.0411862,0.944
DGX-2019-Q3-2019-10-22,83,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So all three continue to be our focus going forward and you will see that and we're still confident around our guidance we provided around 2% on a CAGR basis over a multi-year period of time.,0.5383855,0.494
DGX-2019-Q3-2019-10-22,84,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And you asked about opioid testing and the tailwind certainly our prescription drug monitoring business, which is subset of that opioid testing has been a strong growth engine for us for a number of years and continues to be a nice growth driver. Like anything else, when something gets large enough, the payers start putting in policies and all sorts of barriers to reimbursement that dampen that somewhat, despite some of those restrictions around frequency of testing, pre-authorization, and other things that they're putting in, it's still a nice growth driver for us. It just will be even larger if they hadn't made those changes.",0.0118483,0.963
DGX-2019-Q3-2019-10-22,88,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so let me first touch Jack on the longer term. So I'm not going to talk to 2020. But what I did talk about at the Investor Day was on a full year outlook that we could grow earnings faster than the top line. And talked about the assumption, although that may not play out depending on how we deploy our cash, but that's on the flat share count, so therefore we're actually growing earnings not earnings per share. So that implies margin expansion that I can tell you that we are not expecting some sort of the tax windfall. So that's before tax margin growth.",0.2836903,0.895
DGX-2019-Q3-2019-10-22,89,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I can't assure you that will happen every quarter. I can't assure you that I'm not going to get into 2025 adding every year, but over multiple years, we expect to grow our earnings faster than our top line. And it's really having the efficiency program continue, we talked about it being 3% per year, we've got really good at that. We need that. We'll continue to do that with over time tempering pricing headwinds. In this quarter, we shared the pricing headwinds of 250 basis points. Obviously, that all drops to the bottom line for a very small piece for the bad debt element, but basically it drops to the bottom line.",0.5324547,0.629
DGX-2019-Q3-2019-10-22,90,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we had enough efficiency and some lift from volume, how much of that is the extra day, how much of that is just the volume growth. Obviously, we have a higher drop through we shared on organic volume growth, enough to offset the pricing headwinds and basically hold our margin pretty flat in the quarter.",0.4639209,0.881
DGX-2019-Q3-2019-10-22,91,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So I may be getting any more precise than that, I'd be stretching my credibility and ability to give that map. So I would just say that, you can see that despite some pretty significant pricing headwinds, is how their margins in this quarter and that as we continue to drive strong organic volume growth and deliver our 3%, over a period of time, we're going to grow our earnings faster.",0.6889621,0.61
DGX-2019-Q3-2019-10-22,94,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so we've raised our guidance for the year. Importantly, we're signaling stronger finish to the year than we did at the beginning of the year. And until now we've not signaled anything above original guidance. So, hopefully people are taking that as a positive message, which we're saying based on our performance through three quarters of the year and what visibility we have for Q4, we're feeling confident that we're going to over-deliver relative to what we said at the beginning of the year.",0.8876442,0.96
DGX-2019-Q3-2019-10-22,95,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, in terms of the spending, there's nothing out of the ordinary in Q4. The only thing that's out of the ordinary is the easy compare on the top line which we've talked about.",0.9489292,0.572
DGX-2019-Q3-2019-10-22,100,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me start on this. For some reason, there's always a lot of focus around G&A thinking about a lot of our invigorated savings show up in the expense categories. To the contrary, most of our invigorated savings actually sort of show up in our costs of sales. So if you think about what's in our expense category, a lot of it is G&A and we've made really good progress over the last seven years. So getting more efficient with everything that's in the category in the P&L, from IT cost to cost running our finance organization, the cost associated with our billing operations, with our relationship with Optum. And outside the general and administration, it's our sales and marketing costs, which we're always evaluating and getting more efficient.",0.2520593,0.939
DGX-2019-Q3-2019-10-22,101,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So we have taken a lot of cost out already. And we're also leveraging that fixed cost going forward. So the lift we generally get now has to do with that operational leverage related to the top line growth while maintaining the same cost perspective and that's what you see this year. So a lot of the 3% productivity gain will show up in productivity gains in our cost of sales and not in the expenses.,0.1621087,0.848
DGX-2019-Q3-2019-10-22,103,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, I just would like to add that yes, over time, well Steve is absolutely correct that a large proportion if not a majority of that efficiency is going to drive margin and gross margin will be in the cost of sales will continue to focus on G&A. You can't really look quarter-to-quarter. In this quarter, we had some couple of high-cost health claims. Over time, we're going to deliver what we expect, and we've done a really good job in managing, it's very, very minor increases in our self-funded employee healthcare costs. But in a given quarter you get a couple of large claims that can make some noise quarter-to-quarter.",0.5229068,0.891
DGX-2019-Q3-2019-10-22,104,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So there's no trend, where there's - nothing should be read in terms of we've lost our ability to continue to drive efficiency, there's always going to be noise on that line quarter-to-quarter.",0.1291469,0.006
DGX-2019-Q3-2019-10-22,110,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay, so let me take the first part Mark will take the second part. And the first part, so this is a comprehensive review that we perpetually look at with our suppliers on how we run our laboratories. And we work actively with all our suppliers and that over the past seven years we've worked hard to make sure that we really have more of a strategic relationship with all our suppliers, particularly those that are driving a large portion of our spend. And so in that regard, in the IVD automation states, there is consolidation with a number of those platforms as Mark mentioned. And there are a number of suppliers that we buy from that are bringing to the marketplace platforms that will allow us to replace up to about five different work cells with different manufacturers over time.",0.030313,0.834
DGX-2019-Q3-2019-10-22,111,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so what we have done is evaluate those vendors that have a product either in the marketplace or will have a product in the marketplace and we do that through a review process with their sales force on understanding what they'll have, and what they'll have for functionality at one time, and then also what the economics around their offering are. We narrowed that down to a few. We actually put in place a few of those platforms in some of our facilities to do some trial runs and then we're at the final strokes of selecting one of those suppliers going forward. And we believe that we will choose a vendor that meets all the requirements of what we need.",0.4158155,0.0
DGX-2019-Q3-2019-10-22,112,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And yes, a portion of this is economics. That is how cost - how much productivity we're going to get for getting more throughput by - being able to consolidate those operations. But also we think about it holistically. You need to make sure that you have good confidence around their ability to service us, good confidence around their quality, good confidence around what's in their installed base. So it's a very comprehensive, operational review of who will be our strategic provider for this new platform going forward. And as I said we're at the final strokes of deciding that and shortly it will be announced.",0.229654,0.979
DGX-2019-Q3-2019-10-22,113,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so on your second question, last year there were a couple of drivers that led us to the change in estimates and obviously the change that we made in Investor Day on our outlook for 2018. Two of them really relate to patients. The first one was that there was more patient responsibility in the year than we saw it coming. And again, we're always accruing based on a forward-looking expectation of how the revenue is going to play out. We looked at all the available data at the beginning of the year as we shared whether great growth with the amount of people with high deductible plans, we assumed it would be a pretty flat year in terms of the proportion of our revenue from patients. And instead what happened was there were more patient responsibility because the deductibles themselves have gone up markedly as we found out in the September timeframe, which started to actually validate why our cash collections were lagging what we expected from the payer.",0.314376,0.95
DGX-2019-Q3-2019-10-22,114,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So anytime, as we've shared, we almost collect a hundred percent of the accepted claims that we're owed from third party payers. And we've shared that we collect about $0.70 on the dollar from patients. So you move 1% of revenue from the third party to the patient. That's a 30 basis point headwind. So it's pretty significant.",0.6520537,0.942
DGX-2019-Q3-2019-10-22,115,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The good news is this year nothing changed significantly from last year. We're very confident with that, there was no surprise. Obviously going in, we were very, very diligent in watching that, being conservative and there's no surprises in terms of the proportion of our revenue coming from patients.",0.6611374,0.718
DGX-2019-Q3-2019-10-22,116,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The second piece really with patients was we had more patient concessions, not just because more revenue was coming from them, but we actually had some issues we've talked about in our lab conversion in the south. And that delays some billing because of the way these conversions go. And because of that the more bills age out, the more you're going to have concessions less like you are going to collect it. So that's well behind us, we're fully converted, we don't have that anymore. So that's behind us.",0.3917852,0.708
DGX-2019-Q3-2019-10-22,117,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then also related to that we had some higher level of denials because of some time with filings, and so on, because lab conversion themselves we always have been dealing with denials, but they spiked the mid to late last year when we went to this lab conversion. So when you add all those things up, they've been cleaned up. The issues that we had last year are well behind us.",0.6891785,0.392
DGX-2019-Q3-2019-10-22,121,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so we're continuing to move forward with our retail strategy as we call it. We have about 2,100 patient service centers and of which can you characterize from above 35% to 40% of those are more retail like, several of which are within Safeway stores and Walmart. The Safeway relationship continues to be a good one. We actually have some new opportunities with Safeway going forward as we kind of work that relationship, so we're optimistic there.",0.2072488,0.911
DGX-2019-Q3-2019-10-22,122,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then second, as we continue to build our presence with Walmart as well. And as you mentioned, they opened up new health concept store and we are their laboratory provider for that store, so they're still working through how that works. And as you know if you know anything about Walmart, they probably like a lot of things and they're seeing how well that goes to be able to tune out and we're working with them proactive on that content going forward.",0.7205931,0.818
DGX-2019-Q3-2019-10-22,123,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as what we said is our goal is to be north of 50% of our patient service centers. So we have some ways to go. And there's a number of things for us, one is we think it's a better customer experience, consistent with our strategy, could be the most consumer-friendly laboratory. And we think this will continue to be a differentiator for us in the marketplace.",0.4682043,0.494
DGX-2019-Q3-2019-10-22,124,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is it's better for employees in a lot of ways and it also allows us to manage the demand and when people are there if we can have larger patient service centers with more providers, it just gives you a lot more operational flexibility to manage the demand based upon location and time of day that patients are coming in over extended period of time.",0.8573311,0.554
DGX-2019-Q3-2019-10-22,125,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally as the patients really the feedback is quite good. They come in, they have flexibility to walk the store where they wait they have flexibility to do some shopping after their visit. Then we believe that improvement in access and the quality of that access will allow us to differentiate ourselves in the marketplace and pick up share gradually over time. So it's going well, we're pleased with it.",0.121911,0.954
DGX-2019-Q3-2019-10-22,126,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then lastly, I will just say, yes, we have the relationship with Safeway, and yes we have relationship with Walmart, but we continue to work with others in the marketplace, so we continue to work with CVS, Aetna, the MinuteClinic and what we're doing around their strategy is they are a partner of ours.",0.7383855,0.402
DGX-2019-Q3-2019-10-22,134,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes so for labs not in the network, it would be the typical out-of-pocket determined by their plan benefit design. So, with a high deductible plan they just had some sort of cover insurance, but there won't be zero. So if you think about the average requisition being somewhere between $40 and $50 and typical patient responsibility over time, employing proper responsibility over time by be it 20% to 25% of their healthcare dollars, with the balance being paid for by the company, you can do the math. Now that's an average. Obviously there's some very high cost tests. So it'd be a big, big advantage if you have a genetic test or some of the other screening tests that could run hundreds of dollars.",0.2298578,0.619
DGX-2019-Q3-2019-10-22,135,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"But just the simplicity of the message of not having to worry that, hey the same series of tests would be $50 from a national lab and $500 from this hospital. And what does that mean for me? It's just you don't have to worry about it. They're not as good and it's not just about price, it's also about quality, and service and access. So those are all the metrics that were required to get in. We did not change our price with the United in order to get into the pervert lab network, nor do we think anybody else did, but we know we definitely did not. So this is really about the total value of the offering. So if you want to go to the best lab with a great price and also have zero out-of-pocket, it's a very simple decision for the patient. So that's important.",0.700237,0.975
DGX-2019-Q3-2019-10-22,136,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"There's also in United you should talk about this, but there's also some things that they're doing around in sending physicians as well. So it's not just a patient-driven initiative and I'll let you talk to United about what they're doing on that end.",0.8151659,0.805
DGX-2019-Q3-2019-10-22,137,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then obviously you can imagine we're doing a lot of work in the field with our own commercial sales force to make sure that physicians are aware because this is really good for patients. And most physicians their number one priority is their patient, not their owner, not anybody else, so when they know this was good thing for their patients, they like that. The other thing is it's a source of some patient satisfaction is getting a bill.",0.1765403,0.928
DGX-2019-Q3-2019-10-22,138,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And so now you don't have to call to the office about, hey, that lab you ordered from me, I got a bill, I thought it was covered by the office visit, et cetera, et cetera. So reduces noise for the payer, reduces noise for the physician's office, obviously a good thing for us and a good thing for patients.",0.6911532,0.7
DGX-2019-Q3-2019-10-22,139,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes I'll just add to what Mark just said, obviously the savings here is zero coinsurance and copayments, but the biggest driver as you're moving through the laboratory that has a significant lower reimbursement rate then if they're working with enough for lab network. So the savings to the consumer is very considerable. But the biggest portion of that has to do with the rate differential, not necessarily with the patient responses they might have or not have with us. So a big opportunity and we're hopeful. As we mentioned it's just getting started this month, it's early. But we're hopeful, this change coupled with the changes that we spoke to take place in 2020 will continue to allow us to grow our presence and our share with United, but also with other payers because we do believe it's a trend overall in the marketplace.",0.6418451,0.972
DGX-2019-Q3-2019-10-22,144,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so we talked about the fact that the about the fact that the extra day net of hurricane Dorian gives about 100 points. So you can kind of take that math in your thinking. Obviously each corner has different puts and takes in terms of the amount of revenue days, and we usually try to be very transparent about how that all plays out. At the beginning of the year we've talked about Q1 having Saturdays and Q3 having an extra day. And obviously next year we have leap year and the quarter's will play out a little bit differently. And we'll give you as much transparency on that as possible. But really when you think about the whole year the next year you're just thinking about generally revenue days are pretty similar year-over-year other than when you have a leap year.",0.2330174,0.852
DGX-2019-Q3-2019-10-22,145,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then we did talk about the capitated volume, which is not impacting the bottom line. But if you're just focused on revenue, at some point next year we laugh that change. So that was about a 100 basis points this quarter. If you recall, we shared about 70 basis points in Q2. So at some point that volume headwind gets behind us.",0.135466,0.823
DGX-2019-Q3-2019-10-22,146,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now I'll just to share a little additional color in the quarter, our a employer pre-employment testing business is actually a headwind to our growth that was pretty flat. So that's the non-DIS if you remember then about a 20 basis point higher growth rate I shared at the beginning of my prepared remarks for our core clinical business. So we'll see how the pre-employment drug screening business goes, but that was if you want to really think about the clinical business, which is what where we're benefiting from the expanded access and the volume performance is actually slightly stronger than it may have appeared on the surface.",0.1848341,0.871
DGX-2019-Q3-2019-10-22,147,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, is it going to be 5%? Obviously we're not going to have an extra day every quarter. But is it going to continue to be really positive organic revenue growth into the future? Absolutely that's our expectation as we work our way to that fair share I talked about as eventually getting into $1 billion of revenue in these new lives with the three expanded access plans.",0.6034755,0.885
DGX-2019-Q3-2019-10-22,154,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so let me go back to our capital deployment strategy. So as we've shared, we're going to do M&A where it's value accretive to our shareholders, there's a clear path. We're not going to do an M&A just to meet some outlooks that we gave. But with that said, we're very confident in that 2% CAGR. So we never include unexecuted M&A in our guidance. So just because we at this point are implying a low level of M&A either in Q4 or early in the next year, doesn't mean that we might not be close to something, but that's just not in our practice. So we don't actually include M&A in our guidance until we have a signed contract, and so on.",0.0983412,0.708
DGX-2019-Q3-2019-10-22,155,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we're very confident in that 2% CAGR. If you look at what we've done, last year and what we're applying this year we're going to be well north of that 2% after two years. We're highly confident that in the next two years to complete that four year CAGR. We're going to be at that level if not beat it, because there is a lot of interest. As Steve shared and as we've talked about these deals have just taken a while it doesn't mean they have fallen by the wayside, we're still working on the same deals that we thought we'd would have gotten done several months ago. But we're very optimistic some of these are going to get completed.",0.6046603,0.934
DGX-2019-Q3-2019-10-22,156,Answer,2019-10-22,3,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,And I'm not going to give you any guidance for 2020. What I'm comfortable with obviously we'll give guidance in late January for the year. I'll talk about the organic M&A mix and then at that point if we have some additional deals that have closed in the interim those will be included. But otherwise we don't typically do that - include that in our guidance.,0.3131912,0.511
DGX-2019-Q3-2019-10-22,163,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so at this point we share where our sources of revenue are. And so at this point, patient responsibility is not grown significantly year-over-year. So despite what the Kaiser report is talking about in terms of increased deduction, this year it's not impacted us per se year-over-year. One of the things we did in response to some of the surprise we had last year was we shortened our timeframe. So the way we do our revenue recognition, we're looking at more recent trends that we use to have a longer term trend that worked for us for years, and years and years. So we're looking at a lot more recent, which would allow us to not have surprises like we had last year.",1.0065898,0.737
DGX-2019-Q3-2019-10-22,164,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we've been on top of this. We're very comfortable with what we've been accruing. We're very comfortable with our cash collections. We have a very robust process. And as we look at that we've done better on patient concessions, partially because last year was a particularly poor year for some of the reasons I shared earlier, but part of it is we continue to roll out the tools and partner with Optum, our partner around doing things like offering credit card collections upfront.",0.8023064,0.918
DGX-2019-Q3-2019-10-22,165,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We support that with our real-time estimation tool, where if you come into our patient service center, you go to an office where we have an in-office lobotomist. We can tell you on the spot whether the test is covered or not and importantly what your responsibility will be based on that coverage decision and then have an opportunity to say and how would you like to pay for the upfront like most of healthcare has done. So we're collecting more of our cash up front that makes a significant difference in the overall collectability.",1.0573311,0.838
DGX-2019-Q3-2019-10-22,166,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've also seen an improvement in denials. So some of the things we talked about last year, especially in the PBM space where we're surprised by a couple of major payers, I will tell you as I shared earlier, the payers in general continue to throw us curve balls, we're always having to deal with new policy changes, new opportunities for them to deny, but we cleaned up some of the things last year that were more significant. So we've reduced our overall denials in a couple of key test periods. That's helpful.",0.9518946,0.862
DGX-2019-Q3-2019-10-22,167,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've also shared in the past that we continue to get some preferential treatment from a couple of payers where they put in pre-authorization requirements for certain tests and they actually wave that for a couple of labs, including us because they know we do things, right. We don't do excessive testing, we partner with them on what clinically appropriate panels are and approach to testing are. So that not only reduces our denial rate because pre-auth is great challenges for the labs, but it also makes us advantageous for the prescriber because they don't have to worry about pre-auth based on the work to us.",0.969687,0.519
DGX-2019-Q3-2019-10-22,168,Answer,2019-10-22,3,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So all of those things together are actually helping revenue growth, and they're helping our overall margin and part of our Invigorate is on the top line. It's not all on costs, some of it is actually getting paid for more of the work we do as Jim Davis has said at multiple Investor Days. So we're seeing good positive improvement in that space.",0.1390445,0.961
DGX-2019-Q3-2019-10-22,169,Answer,2019-10-22,3,2019,Shawn Bevec,Executive Director-Investor Relations,"Okay. Well, we thank everyone for joining us today. We appreciate your support. Have a great day, and talk to you soon.",0.3323631,0.933
DGX-2017-Q4-2018-02-01,3,Remarks,2018-02-01,4,2017,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I am here with Steve Rusckowski, our Chairman, President, and Chief Executive Officer; and Mark Guinan, our Chief Financial Officer.",0.1907912,0.66
DGX-2017-Q4-2018-02-01,4,Remarks,2018-02-01,4,2017,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and will discuss non-GAAP measures. For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS excluding amortization expense. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K, and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K.",0.114316,0.013
DGX-2017-Q4-2018-02-01,5,Remarks,2018-02-01,4,2017,Shawn Bevec,Executive Director-Investor Relations,This quarter we have included a 2018 adjusted EPS bridge on the Investor Relations page of our Web site. The text of our prepared remarks will be available on the site later today.,0.2807621,0.226
DGX-2017-Q4-2018-02-01,7,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. This morning I'll provide you highlights for the fourth quarter and full-year 2017, and review progress on our strategy. And then Mark will provide more detail on the results and take you through our 2018 guidance.",0.2873147,0.823
DGX-2017-Q4-2018-02-01,8,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, we finished the year on a high note by delivering a strong fourth quarter. Revenues grew 4%. Reported EPS grew 67%, and adjusted EPS grew nearly 7%. For the full-year 2017, revenues were up 2.6% on a reported basis, and up 2.9% on an equivalent basis versus 2016.",0.6112026,0.66
DGX-2017-Q4-2018-02-01,9,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","EPS was up 22% on a reported basis, and more than 10% on an adjusted basis. Cash provided by operations was up by nearly 10% from 2016. 2017 was a good year. I'm pleased to announce we are increasing our quarterly dividend by 11%. This is the seventh increase since 2011. Before I describe the progress we have made, what I would like to do is to talk about two dynamics impacting our industry, PAMA and Tax Reform. PAMA represents a significant headwind. In November, we said that we expect the impact of the final rates on the PAMA to be approximately 4% of our revenues from the clinical IP schedule in 2018, and approximately 10% in both 2019 and 2020.",0.4668863,0.936
DGX-2017-Q4-2018-02-01,10,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As you know, in December, we fully supported ACLA's lawsuits charging that incentives from Medicare and Medicaid services, failed to follow our congressional directive to implement a market-based laboratory payment system, and we believe we could have a decision from the judge by midyear. In the meantime, our trade association will continue to work with Congress to secure a legislative solution.",0.7268534,0.531
DGX-2017-Q4-2018-02-01,11,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now turning to tax reform, Quest is a significant beneficiary of lower corporate tax rates, which will enable us to grow earnings per share invested in our business and our people. We will realize approximately $180 million in tax savings on an adjusted basis in 2018. With those tax savings, we are reinvesting roughly $75 million before tax into the business and our people. Some of these initiatives include advanced diagnostic innovations through new test, and the high touch configured services.",0.2355848,0.71
DGX-2017-Q4-2018-02-01,12,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Investments to deliver consistently excellent consumer experience both online through our MyQuest patient app, and all of our patient service centers. And then, finally we will pay a bonus of up to $500 to about 40,000 employees as the way of saying things. We're playing a vital role in our success. This bonus will be based on the company's performance and accelerating growth in 2018.",0.2978583,0.962
DGX-2017-Q4-2018-02-01,13,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now turning to the progress we made in the fourth quarter. We delivered on all five elements of our strategy to accelerate growth. The first outlet of our growth strategy is to grow 1% to 2% per year through strategic aligned accretive acquisitions, which we achieved for the fifth consecutive year.",0.63229,0.791
DGX-2017-Q4-2018-02-01,14,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We had another very productive quarter for M&A. We completed our previously announced acquisitions of Cleveland HeartLab, which builds on our position and advanced diagnostics and shield medical laboratory, which will further strengthen our position in the New York metropolitan marketplace. Our M&A pipeline remains very strong, and our strategy is delivering growth. And this is evidenced by originally announced acquisition of Mobile Medical Examination Service or MedXM, a leading national provider of home-based health risk assessment and related services.",0.6388797,0.812
DGX-2017-Q4-2018-02-01,15,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Our seven announced acquisitions in 2017 will enable us to exceed our long-term M&A objective of 1% to 2% top line growth for 2018. And of course any earnings accretion realized from these acquisitions in 2018 will help offset the impact of new Medicare rates.,0.4332784,0.727
DGX-2017-Q4-2018-02-01,16,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Under the second element of our growth strategy, we continue to expand relationships with hospitals and health systems. Our professional life services revenues grew by double-digits in 2017, and delivered healthy operating margin as more hospitals benefited from the standardization, scale, and innovation that we bring to these relationships. While the new Medicare rates are headwinds for us, we also believe that rates will be a catalyst for consolidation later in 2018 and beyond as hospital systems face increasing pressure from lower Medicare rates. We've had a number of conversations with hospital C suits that indicate their increased sense of urgency about rethinking their lab strategy.",0.168369,0.802
DGX-2017-Q4-2018-02-01,17,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We took a number of actions to deliver on the third element of our gross strategy, which is to offer the broadest access to diagnostic innovation. In women's health, we continue to be excited about the progress we are making in noninvasive prenatal screening. Our Q-Natal test enjoyed strong double-digit growth in 2017. Our contributors to growth in 2017 were prescription drug monitoring with growth in excess of 20%, QuantiFERON tuberculosis testing, Hepatitis C screening which posted double-digit growth of 2017. We also established new advanced diagnostic centers for excellence for cardiovascular testing and precision oncology in conjunction with our acquisitions of the Cleveland HeartLab and Med Fusion.",0.0925865,0.978
DGX-2017-Q4-2018-02-01,18,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to make strong progress executing the fourth element of our growth strategy, which is to be the provider of choice for consumers. We opened six locations in Wal-Mart stores in 2017; five in Florida, and one in Texas. The early feedback from our patient satisfaction surveys is extremely positive. Our customers appreciate the convenience of being able to get their testing done where they shop. The ease of the check-in provided this easy enablement and the professionalism of our phlebotomists are noted in all the surveys. There is more to come in 2018 as our collaboration with Wal-Mart expands to include basic healthcare services. So we'll keep you posted on our progress.",0.0879736,0.978
DGX-2017-Q4-2018-02-01,19,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our relationship with Safeway, which is down in second year continues to expand. We're now operating in 184 stores in 12 states. We have similar positive feedback from both our employees and our customers on their experience in these locations. We are also powering the healthcare consumer with our MyQuest mobile application, which is now delivering rapid results into the hands of nearly 5 million users. This is an increase of more than 1.3 million users in 2017.",0.0797364,0.802
DGX-2017-Q4-2018-02-01,20,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The fifth element of our growth strategy is to support population health with data analytics and extended care services. We are building a solid data analytics pipeline with a strong number of partner's interest in leveraging our data, including pharma, CRO, and health plan customers. We are very excited about our acquisition of MedXM. This will give us access to more mobile healthcare professionals, which expands our scale and reach into the mobile and home segments, as well as bolstering our overall capabilities in extended care.",1.3390445,0.973
DGX-2017-Q4-2018-02-01,21,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second element of our two-point strategy is to drive operational excellence. I'm very pleased to that we have exceeded our $1.3 billion goal of cumulative run rate invigorate savings as we exited 2017. We will maintain our discipline in this area; continue to drive efficiency and effectiveness. Every year, we need to cover the cost of wage inflation and price compression. Given our track record of delivering in this area over many years, going forward we will provide periodic updates on our progress in lieu of a specific run rate savings growth.",0.3920923,0.952
DGX-2017-Q4-2018-02-01,22,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quality and efficiency go hand-in-hand. And as we drive operational efficiency, we continue to prove the customer experience. More than half of our 2,200 patient service centers are live with the check-in kiosk, which improved the patient experience. By the end of the year, we expect to have that capability in all of our locations. E-check-in enables phlebotomists to spend less time on clinical tests and more time to deliver the better patient experience.",0.0095552,0.875
DGX-2017-Q4-2018-02-01,23,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to our outlook, our guidance for the full-year 2018 reflects expectations for continue acceleration of top line growth of 4% to 5%, and more than 20% adjusted earnings growth, driven in part by solid mid-to-high single-digit adjusted earnings growth from operations.",0.047117,0.848
DGX-2017-Q4-2018-02-01,24,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, I would like to turn it over to Mark, who will take you through our financial performance and our 2018 guidance in more detail. Mark?",0.6939044,0.361
DGX-2017-Q4-2018-02-01,25,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. Starting with revenues, consolidated revenues of $1.94 billion were up 4.1% versus the prior year. Revenues for Diagnostic Information Services or DIS for short grew 4.5% compared to the prior year, with approximately 210 basis points attributed to acquisitions. Volume measured by the number of requisitions, increased 2.4% versus the prior year with acquisitions contributing approximately 150 basis points in the quarter. The impact of hurricane Maria on our operations in Puerto Rico presented a headwind of approximately 20 basis points to volume in the fourth quarter.",0.0746445,0.649
DGX-2017-Q4-2018-02-01,26,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per acquisition in the fourth quarter grew by 2.1% versus the prior year. As a reminder, revenue per acq is not a proxy for price; it includes a number of variables such as unit price variation, business mix, test mix, and test per acq. Unit price headwinds remained less than 100 basis points in the fourth quarter, consistent with the trends we observed throughout 2017. Excluding the impact of PAMA, we would expect unit price headwinds in 2018 to remain less than 100 basis points, with PAMA adding an additional headwind of approximately 50 basis points on our DIS segment.",0.7176145,0.077
DGX-2017-Q4-2018-02-01,27,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"After many changes to PAMA, Medicare reimbursement pressure will step-up in 2019 as we have indicated previously. Beyond unit price that we impacted growth in our POS partnerships other mix settlements including test mix was strong contributing more than 200 basis points in the quarter. This trend has remained consistent over the last couple of year. Reported operating income for the quarter was $269 million or 13.9% of revenues, compared to $276 million or 14.8% of revenues a year ago. On an adjusted basis, operating income was $317 million or 16.4% of revenues compared to 305 million or 16.4% of revenues last year.",0.6409953,0.572
DGX-2017-Q4-2018-02-01,28,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was a $1.82 in the quarter compared to a $1.9 a year ago. The increase is related to a net tax benefit recorded as a result of the recent tax legislation. Adjusted EPS was a $1.40 up nearly 7% from a $1.31 last year. The company recognized in ample tax net benefit totaling $74 million within the quarter. This primarily reflects the tax benefit mentioned previously, partially offset by system conversion, restructuring, integration and other charges. The net impact for these items increased our reported EPS by $0.53.",0.7847551,0.883
DGX-2017-Q4-2018-02-01,29,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our reported fourth quarter tax rate is significantly lower than the prior year as a result of tax reform. In the quarter, we recorded approximately $0.02 per diluted share of excess tax benefit associated with stock-based compensation or ETB compared to approximately $0.01 per share benefit last year.",0.4111374,0.802
DGX-2017-Q4-2018-02-01,30,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In the full year 2017, we recorded $0.27 per share of ETB, which is an increase of $0.21 year-over-year. At this point, I would like to highlight that January 2018; we will exclude ETB from our adjusted EPS calculation. We believe we have changed for providing with better insights into the operational performance of our business. Bad debt expense for the fourth quarter as a percentage of revenues was 3.8% 20 basis points higher than last year and 20 basis points lower versus the prior quarter.",0.5469984,0.052
DGX-2017-Q4-2018-02-01,31,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"For the full year 2017 bad debt was 4.1% flat year-over-year. As a reminder beginning in 2018, new revenue recognition rules will require us to classify un-collectable balances associated with pace of responsibility as a reduction in net revenue as oppose to bad debt expense. As you think about 2018, considering the impact of this change on our revenue for each quarter of 2017 which is shown in no aid at the end of this morning's earnings press release. You should use this adjustment as the basis for comparability in 2018. The reduction in revenue for each quarter in 2017 is accompanied by an equal reduction in SG&A expense with no impact operating or net income.",0.7539494,-0.955
DGX-2017-Q4-2018-02-01,32,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Turning to cash provided by operations, we generated $1.2 billion in 2017 versus $1.1 billion last year. Capital expenditures during the year were $252 million compared to $293 million a year ago.",0.8238547,0.0
DGX-2017-Q4-2018-02-01,33,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now turning to guidance, we are providing with following outlook for 2018, revenues to be between $7.7 billion and $7.77 billion an increase of 4% to 5% versus the prior year. Reported diluted EPS to be between $5.42 and $5.62 and adjusted EPS excluding both amortization and ETB to be between $6.50 and $6.70. Cash provided by operations to be approximately $1.3 billion and capital expenditures to be between $350 million and $400 million.",0.8874408,0.44
DGX-2017-Q4-2018-02-01,34,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Here are some items for you to consider, given all the moving piece as in 2018. First, as a result of tax reform, we expect our effective tax rate in 2018 to be approximately 24%. We expect to realize approximately $180 million in adjusted tax ratings. Of this amount, we expect to deliver roughly $120 million after-tax or approximately $0.85 to our adjusted EPS in 2018. Additionally, we intend to reinvest approximately $75 million before tax as the benefit to support our two-point strategy. From a cash perspective, we expect our lower tax rate to increase cash from operations by approximately $160 million in 2018.",0.3116114,0.836
DGX-2017-Q4-2018-02-01,35,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Second, we expect unit price reimbursement price shown on our DIS segment to remain less than 100 basis points excluding PAMA, with an additional headwind of approximately 50 basis points including PAMA. In the gone November, we sized the impact of PAMA as approximately 4% of 2018 Medicare revenue from the clinical lab fee schedule and approximately 10% in both 2019 and 2020. Our forecasted impact on the business over the next three years from the fee schedule reduction remains unchanged.",0.4514218,0.0
DGX-2017-Q4-2018-02-01,36,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Third, our revenue guidance for 4% to 5% growth includes all the M&A that we have closed to date including MedXM. We estimate the revenue impact of recently closed acquisitions as well as carry over from acquisitions that closed earlier in 2017 to be roughly 2.5% in 2018. The earnings accretion from these deals will ramp throughout 2018 and into 2019.",0.9948657,0.572
DGX-2017-Q4-2018-02-01,37,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Fourth, our 2018 revenue guidance reflects the classification of patient related bad debt against revenue in accordance with the new revenue recognition standard. Fifth, as Steve noted earlier, we exceeded our $1.3 billion goal of cumulative run rate Invigorate savings to the end of 2017. Our efforts around Invigorate will continue indefinitely as we should. Best-in-class organizations take out at least 3% of cost per year. We believe Quest is a best-in-class organization and will continue to drive operational excellence to drive annual efficiencies of this magnitude.",0.9766983,0.671
DGX-2017-Q4-2018-02-01,38,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As Steve mentioned, given our track record of delivering in this area, going forward we will provide periodic updates in lieu of the specific run rate savings goal. Sixth, as I highlighted earlier and as noted in our earnings release, beginning in 2018, we will exclude ETB from our adjusted EPS calculation. For historical comparisons, our adjusted EPS results for 2016 and 2017 included $0.06 and $0.27 of ETB respectively.",0.8582148,0.128
DGX-2017-Q4-2018-02-01,39,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Seventh, the increase in our CapEx guidance reflects in large part, the planned start of our multi-year new lab construction in New Jersey. Additional investments in our advance and consumer growth strategies as well as final build out cost associated with headquarters moving to Secaucus. And finally, as you think through your models for the first quarter of 2018, please note that to date we have already experienced nearly as much weather impact as we did in the entire first quarter of 2017.",0.6188784,0.807
DGX-2017-Q4-2018-02-01,40,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Before I turn it back to Steve, I would like to provide some final comments on our capital allocation philosophy and 2020 outlook. Our capital deployment philosophy has served us very well over the last several years and remains unchanged. We expect to continue to return the majority of free cash flow to shareholders through a combination of dividends and buybacks. We continue to prefer to use the remainder of free cash to fund M&A activity which we believe will be more robust over the coming quarters in light of PAMA.",0.5434439,0.921
DGX-2017-Q4-2018-02-01,41,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We regards to our 2020 outlook, we remain confident in targets that we have outlined for 2017 through 2020. These targets include a revenue CAGR of 3% to 5% with 1% to 2% growth expected from acquisitions. And adjusted earnings CAGR faster than revenue in the mid to high single digit range. Last quarter, we shared that this outlook implied adjusted EPS in the range of $6 to $7 by 2020.",0.335703,0.802
DGX-2017-Q4-2018-02-01,42,Remarks,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We also shared at that time that we would expect to be towards the lower end of this range given the reimbursement cut associated with PAMA. While the cumulative PAMA headwind to 2020 remains severe, we now believe we will exceed $7 in light of tax reform.",1.2488152,-0.542
DGX-2017-Q4-2018-02-01,44,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Mark. Well, to summarize, we delivered a strong fourth quarter. In 2017, we made great progress accelerating growth and driving operational excellence. Our guidance for the full-year 2018 reflects expectations with this continuation of acceleration of the top line and bottom line growth. Quest benefits from tax reform. And we are investing in our business and our people.",0.0174629,0.98
DGX-2017-Q4-2018-02-01,45,Remarks,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Now we will be happy to take your questions. Operator?,0.6477759,0.572
DGX-2017-Q4-2018-02-01,50,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. Amanda, thank you. Well, we are pleased to be able to provide the guidance for 2018 we just did which is 4% to 5% growth. We feel good about that. Our strategy historically remains in 2018 is a balance between acceleration of our organic growth and also to achieve at least 1% to 2% growth through acquisitions. And as what I said in my remarks, we have exceeded that high end and that range of 1% to 2% through acquisition, but what I will say in that 4% to 5%, you see both. You see an improvement in organic growth. And you also see an improvement in growth through acquisitions and that's in that 4% to 5%. As far as the growth drivers organically, we continue to see good growth in our professional lab services business. We continue to get good interest.",0.3522241,0.992
DGX-2017-Q4-2018-02-01,51,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as we have talked about this - there is a couple of things, one is we have an acceleration in the number of conversations we having with C-suites of integrated delivery system with around their lab strategy. And that hits many aspects of our strategies for growth. First of all, they are quite interested in what we could do with them to make it more efficient and this is our professional lab services business. And so, that has impacted growth in '17 and will continue in '18. Second is we sell them our most sophisticated testing. And so, that acceleration advanced diagnostics will continue as well into '18. And then finally in some cases, like in example of PeaceHealth in 2017, they want us to buy their outreach business. So implied in our guidance is the continuation of that strategy which hits on three aspects of our growth strategy going forward. So, again, a balanced guidance that with both the acceleration of organic growth as well as an acceleration of growth through acquisition. Mark, anything you would like to add to that?",0.3285008,0.986
DGX-2017-Q4-2018-02-01,52,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, I appreciate the comment Amanda that there is lot of moving parts, but on the top line, the restatement of bad debt really should not change the growth in revenue because bad debt is not going to vary dramatically year-over-year. So, the 4% to 5% is a solid number that it doesn't have a lot of moving parts to it. And then in terms of your questions around the future, we would expect more of the same. Continued friendship towards advanced diagnostics, as Steve, said which should benefit our revenue per acq, but also continued strong growth in POS which will offset that - partially from that. And in price, I covered that pretty thoroughly which is more of the same; some headwinds on the non-government side and then the additional 50 basis points coming from PAMA.",0.4861769,-0.052
DGX-2017-Q4-2018-02-01,58,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so we - never volume with requisitions. And what we have also reported is that we continue to see increasingly dense requisitions. So in fact, costs are growing faster than the volume reported. That's really what we do is we do test. So we don't fully understand the trend. We talked a little bit of this, but certainly there is things that are being added. When someone goes in for general healthy checkup whether it's a baby boomer getting the hep C test and that's certainly well back as adding Vitamin B. So, people getting more done when the y go in to get our services in the given encounter. So really we talked about a desire to give you better - inside of the volume was really test, we didn't - found a way to do it yet. So don't read too much into volume as reported by our requisitions. So certainly POS as we mentioned is a double digit grower, but volume trends continue to be solid. We don't see anything that suggests the market shift in utilization. We continue to accelerate our growth and that's what we are expecting during 2018 as well.",0.78594,0.987
DGX-2017-Q4-2018-02-01,62,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Well, Kevin as I mentioned in the remarks, we continue to make nice growth out of our Q-Natal testing and prenatal testing, number one. Number two is [indiscernible] continues to grow. We have got long ways to go as far as testing the baby-boomers in this country. That continues to grow nicely. Prescription drug monitoring continues to be a big grower for us. We are the market leader in that regard, and that's growing strong double-digits. So you look across the Board and many of our diagnostic testing categories, we're getting some nice growth.",0.3031301,0.969
DGX-2017-Q4-2018-02-01,65,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, the first part, Mark will take around what's in our guidance for price, and the second part I will take on where this is all going with transformation of healthcare. Mark?",0.5321252,0.402
DGX-2017-Q4-2018-02-01,66,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. And Ricky thanks for the question. So, on the pricing, I think you are referring to revenue per acq and - which includes mix. Pricing itself well is apples and apples, real price, and it will continue to be less than 100 basis points headwind as we mentioned. Obviously when we narrow the mixed elements, including PLS, including tests, payer mix, density of our acquisitions, we have seen an increase in revenue per acq in that space on mix. So we don't expect any change in trends in 2018 relative to what we have seen in the last couple of years in our business.",0.4593207,0.876
DGX-2017-Q4-2018-02-01,67,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Regarding M&A, there is really not a mixed element of the M&A for the most part, and in certainly the possible acquisition deal that we do, you know, book of business is very similar to our core book of business. Obviously the reimbursement is going to be somewhat different by payer type, but generally the same pricing. So M&A unless it's a very different business like in MedXM or something like along those lines, Med Fusion had a different mix, but generally our M&A will not change revenue direct dramatically. I will turn it back to Steve to answer your further part of your question.",0.6670616,0.84
DGX-2017-Q4-2018-02-01,68,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. News now on these consolidations and particular interest around sponsor health plans and what that segment of the population or the industry could do, we think it's very positive for - the strategy that we've been on for number of years now. So as we've talked about, we as one of our strategies want to be the most consumer-oriented laboratory, we talked about that in our prepared remarks, there are multiple aspects, there is an aspect around our experience, there is an aspect around data, around products, and around information. And I mentioned MyQuest app, and this is making a lot of progress, and 2018 will really be a watershed year of really fulfilling lot of our promises in that space.",0.3192751,0.948
DGX-2017-Q4-2018-02-01,69,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","If we go there, then all of it - it is all about serving the consumer and the customer. And number of these mergers and discussions are all about what needs to do - what needs to happen to get better access for consumers or the consumers getting to be more and more involved in healthcare decision-making. And important to address is we partnered with a number of these players already. So we are in the middle of these discussions. So we are all waiting to see about the merger of CVS and Aetna. We have strong relationships with both. We work with both already. Second is relationship with Wal-Mart. We will continue to extend itself.",0.2210873,0.852
DGX-2017-Q4-2018-02-01,70,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We mentioned our patient service centers opening up in their stores. And also in that regard, we're going to provide health services. And then third is we have the employer business, we sell our [indiscernible] wellness products into large employers. And as we know, 170 million people roughly in this country get their insurance from their employers. And we've been all over this as an opportunity of working with these employers and working with our healthcare insurance partners to do a better job within the cost curve for those corporations, as well as for their employees. And we've actually done this at Quest.",0.7808896,0.866
DGX-2017-Q4-2018-02-01,71,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We've been working on this for a couple or three years. We've changed the organizational model. We've got more data, and we're working with a number of partners, and actually what we have seen is we have been their cost curves. So we're quite excited about these new developments, and we believe we're really strongly positioned to take advantage of those going forward.",0.7943987,0.768
DGX-2017-Q4-2018-02-01,73,Question,2018-02-01,4,2017,Bill Quirk,Piper Jaffray,"Hi, thanks. Good morning everybody. Just a couple of quick ones here; first off; Steve; can you just talk a little bit about M&A deal flow and whether or not any valuations have been reset given PAMA or maybe it's just little too early to see those resets at this point? And then secondly, I know that flu doesn't have a big direct impact on the business, but is there any sort of ancillary testing that you tend to pick up just considering that the very severe season that we're going through right now?",0.2296391,-0.477
DGX-2017-Q4-2018-02-01,74,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So on M&A, we did seven deals. We're now seven deals. That's reflected in our guidance for 2018. That's beyond the 1% to 2% that we've stated as our strategy; we feel good about that. And as we said, the deal flow continues to be strong, and we're optimistic going forward. And there is a lot more interest in what integrated delivery systems will have in their lab strategy going forward, given potential pressure there will be either with PAMA or commercial rates on the ancillary services side. So that continues to be an opportunity for us.",0.3990115,0.934
DGX-2017-Q4-2018-02-01,75,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As far as resets, we already in our modeling are prudent as far as how we price things and work out our - in terms of what we've guided business and we restated for that business in our hands. We do take into consideration what might happen with Medicare rates. And we feel past deals and forward looking deals we will take that in consideration because that's a real consideration that we do consider in the model to make sure we are back any of us we make an acquisition for our shareholders. So, Mark you want to drill in the second part of the question.",0.1591433,0.434
DGX-2017-Q4-2018-02-01,76,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. Steve's points recalled that our valuation really is independent of what the business might look like in their hands. When we go back to Investor Day, we went through an example, so the revenue is still adequate because of commercial payers and then the cost, and even more the portion lower given the economies of scale, and that's how we create value. So really our pro forma P&L looks nothing like the P&L that it was in the hands of the seller. So have things changed? Absolutely. Because we're taking into account to change in government reimbursement which impacts both the seller and the buyer, we've been modeling some potential for that for several years now. So it's not lease, and will be taken that into account, but obviously with the new publication of rates, we're building those rates right now as an assumption and to what the future is, ensuring that we pay appropriately for any acquisition. And then on the full piece scale on",0.3187204,0.748
DGX-2017-Q4-2018-02-01,77,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. We track a number of dynamics in the industry, and we do believe rate is up, that it would impact on - let's just call it activity or utilization into physician's offices. So there's some modest increase from it. But this, as you know, many variables, and as Mark said earlier, when we look at our same-store analysis, we feel that the market is stable. So it's not a big mover, but we did notice the change.",0.198682,0.586
DGX-2017-Q4-2018-02-01,80,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Absolutely, absolutely. So first of all, when we talked about concierge, we talked about advance diagnostics; there's a lot of science. And it is an innovation business. And we have a new leader that stared about a year ago, [indiscernible], and she's updated our strategy, we're putting more resources in it, and a portion of our incremental investment from tax reform benefit will be invested in our business. And as part of it, yes, there is more science, there is just more capability to do test that will bring to the marketplace but the large part of what you also deliver advanced diagnostics, particularly our genetics. It's that whole experience for the patient and making it seamless and easy for the physician that's ordering that test and so what if it's more resources in that part of it, it's the pre-authorization piece, it's the ordering piece, it's the resulting piece.",0.4082372,0.84
DGX-2017-Q4-2018-02-01,81,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So my comment in my prepared remarks had to do with that portion of what we describe is concierge services. The second part of your question had to do with a consumer strategy, we've been on this for a multiple years, we made excellent progress in '17 and in '18 I will tell you by the end of '18 we are going to be long ways along with what our vision was. First of all, it's around the whole experience, we are contemporizing bad experience free unit to this new world. So we enabled in a big way, I mentioned the kiosk and now in about half of patient service centers. We are going to that experiences are completely different experience in the old days and I would argue some portion as market where you have labs that are not nearly our size that can't make these investments so we are really excited about that.",0.2270181,0.817
DGX-2017-Q4-2018-02-01,82,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is the whole information flow, so my question is our app that allows the consumer, the patient to get access for the results we have 5 million users that continue to grow and we will provide more and more capability on that app to schedule appointment, to get your results and to do other things in your healthcare going forward. So we are excited about that.",0.6477759,0.395
DGX-2017-Q4-2018-02-01,83,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And third, as we bring new products to the marketplace, we've tested this over-the-counter, direct-to-consumer models in a number of states will realize there is a market where consumers want to directly order cholesterol testing or glucose testing, hemoglobin A1c or such transmitted diseases without going to physician. So we are going to grow that business as well. So you put that altogether and what you are going to get from Quest Diagnostics is completely different experiences of different set of capabilities in a brand but consumers will recognize and as healthcare continues to evolve, where more and more choice will give to consumer who they use, they can look for the best value and we offer the best value on the planet.",0.7281713,0.967
DGX-2017-Q4-2018-02-01,84,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We are proud of that and it's getting better every day. Now the second part of this is related to you take all that data and you take that experience and you combine it with healthcare services and retail healthcare services are the basic healthcare services. This is where we have an amazing capability, we have over 10,000 phlebotomists, we have over 10,000 healthcare workers that going home already you mentioned our life insurance business, our wellness business. And so, those 20,000 employees and also with their other let's just call it operational capabilities are 3500 per years and our cost centers can be applied in managing lives in a better way and so the ambition we have with our partner with Wal-Mart and other partners is to take our gain up, point us in direction and provide those healthcare services to surround those lives in a more efficient effective way and typically as we know in healthcare 5% of the population and 50% of cost and we believe with better data, with better oversight over those individuals in a convenient good access location, we can do something about it and we have a lot of assets to bring the table.",0.1321252,0.987
DGX-2017-Q4-2018-02-01,85,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, this is what we called our data in extended care service portion of our strategy and obviously we are going to need some partners we benched in a few and I'm sure there is going to be many others because healthcare is local I mean what we do and different space will be different, so we are excited about the prospects of leveraging our capabilities and we see this is where the market is going. It's all about the consumer, it's all about better quality, lower cost and we are nicely positioned in that respect.",0.3670511,0.944
DGX-2017-Q4-2018-02-01,90,Question,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, I appreciate the question. I can assure you with that plenty of motivation to be price disciplined for many years. So it doesn't change that. I think that PAMA gives as I described in JP Morgan is that the payers now are understanding that the market is involving and this world where somehow the commercial rates for though independent labs obviously for a lot of the hospitals and some of the physician mandatories and so on, the rates that are still well higher CMS rates but certainly for the independent lab it's been lower and there is full transparencies that we can go under them and say here is the data that was collected by CMS you know, where the market is and so there is no one certainly around where ratings are compared with the rest of the commercial market and therefore let's talk about what's there, let's talk about how we partner together in the long run you know, that we succeed and failed together.",0.4968404,0.756
DGX-2017-Q4-2018-02-01,91,Question,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So I might feel good to try to get some sort of price concession in the short run, but you know, that's not your best long-term interest because we are part of the solution, we give the best value you know, that when you drive more volume through one of the national labs, it's much better than it's going somewhere else. Everything from the data we provide to the services that Steve mentioned, which differentiate as per many of the other providers and obviously to the cost. So, much more of an opportunity to talk partnership, get the conversation away from price or if anything, get the conversation towards, we need prices to migrate towards that need. You can't have a subset that's significantly lower and a subset significant higher getting to an average everyone is kind of be in a market price, which ultimately is what CMS wants to get to, so that enables the conversation to enhance the conversation that we've been having for several years.",0.6662717,0.855
DGX-2017-Q4-2018-02-01,92,Question,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"It doesn't change our motivation which has been very strong and if you look at what we've accomplished over the last couple of years, we did significantly mitigate the prices that we are facing four, five years ago through that discipline and when we talked about the fact that some prices aren't sufficient then we will walk away from volume if we don't feel that's appropriate. Not volume at any price it's like greater than therefore we have shown a desire, willingness and descended our value proposition to those payers and I think we are viewing the results.",0.9170616,0.959
DGX-2017-Q4-2018-02-01,95,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so for '18 I assume the continuation of our setup if you will with our access through the national players as well as through the regional players. I would argue that our access through healthcare insurance has gotten better over the years and obviously our objective which we talked about is to continue to get a better test 2018 to 2019. So what I'm saying in that regard is we can see you enjoy from a national exclusivity relationship with Aetna that's implied in our guidance for 2018 we feel good about that relationship is potential merger with CVS, we think it is an interesting development that might happen. We have a strong working relationship with CVS as well, so feel good about that and that's assumed in our guidance for '18.",0.1835255,0.973
DGX-2017-Q4-2018-02-01,96,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is we talk about that is how we know that a contract with United, with our largest dependent expires in '18. We love to get access through United as one of the national partners. We've described that we are working on that, we feel good about progress make. We have nothing to share there, but we continue to be hopeful that as we enter '19 we will have strong access and we do have access already with United Lives as another network provider in some states and for some carve-out plans that they have, and as I mentioned, the relationship continues to get stronger. We've announced a strategic relationship with Optum lifecycle management that continues to go well. Optum continues to buy physician practices that depending on our biggest customers in those physician practices so that will continue to build. And then, throughout the rest of our hundreds of contracts we have, you should assume in '18 that we have good expansion of those, and good - continuation of those and the price assumption that Mark talked about is the continuation of the access to our many partners we have throughout the United States.",0.521911,0.988
DGX-2017-Q4-2018-02-01,97,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And just to add to that specifically interesting question. We gave a pretty broad range 3% to 5%. So 200 basis points, so well I can't tell you explicitly what that means for getting that in the United or any other sort of potential changes. I can tell you that it's likely covered within that range whatever scenario might happen in within 2019 and beyond and then if we do get to appoint where there is something to share as Steve mentioned we will consider some change like that materially offset. We would communicate in a very time with fashion like you know, what's going on at that point and obviously give you some idea of what we think it might mean and then obviously as we got further in the year, we are planning another Investor Day in the call. We will give more detailed update on what the specs are as we near given everything we know at that time.",0.571485,0.949
DGX-2017-Q4-2018-02-01,99,Question,2018-02-01,4,2017,Ralph Giacobbe,Credit Suisse,"Thanks. Good morning. I was hoping you can talk a little bit about expectations around, wage growth just given tight labor market. Do you expect pressures there and then maybe what you see is underlying wage growth over kind of the next couple of few years?",0.0714804,0.889
DGX-2017-Q4-2018-02-01,100,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Ralph, we continue to look at our competitiveness of our wages to our broad workforce we employ about 45,000 people many of which are frontline employees. We believe we've been competitive in the past and the expectation for 2018 is the inflation we have on wage bill is about what we've been running at. Matter of fact, we track attrition of our employees and we put a lot of time in energy into retaining our employees. So we've actually spent a lot of time as a management team looking at the other aspects like people come to work around things like scheduling and the environment and their supervisors and so actually we've seen a slight reduction in our attrition of employees so forget about the value proposition we have on employees.",0.2576606,0.859
DGX-2017-Q4-2018-02-01,101,Answer,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then prospectively, we think employees until has have better and better about working across diagnostics we run an engagement survey where we have a phenomenal participation rate about 90% of employees show up in a survey. And our engagement course for 2017 has never been higher; they are much higher than in '16. So we had nice pickup in engagements course and as you see in our announcement this morning we want to thank all those employees because these are the frontline employees in many aspects, so we have more attrition in other places that has helped us through this journey we've been on and so the $500 recognition that we are going to provide this year that's tagged to companywide initiatives. We think we will again get a lot of this people a good feeling about working at Quest, so we want to thank them for their hard work. So 2018 is above what you see in the past in terms of inflationary pressure on our wage though.",0.2299835,0.968
DGX-2017-Q4-2018-02-01,102,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And to answer I think probably an impressive question, a many of our wage employees earn about, where at the middle of wages are targeted to end up, we also you know, obviously have many week employees who are not in the states or the cities that have this increase in minimum wage. So we are already above that market. If you are thinking about minimum wage and so when we look at the pressure on our wages certainly that's not a huge factor. But, the timing of the labor force is going to bring, unknown. But at this point, we've not experienced any dramatic pressure.",0.8404423,0.452
DGX-2017-Q4-2018-02-01,103,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"To Steve's point certainly wages are one part of the equation, but we also provide health benefits for our employees and it's highly valued. And then the work experience itself is greatly improving. I'll give you one example, a lot of the investments we're making in our peaks and service as Steve referenced through enablement, we are also doing some of significant refresh to those centers, updating them et cetera. That makes phlebotomists work experience much more positive as well. They're really like not having to handle as many of administrative duties, they now can be done electronically and they can focus on phlebotomy, so there're other things that we're doing to offset some potential wage pressure but certainly we addressed where we needed to. So, market adjustments and we're not exposed heavily to inflation from general wage increases because we already generally pay a lot of our people at that minimum wage.",0.78594,0.982
DGX-2017-Q4-2018-02-01,106,Answer,2018-02-01,4,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, well, it's been nature's cold. I mean, we had precipitation events, you had [indiscernible] in Northern Florida, though certainly we had a number of weather events from ice to snow in areas which is unusual to some snow in Massachusetts and then some cold, although we know it's hard to really attribute cold, I mean, there are some times when it's been so cold where everything is closed, schools are shut down and so on. But generally cold, warm I guess some impact, we don't really calculate on our weather. So weather is more we see a day, weather is something going on that it have its travel to the extent that we look at that day's activity, we say, ""Hey, there's definitely an impact, this is out of the norm,"" and so it's - there are some to that calculation, but we've been doing it long enough that we feel it's directionally crap. We just wanted people to be aware as they're thinking about the modeling from a various quarters that we don't know what the next couple months are going to blame, but last year January was pretty benign. We didn't get our weather until later in the quarter, and this year we've already had handful of weather events that kind of puts us already where we were for the full quarter last year.",0.0367299,0.727
DGX-2017-Q4-2018-02-01,108,Closing,2018-02-01,4,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. Well, thanks again for joining us today. We appreciate your support and interest, and have a great day.",0.5940692,0.955
DGX-2020-Q4-2021-02-04,3,Remarks,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"Thank you and good morning. I'm on the line with Steve Rusckowski, our Chairman, Chief Executive Officer, and President; and Mark Guinan, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release.",0.9949722,0.66
DGX-2020-Q4-2021-02-04,4,Remarks,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"Actual results may differ materially from those projected. Risks and uncertainties, including the impact of the COVID-19 pandemic that may affect Quest Diagnostics' future results include, but are not limited to those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K.",0.2974332,-0.065
DGX-2020-Q4-2021-02-04,5,Remarks,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"The company continues to believe that the impact of the COVID-19 pandemic on future operating results, cash flows, and/or its financial condition will be primarily driven by the pandemic's severity and duration, healthcare insurer, government and client payer reimbursement rates for COVID-19 molecular tests, the pandemic's impact on the U.S. healthcare system and the U.S. economy, and the timing, scope, and effectiveness of federal, state and local governmental responses to the pandemic, which are drivers beyond the company's knowledge and control.",0.6041281,0.0
DGX-2020-Q4-2021-02-04,6,Remarks,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS from continuing operations and references to adjusted EPS refer to adjusted diluted EPS from continuing operations. References to base testing volumes or base business refer to testing volumes, excluding COVID-19 molecular and serology testing volumes.",0.556761,0.0
DGX-2020-Q4-2021-02-04,7,Remarks,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"Growth rates associated with our long-term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth are compounded annual growth rates. Finally, revenue growth rates from acquisitions will be measured against our base business.",0.0457793,0.945
DGX-2020-Q4-2021-02-04,8,Remarks,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"Now, here is Steve Rusckowski.",0.8290553,0.0
DGX-2020-Q4-2021-02-04,9,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Shawn, and thanks everyone for joining us today. So, in the year dominated by the pandemic, Quest brought critical COVID-19 testing to our country, and delivered record revenues, earnings, and cash from operations for the fourth quarter and the full-year 2020. The pandemic has tested our nearly 50,000 employees and they have responded as heroes, by developing COVID-19 tests, building test capacity, innovating new testing models with our retail partners, transporting specimens, delivering results, and of course, supporting our customers.",0.7584843,0.866
DGX-2020-Q4-2021-02-04,10,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We finished the year as one of the country's leading providers of COVID-19 testing. I'm very proud of what we have achieved and optimistic about what we can accomplish in 2021. So, this morning I'll discuss our performance for the fourth quarter and full-year 2020, our ongoing role in the COVID-19 pandemic, and update you on our non-COVID base business and then Mark will provide more detail on our financial results and our financial outlook for the first half of 2021.",0.8197694,0.817
DGX-2020-Q4-2021-02-04,11,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, before we get into the details of the quarter and the full-year 2020, we wanted to share our perspective on the new strategy for fighting the COVID-19 pandemic proposed by the new administration. We are pleased by the efforts to expand access to testing across the country, especially in the underserved communities where there are known disparities in health care.",1.2075783,0.796
DGX-2020-Q4-2021-02-04,12,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We support the new administration's approach to controlling the pandemic by expanding the availability of testing supplies; enhancing laboratory testing capacity; and ensuring a clarity of messaging about the use of tests and insurance coverage. We also support the efforts of COVID-19 pandemic testing board and we look forward to additional details in days and weeks ahead.,0.921911,0.848
DGX-2020-Q4-2021-02-04,13,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now turning to our results, continued high demand for COVID-19 testing drove our performance throughout the quarter and the second half of the year. For the fourth quarter, total revenues grew by more than 55% to $3 billion, earnings per share increased by more than 126% on a reported basis to $4.21 and nearly 168% on an adjusted basis to $4.48.",1.2958814,0.422
DGX-2020-Q4-2021-02-04,14,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","For the full-year 2020, total revenues grew by more than 22% to $9.44 billion, earnings per share increased by nearly 71% on a reported basis to $10.47, and more than 70% on an adjusted basis to $11.18.",1.324547,0.511
DGX-2020-Q4-2021-02-04,15,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Cash provided by operations increased by more than 61% to $2 billion. We announced today that we are increasing our quarterly dividend by 10.7% to $0.62 per quarter. This is our tenth increase since 2011. Additionally, our Board of Directors has increased our share repurchase authorization by $1 billion. The increased authority is on top of the approximately $900 million that was available as of December 31, 2020.",0.4741351,0.872
DGX-2020-Q4-2021-02-04,16,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In the fourth quarter, we continued to see strong COVID-19 testing volumes. Demand clearly spiked as the virus surged and people got tested in advance of holiday gatherings. We performed an average of 135,000 COVID-19 molecular tests today in the fourth quarter, well below our current capacity. We continue to innovate to further expand capacity, reduce turnaround times, and gain efficiencies.",1.260626,0.963
DGX-2020-Q4-2021-02-04,17,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And finally, we are focused on addressing health disparities in underserved communities through our Quest for Health Equity initiative. We recently held our first COVID-19 testing event at Abyssinian Baptist Church in Harlem in conjunction with leading Black Clergy and the United Way of New York City. Testing is more important than ever as the vaccines roll out over the coming months to get at-risk patients into care when therapy can still be effective and to isolate infected individuals.",1.16771,0.831
DGX-2020-Q4-2021-02-04,18,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We expect 2021 to be another very strong year for COVID testing, although demand for COVID testing is likely to decline throughout 2021 as more people become vaccinated and fewer new cases are reported. We believe that COVID-19 testing will continue into 2022.",1.4500824,0.475
DGX-2020-Q4-2021-02-04,19,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, turning to our base business, organic volumes recovered rapidly throughout the summer and fall. However, the recovery stalled at the end of November and into December, due to the surge in COVID-19 infections across the country. Mark will provide and share more details regarding the trends in our base business later. With that we continue to make progress on our two-point strategy to accelerate growth and to drive operational excellence.",1.183196,0.872
DGX-2020-Q4-2021-02-04,20,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me share some of the highlights from our strategy to accelerate growth. Our M&A pipeline remains strong, and we achieved our goal to exceed a 2% growth CAGR from acquisitions in our base business over the last three years. We continue to see increasing interest from our hospital partners about how we can help them with their lab strategy, which includes discussions around both outreach acquisitions and professional lab services arrangements.",0.1947282,0.948
DGX-2020-Q4-2021-02-04,21,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The deals we closed in 2020, particularly the Memorial Hermann outreach and MACL acquisitions, position us well to achieve our M&A growth target this year. We remain confident that this year we will execute on more similar types of outreach or tuck-in deals in our pipeline.",0.5446458,0.878
DGX-2020-Q4-2021-02-04,22,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Last year was also a record year for our professional lab services strategy, or PLS, and this is the business that partner with hospitals to help them run their inpatient labs more efficiently. In the fourth quarter, we announced two small PLS partnerships with hospital systems in New York and Indiana; and then in December we announced our largest PLS relationship to date with Hackensack Meridian Health, the largest integrated health network in New Jersey.",0.4286656,0.869
DGX-2020-Q4-2021-02-04,23,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest will manage laboratory operations and perform reference testing for 11 Hackensack Meridian Health hospitals. We also continue to execute our health plan strategy by shifting the dialogue to value-based contracting efforts from the recent past when discussions focused largely on price. We continue to make progress with our new strategic relationship with Anthem to improve quality and efficiency in the delivery of laboratory services. We're advancing our position with United Healthcare within its Preferred Lab Network, and also are building momentum with many of our other national and regional health plan partners.",0.9060956,0.912
DGX-2020-Q4-2021-02-04,24,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally, we continued to grow our direct-to-consumer services in the quarter. In December, we announced our [zero] out-of-pocket QuestDirect COVID-19 testing option. This service offers appointment scheduling and specimen collection at more than 500 participating Walmart drive-thru locations. And also in the quarter, we saw an acceleration in the number of consumers signing up for our MyQuest patient portal.",0.6764415,0.077
DGX-2020-Q4-2021-02-04,25,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Today, roughly 15 million patients have a MyQuest account, an increase of nearly 2 million since October. And recent market research indicates that our brand is strong and has strengthened over the past year, with industry leading net promoter scores. We have a strong foundation to accelerate growth in our consumer offerings.",0.7594728,0.923
DGX-2020-Q4-2021-02-04,26,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second part of our two-point strategy is to drive operational excellence. We continue to pursue our goal to reduce our cost base by 3% per year. We also see more opportunities ahead to drive further productivity gains and at the same time enhancing the customer experience. Once again, our Invigorate program delivered approximately $200 million of cost savings in 2020. And we continue to see more opportunities to deliver future efficiencies in our cost base.",0.5680395,0.95
DGX-2020-Q4-2021-02-04,27,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our new flagship laboratory in Clifton, New Jersey went live on January 4. This is the most highly automated laboratory in our network. And over the course of 2021, we expect to consolidate volumes from Teterboro, Baltimore, and Philadelphia labs to this state-of-the-art facility.",0.7103789,0.103
DGX-2020-Q4-2021-02-04,28,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, before turning it over to Mark, I'd like to announce that we plan to update you on our strategy and market overview at our upcoming virtual Investor Day and it will be held on Thursday, March 11. So, stay tuned for more details. Mark?",0.831631,0.361
DGX-2020-Q4-2021-02-04,29,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the fourth quarter, consolidated revenues were $3 billion, up nearly 56% versus the prior year. Revenues for Diagnostic Information Services grew approximately 58%, compared to the prior year, which reflected ongoing demand for COVID-19 testing services, offset by a modest decline in our base testing revenue. Volume, measured by the number of requisitions, increased 26.8% versus the prior year with acquisitions contributing 4.5%.",0.9660348,0.586
DGX-2020-Q4-2021-02-04,30,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As we highlighted in our 2020 outlook update in mid-December, organic testing volumes ordered in our base business were down mid-to-high single digits versus the prior year in October and November. The recovery stalled in late November with organic testing volume trends down high-single-digits versus the prior year in December due to the surge in new infections across the country.",0.10703,-0.202
DGX-2020-Q4-2021-02-04,31,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Additionally, many state and local governments imposed new orders designed to reduce the transmission of COVID-19. Compared to December, organic base volume trends remained relatively steady in January versus our pre-pandemic 2019 baseline. For the entire fourth quarter, total testing volumes declined roughly 2% versus the prior year and benefitted from M&A and new PLS partnerships that began in 2020. Excluding M&A and new PLS wins, base testing volumes declined approximately 8% in Q4 versus the prior year.",1.7578989,0.847
DGX-2020-Q4-2021-02-04,32,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"COVID-19 testing continued to be a meaningful contributor to volumes during the fourth quarter. We resulted approximately 12.5 million molecular tests and 1 million serology tests, contributing approximately 29% to volume growth in Q4. We exited the fourth quarter averaging approximately 130,000 COVID-19 molecular tests and 10,000 serology tests per day.",1.6868088,0.599
DGX-2020-Q4-2021-02-04,33,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per requisition increased 25.2% versus the prior year driven largely by COVID-19 testing. This was partially offset by unit price headwinds of approximately 1.6% in the fourth quarter, which includes the impact of PAMA and was in-line with our prior expectations. Reported operating income in the fourth quarter was $795 million or 26.5% of revenues, compared to $363 million or 18% of revenues last year.",1.835703,0.273
DGX-2020-Q4-2021-02-04,34,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On an adjusted basis, operating income in Q4 was $860 million or 28.6% of revenues, compared to $329 million, or 17% of revenues last year. The year-over-year increase in operating margin was driven by the strong revenue growth in the fourth quarter, due to continued high demand for COVID-19 testing. Reported EPS was $4.21 in the quarter, compared to $1.86 a year ago.",1.2132701,0.772
DGX-2020-Q4-2021-02-04,35,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Adjusted EPS was $4.48, compared to $1.67 last year. Cash provided by operations was approximately $2 billion for the full-year versus $1.24 billion in 2019. As a reminder, in the fourth quarter, we returned approximately $138 million of provider relief funds we had received under the CARES Act. Our financial position remains very strong.",1.4921011,0.887
DGX-2020-Q4-2021-02-04,36,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As we announced this morning, we increased our quarterly dividend approximately 10.7% to $0.62 per share, and the board expanded our share repurchase authorization by $1 billion, so we now have nearly $2 billion available for future share repurchases. We resumed share repurchases in Q4 and bought back 250 million of company stock during the quarter.",0.4154818,0.836
DGX-2020-Q4-2021-02-04,37,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Turning to guidance, there continues to be a lot of uncertainty around the trajectory of the pandemic and its impact on COVID-19 testing trends, as well as further recovery in our base business. Therefore, we are currently providing an outlook for only the first half of 2021 and expect to provide updates as the year progresses.",1.1248025,-0.077
DGX-2020-Q4-2021-02-04,38,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our outlook for the first half of 2021 is as follows: Revenue is expected to be between $4.85 billion and $5.15 billion, an increase of approximately 33% to 41% versus the prior year. Reported EPS is expected to be in a range of $5.07 and $6.07, and adjusted EPS to be in a range of $5.90 and $6.90. Cash provided by operations is expected to be at least $800 million; and capital expenditures are expected to be approximately $200 million.",1.0059242,0.318
DGX-2020-Q4-2021-02-04,39,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The demand for and duration of COVID-19 testing, as well as the continued recovery in the base business, are significant swing factors that remain challenging to forecast. With that high degree of uncertainty in mind, please consider the following: Our first half outlook generally assumes a gradual improvement in base testing volumes, but we expect the base business to remain below our pre-pandemic 2019 baseline throughout the first half of the year.",1.5706951,0.45
DGX-2020-Q4-2021-02-04,40,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"COVID-19 molecular testing volume is averaging roughly 100,000 tests per day in the first half of the year. However, we expect average daily volumes to decline throughout the first half of 2021 as more people become vaccinated. Therefore, we assume COVID-19 molecular volumes will be lower in the second quarter, compared to Q1. COVID-19 serology testing volume is averaging 15,000 tests per day for the first half of 2021, with demand expected to increase modestly throughout the first two quarters of the year.",1.4170616,-0.103
DGX-2020-Q4-2021-02-04,41,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Given the strength of our financial position and high cash balances, we expect to complete a larger amount of share repurchases in 2021 than we have done historically, while maintaining significant flexibility to execute on our M&A pipeline. However, at this point our EPS ranges only assume enough share repurchases to maintain a stable share count. We expect to share more details about our capital deployment priorities at our upcoming Investor Day in March.",1.0774092,0.937
DGX-2020-Q4-2021-02-04,42,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"While we aren't providing a detailed outlook for the full-year at this time, I'd like to offer some additional considerations for 2021. As a reminder, there will be no Medicare reimbursement cut under PAMA this year given the one-year delay included in the CARES Act. We expect organic base testing trends to slowly recover throughout the year with volumes likely approaching a full recovery, compared to our 2019 baseline by the end of the year.",1.6334913,0.161
DGX-2020-Q4-2021-02-04,43,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"If the country vaccinates a significant portion of the population by the summer, we would expect a continued decline in COVID-19 molecular testing volumes in the second half of 2021, compared to our expectations for the first half. Similarly, demand for COVID-19 serology testing is likely to wane in the back half of the year.",1.2405213,0.077
DGX-2020-Q4-2021-02-04,44,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Finally, COVID-19 molecular reimbursement is likely to trend lower in 2021, compared to last year. As many of you know, beginning January 1, CMS moved to a new reimbursement model, with a rate of $100 for all tests reported within two days and $75 for all other results. Several commercial payers have now moved to this new reimbursement model as well. Also, while we are encouraged that HHS now plans to extend the public health emergency throughout 2021, prospective changes to COVID molecular reimbursement are still possible.",1.1169036,0.128
DGX-2020-Q4-2021-02-04,45,Remarks,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Furthermore, direct client bill reimbursement for COVID testing services remains competitive.",1.1465245,0.178
DGX-2020-Q4-2021-02-04,47,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Mark. Well to summarize, I'd like to thank all Quest employees who have worked tirelessly over the past year. They have delivered a significant portion of the country's COVID-19 testing, while serving the needs of people who rely on Quest every day. Thanks to their heroic efforts, we delivered record revenues, earnings, and cash from operations for the fourth quarter and the full-year 2020.",1.583196,0.946
DGX-2020-Q4-2021-02-04,48,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In light of the company's strong financial performance, we have increased our dividend and share repurchase authorization while maintaining flexibility to pursue our M&A strategy. We look forward to sharing a more in-depth update on our market views and strategy at our upcoming virtual Investor Day to be held on Thursday, March 11. Stay tuned for additional details on that day.",1.7074135,0.896
DGX-2020-Q4-2021-02-04,49,Remarks,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, we'd be happy to take your questions. Operator?",1.8421746,0.572
DGX-2020-Q4-2021-02-04,52,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Mark, you want to start it?",1.2310427,0.726
DGX-2020-Q4-2021-02-04,53,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So, you know, we are expecting, you know, to still do quite well in terms of reimbursement in the near term. We believe we can meet the turnaround times, certainly the threshold that's required to be eligible for the higher rates, and then we get paid, obviously, based on the individual tests.",0.4960506,0.19
DGX-2020-Q4-2021-02-04,54,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, you know, we're still thinking in the near term that our average weighted reimbursement is going to be pretty strong, but we also recognize the reality, you know, the pressure on the industry, from all the various payers, especially the commercial payers, and so therefore, as we mentioned, you know, throughout the first half of the year, we would expect, you know, some reduction in that reimbursement, not something, you know, that would be momentous, but certainly some downward pressure.",0.4703791,0.913
DGX-2020-Q4-2021-02-04,55,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And as we said, the client area is very, very competitive. So there's, you know, quite a few labs at this point, given the demand that have significant capacity. And so therefore, in the [client area] it's very, very competitive. You know, in terms of your questions, I'm sure you can appreciate Ralph that first off, we don't feel we're getting paid excessively for COVID PCR, and we feel like we're being paid appropriately. But even if you could exactly forecast the volume of our COVID testing, and forecast the base business, you know, over a period of time, which obviously would be nearly impossible, you know, I'm not sure that we need to trade off anything.",1.2503949,0.939
DGX-2020-Q4-2021-02-04,56,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're very happy with the relationships that we built, as Steve mentioned, with the payers, we've moved away from a focus on price and move toward more of a partnership and a, you know, alignment around value creation, where, you know, they're looking for us to save the money and create value and big piece of that is moving more work to us because we're already - they're very, you know, high value compared to the rest of the industry and, you know, possible choices for patients. So, you know, good question, Ralph, certainly appreciate it, but for practical and for strategic reasons, because of where we think we are with the payers already with some of these new contracts, certainly not something that we're looking to pursue right now.",0.660626,0.671
DGX-2020-Q4-2021-02-04,57,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me just add to that. Speaking to demand, [indiscernible] shares that over the course of the last 10 months, we've brought up our capacity considerably, and we're going to continue to build it. And the reason for that is, we want to continue to be prepared in the event that we do have another surge. And then secondly is, we want to make sure we really have a capability to meet turnaround times that are expected in the market.",1.7512356,-0.126
DGX-2020-Q4-2021-02-04,58,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And over the last 10 months, obviously, a lot of retesting has been for the clinical purpose and what we believe as we entered the second half, and we're having many discussions in this regard, there's going to be a lot more demand for return to work programs with employers, which have been pushed out, as you all know, return to leisure activities, there's a number of cities that have large tourism bases that are thinking about what they need to do to get people back into those venues.",1.0560132,0.927
DGX-2020-Q4-2021-02-04,63,Question,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Hey, good morning. This is Justin Bowers on for Pito. Just with respect to the guide, can you kind of frame the high-end and the low-end for us in terms of your testing assumptions, and then also the through process on the increase in serology testing through the quarter?",0.5963665,0.772
DGX-2020-Q4-2021-02-04,64,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. Sure Justin. So, you know it's multivariable. So there's several ways you could come to the high and low-end. So, what I would say is, you know, they're all based on the three major drivers with most of it being on the base volume recovery, and the level of PCR, you know, volume to lesser extent, serology. So, you know, if we don't see a significant fall off from where we stand today, in PCR, or if it, you know, surges up again, you know, because of these variants, or some other unknown factors, certainly that would take us, you know, to the higher-end combined with, you know, if the base business also were to continue to recover and not, you know, go the opposite direction as COVID surged again.",1.1477093,-0.572
DGX-2020-Q4-2021-02-04,65,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, there is some negative correlation, obviously, between the two. But if they both move in the same direction, that would move us to the higher-end. And then if for some reason COVID fell off markedly, even more than we're planning, and as we talked about, we are planning for a decline over time in the first six months, as that midpoint, and the base business did not show recovery, or even, you know, potentially take a little bit of step back for economic or other reasons.",1.5864929,-0.285
DGX-2020-Q4-2021-02-04,66,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And that would take you to the low end, but you know, I can't at this point, provide exact, you know, changes in the base and COVID, because, obviously, there's multiple ways to get to either one, but directionally that's what, you know, [indiscernible] that our guidance with the midpoint being, as I said, you know, a modest recovery, but not full for the first six months of the base business. And then some step off, but still significant COVID testing for the first six months with the second quarter being, you know, markedly lower than the first quarter.",1.3349131,0.907
DGX-2020-Q4-2021-02-04,67,Question,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Okay, got it. And then just to clarify the earlier comments, it sounded like the base business right now is kind of running stable month-over-month from December levels, are we interpreting that correctly? And then, just in terms of the molecular tests, reported on the website at, you know, 32.8 million is that the right number, look like kind of a huge step-up from February to January, but more importantly is that kind of where you guys are now for total molecular? And I'll hop back in queue. Thank you.",2.1196682,0.625
DGX-2020-Q4-2021-02-04,68,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. Steve, do you want to take that or would you like me to.",1.0184514,0.66
DGX-2020-Q4-2021-02-04,69,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well let me - the step-up is, you know the step-up that we've seen based on the strong delivery that we had in the fourth quarter in the beginning of January. So, we are - as I said in my introductory comments, you know, we are one of the leading providers of COVID-19 testing. Second is, it does not include serology and did ask a question about serology, because we do believe there'll be an increasing role of serology throughout 2021.",1.276112,0.866
DGX-2020-Q4-2021-02-04,70,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We seem to see some early indications that there's interest in understanding whether you have the antibodies or not, which might inform patients and physicians around, you know, their urgency of getting vaccinated. And at the same time, we're bringing out a new capability called [quant serology] testing, and this will allow physicians and patients to see if in fact, they do get the spike protein from the vaccines. And we'll be bringing that out at platforms in the next few weeks. And you know, this can help us, you know, determining the vaccine is being effective.",0.9917628,0.778
DGX-2020-Q4-2021-02-04,71,Answer,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"So, we do believe that there will be some increased demands for serology, and this is on top of what we already do. And serology is providing a really important role for management of the disease, overall surveillance, epidemiology, and in measuring the response of what's happening pre and post-vaccinations and broad population. So, we believe there's an opportunity in front of us in 2021 in that regard.",0.5498809,0.402
DGX-2020-Q4-2021-02-04,72,Answer,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"And Justin, just to close out on your other question, yes, 32.8 million was the total through as of Monday, and that was up 1.8 million over the prior two weeks. So, about 130,000 a day in the prior two weeks. Operate our next question.",0.1410426,0.0
DGX-2020-Q4-2021-02-04,75,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, Jack.",1.1647446,0.697
DGX-2020-Q4-2021-02-04,76,Question,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hey, good morning. Steve, you mentioned the focus of the new administration on COVID testing, can you talk about how you think Quest role might change at all, serving the pandemic? And if we start to see greater adoption of home testing, how do you think Quest is going to be positioned for that?",1.3149918,0.296
DGX-2020-Q4-2021-02-04,77,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, so I think, you know, the new administration is leveraging what we've done in the past as a country and as an industry, and taking it to the next level. I mean, you see the capacity that's out there around the country. Back a few weeks ago, we were doing about 2 million COVID-19 molecular tests. So, obviously up considerably from where we all started last March. But going forward, Jack, I do see that there'll be a change beyond the PCR test.",0.8751236,0.776
DGX-2020-Q4-2021-02-04,78,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As I mentioned earlier, now there's going to be a greater demand, you know, for programs that get to portions of the population that help us get back to work, back to leisure activities, get back to life. And so, we're having a number of dialogues around that. And that will include the role of antigen testing, and more rapid testing workflows that allow us to see if the fact a person that wants to engage in whatever the activity is, is negative and safe for a reasonable period of time to participate.",0.9153213,0.892
DGX-2020-Q4-2021-02-04,79,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, when we get into that world, you know we'll obviously be providing the testing, but as I said earlier, there's a number of services, and also IT solutions that you need to provide. And, like so much in healthcare, you see one, but we're currently engaged with a number of organizations, a number of municipalities, and a number of corporations, and what they will be doing in this regard, particularly in the second half.",1.0388797,0.914
DGX-2020-Q4-2021-02-04,80,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I think, you know, the first quarter is outlined in our guidance [when we] start to see improvement as we get into the second quarter. I think the second quarter will be a telling quarter for us all. And we do see a lot of people getting prepared for, you know, better infection rates, you know, better position for populations to get back to work life and leisure activities, and we're going to start to see more of that and Quest has a significant role in helping in that regard.",0.9169687,0.903
DGX-2020-Q4-2021-02-04,81,Question,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Great. And then just to follow up, I have a two-parter on unit pricing. I was curious if you could weigh in, do you have any notable commercial contract renewals in 2021? And then maybe more broadly, as you have discussions with commercial payers now, you know, do you feel like you have a little more of a, you know good footing you know in terms of negotiating price given, you know, the role the labs have served, you know, amidst the pandemic?",1.2270181,0.945
DGX-2020-Q4-2021-02-04,82,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","You know, let me start with where you ended, I think our relationship with health plans has never been better. As you've seen over the last number of years, we've increased our presence, we have the best access to lives now that we've had in over a decade. And so, we are in a very strong footing. And also, during the pandemic I'll share that we were deeply engaged with many of the plans of what they needed to take care of their membership, and also their employees.",1.183196,0.941
DGX-2020-Q4-2021-02-04,83,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the relationship is continued to strengthen. And as I said, in my introductory remarks, and Mark said, as well, we're shifting the dialogue away from exclusively price to the value we deliver. And when you go back to what we talked about in the past around what we bring to the table in terms of our value proposition around quality, our service performance, our innovation, all at a very affordable price, we believe our value proposition is really second to none. And as I said, you know in the course of the last year, we've done service, look at our reputation in the industry and net promoter scores, and those are quite strong.",1.1146623,0.9
DGX-2020-Q4-2021-02-04,84,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, when you bring those facts to the table Jack, our position in terms of working out, the forward-looking relationships has, you know, provided a much stronger foundation, and a better understanding on the other side that we really do deliver a lot more value. So, we're in a good position with our plans. We're in good position with our contracts. We obviously don't provide specific details, but we feel very good about that.",0.7963756,0.907
DGX-2020-Q4-2021-02-04,86,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, Mark anything you could like to add there?",0.6176935,0.625
DGX-2020-Q4-2021-02-04,87,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So Jack, I understand the question and several years ago, I think there was an expectation where, you know people holding their breath, every time we extended a contract with a major payer because it would imply some sort of major price concession. I can tell you, you know, this has become largely invisible to you all, you know unless we talk about it like Anthem, which was really a new contract and brought together a number of states under a single contract, as opposed to having, you know different periods of time in which we were negotiating across the Anthem network.",0.7124803,0.66
DGX-2020-Q4-2021-02-04,88,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We just extended with a major commercial payer. You didn't hear about it, because there was no price concession. And in fact, we made huge headway with this payer. And, you know, getting them to acknowledge that in the world of PAMA, the whole notion of a discount to the CMS NLA rates no longer will apply going forward. And that, in fact, you know, CMS will be setting the market and that they should feel confident, is a market rate that they can feel comfortable and represent to their prospective or current members.",0.9905213,0.933
DGX-2020-Q4-2021-02-04,91,Answer,2021-02-04,4,2020,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",1.4996031,0.0
DGX-2020-Q4-2021-02-04,93,Question,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Great, thanks for the question. This is Adam Noble in for Kevin. I just wanted to, I guess double back to your comments around reimbursement for COVID PCR, you know wanted just to confirm that you're assuming throughout the first half, that the PHE is extended so that the Medicare rate, you know with the add-on payment remains 100? And then you talked about the, kind of the commercial reimbursement, you know, potentially declining over time, just any thoughts around kind of what the magnitude of changes on the commercial side you guys could potentially see in PCR?",0.2543444,0.848
DGX-2020-Q4-2021-02-04,94,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, sure. I'll comment on then Steve may want to add. So yes, we would expect that as long as the, you know, [federal health emergency] continues that this structure with the, you know, opportunity to earn $100 per test from CMS will continue now, you know, that is a very small portion of our volume. But we would expect that however, as I said in the prepared remarks, there is some risk, they could decouple it. There's no guarantee that that will continue.",0.4557662,0.968
DGX-2020-Q4-2021-02-04,95,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, and - you know and not only could they decouple the reimbursement with the [FHE], but they could also, like they did January 1 change the approach. However, you know, at this point, yes, we're assuming the highest probability is that as long as the [FHE] continues, CMS will continue to pay us under this new method. You know, on commercial, obviously, we're not the only player. And so, you know, while we defend, and, you know, feel like we do a good job of explaining why our reimbursement makes sense, as we've negotiated some, you know, new payment methodologies, including some who wanted to move to the Medicare methodology, and we think we've done a good job, but obviously, there are other labs as well. And, you know, to the extent that other labs, you know, don't do as good a job as we do, there could be additional pressure on us.",1.1007109,0.906
DGX-2020-Q4-2021-02-04,96,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So that's why it's hard for us to predict exactly where this is going. But certainly, in our mind, you know, we would expect to continue to defend commercial contracts as well to the [FHE] seeing the same basis for CMS paying us at that rate should apply to the commercial payers as well. I also want to remind everybody that, as long as the zero patient out of pocket applies, that is also a huge tailwind for us because, you know, to avoid having to build patience, where historically, we've shared that we get about, you know, $0.70 on the dollar, and actually get, you know 100% of that payments from the third party is also a large enhancement to our revenue and our profitability as well. So that's, that's a factor I don't want people to forget about. Steve?",1.3792422,0.869
DGX-2020-Q4-2021-02-04,97,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, just to add to the CMS new methodology for reimbursement. As you know, we are reimbursed at $100 when we report the results in two days and $75 for all other results. And to Mark's comments, we have seen a few payers to look at this model as well. But we're encouraged by the public health emergency extension through 2021. And also, just to share our timeliness of our results are quite good. We have met that threshold of 50% of COVID. Molecular tests resulted in less than two days. We did that in the last few months. And I'll share that, you know, the majority of our testers are resulted in two days or less.",1.369028,0.922
DGX-2020-Q4-2021-02-04,98,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, in my other comments, I did mention that we continue to build capacity, because it just gives us a lot more operational flexibility to meet better turnaround times based upon where the demand is coming from. So, I think we're progressing well. We're very good provider of the test. You know, time is one element and quality and reliability, and also the type of testing we have done, you know, our methodology for PCR tests, both on the LDT side, and obviously, the kits are somewhat consistent throughout the industry, are really quite strong.",1.0514003,0.494
DGX-2020-Q4-2021-02-04,103,Question,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Good morning and thank you for all the color around guidance. Apologies if I missed this, but have you guys provided the average reimbursement levels for the PCR testing in Q4? And can you comment whether you're embedding similar levels in the first half guidance?",0.549763,0.226
DGX-2020-Q4-2021-02-04,104,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. So we didn't specifically call that out, but I can tell you that it did not change much in Q4 from where it was in Q3, you know, so, you know, it was above $90. We, you know, we do have some client bill customers that are less than 100. And we don't, you know, get paid for 100% of the testing, sometimes due to missing date, and so on and so forth. We do get some denials. But you know, certainly north of 90 was AWR previously.",1.4553712,-0.296
DGX-2020-Q4-2021-02-04,105,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, we did talk about the fact that we expect that to have some pressure and reduce over time in the first half. That doesn't mean that it absolutely will. But in our guidance, in the midpoint of that guidance, we did make an assumption that, you know, given the new model with the $75, not just with CMS with some commercial payers, we're not going to get paid or 100% of our tests at that 100, where we have been done previously, still a large majority, as Steve said, meet that two-day turnaround time.",0.4281201,0.725
DGX-2020-Q4-2021-02-04,106,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, that'll create a little bit of erosion. And then also, I mentioned that, you know, there's a lot of capacity there for a very competitive environment in that client bill arena aside from the third party.",1.0829384,0.655
DGX-2020-Q4-2021-02-04,107,Question,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Got it, thank you. And just as a quick follow-up, on the base business, can I confirm you said, you don't think you'll get back to pre-pandemic levels in first half? And is that compared to 2019 or does that include our [acquired volume] as well? Thank you.",0.7373618,0.144
DGX-2020-Q4-2021-02-04,108,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, that is correct. We would - I said was, you know, as we're looking at the back half, even though we're not giving guidance because there's too much uncertainty around it. We expect it to be back to pre-pandemic levels towards the end of 2021. So, in the first half, we still expect to be down versus 2019. We felt, even though the pandemic didn't start largely for our business till March, easiest compare and how to talk about it is 2019 volumes.",0.5920221,0.758
DGX-2020-Q4-2021-02-04,109,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We did have a large growth for the first two months of 2020 as we share that in our first quarter earnings call, you know, so that compounds things a little bit on a year-to-year comparison. But, yes, we're going to talk about our volume performance relative to 2019 because it's the cleanest compare for the whole year.",1.321911,0.382
DGX-2020-Q4-2021-02-04,110,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And when we speak to that, I heard it in your question. We are looking at organic growth. And so you know, we spoke of a couple of acquisitions that we closed last year. And you know, in our organic discussions we're excluding those and any other deals we might do prospectively. So, it's organic, based business we're talking to.",0.5971564,0.727
DGX-2020-Q4-2021-02-04,111,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And we think the best representation of utilization, so that's why we think it's important. Our organic performance versus 2019, kind of gives a sense, because of our size and reach. We think were the market overall is performing.",1.3271829,0.778
DGX-2020-Q4-2021-02-04,112,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So, the acquisition revenue will be on top of that. We obviously announced a couple of deals and what we said is, we have a good funnel and anything we might do prospectively be on top of what we said.",0.9855025,0.0
DGX-2020-Q4-2021-02-04,114,Question,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Hi, great. Thank you and good morning. So, just one quick one. Can you provide a little bit more color on how should we think about the margin progression throughout 2021? And particularly how much of your, with the core business still being down, how much of that is the margin headwind? Just sort of thinking about the dynamics as we go from the first half, the second half with COVID volumes testing coming down, and you've returned to price to be more normal for the core business, just wanted to go get some thoughts on the margin progression of work flow, please? Thank you.",0.1469194,0.856
DGX-2020-Q4-2021-02-04,115,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So, it depends, when you when you say is it a headwind? It depends on to what you're comparing it. So, as we, you know, expect the base business to improve. That's a significant margin tailwind versus the prior period, because we are in any given window of time, a highly fixed cost, you know, operation on our base business. And while we took some significant cost actions in the second quarter of last year in response to the significant downturn in our volume, and we've continued to manage our costs very, very tightly to the back half recoveries, and not get out in front of ourselves, you know, we're not planning on any significant restructuring in the near term with, you know, volumes that are down single digits at this point.",1.2424961,0.502
DGX-2020-Q4-2021-02-04,116,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, our cost structure on the basis business is, to some extent, what it is, and we'll add small, you know, pieces that are necessary as it recovers. But that, you know, growth and recovery in that base business sequentially is a nice tailwind. Now, on the other side, as we talked about, you know, expect erosion in our COVID volumes, you know that, you know, greater headwinds, and how those two pieces offset each other is hard to predict slightly, you know, [understood me] specifically. But, you know, I would at this point expect that the COVID reduction, more than offsets the base, but at least they do partially offset each other as we as we move forward.",1.178515,0.422
DGX-2020-Q4-2021-02-04,120,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, Lisa.",0.1261944,0.943
DGX-2020-Q4-2021-02-04,121,Question,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks very much. Good morning. Thanks for taking my question. I just wanted to follow up on your comment around the acquisition opportunities. Steve, you know, one of the things that was anticipated that with PAMA there'd be a lot of pressure and you'd see more acquisition opportunities with PAMA now being pushed out, does that change anything? Number one. And number two, when we think about reimbursement, as we've been talking about, for molecular tests, etcetera. I would think a lot of these labs have done well during this period of time, does that change what their expectations are at all around what their business is worth as we think about acquisition opportunities?",0.4497529,0.979
DGX-2020-Q4-2021-02-04,122,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So, thanks Lisa for the question. So, the first part is really about acquisition opportunities around hospitals. And, you know, you see that we announced a couple of deals last year that we were happy we did and that's going to help us and we continue to see a nice funnel for 2021 as well. And as you all know, hospital volumes up and down through 2020. They have recovered for us. However, what we do see is, a lot of renewed interest of looking at their lab strategies, which includes, you know, acquiring their outreach business and includes professional app service agreements, like we just announced in the fourth quarter.",0.4105437,0.459
DGX-2020-Q4-2021-02-04,123,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now that relationship we announced in the fourth quarter with Hackensack Meridian Health system is the largest we've ever done. And I can tell you, it took a long time to get there. And I believe the prospective reality of what's happening in the healthcare market this year help bring that to a conclusion. And I believe that that will happen with a number of dialogues we have going on with hospitals right now. So that's one piece.",0.3736409,0.637
DGX-2020-Q4-2021-02-04,124,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second is on other commercial laboratories. Yes, you're right. Number of commercial laboratories have jumped into the COVID testing arena. You see it with, you know, all the capacity we've added in the country. However, as that starts to be pulled back, and they start to see what the prospects are, given what we're driving as an industry, with consolidation, with tighter contracts and networks around health plans, we believe that, you know, there still will be a catalyst in the marketplace for us to continue to consolidate.",0.7291598,0.971
DGX-2020-Q4-2021-02-04,125,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, yes, there's been a short-term opportunity for a number of labs to take advantage, if you will, the opportunity to provide COVID-19 testing. But as that starts to change, you know, as we get throughout 2021, we believe the realities of what the new world will be with, you know, tighter networks, more consolidation will play nicely into our strategy and allow us to acquire more going forward. And obviously, given our cash position and strong balance sheet, we're in a very nice position to continue to do that. And also, Lisa, there's been a lot of discussion around all this additional capacity out there.",0.0711697,0.71
DGX-2020-Q4-2021-02-04,126,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","People have added new systems, and, you know, potentially, does this present a risk for us that these people are going to get into other businesses outside of COVID, like [women's health]? You know, we are watching it, you know, obviously, some hospitals have moved their molecular capacity to COVID. And we help them with some of the other work, but for other commercial laboratories and hospitals to use that capacity to get into competing with us, by the way, good example, [women's health] that's a long stretch.",0.9660626,0.941
DGX-2020-Q4-2021-02-04,127,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I mean, there's a lot to - lot more to getting a client to flip over than the lab capacity, you have to have a Salesforce, [you have to have] logistic capabilities, you have to do electronic interfaces, you have to work with the physicians, you have to be in a contract with the health plans. So, we are watching it, but at the same time, we're a little, you know, little cautious in, in the belief that some of this will have a significant effect. At the same time, we're watching it carefully to make sure it doesn't. And then we're staying on top of our clients to make sure we serve them well. Thank you.",1.3218799,0.612
DGX-2020-Q4-2021-02-04,128,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, if I could add Steve, just a couple things. Lisa, around your question, around our pipeline, at any given point in time, you know, we've got multiple opportunities that we're discussing, I can tell you that, you know, none of the potential sellers that we're speaking to right now are getting, you know expecting to get paid for that PCR bubble. So fortunately, I could see a mentality that, you know, hey, my value has gone up dramatically because of COVID testing. But you know, the people we're talking to right now recognize that that's short-term, and that should not be a part of the valuation discussion.",1.6737757,0.328
DGX-2020-Q4-2021-02-04,129,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then the, you know, while PAMA gets a pause this year, you know, there's still, you know, some risk. But more importantly, as you know, we've mentioned, and I'm sure you've seen, it's not just CMS, but the commercial payers are starting to, you know, put pressure on these high hospital outreach rates, you know, re-contracting, that work that's outside, you know, the patients who are in the hospital, either admitted or outpatient, at independent laboratory rate.",1.7247235,0.935
DGX-2020-Q4-2021-02-04,130,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So it's not - this pressure is not just coming from Washington, it's coming from the commercial payers as well. And from quite frankly, patients who, you know don't like those high prices when they have a high deductible plan. So, there's a number of things that are getting the C suites of large hospital systems with outreach to think about. Do they really want to be in this business? And will this be a good time to monetize? And so therefore, I really don't see the pipeline of interest having been impacted over the last 12 months negatively.",2.5868878,0.0
DGX-2020-Q4-2021-02-04,132,Question,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, good morning. As I think about the various components of your response to COVID-19, and you're role in testing, two things that stick out as step changes from a pre-COVID [world and the] capacity, and then consumer engagement. I think the number of patients using QuestDirect has doubled in the last 15 months. So, just curious, what can you do and as we move to sort of a post-COVID world to leverage that increased consumer facing presents consumer engagement, as well as the added capacity that it sounds like you're still bringing on?",0.5934102,0.951
DGX-2020-Q4-2021-02-04,133,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Thanks for the question. And we're very bullish on our consumer strategy. As you all know, we have five strategies for growth, one of which is the consumer strategy and our direct-to-consumer business that we've built over the last several years has done quite well and we do believe that the pandemic has now been an accelerator for that. We're providing COVID-19 testing through that platform. We're going to look at using it for consumer genetics. And as I said, in my introductory comments, interesting part of the pandemic is brought to the forefront the strong role of testing and overall health care. And questioning has been out there more than ever, and our brand has been built.",0.7390445,0.893
DGX-2020-Q4-2021-02-04,134,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And our brand is really second to none in our industry. And we coupled that with our service performance. And so we have this strong foundation coupled with the change in the marketplace. And we do believe, you know, there's going to be a continuation of the number of consumers that are engaged, that will engage differently with healthcare delivery systems, and how they engage with the physician.",0.8866557,0.718
DGX-2020-Q4-2021-02-04,135,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","With telehealth, we have a very strong presence with telehealth providers and with integrated delivery systems that offer the telehealth option. But at the same time, a lot of patients as well, and consumers will want to receive their basic health checks and testing online as [they buy] so much else in their lives.",1.1700165,0.778
DGX-2020-Q4-2021-02-04,136,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so we're very well-positioned with reputation with capabilities. And so, we are investing in that in a significant way more so than we would have, if we did not have the pandemic. And so, we think about, you know, the growth drivers going forward, and we'll talk about this some more in our Investor Day. We're very bullish about the opportunity we have in front of us around our QuestDirect, but also the consumer opportunity in general.",0.8171334,0.25
DGX-2020-Q4-2021-02-04,139,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Mark, you want to take that?",1.1030806,0.964
DGX-2020-Q4-2021-02-04,140,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. So, we, you know, we don't typically announce the revenue impact of deals like this, and again, I want to remind you, this is organic. So, this is not something we bought. We worked with Hackensack and demonstrate to them that we can perform the same work they do in their lab at a better cost better value. And you know, for a system that size, you know, they're significant lab spend. So this is - is going to be quite impactful and beneficial to them, and we see that as a, you know, opportunity, obviously to also get other clients, who will get their attention to see Hackensack, you know, thinks that this will work well, you know, in addition to some of the other hospital systems that we've learned over the last couple of years.",1.0466035,0.925
DGX-2020-Q4-2021-02-04,141,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, we're very, very excited about it. It is a large deal. It's the largest deal we've ever done. It will be, you know, material to our growth. And we talked a couple years ago at our Investor Day and we'll likely give an update on this. We thought we could get more than 100 basis points, and you know, somewhere between 100 basis points to 200 basis points of growth every year from our PLS business and certainly this one is a large contributor to that, and might even give us an opportunity to exceed that.",1.428515,0.0
DGX-2020-Q4-2021-02-04,142,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, you know, very large deal, but you know, we are not going to, we haven't had a historical precedent of pulling out the exact revenue, but it will be noticeable, and material as we go into 2021 and beyond.",1.3495261,0.0
DGX-2020-Q4-2021-02-04,144,Question,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Hi. Good morning. So, I mean, clearly, there's a lot of uncertainty around second half in the trajectory of the combat for more normalized utilization level, but if we step away from the timing and just think about the margin trajectory, how should we think about core margin trajectory from where they were, let's say in the fourth quarter, to where they can expand to as utilization comes back to a more normalized level? So again, the question is more about the margin trajectory, as it relates to utilization, not about the timing. And then my second question is more about, sort of a market demand. So, how do you think about changes in physician behavior patterns? And you know, we're seeing telehealth becoming more integrated into the workflow. So, do you think that there's going to be any impact on longer term lab testing demand curve because of that, I don't know if the experiences early in the year could shed some light on that?",0.3594728,0.382
DGX-2020-Q4-2021-02-04,145,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. Mark, you want to take the first part. I'll take the second.",1.4597156,0.904
DGX-2020-Q4-2021-02-04,146,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, Ricky, obviously, the, you know, size of the revenue we've generated from COVID, which more than offset the base business has materially impacted our margins and expanded them greatly relative to our historical margins. So, as we, you know, progress. We'll talk more about this at Investor Day, but we progress into a future where, you know, COVID testing is still around for, you know, for a while. As Steve said, we don't expect it to go away completely, certainly, by 2022. It's going to be less material to our top line and to our margin.",1.3680885,0.914
DGX-2020-Q4-2021-02-04,147,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, where will our base business be? Once we get back to the pre-pandemic levels of 2019, I would expect our base business to be, you know, slightly higher margin than it was pre-pandemic. Because as you look at, you know, our invigorate program, which we continue to drive, even during the pandemic, and you look at the offsets of the pay for is that we usually talk about, including wage inflation and price erosion, you know, given the pause on PAMA this year, and given, you know, the fact that we've done really well and other price concessions, despite, you know, significant increases in our [SWB] that was warranted during the pandemic, you know, as we wanted to reward our employees for their incredible contributions in getting us up and running, operating well threw it, and obviously driving strong company results.",1.5627962,0.962
DGX-2020-Q4-2021-02-04,148,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And when I net all those together, you know, that level of business should be more profitable. And then going forward from that, when we get back to the growth that you saw in 2019, and you saw in the first two months of 2020, and our ability to leverage that growth, you know, I would expect to see margin expansion on the base business, but of course, that will be partially offset for a period of time, as the COVID revenues and margins, you know, fall down. So, you know, longer-term, the good news is, you know, we were on a good path on growth and margin expansion pre-pandemic, and we will, you know, we'll get back there. But for a while, it'll be somewhat masked by the COVID decline that's inevitable, you know, over the next, certainly 18 months or so.",0.5360791,0.879
DGX-2020-Q4-2021-02-04,149,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. And the question about physicians, Ricky, we're watching this carefully, because we do believe going back to an earlier question about the consumer activity there will be a transition here now going forward with physicians serving the market in a different way. You know, as we said before, about half the physicians have either sold their practices to integrate delivery systems or have strong affiliations with integrated delivery systems. And, you know, that will be consistent going forward. But the other half of the market, we believe there will be a growing percentage of that portion of physicians that are served by telehealth and we have a very strong position with those telehealth providers, and that was before the pandemic.",1.091598,0.826
DGX-2020-Q4-2021-02-04,150,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And those telehealth providers are not going to work with [indiscernible] of laboratories who will work with a few. And they will have a real type for lab network as you would expect. And as you would expect, Quest would be one of those options. So, we feel good about that. Second, as you see more consolidation going on in physicians and we see what's happening, particularly with one of the health insurance companies, [Optim], acquiring physicians and a number of those physician practices, or customers. You think about debt consolidation, and think about their role, not thinking about where they add value bringing all those physicians together. We believe there will be an opportunity for us to work with a consolidator, like [Optim], to provide lab services more broadly, and in really reduce the variation they have with other physicians.",1.0701812,0.827
DGX-2020-Q4-2021-02-04,151,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And just one last point to show that, you know, this world is moving towards tighter network of lab providers. In the fourth quarter of last year, United Healthcare actually announced the removal of lot of network benefit for some of their fully insured members. And so, it's just another example of a major health plan tightening up their network. So, we think the physician side will change and there'll be a different way of providing physician services to patients going forward. And that trend, we believe is a good trend and will provide tailwind for us to consolidate the market.",0.3044481,0.382
DGX-2020-Q4-2021-02-04,153,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Hi, Erin.",1.0098847,0.932
DGX-2020-Q4-2021-02-04,154,Question,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks. Thanks so much for sneaking me in. Just a follow up on that competitive landscape and consolidation. So it sounds like you don't expect there to be any sort of meaningful impact on your opportunity around consolidation just even given the dramatically expanded install bases, PCR instruments across the U.S. over the past year. I mean, I would assume that customers do want to monetize those investments to some extent, I'm just curious what you're seeing in terms of market share shifting outside of maybe COVID testing that you're seeing already, if that's happening at all? I mean, it sounds like everything still remains an opportunity from an M&A perspective and consolidation standpoint. And then my second question is just on how should we be thinking about the long-term dynamics as it relates to COVID testing? It will obviously diminish with the vaccine rollout, but could it evolve into something more similar to like flu testing in future years? And can you remind us of the flu testing exposure you do have? Thanks.",0.1723229,0.922
DGX-2020-Q4-2021-02-04,155,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. So as I said earlier, we believe that hospitals will be now increasingly looking at their options to become more efficient, given the pressure, the pandemics put on any of them. And we're encouraged by, you know, the level of discussions we had, and, you know, the deals we've closed as an example that this is happening. So, we think that's good. On the commercial laboratory side, we believe that, you know, some have gotten into the COVID testing opportunity, it's provided somewhat of an opportunity for them to get through this year. But as you know, the dust settles and testing volumes go down, you know, the reality of what we talked about in [indiscernible] doesn't change.",0.0434926,0.524
DGX-2020-Q4-2021-02-04,156,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And we think there will be many of those that would be looking at their options. And we do believe that COVID testing will continue into 2022. We believe that this, you know will be a virus that we'll have to manage. So, it will be more flu like, and something that will, you know, will be behind us and beyond 2021. And, you know, it's hard for us to scale at this time what that will be. But you should not think that this is going to be the testing opportunity that will go away at the end of this year. But we do believe there will be with us in 2022, as well.",1.3518946,-0.077
DGX-2020-Q4-2021-02-04,157,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And as far as the flu, you know, we talked about prior earnings call that we have offered a combination panel that when a patient presents itself with symptoms, the physician wants to rule out the flu, and also COVID. And so, we have seen, you know that be accepted, but as you all know, the incidence of flu this year is down considerably because of all our behaviors in the United States. So, that has changed somewhat. Shawn or Mark, you want to add something to food testing in general and exposure to answer the PAMA point of the question?",0.6386256,0.296
DGX-2020-Q4-2021-02-04,158,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, I don't have anything to add. Shawn.",0.6879937,0.0
DGX-2020-Q4-2021-02-04,160,Question,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Hey, good morning, and thanks for squeezing me in. I guess just one quick question. Mark, as I think about your capital deployment, obviously, you're generating a lot of cash. And it sounds like the hospital acquisition opportunities are the pipeline's there, but maybe a little slow in coming through. So, how should we be thinking about your willingness to buy back more aggressively in the front end? You know, and how should we be thinking about, just other capital deployment opportunities, whether it's internal, on the CapEx side for growth?",1.2061611,0.896
DGX-2020-Q4-2021-02-04,161,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So, we are investing quite a bit internally. You know, as you may have seen or you will see our, you know, capital spend for 2020. You know, we ended up 418 million, which was above the initial range. A lot of that was related directly to the COVID capital that was necessary. But we certainly have not stepped back on investing internally, because we think that's the best way to drive returns. A lot of that, obviously, is related to our invigorate program.",1.4454976,0.0
DGX-2020-Q4-2021-02-04,162,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"You know, we are moving all of our new [indiscernible] test to a single platform, we continue to move forward on that, and then a big piece of the 2020. And the first half of 2021 was related to Quest and our new facility. Although we started operating in early January, we still have some final set out in equipment to put in a narrow drive some of the spending in the first half. So, we absolutely have a high priority on internal capital. And we'll continue to do so. You can see we guided to 200 million in the first half, which is you know, about 50% of what we spent in 2020 as we step back a little bit from COVID capital, but we have some continued spending on Clifton and then also the normal priorities on which we spend.",1.8404423,0.964
DGX-2020-Q4-2021-02-04,163,Answer,2021-02-04,4,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On share buybacks, as I mentioned, I will give a lot more color on the Investor Day. The reason for that is, you know, we do have some things that we're monitoring around potential cash deployment. We will have greater clarity on as we move over the next couple of weeks. We also wanted to get a little more of 2021, Q1, you know, behind us to see how that performance continues, and what our expectations, you know, for Q2 look like at that point, because every day, every couple of weeks, every month certainly gives us you know, better line of sight and expectations. But, you know, by announced by, you know us seeking and getting approval and announcing a billion dollar increase in our authorization, certainly you correctly are taking that as a signal.",1.1650869,0.812
DGX-2020-Q4-2021-02-04,164,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as I said, specifically in my prepared remarks, that we're going to do more share buybacks than we have done historically. And I'll remind you that our capital allocation strategy, which we have not changed to this point is to give the majority of our free cash flow back to our shareholders to our dividend. And our share repurchases, we suspended them for 2020 for a period of time. But even with the 250, you know, we spent in Q4 and the increase in dividend over time, you know, we're behind that 50%. So, we have some catch-up to do.",0.5291598,0.898
DGX-2020-Q4-2021-02-04,165,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me just add to that performance we had in 2020 and the performance that we're indicating, with our guidance in 2021, is affording us an opportunity to invest in our growth strategies. And that includes what we've talked about on this call. Working on the relationships with health plans are gaining traction was presenting our lab strategy view to health systems, hospital health systems, what we're doing around advanced diagnostics, and then finally, what was asked about earlier around the consumer opportunity in front of us. So, implied in the guidance is an increase in investment for those growth drivers to accelerate growth of our base business within 2021, but as we enter 2022 as well.",1.1578254,0.955
DGX-2020-Q4-2021-02-04,166,Answer,2021-02-04,4,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So if there are no further questions. I like to thank everyone for again joining us on this call. We appreciate your continued support and interest and you have a great day. Take care.,0.8108731,0.527
DGX-2019-Q1-2019-04-23,3,Remarks,2019-04-23,1,2019,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I'm here with Steve Rusckowski, our Chairman, President and Chief Executive Officer; and Mark Guinan, our Chief Financial Officer.",0.8047102,0.66
DGX-2019-Q1-2019-04-23,4,Remarks,2019-04-23,1,2019,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and we'll discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.",0.2974332,-0.065
DGX-2019-Q1-2019-04-23,5,Remarks,2019-04-23,1,2019,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS, excluding amortization expense, references to adjusted operating income for all periods now excludes amortization expense. Finally, growth rates associated with our long-term outlook projections including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth, are compound annual growth rates.",0.2230749,0.941
DGX-2019-Q1-2019-04-23,7,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. Well, this morning, I'll discuss the first quarter and review progress on our two-point strategy. And then Mark will provide more detail on the results.",0.6392092,0.866
DGX-2019-Q1-2019-04-23,8,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","While we're off to a good start in 2019, for the first quarter, we grew revenues despite one less revenue day and significant reimbursement pressure. Reported EPS was $1.20, down 5% from the same period of 2019. Adjusted EPS was $1.40, down 8%. We're pleased with our revenue and adjusted EPS results given the expectations we shared with you in mid-February. Volume growth was very strong at 3.6%. So Quest is well positioned in 2019 to grow share and deliver revenue growth.",0.1275124,0.959
DGX-2019-Q1-2019-04-23,9,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Performance in the quarter reflects volume growth from expanded network access. Acquisitions improving performance in our hospital reference business and favorable weather. We've made progress in the quarter despite significant reimbursement pressure and higher patient concessions.,0.0257002,0.891
DGX-2019-Q1-2019-04-23,10,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As we shared before, Quest is poised for growth based on three fundamental changes in the marketplace. First, PAMA driven reimbursement pressure is a catalyst for structural change. Reimbursement experience in the first quarter is in line with the expected 10% reduction in Medicare rates and we expect a similar reduction in 2020. We also said the impact of these cuts will be more significant on smaller independent and hospital outreach laboratories. We believe the cuts could potentially eliminate the majority of their profit and we'll provide a catalyst for market consolidation.",1.8214168,0.757
DGX-2019-Q1-2019-04-23,11,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Just in this quarter, the nation's largest nursing home lab operator filed for Chapter 11 bankruptcy reorganization. The company provided a clinical laboratory testing services to more than 12,000 facilities in more than 35 states. According to the press reports, PAMA was cited as a major reason for bankruptcy as the Medicare cuts wiped out the company's slim profits and caused it to cut back services.",0.1736409,-0.103
DGX-2019-Q1-2019-04-23,12,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second, payers are more focused than ever on driving better value in their lab spend, which supports our plan to gain share. This is clearly evidenced by the opening of the major health plan contracts at the large national laboratories, which provides the best value and quality for patients, physicians and payers. We're very pleased to be named a UnitedHealthcare Preferred Lab Network provider effective July 1, 2019 meeting exceptional criteria for access, costs, data, quality and service. Quest and our AmeriPath subsidiary were two of only seven labs selected to participate in the Preferred Lab Network.",0.3568369,0.983
DGX-2019-Q1-2019-04-23,13,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Finally, nobody cares more about the variation in healthcare costs than the employers and their employees, the country's largest payers. Increasingly, patients are motivated to find high quality and service providers with low prices like Quest Diagnostics. More and more we're seeing evidence of increasing price transparency in the lab marketplace. Massachusetts has been a leader in price transparency by launching its own website to help consumers understand the wide variation in healthcare cost.",0.060626,0.844
DGX-2019-Q1-2019-04-23,14,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","During Governor Charlie Baker's recent visit to our Marlborough lab, we pledged our continued support to Massachusetts' efforts to help consumers understand their true cost of care. We are well positioned to benefit from these trends, which we serve as a catalyst request to continue to gain share.",0.2599671,0.964
DGX-2019-Q1-2019-04-23,15,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our strategy to accelerate growth has five elements; grow more than 2% per year through accretive, strategic in-line acquisitions; expand relationships with health plans and hospital health systems; offer the broadest access to diagnostic innovation; be recognized as the consumer-friendly provider of diagnostic information services; and then finally support population health and data analytics and extended care services.",2.9617792,0.869
DGX-2019-Q1-2019-04-23,16,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me take you through several highlights from our strategy to accelerate growth in the quarter. Recall, we shared in our initial guidance that we carried over 1% growth into the year. The nine yields we've announced and closed since the beginning of 2018 positioned as well to meet our M&A growth targets in 2019, including our recently completed acquisition of the clinical laboratory services business of Boyce and Bynum.",1.3482702,0.883
DGX-2019-Q1-2019-04-23,17,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our pipeline remains strong and we're having several conversations with health systems to evaluating their hospital outreach lab strategy. We delivered strong organic growth to the quarter, thanks to the best access to insured lives this company has had in over a decade. In January, we saw a rise in volume attributable to health plans, where we recently gained access. And the year-over-year growth rate accelerated throughout the quarter. We're working hard to educate a whole new group of physicians on the Quest value proposition but it does take time. As we said, gaining market share through expanded network access will be a gradual process.",0.321911,0.957
DGX-2019-Q1-2019-04-23,18,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we're pleased by the progress we're making in our access improvement as well as we're making progress in our hospital reference testing, which reflects our recent PLS relationships and reference testing wins. Trends in our reference testing business has shown improvement relative to last year. Key test growth drivers in the quarter included tuberculosis testing, Cardio IQ, drug monitoring and hemepath blood cancer testing, all of which showed strong revenue growth for the quarter.",0.2787479,0.974
DGX-2019-Q1-2019-04-23,19,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","QuestDirect, our consumer initiating testing service is being well received by consumers who are looking to take charge of their health. Our offerings are popular across the entire demographic spectrum, with the largest percentage of consumers coming from the 25 to 34-year-olds. Earlier this month, we launched three new STD test packages along with consumers to get tested after discretion.",0.046458,0.66
DGX-2019-Q1-2019-04-23,20,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second part of our two-point strategy is to drive operational excellence. Construction of our new flagship laboratory in Clifton, New Jersey is well underway. The lab builds on the success of our Lab of the Future of Marlborough, Massachusetts, incorporating innovative uses of building design and automated technology to provide a broad range of advanced diagnostic and information services to more than 40 million people. We expect the lab to be operational in 2021. We also continue to drive increases in productivity. We have rebalanced resources and reduced expenses in some areas while ensured we have the operational resources needed to deliver on the volume growth that we see.",0.3308072,0.95
DGX-2019-Q1-2019-04-23,21,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Productivity gains have enabled us to effectively manage our headcount growth. So here are a few proof points. We're seeing improved electronic order rates as we increase volume from the expanded network access which improves our lab productivity. We continue to re-enable our enterprise workflow, which has allowed us to reduce the number of specimen pickups and the number of client calls through acquisitions to our call centers. We've also driven increases in our supplies efficiency.",0.1815486,0.953
DGX-2019-Q1-2019-04-23,22,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, our labor productivity gains have enabled us to reduce our labor cost per acquisition in the first quarter while providing salary increases for our front-line employees.",0.109061,0.34
DGX-2019-Q1-2019-04-23,23,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now I'd like to turn it over to Mark, who will bring you through the financial performance. Mark?",0.3904448,0.361
DGX-2019-Q1-2019-04-23,24,Remarks,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the first quarter, consolidated revenues were $1.89 billion, up 0.4% versus the prior year. Revenues for Diagnostic Information Services grew 0.5% compared to the prior year, driven by strong volume growth and favorable weather, partially offset by increasing reimbursement pressure and higher patient concessions. Volume, measured by the number of requisitions, increased 3.6% versus the prior year.",0.2026066,0.902
DGX-2019-Q1-2019-04-23,25,Remarks,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Excluding acquisitions, volumes grew 2.4%. Favorable weather in the first quarter provided a tailwind of roughly 50 basis points. However, there was approximately one less revenue day in the quarter that negatively impacted volume growth by roughly 120 basis points.",0.1947077,0.691
DGX-2019-Q1-2019-04-23,26,Remarks,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per acquisition in the first quarter declined by 3% versus the prior year, driven primarily by increasing reimbursement pressure and higher patient concessions. Year price headwinds were consistent with our expectations at approximately 2.5%. This concludes the impact of PAMA, which amounted to a headwind of slightly less than 120 basis points.",0.200237,-0.296
DGX-2019-Q1-2019-04-23,27,Remarks,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Note, the PAMA impact includes both direct cuts to the current lab fee schedule as well as modest indirect price changes for Medicaid and then small number of floating rate contracts. Reported operating income was $248 million, a 13.2% of revenues, compared to $272 million or 14.5% of revenues last year.",0.0185624,0.052
DGX-2019-Q1-2019-04-23,28,Remarks,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On an adjusted basis, operating income was $286 million or 15.1% of revenues compared to $325 million or 17.2% of revenues last year. The year-over-year decline in operating margin was attributable to one less revenue day in the quarter, higher reimbursement pressure and higher patient concessions.",0.0197472,-0.296
DGX-2019-Q1-2019-04-23,29,Remarks,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $1.20 in the quarter, compared to $1.27 a year ago. Adjusted EPS was $1.40, down approximately 8% from $1.52 last year, which is roughly in line with the expectations we shared last quarter. Cash provided by operations was $275 million in the first quarter versus $180 million last year. Capital expenditures were $47 million compared to $73 million a year ago.",0.1532385,0.34
DGX-2019-Q1-2019-04-23,30,Remarks,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now turning to guidance. We are reaffirming our outlook for 2019 as follows. Revenues expected to be between $7.6 billion and $7.75 billion, an increase of approximately 1% to 3% versus the prior year. Reported EPS expected to be greater than $5.16 and adjusted EPS to be greater than $6.40. Cash provided by operations is expected to be approximately $1.3 billion, and capital expenditures are expected to be between $350 million and $400 million.",0.2808057,0.743
DGX-2019-Q1-2019-04-23,31,Remarks,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I'd like to leave with a few reminders as you think about the remainder of 2019. First, we continue to expect more than $200 million of reimbursement pressure this year. This headwind should be relatively evenly spread throughout the year. Second, we continue to expect that volumes will gradually increase as we progress through 2019, just as we saw through the first quarter. Third, the Easter and passover holidays falling entirely in April will create a modest year-over-year headwind in the second quarter. Fourth, we have approximately one extra revenue day in the third quarter. Finally, we expect the strongest revenue and earnings growth in the fourth quarter of 2019 because of an easier comparison.",0.1251975,0.939
DGX-2019-Q1-2019-04-23,33,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. Well to summarize, we're off to a good start in 2019. While our industry faces significant reimbursement pressure. We are pleased with our results in the quarter. We're driving volume and market share based on being a network of approximately 90% of the commercial insured lives in the United States. We believe we are well positioned to meet our commitments in 2019.",0.0658979,0.943
DGX-2019-Q1-2019-04-23,34,Remarks,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","With that, we'd be happy to take any of your questions. Operator?",1.0415157,0.572
DGX-2019-Q1-2019-04-23,39,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Thank you, Dan. Well, first of all, as we said going into the year, we expect that we'll have initial pickup in the first month in January, given all the work we did in 2018 to get the word out about our access changes, and we did see that. And then also what we said at the beginning of this year is we do expect that it will continue to build, and it continued to build in Q1 so we saw an improvement in February and also in March. While equally, we expected it continue to gradually build throughout the year. So as we've said, this is a nice growth opportunity for us in 2019 while we see an opportunity in 2020 - in 2021.",0.1209226,0.96
DGX-2019-Q1-2019-04-23,45,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Thanks, Ross. Well, first of all, we're excited to be part of the Preferred Lab Network. As we mentioned in our comments, we're two out of seven. So very tight network and this will start on July 1, however, the word is out. And as you all know, the word was out when we announced that we're back in network last year. So we've had quite a lot of interest from the other national payers about what this means to some of the large regionals. And needless to say, we think it's the beginning of a trend that we would like to continue to see in other relationships that we have.",0.0616145,0.931
DGX-2019-Q1-2019-04-23,46,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","What this means will become more clear as we get into it. But what we indicated clearly there will be incentives for physicians and patients in the event that designs to move more of the volume through the high-value lab providers, like Quest Diagnostics. Second is we need to continue to perform. So we are high-quality lab, both in service and in lab quality, we'll be providing statistics quarterly to demonstrate that.",0.0833608,0.855
DGX-2019-Q1-2019-04-23,47,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, we'll continue to move with the opportunities we see in the marketplace to consolidate the marketplace and pick up share, which will include continue to work on our hospital strategy, picking up share for some of those hospital outreach labs. So we think this is a good first step and a trend that will continue. It's not going to be just with United but other payers will follow.",0.0230643,0.751
DGX-2019-Q1-2019-04-23,48,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So Ross, if I could just add quickly because I think it's certainly important. In the past, there were health plans that had preferred providers in the lab space and, obviously, in other areas. And a lot of that was generally around price. So who's willing to give the lowest price and I'll call and provide - preferred provider. In this case, contracts were negotiated separate from this decision that United just made. Obviously, everyone's prices are determined by individual negotiations. And this is really about evaluating the value that you bring",0.6666667,0.872
DGX-2019-Q1-2019-04-23,49,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So yes, price is an important component. But when we looked at the application and, as Steve shared, access, service and quality are the things that drive value. And as we've been talking about for a while, we feel we are positively differentiated versus most of the market and here is an acknowledgment by a large payer, obviously, agreeing with that and then getting behind that by naming us as one of those preferred providers. So that consumers of our services, both the patient and the physician, will recognize that. Because obviously, it's hard for them to know and see and compare across the various options that they have.",0.5375197,0.918
DGX-2019-Q1-2019-04-23,50,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we're very excited about this because this is not a price play. This is about the value you're offering on many parameters, and we are well down the road in conversations with several other nationals on similar concepts and so they recognize as well this is an opportunity to bring better value into the members.",0.3329384,0.928
DGX-2019-Q1-2019-04-23,51,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And Ross, one of the things that I wanted to make clear, just baked on some questions that I was receiving last night, is that we are - there's no additional contracted change or price change for us to be in the Preferred Lab Network. We have contracted rates with United and those are the rates that we'll live with them in the Preferred Lab Network. So there's no additional step down.",0.3700165,0.25
DGX-2019-Q1-2019-04-23,53,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So Ross, it just comes backs too, we think we have a unique setup in our industry to gain share. PAMA is the big change and it changed the underlying profitability of the industry. When we were at our Investor Day, we talked about roughly half the profit coming out of the industry and whenever you take half the profit out of the industry consolidation and we're the market leader and we're going to consolidate. Second is you do see now with the Preferred Lab Network for United and what Mark just said with other payers following, there will be tighter purchasing with the payers.",0.1802306,0.934
DGX-2019-Q1-2019-04-23,54,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, this is driven in part by members pushing back on the high cost of healthcare and the movement to more transparency with much more visibility and wide variation in health care cost. And Quest Diagnostics is really second to none in terms of our quality or service and at very, very competitive prices. So we believe this is a different place at a different time and we've gotten an opportunity to pick up share.",0.2685338,0.858
DGX-2019-Q1-2019-04-23,58,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So Shiel - I don't know you referenced [indiscernible] since we closed Shiel more than a year ago but we don't specifically comment on individual deals. But what we have said is that we're very confident in our ability to integrate acquisitions especially around the core lab space whether its outreach or regional lab like Shiel. So we're pleased with our progress and certainly, it's contributing to some of our growth.",1.1879937,0.983
DGX-2019-Q1-2019-04-23,59,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,So this is something we've gotten really good at over the last several years. We've got it institutionalized in our organization. We've got a team that spends time dedicated on these integrations. We got a playbook and we roll out every time that we do one of these deals. And largely what we're really doing is we're just moving that volume into our existing infrastructure be in our draw centers or logistics or laboratory.,0.1398104,0.735
DGX-2019-Q1-2019-04-23,60,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So as we've said before, it's pretty much always a cost play, it's the easiest one to deliver. So we're very confident in our ability to deliver those synergies and then importantly, because of all the things we talked about around our service and our quality and the amount of attention we pay to these integrations, we have been successful in maintaining a vast majority of that volume. So we're confident in what we do going forward based on our ability that we've demonstrated over the last couple of years.",0.2630332,0.976
DGX-2019-Q1-2019-04-23,61,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And Patrick, the second part of your question has to do with our funnel and activity and just in general is more interest of particularly, I think, you're referring to hospitals - hospital outreach laboratories selling their business. If you go back a year ago, what we've said is PAMA was announced in the first year of payment cuts and what it says in our travels is that very few hospital CEOs were aware of PAMA back a year ago.",0.2889621,0.51
DGX-2019-Q1-2019-04-23,62,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","That has changed, made more are aware of it, it's been getting much more visible. What we continue to push in terms of having to think through our - their lab strategy is continue to get traction. And so we're in active dialogues, as I said in our prepared - my prepared remarks with a number of systems around their lab strategy, which includes outreach. Now you couple PAMA with what you're hearing about the payers putting pressure on the Preferred Lab Network and as you know, the most significant price differential is typically with hospital outreach labs.",0.2576606,0.846
DGX-2019-Q1-2019-04-23,63,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So when we have this conversation, clearly you hear about PAMA, it's certainly - potentially a 30% cut for their Medicare business, which will also see pressure on the payer side. And then thirdly is they are hearing from their physicians that their patients are pushing back on their high out-of-pocket cost. So in general, this is putting more logs on the fire of consolidation and our hospital strategies is in the works of getting more and more opportunities in front of us.",0.0421746,0.373
DGX-2019-Q1-2019-04-23,67,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So Ricky, let me just address the guidance and then I'll turn it back to Steve. As you know, we have a pretty broad range of 1% to 3%. So there's a lot of different things that come to play in that. So what I would say at this point is in order to meet our guidance, certainly, somewhere in the middle, we're not counting on significant volume coming from the Preferred Lab Network. Obviously, at this point, we don't know yet know the details. United has not announced those details.",0.0699052,0.848
DGX-2019-Q1-2019-04-23,68,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we're awaiting that. We're optimistic and hopeful that it's going to be something that's going to have some significant impact. But you naturally expect that would grow and certainly probably more in 2020. We could get some benefit in 2019. But we need to wait until they announce exactly it's going to work, what those details are and so forth. So we're not counting on a kind of volume lift in the back half from the Preferred Lab Network.",0.1433649,0.896
DGX-2019-Q1-2019-04-23,69,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. If you look at the seven, what we mentioned as two are Quest and that's Quest in general and then our AmeriPath subsidiary, which is our anatomic pathology business. If we see - you see two from Bio-Reference and so if you look at the list of seven, essentially what you find is two national laboratories broadly and Bio-Reference within reason for, let's say, the general diagnostics and then all of us for intensive purposes compete in the what we refer to as advanced diagnostics.",0.5874794,0.572
DGX-2019-Q1-2019-04-23,70,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The specifics of incentives around that are still to be defined by United. And when we have more that we can share with you, we will. But clearly, it will drive at least incentives in place to drive volume from the general diagnostic side as well as the advanced diagnostics side.",0.3136738,0.925
DGX-2019-Q1-2019-04-23,74,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. As I shared in, we estimated about 120 basis points of impact from one less day and I also shared, we're going to - it's not precise but pretty much picked that up in the third quarter. So there's the offset for the year. In terms of bad debt, I think you're referring to patient concessions. Our bad debt actually was slightly up. This year, we had one bankruptcy within our client bill business that impacted our bad debt in the quarter. Certainly not a trend, it's kind of a one-off.",0.1899684,-0.983
DGX-2019-Q1-2019-04-23,75,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"But patient concessions, probably about a 50 basis point headwind. And what we're really seeing is some of the patient responsibility trends that we saw in the latter half of last year, we're now carrying it forward with the expectation that, that ratio will continue. So therefore, our expectation would be in the first half we have some headwinds around patient concessions and then assuming that things don't change dramatically within the marketplace in 2019 that in the back half maybe we get some of that back.",0.1015008,0.0
DGX-2019-Q1-2019-04-23,76,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So that's what I would frame the - some of the trends. Around drugs of abuse, we did get some recent news that the national payer that had been denying same day of service were the presumptive and definitive testing and the reimbursement has changed and we haven't got the definitive date when that's going to be implemented. But we have got a confirmation writing for them that they're going to change that. So that was certainly good news.",0.1650869,-0.259
DGX-2019-Q1-2019-04-23,77,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then in terms of lapping some those changes, we are beyond when they started. So from a year-over-year comparables, they're behind us. And then the big payer change last year in Q2 on vitamin D, obviously, we've lapped that as well now that we're in the second quarter but it was a headwind in Q1 certainly for us. We've also shared that Aetna is going to move to that similar approach for screening of vitamin D. However, with Aetna, there is a difference because we can bill the patient.",0.3013428,0.879
DGX-2019-Q1-2019-04-23,78,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Whereas with the other payer, we just had to do the test for free, which is just something we're working on with that payer. But as per the contract, we were not able to revert to a patient bill. So while Aetna certainly were not thrilled that they're moving to a similar policy, it's not going to be as much of a headwind as it was with the other payer.",0.1224329,0.551
DGX-2019-Q1-2019-04-23,82,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Well, I'll start with utilization. As Mark talked about where volumes fit in with what we expected in the quarter, but utilization is stable. As we said in the past, we look at this on a different directions as you all do and from what we can tell, utilization in general is stable and that's - I would argue for our physician business and not hospital business as well as our hospital business. Mark, volumes relative to what we expected?",0.060626,0.807
DGX-2019-Q1-2019-04-23,83,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So as you know, we had guided to flat to down, we actually grew revenue. So volumes were slightly above our expectations. I would attribute a large part of that to weather. As we've talked about in the past, we can't predict the weather. So we always kind of take an average level of weather and build that into our expectations and into our guidance, and we had 50 basis points of favorable weather this year.",0.1528436,0.7
DGX-2019-Q1-2019-04-23,84,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So as Steve said, we're very pleased with volumes. We had expected a significant lift. If you adjust for the one fewer day, even more impressive volume growth, certainly, something we've not seen in a long, long time at Quest, especially on the organic side. So meeting our expectations and finally, a little bit better literally because of the weather.",0.0367299,0.938
DGX-2019-Q1-2019-04-23,89,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Close enough, Kevin, yes.",0.6488942,0.402
DGX-2019-Q1-2019-04-23,94,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So obviously, we're not going to get into specific payers but the lift didn't all come from the new access. We certainly have seen growth in some of the other payers really across the board in the regions that are growing as one might expect because as we go in and talk about our broad access, we're winning accounts. And so those accounts obviously are bringing with them volume from the payers with whom we recently gained access but obviously we're getting some volume as well.",0.4549763,0.964
DGX-2019-Q1-2019-04-23,95,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We did expect and we did see some losses in Aetna. It's within our expectations and our outlook, and actually it stabilized throughout the quarter. So we saw something early and then since then, actually we've won some of that back and it's not only not that gotten any worse but actually got a little bit better. So that's about as much detail, Kevin, as I can go into in terms of the access changes.",0.3191153,0.437
DGX-2019-Q1-2019-04-23,96,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Next question, operator.",0.1973641,0.0
DGX-2019-Q1-2019-04-23,99,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So I don't know what your expectations were, Kevin. To be fair, gross margin wasn't significantly different than what we were expecting. The actual - the only area that was a little bit off our expectations was in SG&A. But there's actually a geography issue in there that I want to make sure people understand. We have some portfolio investments related to the retirement plan that we have and the accounting dictates that if there's gains or losses in that portfolio that you can either have expense or offset to expense above or below the line.",0.7792259,0.494
DGX-2019-Q1-2019-04-23,100,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We actually had $9 million of expense above the line. There's an offset in other expense below line. So there's no impact to our net earnings and our EPS and so forth. It's a geography issue. But that didn't inflate our SG&A $9 million relative to what we would have expected based on these investments. And last year, we had about $0.5 million actually decrease. So it's a significant change year-over-year, about 50 basis points of impact. So I just wanted to make sure people understand, naturally geography, it's not any sort of a trend in our SG&A. But from a gross margin standpoint, we were pretty much where we expected.",0.1129542,0.25
DGX-2019-Q1-2019-04-23,103,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So when you think of the determinants of gross margin, obviously, it's price, which is pretty much set for the year. As we've said that $200 million of pricing headwinds should cycle pretty at least proportionally over the four quarters. Obviously, not every quarter is equal in terms of the volume. In terms of mix, we've had a trend but we will see if that continues in terms of better test mix as our advanced diagnostics grows faster than our routine business. But we also have some of that offset through our PLS business as well. So mix can be a driver that goes both directions, we'll see.",0.2077409,0.905
DGX-2019-Q1-2019-04-23,104,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then the other one that I'd point to is certainly volume within a quarter. So when we talk about one fewer day having about 60 basis points of impact in the first quarter on our margins because in a short period of time, a lot of our costs are fairly fixed. That's not all SG&A. Some of that is in cost of sales. When you think about our Patient Service Centers within a short period of time, that's a fairly fixed cost. Our logistics and even somewhat some of our laboratory expense, although obviously reagents and some labor are variable.",0.056872,0.34
DGX-2019-Q1-2019-04-23,105,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So other determinant certainly as we get that extra day back in the third quarter, that's going to be a tailwind to our gross margin, not just our overall margins and so we have one fewer day in the first quarter was a headwind to that.",0.3009479,0.011
DGX-2019-Q1-2019-04-23,108,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Let me take the Preferred Lab Network and then Steve will address the PAMA. So as I mentioned, we didn't contemplate significant change and that obviously would be positive for 2019 in our guidance because we don't have the details yet. In terms of the number of labs that have been included, we didn't know. Obviously, we knew the bar was pretty high because we filled out the application, and we certainly have enough sense around the industry, and we knew it would be difficult for a lot of people to meet the criteria around service, access and quality",0.4344392,0.832
DGX-2019-Q1-2019-04-23,109,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we were, I guess pleasantly surprised but not completely surprised that it's a fairly short list because of what United's looking for in terms of the requirements. So that's kind of where we stand and once we hear from United, some of the details, we'll be able to comment more about exactly what this means and how quickly we think it will become a tailwind and to what extent. In terms of PAMA.",0.2026066,0.82
DGX-2019-Q1-2019-04-23,110,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So we are - as far as PAMA, as we've said, we are planning on the worse and working to get a better outcome. So what we've planned in our guidance and what we've planned in our outlook assumes the full impact of PAMA through 2021. Excuse me, 2020. And what's happening as we speak is actually today, they're hearing of a oral argument of our appeal. If you recall the District Court that saw on our case, decided not to rule on it because of jurisdiction issues, we appealed that and so we're having our oral argument today. That will be heard. They will digest that and make a decision. But if it's a favorable outcome in our behalf then we'll be able to court begin, the senses that we'll hear something this year and our argument and then the case will follow thereafter.",0.2777595,-0.153
DGX-2019-Q1-2019-04-23,111,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is we don't get a positive outcome then we could appeal in the Supreme Court will cross that bridge when we get to it. In parallel to all that, we continue to push with members of Congress that CMS got it strong. We need to take the time to get it right. We need to make sure that given all the data, because that was what was intended, that was the congressional intent and so we're working with members of Congress on the legislative fix to make sure that we take the time to get it right.",0.2257002,0.934
DGX-2019-Q1-2019-04-23,112,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And essentially, what that would mean is push out the data collection period for some period of time to get the right amount of time for everyone's future to submit the data. And again, that'd be 2019 data. So the data for first half of 2019 will be what is submitted, but we're pushing to make sure that's delayed. So that's where PAMA stands.",0.4813839,0.153
DGX-2019-Q1-2019-04-23,115,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Can you speak up with - on your question regarding QuestDirect? Sorry, we couldn't hear you.",0.6552133,-0.077
DGX-2019-Q1-2019-04-23,117,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So I would just say, we introduced our new offering for the fourth quarter last year. It's off to good start. We're seeing a nice month-to-month progression of growth. Nice adoption in the number of test categories. We did mention in the prepared remarks, our inclusion of a few bundles around sexually transmitted diseases. So we're pleased with progress so far, and we did contemplate that in our guidance for the full year.",0.2823723,0.964
DGX-2019-Q1-2019-04-23,121,Question,2019-04-23,1,2019,Bill Quirk,Piper Jaffray,"Couple questions. First off, Steve, you talked about pricing transparency in your prepared comments. And this is a topic that you've touched on couple of times in the past. I guess bigger picture question here is, how should we think about this rolling out beyond Massachusetts. And then secondly, I guess following-up on Aaron's question, given that we are into the data collection period second around PAMA, how should we think about the expanded number of participating labs and what that impact might have in the 2021through 2023 period?",0.4375599,0.296
DGX-2019-Q1-2019-04-23,122,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. First of all, transparency in general. So the number of national payers, and I would say regional payers too, have pushed on educating their membership on a wide variation of healthcare costs. And yes, it's about lab and it's about everything. So a lot of visibility around radiology, a lot of visibility about every kind of procedures. So depending upon who you might have your insurance with, you probably have seen some of us. So that drum has been beaten and that it will continue to beat.",0.230313,0.49
DGX-2019-Q1-2019-04-23,123,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In parallel to that is employers are hearing a lot of pushback from their employees about the cost of health care. We hear it at Quest Diagnostics, and we haven't talked about it but we actually have done a lot of work to prevent the cost of Quest Diagnostics with their - our health care costs. And in doing so, where we've managed about 50,000 lives, we've actually built the cost curve. And the reason for that is employees are pushing back on their employers what they're paying for out of pocket. So this is a premium cost. It's a high deductible. So it's the co-pays and full insurances.",0.0082372,0.762
DGX-2019-Q1-2019-04-23,124,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so they give you a lot of noise and also those patients are pushing back on their physicians and physicians or pushing back on administration. So what I'll say is this has picked up a lot of steam, and we are encouraged because when you look at the facts, you look at our medical quality, you look at the service performance and you look at our price points, we're really second to none. And that's reinforced with the Preferred Network with United Healthcare and there'll be other payers that follow.",0.3545305,0.649
DGX-2019-Q1-2019-04-23,125,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So it will continue. We talked about Massachusetts as the state that has really put more out there, but we think more states will follow and more payers will follow and as more payers go down this path of a Preferred Lab Network, part of this will be around you can get the best quality, best service at the lowest prices from a company like Quest Diagnostics. So it's going to be one of the opportunities that we take advantage of to pick up share.",0.1864909,0.969
DGX-2019-Q1-2019-04-23,126,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And I just want to add to that, Bill, that the data collection period is actually in the fall. It's the work that we do in the first half of 2019 but actually the submission and the collection is later in the year. And as Steve mentioned earlier, we're working to try to get that delayed because we're not clear on the changes, the impact of those changes and how much it's going to expand to the hospital and others that did not submit last time. But we do know and agree that it's going to be challenging for many of them to comply.",0.1172986,0.481
DGX-2019-Q1-2019-04-23,127,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And therefore, that's why Steve mentioned for the trade association we're lobbying to get that delated to give them a chance to do that and make sure that it comes in because we see that as the benefit to be more representative of the overall commercial market but also that they can get it done in a quality fashion. So there's a lot of rationale for slowing this thing down. But it doesn't happen until later in the year.",0.1169036,0.459
DGX-2019-Q1-2019-04-23,130,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. Thanks for the question, Stephen. We recognize what you said that it could imply potential impact to the lab industry. At this point, based on the conversations we've had, I believe that, that was unintended. So we're in dialogue around addressing that. So we have not changed anything to our compensation program in response to that, and we're feeling comfortable. We're obviously doing the right things to ensure that, that gets amended. That was not the intent.",0.0011848,0.9
DGX-2019-Q1-2019-04-23,133,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. The term I'd use is stable. We keep on doing our same-store or same-account measurement when we look at 100 accounts. You know they're accounts of Quest Diagnostics, and we look at their volumes year-on-year. And we've tracked this for years. And what we see is it's a stable environment, and this is for the nonhospital portion of our market. And equally for the hospital portion, we believe that's stable as well if you look at the volumes that we see out there in the marketplace. We believe both are stable.",0.2355848,0.891
DGX-2019-Q1-2019-04-23,135,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","NO, no. Because I would say that it bounces around a little bit. But in general, we're feeling that, that - it is within the range of a normal variation that we've seen historically. So stable is a good way of characterizing what we see.",0.1291598,0.256
DGX-2019-Q1-2019-04-23,136,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And I mean, Lisa, I guess the tightest I could quantify it is that we've talked about a market that we think volumes are growing about 2% based on demographics and so on, which the given price headwinds pretty much take the revenue growth in the lab market to flat. And so as we look at the overall performance in the first quarter against our expectations and all the factors that play into it, including our competitiveness, there's nothing that we saw in the first quarter that suggested a significant deviation from what we were expecting in terms of if you would call utilization, the overall market consumption of laboratory services.",1.050158,0.866
DGX-2019-Q1-2019-04-23,139,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Several things. One is when we started with takeaway stores, we've shared in the past that, that's going well. Good results from those stores. Second is we've started a joint venture with Walmart. That has been progressively building and results have been very good. As you'll recall, we started with Texas and Florida, we're now beyond Texas and Florida. We're in multiple states. We're greater than 50 stores, approaching 75 to 80 stores throughout the United States. Again, what we're finding is that it benefits all stakeholders. We think it's good for Quest Diagnostics.",0.9911038,0.97
DGX-2019-Q1-2019-04-23,140,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And we've shared in the past that this is not about our savings in real estate. It's actually an opportunity for us to get more productive with our phlebotomists as we consolidate those in one location. Second is its better location. So it's better for employees, it's also better for our patients that we serve. So they walk again for other purposes to get your script filled, do some grocery shopping, by the way they can stop at Quest. We give them a locator. They walk in the store. They come in conveniently. Many of those people are fasting. So they would like to eat before they leave. So good patient experience.",0.0635914,0.947
DGX-2019-Q1-2019-04-23,141,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, Walmart likes it because it's more patient volume and it's a good experience in their stores. And what we're finding in those ZIP codes where we've done this, we do have an opportunity to pick up some share because it's - again it's a much more convenient location for us in that marketplace. So the patient has the choice they're going to be going to the convenient location. And so what we're driving to is if you look at the 2,200 Patient Service Centers that we have throughout the United States, we'd like to have about 50% of those Patient Service Centers eventually in more of a retail-like setting.",0.0718287,0.933
DGX-2019-Q1-2019-04-23,142,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So it gives you an idea of the extent of our strategy. And when I say that, we already have a retail-like strategy beyond Safeway and the Walmart locations because we've already had some of our Patient Service Centers in more of a retail environment than a medical environment. So of - the progress so far is - continues to be a good one. We're encouraged by it and there would be progress made this year.",0.0299835,0.889
DGX-2019-Q1-2019-04-23,143,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And so just to add to that, Matt, it's not as much a cost play around the fixed cost because the phlebotomist obviously gets paid the same regardless of where we put them and the overall rent is not that much different. But really is it's the volume leverage we get. So these are highly productive sites, especially in Walmart. And some of the reasons for that, obviously, as Steve said, it's great access and convenience but some of our key stakeholders, the payers and the physicians, like that when they hear about, hey this can bring further patient because actually you want them to get the testing done.",0.7203791,0.788
DGX-2019-Q1-2019-04-23,144,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So as we talk about being positively differentiated from a vast majority of the market, certainly our retail locations, it's not all about cost. Some of it is really around getting more volume and being more attractive commercially. And from some of the key stakeholders, we're influencing or driving those decisions where they want to get their lab work done.",0.5683254,0.852
DGX-2019-Q1-2019-04-23,145,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes and as you'll recall, as part of our strategy, we're using our data to support population health with extended care services. And so what you'll hear more of is basic health care services that we're also providing in those stores to manage a population. More to come on that but it's beyond draw services for Quest Diagnostics as we go forward.",0.8790774,0.71
DGX-2019-Q1-2019-04-23,152,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So the - to answer your question, Mark, remember the outlook - four-year outlook I provided was revenue, not volume. And while our volume, if you adjust for the weather and the days, was north of 3%, our revenue was obviously in the single-digit basis points, 10s of basis points, not as high. So I think as we've mentioned, we expect that to continue to build. And obviously, in the four-year time frame, we're expecting to get some of these pricing headwinds significantly lowered, if not eliminated, which will help the revenue relative to the volume. So I think that - hopefully that answers your question around the outlook and our performance in the first quarter. On HCA, Steve?",0.1251975,0.633
DGX-2019-Q1-2019-04-23,153,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. On HCA, we believe that it's going well. We believe if you ask HCA that question, they would give you the same feedback. Remember, this is in their Continental Division. So it's actually one of our Professional Lab Services engagements where we help them become more efficient with their hospital laboratories. So we now again demonstrate, now that we've been into it for a couple of years, that we are saving them money, and they're pleased by that and the quality has not anywhere - way deteriorated. So we're hopeful, given the success there that we could take that model and try it in some other locations throughout HCA. We're actively discussing that possibility as you would expect. But no firm indication that they will expand beyond it. But it is a success story for us within very large core profit system.",0.0382208,0.983
DGX-2019-Q1-2019-04-23,154,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And just to add quickly, I know you all can do the math. With about 40 basis points of revenue growth, if you adjust for the two factors you mentioned, that gets us north of 100 basis points. So in the year when pricing headwinds are obviously extreme, where it hits the low ends, but within that three-year CAGR of revenue growth that I provided at the Investor Day.",0.7026066,0.565
DGX-2019-Q1-2019-04-23,158,Answer,2019-04-23,1,2019,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. I'll take the beginning of that and then turn it to Mark to tell us what's in our guidance, if you will. So yes, it is Trident. What we referred to is what you can read yourself related to their lab business where they served the nursing home marketplace. We have very little exposure to the nursing home business. It's a tough market. We have a little bit of nursing home business. It's not a big market opportunity for us. So the answer to your question, it all depends whether we pick up some of the volume. If we can make money out of it and we can serve the marketplace, well we would consider it. So it all depends on where the volume is and at what price points and whether we can serve the market well to really define the presence of our laboratories and where their facilities are. Mark, you want to",0.124547,0.748
DGX-2019-Q1-2019-04-23,159,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So our remaining bad debt, and that will be separated from patient concessions out of bad debt and into revenue, is pretty small and you occasionally have a blip here. But we don't have any expectations that we're going to have significant headwinds on bad debt. A vast majority of that is hospital - our hospital business and then certainly, a chunk of that is actually physician client bill where in the States it's permitted. The physician is actually marking it up and billing the commercial payer, and we are charging the physician. So assuming that they continue to get paid by the commercial payers, we're certainly not at risk for any lack of payment ourselves.",0.4897314,-0.915
DGX-2019-Q1-2019-04-23,160,Answer,2019-04-23,1,2019,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So when you said are we getting more conservative, are taking any steps in anticipation of payment driving more bankruptcy, I wouldn't expect it to be within our customer base, our client bill base that you're going to see that impact. So there's really not anything we should do or can do beyond. We're very diligent around monitoring collections from our client bill and that's the easiest one. It's not anywhere near as complicated as the third-party billing and involving the patients. So nothing necessary and certainly no significant headwinds expected or built into our contemplated guidance.",0.3850711,0.194
DGX-2019-Q1-2019-04-23,162,Answer,2019-04-23,1,2019,Shawn Bevec,Executive Director-Investor Relations,"Well, thanks everyone for joining us today. We appreciate your support, and have a great day.",0.2577401,0.926
DGX-2021-Q2-2021-07-22,3,Remarks,2021-07-22,2,2021,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I'm with Steve Rusckowski, our Chairman, Chief Executive Officer and President; and Mark Guinan, our Chief Financial Officer. During this call, we may make forward-looking statements and we'll discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties, including the impact of the COVID-19 pandemic that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K.",0.8655729,0.35
DGX-2021-Q2-2021-07-22,4,Remarks,2021-07-22,2,2021,Shawn Bevec,Executive Director-Investor Relations,"The company continues to believe that the impact of the COVID-19 pandemic on future operating results, cash flows and/or its financial condition will be primarily driven by the pandemic severity and duration, health care insurer, governments and clients payer reimbursement rates for COVID-19 molecular tests, the pandemic's impact on the US health care system and the US economy and the timing, scope and effectiveness of federal, state and local governmental responses the pandemic, including the impact of vaccination efforts, which are drivers beyond the company's knowledge and control.",0.3416248,0.751
DGX-2021-Q2-2021-07-22,5,Remarks,2021-07-22,2,2021,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS. Any references to base business testing, revenues or volumes refer to the performance of our business, excluding COVID-19 testing. Growth rates associated with our long-term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth and adjusted earnings growth, are compound annual growth rates. Finally, revenue growth rates from acquisitions will be measured against our base business.",0.3503572,0.945
DGX-2021-Q2-2021-07-22,7,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks, everyone, for being us today. We had another strong quarter and continued to build momentum, thanks to faster than expected recovery in our base business. Organic based testing revenues grew compared to 2019 levels in the quarter. This is the first quarter since 2019 that organic base testing revenues grew. The growth was driven by contributions from new hospital lab management contracts as well as people returning to health care systems. We are well positioned to continue our momentum and support the return to health care in the coming months, which is reflected in the outlook we have provided for the remainder of 2021.",0.5176277,0.977
DGX-2021-Q2-2021-07-22,8,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","This morning, I will discuss our performance for the second quarter of 2021, provide perspective on industry dynamics and update you on our base business. And then Mark will provide more detail on our financial results and talk about our outlook and underlying assumptions. First, with regard to COVID-19 testing. We are closely watching the rapid spreads of the delta variant where testing continues to help control the spread of the virus. In recent weeks we have seen PCR volumes stabilize and begin to increase modestly. Positivity rates have increased in all geographies served by our performing laboratories over the last two weeks. COVID-19 testing also remains critical as employees return to the workplace and students return to the classroom in a few weeks. And whilst we experienced another milestone, we expect people to return to pre-pandemic health care and in some cases, catch up with health care they might have postponed during the pandemic.",0.5116969,0.93
DGX-2021-Q2-2021-07-22,9,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now I'll turn to PMO, the recent FedCap report mandated under the LAB Act. We were pleased that MedPAC found it feasible to change the CMS data collection process to a statistically valid sample of private payer rates for independent labs, hospital labs and physician office labs. This approach would produce an accurate representative market view of laboratory rates while reducing the burden of reporting laboratories, which is consistent with the charge of the LAB Act and the original intent of PAMA. The MedCAP report estimates that Medicare spending for the top 100 tests on the clinical lab fee schedule could increase by 10% to 15% over current rates based on certain rate and volume assumptions.",0.5291598,0.758
DGX-2021-Q2-2021-07-22,10,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And separately, our trade association recently appealed is legally challenged to PAMA, which was dismissed by a US District Court in late March. HLA has the service right to challenge the regulatory overreach by HHS in the implementation of PAMA. Along with our trade association, we will continue to work with policymakers to establish a clinical lab fee schedule that is truly representative of the market and supports continued innovation and access to vital laboratory services for Medicare beneficiaries as Congress originally intended. Now is the time to strengthen our laboratory infrastructure and support continued access to high-quality lab services that patients depend on.",0.55486,0.946
DGX-2021-Q2-2021-07-22,11,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to our results for the second quarter. Total revenues grew by nearly 40% to $2.6 billion. Earnings per share increased by more than 264% on a reported basis to $4.96, and nearly 124% on an adjusted basis to $3.18. Cash provided by operations increased by more than 30% to $460 million. In the second quarter, we continue to see a better than expected recovery in our base business with organic based testing revenues essentially returning to pre-pandemic levels in June. We're seeing strong recovery in most of the country and a slower recovery in the Northeast. Demand for our COVID-19 testing slowed in the quarter as expected, reflecting an industry wide trend. Though in the last few weeks of June, demand stabilized and has since increased modestly, which we believe is attributable to some extent to the emergence of the delta variance.",0.6807249,0.893
DGX-2021-Q2-2021-07-22,12,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We performed an average of 57,000 COVID-19 molecular tests a day in the second quarter, well below our current capacity of approximately 300,000 tests per day. We have engaged with businesses in the travel and [education] sectors in the quarter and working with partners to support a safe return of students to the classroom. We're also collaborating with CIC Health, Gingo Bioworks, Betel Memorial Institute to make testing easy, fast and affordable for school systems and other group settings across the country. We continue to make progress on our two point strategy to accelerate growth and drive operational excellence, and here are some highlights from the second quarter. We continue to execute on our M&A strategy. In June, we announced the completion of our acquisition of an outreach laboratory services business of Mercy Health, one of the nation's most highly integrated multi-state health care systems with providers and patients in Arkansas, Kansas, Missouri and Oklahoma.",0.9169687,0.981
DGX-2021-Q2-2021-07-22,13,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","With this acquisition we are on our way to grow our base business revenues approximately 2% from accretive strategic acquisitions this year and with additional M&A opportunities in the second half of the year. We continue to grow our health plan business and made progress in the quarter with value based programs with UnitedHealthcare and Anthem. Our volumes of these health plans are growing faster than the company average. We have also invested an additional employee headcount to better support these important relationships. During the quarter, we were also pleased to renew our longstanding contractual relationship with one of our largest health plan customers Aetna. We remain a preferred laboratory provider and partner of Aetna's network. In addition, for the first time in over a decade, Quest is one of Primark Delaware's in-network nonhospital affiliated preferred labs, serving more than 450,000 members. It's good to be back in the market, competing on the basis of quality, service and value.",0.6682043,0.969
DGX-2021-Q2-2021-07-22,14,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're helping all of us be focused on health care's Triple Aim of improving population health, enhancing the patient experience and reducing costs. And towards the end, we are launching a new campaign designed to remind customers that the value that Quest brings to health care. Our power and affordable care campaign speaks about our leadership in clinical innovation, our ability to enable better clinical outcomes for quality, speed and accuracy of test results, our improved patient experience with accessible easy to use patient resources and finally, our ability to reduce cost of care. Base consumer initiated testing revenues continued to grow in the quarter. Today, more than 17 million patients have an account on the MyQuest app and patient portal with nearly 100,000 patients enrolling each week. In the 5 million advanced diagnostics, we're pleased to see full recovery in the growth drivers we're investing in, which we discussed at our recent Investor Day and are tracking to accelerate growth.",0.7495881,0.991
DGX-2021-Q2-2021-07-22,15,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now turning to our second strategy. We made progress driving operational excellence. We're on scheduled to complete the full transition to our new flagship laboratory in Clifton, New Jersey next month. This highly automated facility has consolidated testing previously performed in Teterboro, Baltimore and Philadelphia. There continues to be intent effort and energy around our invigorated productivity initiatives and we're on track to deliver our targeted 3% improvement across the business. We are focused on getting paid for what we do. We have made steady progress in reducing payer denials also patient concessions for our base revenues were down in the second quarter to 2019 levels, driven by a focus on collection improvements. One positive outcome of the pandemic has been the patient and physician acceptance of the digitization of our experience. We are more customer focused and efficient today with more self serve options for customers and we have moved a greater percentage of volumes to digital paperless transactions.",0.307084,0.987
DGX-2021-Q2-2021-07-22,16,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Now I'd like to turn it over to Mark to provide more details on our financial performance and our outlook for the remainder of 2021. Mark?,0.9268534,0.361
DGX-2021-Q2-2021-07-22,17,Remarks,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the second quarter, consolidated revenues were $2.55 billion, up approximately 40% versus the prior year. Revenues for Diagnostic Information Services grew 40.2% compared to the prior year, which reflected the strong recovery in our base testing revenue, slightly offset by lower revenue from COVID-19 testing services versus the second quarter of last year. Compared to 2019, our base CIS revenue grew nearly 5% in the second quarter and it was up more than 1% excluding acquisitions. Volume, measured by the number of requisitions, increased 45.2% versus the prior year with acquisitions contributing approximately 5%. Compared to our second quarter 2019 baseline, total base testing volumes increased nearly 7%. Excluding acquisitions, total base testing volumes grew approximately 2% and benefited from new PLS contracts that have ramped up over the last year. Importantly, compareto our 2019 baseline, our base testing volumes were [Audio interrupted]",0.0256714,0.902
DGX-2021-Q2-2021-07-22,18,Remarks,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We discussed making approximately $75 million in targeted investments to support our long term strategies to accelerate growth. These investments are ramping with $50 million expected to fall in the second half. We also continue to incur expenses to comply with CDC guidelines, address supply chain challenges and maintain staffing levels to ensure high levels of service and quality as the base business recovers faster than expected. We forecast these expenses to be approximately $30 million in the back half of the year. Finally, the low end of our outlook assumes an average of at least 20,000 COVID-19 molecular tests per day and 3,000 serology tests per day. It also assumes low single digit revenue growth in our base business in the second half of '21 versus 2019. The midpoint of our guidance assumes slightly stronger COVID-19 molecular testing volumes and a modestly faster recovery of the base business and the high end of our guidance assumes both a greater level of COVID-19 testing and the strong continued recovery in the base business.",2.0398894,0.929
DGX-2021-Q2-2021-07-22,20,Remarks,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. Well to summarize, we had another strong quarter with a faster than expected recovery in our base business. We are well positioned to continue our momentum and support the return to health care in the coming months. And then finally, I'd like to thank all Quest employees and the team to serve the needs of people who rely on Quest every day. Now we'd be happy to take any of your questions. Operator?",1.7390445,0.972
DGX-2021-Q2-2021-07-22,22,Question,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I just have a question on -- I think you just said your guidance assumes about 20,000 molecular tests per day. Is that average for the entire second half or is that exiting the year? Also, can you just talk about what your guidance assumes for any kind of labor and inflation pressures for the second half? And do you see that those getting worse or are they stable throughout the year?",0.3424171,0.627
DGX-2021-Q2-2021-07-22,23,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So Ann, at 20,000 is not the exit rate, it is the average for the back half. The 20,000 was the baseline for the low end of guidance. To get to the middle part of guidance, we would expect somewhat stronger than 20,000, of course there's moving pieces because it's also dependent on how the base business moves. And then the high end of guidance would be significantly more COVID testing and then a stronger base business recovery more in the mid single digits revenue. So that's how we try to dimentionalize the range for you. In terms of labor pressure, we certainly saw some of that and we responded to it and that's built into the whole year. It's not accelerating at this point in our outlook in the back half. So we have a process where we make annual salary and wage adjustments that was implemented earlier in the year. We certainly make some market adjustments periodically, which we've done and that's not unusual. So there's nothing extraordinary in the back half of the year in terms of labor inflation.",0.2381517,0.0
DGX-2021-Q2-2021-07-22,25,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I guess my question for you, Steve. As we think about the PLN and the preferred networks, it sounds like we're seeing some progress there. But any color you can give us on the recovery and the uptake and the traction you're getting there, especially as we exit the COVID drag.",0.1568369,0.989
DGX-2021-Q2-2021-07-22,26,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we're feeling about the programs we've put in place over the last couple of years, Brian. We started these with United, as you know. And then we mentioned that we have a program that we're working with Anthem across the country, so we feel good about. We continue to work on the programs with other payers that see this as an opportunity as well. And what I said in my remarks, we do see those payers and the volume going through those payers growing faster than our other base recovery. So we feel we're actually getting some traction where everything was put in place. And I can tell you the engagement between us and those organizations are quite good. And I've said before in my remarks, we see an opportunity to get a variation to move with a high quality low cost value laboratory like Quest Diagnostics and then tighten up the network to what we describe as for lab network. And it's really all about what we've talked about in my remarks around the triple aim and primarily in affordable care. So good progress. What we've done already is making advance in the opportunity and we see more opportunities in front of us.",0.8955519,0.0
DGX-2021-Q2-2021-07-22,28,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",I wanted to dig in a little bit more on the base business recovery. Was it fairly linear since the end of March to the commentary you made around June? And then was curious if you're seeing any sort of pent-up demand and whether you thought that might have helped the trajectory? Any commentary around test per acquisition that would be helpful.,1.1008237,0.666
DGX-2021-Q2-2021-07-22,29,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we are seeing a nice step by step improvement in base business. I would say it's been a nice recovery over the sequence of the first half. You remember we entered the half with our base business being down somewhat around high single digits and kind of improved throughout Q1 and that continued into Q2. And there's different ways we look at it what is the clinical cost and we actually see good recovery in our general health business or current [metabolite] business. I mentioned in my remarks, our advanced diagnostics business, which includes a portion of cancer and genetic [binocular] testing to recovery. We still see our prescription drug monitoring and toxicology business being somewhat of a laggard, but they're actually starting to recover, not back to '19 levels but it's coming along.",0.3360791,0.806
DGX-2021-Q2-2021-07-22,30,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then on a geographic basis, we do see much of the country of the after '19 levels. And as I said before, the Northeast is stubborn -- we started to move in the right direction, Massachusetts and Connecticut and New York City being the slowest recoverer, if you will, and that's all boroughs, not just been happening. And we're hopeful as the opening continues as people get back into life within that's happening in New York that, that will recover as well. So to answer your question you started with it has more of a nice steady progression clinically and also geographically. Mark, anything you'd like to add to that?",0.7523697,0.864
DGX-2021-Q2-2021-07-22,31,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The only thing I'll add, Jack, is that it is somewhat uneven even though it has been steady nationally. And we do have a couple of regions that are actually back to the volume growth we had in those first couple of months of 2020 before the pandemic. So that's why we're feeling good not just about utilization recovery, we're really good about getting back and working on the things with our key partners such as the PLN and other relationships that we've called out with some of the payers around value based contracting and then really continuing to have our strong relationships with hospital systems. And we've talked about how much progress we've made around POS. So the good news is that things are open for business. We're able to go back in to the offices, not completely, but much more than we were over the last 12 months plus. And therefore, we're getting back to what we were doing before the pandemic started.",1.1520537,-0.128
DGX-2021-Q2-2021-07-22,32,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",And was there anything relating to pent-up demand that you saw?,2.0892916,0.964
DGX-2021-Q2-2021-07-22,33,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","You know it's hard to tease out. What we talked about in our calculation of revenue per req is that we are seeing more tests per requisition. So one could assume that some of that is tag on the test because the divisions show a step up in the office and they haven't been there for 16 months. So hard to tell, you got to believe there's a little bit of that in my prepared remarks as people return and catch up on pre-pandemic levels. But we've also, to Mark's point, that we've done into '19 but remember when we started '20, we have some nice growth in the first couple of months. So we've got more opportunities in front of us to continue to recover and also build on top of what we see to gain that share we're planning for.",0.9930807,0.0
DGX-2021-Q2-2021-07-22,35,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Just a quick follow-up and then sort of my main question. Just on the follow-up, you mentioned that you renewed the Aetna contract. So just wanted to understand how should we see the remodel, how should we think about the pricing impact for the next 12 months? And then when we think about the value based programs that you're now signing with payers. I think, Steve, you mentioned that it's actually growing faster than the rest of your book. Can you maybe give us some color on where you're seeing these value based relationships and mostly focused on commercial versus Medicare? And also what's the framework, are you sharing upside from the savings or are these more sort of fixed price contracts with some downside protection.",0.5304778,0.077
DGX-2021-Q2-2021-07-22,36,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Mark, do you want to talk about what's in",1.2310427,0.977
DGX-2021-Q2-2021-07-22,37,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So first off, the Aetna contract was extended. It will be invisible to you because there was no significant change in pricing. And in that contract, we continue to build stronger elements of what we call value based programs and I'll touch on that in a minute, Ricky. So it's more focused on commercial, although obviously, Medicare Advantage as well. There are certain things you can do in the [pure] commercial that are harder to do in Medicare Advantage because some of the rules around that program. But the framing is not us sharing our upside with them but really they're sharing their upside with us. So we win together. So as we show greater value for their membership by getting more work to a better value lab like ourselves relative to out of network providers or in some cases other high cost providers in network, obviously, their members or for their fully insured book, they themselves pay money, and then we earn upside to a base level contract. And that base contract is not at a discount, it's really been kind of a historical level.",0.1015008,0.987
DGX-2021-Q2-2021-07-22,38,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we didn't have to give up in order to gain. But it was really more about the case that we've been making for years that's getting more and more buy-in from the payers that we're part of the solution. And working with us and not focusing on our price but focusing on what we can do to drive better quality, better service and better value for their members is good for everybody in that ecosystem. So that's really the elements we shared. Steerage when they give us list of accounts where a lot of efforts going to out of network or higher cost providers. We go in with their support, calling those to educate for the people who have [national] plans, coinsurance, et cetera. So the patients are bearing some of that higher cost, which obviously has more influence benefit that's fully covered by the payer in terms of the doctor.",0.7578989,0.989
DGX-2021-Q2-2021-07-22,39,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then we talked about M&A incentives where in the past when we would buy hospital outreach as soon as we start billing it and fall to our price, obviously, and the huge windfall to the payers but that it's good for them if we buy outreach and therefore, instead of taking that debt immediately, maybe a step down in those rates and we share some of those savings over those first couple of years. And that's an element we've gotten into just like every one of the major payer contracts. So it's things like that, Ricky, where we've made the case and they're finally buying in that when we're successful and they're successful together we can do more of that and therefore, there is upside than in the past we didn't see that now we have a chance to earn when we prove that we've actually saved them money and driven improvement for their members.",0.1658768,0.0
DGX-2021-Q2-2021-07-22,40,Question,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So just one follow-up on the upside payment to base levels. So should we think about that now that sort of at the end of the year as you calculated by the upside, we could see upside to numbers from payments at the end of the year, or is this something that would just kind of flow through on a quarterly basis?",0.3467615,0.911
DGX-2021-Q2-2021-07-22,41,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Well, I'll address the two examples I gave. So in the steerage one, where we're moving work, it's really more quarterly. So it's a constant look at that. We have a formula for doing that and then we're reimbursed more regularly. It's not a once a year catch-up and that's much better for us for a lot of reasons, not just for more regular rev rec but also for accounting purposes and so on for both of us, that's a better approach. On the M&A, obviously, that would be somewhat invisible to you. Because when we do a deal what it just means is that we get paid more than we would have historically a little bit with some of a premium over what our negotiated rates would be for the volume that clearly has moved from that hospital system to us, the hospital outreach business. So you're not going to really see that. Again, that's going to be a regular monthly quarterly thing, not a catch up.",0.3834913,0.0
DGX-2021-Q2-2021-07-22,43,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So you mentioned PAMA in the prepared remarks, and looks like the cuts are likely to restart next year. Maybe just remind us the headwind. And then at your Analyst Day, you suggested an EPS range for 2022 and kind of pointed to the higher end, I think, closer to an $8 number. Just wanted to confirm that, that assumed PAMA was coming back. And then just your comments on incremental investments that you talked about in the back half. Just wondering does that change anything related to that $8 number that we should be thinking about for 2022?",0.5242175,0.659
DGX-2021-Q2-2021-07-22,44,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Let me start with PAMA. So remember we said in our remarks we're filing hard to get a better answer on PAMA. And so hopefully, that was clear in the remarks. We do believe that the MedPAC report, those gave us some data that suggests that we were right with saying that if you collected all the data, it was representative that there will be a 10% to 15% reduction in the rates versus what we see now. And we obviously have some work to work with reduction in the price cost, not a reduction in the clinical outreach, just to make that clear, an increase of 10% to 15%. And in that regard, we have some work to do to get that through congress because it's going to be a legislative fix but we're going to keep on pushing on that. But with all that said what I'll keep on saying is we're assuming worst case in our outlook that in '22, we'll see another top. So that's clear. And then Mark, do you want to talk a little bit on the range and where are we pointed to at Investor Day.",0.549763,0.586
DGX-2021-Q2-2021-07-22,45,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So what I would say is that I laid out the CAGRs from 2018 and said obviously, the pandemic has clouded issues with the base business. And at some point, we all hoped COVID is a much smaller piece of our revenues. And the base business CAGR that we laid out would have suggested [$748], and what we were saying is based on a base business being fully recovered by the end of the year and everything else that we're confident we should be in that range. And yes, we felt because of everything we knew at that point that it should be in the upper end of that [$748]. PAMA was absolutely included in that. As I shared that at this point, if nothing changes, should be the last year of the sizable reductions that we've had since PAMA was implemented. So based on the current fee schedule and the current methodology, there can be 15% cut on any CPT code next year. And we estimate our overall book of business is going to be somewhere between 10% to 15%, so higher than 10% but less than 15% based on what we can see.",0.9091627,0.867
DGX-2021-Q2-2021-07-22,46,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","However, because that traditional Medicare book of business is much smaller than it was when we started, the dollar impact is actually going to be similar to what it was in the first couple of years of PAMA. So it's still a large number, somewhere around 1% of our overall revenues. And then once you get beyond that, even if PAMA isn't fixed, based on our understanding of commercial pricing and we don't know everything but certainly, we know our prices and we've shared that we've really stabilized commercial pricing, combined with some competitive intelligence in the marketplace. We feel that while there might be some cuts with the recalculation they're going to be relatively small compared to what we incurred for several years.",0.5802306,0.984
DGX-2021-Q2-2021-07-22,47,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And we continue to feel good about the investments we're allowed to make on the additional resources. We talked about at Investor Day, about $75 million worth of investments. We talked today that continues in the back half of the year, that's guidance in the outlook or the guidance we provided. And it's entirely consistent with what we teed up at Investor Day and on our growth platforms. We're investing in both self plans relationships with hospital opportunities we see. We see opportunities to accelerate advanced diagnostics. We feel good about the recovery we've seen there and then also the opportunity we see around the consumer and consumer initiated testing. So our performance is allowing us to make these investments to accelerate growth, to get to the outlook that we provided to you for '22 and beyond, which is the 4% to 5% top line growth in high single digit earnings growth. So we feel good about our ability to make those investments and we're are making them. So we're hiring the people, we're spending the money and it's included in the guidance in the back half.",0.4652449,0.844
DGX-2021-Q2-2021-07-22,48,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then the revenue as well. So some of these are several years in the coming in terms of the return and some of them we get much more immediate. On consumer, we've talked about potential $0.25 million business by 2025, that's coming from small [millions] before the pandemic. And so you could imagine that with some of the things we're doing, we're going to be building significant incremental revenue to get to that $250 million over the next couple of years. It's not going to all come in the last year or something like that. So we're getting revenue growth upside as well for those investments, not just incremental expense.",0.4537915,0.0
DGX-2021-Q2-2021-07-22,50,Question,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Two quick follow-up questions here. On the 2021 guidance, you quantified the COVID assumptions and base business assumptions for the low end of guidance. Can you quantify the same levels for the midrange and the high range guidance? And just to clarify on the last question, the investments that you're making this year, does this continue into 2022 and beyond? Are they onetime in nature or do you have to add additional investments next year?",0.150079,0.218
DGX-2021-Q2-2021-07-22,51,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So I didn't intend to quantify with specificity been at high end, because it's a multivariable equation. So what I wanted to do was make clear the low end for a lot of reasons. You can imagine, we wanted to make people understand how we might get to that low end. And it's not a base business recovery that stalls or goes backwards so it's really a much slower than what we've seen and that we would expect. And we don't think there's a high probability for that. But one thing we've learned this pandemic is all these things are somewhat volatile and hard to predict. If you saw a lot of retrenchments across the country because of the celta variant or other things that might cause geographies to shut down, we want to make sure that we provide you guidance that are 95% plus deliverable or even more.",0.0904423,0.718
DGX-2021-Q2-2021-07-22,52,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So once you get beyond the floor, there's so many different moving parts that could go in opposite direction. It's kind of harder to give you a point estimate. We wanted to make sure that people also understood that the COVID average per day, we anticipate for the balance year significantly lower than we're getting right now. As you might imagine, we've been working on this outlook for a while. The recent news with obviously delta driving up the positivity rate cases, obviously, our volume is increasing. One thing we've also learned is not to overact the short term. So we're very transparent. So we give you those volumes every two weeks. So we felt that we can build reasonably deliverable, highly deliverable outlook to make clear what those assumptions are and especially around the COVID volumes, you're going to see that every two weeks. So you're going to know where we're going in terms of net outlook range that I laid out this morning.",0.5775947,0.872
DGX-2021-Q2-2021-07-22,53,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As far as the investments, some of the investments are temporal within '21. But as you would expect, we're investing in long term capabilities that will continue into '22. But rest assured that to be reapplied business case and the revenues associated would be there as well. So yes, we will have the outlook assumptions, we'll have some portion of these investments to '22 and trust that those investments are investments for us to do that.",0.7432859,0.923
DGX-2021-Q2-2021-07-22,54,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And back to Ralph's question, again, I want to emphasize those were built into the outlook that I provided in Investor Day. So we've tried to make clear that we see these growth opportunities. The COVID revenue upside give us the opportunity not just to deliver some record earnings for the last couple of quarters but actually to invest and accelerate the long term prospects for our base business. So we thought it was the right balance between near term delivery results as well as the long term growth of the business. And so when I gave you that multiyear outlook for years and then when I frame 2022, those all fully contemplated these investments.",0.0197472,0.382
DGX-2021-Q2-2021-07-22,58,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","This is actually Tim Daley on for Dan. So I just wanted to dig a bit more on Pito's question. So I believe the back to school total opportunity has framed as upside in relation to the guidance for the second half of the year. So first, I just wanted to clarify, is there any back to school testing baked into the COVID guidance or company level ranges discussed? And then secondly, given we are kind of weeks away from kids heading back to school. I'm sure there's been some discussions, but could you give us some insight into the internal on the ground discussions happening? Like are there broad based general screening plans for back to school and maybe a big one off push at the start of the year? Just any more additional color there would be really helpful.",1.5008237,0.908
DGX-2021-Q2-2021-07-22,59,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So Mark just laid out expectations around COVID testing. We did assume that the clinical testing would come down and the return to life testing would go off and a portion of that return to life has to do back to school programs. And what we highlighted is we've been working with the different partners with two programs that are funded with the funding for testing. One is the 600 million program for return to school programs where we have partners to help us with that and school systems throughout the United States could apply for that money and get money to reimburse whatever program come up. And then there's a larger program to about $10 billion. But as you can understand, I mean, every school system throughout the United States is going to have its own plan. And so they're going to start ramping up soon than into the month of August and in September. And I think there is going to be a fair amount of variance across the United States and who does what, when.",0.6191104,0.962
DGX-2021-Q2-2021-07-22,60,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And I do believe that given what we see now with the delta variant, I'm sure that will have some bearing on the need for testing to make sure that we're safe when kids return back to school. And also return to office programs, we do expect that there will be more returning to the workplace, those people that have been working remotely. I think clearly, there's been heightened level of safety with that happening. And as I said in my earlier remarks, testing is vital to that. So we've embedded that in our expectations as well. But we assume that clinical testing would come down. We believe that a lot of our capacity is not used for the hospital portion of COVID testing as in the early days of COVID testing. And some of the recent increase that we've seen has been related to some of the effects we see from the delta variant so far in the last week or two. So hopefully, I've provided some color on what's assumed in the guidance so far.",0.7373618,0.832
DGX-2021-Q2-2021-07-22,61,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I just want to remind everybody how that surveillance testing works. It's very different than our clinical testing. So if you think about the PCR test today where we're averaging over $90 per test, that's not economical for surveillance. So what we have come up with the numbers are as well, our methodology is a heavily pulled approach. We pull a handful of samples today when we're testing in low positive regions for economic reasons. But it's our responsibility if we are positive to retest those individual samples. So you don't want to pull too many because the math suggests that you're going to be retesting a lot of samples. And so when you go to surveillance, the assumption is that nobody has it. And so therefore, you're going to do a lot less retesting. But actually, in this case, we're not obligated to do it because they're not even identified.",0.6737757,0.873
DGX-2021-Q2-2021-07-22,62,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So what happens is the collections done, the entity, in this case, the school, knows whose 10 samples, let's say, are in that specimen collection device. It's not shared with us. All we do is test it and we say this is negative hopefully. And in the case where it's positive then they, the administrators, know which students need to be retested. And then that's a separate order. That's a separate payment, et cetera. And so the reason that's important is that in order to make this economic and because the economies can be kept with this huge coin, we have to do approximately 10 specimens to equate to a single one for our core PCR vessel. So the volumes have to be 10 fold at the same dollar values for our top line. So yes, there's absolutely some contracts we won, we've got some of that volume. But to really move the needle it has to be really broadly endorsed and embraced. And while the funding there, to this point, we've seen some momentum but not enough to be significant at this point and really move the needle to offset the decline in the clinical testing we've seen over the last several months.",0.3246445,0.0
DGX-2021-Q2-2021-07-22,64,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So twp quick questions. Just a little bit more color on the recovery in the base business, just are you seeing anything in particular in terms of oncology and esoteric versus routine testing? Just a little bit more color on that. You gave some geographical differences, but I'd love some mixed differences. And then another question that keeps coming up. In contrast, you're guiding to -- we just got off the [Danaher] and they're talking about, they went from 10 million point of care tests in the first to 14 million point of care tests in the second quarter. So one of the question we continue to get on the central lab is the impact longer term on the business on point of care testing, is this trend going to continue, particularly given the number of players that are sort of entering this market from the point of care and at home space. So I'd love to hear your general thoughts on sort of your spot on volume shifts to certain applications into the point of care market? Thank you.",1.3650741,0.927
DGX-2021-Q2-2021-07-22,65,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me start with the first one. So what we said is our general health and our cardio metabolic testing, which is sometimes referred to by us as our general diagnostics and I would say the industry sometimes is also -- routine type of prognostic and that's in the United States and that's recovered there. Second, as you asked about oncology, we've seen some recovery at our AP business and pathology business. And as I said in my remarks, our advanced diagnostics business, which is our definition of sometimes called esoteric has actually recovered nicely, and we are making investments there, and we think we're tracking well against our investment accelerated growth plan. So we feel good about that.",0.7080725,0.96
DGX-2021-Q2-2021-07-22,66,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the second question, which has to do with point of care. And when I say point of care, the PCR point of care and then also the antigen test. We do believe there's some portion of the testing demand, if you will, that's taking place with these new approaches. We do believe there is a place that we would return to work programs related to testing and some of the point of care applications. Well equally what you see with our volumes somewhat stabilized, as you saw in the second quarter when we report our numbers and the modest increase that we saw is PCR continues to be the gold standard. And so in many cases, they do reflex back to the PCR testing when there is a positive for sure, questionable negative metric not the false negative. So we do believe we did a good place in the marketplace and we do believe there is point of care devices, including the antigen as well as PCR going forward.",0.8065898,0.0
DGX-2021-Q2-2021-07-22,68,Question,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,This is Julia on for Tycho today. A lot of my questions have been answered already. So just following up on an earlier question about your payer program. It's great to see that you're having success with United and Anthem and recently with new contract with Aetna as well. You previously said the volume through these relationships are growing faster than the rest of your book. Just curious if you can provide some additional color on how much faster these volumes are growing? And what kind of investments you are making to capitalize on these opportunities?,1.6587678,0.94
DGX-2021-Q2-2021-07-22,69,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So as you might imagine, there's not an answer to how much faster because they're not all equal. And also there are more -- each of them have more concentration in certain geographies. So as we shared with Northeast and specifically New York City is growing at different rates. So if you assume that payer there, more membership there, we might have a different answer than the payers that are in Texas. So Florida, I would say, or even California. So we've looked at, because it's one of our key -- you know, we have a full process, we call the [oceans] and we have these breakthrough objectives, one of them is growing our share in these health plans. And we look at it regularly and we share information back and forth to understand kind of our share of wallet with those. And so we have chance to see as they themselves also are recovering in terms of the volume that's going through their membership, whether we seem to be growing at the same pace in that recovery. And that's the basis for our saying that we're growing faster.",0.1836493,0.94
DGX-2021-Q2-2021-07-22,70,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So you know in this business a couple of hundred basis points is a big difference. It's not going to be half a percent or double digit kind of differential. But couple of hundred basis points of share growth is meaningful. That's clearly what we saw before the pandemic started as you look back to our 2019 performance, what we shared in the first two months of 2020. So line of the business utilization becomes fully recovered what happen is that we'll get back to that, not just historical growth of market but finally getting to growth above that by share gains. And that's what we laid out in our multiyear outlook at Investor Day.",0.7301483,0.881
DGX-2021-Q2-2021-07-22,71,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And as far as investments, what Mark said is everyone plans all the detail, plan of what we're going to do to gain that share. And some of that happens nationally and some of it happens locally and some of it happens by line of business. So we do have some programs to go with the payer to grow national talents and their plan sponsors and plan sponsors. And so a lot of that is local. And so you asked the question where we're making investments. We'll put those investment dollars where we think we need extra capacity to drive those programs by payer. And there's a lot of variation around where those opportunities are by payer and that detail is what we're speaking to when we talked about investments in the health plans.",0.385861,0.818
DGX-2021-Q2-2021-07-22,72,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I'll just give you one other example, which we've shared in the past, but it's really expanded broadly. So take toxicology in perspective of monitoring. The payers as that is starting to grow and there was some concern the payers part around the behavior of some of the providers, they put in some really onerous rules in place, such as pre-authorization and so on. Of course that impacts everybody, including the people like ourselves who are very responsible around our panels and how we conduct ourselves. And so we went for some of the payers, talked to them about that and said, hey, not only is that not right for us, it's not right for the patient, because it's going to be make it more difficult for them to get testing they need. But also if you got rid of that, you would actually steer more work to the good less.",0.4131122,0.839
DGX-2021-Q2-2021-07-22,73,Answer,2021-07-22,2,2021,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And when I say it's not just certainly our chief competitor and some others are just like us, they're very responsible. We do good work and tops calling prescription monitoring. So they put in rules in place where we're actually vented from pre-op. So that's another example where it's really not an investment, it's an investment of time to work with them to get them to understand and get them to change some of these rules and behaviors. But again, as an example where we're benefiting but so are the patients and a lot of other people, because it's a more thoughtful approach to rules around lab testing.",0.85703,0.0
DGX-2021-Q2-2021-07-22,75,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So the Clifton lab went live in January and Steve, I think you said the consolidation from it will wrap up here next month. In the past you talked about sort of doubling throughput, 30% more capacity, I think 50% increase in productivity. Just curious if there are any data points to share so far on how the consolidation is going, and how we should think about the impact to margins as volumes consolidated into Clifton?",1.6995058,0.99
DGX-2021-Q2-2021-07-22,76,Answer,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So we're pleased with what we're able to do. It's pretty remarkable that we built this facility in the middle of the pandemic and for all intents and purposes that are on track and it's up and running. And we bring in this facility to do that consolidation, we have to continue our program around organizational processes and harmonization around systems to get them all in the same platform within the new facility. So we're on the final strokes of that implementation, we feel good about it. And then in that facility, we have implemented a lot of the new systems we've been in place for our new immunoassay platform from Siemens, we talked about, it's a big investment for us. We are getting some pretty good gains for them and more to come. We'll put in place new front end automation and through the lab automation with our partner Inpeco. And actually, Siemens has done the systemization with that as well. So we are pleased with the progress made so far and we're looking forward to more productivity from that going forward as we continue to burn in systems and work out some of the early details and those improvements are already part of the 3% productivity gains that we have in our operational excellence program and that are already included in our outlook that we provided at Investor Day.",1.1723229,0.44
DGX-2021-Q2-2021-07-22,78,Question,2021-07-22,2,2021,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. So thank you, everyone, for this call, and we appreciate your continued support. You have a great day.",0.9736409,0.527
DGX-2017-Q1-2017-04-20,3,Remarks,2017-04-20,1,2017,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I am here with Steve Rusckowski, our Chairman, President and Chief Executive Officer; and Mark Guinan, our Chief Financial Officer.",0.5138926,0.66
DGX-2017-Q1-2017-04-20,4,Remarks,2017-04-20,1,2017,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and also discuss non-GAAP measures. For this call, references to adjusted EPS refer to adjusted diluted EPS excluding amortization. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in Quest Diagnostics' 2016 Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. The text of our prepared remarks will be available later today in the Investor Relations page of our website.",0.4583223,0.34
DGX-2017-Q1-2017-04-20,6,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks, everyone, for joining us today. This morning I'll provide you with highlights of the quarter and review progress on our strategy and then Mark will provide more detail on the results and take you through updates on our 2017 guidance. We began 2017 with a strong first quarter across the board drawing revenues, EPS, operating income, margins and operating cash flow.",0.3456343,0.898
DGX-2017-Q1-2017-04-20,7,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Here are some of the key highlights -- revenues were up approximately 2% on a reported basis and 3% on an equivalent basis. Reported EPS of $1.16 increased 63% in 2016. Adjusted EPS grew approximately 18% to $1.33 which includes $0.11 of excess tax benefit associated with the employee stock-based compensation; more on this later from Mark.,0.9215815,0.625
DGX-2017-Q1-2017-04-20,8,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Cash from operations increased 28% to $196 million. Now before I describe the progress we've made to accelerate growth and drive operational excellence, I would like to briefly discuss PAMA. CMS postponed the deadline for labs to report private commercial payer pricing data under PAMA for 60 days until May 30. We fully support the decision. However, we continue to have some concerns about the current definition of applicable laboratory, which are those laboratories per quarter to report private commercial payer data.",0.4675453,0.936
DGX-2017-Q1-2017-04-20,9,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","According to the office of Inspector General's analysis, the current definition of applicable laboratory would cover only 5% of laboratories, representing only 69% of Medicare payments for lab test in 2015. While we support reform of Medicare payment system, we believe any modification should be market-based and appropriately include all applicable independent and hospital outreach laboratories.",0.475453,0.586
DGX-2017-Q1-2017-04-20,10,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now let's review progress we've made. As we detailed at our Investor Day at November, our two-point strategy is to accelerate growth and drive operational excellence. We grew revenue in the quarter empowered by continuing to expand relationships with hospital health systems. Our existing professional lab services relationships including RWJ Barnabas in New Jersey, HCA in Denver and most recently, Montefiore in New York City are performing better than expected and our pipeline for new relationships remains strong.",0.6135091,0.952
DGX-2017-Q1-2017-04-20,11,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So in the first quarter we announced the acquisition of an outreach operation of PeaceHealth Laboratories and expect to close in the second quarter. In addition after the close, we will execute a professional laboratory services agreement to manage 11 PeaceHealth Laboratories serving medical centers in three states in the Pacific Northwest.",0.2286656,0.649
DGX-2017-Q1-2017-04-20,12,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We are hardening with health plans to improve the patient experience by improving price transparency which will also reduce bad debt. Our real-time payment determination which we begin piloting in early 2016 enables us to get patients an accurate picture of their financial responsibility or lab testing while those patients to pay at the point-of-care. We are currently live with Aetna, Highmark, UPMC, Florida Blue, and we expect to have more payers in place by the end of the year. The service benefits Quest and the entire healthcare systems; patients, providers and payers.",0.7617792,0.382
DGX-2017-Q1-2017-04-20,13,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Avis Diagnostics which generally includes our genetic and molecular based test grew in the quarter along with non-routine testing. Major drivers included neo-natal genetic carrier screening, prescription drug monitoring, hepatitis C and QuantiFERON TB testing.",0.4375618,0.0
DGX-2017-Q1-2017-04-20,14,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In the quarter we also announced the launch of the new test service that helps physicians evaluate the patient's response to the drug therapy used to treat infection with hepatitis B virus, HBV; this is the first test of its kind available in the United States. Physicians can use it to tailor more effective treatments for up to 2.2 million individuals infected with HBV.",0.5258649,0.893
DGX-2017-Q1-2017-04-20,15,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're also making progress executing our strategy through provider-of-choice for consumers. In late January, we began providing genotyping for ancestor DNA, a service that today identifies and quantifies individual's ethnic origin based on results of DNA testing. We are pleased with the initial execution of this program and look forward to building on a relationship with ancestors. We continue to expand our relationship with SafeLink that are now operating at 65 stores. Consumer and employee satisfaction remain high and we are on-track to open a total of 200-patient service centers and Safeway stores by the end of 2017.",0.415486,0.872
DGX-2017-Q1-2017-04-20,16,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to drive operational excellence and remain on-track to deliver $1.3 billion of run rate savings as we exit 2017. Our revenue services partnership with Optum is on-track in helping us to drive down bad debt and denials. As we have often said, quality and efficiency go hand-in-hand. We continue at near Six Sigma levels of many areas and in the quarter of mid year-over-year gains and many quality measures including reduced patient service center wait times and approved test turnaround times.",0.5654036,0.718
DGX-2017-Q1-2017-04-20,17,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We expect our commitments to enable our processes will deliver results. We expect to cut paper acquisitions by 50% by the end of 2017. It will enable patients to check-in electronically at roughly half of our patient service centers by the end of the year. Additionally, we expect our lab systems to be 85% standardized by the end of the year. We received some meaningful recognition in the quarter, once again being named one of the World's Most Admired Companies by Fortune magazine. Quest was one of only six companies in healthcare, pharmacy and other services industry and the only diagnostic information services company to attain most admired status.",0.6125206,0.835
DGX-2017-Q1-2017-04-20,18,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Looking forward to the remainder of 2017, we are well-positioned to continue to accelerate growth and drive operational excellence. We have the right strategy and the right team to execute and create value for our shareholders.",0.3940692,0.881
DGX-2017-Q1-2017-04-20,19,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, let me turn it over to Mark who will take us through our financial performance in detail. Mark?",0.8691928,0.0
DGX-2017-Q1-2017-04-20,20,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. Starting with revenues, consolidated revenues of $1.9 billion were up 1.9% versus the prior year on reported basis while equivalent revenues grew 3%. Revenues for diagnostic information services grew by 3.2% compared to the prior year. Most of this growth was organic with approximately 90 basis points attributed to the 2016 acquisition of Clinical Laboratory Partners. Volume measured by the number of requisitions increased 3.5% versus the prior year, of which 2.6% was organic. The year-over-year impact of weather was negligible in the quarter.",0.6879937,0.824
DGX-2017-Q1-2017-04-20,21,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per requisition in the first quarter decreased by 20 basis points versus the prior year. As a reminder, revenue-per-req is not a proxy for price, it includes a number of variables such as unit price variation, business mix, test mix and test per req. Unit price headwinds in the first quarter continue to be moderate in less than 100 basis points. We note that price fluctuations can vary from quarter-to-quarter, but we continue to expect that unit price headwinds will remain consistent with the last few years. Beyond unit price and the impact of growth in our POS partnerships, other mix elements including test and fair mix contributed more than 1% to revenue-per-req in the quarter.",0.8511058,0.758
DGX-2017-Q1-2017-04-20,22,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income for the quarter was $279 million or 14.7% of revenues compared to $257 million or 13.8% of revenues a year ago. On an adjusted basis, operating income was $297 million or 15.6% of revenues, compared to $281 million or 15.1% of revenues last year. Please keep in mind our focused diagnostics products business contribute approximately $8 million of adjusted operating income in the first quarter of 2016. Excluding the impact to focused, adjusted operating income would have grown approximately 9% and adjusted operating margin would have increased 80 basis points year-over-year, consisting of 30 basis point of operating margin tied to focused in 50 basis point of adjusted operating margin growth.",0.742891,0.915
DGX-2017-Q1-2017-04-20,23,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $1.16 in the quarter, compared to $0.71 a year ago. The prior year a quarter included a charge of $30 million after tax or $0.21 per diluted share related to the early retirement of debt. Adjusted EPS was $1.33, up 18% from $1.13 last year. The company recorded after tax charges totaling $11 million in the first quarter or $0.08 per diluted share, representing restructuring and integration cost. Our effective tax rate in the quarter was approximately 32%, compared to approximately 39% last year. The decrease in the effective tax rate was a result of $16 million or $0.11 per share in excess tax benefit associated with stock-based compensation, compared to a $2 million or $0.01 per share benefit last year.",1.1875987,0.937
DGX-2017-Q1-2017-04-20,24,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Bad debt expense as a percentage of revenues was 4.4%, 20 basis points better year-over-year, but 80 basis points higher than the fourth quarter of 2016. As a reminder, bad debt expense rate typically increases sequentially in the first quarter due to the reset of payings in health insurance deductibles at the beginning of the year. As in the prior years, we expect the bad debt rate to improve gradually throughout the year. Note that the year-over-year compare was also negatively impacted by the fact that our products business had a lower associated bad debt rate.",0.8850711,-0.986
DGX-2017-Q1-2017-04-20,25,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Cash provided by operations in the first quarter was $196 million versus $153 million last year. Recall the retirement of debt lowered our operating cash flow by approximately $47 million during the first quarter of 2016. Capital expenditures during the quarter were $42 million, compared to $47 million a year ago.",0.6093997,-0.459
DGX-2017-Q1-2017-04-20,26,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now turning to guidance. We are providing the following updated outlook for 2017. Revenues unchanged to be between $7.64 billion and $7.72 billion, an increase of 1.7% to 2.7% versus the prior year on a reported basis and an increase of about 2% to 3% on an equivalent basis. Reported diluted EPS to be between $4.73 and $4.88 and adjusted EPS to be between $5.45 and $5.60. Cash provided by operations is also unchanged and remains at approximately $1.1 billion, and finally, capital expenditures remain between $250 million and $300 million.",0.7318325,0.557
DGX-2017-Q1-2017-04-20,27,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our increased EPS guidance reflects the higher expected level of excess tax benefit associated with stock-based compensation and was included in our previous guidance. Note that our original EPS guidance assumed a similar benefit in 2017 as we recognize in 2016 for the full year which was about $0.06. As you are well aware, our share price appreciated substantially in 2016, which yielded a significantly higher tax benefit in Q1 2017 based on equity vesting and auction exercises. Our updated reported and diluted EPS guidance for 2017 assumes another $0.03 of benefit over the remainder of the year. However, fluctuations on our shared price and auction exercise activity could add volatility to this figure.",0.7180095,0.973
DGX-2017-Q1-2017-04-20,28,Remarks,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Going forward, we would expect to experience some level of excess benefit over the next several years. However, the time frame and absolute benefit is difficult to forecast given its dependence on our share price and the timing of option exercises. Now, let me turn it back to Steve.",0.8977093,0.691
DGX-2017-Q1-2017-04-20,29,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. Well, to summarize, we delivered strong growth across the board in the first quarter with gains and revenues margins, operating income, EPS and operating cash flow. Our agreement with PeaceHealth will further booster our growth later in the year and we are laser-focused on our two-point strategy to accelerate growth and to drive operational excellence.",0.9799012,0.974
DGX-2017-Q1-2017-04-20,30,Remarks,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I'd like to now open up for any questions you might have. Operator, please?",0.2530478,0.361
DGX-2017-Q1-2017-04-20,33,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","You know, so thanks, Ross, certain I'll start and Mark will add to that. Sure, first of all we're off to a good start, we're pleased with our first quarter performance here. Yes, there's up a number of elements that contributed to the growth in the first quarter, we highlighted some of those in our script. First of all we do believe that will continue to get growth from our professional lab services work that we're doing. We saw some growth from that. Second is we continue to get nice growth from our advanced diagnostics portfolio and some of the more advance, what is typically referred to as esoteric testing that we do would call about some of those, and we've mentioned in the past the prescription drug monitoring and the work we're doing with the TV coiffure opportunities drive serious growth for us.",0.63229,0.987
DGX-2017-Q1-2017-04-20,34,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also got some nice growth through some other areas of the business, like our Wellness business, some or other -- some of our other services business. Across the board good balance growth consistent with our strategy that we had to focus at hospitals. That focus on our clinical franchises and bring new products to the marketplace to commercialize those better than we have in the past. And finally just good execution across the board. So let me turn over to Mark, to give some color round this and throughout the rest of the year.",0.4866557,0.964
DGX-2017-Q1-2017-04-20,35,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure, thanks for the question, Ross. As I mentioned in the prepared remarks we got about 90 basis points in volume and revenue from M&A, largely that was CLP, work lapping CLP at the end of the first quarter, so we no longer have in that a tail wind. Part of this pretty largely ramped up so that annualize in the first quarter as well. So those are behind us in terms of strong year-over-year drivers of growth.",1.299763,0.937
DGX-2017-Q1-2017-04-20,36,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now what we do have in front of us is continued ramp up of HCA, we are just in the early stages of Montefiore, and then obviously we announced Peacehealth which has an outreach element and also in professional laboratory services element that we expect to execute have not close that yet. When we give our original guidance 2% to 3% to the global in growth. The only M&A included in that was CLP because that been executed, and while we are very optimistic about the closing piece and there's the heat pipeline of other potential M&A opportunities. Given the fact that we got a pretty broad range of 100 basis points in the work, cautiously optimistic after the first quarter we didn't feel this point compelled to change our revenue guidance yet.",1.4131122,0.945
DGX-2017-Q1-2017-04-20,38,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First of all it is going well, we announce it in the fourth quarter of last year. And a big component of it is what we're going round revenue cycle management and our billing operations and as a I said in our opening remarks it's going very well, we're pleased with that. Like you said this is a relationship so there is multiple areas beyond what we're doing around billing, we continue to build on that relationship and it's -- it's going well as well. We have a good relationship around our wellness business, we are their partner for wellness along with other -- other partners that we sell-through.",0.6925865,0.963
DGX-2017-Q1-2017-04-20,39,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is we continue to work with them on what we do with clients around data and population health and if you think about what we're doing with our professional laboratory services business, we're calling on the same people that are trying to become more efficient and better in delivering integrated delivery system and so that areas is promising as well; so often good start, doing what we said what we would do and the relationship will only get stronger overtime.",0.6813839,0.929
DGX-2017-Q1-2017-04-20,44,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thank you. First of all the pipeline as we said is the support of our long-term goal of 1% to 2% of growth through acquisitions; we're hopeful about that going forward. As far as competition -- I would say the competition is stable versus what we've seen in the past. And finally is in regards to the PAMA, I think PAMA in general is changed that some would argue -- could look more catalyst in hospital outreached business as considered their strategy going forward. So when we engage with hospital systems run their lab strategy, many CEOs that are engaged with do understand that both the commercial rates as well as the clinical lab fees schedule rates will be under pressure. And this is one of the considerations that they think about as far as potentially selling their business or partnering with us in their business going forward.",0.9205931,0.935
DGX-2017-Q1-2017-04-20,45,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So if in fact there is some price pressure related to the refresh of the clinical fee reschedule that could be a further catalyst to accelerate some of this going forward but as you know, PAMA -- the data submission has been postponed by 60 days, we're still believing based on what they've told us so far that they are committed to trying to refresh the clinical lab fee scheduled by the beginning of '18 but we'll see on that. But there is another fact that we think is helping us with our discussions with hospital systems around their lab strategy.",0.6757825,0.392
DGX-2017-Q1-2017-04-20,46,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So if I could just add two pieces of color to that Dan, one is that -- recall that when Medicare changes reimbursements we're equally impacted. So the buyer and seller are both equally impacted in terms of the value. If they get credit from commercial rates that doesn't matter to us, it doesn't change our evaluation because obviously we value it as our own commercial reimbursement. So while it might be more of a catalyst, it also reduces the value to both the buyer and the seller. And then in terms of competition, if you recall these outreach skills are largely cost synergy value creation opportunities, and so at any given outreach is likely to not be work the same to multiple competitors because it's highly dependent on where your laboratory is located, where your logistic routes are, where your patient services are currently located and there are geographical differences amongst any competitor who might be looking at purchasing an outreach.",1.4735387,0.96
DGX-2017-Q1-2017-04-20,47,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So in term -- there is always -- you know, larger opportunity likely to be a couple of parties at the table but it's not an auction because quite frankly, we're going to value them differently because it's based on that the infrastructure.",1.1248025,0.705
DGX-2017-Q1-2017-04-20,49,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","It's not that directly linked. I think it's a fact out there that CMS is looking at refreshing -- we couldn't let fee schedule as we often talked and so we get all the data, we don't know what's going to happen with that, but it's just a fact out there that is going to be pressure on rates. And therefore hospital CEOs are thinking about their options for outreach.",1.0853377,-0.039
DGX-2017-Q1-2017-04-20,53,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so thanks Ricky. Let me give you some color around PAMA, now first of all the data put in all the data has been pushed out for 60 days and yet, CMS still is holding to the goal of refreshing the clinical lab fee schedule by the beginning of 2018. Now with all that said, we just took two months of really tight schedule and the way this will work is they'll get all the data by the end of May - let's call it June. They have to work through that for four months in of which in those four months, two of those months are in the summer months and then publish their rates that they will look to comment on in the September timeframe. And then they'll publish upon the rates in the fourth quarter for that beginning of January 2018. So as you think through this, the two-month delay in data reporting clearly is putting pressure on the schedule and that's why people are saying, 'Okay even that they still have the goal, it's impossible that they can get there.' I'll share with you exactly what we're hearing, but there is more pressure on them to put that altogether.",0.8701812,0.089
DGX-2017-Q1-2017-04-20,54,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now with all that said, as trade association, we continue to be actively engaged with CMS. When we're down there for our annual meeting of UCLA several weeks ago, we've met with CMS. This is many members of our industry. They're very, very responsive to us, they listen to our concerns about data. Part of the response to see would postpone of the data collection is because we are engaged with them and we're also having discussions with them and members of congress about the definition of applicable laboratory. In the way CMS is implementing the approach right now is excluding a fair percentage of outreach which is a large portion of this market. So there will be another meeting next week with CMS and this is at the highest level CMS with [indiscernible] to talk about two issues; one is the timeframe and second is applicable laboratory. And we hope to engage as we've done so far as a trade association of being constructive and helpful to get the market-based approach right, which is the intent of the congress with this bill. We continue to work it with them.",0.7742998,0.961
DGX-2017-Q1-2017-04-20,55,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","You also need to understand that this also has the backdrop of them having a lot on their table in the number of positions across the board in HHS and CMS not being filled. We also know that they've got to work through a lot. I'm giving you some of the color, but we're actively working this trade association and we believe that by doing so, it's going to serve this industry well.",0.5212521,0.754
DGX-2017-Q1-2017-04-20,56,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Rick, just to answer your specific question about is there anything we need to do to get ready, the answer is most of what we need to do is behind us. There is quite a bit of work to get the data together and we got it all together by the end of the first quarter when we needed to. Now, really what's in front of us is just once they publish the proposed rates, for us to take a look at it and obviously respond to that if appropriate and then as Steve mentioned, through our trade association, continue to push through what we think is appropriate, which is expanding the definition of an applicable lab. But there's not a lot of work per se between now and when everybody might decide to implement the new rates.",0.9210111,0.361
DGX-2017-Q1-2017-04-20,57,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And just to round this off, we also said in our Investor Day in the fall that if in fact it is implemented in 2018, given the size of this business for us, the effect it could have based upon some of the estimates that we're going to be able to absorb that, given the opportunities we have around operators going forward in normal course of running our business. That's our position. We believe it's already implied in our outlook that there could potentially be some reduction here, but we don't know for certain until we get all the data collected. But we're managing this proactively going forward and we'll see what happens.",0.7485997,0.535
DGX-2017-Q1-2017-04-20,59,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Well, Ricky, as I said earlier, it's just early in the year. We're cautiously optimistic, but its one quarter and obviously, we're optimistic, we're going to continue with strong performance. At this point, you're correct. The entire change in guidance reflected the excess tax benefit over and above what we have built into our original guidance. Operator, next question?",0.657188,0.948
DGX-2017-Q1-2017-04-20,65,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I don't think there's any step change in the environment. If anything, I think we've comment that utilization has improved directionally over a couple of quarters, so we are seeing some good signs in utilization. We've mentioned in the past that we monitor what we call our same source name account performance and certainly, we're seeing improvement in that over the last couple of quarters into the first quarter. These things can happen as well. We don't know whether that's a trend and it will continue, but in the first quarter, if there's anything I could point to outside of the things we talked about, certainly a lot of good deals we've done including things like Ancestry, et cetera are helping to drive some of that growth. I'd really say it's the utilization seem to be a little stronger than it was in the past year.",0.9253555,0.977
DGX-2017-Q1-2017-04-20,66,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And Jack, just to remind everyone, it's this the march we're on with growth. Back when we started with our strategy at 2012, we simply just restore growth and business that was shrinking organically. We have reduced that decline, we stabilized the business, we started to get some organic growth in '16 and our two strategy focus right now is number one, to accelerate growth. So what you see in Q1 is the continuation of that march of improvement and we believe a lot of the investments and capabilities and focus that we've put over the last several years is due to yield the results we expected. We're pleased with Q1. As I mentioned in my earlier comments, the results are a number of areas that led to the growth that you saw in Q1, but we believe we're off to a good start for the year.",0.4200988,0.929
DGX-2017-Q1-2017-04-20,67,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And the only other thing I'd add is that the timing of Easter probably mitigated in some of the pack that we lost at the extra day from leap year last year, so it's hard to predict how much that's going to impact you because it's not consistent every single year, but definitely the calendar shift on the Easter into the second quarter certainly helped Q1.",0.8906003,0.687
DGX-2017-Q1-2017-04-20,70,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"No, there's nothing notable, Jack.",0.8937599,-0.296
DGX-2017-Q1-2017-04-20,79,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Amanda, we've decided that we're not going to break out PLS every single quarter. What I did say at Investor Day was that I would expect over the three year period to 20 that we would get about 100 basis points of less from PLS would be our expectation. So we do have a deep pipeline. It's going to vary quarter-to-quarter, given the timing of deals and so on and so forth. We're not quite there yet, but we're building toward that, so we got some good solid growths from our new PLS businesses and over time, we're expecting a keg around 100 basis point lift, but we're not going to break it out every single quarter.",1.0864929,0.853
DGX-2017-Q1-2017-04-20,81,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"There are absolutely assumptions just like we would in winning accounts in our guidance for the year. We have to make some assumptions around how we're going to perform. So we've got a deep pipeline of PLS opportunities. Unlike anyone would, we do some sort of probability adjusting against that in terms of getting those complete, the timing and so on. So there's absolutely an element of PLS in that original 2% to 3% organic guidance that we gave on an equivalent basis and depending on how things progress, that's why we give a range. It could be slightly more or less than we assume, but we're confident enough to build in the guidance and then on M&A, just given the fact that that's a lot less in our control. We just thought the prudent thing would be not betting on the com and having any unexecuted M&A specifically in that guidance.",1.0778041,0.915
DGX-2017-Q1-2017-04-20,82,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Again, the way I would encourage you to think about PLS is like winning a new account, a new hospital system for our core business, something we go out. It may not be quite as co-competitive because there's only a handful of labs that could actually perform the PLS deal, because it really takes economies of scale to drive that savings and quite often, these are so complicated, it's not even more than one part negotiation. It's just us alone talking to a hospital system. In summary, yes, we have some assumptions around our pipeline getting executed this year in that organic growth and we're very confident just like we've done in the past about our ability to hit that.",1.300158,0.972
DGX-2017-Q1-2017-04-20,83,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Just to make sure it's clear, PLS, it is a business. We're managing a portfolio of professional laboratory services accounts and like for any business, these accounts are different stages of the revolution. In that business, we have a number of accounts that have been with us for some time and like with any business, you're managing those accounts to make sure you have a referable account going forward. That's in our base as well. Second is we're growing new accounts, they're turning on. There might be some more opportunities to expand it into other hospitals so we've got growth within the install base as well with some growing accounts and then we're bringing on board some new accounts.",0.2952224,0.976
DGX-2017-Q1-2017-04-20,84,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So the highlights we've talked about at those new accounts, you put those three together and that has a business in its aggregate growing, but don't forget, we still have this install base of existing business that we could hear ourselves as well. We need to think about it as an existing business with managing accounts, growing accounts and then executing brand new accounts. But with all those three components, this is a growing business for us, it's a good business for us and it positions us nicely with integrated delivery systems.",0.9779242,0.909
DGX-2017-Q1-2017-04-20,85,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Next question, operator?",1.9221959,0.0
DGX-2017-Q1-2017-04-20,88,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me start. First of all, the relationship with Optum for revenue cycle management has three components. First of all, we believe by working together with them, we can continue to become better and more efficient in our building operations and the efficiency associated with that, A.J. is part of our $1.3 billion bigger rate savings and efficiency goal that we have. So this is parts of many programs we have to drive efficiency. So a portion of our results and a portion of our achievement against that goal will include what we're doing here. Second is we believe by getting smarter with them around the interaction between class and patients and payers, we can go a better job of bad debt and denials and specifically, they will help us with what we talk about as far as real-time adjudication with patients that we've mentioned, four payers that are initially working with us on that, but we expect with Optum's help, we could get some more. And then finally, it's just completing the data set and their relationship with payers in general we think will be helpful of getting paid both from a standard perspective of bad debt, but also with the denials associated with more advanced diagnostics. Mark, anything you like to add to that?",0.5008237,0.859
DGX-2017-Q1-2017-04-20,89,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"A.J., as we've shared before, we signed a 10-year agreement with them to manage our revenue cycle management and we do have commitments for them on cost savings to run that operation and yes, that started in Q1, but it gets feathered in over the life of the contract. And then the second element is Optum helping us reduce denials and bad debt as Steve mentioned. Although we started the real-time adjudication prior to the relationship, Optum is helping us to drive that faster and more deeply and maybe we could have done on our own. We feel very good about what they're doing and I can tell you that early on, we've seen a reduction in patient bad debt in the areas where we roll this out. So we're feeling good about it, we're seeing what we would expect. It's still early because at this point, it's largely just the patients who are engaging our patients service centers. We're working on solutions that will be available in obviously the change managements plan to roll it out in the physician office where about 60% of our volume comes from.",0.8550553,0.401
DGX-2017-Q1-2017-04-20,90,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So today, it's really patient service centers moving in office phlebotomist and then eventually moving into the physician's office where ultimately we'll get the full benefit. But we're very encouraged and we're absolutely seeing a reduction in the rate of patient bad debt where we've rolled out this real time adjudication.",0.4830174,-0.298
DGX-2017-Q1-2017-04-20,92,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, A.J. Safeway relationship, we believe is the beginning of our consumer initiative working with retailers in a bigger way and part of this is around providing better access. We believe we have unparalleled access in the market, we're 2,200 patient service centers, we have 2,800 phlebotomist and physicians' offices, about 6,000 access points, but we believe some of these retailers we could be working with and safely as one had better locations and there is anywhere from 15% to 20% of laboratory requisition orders that go unfulfilled. So we're helpful by having better access. We're going to get more fulfilled requisitions and that's going to help our growth and also help some share if we have better access. We hope when a patient has a choice and who ask the question, 'who do you like to go to?' for their laboratory testing, that the patient will remember a better experience in a more convenient location for that experience and they'll choose Quest based upon our movement here. That's both growth, but also as you would expect as we start to come on board with some of these centers, we rationalize our presence in a zip code and we might shut down some of our smaller patient service centers and saves us some money as well. It's both growth and efficiency.",0.5321252,0.996
DGX-2017-Q1-2017-04-20,93,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And we do continue to have relationships and we do continue to have pilots with some of the other players in this retail space. We continue to have UBS as the client and we're optimistic about other retailers as they continue to evolve their health strategy. They see it as a nice expansion from what they do today around pharmacy and also it helps these retailers for getting traffic into their stores as well. It's a multi-faceted program for us that directionally, we're very, very optimistic about and I think we're off to a great start.",0.8257002,0.935
DGX-2017-Q1-2017-04-20,96,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. All that you mentioned are strategically in-lined with our direction. So we have for the last several years cleaned up our portfolio, we're entirely focused on diagnostic information services. Our first filter for any deal is does it fit into our scope of our strategy and from what you just mentioned all do. Second is we do believe that there's our growth strategies and we've outlined in the fall five areas that we're focused on for accelerating growth. One is related to partnering with hospital systems and so, the hospital average deal fits in that strategy as well. Second is to continue to invest in advance diagnostics and bringing new capabilities to the marketplace. So some of the potential acquisitions we could do there would fit there as well. As part of these priorities, what we have shared in the past is we continue to be very, very rigorous in making sure that if their strategically in-lined, that we have the thresholds we expect to make for our shareholders with any acquisition. I would say that's generally more of the cut we have is we're the strategic in-line where they fall out in terms of use of our cash and are they getting acceptable returns of invested capital, providing us with the growth we expect and at the same time, become accreted to earnings in a reasonable period of time. That's generally how we rack and stack acquisitions and it served us well so far. That fits into the strategy that we had or 1% to 2% growth of acquisitions.",0.7420099,0.98
DGX-2017-Q1-2017-04-20,97,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As you can see from our prior acquisitions over the past four or five years, do you see all those categories and it's more of a matter of when that come in and when we can execute it and less to deal with the sorting of what we'd like more of a priority than others. But we haven't had the problem having not enough cash to execute things. We think we should do strategically and also that we think has a good return for our shareholders. So Mark, anything you like to add to that?",0.5301483,0.679
DGX-2017-Q1-2017-04-20,100,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Right. When you say hospital relationships, that's multi-faceted. I think it might be specifically time about special laboratory services where we're actually serving them for the work that is not explicitly billable. So it's the laboratory work they have to perform in order to get paid under the DRG for inpatient outpatient et cetera. Those margins as we've shared are lower than our core, but double-digits. That's as explicit as we've been and then in terms of our relationship and that word is really important, when we have our relationship with a hospital and we do professional laboratory services, we typically get most - if not all of the reference work. So we've talked about the fact that we do reference work for half the hospital in the country. That is the high end at more esoteric type work, but either they are not able to, or have made a rational decision not to perform given limited size and scale, so there's a handful of people that do their work. We have the largest reference work at any laboratory.",0.8819115,0.305
DGX-2017-Q1-2017-04-20,101,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So that's another part of our relationship with hospitals and then certainly the other part of the relationship is we've got other businesses that [indiscernible] hospitals their large employers, we've got our wellness business so we can help them keeping their population healthy. We've got some of our diagnostic tools that certainly can help them manage everything laboratory spend to benchmarking their clinical practice of utilization of diagnostic. So there's a lot involved in a relationship with a hospital, but specifically on the PLS, its double digits, but slightly lower than our core margin.",1.5114534,0.81
DGX-2017-Q1-2017-04-20,102,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me just underscore what Mark just said and remind you what we shared with you in the fall because it's important in our strategy in what we're doing every day. When we're talking about hospitals, it's about 60% of our market if we look at it and we have laid that out in three ways - one is what we could do to help them with their inpatient laboratory cost. These are cross centers that we could save the money. Number two, what Mark just went through as far as the reference testing, the advanced diagnostics to sell the hospital that they can't do themselves, they rely on laboratories like ourselves and then finally is outside of the hospital and some have outreach businesses, but they also are buying physicians and they're looking at serving geographic area and providing the laboratory services with those physicians that they now own or affiliate with.",1.4906096,0.791
DGX-2017-Q1-2017-04-20,103,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So when we have a discussion, it just was last week with a very large integrated delivery system, their lab strategy includes all three. We talk about our relationship with hospitals, yes it's the inpatient laboratory but it's a holistic view of how we approach the marketplace in a much more progressive holistic view as they build integrated delivery system. S it's all three components when we approach the systems and it's serving us well as you see in our good start of the year.",0.6514003,0.81
DGX-2017-Q1-2017-04-20,106,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So as we engage with PeaceHealth, the decision was made to sign with us on PLS deal, they are selling us their outreach and then obviously we have a reference relationship with them as well. Next question, Operator?",0.4332543,0.784
DGX-2017-Q1-2017-04-20,109,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, appreciate it. In our advanced diagnostics business, we have our oncology franchise and related to that, if you recall several years ago, we formed a relationship with Memorial Sloan Kettering where we put together a product that's called OncoVantage. It's going to take some of their content, some of the research with 34 actionable genes. OncoVantage essentially is a product that delivers on precision. That is [indiscernible] oncology. And what we also realized with Memorial Sloan that we needed a cognitive computing partner. So we at this fall announced now teaming up the two of us with IBM and this is for IBM Health Watson. They are our cognitive computing partner. So collectively now, the threesome is going at the market and the opportunity in front of us is about 70% of oncology here is in community healthcare centers, not in large urban centers like what Memorial Sloan will be serving.",1.0090837,0.893
DGX-2017-Q1-2017-04-20,110,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"This is a big opportunity for us and we have our own dedicated sales force, it's backed up with a brand and the content from Memorial Sloan, but now when working with IBM, we believe that their sales force and their presence with integrated delivery systems and also just in general, public awareness of precision medicine in computing and healthcare is being helped by IBM. You might have seen some of the ads. They have been running and one of those specific ads that need to actually do highlight the work they're doing with us in Memorial Sloan in the field of cancer. So we think it's a step in the right direction and it's often running well.",1.1319115,0.153
DGX-2017-Q1-2017-04-20,112,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue with all our partnerships, so this is the beginning. There's other things we could do with IBM. I'm not prepared to talk about that, but we believe all our partnerships start with something and they go from there.",1.0326194,-0.086
DGX-2017-Q1-2017-04-20,113,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Don. Operator, last question please?",0.3147709,0.44
DGX-2017-Q1-2017-04-20,116,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First of all, the refresh of the clinical lab fee schedule from PAMA -- I would just argue is a reality that's creating some catalyst on hospital systems; I must say all laboratories to consider their options going forward. And I would argue that as independent of whether any refresh takes place in 2018, 2019 or even 2020, it's just sitting there; that how they get paid for Medicare is being revisited and even though you've said that, its cuts is unclear on what the outcome will be until we gather all the data and we've talked about this before. Until we gather all the data, we don't have the visibility about the data, it's uncertain of what effect it would be. But we review that in general this review and the pressure that's on payment in general and we believe it's on the Medicare side with PAMA, but also on the commercial side is a good catalyst for us having these conversations with integrated delivery systems without the laboratories on the strategy going forward. So that's the first point I'd like to make.",0.5752883,0.459
DGX-2017-Q1-2017-04-20,117,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second is the goal is still 2018; obviously if that's postponed or delayed, and if in fact you had a negative consequence associated with how we get paid, it would be helpful in 2018. But right now we're assuming that what they tell us is what they're going to do and therefore 2018 is what we're assuming and we'll see if that does happen.",0.092916,-0.557
DGX-2017-Q1-2017-04-20,118,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So while the other element, Steve, is that if it's delayed because they expand the definition of applicable lab, we would assume that's probably a positive for the industry and certainly for us; and I can assure you that when I laid out the view from 2020 in terms of the 3% to 5% top line growth and mid to high single digit bottom line growth, I was building in some level of COGS on the clinical lab fee schedule into our revenue growth assumptions, but that was not building in some sort of a steep change in the competitive environment where we were picking up significant volume because people couldn't survive in a world where Medicare cuts were made. So I would be cautious about assuming that we're hoping that cuts happen as large as possible, as quickly as possible; we certainly would not -- be disappointed if things get delayed.",1.5315956,0.892
DGX-2017-Q1-2017-04-20,120,Answer,2017-04-20,1,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Well, it's absolutely all other things equal going to be a volume headwind in Q2, just like it helps us a little bit in Q1. But you know, there is so many factor that go in, it's just one element of growth in the second quarter. But if you're looking at -- if there is something in the second quarter that would be a headwind, yes, the fact that Easter is in the second quarter is something to factor in.",0.621643,0.889
DGX-2017-Q1-2017-04-20,121,Answer,2017-04-20,1,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay, we appreciate all the questions. Thanks again for joining the call. As you heard, we had a strong quarter and we're off to a solid start in 2017. We're looking forward to meeting your commitments by our two-point strategy which is to accelerate growth and to continue to drive operational excellence. We appreciate your support and you have a great day.",0.7914333,0.98
DGX-2017-Q3-2017-10-19,4,Remarks,2017-10-19,3,2017,Shawn Bevec,Executive Director-Investor Relations,"Thank you and good morning. I am here with Steve Rusckowski, our Chairman, President and Chief Executive Officer, and Mark Guinan, our Chief Financial Officer.",0.0674782,0.66
DGX-2017-Q3-2017-10-19,5,Remarks,2017-10-19,3,2017,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and will discuss non-GAAP measures. For this call, references to reported EPS refers to reported diluted EPS and references to adjusted EPS refers to adjusted diluted EPS excluding amortization. Actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K, and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K. The text of our prepared remarks will be available later today in the Investor Relations page of our Website.",0.3027256,0.34
DGX-2017-Q3-2017-10-19,7,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. This morning I'll provide you with some perspective on PAMA, highlights on the quarter and review progress on our two-point strategy, which continues to drive results. Then Mark will provide more detail and take you through updates on our 2017 guidance.",0.2599671,0.823
DGX-2017-Q3-2017-10-19,8,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, we delivered another strong quarter of revenue growth in spite of some weather challenges. We completed two previously announced acquisitions and agreed to purchase Shiel Medical Laboratory and then yesterday we announced a strategic relationship with Cleveland Clinic that includes the acquisition of Cleveland HeartLab.",0.4247117,0.718
DGX-2017-Q3-2017-10-19,9,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Here are some highlights from this quarter. Revenues were $1.93 billion up 2.4%, reported EPS of $1.15 was down 14% from 2016, adjusted EPS grew 150 basis points to a $1.39, which includes an increase of $0.02 over the prior year of excess tax benefit associated with stock-based compensation.",0.3947282,0.649
DGX-2017-Q3-2017-10-19,10,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our updated guidance for our full-year 2017 primarily reflects the impact of hurricanes in the third quarter, which impacted geographies where we have a large presence as well as our recently closed acquisitions.",0.6912685,0.273
DGX-2017-Q3-2017-10-19,11,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before I describe the progress, we have made to accelerate growth and drive operational excellence, I'd like to discuss PAMA. We continue to urge CMS to delay the implementation of PAMA to take the time to get it right. The preliminary rates that CMS released are not market-based rates as Congress indicated.",0.1093904,0.866
DGX-2017-Q3-2017-10-19,12,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Unfortunately, only 1% of all laboratories submitted data and over 99% of hospitals and physician office laboratories were prohibited from reporting their rates. Also based on data submitted through CMS, Quest alone represented nearly 40% of all the market data CMS collected.",0.5822076,-0.527
DGX-2017-Q3-2017-10-19,13,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As you're aware from previous days, our estimated share of the Medicare market is less than 15%. Instead of protecting access to essential laboratory testing, this flawed approach could greatly compromise Medicare beneficiaries access to testing. A large portion of the Medicare population receives their services from small laboratories and PAMA could put them at risk.",0.6794069,0.488
DGX-2017-Q3-2017-10-19,14,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We've been collecting facts that demonstrate the many ways that CMS has disregarded the intent of Congress and we've been finding the receptive audience among legislators and policymakers in Washington DC for our call to take more time to get the implementation right.,0.8747941,-0.382
DGX-2017-Q3-2017-10-19,15,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The clinical lab industry is a critical element in the healthcare and economic landscape of this country, creating jobs, driving economic activity and generating tax revenues for the federal and state governments. Our trade association's recent economic study found that this industry directly and indirectly employs over 600,000 people that contributes $13 billion in tax revenues. The impacts of these proposed cuts are far-reaching to this vital industry.",0.5383855,0.052
DGX-2017-Q3-2017-10-19,16,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","These rates should not be finalized as proposed and this view is shared by 22 respected medical societies and health groups, including the American Medical Association, the American Hospital Association and the American Hospital Association is very much back of our plan.",0.7192751,0.671
DGX-2017-Q3-2017-10-19,17,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In October, we -- on October 6, sent a letter with these leading voices in healthcare, calling for CMS to take immediate action to address the significant deficiencies in its progress to establish new clinical laboratory payment rates. Along with our trade association, we are exploring every option to ensure that Medicare beneficiaries have access to diagnostic information services.",1.3037891,0.84
DGX-2017-Q3-2017-10-19,18,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In whatever form CMS might implement PAMA, Quest will be prepared and we remain confident in our ability to meet the long-term commitments outlined at our 2016 Investor Day. Mark will touch on this later.",0.3205931,0.785
DGX-2017-Q3-2017-10-19,19,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to the progress we've made in the third quarter, we delivered on all five elements of our strategy to accelerate growth. The first element of our growth strategy is to grow 1% to 2% per year through strategically aligned accretive acquisitions, which we're on track to achieve for the fifth consecutive year.",0.2652389,0.791
DGX-2017-Q3-2017-10-19,20,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We had a very productive quarter. We completed two previously announced acquisitions and agreed to purchase Shiel Medical Laboratory, which we will further strengthen -- which further strengthens our position in the New York metropolitan market.",0.9518946,0.751
DGX-2017-Q3-2017-10-19,21,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yesterday we and also announced the acquisition of the Cleveland HeartLab from Cleveland Clinic. This lab will become our advanced diagnostic center of expertise in cardiovascular testing, an agreement build on our existing relationship with the Cleveland Clinic. Our M&A pipeline remains very strong and our strategy is delivering growth.",0.7897858,0.886
DGX-2017-Q3-2017-10-19,22,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","With the acquisitions we've completed this year and those expected to close by the end of 2017, we are well-positioned to exceed our long-term M&A objective for 2018 and of course in accretion realized from the deals in 2018 will help offset the potential impact of new Medicare rates.",0.35486,0.402
DGX-2017-Q3-2017-10-19,23,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Under the second element of our growth strategy, we continue to expand relationship with hospital systems. Our relationship with PeaceHealth is progressing well. As you recall the relationship includes the acquisition of the outreach laboratory as well as a professional laboratory service agreement to manage laboratories at 11 PeaceHealth Medical Centers in Washington State, Oregon and Alaska. This relationship is fully operational and already contributing revenues and adjusted earnings growth.",0.6016474,0.933
DGX-2017-Q3-2017-10-19,24,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The third element of our growth strategy is to offer the broadest access to diagnostic innovation. In the third quarter, we completed the acquisition of Med Fusion and Clear Point in Texas forming a national precision oncology center of expertise and we are very pleased with the integration efforts to date.",0.1100494,0.875
DGX-2017-Q3-2017-10-19,25,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In women's health we continue to be excited about the progress we've made in noninvasive prenatal screening. Our Q-Natal test is providing strong double-digit growth year-over-year. We recently complimented our women's health offering with QHerit, a screening panel that helps both women and men across multiple identify the risk of passing 22 genetic diseases to their children.",0.4955519,0.925
DGX-2017-Q3-2017-10-19,26,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We also introduced the cholesterol test with an improved method for assessing heart disease risk in aiding treatment decisions. Unlike most lipid tests that does not require fasting and patient's life is added convenience.,0.1205931,0.25
DGX-2017-Q3-2017-10-19,27,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We all made progress executing the fourth element of our growth strategy, which is to be the provider of choice for consumers. Our relationship with Safeway continues to expand as we are now operating in 128 stores and are expected to open about 30 more before the end of 2017. In addition, our collaboration with Walmart will open new locations in 2017.",0.7568369,0.772
DGX-2017-Q3-2017-10-19,28,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In this exciting era of the empowered healthcare consumer, are MyQuest mobile application is now delivering lab results into the hands of 4.5 million users. Payers are taking notice of the progress we are making on our consumer strategy, especially with convenience, value and the number of access points we provide.",0.3324547,0.839
DGX-2017-Q3-2017-10-19,29,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The fifth element of our growth strategy is to support population health and data analytics and extended care services. We're building a solid pipeline with data analytics with a number of partners interested in leveraging our data, including pharma, CRO and health plan customers.",0.4523888,0.902
DGX-2017-Q3-2017-10-19,30,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to the second part of our two-point strategy to drive operational excellence, we remain on track to deliver $1.3 billion to invigorate run rate savings as we exit 2017. As we drive operational efficiency, we continue to improve the customer experience. Over 950 of our 2,200 patient service centers are live with e-check-in, which improves the patient experience.",0.9891269,0.935
DGX-2017-Q3-2017-10-19,31,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Our total e-check-in volume is over 12 million encounters to date. We expect to have this capability in most of our patient service centers by the end of this year.,0.8573311,0.0
DGX-2017-Q3-2017-10-19,32,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Now let me turn it over to Mark who'll take you through our financial performance in detail. Mark?,1.2270181,0.0
DGX-2017-Q3-2017-10-19,33,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks Steve. Starting with revenue, consolidated revenues of $1.93 billion were up 2.4% versus the prior year. We estimate the impact of the recent hurricanes reduced our revenue growth by approximately 130 basis points in the third quarter, which is slightly lower than what we had estimated in late September.",0.2203791,0.556
DGX-2017-Q3-2017-10-19,34,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Revenues for diagnostic information services grew by 2.8% compared to the prior year with approximately 140 basis point attributed to recent acquisitions. Volume measured by the number of our acquisitions increased 1.6% versus the prior year of which about 60 basis points was organic.,0.1844392,0.34
DGX-2017-Q3-2017-10-19,35,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"However, note that the impact of hurricanes presented a headwind of approximately 140 basis points to volume in the quarter. Revenue per acquisition in the third quarter grew by 1.2% compared to the prior year. As a reminder revenue per rep is not proxy for price. It includes the number of variables such as unit price variation testament and test per rep.",0.8349131,0.077
DGX-2017-Q3-2017-10-19,36,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Here price headwinds in the third quarter remain less than 100 basis points. While price fluctuations can vary from quarter to quarter, we continue to expect that unit price headwinds will remain moderate through the final quarter of 2017 and consistent with the last several quarters.",0.6220379,0.0
DGX-2017-Q3-2017-10-19,37,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Beyond unit price and the impact of growth in our PLS partnerships, other mix elements including test mix contributed to the slightly more than the positive 100 to 200 basis point trend we've observed for several quarters.",0.5485782,0.818
DGX-2017-Q3-2017-10-19,38,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income for the quarter was $298 million or 15.5% of revenues compared to $322 million or 17.1% of revenues a year ago. Keep in mind, our reported operating income in 2016 included a gain on Escrow recovery associated with an acquisition.",1.1165087,0.527
DGX-2017-Q3-2017-10-19,39,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On an adjusted basis, operating income was $325 million or 16.8% of revenues compared to $320 million or 17% of revenues last year. We estimate the impact of hurricanes produced adjusted operating by approximately $18 million in the third quarter, which adversely impacted operating income growth by nearly six percentage points.",0.4861769,0.202
DGX-2017-Q3-2017-10-19,40,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Excluding the impact of the hurricane, adjusted operating income would have grown more than 7% and adjusted operating margin would have expanded 50 basis points year-over-year. Reported EPS was $1.15 in the quarter versus a $1.34 in the prior year period. As noted previously, our third quarter 2016 results included a gain on Escrow recovery associated with an acquisition.",1.1777251,0.527
DGX-2017-Q3-2017-10-19,41,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Adjusted EPS was $1.39 up 2% from a $1.37 last year. We estimate the impact of hurricanes in the third quarter reduced adjusted EPS by approximately $0.08 or nearly 6%. The company recorded net after-tax charges totaling $20 million in the third quarter or $0.14 per diluted share, representing system conversion, restructuring, integration and other one-time costs.",0.7448657,0.026
DGX-2017-Q3-2017-10-19,42,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our effective tax rate in the quarter was approximately 36% versus 33% last year. Last year's rate benefitted from the previously mentioned Escrow recovery, which was nontaxable. In the quarter, we recorded approximately $7 million or $0.04 per diluted share of excess tax benefit associated with stock-based compensation or SBC compared to $3 million or $0.02 per share benefit last year.",0.5675355,0.935
DGX-2017-Q3-2017-10-19,43,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Year-to-date we've reported $36 million or $0.25 per share of excess tax benefits associated with SBC, which is an increase of $0.20 year-over-year. Bad debt expense as a percentage of revenues was 4% flat versus last year and 20 basis points lower versus the prior quarter.",0.4095577,-0.477
DGX-2017-Q3-2017-10-19,44,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Turning to cash provided by operations, we generated $852 million in 2017 year-to-date versus $765 million last year. Capital expenditures year-to-date were $170 million compared to $165 million a year ago.",0.6386256,0.0
DGX-2017-Q3-2017-10-19,45,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now turning to guidance, we are providing the following updated outlook for 2017. Revenue is now expected to be approximately $7.71 billion, an increase of about 2.6% versus the prior year on a reported basis and an increase of about 3% on an equivalent basis. Reported EPS to be between $4.87 and $4.92 and adjusted EPS to be between $5.62 and $5.67.",0.7496051,0.557
DGX-2017-Q3-2017-10-19,46,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Cash provided by operations remains at approximately $1.2 million and finally capital expenditures remain between $250 million and $300 million. Despite the impact of recent hurricanes, our full year revenue guidance is in line with our prior outlook and operating cash flow guidance remains unchanged.",0.7626382,0.0
DGX-2017-Q3-2017-10-19,47,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our updated EPS guidance reflects the approximate $0.08 hurricane impact noted previously, the impact from recently closed acquisitions, a $0.02 year-over-year increase of excess tax benefits associated with SBC recorded in the third quarter and a small but ongoing impact from hurricane Maria on our quarterly cooperation in the fourth quarter.",0.7527646,0.351
DGX-2017-Q3-2017-10-19,48,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"It's also important to remember that despite these headwinds just mentioned, our updated guidance is in line with or exceeding the outlook we provided to you at the beginning of 2017. While we aren't prepared to providing 2018 guidance at this time, we want to remind you that we do not expect the same levels of excess tax benefits associated with SBC in 2017 to recurrent next year.",0.9111374,0.681
DGX-2017-Q3-2017-10-19,49,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Therefore, as you think about 2018, we would encourage you to focus on our 2017 EPS guidance, excluding the $0.20 year-over-year increase of excess tax benefits associated with SBC and assume the same $0.06 we saw in 2016 as a jump-off point for 2018.",0.8819115,0.802
DGX-2017-Q3-2017-10-19,50,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Finally, I'd like to make a few comments on our long-term outlook, which we had reaffirmed today. Recall at 2016 Investor Day, we provided a long-term outlook from 2017 through 2020, which included a revenue CAGR of 3% to 5% with 1% to 2% growth expected from acquisitions.",0.7077409,0.625
DGX-2017-Q3-2017-10-19,51,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,It also included an adjusted earnings CAGR faster than revenue in the mid to high single-digit range. Note that this earnings outlook contemplated a starting point of $5.15 and adjusted EPS in 2016 and did not include any tax benefits associated with SBC beyond the base level of $0.06 recorded in 2016.,0.7365719,0.382
DGX-2017-Q3-2017-10-19,52,Remarks,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"This outlook implies adjusted EPS in the range of $6 to $7 by 2020, excluding the impact of excess tax benefits associated with SBC. With regard to PAMA, the cost in the current proposed fee schedule are deeper than expected. If the proposed fee schedule is finalized as its currently stated, we remain confident that we can achieve our long-term outlook, while our earnings outlook is more likely to be at the lower end of the range we provided. That said, M&A activity beyond our 1% to 2% growth target represents potential update to this outlook.",0.7448657,0.735
DGX-2017-Q3-2017-10-19,54,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Mark. We've summarized a very busy and productive quarter we turned in another strong quarter and are delivering on all five elements of our strategy to accelerate growth. Our updated guidance for our full-year 2017 reflects the impact of hurricanes in the third quarter, which impacted geographies where we have a large presence as well as the impact of recently closed acquisitions.",0.2817133,0.872
DGX-2017-Q3-2017-10-19,55,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, we remain confident in our ability to meet the long-term commitments outlined at our 2016 Investor Day.",0.401318,0.718
DGX-2017-Q3-2017-10-19,56,Remarks,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now we'd be happy to take any of your questions, operator?",0.3258649,0.572
DGX-2017-Q3-2017-10-19,61,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah thanks Isaac. Well first of all we've been in the consolidation mode as far as our strategy for the past five years, a significant part of our growth strategy is to get that 1% to 2% of growth through acquisition. What you see from us this quarter is we announced two acquisitions, puts us in that range of 1% to 2% for 2017 and while we said that puts us in a very good place for 2018.",0.3100494,0.937
DGX-2017-Q3-2017-10-19,62,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, our acquisition strategy continues to be part of our consolidation strategy. We continue to see interest in companies or laboratories looking at their strategic options and so we believe that's still a good part of our strategy. And then secondly, is we're confident that our guide proposition in the marketplace is really second to none.",0.2105437,0.844
DGX-2017-Q3-2017-10-19,63,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Our value of how we deliver our services is very strong in the marketplace from a quality and our service. You couple that with what we're doing on our consumer strategy. I mentioned in my prepared remarks about the convenience of what we're doing moving around our enablement of the whole process and are our better and better access for the consumer. Our value proposition of the marketplace is quite strong.,0.7739703,0.956
DGX-2017-Q3-2017-10-19,64,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, I also mentioned Isaac is that payers are taking notice to that and if you look at our assets today through our health plan relationships, it's really much stronger than what we've had in the past that will continue to build and as we get that better access we health insurance companies, we will continue to grow faster than the market place, both through acquisitions and organically.",0.1136738,0.756
DGX-2017-Q3-2017-10-19,65,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, tracking well with our plan to accelerate growth and we believe that that is the right strategy for us going into the future. So, thanks for the question.",0.5403624,0.8
DGX-2017-Q3-2017-10-19,68,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure Isaac. So, I was qualifying that we would be in the lower end if PAMA moved forward under the currently proposed fee schedule. So obviously while the things we've shared we're trying to influence that. So, at this point we're not locked into that.",0.5130148,0.361
DGX-2017-Q3-2017-10-19,69,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","What we're saying is that would be the likely outcome or the cost to be a significant or seeing in the original proposal, but we're obviously commenting on that and there is still some more work to be done to see where that settles down.",0.9749588,0.262
DGX-2017-Q3-2017-10-19,70,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, I wouldn't say at this point we're signaling the lower end. We're just saying there is significant impact and impairment while we certainly contemplated that with that outlook in November of 2016. That's why we gave a range. This is in the high end of what we might have expected coming our CMS. So, I would not lock into that at this point.",0.9479407,0.25
DGX-2017-Q3-2017-10-19,71,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In terms of M&A other than the deal that we have already executed, do not have any earnings projections that are based on future M&A. Certainly in our revenue, we've talked about getting 1% to 2%, but we all know that it takes a period of time generally 12 to 18 months before you get to a run rate level of earnings contribution.",0.8395387,0.178
DGX-2017-Q3-2017-10-19,72,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, in that mid to high single digits, so I am not counting on significant contributions from unexecuted M&A on the bottom line only on the revenue side.",0.6981878,-0.151
DGX-2017-Q3-2017-10-19,77,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. I'll take this. The first part of that question I'll give to Mark for the second part. So, we're actively working this and we've been working on it for years as we talked about. We've people engaged with the CMS on the implementation PAMA in the quarter and the principles of that we don't disagree which is market-based pricing for the refresh of the fee schedule.",0.3904448,0.61
DGX-2017-Q3-2017-10-19,78,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But while we've been helping them was but unfortunately, we think with what we've the draft rates they got wrong. We've been helping with the implementation of gathering the data to make sure the data is correct and then working through the competition of the data to establish new rates.",0.5252059,-0.226
DGX-2017-Q3-2017-10-19,79,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we've hard at work with them three years, but I'll share with you since we got the draft rates we have provided them feedback on where we see -- where we have questions or where we see some issues with what we see so far with the draft rates and so they listen to that and that's the first part of how we're engaging in this.",0.0118616,0.677
DGX-2017-Q3-2017-10-19,80,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is before we saw the draft rates and now since we see the draft rates for all over our congressional leaders to make sure they understand the difference of what CMS has proposed from those rates versus what the intention was with PAMA and we feel good about the receptivity of that and also, we've been engaged with the administration on that as well. So, hitting all branches of government and that we're very active.",0.538715,0.9
DGX-2017-Q3-2017-10-19,81,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We'll cement our formal covenants of the trade association and I'll say trade association all partners and all members of the trade association were actively engaged in that and that will go in before the deadline, which is October 23. I'll also tell you that other trade associations are deeply engaged in this.",0.2135091,0.772
DGX-2017-Q3-2017-10-19,82,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The device trade association appalment is deeply engaged in this. The smaller laboratories are engaged, the American Hospital Association, American Medical Association, I said that in my comments are deeply engaged and so we have a lot of support broadly, and then also employees are deeply engaged.",0.0365733,0.928
DGX-2017-Q3-2017-10-19,83,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We have grassroots, mailings going into congressmen and women and centers throughout all the different states telling and urging CMS that they need to take the time to get it right. So that's happening. We'll see what CMS does with this feedback. The schedule says the world then people comments into consideration and to give us the final rates in November, we'll see.",0.1799012,0.0
DGX-2017-Q3-2017-10-19,84,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","They could decide to take the time to get it right and to like the implementation. We're not sure whether they will or will not do that. If they go forward with the rates, we'll see what that means and what the comments to take into consideration and then we would need to consider legislative action depending upon what we see there with the help of the Congress members that we have been speaking to.",0.7848435,0.5
DGX-2017-Q3-2017-10-19,85,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",And then also what we're looking at two of the trade association is what legal alternatives we might have in the event that they go forward with final rates that clearly do not represent the congressional intent of PAMA. So that's what we mean by exploring all options and as you could tell from my commentary we're all over this and I'm not along to get a lot of help from my colleagues in the trade association.,0.7647446,0.71
DGX-2017-Q3-2017-10-19,86,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, I feel very good about the effort we're putting into this and CMS is hearing loud and clear that we believe that long and they need to take the time to get it right. So, Mark, do you want to talk about commercial rates?",0.6777595,0.747
DGX-2017-Q3-2017-10-19,87,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, Kevin, so couple things. First off as we shared previously, we had very little of our commercial contracts revenue tied to floating rates. We've been cleaning that over the last couple years in anticipation for some reductions in MAA. So, it's a very small portion and we very soon not have any contracts that are in any way floating an index MAA.",0.1587678,0.422
DGX-2017-Q3-2017-10-19,88,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of predicting the future, it's always hard to predict the future, but I can assure you that in the conversations with the large payers recently, they understand the significant impact of those trends in industry and certainly to us and they actually have entity for that, so versus it being an opportunity to take advantage of that and the messaging being we want to keep this ratio to Medicare.",0.4865719,0.931
DGX-2017-Q3-2017-10-19,89,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Of course, the conversation as you understand the intent of this is to incorporate commercial rates and Medicare rates. So that is an impossibility. So, at the end of the day, you're going to be basically in the same curve as the Medicare rates and given the significant impact and the fact that largely they agree with our premise that we are part of the solution on laboratory spending and pay significantly more to other providers of laboratory diagnostic and patient services.",0.5351501,0.637
DGX-2017-Q3-2017-10-19,90,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And also, were a part of the solution in terms of overall healthcare spend given the amount of influence that we have our data. Many people say one to two thirds of the other spend that we're actually all of our good guys and a good partner. So, they understand that and they you look for us to be successful and so the tenor of the discussions around price, I can assure you has not gotten worse given PAMA and certainly become neutral or got better in most cases.",0.9601106,0.965
DGX-2017-Q3-2017-10-19,91,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, should not expect any significant commercial price erosion going forward and just to remind people, we shared before, all our labs are typically paid one and half to two times but we're paying and then hospital laboratories are often 2.5 times or more the same rate.",0.3021327,0.104
DGX-2017-Q3-2017-10-19,92,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, I would expect some evolution in that over time as opposed to looking for credit concessions from the independent national labs.",0.0545024,0.382
DGX-2017-Q3-2017-10-19,94,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. Look what we've said in the past we'll say this quarter again, we feel stable. We look at all the different indications in the marketplace and overall if you look at the amount of healthcare people are using in this country and what we see from our established accounts, we feel stable.",0.0553542,0.691
DGX-2017-Q3-2017-10-19,95,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We feel good about our organic revenue growth in the quarter. We do look at to the effect that the larger storms over the third quarter had on us and we adjust for that. We actually feel very good about the progress we're making accelerating growth. So, we're making progress in a stable marketplace to accelerate growth.",0.524547,0.961
DGX-2017-Q3-2017-10-19,102,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, yes Jack of course that's our strategy is to push to two-way negotiation. So, at this point, I am not going to speculate our -- I promise where that could end up, but yeah, that is the position that we're taking and you already have excellent rates and there are other people whose services arguably are little better in some cases are as good as we're providing given the fact that for example we provide all of our data to the payers and quite often they don't get the data from other people to provide laboratory services within their network. So that's one argument actually to get a better product.",0.1028007,0.947
DGX-2017-Q3-2017-10-19,103,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",And then some of the things that Steve walked through in terms of the consumer experience that resonates because they're understanding that the outside customer which are your members and when they compete with other health plans there is certainly some value beyond the result of laboratory tests and the services that they provide and it can positively differentiate them if they bring some partner and work with us and see some of the value that we bring and the other providers don't.,0.8701812,0.863
DGX-2017-Q3-2017-10-19,104,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So that's part of our value proposition that we're discussing with them and I can assure you that over the last couple years we have gotten rate increases with some contracts given our value proposition explanation and that comes part and parcel with what I would call it try spirit of partnership whereas I said earlier, they see what part of the solution.",0.6777595,0.848
DGX-2017-Q3-2017-10-19,105,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the more they can field work to us, the better from some of those higher cost providers who arguably don't have good value given the service they provide, the better they're going to be and the more they're going to solve their laboratory spend.",0.9285008,0.872
DGX-2017-Q3-2017-10-19,106,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as I said earlier appropriately drive the use of that data for other healthcare cost. So, I feel really good about the relationships that we've been building and any time of course there is everybody wants to maximize value in their side of the equation.",1.3911038,0.706
DGX-2017-Q3-2017-10-19,107,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But I think as I said earlier, the tenure of the discussions and the lot more in the spirit of partnerships with the health plan and there are more of more seeing us as part of the solution and that's what's going to help us to defend the value of the price that we offer today and into the future.",0.8817133,0.811
DGX-2017-Q3-2017-10-19,109,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So, we continue to drive on an invigorate despite PAMA and what we've shared and this has been our philosophy for filing out years that we need to continue to get better in what we do and better probably the both in quality and the service as well as efficiency.",0.2359143,0.942
DGX-2017-Q3-2017-10-19,110,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as you see in our results we continue to get more efficient and we feel about tracking to that $1.3 billion goal. And if you recall in 2016 Investor Day, we said we're not done yet. So, we got a lot more in front of us. We provided some visibility in color to that in 2016.",1.109061,0.475
DGX-2017-Q3-2017-10-19,111,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we see more beyond the $1.3 billion and so we were anticipating that there might be some more price pressure going into '18 and '19. So, what you see implied in our guidance is the continuation of invigorate test what we'll do this year and into 2018 along with just driving productivity in general.",0.6065898,0.108
DGX-2017-Q3-2017-10-19,112,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And when you go through the math based upon what we have said, obviously we feel strong. We've had the convenience of the outlook that we provided in our Investor Day in 2016 because we've been working so hard for years. It's not a new program we're going to the continuation of the existing program and we have more efficiency to get out of this organization.",0.9897858,0.64
DGX-2017-Q3-2017-10-19,116,Question,2017-10-19,3,2017,Nicholas Jansen,Raymond James,"Hey guys. Good morning. Just two questions for me. First just wanted to dig a little bit deeper into margin trends and expectations as we think about PAMA being rolled out over the next two years. Certainly, you're showcasing very nice progress in 2017 on margins, I think up 50 basis points in the most recent quarter ex hurricane.",0.5240478,0.888
DGX-2017-Q3-2017-10-19,117,Question,2017-10-19,3,2017,Nicholas Jansen,Raymond James,"So just wanted to get your sense is 2017 peak margin year and how we think about if you analyze the next three years, how much does margin degrade associated with PAMA, thanks?",1.2860717,-0.44
DGX-2017-Q3-2017-10-19,118,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah Nick, so thanks for the question. The outlook that we gave is a CAGR. So that will be put as a CAGR. So, it's not year-to-year, we're not until we see some variability especially depending the way some of the PAMA cuts get rolled out.",0.5300158,0.493
DGX-2017-Q3-2017-10-19,119,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"But with that said what we've committed to is growing earnings faster than revenues. So, by definition that we says that we expect to expand margins. So, then it may not be every quarter, it may not be every single year in the period year-over-year, but over the next several years we're looking for continued margin expansion because we're committed to growing our earnings faster now.",0.1820695,0.739
DGX-2017-Q3-2017-10-19,120,Question,2017-10-19,3,2017,Nicholas Jansen,Raymond James,"And just a clarification on that regarding the structure of PAMA, does that mean -- my understanding is that 2019 would be a worse year than 2018 as we think about the size of the headwind. Is that the right understanding?",0.9666389,-0.477
DGX-2017-Q3-2017-10-19,121,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",The honest answer this point is I don't know because there are still so many things up in the air regarding how they're going to imply some of their rules and in pricing practices and without getting into too much detail because it's very complicated.,0.5515651,0.511
DGX-2017-Q3-2017-10-19,122,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But just in summary a lot of the billings to Medicare are panels and the way Medicare pays panel is very, very complicated and the more analyzing the panels, the more it impacts the overall price and it's not the positive fashion.",0.4026359,-0.445
DGX-2017-Q3-2017-10-19,123,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, they already have historically deviated from what people who are close to the industry might not understand which is you don't get in a way for every single analyze unless you start putting things together in a panel.",0.7973641,0.0
DGX-2017-Q3-2017-10-19,124,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the question we have is how our panels get paid and how we price which is the course to market because in many cases there is not a comparable code within the commercial world with a very, very complicated issue that we're trying to sort through and that's why even if at this point we were in a position to know and really interested in sharing the estimate by year, I don't have that answer.",0.6352554,0.723
DGX-2017-Q3-2017-10-19,125,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So still more to come. So, I would say at this point, do not assume that '19 is worse than '18 and vice versa. We will tell you as soon as we have people understanding to provide you some reliable information.",0.8942339,-0.477
DGX-2017-Q3-2017-10-19,126,Question,2017-10-19,3,2017,Nicholas Jansen,Raymond James,"That's very helpful and then just one quick -- just a numbers question. I understand the tax dynamics the stock-based compensation benefit you're seeing this year. Any way you can just share what we should be plugging in for '18? Is it kind of the 35 to 37 range, just wanted to get a sense of how we should be modeling tax specifically in '18, thanks.",0.6622185,0.906
DGX-2017-Q3-2017-10-19,127,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah so, I am sure you understand that, what drives that is a couple of factors. As long as the share price is higher than it was at the time of the brand of the equity and that you're going to seek in some value.",0.0272512,0.812
DGX-2017-Q3-2017-10-19,128,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So certainly, when you see a year like 2017 where we had significant stock appreciation that was versus previous years that was driving a lot of this benefit. The other thing is option exercises, which of course we can't predict.",0.028831,0.915
DGX-2017-Q3-2017-10-19,129,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, we're investing performance shares investing that will drive some level of benefit consistently assuming that the stock price continues to appreciate to some degree, but we can't predict the timing of the option exercises, which is a huge variable.",0.0264613,0.751
DGX-2017-Q3-2017-10-19,130,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, what I will say is the sixth sense that we shared when we say the base level assuming that the stock is stable and continues to go up to some degree that is pretty reliable but that's kind of be there, but the large swing is beyond that will be highly dependent on appreciation of the stock movement and the amount of option exercises and that's what we can't predict.",0.4901264,0.85
DGX-2017-Q3-2017-10-19,131,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, I would say sixth sense and we'll continue to update if that change is kind of a base level you should consistently expect and anything beyond that is dependent on those other factors.",0.4774882,0.0
DGX-2017-Q3-2017-10-19,132,Question,2017-10-19,3,2017,Nicholas Jansen,Raymond James,Thanks for all the detail guys.,0.9577426,0.44
DGX-2017-Q3-2017-10-19,136,Question,2017-10-19,3,2017,Bill Quirk,Piper Jaffray,"So, you addressed the commercial rate in Medicare relationship with respect to Kevin's question. I was hoping you could comment on the percent of Medicaid business that's tied into Medicare rates and how you're thinking that -- thinking about that rather over the next couple of years assuming that PAMA goes into effect?",0.0549345,0.71
DGX-2017-Q3-2017-10-19,137,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the best of our understanding, Medicaid rates are not largely tied in terms of being an index in terms of a mechanistic fashion. Certainly, they look at Medicare rates to make sense and the states set those rates.",0.8721582,0.783
DGX-2017-Q3-2017-10-19,138,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",But it doesn't look like there is a formulaic relationship in most cases again to the best of our understanding and we've looked at this pretty deeply and will automatically trigger changes in Medicaid. So that's going to be pretty much up to the states.,0.709061,0.935
DGX-2017-Q3-2017-10-19,139,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And again, reminding you only about 2% or 3% of our revenues are paid by traditional Medicaid fee for service. A lot of the Medicaid are removed to management and the one thing that it won't say is that there are rules around the fact that Medicaid cannot pay more than Medicare.",0.9621087,0.076
DGX-2017-Q3-2017-10-19,140,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, in any case where there is a state Medicaid rate where the fee for service is close to Medicaid and there is a Medicare reduction, you will see a reduction to ensure that Medicaid is not higher than Medicare. But beyond that at this point still more to learn, but I would not expect this will trigger significant reductions in state Medicaid rate and again given the small portion of our revenue that comes from 3% Medicaid, I wouldn't expect it to be a major headwind for us.",0.3429984,0.296
DGX-2017-Q3-2017-10-19,141,Question,2017-10-19,3,2017,Bill Quirk,Piper Jaffray,"Okay. No, I appreciate the color around that, thank you. And then just separately can you guys comment on I guess the consumer outreach programs that you have with Safeway and Walmart and help us think a little bit about the relative profitability of those as compared to say your traditional draw station and traditional diagnostics business, thanks?",0.2296391,0.869
DGX-2017-Q3-2017-10-19,142,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Yeah Bill thanks. It's our consumer strategy and I outlined the five elements of our growth strategy one of which is to be most consumer oriented laboratory and there are multiple facets as far as that is concerned. One is we're putting a lot of work and e-enabling our whole consumer process and we're talking about e-check-in.,0.6065898,0.772
DGX-2017-Q3-2017-10-19,143,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, moving really our experience that we have our consumers to contemporary experiences that people experience in the consumer world. Making a lot of progress there. The feedback is great. It helps patients. It helps our employees and as I mentioned, our healthcare insurance partners feel great about their experience as well because they're working on that.",0.7680395,0.954
DGX-2017-Q3-2017-10-19,144,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second is around information. We got MyQuest, we have 4.5 million users, which is a phenomenal number given that we only brought this to the marketplace in a little over two years. So, it's just picking up the volume of users that we have and we put more and more content around that and also want people to navigate into our whole experience through MyQuest, which is a nice consumer touch if you will.",0.4672158,0.527
DGX-2017-Q3-2017-10-19,145,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",The third is around products. We see a lot more from us and we have direct to consumer testing. We mentioned we tested this in our marketplace last year. We're bringing this into Missouri and Colorado. We're actually are encouraged by some of the early returns that consumers are interested in paying out of pocket from their own ordered diagnostic test.,0.661944,0.637
DGX-2017-Q3-2017-10-19,146,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","It could be cholesterol, it could be hemoglobin, glucose or such are transmitted, but there is a market there and so we're going at that market. And the last place we're investing in which is what you -- and that is a bit part of your questions is what we're doing around access and I'll say access because it's important that we have access for our draw stations.",0.0042834,0.296
DGX-2017-Q3-2017-10-19,147,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, we're looking at how we can augment and in some place, replace our patient service centers with some of these locations at Safeway. We're making excellent progress of implementing patient service centers in those Safeway stores and also relationship with Walmart. And so, we will open some centers in Walmart in Florida and Texas this year.",0.570346,0.758
DGX-2017-Q3-2017-10-19,148,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, what they have allowed to do is by zip code is look at where we have access points and in some cases, we can consolidate what we have in those stores. And that allows us to get more efficiency in some cases around the real estate cost but also around phlebotomist productivity.",0.5963756,0.226
DGX-2017-Q3-2017-10-19,149,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The biggest cost of drawing is not real estate it's the labor, it's a phlebotomist. So, if we can have more density of phlebotomists in better locations and convenient locations that serve the consumer better, better off we're go to be.",0.8583196,0.827
DGX-2017-Q3-2017-10-19,150,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Remember a lot of our patient service centers even though we have unparalleled access the 2,200 patient service centers and we have over 3500 phlebotomists in physician's offices so close to 6,000 access points.",0.3449753,0.0
DGX-2017-Q3-2017-10-19,151,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our medical office buildings and these are not nearly as convenient locations is where you'll find a Safeway store and where if you find a Walmart with big wide-open parking lots, easy access to the store and ability to do some shopping and other activities around that experience.",0.9558484,0.637
DGX-2017-Q3-2017-10-19,152,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we're quite encouraged. We think we're on the track again as we talked earlier, our value proposition to the healthcare value proposition is we want to be the most consumer-oriented laboratory. And we think our value proposition is getting stronger and stronger every day because we're focused on this. So, we're making a lot of good progress. Operator, next question.",0.8121911,0.969
DGX-2017-Q3-2017-10-19,157,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, so the jumping off point shouldn't be adjusted for the hurricane, but you may argue that the year-over-year growth compare is easier given the fact that we had hurricanes in 2017.",0.3376777,0.681
DGX-2017-Q3-2017-10-19,158,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, the jumping off point you're right takes the midpoint of our guidance and take out the $0.20 and that's out of the way we are thinking our starting point given that at this point we would project only $0.06 of excess tax benefits from stock-based compensation.",0.2460506,0.382
DGX-2017-Q3-2017-10-19,159,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And that's how we would build our initial plan for 2018 and certainly taking into account that the hurricane impact this year, that can give us an easier compare to next year.",0.1947077,0.637
DGX-2017-Q3-2017-10-19,161,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Exactly. Not off the guidance that's includes the $0.20 excess with stock-based comp around.,0.5835255,0.0
DGX-2017-Q3-2017-10-19,163,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",No as I said earlier - maybe wasn't as clear as I intended to be given that there are so many things that have to be sorted out. So many unanswered questions we're still trying to figure out obviously looked at it deeply and we have a huge range of potential outcomes depending on the answers to some of those questions.,0.4747941,0.402
DGX-2017-Q3-2017-10-19,164,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, it would not be helpful at this point to share that information as I said in a minute we expect to get more clarity in the not too distant future as soon as we're in a position to share something we'll certainly do so.",0.6477759,0.755
DGX-2017-Q3-2017-10-19,166,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"With that said we obviously have reconfirmed our views on outlook and the view outlook took into consideration what we saw in the draft rates. And so, our feedback to CMS is that there is a lot of areas that we think they got wrong and therefore we think the rates are too low.",0.0015798,-0.637
DGX-2017-Q3-2017-10-19,167,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, we think as we contemplate what we just shared with you this morning we are confident we feel with those outlook despite what might happen or not happen given our dialogue with CMS.",0.1828594,0.681
DGX-2017-Q3-2017-10-19,169,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Sure. We've shared that we have very robust specific metrics around evaluating our deals that involves a return to invested capital metric where it would be accretive by the third year relative to our plan of record and we have a plan of record based on our performance shares.,0.3021327,0.822
DGX-2017-Q3-2017-10-19,170,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, every year we put forward our forecast for our return on invested capital for the base business and half of our performance shares our based on that. So, we need to do deal that are accretive to do that by the third year. And we have also have an MPV metric and obviously the MPV level that needs to be exceeded before you will consummate a deal.",0.1690363,0.296
DGX-2017-Q3-2017-10-19,171,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, the multiple question is a tough one because their P&L generally has no relationship to our P&L as I shared at the Investor Day. I went through actually Strawman example and in most cases, it's not all of their revenues are higher than ours.",0.5529226,-0.077
DGX-2017-Q3-2017-10-19,172,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"When the business becomes part question, we get paid at the rates at which we negotiated, but the cost structure is so dramatically different than despite that revenue and synergies, we still significantly make more margin typically then the individual.",0.0876777,0.0
DGX-2017-Q3-2017-10-19,173,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, taking a multiple of their P&L really does not make any sense as we shared the revenue multiple look like -- they look a great deal based on when it was in their hands and the earnings multiples, or EBITDA multiples look like we way overpaid it, but it's really not meaningful.",1.2547393,0.439
DGX-2017-Q3-2017-10-19,174,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"If you look at our pro forma, you would see multiples that are the opposite, which says based on the earnings it was good and based on the revenue maybe you paid a little bit too much, but we cannot pay significantly more than our current enterprise multiple because by definition the math doesn't work and then we're not able to hit that rolling target.",0.5454186,0.339
DGX-2017-Q3-2017-10-19,175,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, when we actually use return on invested capital, not our cost of capital, which some other companies use to evaluate deals so in fact we have a risk premium built into our MPV and built into our return expectations that we think make sense that's good for our shareholders.",0.1962875,0.202
DGX-2017-Q3-2017-10-19,183,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so let me start the contracting. We obviously want to have the best access as possible and I said in my earlier comments that we should really good about our growing access and it's helping us accelerate in growth and that continues to be our strategy going forward as you are aware one of the nationals that we don't have our preferred relationship is united what we shared in the past we know that contract expires in 2018 with our nearest competitor.",0.616804,0.964
DGX-2017-Q3-2017-10-19,184,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",And as we said we would like to be on contract with United and our relationship continues to be strong in building so we did contemplate in our outlook is growing capability for us to have many of your insurances also on network then what we currently enjoy. And so that is contemplated in outlook and Mark second part of the question.,0.7199341,0.91
DGX-2017-Q3-2017-10-19,185,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, Amanda we're going to stick with our capital deployment strategy in terms of earnings growth being low to actually mid to high single-digit that is earnings that's not earnings per share so does contemplate significant buybacks two step earnings-per-share as well as earnings from cash",0.4123223,0.417
DGX-2017-Q3-2017-10-19,186,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And so, we will continue our strategy which says in the near-term accretive opportunities that used of that cash to do M&A that will be a priority once we satisfy that majority of free cash flow back to our shareholders as we've talked about before the dividend gets a long way towards that objective and use of supplemental share buybacks to get at least to 50%.",0.3380727,0.878
DGX-2017-Q3-2017-10-19,187,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Our free cash flow again with the other 50% of our free cash flow will be opportunity dependent if we have M&A that will be the preference and if we don't have M&A then that is a better use of cash and we will buy back more shares.,0.3637441,0.93
DGX-2017-Q3-2017-10-19,188,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,But at this point the outlook does not include a reduction in our way so to get to higher levels of earnings. The growth rate that I share at the CAGR is real earnings.,0.4774882,0.586
DGX-2017-Q3-2017-10-19,191,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","You're correct. That is a mitigation and any sort of price declines from the NOA because there are some reasons that we're already paying less than NOA. So, by definition there's less of a decrease at least in the first year depending on what the overall cuts might be over a multiyear period.",0.6191104,-0.296
DGX-2017-Q3-2017-10-19,192,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And actually, on that note that is the issue with the panel. So, in the case of any of the panels, if you added up the individual components in there NOA, we've not been getting paid that total amount. So that would also be a mitigation assuming that they don't change into some sort of other methodology.",0.5621087,0.0
DGX-2017-Q3-2017-10-19,193,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So that's what makes it a little bit complicated, but I did want to acknowledge that if you just look at the fee schedule and tried to say okay if the Medicare revenues are X and it looks like and this isn't the case. Every code was reduced by 10% if I can do the math.",0.3640857,0.723
DGX-2017-Q3-2017-10-19,194,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now it's a lot more complicated than that because in most cases, we're not getting paid NOA for the work that we do for Medicare.",0.831631,0.0
DGX-2017-Q3-2017-10-19,200,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, let me clarify so on the efficiency program, I wouldn't model in a significant change from what we've been doing. I think Steve said that there is more to be done and then certainly we'll continue to deliver significant efficiencies, so that's part and parcel with the outlook that we gave.",0.4411532,0.854
DGX-2017-Q3-2017-10-19,201,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now with that said of course depending on the PAMA outcome, the timing of it and how severe it is, we're going to do what we need to do. So, we're going to get to that outlook. We have enough levers to pull that we're very comfortable and we're not reaffirming the outlook if weren't confident that we have the ability to do that despite where PAMA might come out.",0.5003949,0.757
DGX-2017-Q3-2017-10-19,202,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And certainly, in this case, where we have the plan and it contemplates the worst-case scenario which is what they proposed. And then in terms about the share buybacks. So, there will be some share buybacks, but I think a lot of that is really just to prevent dilution given our equity program.",2.0663507,0.534
DGX-2017-Q3-2017-10-19,203,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, I wouldn't assume that any reduction in ways. So that is not in my outlook for this point. As I said again that growth is in earnings. And therefore, at this point given all other factors you should assume that earnings per share for both earnings and then depending on that's where to create value that could vary because we get more M&A and because we do more share buybacks.",0.0659558,0.859
DGX-2017-Q3-2017-10-19,204,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And yes, the 1% to 2% is what we're counting on, but while we're signaling back to it's original question is we think although we've been doing consolidation, this could be a trigger for acceleration in the consolidation.",0.3613744,0.586
DGX-2017-Q3-2017-10-19,205,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, we are just knowing that there could be an opportunity for an acceleration and for more M&A but I'm not modeling that in the outlook at this point.",1.0185624,0.226
DGX-2017-Q3-2017-10-19,207,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Ann, my commentary was that we're working on it, but it's the current status quo is whether it stayed that way or not. We still feel confident with our outlook.",0.2009885,0.649
DGX-2017-Q3-2017-10-19,208,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Okay. So that's the way you should think about it is your current access is getting stronger. We are working to get it even stronger but our outlook contemplates staying where we are as well.,0.1327842,0.691
DGX-2017-Q3-2017-10-19,211,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The big change let me give you a little color around this. So, when we went off around and talked to our members of Congress and Southerners and the administration, we explained our concern but it was a concern without a lot of facts and a lot of our stakeholders said well, I understand, but let's see what the data says.",0.2075783,0.392
DGX-2017-Q3-2017-10-19,212,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so many of them were waiting for these draft rates. And so, the good news is the draft rates are out and the draft rates are severely flawed with the amount of data that was collected a very small percentage that is 1% with a lot of the data coming from ourselves, so the majority of the rates are based upon the large nationals and that was not the congressional intent.",0.354201,0.046
DGX-2017-Q3-2017-10-19,213,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the data being out there and is helping us now get more momentum with our stakeholders to say well okay what these guys have been talking about before we have addressed, they were right, they really got along and their message around taking time to get it right we now understand. Now the question is what do we do about that.",0.8494234,0.637
DGX-2017-Q3-2017-10-19,214,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So strange way the draft rates have been helpful to move the dialogue along.,0.9159802,0.18
DGX-2017-Q3-2017-10-19,215,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And one example, Ann, is the OIG in some of the reports over a month ago have said based on the definition of the applicable lab they were expecting about 5% of the labs, but close to 70% of the volume to be reflected.",0.478673,0.0
DGX-2017-Q3-2017-10-19,216,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As you heard us say today only 1% of the labs actually ended up submitting for various reasons. So back to Steve's point around okay, I get your concerns, but we'll see where it comes out, certainly those kind of facts are weighing in the conversations we're having right now.",0.3680885,0.55
DGX-2017-Q3-2017-10-19,217,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the vast majority of the data they're looking after these drafts from the large laboratories and we know from Medicare data that roughly 50% of what they buy is laboratory services from hospital at which laboratories as well as physician office labs. And from the two large nationals, it's only 20% of their purchases roughly.",0.5383855,0.273
DGX-2017-Q3-2017-10-19,218,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the sampling is flawed and they need to take the time to get it right and the whole philosophy of PAMA is to make sure that they look at this different cost of served issue in this industry to make sure they're paying market based rates and those market base rates are not the rates of large nationals that generally have the density of large centers.",0.6777595,0.557
DGX-2017-Q3-2017-10-19,225,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well first of all, in Aetna our relationship continues to be strong. Yes, we have preferred national relationship and we haven't commented where we'll continue or not, but we do have one extended contract, which we feel good about and we've secured.",0.616804,0.899
DGX-2017-Q3-2017-10-19,226,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And second, as far as our philosophy with all of your insurance companies, we do believe that it is good to have a smaller network and frankly given our value proposition, we actually like those contracts where we are on contract with other nationals, where we have the opportunity to compete for the business because when we do compete for the business, we do quite well.",0.0392092,0.9
DGX-2017-Q3-2017-10-19,227,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",So philosophically and strategically that's the position we've taken and as you see three out of the five nationals do have both their competitor on par and we feel good about those relationships as there is a different approach.,0.7822076,0.44
DGX-2017-Q3-2017-10-19,228,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We feel great about that relationship and we're working with United. All of those supplies have different relationships and I'll remind you we spend a lot of time talking multinationals but a large part of our business is not with the nationals.,0.9762768,0.535
DGX-2017-Q3-2017-10-19,229,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We have a lot of regionals. We have hundreds of contracts and those contracts continue to provide great access for us as well. So, Lisa just to clear, yes, our network rates are higher and in some cases significantly higher than the network rates, but there is also some supplies that don't have that network benefit, typically they're falling short.",0.2800659,0.834
DGX-2017-Q3-2017-10-19,230,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we don't get paid quite the premium being out of network that some people might think because there's some work we receive that we do basically for free because we don't get paid for those full insurance. So, if we get any network in a plan where we're on a network, there is countervailing forces.",0.6639209,0.511
DGX-2017-Q3-2017-10-19,231,Answer,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","One is the network rate obviously typically is lower than the other network rates but then for the supplies that didn't have that benefits we actually get paid. So, there will be certainly some pricing headwind offset by what we will consider to be significant volume increase for any time we get into a network where we were previously out of network, but it's not as large a price headwind that some people might come to surface.",0.7983526,0.877
DGX-2017-Q3-2017-10-19,234,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So, as I shared in the prepared remarks, pricing continues to be less and on a apples-and-apples price and then we've also shared in the past that there was any mix element that suppresses revenue correct from our PLS business.",0.342812,0.862
DGX-2017-Q3-2017-10-19,235,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So really when you look at the revenue per rep, it's the positive mix that we've experienced pretty consistently for several quarters, which is around the tax mix and then also then to the acquisitions where we tend to consistently have been growing our test per rep ratio.",0.5438389,0.818
DGX-2017-Q3-2017-10-19,236,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,So those are the drivers. The other mix elements have been favorable more of our advanced diagnostic testing and then more test per acquisition have all set the negative mix impact of PLS on revenue per rep.,0.3376777,0.401
DGX-2017-Q3-2017-10-19,237,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"When you look at the diagnostic services business, it's largely our risk assessment businesses. There is a couple of other things in there, but that's a big driver. That is the work we do for individuals who are looking to secure life insurance policies and in front of that is how independent on the industry itself and the number of policies that are being written and recently that's a little softer.",0.0165877,0.459
DGX-2017-Q3-2017-10-19,238,Answer,2017-10-19,3,2017,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, it has nothing to do with the competitive environment per se losing the competition really have to do with the market and the market has slowed in full recently.",0.2180095,-0.226
DGX-2017-Q3-2017-10-19,240,Question,2017-10-19,3,2017,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. So, thanks again for joining us today. As we've said, we had another strong quarter in the third quarter 2017. We look forward to make our commitments and executing our two-point strategy of accelerating growth and driving operational excellence. We thank you for your continued support and have a great day.",0.1904448,0.975
DGX-2020-Q2-2020-07-23,3,Remarks,2020-07-23,2,2020,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I'm on the line with Steve Rusckowski, our Chairman, Chief Executive Officer, and President; and Mark Guinan, our Chief Financial Officer.",1.3244245,0.66
DGX-2020-Q2-2020-07-23,4,Remarks,2020-07-23,2,2020,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements, and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially from those projected. Risks and uncertainties, including the impact of the COVID-19 pandemic that may affect Quest Diagnostics' future results, include but are not limited to, those described in our most recent Annual Report on Form 10-K, and subsequently filed quarterly reports on Form 10-Q, and current reports on Form 8-K. The company continues to believe that the impact of the COVID-19 pandemic on future operating results, cash flows, and, or its financial condition will be primarily driven by the pandemic's severity and duration, the pandemic's impact on the U.S. healthcare system and the U.S. economy, and the timing, scope, and effectiveness of federal, state, and local governmental responses to the pandemic, which are drivers beyond the company's knowledge and control.",1.3871395,-0.065
DGX-2020-Q2-2020-07-23,5,Remarks,2020-07-23,2,2020,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS from continuing operations, and references to adjusted EPS refer to adjusted diluted EPS from continuing operations. References to base testing volumes or base business refer to base testing volumes, excluding COVID-19 molecular and serology testing volumes. Finally, growth rates associated with our long-term outlook projections, including total revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth, are compounded annual growth rates.",1.2275734,0.927
DGX-2020-Q2-2020-07-23,7,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks, everyone, for joining us today. Well, in one of the most challenging periods of our history, Quest Diagnostics stepped up and expanded COVID-19 testing for the country, and delivered stronger than expected performance in the second quarter. Second quarter results were driven by COVID-19 testing and the rapid recovery of our base testing volume. I'm very proud of Quest employees who have been on the frontlines of healthcare, answering the call, and fighting the COVID-19 pandemic.",2.9370675,0.906
DGX-2020-Q2-2020-07-23,8,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, this morning, I'll discuss our performance for the quarter, our role in the COVID-19 pandemic, and update you on our non-COVID base business. And then Mark will provide more detail on the second quarter results and our financial position. We have reinstated our financial outlook for the remainder of the year with a broad range, which reflects uncertainty caused by the pandemic. Mark will talk about our outlook in an underlying subject just in a few minutes.",1.7008237,-0.34
DGX-2020-Q2-2020-07-23,9,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our financial performance in the second quarter was stronger than anticipated, also lower than the same period of 2019. For the quarter, total revenues declined approximately 6% to $1.83 billion. Earnings per share decreased by approximately 10% on a reported basis, so $1.36; and approximately 18% on an adjusted basis, so $1.42. These results were driven by a strong bounce back in our base testing volumes for March and April, as the healthcare system began to resume non-urgent care and elective surgeries sooner than we had anticipated. Heavy demand for COVID-19 molecular testing helped partially offset the base volume decline as well. Demand came in from a number of areas with the continuing spread of the virus throughout most of the country, the pent-up need to test non-COVID-19 pre-surgical patients, people in high-risk populations like nursing homes and prisons, the proliferation of retail testing sites, and finally, employer interest in testing employees before they return to work.",1.8873147,0.933
DGX-2020-Q2-2020-07-23,10,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest Diagnostics has continued to play a pivotal role in bringing COVID-19 testing capacity to the nation. We performed roughly 8.5 million COVID-19 molecular diagnostic tests, and more than 2.5 million antibody or serology tests. We now have the capacity to perform up to 130,000 molecular diagnostic tests today, double the capacity since mid-May. Over the next couple of weeks, we expect to have the capacity to perform approximately 150,000 molecular diagnostic tests per day. Cumulatively, Quest has delivered nearly 20% of all the testing included in this country.",1.4069193,0.34
DGX-2020-Q2-2020-07-23,11,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Working together with large national retailers like Walmart and CVS, we've built a new model for consumers to access testing. We're also supporting HHS and state drive-through testing initiatives across the country. I'm very proud of the progress we have made in rapidly scaling up capacity since the pandemic began. However, demand for testing has soared in recent weeks. And we are providing testing results in about two days for the highest priority patients, and the average turnaround time for non-priority patients is at least seven days.",1.9518946,0.878
DGX-2020-Q2-2020-07-23,12,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we're doing everything we can to bring more COVID-19 molecular testing to patients and speed the delivery of test results. We continue to add testing platforms and work with our suppliers to ensure access to testing equipment, reagents, and personal protective equipment. We're exploring a range of new technology options, like last week, the FDA granted Quest the nation's first emergency use authorization to use specimen pooling for COVID-19 molecular testing. This technique, which is commonly used with blood banking, will help expand capacity, especially among populations with low estimates. Through our lab referral program, we're partnering with other quality laboratories to expand our available capacity. And in recognition of the magnitude of the current demand for testing, we have asked customers to help us prioritize patients we test for COVID-19 at this time.",0.5107084,0.872
DGX-2020-Q2-2020-07-23,13,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest colleagues have stepped up in so many ways over the last few months to fight the COVID-19 pandemic. Our company has been central to the crisis response, and I'm proud of our employees on frontlines who are serving patients, customers, and communities every day. In June, we offered financial assistance to about 23,000 of our frontline colleagues and their supervisors to encourage increased expenses during the pandemic. In April, we took us a series of temporary workforce actions to manage our costs. These included the furloughs, reduced hours, and pay cuts for salaried employees. And then today, I am very pleased to report that a vast majority of these actions were reversed a month earlier to enable us to continue to respond to our customers' increased demand for testing.",0.0777595,0.458
DGX-2020-Q2-2020-07-23,14,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Since March, we've been fighting COVID-19, but we've also been focused on accelerating growth in the base business. And as a reminder, the five elements of our strategy to accelerate growth are to grow more than 2% per year through accretive [indiscernible] acquisitions, to expand relationships with health plans and hospital health systems, to offer the broadest access to diagnostics innovation, be recognized as a consumer-friendly provider of diagnostic information services, and then finally, support population health and data analytics in extended care services.",2.52257,0.974
DGX-2020-Q2-2020-07-23,15,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, let me take you through a few highlights from our strategy to accelerate growth. Through the pandemic, the M&A environment understandably slowed. But despite that, we were able to complete the acquisition of a Memorial Hermann outreach business in April, and are pleased with the early progress. We also recently announced our plan to acquire all of Mid America Clinical Laboratories, or MACL. Once we complete this transaction expected this quarter, Quest will wholly own MACL's laboratory in Indianapolis, and about 50 patient service centers across Indiana. Also, we'll provide professional lab services under a long-term agreement for 30 hospital labs owned and operated by MACL founding hospitals, Ascension St. Vincent and Community Health Network.",0.0843493,0.912
DGX-2020-Q2-2020-07-23,16,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our M&A pipeline remains strong. Given the many challenges that hospitals will face, we expect many more to be open to discussions about how Quest can help them achieve their lab strategies. At the same time, we know that all our regional laboratories have had their own challenges. This could also produce more opportunities for tuck-in acquisitions. If anything, the pandemic could be an additional catalyst to help drive industry consolidation. Some transactions in the pipeline that were paused because of the pandemic are being revisited, based on the new realities that the healthcare system is experiencing at this time. We also continue to make progress on our health plans strategy. We entered our second year of being a member of your UnitedHealthcare's Preferred Lab Network, and we are pleased with the results to date. We have met or exceeded key quality metrics, such as electronic ordering and resulting, and patient service center appointment rates. We've also secured business for more than 180 out of network UHC labs, saving money for patients and lowering the overall cost of care. We look forward to making continued progress with the Preferred Lab Network in the second year.",0.6092257,0.974
DGX-2020-Q2-2020-07-23,17,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Over the last few months, we've seen a remarkable surge in the sign-ups of our MyQuest patient portal. Today, more than 11 million patients have a MyQuest account to make appointments and receive their results through their smartphone or computer. Since late April, we've seen a more than three-fold increase in weekly registrations, which accelerated at the end of the second quarter. We believe that our patients see and appreciate the ease and convenience of our consumer experience.",0.5630972,0.885
DGX-2020-Q2-2020-07-23,18,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, I'd like to turn it over to Mark, who will take you through the results. Mark?",0.7937397,0.361
DGX-2020-Q2-2020-07-23,19,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. In the second quarter, consolidated revenues were $1.3 billion, down 6.4% versus the prior year. Revenues for diagnostic information services declined 5.7% compared to the prior year. Although revenue declined year-over-year, our second quarter results were stronger than we communicated back in June, reflecting the stronger than expected recovery in base testing volumes, as well as growing demand for COVID-19 testing services. Volumes, measured by the number of requisitions, decreased 17.7% versus the prior year, with acquisitions contributing approximately 50 basis points.",1.4423381,0.866
DGX-2020-Q2-2020-07-23,20,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Testing volumes in the company's base business declined approximately 34% versus the prior year. In April, base volumes declined in excess of 50% compared to last year, as stay at home measures were implemented across the U.S., hospitals began to limit elective procedures, and many physician offices were temporarily closed for business. Base volume trends began to improve in May, down more than 30%, as stay at home measures [Audio interrupted], many hospitals reintroduced elective procedures, and some physician offices reopened. The base volume recovery continued in June, down less than 15%, as the trends in May gained momentum.",0.0114534,0.671
DGX-2020-Q2-2020-07-23,21,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Throughout the quarter, the strongest recoveries were observed in the states that opened more quickly than others, such as Texas and Florida. As we exited June, base volume declines had moderated to approximately high single digits. However, due to the recent spike in COVID-19 cases across the country and the rollback of several state reopening plans, we have seen a slight softening of our base business in early July. While base testing volumes remain down year-over-year, COVID-19 testing was a meaningful offset in the second quarter. We exited the second quarter averaging approximately 110,000 and 26,000 COVID-19 molecular and serology tests respectively each day. Over the next couple of weeks, we expect to have the capacity to perform 150,000 molecular diagnostic tests per day.",1.6607425,0.765
DGX-2020-Q2-2020-07-23,22,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per requisition increased 15.3% versus the prior year, primarily driven by reimbursement for COVID-19 molecular testing. Unit price headwinds were slightly less than 2% in the second quarter, in line with our prior expectations. This includes the ongoing impact PAMA. Reported operating income was $283 million or 15.5% of revenues, compared to $307 million or 15.7% of revenues last year. Reported operating income second quarter includes $65 million of proceeds from the CARES Act. On an adjusted basis, operating income was $294 million or 16.1% of revenues, compared to $352 million or 18% of revenues last year. The year-over-year decline in operating margin was due to the significant decline in revenue associated with our base testing volumes, partially offset by COVID-19 testing and our cost reduction actions. Adjusted operating income does not include proceeds from the CARES Act.",1.3009479,0.885
DGX-2020-Q2-2020-07-23,23,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $1.36 in the quarter, compared to $1.51 a year ago. Adjusted EPS was $1.42, compared to $1.73 last year. Cash provided by operations was $602 million year-to-date through June 30, versus $596 million in the same period last year. Cash from operations in the second quarter included the $65 million of provider disbursements under the CARES Act I just mentioned. Our financial position remains very strong. During the second quarter, we amended our revolving credit facility, allowing us greater financial flexibility. We completed a $550 million debt offering in May, which may be used to redeem or repay our senior notes due in 2021. Given the better than expected second quarter results, our debt to EBITDA ratio was only slightly above where we ended Q1. We ended the quarter with nearly $1 billion in cash on the balance sheet. Finally, our Board of Directors remains committed to the company's quarterly dividend at this time.",0.9770932,0.93
DGX-2020-Q2-2020-07-23,24,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"This morning, we reissued our full-year 2020 outlook as follows. Revenue is expected to be between $8 billion and $8.6 billion, an increase of approximately 3.5% to 11.3% versus the prior year. Reported EPS is expected to be in a range of $5.66 and $7.66, and adjusted EPS to be in the range of $6.60 and $8.60 8 per share. Cash provided by operations is expected to be at least $1.25 billion, and capital expenditures are expected to be between $375 million and 400 million. We continue to operate under extremely uncertain conditions due to the COVID-19 pandemic, which is evident in the wider than usual outlook ranges we shared in our quarterly press release today.",0.0548973,0.528
DGX-2020-Q2-2020-07-23,25,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As you consider our new 2020 outlook, I'd like to share the following considerations and assumptions. First, regarding base testing volumes, we expect base testing volumes to remain below prior year levels for the remainder of the year. While the magnitude of the year-over-year decline is likely to fluctuate geographically as states throttle reopening phases, our current outlook does not contemplate the magnitude of base volume declines observed in April and May, and the low end of the outlook assumes an average 20% decline in base testing volumes through the remainder of the year. Regarding molecular COVID-19 testing demand and capacity, we continue to drive towards molecular COVID-19 testing capacity of 150,000 tests per day over the next couple of weeks. Keep in mind this represents peak capacity, operating under optimal conditions. Due to various factors, such as routine maintenance and planned downtime, we generally operate at somewhat under peak capacity. We expect demand for molecular COVID-19 testing to remain high, at least through the third quarter.",0.0770142,0.477
DGX-2020-Q2-2020-07-23,26,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Please note, that the low end of our outlook assumes recent molecular COVID-19 testing volume trends continue at a similar level throughout the third quarter and then step down in the fourth quarter. Regarding Medicare reimbursement from the molecular COVID-19 testing the existing $100 Medicare reimbursement for molecular COVID-19 testing is tied to the public health emergency declared by HHS. HHS officials have recently indicated they plan to extend the public health emergency for an additional 90 days beyond the current expiration of July 25. Our outlook assumes this level of reimbursement continues through late October. To be clear, we believe HHS to continue the Public Health Emergency while the crisis continues and we are not aware of any plans for it to end.",0.2733017,-0.813
DGX-2020-Q2-2020-07-23,27,Remarks,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Regarding COVID-19 serology testing, COVID-19 serology testing also continues to help offset declines in base testing volumes. We continue to believe there is meaningful potential within serology testing but rising customer demand remains in front of us. Regarding the cost actions we've undertaken, as Steve mentioned, we have rolled back many of these cost actions we took in April with most remaining actions expected end of July. Finally, as we develop this outlook we contemplated a range of potential outcomes in the second half of 2020. The low end assumes the variability and uncertainty I just described. We have greater degree of visibility in the third quarter and there are far more unknowns in the fourth quarter. Therefore, we currently expect third quarter results to be stronger than the fourth quarter.",0.1046603,0.392
DGX-2020-Q2-2020-07-23,29,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. With the sunrise in the second quarter, Quest Diagnostics step up and rapidly expanded COVID-19 testing for the country and delivered stronger than expected performance. Looking forward to the rest of the year, we will continue to expand COVID-19 testing capacity while also serving the unmet needs of healthcare community and drive our strategy to accelerate growth. We reinstated our financial outlook for the full year of 2020 with the broad range, which reflects the continued uncertainty caused by the pandemic. Finally, I'm very proud of our Quest employees who have been on the frontlines of health care, answering the call and fighting the COVID-19 pandemic",1.0052718,0.902
DGX-2020-Q2-2020-07-23,30,Remarks,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, we'd be happy to take any of your questions. Operator?",1.230313,0.572
DGX-2020-Q2-2020-07-23,33,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So it sounds good. Well, on serology we are doing serology as we speak. We brought that up in April. We have in our outlook for the year some serology volume. What I will say is there is growing evidence of the value of serology. There has been some debate of the evidence that would suggest if you have the antibodies that, in fact, it provides the ability for a period of time. It is clear that people are starting to weigh in that, in fact, those antibodies do provide confidence that there will not be a re-infection. As that confidence builds and as we get into the fall and into next year, I do believe there will be a pickup in serology particularly as we start to think about who should get the vaccine and who should not get the vaccine. So I think some of that is in front of us, but we do have some of that in our outlook. As far as molecular testing and pooling in the numbers that I provided particularly getting to 150,000 per day in a couple of weeks, some portion of that will be driven by the opportunities we see with pooling. Some portion of that is also driven by adding new systems and new resources to increase our capacity. What I'll say is we're not stopping there. There's opportunities in front of us beyond that 150,000.",0.369028,0.963
DGX-2020-Q2-2020-07-23,34,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I just would like to add in certainly, serology testing is meaningful and we shared in Steve's prepared remarks we've done 2.5 million. That's certainly meaningful. It's just different than molecular where the demand is exceeding our capacity. We had shared earlier that we had capacity of 200,000 serology tests a day with an expectation that demand could possibly be at that level. For various reasons, it's nowhere near that. But certainly, the amount of serology testing we're doing is very meaningful to Quest and is one of the offsets to the base business decline right now.",0.056872,0.954
DGX-2020-Q2-2020-07-23,38,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure. First, as far as demand, where is it coming from. In our prepared remarks, we took about the different elements of demand and what I'll share with you is that we have demand right now that is exceeding our capacity and we're doing what we can to obviously bring up the capacity. Also, we said in prepared remarks is working with our customers and clients on prioritizing those specimens that we're getting in to make sure we're testing the most urgent need in the country and we're making progress. As we bring up the capacity and we manage our demand over the next several weeks and get into August, we believe as we get through August and into September, we'll have a higher level of capacity, but also a higher level of demand and we'll be able to get to turnaround times that are in the acceptable levels that we've had in the past. So it's in front of us. We're working hard getting there and I think all elements that you described will allow us to be successful through the next several weeks.",0.2853377,0.91
DGX-2020-Q2-2020-07-23,39,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As far as demand, Steve, you talked about return to work programs. It's starting to come into our demand. We're managing it with employers. We also see in front of us the demand for return to universities and colleges. There'll be a lot of testing required in the month of August around that. We also see physicians bringing up their offices and more physicians are actually sending us persons that they've collected. So we see that adding to the demand. Then there has been broader access and broader availability of testing where people have now at access to asymptomatic testing and very convenient locations. Then I mentioned that our remarks the access we provided with CVS stores and also with Walmart has increased the demand. So, I would say across the board, it's growing in all areas.",0.5136738,-0.178
DGX-2020-Q2-2020-07-23,40,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We do believe though as we get into the September months when we hope there is still a number of employers that are bringing employees back to the office or to work that we are going to be in a place where our capacity will meet the demand that we see in our funnels.,0.0395387,0.477
DGX-2020-Q2-2020-07-23,41,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Stephen, did you ask about pacing concessions? I didn't quite pick up your last question.",0.0181675,0.0
DGX-2020-Q2-2020-07-23,43,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"That's really formulaic approach. Cash collections are stronger as expected. We did have some delayed billing around COVID testing because the payers needed to update their systems and many of them needed 30 days or more to do that so we were holding on some billing, but I can assure you that at this point in terms of our reserves and our cash collections and everything we're very, very comfortable with where we're in our balance sheet. As you can see the operating cash flow was benefited from the CARES Act. $65 million was pretty strong year-over-year despite the depressed volumes revenues and earnings in the second quarter.",1.6018957,0.982
DGX-2020-Q2-2020-07-23,47,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Let me start with we're going into second half and clearly, our base business is going to continue to be down versus 2019. We are hopeful that we'll start to continue to see some recovery in the back half of the year, but we're not necessarily contemplating any of that in our outlook for 2020. As we get into 2021 it goes back to us continue to work our strategy for accelerated growth and we do believe we have the right strategies and we wanted to share with you in our prepared remarks that we're working those hard. I actually believe that the strategies are actually more appropriate given the pandemic than they were before. So if you think through those, one is, we do believe there could be more acquisitions in front of us for growth through acquisitions. We announced the two deals recently that will prepare us nicely in the back half of the year for growth through acquisitions and sets us up for 2021 too with that carry over on that and the funnel that we're seeing and we're going to push on that front. It will give us some nice growth through acquisitions as we keep on working those in the back half help us in 2021.",1.9785832,0.985
DGX-2020-Q2-2020-07-23,48,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is as far as organic growth in our base business, we continue to work our relationships with the health plans. I would say that our work in the preferred lab network with United is going well. We're going to continue to gain share with them and we're pushing that same type of approach in concept with many peers throughout our route or contracts and we believe there is an opportunity for us to pick up share as we've said in our strategy. We also continue to work with hospitals. We talked about the Mako systems, professional lab services deal. We have a number that are being finalized as we speak that we feel good about and those will give us continued organic growth next year. Then also as we think about our advanced diagnostics and the capabilities we're bringing to the marketplace with gene sequencing and consumer genetic offerings, we believe those strategies will give us some nice opportunities for continued growth next year. So we're continuing to push on the base business growth platform.",1.3265239,0.986
DGX-2020-Q2-2020-07-23,49,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","At the same time, we'll have some natural recovery in our base business as the economy and as healthcare recovers and also through acquisitions. We think we'll be in a good place as we get into 2021 to deliver on that objective that we have of 2% growth through acquisitions. Mark, anything you'd like to add to that?",1.6174629,0.859
DGX-2020-Q2-2020-07-23,50,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. To answer your EBIT question about margin dropdown, Jack. As we've shared in the past in a short window, we are a highly fixed cost business on our base business, so generally any plus or minus will be 80% or so drop through. It's really supplies and reagents that are the variable costs. The most of it, everything from their logistics infrastructure to phlebotomy to even largely the labour in the laboratory in a window is fixed so variation, good or bad around the base business has a very high drop through. Although we certainly have good margins on our COVID testing there is more variable cost in the COVID testing so it's not quite as high a variable margin on any sort of plus or minus is from our base case, but still very attractive.",2.7626382,0.721
DGX-2020-Q2-2020-07-23,55,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I'll let you handle the vaccine question, then I'll just talk about the assumptions. Ricky, I appreciate the question. If there is one thing that has been demonstrated over the last several months is we don't have the ability to predict some of these things so I don't think any of us here envisioned a 50% decline in our business in April even when the pandemic first started. Then on the other side, we didn't expect the fast recovery that we saw throughout May and June, given what had happened in April. So we want to recognize that some of these things are out of our control and we want to talk about some ranges of potential outcomes and how they might impact our financial results to take away a little bit and hopefully a large degree of that uncertainty, we've been living with over the last couple of months where people were wondering what might be happening at Quest. But when we talk about PCR molecular volumes falling off in Q4, it's not because we have a vision of that happening, but we had to make some assumptions in the guidance. Since that's several months away and we've shown that even a month or two in the future it's hard to predict that, we didn't expect the surge in June that happened. Therefore we're just being I think appropriately cautious and explaining what those assumptions are, so we don't have any sense that it will follow-up. I think all of us for society are hoping it will follow-up as the infection rate dampens but also note that some of the non-clinical work, the work we're doing for return-to-work for employers and students should be heavy in Q3 and some of that we might expect to step down in Q4.",1.6947077,0.7
DGX-2020-Q2-2020-07-23,56,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, that is one driver that might lead you to believe that demand would dampen a little bit in Q4, but it's not as if we know how the virus is going to proceed and the infection rate and certainly some people would say that when we get the flu season, we might even have another spike. So we don't know but we wanted to be very clear around those assumptions.",1.5758294,0.509
DGX-2020-Q2-2020-07-23,57,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Ricky, on your question about next year and specifically the vaccine. So, first of all, we believe there will be COVID-19 testing next year in 2021. Second is, if we assume we'll have a vaccine next year or sometime, and you go back to what I said earlier about the role of serology and evaluating and prioritizing who should get the vaccine, we do believe there will be a role of testing in 2021 for us. Then finally, in terms of working with those that are developing the vaccine, we are actively in conversations of using our data in a productive way to recruit patients. Some of this is around the vaccine development but also using our data to help with the donation of plasma for the country.",0.5937397,0.637
DGX-2020-Q2-2020-07-23,58,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, good use of our data, which is part of our strategy again for growth -- the user data, the smart way as a diagnostic information services provider to help with the pandemic.",1.1505766,0.881
DGX-2020-Q2-2020-07-23,60,Question,2020-07-23,2,2020,Ralph Giacobbe,Credit Suisse,"Hey, good morning. Sorry to harp on this, but I do want to go back to the guidance. Because when you first updated in early June, you expected breakeven is slightly positive for the quarter, you obviously ended up at $1.42. That essentially implies all of the two key earnings came in June. So if I just run rate that number for six months, I'm already at $8.40 in earnings before I even contemplate the over $2 you put up in the first half.",0.5475327,0.8
DGX-2020-Q2-2020-07-23,61,Question,2020-07-23,2,2020,Ralph Giacobbe,Credit Suisse,"So -- and again, my guess is COVID testing trajectory moves higher and assuming some continued core recovers, I'm still struggling a little bit to understand the offsets or the headwinds on what appears a pretty extremely conservative range, particularly at the lower end, but just want to make sure I'm not missing anything else.",0.399492,0.637
DGX-2020-Q2-2020-07-23,62,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Well, we laid out for you in pretty detailed fashion in the low end. So you can take a look at those assumptions. And,, you can have your own point of view, and that's why we wanted to be very, very clear about that assumption. So your notion that Q2 earnings were all pretty much in June is spot on. And the issue with multiplying that times six for the back half would be a couple things. One is our base business was down exiting the month high single digits of average 15 in June. And the question is, is that sustainable? We'll take a step back, we'll look at worse. We don't know.",0.7867299,0.756
DGX-2020-Q2-2020-07-23,63,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So certainly, if it were to improve, or were to hold for the whole six months, would say down 10% versus that 20% assumption on our floor, that would make a material difference for the business. And as I just described, at an 80% drop down, you can do some of the math, but our core business was about $2 billion on quarter before COVID. So you know, 1000 basis points is a pretty significant difference on revenue and OM. On the PCR, we shared that we're assuming the volumes dropped down in Q4, not because we have any foreknowledge, but because as I said, return to work and back to school will largely be behind us, and because we don't know. So we want to be cautious about putting on a guidance that counts on the level of PCR testing that at this point is unpredictable. Obviously, we go through Q3 and we get better knowledge towards Q4 and see a need to update that, we would do so. But, given how things have moved around, we want to be really careful.",0.9830174,0.959
DGX-2020-Q2-2020-07-23,64,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The other thing is, as I said, we fully expect, if we continue to have high levels of COVID and ease-of-testing that the Federal Emergency will continue, but because that's unpredictable, it could actually be revoked at any time. We want to be very careful about assumptions on reimbursement for our molecular tests. And so, at this point, we're only building in that reimbursement through a 90-day extension, since that's been voiced by HHS. And while we would hope and expect if COVID continues that that reimbursement will continue into Q4, that would make a very significant difference as well. But that is not in either the bottom or the high-end of our current guidance.",1.4877567,0.879
DGX-2020-Q2-2020-07-23,67,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so let me start with pooling. So what you mentioned is true, that is, it's more beneficial in areas that have low prevalence. We've started to ramp up our capacity that will be driven for getting some nice boost in our capacity, which we're planning for, as I mentioned, to get to that 150 in a couple of weeks. So we're going to apply those concepts in our laboratory developed test locations and try to steer it towards the low prevalence areas to be able to get the best bang for the buck. So we'll push that and the multiplier is considerable when you have low prevalence, so that would be very helpful to bringing up our capacity. We'll keep on pushing on it. As far as testing for non-US geographies, frankly, we are focused entirely for all-intensive purposes on the US. We could consider it in 2021, but it's not in our plans right now and we haven't spent a lot of time thinking about it, as we sit here dealing with the pandemic in the US.",2.3196046,0.855
DGX-2020-Q2-2020-07-23,70,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, well, obviously, this is beyond Quest Diagnostics and rationing or prioritizing who should get it first, and what's the progression and how you distribute it throughout the United States. But like with other vaccines, you'd like to get it to the higher-risk groups. And the higher risk groups are those groups that we actually tested initially, higher on the priority list for COVID testing. And so, those were with pre-existing conditions, over the age of 65, and obviously, people that have been compromised with other respiratory illnesses in the past. So independent of serology and antibody testing, my assumption would be those at-risk groups would be high on the priority list.",1.6319605,0.743
DGX-2020-Q2-2020-07-23,71,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then, the second priority list would be everyone else. And if, in fact, you were to test positive for the antibodies, then my sense is there will be evidence at that point that will suggest that, in fact, you'll have immunity for a period of time. And the question will be, how much of this would be public policy versus independent choice of whether you want to have the vaccine or not. That's all speculative on my part, a lot to be determined. First of all, where the vaccine will come from, when it's going to be available, how much will the US get. And also, this is going to be I'm sure debated throughout the United States as we get into it.",0.9344316,0.878
DGX-2020-Q2-2020-07-23,74,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Sure, sure. So first of all, we do have an assumption that commercial rates are aligned with Medicare rates and, Mark, why don't you just remind everyone what we have in the outlook going forward as far as our assumptions for reimbursement?",2.2474465,0.557
DGX-2020-Q2-2020-07-23,75,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So we -- the emergency use -- obviously the Federal Emergency expires on July 25th. HHS has expressed a view that they're going to extend that 90 days, so we've built that $100 price which is not our AWR, you know, we don't fully get $100; but that $100 priced into our -- pretty much our full book. And so, the commercial as we shared previously, the commercial payers pretty much fell in line with the Medicare reimbursement rates as a couple of additional state Medicaid plans that didn't quite get there. But for the most part, we get that price from everybody, regardless of who they are. Therefore, we would expect that to continue. So, as long as the Medicare rate stays up, that doesn't mean there wouldn't be some pressure, but we would expect the commercial payers to stay in line with that, because obviously, if it stays, there's a federal emergency, and it'd be hard to argue. They should be cutting the rate for a test that's quite so important.",4.3870458,0.522
DGX-2020-Q2-2020-07-23,76,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And nonetheless, we will get some pressure. Once we get through that, where the commercial rates end up, obviously, we will take a position that says it shouldn't be less than Medicare. It will be very transparent with what our costs are and the continued importance of that test, even post-emergency and we'll do our best to keep it at the Medicare rate and not something less than that. But that's still -- it's obviously still in front of us.",0.064376,0.671
DGX-2020-Q2-2020-07-23,77,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As far as payment policy, reimbursement policy, it is evolving. What I'll share is that frequency policies, first of all, as we all know, you could test negative one week and the next week, it'd be positive. So therefore, it's quite important that people feel that they should get tested if they've been exposed, and if, in fact, they believe that they might have some early symptoms. So, we'll continue to take that as the position and I think by and large people support that notion, but you have seen positions taken on return-to-work programs that employers are moving with, and in many cases, these employees are self-insured. So it's sort of a moot issue, what pocket it comes from. But for those fully insured employers, there is positions by some of the insurers that that's not included in their healthcare reimbursement policies. So therefore, it should be paid for by the employers. And then equally with universities and colleges, whether the students -- free on campus testing is included in the reimbursement like a physical would be, if they're going back to school or playing sports or going -- there's some debate around that. So I would say, characterize it as people are debating some of this. We're seeing kind of a growing trend with some of this.",3.830972,0.923
DGX-2020-Q2-2020-07-23,78,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then, also as we evolve, we're trying to understand who should get tested and who should not get tested. There is even some question of whether, after you've been tested positive and out for 14 days right now, most people are operating on a protocol that you get retested again, but there's some views that maybe that second test to verify your negative is not of great value, and therefore, this might help reduce the demand that we have on the system right now. So that's being debated, as well. So it's evolving, a lot of discussion. And Mark, anything you'd like to add to reimbursement in general on COVID?",0.3028007,-0.467
DGX-2020-Q2-2020-07-23,79,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I would just add that we have not had a significant amount, it would be very few of any denials or frequency limitations. So, while things might evolve, Lisa, to this point, we've not run into issues with the payers around frequency for the molecular tests, and for the return-to-work and back-to-school programs, we are not taking the risk on those. So we are either arranging client bill where we get paid directly contractually by the customer, or in some cases where they think they have coverage from the payer, we have a fall back to where, if we do get a denial, then we have a right to bill the client directly.",1.0600316,0.057
DGX-2020-Q2-2020-07-23,80,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, we think we're protecting ourselves for the financial standpoint, we have not run into headwinds less far from the payers on frequency [indiscernible].",2.1540284,0.0
DGX-2020-Q2-2020-07-23,83,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Mark, you want to take the first part of this around payments? I think that was the question.",1.8836903,0.077
DGX-2020-Q2-2020-07-23,84,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, I'm sorry, Matt, what is your specific question? Can you repeat it?",0.6678515,0.414
DGX-2020-Q2-2020-07-23,86,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, payer mix did not change materially. The one thing we did see was an increase in uninsured. So beyond that, I don't think there was any -- and we rarely see -- given our size, we rarely see material changes of payer mix and this was no exception. So certainly, the drop in utilization did not impact people with certain payers more than others. The one that we did see was more uninsured.",3.4972354,0.64
DGX-2020-Q2-2020-07-23,87,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, Matt. On return to work programs and university role of let's say point of care devices, we are looking at all those devices and where they can help us, particularly around surveillance. And what we're finding for the initial testing, if you will, the gold standard is the PCR test for like a diagnostic workup and then secondly is for serology or blood based test is the gold standard.",0.3634267,0.878
DGX-2020-Q2-2020-07-23,88,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The sensitivity and specificity of both those are the best. Still to this day, and there are few devices -- there are a few devices that are coming to the marketplace that are -- that are offering we think an opportunity for us to include that in our services that we provide to both employers and to universities, specifically. Some of the antigen devices are coming to the marketplace we're looking at, you know those devices and some of the sensitivity around 85% which is lower than our sensitivity but for surveillance and in combination with possibly serology and just overall biometric screening of some form, it could be a helpful set of tools for us to manage a population over time.",1.8823723,0.765
DGX-2020-Q2-2020-07-23,89,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we are thinking about how we'll include those in our services to employers and also to universities as they have surveillance for their populations going forward.",0.4342669,0.0
DGX-2020-Q2-2020-07-23,98,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Well, first of all, as I mentioned, on my earlier remarks, we are going to push it beyond 150. And we do see capacity -- excuse me do we do see demand going forward, that's going to be beyond 150. And we do believe we'll get to a point where our capacity will meet that demand. And so we will get there. We'll go beyond the 150. And the limiting factors are, you know, combination of machines. So getting, you know, the IVD test systems and laboratory test equipment, and particularly for laboratory developed tests. It's not just the platforms, the PCR platforms, but in our setup, you know, there's actually two other pieces that you need to consider. It's the extraction and then second is the liquid handling. And it's been some machine constraints on us for getting those systems to be able to bring up -- bring up more and more capacity, but we're working with all our suppliers to get as much as we can get to bring our capacity and take it beyond the 150.",1.1390445,0.262
DGX-2020-Q2-2020-07-23,99,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second is just manpower. Yes, we're running 24x7. And as I mentioned in my remarks, you know, doing 8.5 million tests over the last four months, our teams are working nonstop. Remember, this is in our microbiology department that has gone from the backwater of the laboratory to front and center. And we have capacity limits around the people and those that are trained adequately to deliver on this. And then third is just, you know, physically we need to get, you know these systems in place, we need to have the adequate controls and training in place. And that just takes some time. And then fourth is, you know, the reagents. We are rate limited by how much juice we get to run all our different platform. And we're working with our suppliers and getting more. We have had some shortages with some of the suppliers and that has not helped our ability to deliver results.",0.2507414,0.036
DGX-2020-Q2-2020-07-23,100,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so we're working actively to, you know, get them to, first of all, give us more and then secondly to be reliable, what they commit to delivering again. So now, I will also say that everyone is working incredibly well together, the IVD manufacturers working with the task force, White House working at future ideas of where we can get more capacity, we're all pushing hard to get more and more capacity. But to answer your question, those are the rate limiting factors around what we need to do to get beyond 150. But we will get it beyond 150. That's where we want to be to be able to meet the demand we see, particularly as we get into the late August, early September time.",3.1772652,0.676
DGX-2020-Q2-2020-07-23,101,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And Brian, you know, to be clear, you didn't ask this directly, but we are not being conservative. We are doing everything we can. The challenges are not financial, you know, willingness to spend more capital or for that matter, operational expense to get things up and running. They're all operational in our ability to get more equipment and, as Steve said, multiple pieces of equipment, and to get them operating and to get the people who are trained to do it. And we are, you know, moving as quickly as possible.",2.8234597,0.791
DGX-2020-Q2-2020-07-23,102,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As you said, we doubled our capacity from mid-May, you know, we're expecting another 20,000 per day increase from where we are today over the next several weeks. And then as Steve said, we're going to go beyond that. So there's no, you know, hesitancy to add capacity because of uncertainty and demand. We're doing everything we can to increase our capacity and certainly to reduce turnaround times.",1.057267,-0.072
DGX-2020-Q2-2020-07-23,105,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so, you know, Eric, I'm sure you can appreciate that, you know, it's not as if we have a point estimate, forecasts, you know, for every number within that range or even the high-end range, because we've got, you know, multiple factors that can move things material, you know, certainly as we mentioned, the base volume, decline or improvement relative to our assumptions is very material to the outcome. And then that PCR, you know, volume is very, very material, as well. And then finally, the reimbursement rate, you know, beyond the 90-day extension is very, very important. So, you know, there's multi variable so, you know, I really can't answer directly, but, you know, specific number because, you know, we're running scenario planning, but I would tell you that at this point, we have a significant reduction in Q4 demand to get to these guidance numbers.",0.9739703,0.858
DGX-2020-Q2-2020-07-23,106,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So it's not small, it's fairly significant. And again, not because we know that's what's going to happen, but just given the uncertainty of the volumes and the knowledge that the return to work and back to school volumes will largely be gone by Q4.",0.0395387,-0.402
DGX-2020-Q2-2020-07-23,109,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So let me characterize it this way; in primary care, I'll put OB/GYNs in that as well. We've seen a nice rebound as physicians have opened back up their offices and call back some of their patients. In some cases they have extended hours; so we've seen a nice bounce back on that piece of our demand. Secondly, as we are seeing some nice recovery in some of those -- some of those procedures that might have been pent-up and our pathology tissues have actually rebounded in a good way. We're not sure it's entirely sustainable because there might be some of this is reacted to the pent-up demand that is coming back to us that we lost in April and May and we started to see it in June that will come into the summer. And that's why when we talk about outlook, we are cautious to make sure that we're not taking the June run rate as our run rate forever in the summer. We actually might see some slowdown related to that being absorbed, if you will, through the system. And then we'll get to the run rate that we should expect for a reasonable period of time in Q3.",2.6191104,0.893
DGX-2020-Q2-2020-07-23,110,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then, some of our other businesses; we have our life insurance business, frankly, that's down considerably, we haven't seen a big recovery there. Our pre-employment drug testing business is starting to come back as employers start to hire people but is down considerably versus 2019. Our employer population health business where we do wellness programs for employers is down considerably, many of those events have been cancelled. So, I would say it's really a wide variation with the best being primary care and the worst being those that are tied to the economy, and in general, constraints around normal programs like life insurance and wellness and hiring people.",2.5334432,0.931
DGX-2020-Q2-2020-07-23,112,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. I would just add that most of our base business has come back proportionally. As Steve said, oncology has really picked up recently over the last couple of weeks; we'll see how much of that was deferred pent-up demand. But the one category, it's not just in pre-employment but prescription drug monitoring; so the whole drug testing area, that's lagged a little bit some of the other franchises within the base business, not just in our employer business.",1.1611374,-0.296
DGX-2020-Q2-2020-07-23,115,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, you know, think about, you know, the best is obviously the lowest and where we pool, and we could put four specimens in a well, you know, like quadruples, your throughput per batch, if you will, and if there is zero positives, then you get it all. Where you have positives within that run, you have to test those -- that whole well, and, you know, that obviously starts to eat into the productivity game. So, the best is lower than 2%. We actually have a number of states and geographies that are in that range. Actually, right now the Northeast is doing quite well. We hope that is sustained.",2.9640857,0.976
DGX-2020-Q2-2020-07-23,116,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then, as you start to go up to high single digits, it starts to lose it's effectiveness because of all the retesting you need to do. So clearly, less than 5% is in the sweet spot, and greater than 5% starts to get marginally worth it. But we have plenty -- if we look at pooling; again, pooling is applied to our laboratory developed tests, it's a piece of our capacity, it's going to give us more capacity to get us to that 150, and also, we believe beyond. But we're not just doing pooling to get more capacity, we're adding new systems and processes and people everything we talked about earlier. So, it will give us some of the capacity but there's other things we're doing as well.",0.4313015,0.705
DGX-2020-Q2-2020-07-23,117,Answer,2020-07-23,2,2020,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And just a reminder, that pooling is only currently possible on our LDT. And so therefore, you know, it's not as if it's going to be an expander across our whole network, and we can prioritize low prevalence areas or that LDT to a certain extent or to a large extent. And so to Steve's point, we're going to target the areas that we currently have low positivity rates. But the biggest benefit is while we do get costs -- some cost savings on reagents when you can do four samples at once instead of a single one, even despite some retesting; it's really the benefit of the capacity. So, being able to serve more people with the same equipments and more patients is really the benefit, much larger, although there is a certainly a cost of sales savings that comes with pooling.",1.3080569,0.912
DGX-2020-Q2-2020-07-23,119,Answer,2020-07-23,2,2020,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. Well, we appreciate the time on the phone. We appreciate the extent of your interest in our business. And we hope you, like us, are appreciative of everyone at Quest and what we're doing, and we appreciate your support as well. So have a great day everybody.",0.568369,0.984
DGX-2018-Q3-2018-10-23,3,Remarks,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Thank you, and good morning. I am here with Steve Rusckowski, our Chairman, President and Chief Executive Officer; and Mark Guinan, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures. Actual results may differ materially from those projected.",0.5461762,0.66
DGX-2018-Q3-2018-10-23,4,Remarks,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent Annual Report on Form 10-K and subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS, excluding amortization expense.",0.3021963,0.165
DGX-2018-Q3-2018-10-23,5,Remarks,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"As a reminder, adjusted diluted EPS excludes excess tax benefits associated with stock-based compensation. Additionally, net revenues and selling, general and administrative expenses have been restated for the basis of prior year comparisons to reflect the impact of the new revenue recognition standard that became effective January 1, 2018 and was adopted on a retrospective basis.",0.0365176,0.691
DGX-2018-Q3-2018-10-23,6,Remarks,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Under the new rules, the company now reports uncollectible balances associated with patient responsibility, which we will refer to as patient concessions, as a reduction in net revenues when historically these amounts were classified as bad debt expense within SG&A expenses.",0.2310135,-0.791
DGX-2018-Q3-2018-10-23,8,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks Shawn, and thanks everyone for joining us today. This morning, I'll provide you with the highlights of the quarter and review progress on our two-point strategy. Then Mark will provide more detail on third quarter performance and give you an update on our outlook for 2018.",0.047117,0.823
DGX-2018-Q3-2018-10-23,9,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We grew revenues and continued to deliver strong earnings growth in the quarter. Revenues were up nearly 2%, despite the effect of industry headwinds we called out last quarter. Reported EPS was up more than 32% from 2017. Adjusted EPS grew more than 25%. As you saw, we have revised our full-year revenue guidance to reflect lower than expected revenue",0.3551895,0.572
DGX-2018-Q3-2018-10-23,10,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","performance this year, which was affected primarily by two factors.",1.0981878,-0.153
DGX-2018-Q3-2018-10-23,11,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First, as we detailed in the second quarter, we faced headwinds in the areas of prescription drug monitoring, hepatitis C, and vitamin D testing. While we made some progress, these testing areas continued to impact revenue growth in the third quarter. Second, in the third quarter, we also saw a rise in patient concessions, which Mark will touch on later.",0.509061,0.765
DGX-2018-Q3-2018-10-23,12,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before getting into the details of the progress we've made in the quarter, I'd like to provide context on some market trends, starting with an update on PAMA. Last month, a US District Court judge dismissed on narrow procedural grounds our trade association's lawsuit over the implementation of new Medicare pricing for lab tests under PAMA.",0.2985173,0.527
DGX-2018-Q3-2018-10-23,13,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The Court's opinion, however, acknowledges that ACLA's arguments on the merits raise important questions, about HHS's actions. This is, of course, disappointing for our industry; and it is potentially harmful to Medicare beneficiaries.",0.4112026,0.103
DGX-2018-Q3-2018-10-23,14,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Last week, ACLA appealed the District Court's decision, demanding a hearing on the merits. At the same time, the industry continues to pursue a legislative fix. Additionally, CMS and our industry continues to work together on addressing the current PAMA issues. So, as we sit here today, PAMA is having an impact on Quest and the rest of the lab market.",0.0771005,0.202
DGX-2018-Q3-2018-10-23,15,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Increasingly, smaller independent labs and hospital outreach labs are struggling financially, due to lower Medicare reimbursement, not only directly due to PAMA, but also under contracts with pricing indexed to Medicare. Some have begun to exit the business, citing PAMA as a factor. We're continuing to plan and manage our business as if PAMA is here to stay.",0.5341021,-0.238
DGX-2018-Q3-2018-10-23,16,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","At the same time, there has been increasing scrutiny of the wide variation in health care pricing in the popular press. Consumers and employers, who pay for most of healthcare, are becoming more price sensitive. Last month, the Wall Street Journal reported that health plans that exclude costly providers can be much less expensive for consumers and employers.",0.2902801,0.511
DGX-2018-Q3-2018-10-23,17,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest offers a great customer experience, and coupled with our scale and efficiency, it makes us an exceptional value in the market, compared with hospital outreach labs, which often charge two-to-five times more than Quest. So, in short, there are three reasons we believe the market will continue to consolidate and therefore afford us an opportunity to accelerate growth.",0.5021417,0.938
DGX-2018-Q3-2018-10-23,18,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First, reduced reimbursement through the Medicare Clinical Lab Fee Schedule is beginning to have an impact on the laboratory industry. Second, health plans are embarking on a new strategy, looking to national labs to help drive efficiency in lab spending. And the finally, consumers and their employers are more attuned to the variation in healthcare pricing.",0.0220758,0.637
DGX-2018-Q3-2018-10-23,19,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to the third quarter, I'll review our execution against the five elements of our strategy to accelerate growth. The first element of our growth strategy is to grow 1% to 2% through strategically aligned, accretive acquisitions. We announced three acquisitions in the third quarter, which strengthen our capabilities in several key areas.",0.1555189,0.758
DGX-2018-Q3-2018-10-23,20,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First, our acquisition of PhenoPath, which has a strong record of innovation, provides several capabilities that complement and extend our own, particularly in the area of pathology and molecular oncology. It also expands our presence in the Pacific Northwest.",0.5762768,0.791
DGX-2018-Q3-2018-10-23,21,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our acquisition of the U.S. laboratory services business of Oxford Immunotec will extend our capabilities in infectious disease diagnostics. It will also bring us greater choice to physicians who seek innovative blood-based tuberculosis and tickborne disease testing. And then finally, our acquisition of ReproSource expands our expertise in reproductive diagnostics.",0.0069193,0.758
DGX-2018-Q3-2018-10-23,22,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Since the third quarter close, we have also announced the acquisition of Hurley Medical Center's outreach lab operation in Flint, Michigan. In this case the seller indicated reimbursement pressure as a factor in deciding to exit the business. Additionally, we acquired the assets of Provant Health to strengthen our employer wellness business.",0.0184514,0.7
DGX-2018-Q3-2018-10-23,23,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the acquisitions we have announced and will close in 2018, already position us within our 1% to 2% revenue growth target for next year. And, as I indicated, PAMA should further contribute to our strong M&A pipeline. Under the second element of our growth strategy, we continue to expand relationships with health plans and hospital health systems.",0.5123558,0.869
DGX-2018-Q3-2018-10-23,24,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We continue our preparations to take advantage of the opportunity to offer a first-class customer experience for UnitedHealthcare providers and their members when we become an in-network lab provider on January 1. Our commercial team has already been proactively reaching out to educate physician customers about their ability to use Quest for their UnitedHealthcare members.,0.2062603,0.785
DGX-2018-Q3-2018-10-23,25,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The revenue opportunity presented by the United contract will ramp over time. We do expect some portion of this new work to transition quickly. However, the larger opportunity to help UnitedHealthcare drive lower lab spend is expected to be realized over the next several years.",0.570346,0.836
DGX-2018-Q3-2018-10-23,26,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The third element of our growth strategy is to offer the broadest access to diagnostic innovation. Our announced acquisitions in the quarter mentioned earlier will enhance our capabilities in advanced diagnostics, especially in the areas of Women's Health and Infectious Disease.",0.1100494,0.735
DGX-2018-Q3-2018-10-23,27,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to see strong growth in prescription drug monitoring and Quantiferon tuberculosis testing. Additionally, this quarter we saw solid growth in Cardio IQ, as well as testing for sexually transmitted diseases.",0.1799012,0.881
DGX-2018-Q3-2018-10-23,28,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","On our second quarter call, we highlighted several market headwinds that impacted growth in prescription drug monitoring, hepatitis C and vitamin D testing. We saw modest improvement in the third quarter. For example, PDM denials have steadily improved each quarter this year. We've also started to lap hep C headwinds we began to experience roughly a year ago.",0.4777595,0.872
DGX-2018-Q3-2018-10-23,29,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In aggregate, the issues we have mentioned related to these three tests contributed approximately 100 basis points of headwinds this year against our original revenue expectations. We continue to make progress executing the fourth element of our growth strategy, which is to be the provider of choice for consumers.",0.3756178,0.772
DGX-2018-Q3-2018-10-23,30,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest Walmart locations continue to see increased traffic and generate great feedback from our customers. In fact, for locations open more than 6 months, we've seen an uptick in volumes compared to the patient service centers they replaced. We are currently operating inside 21 Walmart stores in Florida, Texas and now Illinois.",0.0243822,0.735
DGX-2018-Q3-2018-10-23,31,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We combined with our partnership with Safeway, we expect to have well over 200 patient service centers in retail store locations by the end of 2018. Consumers continue to embrace our digital experience. We now have more than 6 million users on our MyQuest app that lets them view and analyze test results, schedule their appointments, see patient service center wait times, and then finally pay their bills.",0.1123558,0.459
DGX-2018-Q3-2018-10-23,32,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The fifth element of our growth strategy is to support population health with data analytics of extended care services. We're seeing continued interest in Quest Clinical Trials Connect, which we launched in June. This is a new patient recruitment service to help pharma companies and CROs increase the speed of commercializing new therapies. We're working with several pharma, biotech and CRO companies with this new solution.",0.1736409,0.954
DGX-2018-Q3-2018-10-23,33,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second element of our two-point strategy is to drive operational excellence. At the end of September, we launched a new appointment scheduling system for our patients. This new system utilizes best-in-class technologies to help patients schedule appointments at a convenient location. In the second week of deployment alone, we saw appointment-related calls into the National Customer Service center drop by more than 10%.",0.0382208,0.637
DGX-2018-Q3-2018-10-23,34,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our Online Specimen Pickup option has been a big hit with our physician customers with nearly 20% of routine pickup requests now handled electronically versus making a call. Physicians have given us positive feedback on the ease, efficiency, and simplicity, compared to waiting on the phone and writing down those confirmation numbers.",0.4332784,0.823
DGX-2018-Q3-2018-10-23,35,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then finally, our Invigorate program remains strong, and we're on track to over-deliver on expected savings for 2018. Overall, we continue to make excellent progress on our operational excellence strategy and our leaders will be sharing more insights, successes, and plans with those that attend our Investor Day, which will be held November 29, in New York.",0.0095552,0.974
DGX-2018-Q3-2018-10-23,36,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, let me turn it over to Mark, who will take you through the financial performance. Mark?",0.4065898,0.0
DGX-2018-Q3-2018-10-23,37,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. Consolidated revenues of $1.89 billion were up 1.8% versus the prior year. As a reminder, we now report patient concessions as a reduction of net revenues instead of as bad debt, due to a required change in revenue recognition accounting. Revenues for diagnostic information services, or DIS for short, grew 1.9%, compared to the prior year, driven by acquisitions and an easier compare, due to the hurricane effect last year.",0.0315956,-0.318
DGX-2018-Q3-2018-10-23,38,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Volume, measured by the number of requisitions, increased 2% versus the prior year. Excluding acquisitions, volumes grew approximately 70 basis points in the quarter. Revenue per requisition in the third quarter declined by 80 basis points versus the prior year. As a reminder, revenue per req is not a proxy for price. It also includes a number of variables such as unit price variation, business mix, test mix, and tests per req.",0.1267773,0.402
DGX-2018-Q3-2018-10-23,39,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"During the third quarter, unit price headwinds remained consistent with our expectations for the full-year with a headwind of approximately 50 basis points from PAMA and approximately 100 basis points from all other factors. As we've shared previously, Medicare reimbursement pressure will increase in 2019, due to PAMA. Other mix elements remained positive in the quarter and partially offset the impact of reimbursement headwinds, as well as growth in our professional laboratory services business.",0.2187994,0.869
DGX-2018-Q3-2018-10-23,40,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported operating income for the quarter was $304 million, or 16.1% of revenues, compared to $298 million, or 16.1% of revenues last year. On an adjusted basis, operating income was $311 million, or 16.5% of revenues, compared to $325 million, or 17.5% of revenues last year.",0.4245656,0.0
DGX-2018-Q3-2018-10-23,41,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The decline in adjusted operating margin was due to several factors, including: investments related to tax reform savings, which had a 60-basis point adverse impact on operating margin; integration efforts of acquisitions, which take time to deliver a full margin contribution; and the impact of PAMA.",0.1939179,-0.361
DGX-2018-Q3-2018-10-23,42,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reported EPS was $1.53 in the quarter, compared to $1.15 a year ago. Adjusted EPS was $1.68, up approximately 25% from $1.35 last year. During the quarter, patient concessions, previously recognized as part of bad debt, were up as a percentage of revenue year-over-year.",0.014613,-0.791
DGX-2018-Q3-2018-10-23,43,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We continue to see an increase in patient revenues as a percentage of total revenue, due to the ongoing trend of rising patient deductibles and an uptick in uninsured patients.",0.4996051,0.318
DGX-2018-Q3-2018-10-23,44,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Cash provided by operations year to date was $905 million versus $852 million last year. Capital expenditures year to date were $232 million, compared to $170 million a year ago, which is in-line with the higher CapEx spend planned for 2018.",0.2065561,0.0
DGX-2018-Q3-2018-10-23,45,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, turning to guidance. We are updating our outlook for 2018 as follows. Revenue is now expected to be approximately $7.62 billion, an increase of approximately 3% versus the prior year. Reported EPS to be between $5.57 and $5.64, and adjusted EPS to be between $6.53 and $6.60. Cash provided by operations continues to be approximately $1.3 billion; and capital expenditures continue to be between $350 million and $400 million.",0.1327014,0.318
DGX-2018-Q3-2018-10-23,46,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Our updated guidance reflects the industry headwinds we've experienced versus our expectations in 2018. While we aren't prepared to share 2019 guidance, there are some elements I'd like you to keep in mind. First, we have a significant opportunity to grow with our new UnitedHealthcare contract.",0.14297,0.848
DGX-2018-Q3-2018-10-23,47,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"However, moving in network comes with lower reimbursement versus the out of network services we provide to UHC patients today. Second, as Steve mentioned earlier, we are already on track to deliver 1% to 2% revenue growth from M&A next year. Third, as you are already aware, the impact from PAMA is expected to increase from a headwind of approximately 50 basis points this year to more than 100 basis points in 2019.",0.0781991,0.402
DGX-2018-Q3-2018-10-23,48,Remarks,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And finally, we expect approximately 150 basis points of reimbursement pressure beyond PAMA from our third-party payers, which includes the impact of becoming an in-network provider for United and other health plan contract changes; as well as hospitals and physicians that we bill directly. After considering all these headwinds and tailwinds, we are well- positioned to grow revenue and earnings in 2019. We look forward to sharing more detail with you at Investor Day.",0.4755134,0.765
DGX-2018-Q3-2018-10-23,50,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. Well to summarize, revenues grew and we delivered strong earnings in the third quarter. We're excited about our M&A activity in the quarter, and are well-positioned for top and bottom-line growth in 2019. Finally, we look forward to seeing many of you at our upcoming Investor Day on November 29.",0.3584843,0.92
DGX-2018-Q3-2018-10-23,51,Remarks,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, we'd be happy to take any of your questions. Operator?",0.5189456,0.572
DGX-2018-Q3-2018-10-23,54,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Well, Ross, on patient concessions, you know we have a larger percentage of our revenue coming from patients. And as we've shared in the past, the un-collectability, so it is bad debt for other sources what we call patient concessions from patients proportioned is much, much higher from patients than it is from any others source. So, we all have almost 0 bad debt from all the other revenue sources.",0.9024487,-0.901
DGX-2018-Q3-2018-10-23,55,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, really what was previously bad debt and now is patient concessions is largely a factor of collecting bills from patients. And again, a little bit of it is from the uninsured and most of it really comes from patients who have insurances, who are in the deductible and so they are paying a large proportion on all of their medical cost or it is from their coinsurance. And so, as that mix changes, unfortunately even though we are improving and continue to improve the bad debt rate or patient concession rate, through some of the things we've done such as putting in our Easy Pay in our office phlebotomist and also our patient service centers also giving more transparency of price ahead as we talked about with our transparency tool with large amount of payers or patients know the cost, know the responsibility they have and it gives us a chance to collect upfront.",0.0240916,-0.7
DGX-2018-Q3-2018-10-23,56,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Just because of mix that has been a headwind and as you know now with the accounting changes it's not just a headwind to operating margin, but it's a headwind to revenues as well. To your question why we couldn't see this coming, I mean we really don't know until we start doing collections and so given the cycle itself of performing the service, and then billing the payer, potentially having some back-and-forth claims on the adjudication, and ultimately billing the patient and seeing our collectability, you know it takes some time.",0.7563191,0.392
DGX-2018-Q3-2018-10-23,57,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And so, we obviously don't know if there is any definition of what's driving this, but when you look at some of the recent information that's come out from several sources around deductible, amounts are actually going up on average, so patients are paying a greater proportion of their healthcare, especially the patients that use a lot of our services because large majority is for healthy patients who go to the physician for a regular checkup.",0.1733807,0.778
DGX-2018-Q3-2018-10-23,58,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Therefore, we believe that that's a factor and a second one, there has been a small increase in the number of uninsured patients that we're serving. Obviously, we don't know whether that was driven by some changes in the Affordable Care Act recently or what's driving that, but we definitely have seen that. So that's on the patient concessions. On the pricing, that's what I was trying to do, was to give you all the moving pieces. So, when you look at the totality, obviously we're looking at a very attractive volume opportunity from network access with United, and it does come with a lower price, it comes to more of a market price for in-network laboratory. So, it's a good price, but it is lower than we were being paid previously.",0.2879147,0.96
DGX-2018-Q3-2018-10-23,59,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We just wanted to make sure people have that understanding in their models and then the other price, which we talked about of being 100 basis points or less will continue. A fair proportion of that is not from third party payers it is coming in very competitive hospital market, and also from physicians where we client bill or directly bill that physician and they bill the third-party as opposed to us billing the third-party. So, we wanted to make sure that people understood all the dynamics that are driving price.",0.0920221,0.756
DGX-2018-Q3-2018-10-23,60,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, when you add all those pieces up, they said, PAMA is going to be approximately 100 basis points and we'll have about 150 basis points from other sources in 2019. However, given the M&A pipeline that we have and the deals that we've already signed and have closed recently, and along with the access and continued improvement in some of the market headwinds that are hitting competitors, as well as I ended that section we're very confident of our ability to grow revenue and to grow our earnings in 2019, and I'll shed some more color on that at the Investor Day.",0.264218,0.872
DGX-2018-Q3-2018-10-23,61,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. And this is something on the patient concession thesis. I'm reminding everyone that close to two years ago where we teamed up with Optum and UnitedHealthcare around our revenue cycle management or building operations. So, we're working hand-in-hand with Optum on what we could do to affect bad debt, as well as denials. We have really enjoyed the working relationship. Matter of fact, this week I'll be with that team. We'll talk about what we're seeing and how they can help us here as well. So, that relationship continues to be strong and that's going to help us as there is more and more pressure on this side of our business.",0.03229,0.819
DGX-2018-Q3-2018-10-23,63,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Well, I will take that at the beginning of this which is related to investments. We continue to make those investments we think are prudent for the capacity we're going to need giving what we anticipate is volume increases in 2019. This is as we would expect at the real granular level thinking about where we are at present, where we are going to pick up lives with United and therefore where we will pick up some shares. So, that's happening and it's in our numbers.",0.1202636,0.818
DGX-2018-Q3-2018-10-23,64,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second it is we continue to honor our commitment to our employees paying out a bonus that will come up in November, that is an investment to share with our employees, we feel good about making sure we have a good workforce that feels good about working at Quest and that continues. And then finally, the opportunity to continue to grow the business in the five growth strategies outlined continue to be a promising opportunity for us as we come out of this year and we enter 2019. So, none of that is changing and we're making excellent progress on all those elements.",0.138056,0.989
DGX-2018-Q3-2018-10-23,65,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, Ross when you walk through those three, you know the bonus was a one-time bonus, so that's not going to repeat in terms of the investments for network access expansions. Those become cost of sales. So, when you're adding [indiscernible] people from the laboratory adding patient service across centers then all of that is investment ahead, but then it becomes our cost of sales. And then finally, on the other investments that Steve referenced, we will make those decisions along with everything else. We decide in terms of long-term, short-term results and also affordability to get into that year. And of course, I'll turnover over to Steve the most important piece.",0.1627172,0.79
DGX-2018-Q3-2018-10-23,66,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. You asked also about the offset of working with our providers, excuse me, our suppliers and yes, this is all in an ongoing approach we have had with our invigorate program. As I mentioned in our prepared remarks, we exceeded our goals for this year, part of that is what we do with our suppliers. Our suppliers are well aware of what's happening with PAMA, matter of fact they are working with us on a legislative solution. This is through the AdvaMed organization, which is the device trade association. So, they are actively working this with us and are very much aware of the pressure there will be on this industry.",0.3759473,0.924
DGX-2018-Q3-2018-10-23,67,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And beyond what we do with our suppliers, we continue to look at efficiencies and we hope that many of you will come to our Investor Day, because we'll be outlining more of the opportunities we see beyond 2018 into 2019, 2020 and 2021 with more efficiency gains, because as we shared over the past several years, even though we did hit that $1.3 billion goal, we see more opportunities in front of us to continue to run a higher quality more efficient operation going forward. So, we look forward to you joining us to secure more about that.",0.368369,0.971
DGX-2018-Q3-2018-10-23,68,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And just very quickly, two of the items that Steve referenced in his prepared remarks about appointment related calls dropping by more than 10% and specimen pickups being ordered online versus call, those are part of the efficiency and obviously we expect to continue to reduce the amount of phone calls we get and actually drive you the more efficiency going forward.",0.442733,0.71
DGX-2018-Q3-2018-10-23,72,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","First of all, AJ thanks. I mentioned in the script, we continue to add stores. We're happy with the progress there. We are at 21 stores now and it continues to build and I tell you that that number will be much higher than that by the end of this year. And we focus on the big states of Florida and Texas and also, I said that we moved into the Illinois as well. So, there will be other states beyond those throughout the rest of this year. So that continues to build. So, what you heard from Walmart is aligned with our view.",0.6665568,0.896
DGX-2018-Q3-2018-10-23,73,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is, the experience has been quite good. It's been good for our patients; those patients are also Walmart consumers. Walmart likes the volume in the stores or volume is like the experience as an employee serving their customers better. And in fact, when we look at the volumes that we see in those sites that have been open long enough, we think it actually does have an effect on our market share within that geography. So, all around good presence, but we're not stopping there, the opportunity we talked about continuing to work with this joint venture with Walmart is how we provided other healthcare services and some of those locations, in fact we were detailing that out with Walmart and you will hear more about that.",0.5429984,0.931
DGX-2018-Q3-2018-10-23,74,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We hope to provide more color around those services at our Investor Day in November. And then equally, what CVS, now with the planned merger with Aetna will do with their strategy is a continuation of what we've done with them in the MinuteClinic, and we're hopeful, as well as they continue to walk on those integration plans with Aetna given our great relationship with Aetna, great relationship with CVS, they do see an opportunity with the brick and mortar they have and with some of our capabilities of providing basic healthcare services.",0.3479407,0.96
DGX-2018-Q3-2018-10-23,75,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, when we come to Investor Day, what we will do is, walk you through what we call our diagnostic services, which includes how we use our data and how we use the services and capabilities of Quest to help bend the cost curve. And some of that will be done with our Walmart joint venture and some of it will be done with other partners like CVS, but we do believe it's a great opportunity for growth in the near-term, but also for the long-term because we're just getting started frankly. So, more to come on that and we hope that you show up for the Investor Day in November.",0.1772652,0.965
DGX-2018-Q3-2018-10-23,80,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. On the hep C as we mentioned, that is starting to mitigate because we've lapped year when, you know the [indiscernible] drug started to take significant share. So, at some point, most of that business goes away or it stabilizes or maybe even the drugs make a comeback, I know there is some pricing competition and an area that might change the competitive landscape. So, that should not continue to be significant into 2019.",0.2531596,0.778
DGX-2018-Q3-2018-10-23,81,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On PDM, I want to be clear as Steve mentioned, it continues to be a growth engine for us. Unfortunately, we're doing more volume than we are - revenues. So, revenue is growing, the following is growing faster and that's because of some of these denials. I can't put a stake on the ground at this point as how quickly we're going to address that. I guess the important thing is that even though that headwind may or may not get addressed in the near-term future.",0.0552923,0.78
DGX-2018-Q3-2018-10-23,82,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As Steve also referenced, it's stabilized. So, we're not growing in denials. So, we are reaching a point where the denials are still much higher than it should be and much higher than we find acceptable. It's not going to be continuing to be a year-over-year headwind. And certainly, we make some progress there could actually be a tailwind moving forward. And then on vitamin D, I'd say it's still early.",0.4454976,0.839
DGX-2018-Q3-2018-10-23,83,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As we mentioned, we still believe that a number of these denials are because of miscoding based on a long history of physician coding practices, and not necessarily denials to patient eligibility. And so, how many of these things will be rectified when the physician community understands. For instance, either of these patients is now eligible for vitamin D and I need to use the appropriate code versus now this was just a screening and now it's other others including, as we mentioned, Cigna starting to apply Medicare type of approaches to their coding that this actually would be a denied task. But at some point, again, as you mentioned, you get that behind you and it all continues to be a headwind once the market adjusts and patients are appropriately getting prescribed with the right diagnosis code and then vitamin D continues to move with the market as it has been doing historically.",1.0793839,0.202
DGX-2018-Q3-2018-10-23,84,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, as just to reinforce what we said in the script is that, we have the three together, we looked at our expectations for this year and how it has affected us. It's about 100 basis points and that's our business and I'll just to remind everyone, we've talked about this before. We are the market leader on prescription drug monitoring. So, very strong in that category, continues to grow, but we clearly have more exposure than a lot of people on that space. So, therefore, any effect of those three have a bigger impact on us.",0.0866557,0.689
DGX-2018-Q3-2018-10-23,85,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the 100 basis points is our estimated. And as Mark said, we continue to work this. We started working this in Q2. We've made some modest progress. As I said in my remarks, we will continue that throughout this year and then again as we start to lap it, we'll have less of impact year-on-year, but different than what we expected, but still growing in these three categories.",0.3545305,0.45
DGX-2018-Q3-2018-10-23,86,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then just to add to what Steve mentioned, those three had about 100 basis point negative impact versus our expectations and then the patient concessions were another 30 basis points.",0.8704581,-0.572
DGX-2018-Q3-2018-10-23,88,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. The business opportunity we have is, those customers of ours that have the majority of their laboratory testing coming to us already, but might just have another laboratory because we are not in network with United. So, those are the accounts we've already knocked down their doors, we have shared with them the great news that we're going to be in network starting January 1. We have worked on what we need to do of anything in terms of IT integration, we get those orders in-house and those will come to us early in 2019.",0.3080725,0.945
DGX-2018-Q3-2018-10-23,89,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Those types of customers. The second group of customers that I'll broadly put in this category is that might have multiple laboratories, and our job is to make sure we gain share. And given the access that we have starting in 2019, which is really remarkably better, we believe there is also an equal opportunity for us to gain share beyond those great customers we have for all customers to pick up share. Particularly some of the large states we've talked about this, when you look at Florida, Texas, California, New York, our access is going to be north of 95%. So, great access in the marketplace, great value proposition or quality service, and also pricing, we believe we have an opportunity to pick up share in those accounts.",0.276112,0.99
DGX-2018-Q3-2018-10-23,93,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, the revenue growth was pretty much all M&A in the quarter.",0.599921,0.724
DGX-2018-Q3-2018-10-23,95,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, so we didn't experience any meaningful change, due to seasonality in the quarter around genetic testing. And then, sorry your second question Derik?",0.1868088,0.572
DGX-2018-Q3-2018-10-23,97,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. No, I think the valuations really haven't changed materially. Obviously, you've got to price in the PAMA headwinds. Although, we are hopeful that we can positively impact that at this point. More pricing things as if those PAMA cuts will happen, that's the way we are valuing things. So, therefore, if anything, valuations have come down, and the seller, or potential seller recognizes that as well.",0.8029226,0.859
DGX-2018-Q3-2018-10-23,98,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, just, I believe your question is around consumer genetics. Just to remind everyone, we do have a relationship with Ancestry and we provide a genotyping for their ethnicity offering. It's a modest portion of our business and continue to get growth, but it is modest for us. We're optimistic about the opportunities with the Ancestry because we still believe it is an opportunity for us to work together with that around building awareness overall, around the importance that everyone knowing our family health history, and that's an opportunity for the future, but just with the context, in terms consumer generic testing it is a small portion of business with modest growth this quarter.",0.016804,0.972
DGX-2018-Q3-2018-10-23,99,Answer,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",0.0293728,0.0
DGX-2018-Q3-2018-10-23,102,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, most of the fourth quarter 'improvement' is really coming from the M&A we did, so that's giving us some lift. We don't expect a step change improvement in utilization what we call same account volumes. And then in terms of weather, we have some impact, but it wasn't material enough to call out, but certainly it was a slight headwind to us in the quarter.",0.5110585,0.713
DGX-2018-Q3-2018-10-23,104,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sorry, I was talking about the hurricanes this year. So, we talked about the fact that versus last year we had a favorable compare, I thought you were asking us weather the hurricanes that took place in Carolinas in the third quarter were significant factors? So, we did call out that we had a favorable compare and it was about 150 basis points in the quarter, but there was a slight negative impact this year from hurricanes in 2018.",0.2255134,-0.402
DGX-2018-Q3-2018-10-23,106,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, the 50-basis point isn't tied directly to the United, but certainly directionally United is one of the major drivers there, and I'm sure you are familiar with the way pricing works. So, we had significantly higher reimbursement from United as an out of network provider than what typical in-network takes on and what we negotiated with United. So, yes that's a big driver, but it's not entirely United. And at this point, I'm not going to give any guidance for 2019.",0.0987362,0.981
DGX-2018-Q3-2018-10-23,107,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, what I will reconfirm is that the Investor Day outlook that we provided of having a 3% to 5% topline CAGR, and a mid-to-high single digits EPS CAGR from 2017 through 2020, we still stand by that. Obviously, we have got one full-year and three quarters of a year behind us and when you look at our guidance, it so puts us within that range and so what we're saying is that we work through the next two years. We are certainly still confident that we can deliver within that CAGR range without giving any specific guidance for a given year.",0.3744076,0.552
DGX-2018-Q3-2018-10-23,108,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. Just to reiterate, we will grow topline and bottom line in 2019. We have said that. What we have also said is that, the M&A that we have already shared will get us to comfortably in that 1% to 2% growth in 2019 and when you couple that with the United opportunity that we've speaking about gives us confidence on our ability to say, yes, we will grow top and bottom line next year.",0.0685338,0.973
DGX-2018-Q3-2018-10-23,114,Question,2018-10-23,3,2018,Bill Quirk,Piper Jaffray,"Good morning. First question, Mark, just not to beat a dead horse here on 150 basis points that you signaled for 2019, but is any of that related to additional plans kind of following or trying to follow some of the PAMA rates down, I know historically you've indicated that you don't have a lot of contracts that are tied to Medicare, but just trying to tease any nuances out here?",0.3168317,0.057
DGX-2018-Q3-2018-10-23,115,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"No, it isn't. There are some small changes in some Medicaid rates that states have made, specifically Ohio. I mean, you can argue whether that was in any way related to PAMA. I think they actually had a budget issues, they wanted to fund some Women's Health initiatives and they slammed the laboratory reimbursement rates. There certainly was some dialogue around where Medicare was going in some of the states, if not many of them look at Medicare as a signal for where the Medicaid rates should be, but in terms of commercial plans, no, there isn't any incremental headwinds because the commercial plans are trying to take advantage of PAMA.",0.3254344,-0.226
DGX-2018-Q3-2018-10-23,116,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In fact, as we have shared the dialogue we've been having with the commercial plans as they see that as an issue for them because the more pressure we get from other sources, the more we need to get from them, and therefore it's in their own best interest not to see that because they know in the next collection period that the potential recalculation could be even more severe if we give lower commercial rights. And so, they are very sensitized to that and I can assure you that we are holding very firm in those discussions and make sure that they understand the world where you have a significant difference between commercial rates and government, and certainly Medicare rates is going to go away.",0.1350711,0.872
DGX-2018-Q3-2018-10-23,117,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The whole intent of PAMA is to move go rates to a market type rate, which says that we need to talk about other ways to create value beyond price and that's what we're doing. Increasingly, we're walking in and talking about all the other ways we differentiate ourselves positively, but then I fully appreciate and then some of the things that Steve highlighted in his remarks, around the patient experience, the technology we're putting in our patient service centers, the ability to build a relationship through the MyQuest app schedule appointments make things easier. Because at the end of the day, the payers want their patients to get appropriate necessary testing done, and so therefore that's definitely a good thing. It's also our data the way we feed data and the more critical mass we have the easier it is one them to do the analytics in a world where data is increasingly important for population management.",0.3684834,0.977
DGX-2018-Q3-2018-10-23,118,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, there is a lot of ways that we talk about our value proposition. And then finally it is as Steve mentioned or where they recognized that they have a cost curve. They need to start working with the best value providers and certainly will want those and starting to move volume as a high cost less attractive value providers into the better laboratories and that's the way they are really going to save money and drive better value for their members versus continuing to look to extract price out of those who already have the best prices in the market.",0.3617694,0.984
DGX-2018-Q3-2018-10-23,120,Answer,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",0.4170415,0.0
DGX-2018-Q3-2018-10-23,124,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes, so let me do this. I remind many of you on this call of what we talked about of the opportunity we see with the United, which if you go back and you recall, we've talked about the opportunities that many of the health plans see, it is by working with one of the nationals as ourselves we can do a better job of helping them reduce their laboratory cost. And what we talked about with the United define the opportunity in front of us is, we have talked about Untied estimates that they spend anywhere from $7 billion to $8 billion in laboratory spend a year, and most people have estimated that the nationals maybe providing about a billion of that.",0.1749588,0.962
DGX-2018-Q3-2018-10-23,125,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, therefore, there is a big opportunity as they think about how they do a different job and a better job of serving their membership with Quest and at least one other national provider to reduce that spend. So, when you look at that 1 billion versus the 7 billion or 8 billion you see the opportunity in front of us. And the biggest opportunity in the short run is, as I said earlier is to go after those great Quest accounts, we will do that early, but this is why we believe that this affords us a nice growth opportunity, not just for 2019, but for 2020 and 2021 because it's going to take some time to gain that share and move that work away from the more expensive labs, and this is true for United, but I will also argue, we will be doing this with other health plans as well. So, it's an opportunity to continue to pick up share.",0.4500824,0.991
DGX-2018-Q3-2018-10-23,126,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we will again be coming back together in November, we'll help - provide more visibility to what we believe the opportunity would be within reason, but hopefully at least those remarks will help you kind of size the opportunity in front of us given where we sit today.",0.5571664,0.927
DGX-2018-Q3-2018-10-23,127,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And Ricky, it's a little more complicated being with United and Quest because we had some in network volumes. So, as we shared historically, in our pathology business, we had a couple of states that have been in in-network. And then obviously if you're trying to look at a model for out of network labs' share within large national payers, the fact that it's such a strong business of United a decade ago, we never lost all of that because of the loyalty of some of the providers, and the fact that they could look even out of network, our prices were still better than hospitals and many others.",0.6330964,0.964
DGX-2018-Q3-2018-10-23,128,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, it's a little bit different than if you want to look at other payers and say, hey, how much volume is there out of network. I think Quest had a disproportionate share of volume relative to what other labs might have out of network, but it's still not huge because you are an out of network provider, certainly when they have only insured patients, we don't get paid at all. So, it's really only their administered plans when they have out-of-network benefits where it makes sense for us to keep that volume and continue to try to compete.",0.5691153,0.701
DGX-2018-Q3-2018-10-23,130,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, let me answer the acquisition question. We've shared in the past 12 to 18 months. I'd say on the outreach purchases, they tend to happen a lot more quickly. They're more simple and straightforward. It's really just integrating them into our local laboratory, and then the cost of serving those patients is basically the cost of serving all the other patients we currently do in those markets. So, those might even happen a little quicker in the 6 to 12-month window. And some of these other, I'll call them technology acquisitions, and that could involve site shutdown, it could involve moving the test menu to multiple locations.",0.3886256,0.542
DGX-2018-Q3-2018-10-23,131,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Obviously, it's working through the sales force issues, reimbursement issues and so on and so forth. So, those tend to be on the longer end, and you'll notice that number of the deals that we did in the latter part of 2017 were more like that as opposed to outreach purchases. So, we take a little bit longer. And then on the volume question, Ricky, I know you'd like some great specificity. All I can share is that typically there is a tiny share for an out of network lab in terms of their share of volume within a national payer and we were not tiny, but we certainly were not large.",0.9320695,0.899
DGX-2018-Q3-2018-10-23,132,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And just on the acquisition, remember, we had this feathering going on that we have a nice slug of acquisitions in 2018. We're again giving you some perspective on the outlook that we have for 2019. The acquisitions would definitely be in that 1% to 2%. Those 2018 acquisitions, another year under their belt, 2019 where we get some of the integration done that helps us, and you layer that on top of the new acquisitions we bring in 2019. But we're hopeful we have a more regular cadence around that 1% to 2% that you already see in our numbers. So, as they come in, they take some time to mature with the integration coupled with the ones that are just showing up, that's already in our numbers for past years as well.",0.0537068,0.955
DGX-2018-Q3-2018-10-23,133,Answer,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",0.3151627,0.0
DGX-2018-Q3-2018-10-23,136,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Good morning, Lisa.",1.3439968,0.44
DGX-2018-Q3-2018-10-23,139,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, what we said about the retail strategy, it's a better location in these sites. So, it serves our patients in the market better and therefore it's beneficial to the patients, it's beneficial to our employees, and our partners. In one case, it's Safeway; in the other case, it's Walmart are happy as well. Now, with all that, we've shared in the past, from a rent perspective, the cost of using that space, there is not a big difference between the two.",0.1423394,0.966
DGX-2018-Q3-2018-10-23,140,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","However, we're getting much better space. Many of our patient service centers that we could collapse or patient service centers with one or two phlebotomists. This affords us an opportunity to take down those locations and put them into a better location, and that's better again for all stakeholders. And so, it's not a cost savings, but what it provides us is a better quality and better patient experience. And what I said in my remarks, what we do now have enough data points where we look six months of what we close versus what we open, we believe the volumes are better in those locations.",0.0369028,0.945
DGX-2018-Q3-2018-10-23,141,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, it is positive financially for us and it's one of the ingredients of us gaining share. Now, we said, again, this is for our core business. We also believe this is an opportunity for us, particularly with the Walmart JV to tag on to those physical locations more healthcare services that we'll be working with Walmart, with local partners to be able to bend the cost curve for whatever partner we're working with. So that just affords us another opportunity beyond our core diagnostic service business. So, hopefully that's helpful.",0.2705107,0.961
DGX-2018-Q3-2018-10-23,142,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. And just to add, we have shared in the past that in Safeway, because we've leveraged some of the overhead, there is some cost savings, the greatest cost is the phlebotomists and that doesn't change when we go into a retail setting, but there is some cost savings despite the fact that the rents generally is somewhat comparable, smaller space, higher rates for more attractive market, but the overall footprint costs us relatively the same. But this is a business with small details. So, little bit of cost savings combined with, as Steve mentioned, some volume upside certainly can make a difference, especially as we continue to expand. And then Walmart is a JV.",0.3412322,0.938
DGX-2018-Q3-2018-10-23,143,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, it is different. It's not just putting a phlebotomist draw center within a retail outlet versus one of our independent patient service centers, and what we are starting with phlebotomy, we are definitely intending to add more healthcare services together with Walmart to build their presence within the healthcare. And it is a JV. So, therefore we've got a majority position to who are going to be sharing the economic value creation of that venture with Walmart.",0.0884676,0.84
DGX-2018-Q3-2018-10-23,147,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yes. So, what we said is what we've announced so far, puts us in that 1% to 2%, which, you know it is a good place to be at this point. We also said that given the environment and given the pressure that we see on hospital outreach operations, we think that's a catalyst to afford us a nice pipeline. We just announced another deal of buying an outreach business this week, an outreach activity called out of the Hurley Medical Center in Flint, Michigan, and there will be more to come. So, yes, we will share this point 1% to 2%. We're comfortably there for next year, but we do have a funnel that can add to that going into 2019.",0.4072488,0.855
DGX-2018-Q3-2018-10-23,148,Answer,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",0.7459645,0.0
DGX-2018-Q3-2018-10-23,152,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure, Ann. So, first off, let me clarify. We don't have an incremental 250 basis points of price going into next year. What we talked about was a total of 250 versus something that's more in the lines of 150 this year. So, I want to make sure that I'm clear on that. And about 50 basis points of the increased pricing pressure is PAMA related and the other 50 basis points related to other things.",0.0296209,0.771
DGX-2018-Q3-2018-10-23,153,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In terms of share, obviously we don't get into that level of detail. We're very cognizant of the need to retain our Aetna business. We've got people who have been actively working for the last several months. We continue to work to make sure that we serve those customers appropriately and we retain as much of that Aetna business as possible and certainly have United, as we mentioned earlier. We're very excited about the opportunity. Steve mentioned, we expect that in some of these very loyalist accounts who would be sending us to United, if we were in network and would have been sending it to us, we'll flip very quickly.",0.464455,0.964
DGX-2018-Q3-2018-10-23,154,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"There are those accounts that have multiple providers and we believe together with our value proposition, all the things we've walked through, which does differentiate us from almost all the other providers in a meaningful way around the patient experience, with our app, with certainly the pricing transparency, which is a huge win-win for the physician and the patients to be able to go into one of our draw centers at no upfront, whether something is covered and how much of cost, it's just there aren't many labs that can do that. And therefore the",0.0134281,0.735
DGX-2018-Q3-2018-10-23,155,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, you don't have to worry about problems with the patients for the high cost out of network work. And we think that's pretty compelling, but that's not going to happen as quickly as the first piece. And then obviously the third piece is where we don't have business today. So, now we feel very strong with that same value proposition that we can go in and we can compete more strongly than we could have in the past and flip some of those accounts where we may not have any or very much work at all. So, that's going to take even longer. So, this is a multi-year growth opportunity. It's not all about 2019, and we have plans in place and we have strategies to go after each of those, and we're working hard to make sure that that all comes. So, certainly excited about that and very confident about that.",0.1741706,0.986
DGX-2018-Q3-2018-10-23,156,Answer,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"And just to clarify, that incremental 50 basis points of price pressure next year outside of PAMA, that's primarily going to be coming from the United price headwinds.",0.313575,0.153
DGX-2018-Q3-2018-10-23,161,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, obviously I can't talk about any specific plans around share repurchases, but given the fact that we have announced and are closing a number of transactions this quarter, we're going to be spending a fair amount of cash on those deals and we certainly are excited about the pipeline coming up. So, at this point, we haven't announced anything specific. We'll continue to follow our strategy, which says with half of our free cash flow that's not committed to our shareholders every year, we're going to make situational decisions depending on the M&A opportunities and the attractiveness of those returns versus share repurchases.",0.178515,0.976
DGX-2018-Q3-2018-10-23,162,Answer,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",0.0293728,0.0
DGX-2018-Q3-2018-10-23,172,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Continue with what we've been focused on. One is, the opportunity to run hospital outreach. We think it's a - of course it's a nice opportunity to continue to consolidate the market and we do believe that we'll continue to build. And as I said, we just announced another deal this week. Number two, you saw that we just announced a number of acquisitions that afford us new capabilities. The Immunotec acquisition gives us blood tuberculosis testing capability with tick-borne capabilities. That was a nice add. ReproSource gives us nice women's health capability and then we also talk about PhenoPath up in the Pacific Northwest that has some capabilities around pathology and molecular. So, we'll always look for new capabilities.",0.3456343,0.961
DGX-2018-Q3-2018-10-23,173,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then the third piece is, there's still regional laboratories that we believe we are going to have difficult times than - more difficult time than hospital outreach, and you'll see some regional opportunities. So, if you look back in the last five years and you look at the acquisitions, they fit in those three categories. There's been ebbs and flows of each of the three, but generally, that's what we continue to look and they're all strategically aligned to what we do and we have to have a path to value creation and hopefully you agree with us that we've built up credibility around that. So, we will continue to work on that and go into next year. We already hit that 1% to 2%, and we've got a nice funnel to continue to pursue ideas that we can make money of.",0.1914333,0.952
DGX-2018-Q3-2018-10-23,174,Answer,2018-10-23,3,2018,Shawn Bevec,Executive Director-Investor Relations,"Operator, next question.",0.7975655,0.0
DGX-2018-Q3-2018-10-23,177,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes. So, there is certainly some early transitions. It's not significant enough to call out, but I didn't want you to think we're waiving on everything till January 1. So yes, we absolutely already have some accounts that have moved and some accounts that are committing to move, but at this point, it's still relatively small.",0.3977093,0.806
DGX-2018-Q3-2018-10-23,182,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So, we're happy with MedXM. As I'm sure you're familiar, the reason you put in an earnout into a deal was when the buyer and the seller have markedly different views of the potential, it's one way to get two transactions coined that shares the risk appropriately. So, at this point, not quite 9 months into the acquisition, we feel from an accounting standpoint that it's highly unlikely to pay out the earnout. That doesn't mean that we haven't achieved what we were expecting to achieve.",0.2527646,0.791
DGX-2018-Q3-2018-10-23,183,Answer,2018-10-23,3,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"It just means that the seller had a very different view of where that might go. And so that's all you should read into there. We're very happy with MedXM thus far. It's been a great addition to our portfolio, and I can tell you that as we're talking to payers about our laboratory testing, this is another opportunity to talk to them about ways that we can really help them beyond just the laboratory testing we're doing with great reach and population health and so on. So, it's another point why they want to do business with Quest.",0.2377567,0.961
DGX-2018-Q3-2018-10-23,185,Answer,2018-10-23,3,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Okay. I think we've handled all the questions. We thank all of you for joining us today. We appreciate your support. You have a great day and hope to see many of you at our Investor Day in November.,0.1822076,0.941
DGX-2018-Q1-2018-04-19,4,Remarks,2018-04-19,1,2018,Shawn Bevec,Executive Director-Investor Relations,"Thank you and good morning. I'm here with Steve Rusckowski, our Chairman, President and Chief Executive Officer, and Mark Guinan, our Chief Financial Officer.",0.1907912,0.66
DGX-2018-Q1-2018-04-19,5,Remarks,2018-04-19,1,2018,Shawn Bevec,Executive Director-Investor Relations,"During this call, we may make forward-looking statements and we'll discuss non-GAAP measures and actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our annual report on Form 10-K and subsequently filed quarterly report on Form 10-Q and current reports on Form 8-K.",0.2590632,-0.065
DGX-2018-Q1-2018-04-19,6,Remarks,2018-04-19,1,2018,Shawn Bevec,Executive Director-Investor Relations,"For this call, references to reported EPS refer to reported diluted EPS and references to adjusted EPS refer to adjusted diluted EPS excluding amortization expense.",0.2016406,0.153
DGX-2018-Q1-2018-04-19,7,Remarks,2018-04-19,1,2018,Shawn Bevec,Executive Director-Investor Relations,"As a reminder, adjusted diluted EPS now excludes excess tax benefits associated with stock-based compensation.",1.1061127,0.382
DGX-2018-Q1-2018-04-19,8,Remarks,2018-04-19,1,2018,Shawn Bevec,Executive Director-Investor Relations,"Also, net revenues and selling, general and administrative expenses have been restated for the basis of prior-year comparisons to reflect the impact of new revenue recognition rules that were effective January 1, 2018 and were adopted on a retrospective basis.",0.0280497,0.477
DGX-2018-Q1-2018-04-19,9,Remarks,2018-04-19,1,2018,Shawn Bevec,Executive Director-Investor Relations,"Under the new rules, the company now reports uncollectible balances associated with patient possibility as a reduction in net revenues when historically these amounts were classified as bad debt expense within selling, general and administrative expenses.",0.4898121,-0.791
DGX-2018-Q1-2018-04-19,11,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Shawn, and thanks everyone for joining us today. This morning, I'll provide you with some perspective on PAMA, highlights on the quarter and review progress on our two-point strategy. And then Mark will provide more detail on fourth quarter performance.",0.4639209,0.823
DGX-2018-Q1-2018-04-19,12,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We delivered strong revenue growth despite the negative impact of severe weather and lower Medicare reimbursement under PAMA.,0.0359143,0.625
DGX-2018-Q1-2018-04-19,13,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Earnings growth was driven by continued strong execution as well as the benefits of tax reform.,0.1113674,0.863
DGX-2018-Q1-2018-04-19,14,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also completed our previously announced acquisition of MedXM, which is off to a good start.",0.3258649,0.44
DGX-2018-Q1-2018-04-19,15,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, here are some highlights from the quarter. Revenues were up 3.7%. Reported EPS was up nearly 10% from 2017. Adjusted EPS grew 25%.",0.2332784,0.0
DGX-2018-Q1-2018-04-19,16,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Before I describe the progress we've made, what I'd like to do is to provide an update on PAMA and our investments in the business using a portion of savings from tax reform.",0.0042834,0.649
DGX-2018-Q1-2018-04-19,17,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to PAMA, this was our first quarter operating under the clinical IP schedule, which accounted for approximately 12% of our revenues last year.",0.4,0.0
DGX-2018-Q1-2018-04-19,18,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Since November, we said we expected the impact of the pharma rates under PAMA would be a reduction of approximately 4% in 2018, approximately 10% in both 2019 and 2020. And our actual Medicare reimbursement in the first quarter reaffirms our projected impact for 2018.",0.1591433,0.0
DGX-2018-Q1-2018-04-19,19,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We continue to support efforts by our trade association to implement a market-based laboratory reimbursement schedule.,0.2339374,0.402
DGX-2018-Q1-2018-04-19,20,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","On the legal front, ACLA has sued CMS and both sides have submitted their initial briefs to the court and we still believe we could have a decision from the judge by midyear.",0.8085667,0.128
DGX-2018-Q1-2018-04-19,21,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We want to reiterate that ACLA's complaint is not challenging the new Medicare rates themselves, but rather the process CMS followed to arrive at those rates.",0.030972,-0.171
DGX-2018-Q1-2018-04-19,22,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","As the lawsuit progresses, ACLA has continued to seek a legislative fix to PAMA, coordinating closely with aligned trade associations like NILA, AdvaMedDx and other stakeholders. This issue is about ensuring that Medicare beneficiaries have access to critical laboratory services.",0.2484349,0.494
DGX-2018-Q1-2018-04-19,23,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","While the new rates have impacted us, other laboratory providers, including many serving remote and underserved areas, may be forced to close their doors. So, that's why this is an important issue to us all.",0.6477759,-0.296
DGX-2018-Q1-2018-04-19,24,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to tax reform, last quarter, we shared with you that we will realize approximately $180 million in tax savings on an adjusted basis in 2018. We are reinvesting roughly $75 million before tax into the business and our people and much of this is underway.",0.07743,0.34
DGX-2018-Q1-2018-04-19,25,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Turning to the first quarter, we delivered on all five elements of our strategy to accelerate our growth. The first element of our growth strategy is to grow 1% to 2% through strategically accretive acquisitions, which were achieved for the fifth consecutive year in 2017.",0.1759473,0.637
DGX-2018-Q1-2018-04-19,26,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We had a productive quarter for M&A. We completed our acquisition of MedXM, a leading national provider of home-based health risk assessments related services. More on this acquisition in a few minutes.",0.5634267,-0.273
DGX-2018-Q1-2018-04-19,27,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're integrating the acquisitions announced in the latter half of 2017 and we are pleased by the results. We guided earlier this year we expect to deliver about 250 basis points of growth from M&A in 2018, which is above the top end of our 1% to 2% objective. Our M&A pipeline remains strong and our strategy is delivering growth.",0.3327842,0.904
DGX-2018-Q1-2018-04-19,28,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Under the second element of our growth strategy, we continue to expand relationships with hospital health systems. In March, we entered into a professional lab services relationship with an integrated healthcare delivery system in New England.",0.475453,0.599
DGX-2018-Q1-2018-04-19,29,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We acknowledged earlier that PAMA is a headwind for us. However, reimbursement cuts are bigger headwinds for hospital systems operating outreach laboratories.",0.092257,-0.026
DGX-2018-Q1-2018-04-19,30,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Hospital executives are starting to become more aware of the impact of PAMA and we're having more frequent conversations with them about their lab strategy and how we can help.,0.3258649,0.402
DGX-2018-Q1-2018-04-19,31,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Many of you have asked about the possibility of expanding your access with major health plans. We continue to have productive conversations and make progress with a number of payers.,0.9611203,0.477
DGX-2018-Q1-2018-04-19,32,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Quest offers health plans and their members' unmatched convenience, access, quality and value. And based upon our recent conversations, it's clear that many health plan leaders agree.",0.3107084,0.735
DGX-2018-Q1-2018-04-19,33,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We're delivering on the third element of our growth strategy, which is to offer the broadest access to diagnostic innovation. Key growth drivers in the quarter were prescription drug monitoring, QuantiFERON and non-invasive prenatal screening.",0.6273476,0.778
DGX-2018-Q1-2018-04-19,34,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","In advanced diagnostics, we're making strong progress with our new center of excellence in precision medicine oncology in Texas. The center is helping community oncologists determine the most appropriate treatment of patients with cancer.",0.6392092,0.84
DGX-2018-Q1-2018-04-19,35,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Since we acquired Med Fusion, we've seen an acceleration of growth of their tumor panels. 70% of patients with cancer are treated by community cancer centers and we're excited about the opportunities that Med Fusion is creating with networks of community cancer practices like The US Oncology Network and Texas Oncology, as well as Baylor Scott & White Health, the largest health system in Texas.",0.1179572,-0.66
DGX-2018-Q1-2018-04-19,36,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We continue to make strong progress executing the fourth element of our growth strategy, which is to be the provider of choice of consumers.",0.5321252,0.827
DGX-2018-Q1-2018-04-19,37,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",Our Walmart locations continue to perform well with an increase in patient traffic across the board and outstanding feedback on the customer experience.,0.1828666,0.813
DGX-2018-Q1-2018-04-19,38,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We're expanding into different markets and we expect to open many more locations throughout this year. We're pleased with the progress and excited about the future of this important partnership with Walmart.,0.0369028,0.844
DGX-2018-Q1-2018-04-19,39,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",The fifth element of our growth strategy is to support population health within analytics and extended care services. The integration of MedXM is going well. Customers are excited that we can help them close their gaps in care using mobile healthcare professionals to reach patients when and where it's convenient for them.,0.0896211,0.952
DGX-2018-Q1-2018-04-19,40,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, let me give you one example on this capability, is closing gaps of care. Diabetic eye screening is a key part of diabetes care. MedXM's National Health Plan customers identify at-risk Medicare Advantage or managed Medicaid members.",0.1136738,0.813
DGX-2018-Q1-2018-04-19,41,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","MedXM call centers then reach out to those patients to schedule health risk assessment to visit the patient and perform a series of tests, which include capturing a retinal image. This program helps identify people at risk of diabetes. It enables health plans to improve their quality scores.",0.2873147,0.34
DGX-2018-Q1-2018-04-19,42,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second element of our two point strategy is to drive operational excellence. Earlier this month, we launched the pilot program with Humana MultiPlan, Optum, UnitedHealthcare to use Blockchain technology to improve the quality of healthcare providers data and reduce administrative costs.",0.184514,0.818
DGX-2018-Q1-2018-04-19,43,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We look forward to continuing to use our data and expertise for this project, which we believe can lower cost and improve efficiency within the healthcare system.",0.6177924,0.494
DGX-2018-Q1-2018-04-19,44,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We are continuing to drive efficiency and effectiveness within Quest to cover the cost of wage inflation and reimbursement pressure. So, let me give you a few updates.",0.6177924,0.077
DGX-2018-Q1-2018-04-19,45,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Our collaboration with Optum 360 continues to perform well. As consumers there, in a pre-share share of cost of their healthcare, more of our revenues come from patients, which poses collection challenges.",0.401318,0.557
DGX-2018-Q1-2018-04-19,46,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And despite the pressure from increased patient responsibility, we're succeeding in keeping our uncollectible balances associated with patient responsibility in line with last year.",0.7489292,0.734
DGX-2018-Q1-2018-04-19,47,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We're collaborating with payers to bring price transparency to healthcare through our real-time estimation tool. This tool enables a health plan member at a patient service center to know before a specimen is drawn if the test is covered and what out-of-pocket cost the health plan member will pay for that test.,0.0365733,-0.103
DGX-2018-Q1-2018-04-19,48,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer",We're continuing to enable our business to improve the customer experience. Our e-check-in process has been used in more than 27 million patient encounters. Our patients like the convenience and this information helps us place providers where they are needed most based on the patient flow.,0.0286656,0.791
DGX-2018-Q1-2018-04-19,49,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We have 1,500 sites with e-check-in and expect to deploy in all of our patient service centers by the end of 2018.",0.1248764,0.0
DGX-2018-Q1-2018-04-19,50,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Now, let me turn over to Mark who will take you through our financial performance.",0.6477759,0.0
DGX-2018-Q1-2018-04-19,51,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Thanks, Steve. Starting with revenues, consolidated revenues of $1.88 billion were up 3.7% versus the prior year.",0.2630332,0.44
DGX-2018-Q1-2018-04-19,52,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Please note that due to a change in revenue recognition accounting, we now report uncollectible balances associated with patient responsibility as a reduction of net revenues instead of as bad debt.",0.4826224,-0.691
DGX-2018-Q1-2018-04-19,53,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenues for Diagnostic Information Services, or DIS for short, improved 4.1% compared to the prior year, with approximately 340 basis points attributed to acquisitions.",0.1196682,0.477
DGX-2018-Q1-2018-04-19,54,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Volume, measured by the number of requisitions, increased 2.2% versus the prior year driven by acquisitions, with organic growth essentially flat. Volume was negatively impacted by weather and the timing of major holidays during the quarter.",1.1508689,0.765
DGX-2018-Q1-2018-04-19,55,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,The impact of weather presented a volume headwind of 60 basis points. The timing of the Easter and Passover holidays this year versus last year weighed on first quarter requisition volumes and created a tougher year-over-year comparison.,0.4198262,0.649
DGX-2018-Q1-2018-04-19,56,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Revenue per requisition in the first quarter grew by 1.6% versus the prior year. As a reminder, revenue per req is not a proxy for price. It includes a number of variables such as unit price variation, business mix, test mix and test per req.",0.1844392,0.077
DGX-2018-Q1-2018-04-19,57,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Unit price headwinds during the quarter were approximately 50 basis points from PAMA and less than 100 basis points from all other factors. This is consistent with the outlook we provided in February and is in line with the trends we've observed for several quarters. After many changes to PAMA, Medicare reimbursement pressure will increase in 2019 as we have indicated previously.",0.2112954,0.026
DGX-2018-Q1-2018-04-19,58,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Beyond unit price, other mix elements remained strong in the quarter and more than offset reimbursement headwinds.",0.557267,0.511
DGX-2018-Q1-2018-04-19,59,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Reporter operating income for the quarter was $272 million or 14.5% of revenues compared to $279 million or 15.4% of revenues a year ago.,0.4245656,0.0
DGX-2018-Q1-2018-04-19,60,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"On an adjusted basis, operating income was $303 million or 16.1% of revenues compared to $297 million or 16.3% of revenues last year.",0.2274882,0.0
DGX-2018-Q1-2018-04-19,61,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Operating income decreased by $8 million compared to the prior-year as a result of weather. The decline in operating margin was caused by a mix of PAMA, weather and acquisitions, which are in the early stages of integration and, therefore, not yet delivering full-margin contribution.",0.4146919,0.0
DGX-2018-Q1-2018-04-19,62,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Almost, as Steve mentioned, we're using a portion of our savings from tax reform to reinvest into the business and our people. We expect these investments to help us continue to accelerate growth, which also impacted operating margin in this quarter.",0.7839652,0.649
DGX-2018-Q1-2018-04-19,63,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Reporter EPS was $1.27 in the quarter compared to $1.16 a year ago. Adjusted EPS was $1.52, up roughly 25% from $1.22 last year.",0.7247235,0.0
DGX-2018-Q1-2018-04-19,64,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Note that our adjusted EPS now excludes excess tax benefits related to stock-based comp to provide greater clarity into the underlying operational performance of our business.,0.67891,0.778
DGX-2018-Q1-2018-04-19,65,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Our effective tax rate in the first quarter was approximately 23% compared to 32% last year.,0.3364929,0.477
DGX-2018-Q1-2018-04-19,66,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"As I mentioned earlier, our uncollectible balances associated with patient responsibility are no longer reported in selling, general and administrative expense. That said, we intend to provide periodic updates on the progress we continue to make with our revenue cycle management partner, Optum 360.",0.5529226,0.153
DGX-2018-Q1-2018-04-19,67,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"In the first quarter, our uncollectible balances associated with patient responsibility are flat year-over-year.",0.2630332,0.0
DGX-2018-Q1-2018-04-19,68,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Cash provided by operations in the first quarter was $180 million versus $196 million last year. The year-over-year difference was largely due to movements in our working capital accounts.,0.2934439,0.0
DGX-2018-Q1-2018-04-19,69,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Capital expenditures during the quarter were $73 million compared to $42 million a year ago, which is in line with the higher CapEx spend planned for 2018.",0.0308057,0.0
DGX-2018-Q1-2018-04-19,70,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, turning to guidance. Our outlook for 2018 remains unchanged and as follows. Revenues to be between $7.7 billion and $7.77 billion, an increase of 4% to 5% versus the prior year.",0.6011058,0.318
DGX-2018-Q1-2018-04-19,71,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Reported diluted EPS to be between $5.42 and $5.62 and adjusted EPS to be between $6.50 and $6.70.,0.4245656,0.0
DGX-2018-Q1-2018-04-19,72,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Cash provided by operations to be approximately $1.3 billion and capital expenditures to be between $350 million and $400 million.,0.4304897,0.0
DGX-2018-Q1-2018-04-19,73,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,Recall that our guidance includes only the acquisitions that we've closed to date and that we closed several acquisitions in the back half of 2017.,0.6488942,0.0
DGX-2018-Q1-2018-04-19,74,Remarks,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,We expect the earnings accretion from these deals to continue to ramp up throughout 2018 and into 2019.,0.4332543,0.0
DGX-2018-Q1-2018-04-19,76,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks, Mark. To summarize, we delivered a strong first quarter. We made solid progress accelerating growth and driving operational excellence.",1.4029654,0.946
DGX-2018-Q1-2018-04-19,77,Remarks,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And with that, we'd like to take your questions. Operator?",1.4115321,0.361
DGX-2018-Q1-2018-04-19,80,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah. Sure, Dan. I'll handle that. Certainly, PAMA was in our plan. The reinvestment to some of tax reform - again, this is self-evident, but when you reinvest tax, you're going to see a negative impact to the EBIT margins, obviously, offset by tax with the net results, though, obviously, being an increase in net income as a percent revenue.",0.4154818,-0.039
DGX-2018-Q1-2018-04-19,81,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The one thing that, obviously, we hadn't planned on was the weather. And as I mentioned, there was about $8 million impact of operating margin, which, certainly, you can see, that if that had not happened, we actually still would have grown EBIT margins despite PAMA, despite the reinvestment. Kind of worst part of the holidays. We know that the way the calendar falls has impact. We never quite know exactly how to predict, what that impact might be. So, I think as we look at all those pieces, that's probably what I would say.",0.4032385,-0.026
DGX-2018-Q1-2018-04-19,82,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then, the last piece is acquisitions. That was certainly a part of our plan when we put together a business case and we planned those synergies. We know, as we've shared in the past, that it can take up to 12 to 18 months to get them to be kind of at their going rate of profitability. So, that was certainly in our plans as well.",0.414297,0.856
DGX-2018-Q1-2018-04-19,84,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, Steve here. This is evolving. It has evolved and, I would say, it will continue to evolve. I think there's more and more interest by the FDA on how they will continue to think about oversight and regulatory controls around laboratory developed tests.",0.047117,0.551
DGX-2018-Q1-2018-04-19,85,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And this, I would describe, as one of the areas that they're looking at. So, with the new guidance that's out that did tick a forum that we're actually pleased about because we believe that we do have the process capabilities and the control capabilities to be able to support that.",0.7594728,0.681
DGX-2018-Q1-2018-04-19,86,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then second is, with that, it legitimizes through CMS the value that the tumor panels add to the diagnostic workup of a cancer patient. So, it just brings front and center the importance of getting a full workup when you make that expensive next choice in cancer care.",1.2570016,-0.649
DGX-2018-Q1-2018-04-19,87,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I think given my earlier comments with our acquisition of Med Fusion, about our strong work relationship with US Oncology, our working relationship with Memorial Sloan and IBM Watson, we have a strong and growing presence in the whole space.",0.2500824,0.807
DGX-2018-Q1-2018-04-19,88,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we're very well positioned and actually pleased that there is some certain energy around it and some guidance about the controls in general because, I think, it's very important as we go forward that legitimate operating companies like ourselves that bring a lot of value to the marketplace have tight controls around the value of that, the verification of value of that and then the delivery of that. And we do that quite well. And so, therefore, approval for that and some kind of controls around that, we think, is a good thing.",0.5726524,0.979
DGX-2018-Q1-2018-04-19,93,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah, sure. So, as the industry knows, our nearest competitor's contract expires in 2018, number one. Number two is we've said that, obviously, we would like, under the right terms, to be on contract with United. We have also shared that we are in dialogue and we have nothing to share about that dialogue. And at the right time when we hopefully will have something, we'll share that. So, we're making progress there.",0.1123558,0.93
DGX-2018-Q1-2018-04-19,94,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We also make progress with hundreds of others of health plans. Some big and some small. And we feel, as we enter 2019, we'll be in a really nice shape in terms of our portfolio relationships. And these relationships, yes, they're contractual related to being in network, but they're becoming more and more strategic.",0.1673806,0.585
DGX-2018-Q1-2018-04-19,95,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I mentioned the work we're doing with our Extended Care Services and Population Health, the work we're doing around price transparency and our estimation tool. So, what we're doing is we definitely are showing ourselves as a laboratory. But as we said, we're in the diagnostic information services business.",0.0556837,0.71
DGX-2018-Q1-2018-04-19,96,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the last part of this is our consumer strategy is really resonating. That whole consumer experience, we're upgrading our patient service centers. We're e-enabling it with our e-checking capabilities. We're bringing nice information capabilities with our MyQuest application and this resonates extremely well with the health plans big and small. So, making good progress. And when we have something, we'll make sure that you all hear it quickly.",0.2065898,0.914
DGX-2018-Q1-2018-04-19,98,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I'll turn it to Mr. Mark. The question is how much M&A is in the quarter in Q1. And then, let's make more clarity around what we said around what was in the guidance for the 4% to 5% for M&A and what was excluded. So, Mark, you want to take that about Q1 and then the guidance?",0.0675453,0.286
DGX-2018-Q1-2018-04-19,99,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, in the first quarter, M&A contributed 3.5% of the 3.7% total or the 4.1% of our core business. And we had included 250 basis points or 2.5% in our 4% to 5% guidance for the year. And that, obviously, will be stronger in the first half because we annualized some deals that you work through the year, but there's also potential upside without committing anything for new deals because we do not contemplate that in our guidance.",0.0489731,0.12
DGX-2018-Q1-2018-04-19,100,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Now, MedXM, which we had closed early in the year, was contemplated because it was completed by the time we shared our guidance in late January.",0.4636651,0.34
DGX-2018-Q1-2018-04-19,104,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. Okay. So, first of all, on tax reform, what we shared with our fourth quarter results is we're going to take about $75 million in investment in the business and I would say the majority of this is around accelerating growth.",0.6896211,0.796
DGX-2018-Q1-2018-04-19,105,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","What we've said around up and the kind of the outlines of broad categories, and those broad categories, as you would, are some of our growth strategies. So, Quest Diagnostics, the consumer strategy, but also investing in our people. So, we also announced that we're going to provide a bonus for the vast majority of our employees that don't have equity and that will be payable in the fourth quarter.",0.1555189,0.762
DGX-2018-Q1-2018-04-19,106,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, all of that has started to feather into what you see starting in Q1 and will continue throughout the year. And with that, we believe this will help us accelerate growth around those five strategies.",0.1429984,0.649
DGX-2018-Q1-2018-04-19,107,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second part of your question is around Walmart. We're really pleased with the early returns. We started with the big states - Texas and Florida. They're going well. The customer feedback is really good. And the joint venture continues to look at prospects for other basic health services that we can provide in those stores. And so, we, as you know, formed the JV. This joint venture was about what we do around blood draws and what we do at Quest Diagnostics and our laboratory business.",0.3769357,0.865
DGX-2018-Q1-2018-04-19,108,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","But more importantly, it's all around Extended Care Services and Population Health and providing basic healthcare services to bend the cost curve. And so, we're excited about those prospects as well.",0.091598,0.895
DGX-2018-Q1-2018-04-19,109,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We won't give you a number today about how many stores. We're still kind of working out the details with Walmart around that, but there will be more. We have the initial stores and there will be more because the early returns and progress we're making is quite good.",0.016804,0.846
DGX-2018-Q1-2018-04-19,116,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. So, let me take the first part, which is hospitals. I would say, this is - the pace of awareness is accelerating. What you find is that we have a number of hospital executives that are aware of PAMA. And second is they're greatly aware of all the other pressure that they have in hospitals.",0.6691928,0.0
DGX-2018-Q1-2018-04-19,117,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, if you talk to hospital executives today, there's a lot of pressure, and not just with PAMA. And so, many have cost improvement goals. Many are anxious to understand ways they could become more efficient. And so, our hospital strategy plays nicely into being a program that they can launch with us, to put some point through the board, if you will, particularly around in-patient laboratory cost, which is a key part of our value proposition. So, independent of us, it's accelerating.",0.4023064,0.848
DGX-2018-Q1-2018-04-19,118,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Second is we are accelerating it as well. So, we're knocking on many hospital executives doors to make sure that they are aware, if they're not aware already, and have a conversation around this and specifically around the lab strategy.",0.7920923,0.527
DGX-2018-Q1-2018-04-19,119,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we've engaged with many systems, particularly those that have large outreach businesses to talk about their lab strategy. So, it's a deliberate strategy of our accelerate strategy to make sure that they're well aware and understand what their options could be and think about the possibilities. So, we are helping with the information out there as well.",0.3756178,0.901
DGX-2018-Q1-2018-04-19,120,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second part of your question has to do with our retail strategy. Now, we're working on this retail strategy for years. This has happened overnight. As we said, Walmart departed that. We have Safeway who is a part of that. We do active work for CVS in the MinuteClinic. They've evolved their strategy. We have a great working relationship with Aetna. We'll see if that potential merger becomes a reality, but because of the great relationship with CVS and Aetna. We're actually hopeful that this could help accelerate some of the work we could do with them as well. Number one.",0.0876442,0.969
DGX-2018-Q1-2018-04-19,121,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And number two is the work with Walmart, I said in my earlier comments, is going well. And speculation what they will or will not do on health is for them to communicate about. But just reemphasizes their commitment and energy around this topic.",0.0523888,0.727
DGX-2018-Q1-2018-04-19,122,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And as far as other retailers, we're working on making sure that we have the right number and also don't leave any geography uncovered. And as you know, some of these partners we have announced so far, like Safeway and Walmart, have a center of mass that doesn't necessarily cover the whole population of the United States.",0.047117,0.789
DGX-2018-Q1-2018-04-19,123,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, as we continue to work through this, we continue to understand how there might be fitting different retail partnerships that could complement what we already have. But, fortunately, we're early to the table around this. We're off and running. You see the reinforcement of this with some of the deals that are out in the marketplace. So, our strategy is the right one. And it's being supported by the marketplace and this consolidation is interesting. But, more importantly, is try to bring their resources together with the capabilities. Our capabilities of data and services are quite essential to what this is all about, which is to bend the cost curve. And that was a portion of my prepared remarks about what we're actually doing with MedXM in the middle overall.",0.3113674,0.817
DGX-2018-Q1-2018-04-19,128,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I'll start and I'll turn it to Mark for some more color. First of all, when we walk in and have a conversation with a C-suite, as a matter of fact, this week we just had a leadership group of our top 40 to 50 executives that we want to make sure are prepared to have a broad conversation about all the capabilities of Quest Diagnostics. Part of that is around what we described as our hospital strategy. And in 2016, in our investor day, we shared this with you.",0.1397035,0.778
DGX-2018-Q1-2018-04-19,129,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And this, we have three pieces. One is we ask the question, we want to have a conversation around your lab strategy and is that important to you and you have one.",0.4688633,0.273
DGX-2018-Q1-2018-04-19,130,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Surprisingly to us, initially, but not anymore, many of the CEOs and the C suites have it on their list. It's one of the strategic question, what they're going to do around lab.",0.2853377,0.153
DGX-2018-Q1-2018-04-19,131,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And related to that, there's three pieces. One is what they're doing with their hospital inpatient cost and our simple value proposition there is we have now good confidence, a track record of accounts that are all referenceable that we've actually saved them some money because it is a call center and we do that a variety of ways.",0.1861614,0.886
DGX-2018-Q1-2018-04-19,132,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","When we get into that conversation, then we have a conversation around their sophisticated testing or advanced diagnostics that they send to reference laboratories, we're a player there. We're the market leader in that regard and we believe there's more we could do in terms of consolidation and getting smarter about the diagnostics in the inpatient care setting, classing suppliers and making sure you do the right tests for the right patient at the right time.",0.2675453,0.92
DGX-2018-Q1-2018-04-19,133,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And the part of this is a conversation, if they're in outreach, if they partner with us with inpatient, if they partner with us around reference testing, what's their strategy around outreach. And this is where we have a conversation around what's happening with PAMA with their Medicare volumes, the pressure that's going to be on commercial rates given the reality of what's happening in this marketplace.",0.109061,0.25
DGX-2018-Q1-2018-04-19,134,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, we end with a comprehensive strategy. If you see one, you see one. But we've shared last year with PeaceHealth. That was a good example. We bought their outreach. We're helping with their inpatient laboratories and as well we're helping them with their reference testing. So, when that happens, we're their partner for laboratory services in the integrated delivery system. And that's resonating well given all the pressures they have and all the parties that they have in the current dynamic in the marketplace.",0.2362438,0.952
DGX-2018-Q1-2018-04-19,135,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, Mark, specific to the opportunities around consolidation, you want to share a little bit about how that's going?",0.2187809,0.625
DGX-2018-Q1-2018-04-19,136,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure, Steve. When you're talking consolidation, you mean within the laboratory industry and specifically us as a consolidator. And, yes, specifically about Shiel, Shiel is early. We're pleased with the initial results. I can share a little bit.",0.2527646,0.844
DGX-2018-Q1-2018-04-19,137,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Commercial is fully integrated. From an operational standpoint, largely integrated, including billing, which is critically important. We haven't completely consolidated the entire infrastructure, the draw centers and things like that. That takes a little bit of time. But, certainly, after a few months, we're pleased and on plan. And then, I think, most critically, retention is good. So, if you look at the number of customers that moved over from Shiel to us, relative to expectations and the model, we're doing very well. So, that's what I can share, the point around Shiel. So, feel like it was a very nice deal. And at this point, it's on plan.",0.0604265,0.964
DGX-2018-Q1-2018-04-19,139,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Sure. So, if you look at the dollars, obviously, we're a larger business, especially with the acquisitions. If you look at the days, 47 and change, that's kind of where we typically are. Last year, we ended at a relatively AR level four a couple of different reasons. I think you may have been asking about year-end Q4 to Q1. And when you think about Q4, that is a ramp down quarter. So, October is much larger than December. And then, if you look at Q1, obviously, it's a ramp up quarter. So, March is much larger than January. So, you're always going to see a dollar dynamic where the end of Q1 in terms of receivables is much larger than Q4.",0.0872828,0.599
DGX-2018-Q1-2018-04-19,140,Answer,2018-04-19,1,2018,Shawn Bevec,Executive Director-Investor Relations,"Jack, I'll also add to that. This is Shawn. With the accounting change around bad debt, that's obviously going to impact all of the historical DSO. So, you'd have to go back and recalculate those after you make the relevant adjustment to get a comparison quarter by quarter.",0.2741466,-0.791
DGX-2018-Q1-2018-04-19,145,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Thanks for the question. What was shared in 2016, and we continuously talk about it, we have our two point strategy. First is all around accelerating growth. We talked at great length of our five strategies around that where we made great progress.",0.7482702,0.958
DGX-2018-Q1-2018-04-19,146,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","The second is operational excellence. And what we shared in the end of 2017 is we achieved our goal of $1.3 billion run rate savings. But what we also shared is we have more opportunities in front of us. This is a large, highly complex business and we still have plenty of opportunities to get better.",0.2734761,0.948
DGX-2018-Q1-2018-04-19,147,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And what we shared is - one example of that is we're kind of at the final push of harmonizing our processes and standardizing our systems. When we do that, it allows us to streamline our workflow. And then, second is it reduces our IT cost, by way of an example. This will happen in 2018. You'll see that in 2019.",0.1901153,0.586
DGX-2018-Q1-2018-04-19,148,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We still have some opportunities around consolidation of our laboratory network. We've shared that we're building a new facility, a new laboratory facility in New Jersey. It's a big project for us. When that is completed, it will allow us to consolidate our physical presence in what we call our east region. So, it will allow us to consolidate some of our regional laboratories into one. We're continuing to see a big opportunity around the e-enablement. When we e-enable the process, we can take cost out. In prior calls, we talked about simple things. For instance, we got a lot of calls that came in to our call centers around results. And so, now what we've done is educated our customers that you can get these results online. And so, what it has done is eliminated a lot of call volume coming into our call centers, allows us to reduce cost. Customers are happy.",0.1485997,0.923
DGX-2018-Q1-2018-04-19,149,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, we continuously look at opportunities. And so, we have dialed into our guidance for this year in our outlook. Those opportunities, we haven't given you a specific number. But I'll assure you that it's embedded in those numbers and that allows us to offset the wage inflation and also the reimbursement pressure that we provided you some color around.",0.4682043,0.691
DGX-2018-Q1-2018-04-19,150,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And that will be clearly in our sights in 2018, 2019 and 2020 and beyond. There's a lot of opportunities.",0.3795717,0.649
DGX-2018-Q1-2018-04-19,155,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, the one I brought up is PeaceHealth. That's a great example. They looked at their hospital -- excuse me, yeah, looked at their hospital strategy. And that's the three aspects that I talked about, how we can help them help them with their inpatients, laboratory cost. Second is, can we help them become more efficient and effective, rather, reference testing for inpatients, ordering of diagnostics and then, finally, is they had an outreach business. And we now acquired outreach business and integrating it into our west region. A great example.",0.016804,0.981
DGX-2018-Q1-2018-04-19,156,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","I would share another example. If you recall back a couple years ago, we bought Hartford Hospitals' outreach business. The way we look at all this, Amanda, is these are beachheads. We start there and then we build. We build credibility. We build existing relationships. We manage the account. And in the case of Hartford, we continue to look at how we can help them, consolidate some of their purchases or reference testing. We had a dialogue around their hospital laboratories and should we help them become more efficient. So, a good example where working relationship, even though it starts in one year, it could build.",0.0177924,0.935
DGX-2018-Q1-2018-04-19,158,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So, interesting enough, what you find is there's two pieces of this. One is, what's happening with our share of the marketplace. And then the second is what's happening in the hospital marketplace.",0.3654036,0.75
DGX-2018-Q1-2018-04-19,159,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, actually, what we've seen in Q1 in hospital volumes, given admissions volumes have been relatively flat best - as we talked to hospital executives and this puts a log in our fire to help them become more efficient. There is a lot of pressure on hospitals, both from a volume perspective of patient admissions and second is reimbursement changes. And so, what we see in our reference testing business, even though we might be picking up some more share, volumes are relatively stable.",0.2576606,0.878
DGX-2018-Q1-2018-04-19,160,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And then, second is, in that portion of our business, we do see some price challenges. There's more competition. And what we have is a deliberate strategy. When we have a market like that, for the leader should get stronger and this plays into our strategy. So, many hospital systems are looking at consolidating suppliers, having a more comprehensive strategy. So, we hope over time to continue to build share, but probably more of a more challenging marketplace than two to three years ago.",0.1459638,0.851
DGX-2018-Q1-2018-04-19,161,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And just, Amanda, to add, we don't do a POS deal without a reference deal. The only question is how much of the reference business comes. No, we certainly would not just do POS alone. In many of these cases, as we shared, we serve half the hospitals in the country. And so, I'd probably say most of these cases, if not all, we already were doing some reference work. So, there's an opportunity to expand that footprint and do more or, in some cases, all of it. So, that is part and parcel of the relationship. And as we shared, we therefore locked that up in a five to seven-year contract instead of being subject to periodic RFPs and competitive situation. So, it's a nice longer-term relationship between us and the hospital.",0.1224329,0.903
DGX-2018-Q1-2018-04-19,164,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Good morning, Ross.",0.5588138,0.44
DGX-2018-Q1-2018-04-19,167,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So, we'll tag team this. Mark and I again. First of all, as I mentioned in my quote, we did execute well. And I think as we pointed out, there is a lot of moving parts. A lot of moving parts within the quarter. And so, we had to make sure that we managed all those levers.",0.0200988,0.681
DGX-2018-Q1-2018-04-19,168,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","We mentioned, in Mark's comments, we have acquisitions coming in. We have investments for tax reform. And also, there was an earlier comment about what are you doing around our Invigorate program around cost improvements.",0.3116969,0.637
DGX-2018-Q1-2018-04-19,169,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","And so, within Q1, you've got all that going on. Okay? You've that all going on. And so, what we need to - what we do as a management team is we pull together that integrated plan to continue to sell progress. We get to the outlook that we laid out in the marketplace with those moving parts, with the uncertainty sometimes of what's happening in the market. For instance, you cannot predict the severe winter that we saw, but we had to manage our way through that.",0.2062603,0.2
DGX-2018-Q1-2018-04-19,170,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, with that as a high level summary, Mark, do you want to give a little more color of the pieces?",0.8777595,0.077
DGX-2018-Q1-2018-04-19,171,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yeah, sure. As you know, Ross, price and inflation are headwinds on margin. We talk about our productivity which we've discussed with Invigorate in the past and we said we believe we've got some cost capability. We can drive about 3% a year on a cost base of over $6 billion. So, you can do the math on that.",0.4660348,0.751
DGX-2018-Q1-2018-04-19,172,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Obviously, we have also shared that we did a substantial amount of M&A. A lot of that was skewed towards the back end. So, we expect margin expansion on that new book of business throughout the year, which will help us.",0.1007109,0.71
DGX-2018-Q1-2018-04-19,173,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then, finally, the important piece is organic growth. So, when we grow organically, the way we've been doing, obviously, the drop-through on the incremental revenue is higher than the fully-loaded margin. So, that's another opportunity to offset some of the headwinds in price and inflation.",1.0979463,0.755
DGX-2018-Q1-2018-04-19,174,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, when you add all those together, that's where we came out with reaffirming our longer-term outlook despite PAMA being more significant than any of us had anticipated.",0.5075039,0.272
DGX-2018-Q1-2018-04-19,175,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"We still said we're going be able to do by 2020 what we said in 2016, which is topline of 3 to 5, although I did caution more likely to be in the lower end and the higher end if PAMA stays where it is and then growing our earnings. Not earnings per share, but earnings, mid-to-high single digits. But that, obviously, also directionally has correlation with the topline as well. So, probably more likely to be at the lower end than that.",0.7302528,0.052
DGX-2018-Q1-2018-04-19,176,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"So, in terms of the rest of the year, the investments that Steve referenced, the $75 million, some of those are fairly smooth over the year. Some of them are accounting, like the bonus that Steve mentioned. So, we're clearly that pretty equally. And then, some of them are going to ramp up a little bit as we move throughout the year, but we also have those other factors such as strong organic growth and expansion of our acquired revenue that's been offset, that incremental investment.",0.6698262,0.932
DGX-2018-Q1-2018-04-19,183,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Yes, sure. So, volume is going to bounce around quarter-to-quarter. There is a number of factors. When you look at early last year, we had a couple POS deals that were fairly new. And then, those were obviously ramping up. We didn't close a significant amount of POS late in 2017. And, remember, our POS is organic. We're not buying anything. So, that is organic growth.",0.4936809,0.827
DGX-2018-Q1-2018-04-19,184,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"Certainly, as I mentioned, the timing of the holidays - and the floating holidays have significant impact on our - so, if you have - when you look at New Year's, when you look at Fourth of July and when you look at Christmas, if those fall on a weekend versus a Wednesday, there's a dramatic difference in that quarter in terms of the volume.",0.6457346,0.813
DGX-2018-Q1-2018-04-19,185,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And so, when you look at the way this year started out, the previous year, we had New Year's on a weekend and this year we didn't. So, it's not just that day that you get a little spillover from those holiday right before or right after. Certainly, that had a little impact. So, I wouldn't make too much - read too much into the quarter to quarter slight variation. So, we'll try to share to the best of our abilities what the real drivers are and things that certainly have implications going forward.",1.0059242,0.931
DGX-2018-Q1-2018-04-19,186,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"I'd say, the first quarter, there was a fair amount of noise. And there's significant in terms of utilization or other things that you might be concerned about. And we certainly are very confident of the guidance that we put out and keeping on track with our commitments.",0.6011058,0.859
DGX-2018-Q1-2018-04-19,187,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Yeah. So, just to add to that, one part of reaffirming the 4% to 5%, if you look at Q1 and we go through some of the pieces, and earlier we got a question on what's happening on the hospital side, hospital admissions are stable. But we were very pleased - we kind of look at all the different pieces of the volumes we see from our physician portion of our business, which is the vast majority of where we get our testing, we are actually, when you think through the different pieces, when you think about what Mark described and some of the headwinds, and you couple with that the offset with PAMA in terms of that price reduction in Q1 and when we look at that physician business, we actually felt okay about our performance in Q1 and we thought it was solid. And therefore, we have confidence in the 4% to 5% for this year, which includes that 250 basis points for acquisition. And as you described it, the rest from organic revenue growth.",0.1739703,0.932
DGX-2018-Q1-2018-04-19,193,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Brian, it's becoming increasingly more important, particularly as I mentioned in my introductory comments. If you get into Managed Medicaid and Medicare Advantage, when the payers are, obviously, are taking the risk and they're really trying to understand that 5% of the population represents 50% of the cost. So, what we described with our capabilities in Extended Care Services and specifically called out what we're doing with MedXM. The ability for us to have specific programs where we used the data we have to pinpoint and to identify the patient and then they use our call centers and then our onsite services, which could be in a convenient location like a Walmart, but also it could include one of our care professionals going into someone's home.",0.4408567,0.852
DGX-2018-Q1-2018-04-19,194,Answer,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","So, a lot of interest around, yes, we are the world's largest lab, but what we are is the world's largest diagnostic information services company, which includes using the data to identify the opportunities and then manage the care in a more active way and bend the cost curve.",0.5252059,0.94
DGX-2018-Q1-2018-04-19,196,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And I would also add that some of the things Steve referenced, like our real-time estimation, they see the value of that because one of the difficulties that they deal with is patients being surprised about coverage, patient being surprised about cost. And so, this is, as we shared in the past, one of the win-win-win all around. The patient is happier. We're happier. The payers are happier. So, they actually appreciate us rolling out that tool. It's not just for us. It helps them quite a bit as well. So, patients can make decisions ahead instead of finding out after around coverage and cost and so on. So, really, the value that we bring goes well beyond just the data.",0.2148499,0.981
DGX-2018-Q1-2018-04-19,197,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"The other one is our sales force. So, when you look at how they are struggling to control costs, we are part of the solution. The national labs are great value. And the fact that we can deploy our sales force to help them with physicians, we call it leakage or steerage, we are setting work to high cost providers. And with data from the payer, walk in and say, hey, doc, you've got some patients on high deductible plan. You're costing them money when you send them to this laboratory. Let me show you from their insurance company the difference between setting it up and sending it to this - who you're currently utilizing. That's powerful for the payers. They know that, actually, in that case, we are fully aligned.",0.2247235,0.889
DGX-2018-Q1-2018-04-19,198,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"And then, finally, the retail strategy. They really like that. Yes, they want to control costs, but they want their patients to get their diagnostic work done, especially if you're monitoring a condition, if they're a risk-bearing entity. They've got Managed Medicare, Medicaid. They want those patients to get these things done. And, obviously, if we're putting in more convenient sites, it's more likely the patients will get that critical testing.",0.3590047,0.245
DGX-2018-Q1-2018-04-19,199,Answer,2018-04-19,1,2018,Mark J. Guinan,Chief Financial Officer & Executive Vice President,"A secondary value we bring to the table, I mentioned in my remarks, is around quality scores. So, if the quality scores are right, they are driving the right care process and to close those gaps in care, we help identify those patients which allows them to score better and get higher reimbursement from payers. So, it all fits together. The value is well beyond our diagnostic testing.",0.0817536,0.951
DGX-2018-Q1-2018-04-19,202,Closing,2018-04-19,1,2018,Stephen H. Rusckowski,"Chairman, President & Chief Executive Officer","Okay. Well, we appreciate your time. Thanks for joining us today. We appreciate your support. And you have a great day.",0.1390445,0.952
